The	O
epidermal	B-Protein
growth	I-Protein
factor	E-Protein
precursor	O
.	O

A	O
calcium	O
-	O
binding	O
,	O
beta	O
-	O
hydroxyasparagine	O
containing	O
modular	O
protein	O
present	O
on	O
the	O
surface	O
of	O
platelets	O
.	O

Various	O
human	O
body	O
fluids	O
and	O
secretions	O
contain	O
a	O
soluble	O
form	O
of	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	E-Protein
(	O
EGF	S-Protein
)	O
precursor	O
.	O

The	O
EGF	S-Protein
precursor	O
molecule	O
contains	O
eight	O
EGF	S-Protein
modules	O
in	O
addition	O
to	O
EGF	S-Protein
itself	O
.	O

Using	O
monoclonal	O
antibodies	O
specific	O
for	O
the	O
EGF	S-Protein
modules	O
7	O
and	O
8	O
,	O
we	O
have	O
purified	O
the	O
soluble	O
form	O
of	O
the	O
EGF	S-Protein
precursor	O
from	O
human	O
urine	O
to	O
homogeneity	O
.	O

The	O
protein	O
was	O
shown	O
to	O
have	O
a	O
molecular	O
mass	O
of	O
about	O
160	O
kDa	O
and	O
the	O
N	O
-	O
terminal	O
sequence	O
SAPNHWSXPE	O
.	O

EGF	S-Protein
modules	O
2	O
,	O
7	O
and	O
8	O
of	O
the	O
precursor	O
have	O
the	O
consensus	O
sequence	O
for	O
post	O
-	O
translational	O
beta	O
-	O
hydroxylation	O
of	O
Asp	O
/	O
Asn	O
residues	O
.	O

We	O
identified	O
the	O
presence	O
of	O
erythro	O
-	O
beta	O
-	O
hydroxy	O
-	O
aspartic	O
acid	O
(	O
Hya	O
)	O
in	O
acid	O
hydrolysates	O
of	O
the	O
EGF	S-Protein
precursor	O
(	O
2	O
.	O
4	O
M	O
.	O
M	O
protein	O
-	O
1	O
)	O
.	O

As	O
the	O
DNA	O
sequence	O
encodes	O
Asn	O
in	O
the	O
corresponding	O
position	O
,	O
the	O
Hya	O
represents	O
erythro	O
-	O
beta	O
-	O
hydroxyasparagine	O
(	O
Hyn	O
)	O
.	O

The	O
Hyn	O
-	O
containing	O
modules	O
have	O
a	O
consensus	O
calcium	O
-	O
binding	O
motif	O
immediately	O
N	O
-	O
terminal	O
of	O
the	O
first	O
Cys	O
residue	O
.	O

The	O
synthetic	O
EGF	S-Protein
module	O
2	O
(	O
residues	O
356	O
-	O
395	O
)	O
of	O
the	O
EGF	S-Protein
precursor	O
was	O
found	O
to	O
bind	O
calcium	O
with	O
low	O
affinity	O
,	O
Kd	O
approximately	O
3	O
.	O
5	O
mM	O
,	O
i	O
.	O
e	O
.	O
similar	O
to	O
the	O
affinity	O
of	O
other	O
isolated	O
calcium	O
-	O
binding	O
EGF	S-Protein
modules	O
.	O

EGF	S-Protein
module	O
7	O
,	O
when	O
part	O
of	O
the	O
intact	O
protein	O
,	O
was	O
found	O
to	O
bind	O
Ca2	O
+	O
with	O
a	O
Kd	O
approximately	O
0	O
.	O
2	O
microM	O
,	O
i	O
.	O
e	O
.	O
approximately	O
10	O
(	O
4	O
)	O
-	O
fold	O
higher	O
than	O
that	O
of	O
isolated	O
EGF	S-Protein
modules	O
presumably	O
due	O
to	O
the	O
influence	O
of	O
neighboring	O
modules	O
.	O

We	O
have	O
detected	O
EGF	S-Protein
precursor	O
in	O
platelet	O
-	O
rich	O
plasma	O
and	O
demonstrated	O
it	O
to	O
be	O
associated	O
to	O
platelets	O
.	O

The	O
platelets	O
were	O
found	O
to	O
have	O
30	O
-	O
160	O
EGF	S-Protein
molecules	O
each	O
.	O

Expression	O
of	O
an	O
Aspergillus	O
niger	O
phytase	S-Protein
gene	O
(	O
phyA	S-Protein
)	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Phytase	S-Protein
improves	O
the	O
bioavailability	O
of	O
phytate	O
phosphorus	O
in	O
plant	O
foods	O
to	O
humans	O
and	O
animals	O
and	O
reduces	O
phosphorus	O
pollution	O
of	O
animal	O
waste	O
.	O

Our	O
objectives	O
were	O
to	O
express	O
an	O
Aspergillus	O
niger	O
phytase	S-Protein
gene	O
(	O
phyA	S-Protein
)	O
in	O
Saccharomyces	O
cerevisiae	O
and	O
to	O
determine	O
the	O
effects	O
of	O
glycosylation	O
on	O
the	O
phytase	S-Protein
'	O
s	O
activity	O
and	O
thermostability	O
.	O

A	O
1	O
.	O
4	O
-	O
kb	O
DNA	O
fragment	O
containing	O
the	O
coding	O
region	O
of	O
the	O
phyA	S-Protein
gene	O
was	O
inserted	O
into	O
the	O
expression	O
vector	O
pYES2	O
and	O
was	O
expressed	O
in	O
S	O
.	O
cerevisiae	O
as	O
an	O
active	O
,	O
extracellular	O
phytase	S-Protein
.	O

The	O
yield	O
of	O
total	O
extracellular	O
phytase	S-Protein
activity	O
was	O
affected	O
by	O
the	O
signal	O
peptide	O
and	O
the	O
medium	O
composition	O
.	O

The	O
expressed	O
phytase	S-Protein
had	O
two	O
pH	O
optima	O
(	O
2	O
to	O
2	O
.	O
5	O
and	O
5	O
to	O
5	O
.	O
5	O
)	O
and	O
a	O
temperature	O
optimum	O
between	O
55	O
and	O
60	O
degrees	O
C	O
,	O
and	O
it	O
cross	O
-	O
reacted	O
with	O
a	O
rabbit	O
polyclonal	O
antibody	O
against	O
the	O
wild	O
-	O
type	O
enzyme	O
.	O

Due	O
to	O
the	O
heavy	O
glycosylation	O
,	O
the	O
expressed	O
phytase	S-Protein
had	O
a	O
molecular	O
size	O
of	O
approximately	O
120	O
kDa	O
and	O
appeared	O
to	O
be	O
more	O
thermostable	O
than	O
the	O
commercial	O
enzyme	O
.	O

Deglycosylation	O
of	O
the	O
phytase	S-Protein
resulted	O
in	O
losses	O
of	O
9	O
%	O
of	O
its	O
activity	O
and	O
40	O
%	O
of	O
its	O
thermostability	O
.	O

The	O
recombinant	O
phytase	S-Protein
was	O
effective	O
in	O
hydrolyzing	O
phytate	O
phosphorus	O
from	O
corn	O
or	O
soybean	O
meal	O
in	O
vitro	O
.	O

In	O
conclusion	O
,	O
the	O
phyA	S-Protein
gene	O
was	O
expressed	O
as	O
an	O
active	O
,	O
extracellular	O
phytase	S-Protein
in	O
S	O
.	O
cerevisiae	O
,	O
and	O
its	O
thermostability	O
was	O
affected	O
by	O
glycosylation	O
.	O

Chromatin	O
assembly	O
:	O
biochemical	O
identities	O
and	O
genetic	O
redundancy	O
.	O

Investigations	O
on	O
chromatin	O
assembly	O
in	O
vitro	O
implicate	O
chromatin	O
assembly	O
factor	O
1	O
(	O
CAF1	O
)	O
as	O
a	O
chaperone	O
for	O
histones	B-Protein
H3	E-Protein
/	O
H4	S-Protein
and	O
nucleosome	B-Protein
assembly	I-Protein
protein	I-Protein
1	E-Protein
(	O
NAP1	S-Protein
)	O
as	O
a	O
chaperone	O
for	O
histones	B-Protein
H2A	E-Protein
/	O
H2B	S-Protein
.	O

Deletion	O
analysis	O
of	O
CAF1	O
in	O
vivo	O
suggests	O
multiple	O
redundant	O
pathways	O
for	O
deposition	O
of	O
the	O
histones	S-Protein
.	O

Histone	S-Protein
deposition	O
requires	O
acetylation	O
of	O
the	O
amino	O
-	O
terminal	O
tails	O
and	O
analysis	O
of	O
mutants	O
suggests	O
a	O
specific	O
but	O
redundant	O
role	O
for	O
acetylation	O
of	O
the	O
tails	O
in	O
assembly	O
.	O

Furthermore	O
,	O
studies	O
on	O
the	O
HAT1	S-Protein
acetyltransferase	O
raise	O
the	O
possibility	O
that	O
acetylation	O
of	O
histones	S-Protein
occurs	O
following	O
their	O
transport	O
into	O
the	O
nucleus	O
but	O
prior	O
to	O
their	O
deposition	O
onto	O
DNA	O
.	O

Identification	O
of	O
the	O
factors	O
involved	O
in	O
the	O
redundant	O
pathways	O
of	O
assembly	O
is	O
awaited	O
.	O

Glycated	O
albumin	S-Protein
stimulation	O
of	O
PKC	B-Protein
-	I-Protein
beta	E-Protein
activity	O
is	O
linked	O
to	O
increased	O
collagen	O
IV	O
in	O
mesangial	O
cells	O
.	O

Albumin	S-Protein
modified	O
by	O
Amadori	O
-	O
glucose	O
adducts	O
induces	O
coordinate	O
increases	O
in	O
the	O
expression	O
of	O
extracellular	O
matrix	O
proteins	O
,	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
(	I-Protein
TGF	I-Protein
)	I-Protein
-	I-Protein
beta1	E-Protein
,	O
and	O
the	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
type	I-Protein
II	I-Protein
receptor	E-Protein
in	O
glomerular	O
mesangial	O
cells	O
.	O

Because	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
accompanies	O
the	O
increased	O
mesangial	O
cell	O
expression	O
of	O
matrix	O
proteins	O
and	O
TGF	B-Protein
-	I-Protein
beta1	E-Protein
induced	O
by	O
high	O
ambient	O
glucose	O
,	O
we	O
postulated	O
that	O
glycated	O
albumin	S-Protein
(	O
GA	O
)	O
modulates	O
PKC	O
activity	O
and	O
that	O
PKC	O
participates	O
in	O
mediating	O
the	O
GA	O
-	O
induced	O
stimulation	O
of	O
matrix	O
production	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
examined	O
the	O
effects	O
of	O
PKC	O
inhibitors	O
on	O
collagen	O
type	O
IV	O
production	O
by	O
mouse	O
or	O
rat	O
mesangial	O
cells	O
incubated	O
with	O
GA	O
,	O
and	O
the	O
influence	O
of	O
GA	O
on	O
PKC	O
activity	O
in	O
these	O
cells	O
.	O

Increased	O
collagen	O
type	O
IV	O
production	O
evoked	O
by	O
GA	O
in	O
5	O
.	O
5	O
and	O
25	O
mM	O
glucose	O
in	O
mouse	O
mesangial	O
cells	O
was	O
prevented	O
by	O
both	O
general	O
(	O
GF	O
-	O
109203X	O
)	O
and	O
beta	O
-	O
specific	O
(	O
LY	O
-	O
379196	O
)	O
PKC	O
inhibitors	O
.	O

Total	O
PKC	O
activity	O
,	O
measured	O
by	O
phosphorylation	O
of	O
a	O
PKC	O
-	O
specific	O
substrate	O
,	O
increased	O
with	O
time	O
after	O
exposure	O
of	O
rat	O
mesangial	O
cells	O
to	O
GA	O
compared	O
with	O
the	O
nonglycated	O
,	O
glucose	O
-	O
free	O
counterpart	O
.	O

GA	O
caused	O
an	O
increase	O
in	O
PKC	B-Protein
-	I-Protein
beta1	E-Protein
membrane	O
-	O
bound	O
fraction	O
and	O
in	O
total	O
PKC	O
activity	O
in	O
media	O
containing	O
physiological	O
(	O
5	O
.	O
5	O
mM	O
)	O
glucose	O
concentrations	O
in	O
rat	O
mesangial	O
cells	O
,	O
confirming	O
that	O
the	O
glucose	O
-	O
modified	O
protein	O
,	O
and	O
not	O
a	O
"	O
hyperglycemic	O
"	O
milieu	O
,	O
was	O
responsible	O
.	O

The	O
findings	O
indicate	O
that	O
Amadori	O
-	O
modified	O
albumin	S-Protein
stimulates	O
mesangial	O
cell	O
PKC	O
activity	O
,	O
and	O
that	O
activation	O
of	O
the	O
PKC	B-Protein
-	I-Protein
beta	E-Protein
isoform	O
is	O
linked	O
to	O
the	O
stimulation	O
of	O
collagen	O
type	O
IV	O
production	O
.	O

Nuclear	O
entry	O
of	O
the	O
Drosophila	O
melanogaster	O
nuclear	O
lamina	O
protein	O
YA	S-Protein
correlates	O
with	O
developmentally	O
regulated	O
changes	O
in	O
its	O
phosphorylation	O
state	O
.	O

The	O
Drosophila	O
melanogaster	O
YA	S-Protein
protein	O
is	O
a	O
maternally	O
provided	O
nuclear	O
lamina	O
component	O
that	O
is	O
essential	O
during	O
the	O
transition	O
from	O
meiosis	O
to	O
mitosis	O
at	O
the	O
beginning	O
of	O
embryogenesis	O
.	O

Localization	O
of	O
YA	S-Protein
to	O
the	O
nuclear	O
envelope	O
is	O
required	O
for	O
its	O
function	O
;	O
this	O
localization	O
is	O
cell	O
cycle	O
-	O
dependent	O
during	O
embryogenesis	O
.	O

Here	O
we	O
show	O
that	O
the	O
ability	O
of	O
YA	S-Protein
to	O
enter	O
nuclei	O
is	O
modulated	O
during	O
development	O
.	O

In	O
developing	O
egg	O
chambers	O
,	O
YA	S-Protein
protein	O
is	O
made	O
but	O
excluded	O
from	O
nuclei	O
of	O
nurse	O
cells	O
and	O
oocytes	O
;	O
upon	O
egg	O
activation	O
,	O
YA	S-Protein
acquires	O
the	O
ability	O
to	O
enter	O
nuclei	O
and	O
becomes	O
incorporated	O
into	O
the	O
nuclear	O
lamina	O
in	O
unfertilized	O
eggs	O
and	O
embryos	O
.	O

This	O
localization	O
switch	O
correlates	O
with	O
changes	O
in	O
the	O
phosphorylation	O
state	O
of	O
YA	S-Protein
.	O

YA	S-Protein
in	O
ovaries	O
is	O
hyperphosphorylated	O
relative	O
to	O
YA	S-Protein
in	O
unfertilized	O
eggs	O
and	O
embryos	O
.	O

Through	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
identified	O
443T	O
,	O
a	O
potential	O
phosphorylation	O
site	O
for	O
both	O
cyclin	O
-	O
dependent	O
protein	O
kinase	O
and	O
mitogen	O
-	O
activated	O
-	O
protein	O
kinase	O
,	O
as	O
one	O
of	O
the	O
sites	O
likely	O
involved	O
in	O
this	O
developmental	O
control	O
.	O

Our	O
results	O
suggest	O
that	O
phosphorylation	O
plays	O
a	O
role	O
in	O
modulating	O
the	O
localization	O
of	O
YA	S-Protein
during	O
development	O
.	O

A	O
model	O
for	O
developmental	O
regulation	O
of	O
the	O
nuclear	O
entry	O
of	O
YA	S-Protein
is	O
proposed	O
and	O
implications	O
for	O
understanding	O
Drosophila	O
egg	O
activation	O
are	O
discussed	O
.	O

Epigenetic	O
mechanisms	O
for	O
progression	O
of	O
prostate	O
cancer	O
.	O

Epigenetic	O
mechanisms	O
may	O
be	O
the	O
main	O
driving	O
force	O
for	O
critical	O
changes	O
in	O
gene	O
expression	O
that	O
are	O
responsible	O
for	O
progression	O
of	O
prostate	O
cancers	O
.	O

The	O
three	O
most	O
extensively	O
characterized	O
mechanisms	O
for	O
epigenetic	O
gene	O
-	O
regulation	O
are	O
(	O
i	O
)	O
changing	O
patterns	O
of	O
DNA	O
methylation	O
,	O
(	O
ii	O
)	O
histone	S-Protein
acetylations	O
/	O
deacetylations	O
,	O
and	O
(	O
iii	O
)	O
alterations	O
in	O
regulatory	O
feedback	O
loops	O
for	O
growth	O
factors	O
.	O

Several	O
studies	O
have	O
indicated	O
that	O
DNA	O
hypermethylation	O
is	O
an	O
important	O
mechanism	O
in	O
prostate	O
cancer	O
for	O
inactivation	O
of	O
key	O
regulatory	O
genes	O
such	O
as	O
E	B-Protein
-	I-Protein
cadherin	E-Protein
,	O
pi	B-Protein
-	I-Protein
class	I-Protein
glutathione	I-Protein
S	I-Protein
-	I-Protein
transferase	E-Protein
,	O
the	O
tumor	O
suppressors	O
CDKN2	S-Protein
and	O
PTEN	S-Protein
,	O
and	O
IGF	B-Protein
-	I-Protein
II	E-Protein
.	O

Similarly	O
,	O
histone	S-Protein
acetylations	O
and	O
deacetylations	O
are	O
frequently	O
associated	O
respectively	O
with	O
transcriptional	O
activation	O
(	O
e	O
.	O
g	O
.	O
IGFBP	B-Protein
-	I-Protein
2	E-Protein
and	O
p21	S-Protein
)	O
and	O
repression	O
(	O
e	O
.	O
g	O
.	O
Mad	S-Protein
:	O
Max	S-Protein
dimers	O
)	O
of	O
genes	O
linked	O
to	O
prostate	O
cancer	O
progression	O
.	O

Recently	O
,	O
histone	S-Protein
acetyltransferase	O
and	O
deacetylase	O
activities	O
have	O
been	O
shown	O
to	O
be	O
intrinsic	O
with	O
transcriptional	O
coregulator	O
proteins	O
that	O
bind	O
to	O
steroid	O
receptors	O
(	O
e	O
.	O
g	O
.	O
SRC	B-Protein
-	I-Protein
1	E-Protein
and	O
PCAF	S-Protein
)	O
.	O

Changes	O
in	O
regulatory	O
feedback	O
loops	O
for	O
growth	O
factors	O
with	O
prostate	O
cancer	O
progression	O
tend	O
toward	O
shifts	O
from	O
paracrine	O
to	O
autocrine	O
control	O
where	O
the	O
receptor	O
and	O
ligand	O
are	O
produced	O
by	O
the	O
same	O
cell	O
.	O

While	O
there	O
are	O
several	O
examples	O
of	O
this	O
progression	O
pattern	O
in	O
prostate	O
tumors	O
such	O
as	O
with	O
IGF	O
,	O
FGF	O
,	O
TGF	B-Protein
-	I-Protein
alpha	E-Protein
and	O
their	O
respective	O
receptors	O
,	O
the	O
precise	O
mechanism	O
(	O
i	O
.	O
e	O
.	O
epigenetic	O
or	O
mutational	O
)	O
is	O
less	O
certain	O
.	O

In	O
the	O
context	O
of	O
treatment	O
options	O
,	O
the	O
contribution	O
of	O
mutational	O
versus	O
epigenetic	O
events	O
to	O
prostate	O
cancer	O
progression	O
is	O
an	O
important	O
consideration	O
.	O

Irreversible	O
genetic	O
changes	O
are	O
likely	O
to	O
be	O
less	O
amenable	O
to	O
therapeutic	O
control	O
than	O
are	O
epigenetic	O
ones	O
.	O

Microheterogeneity	O
of	O
serum	O
glycoproteins	O
in	O
patients	O
with	O
chronic	O
alcohol	O
abuse	O
compared	O
with	O
carbohydrate	O
-	O
deficient	O
glycoprotein	O
syndrome	O
type	O
I	O
.	O

BACKGROUND	O
:	O
Chronic	O
alcohol	O
abuse	O
alters	O
the	O
normal	O
N	O
-	O
glycosylation	O
of	O
transferrin	S-Protein
,	O
producing	O
the	O
carbohydrate	O
-	O
deficient	O
transferrin	S-Protein
isoforms	O
.	O

This	O
alteration	O
could	O
be	O
similar	O
to	O
that	O
present	O
in	O
patients	O
with	O
carbohydrate	O
-	O
deficient	O
glycoprotein	O
syndrome	O
type	O
1	O
(	O
CDG1	O
)	O
.	O

We	O
thus	O
compared	O
the	O
alterations	O
of	O
N	O
-	O
glycans	O
present	O
in	O
patients	O
with	O
alcoholism	O
and	O
patients	O
with	O
CDG1	O
.	O

METHODS	O
:	O
The	O
N	O
-	O
glycans	O
of	O
serum	O
glycoproteins	O
were	O
compared	O
in	O
sera	O
of	O
patients	O
with	O
alcoholism	O
,	O
patients	O
with	O
CDG1	O
,	O
and	O
controls	O
by	O
two	O
-	O
dimensional	O
electrophoresis	O
,	O
neuraminidase	O
,	O
peptide	B-Protein
:	I-Protein
N	I-Protein
-	I-Protein
glycosidase	I-Protein
F	E-Protein
,	O
and	O
endoglycosidase	B-Protein
F2	E-Protein
treatments	O
.	O

A	O
specific	O
antibody	O
directed	O
against	O
the	O
amino	O
acid	O
sequence	O
surrounding	O
the	O
N	O
-	O
432	O
N	O
-	O
glycosylation	O
site	O
of	O
transferrin	S-Protein
was	O
prepared	O
(	O
SZ	O
-	O
350	O
antibody	O
)	O
.	O

RESULTS	O
:	O
In	O
patients	O
with	O
alcoholism	O
,	O
the	O
abnormal	O
transferrin	S-Protein
and	O
alpha	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
-	I-Protein
antitrypsin	E-Protein
isoforms	O
were	O
devoid	O
of	O
a	O
variable	O
number	O
of	O
entire	O
N	O
-	O
glycan	O
moieties	O
and	O
were	O
identical	O
with	O
those	O
present	O
in	O
CDG1	O
.	O

In	O
the	O
serum	O
of	O
patients	O
with	O
alcoholism	O
,	O
this	O
finding	O
was	O
less	O
pronounced	O
than	O
in	O
CDG1	O
.	O

In	O
contrast	O
to	O
CDG1	O
,	O
there	O
was	O
no	O
decrease	O
in	O
clusterin	S-Protein
or	O
serum	B-Protein
amyloid	I-Protein
P	E-Protein
in	O
patients	O
with	O
alcoholism	O
.	O

The	O
SZ	O
-	O
350	O
antibody	O
recognized	O
only	O
transferrin	S-Protein
isoforms	O
with	O
one	O
or	O
no	O
N	O
-	O
glycan	O
moieties	O
.	O

CONCLUSION	O
:	O
Antibodies	O
directed	O
against	O
specific	O
N	O
-	O
glycosylation	O
sites	O
of	O
glycoproteins	O
could	O
be	O
useful	O
for	O
developing	O
more	O
specific	O
immunochemical	O
tests	O
for	O
the	O
diagnosis	O
of	O
chronic	O
alcohol	O
abuse	O
.	O

The	O
effect	O
of	O
N	O
-	O
terminal	O
acetylation	O
and	O
the	O
inhibition	O
activity	O
of	O
acetylated	O
enkephalins	O
on	O
the	O
aminopeptidase	B-Protein
M	E-Protein
-	O
catalyzed	O
hydrolysis	O
of	O
enkephalins	O
.	O

High	O
performance	O
liquid	O
chromatography	O
and	O
high	O
performance	O
liquid	O
chromatography	O
/	O
electrospray	O
ionization	O
-	O
mass	O
spectrometry	O
were	O
used	O
to	O
study	O
the	O
effect	O
of	O
N	O
-	O
terminal	O
acetylation	O
and	O
the	O
inhibition	O
activity	O
of	O
acetylated	O
enkephalins	O
on	O
the	O
aminopeptidase	B-Protein
M	E-Protein
(	O
EC	O
3	O
.	O
4	O
.	O
11	O
.	O
2	O
)	O
-	O
catalyzed	O
hydrolysis	O
of	O
methionine	O
(	O
Met	O
-	O
enk	O
)	O
and	O
leucine	O
enkephalins	O
(	O
Leu	O
-	O
enk	O
)	O
.	O

Acetylation	O
imparts	O
a	O
significant	O
enhancement	O
in	O
the	O
proteolytic	O
stability	O
of	O
these	O
two	O
peptides	O
.	O

After	O
30	O
min	O
of	O
the	O
reaction	O
,	O
<	O
10	O
%	O
of	O
both	O
acetylated	O
enkephalins	O
was	O
hydrolyzed	O
.	O

In	O
an	O
8	O
-	O
h	O
incubation	O
period	O
,	O
only	O
a	O
maximum	O
of	O
54	O
%	O
acetylated	O
(	O
Ac	O
)	O
-	O
Met	O
-	O
enk	O
and	O
38	O
%	O
Ac	O
-	O
Leu	O
-	O
enk	O
was	O
hydrolyzed	O
.	O

Vmax	O
and	O
Km	O
[	O
infil	O
]	O
for	O
the	O
degradation	O
of	O
Ac	O
-	O
Met	O
-	O
enk	O
were	O
1	O
.	O
4	O
nmol	O
/	O
min	O
/	O
50	O
ng	O
and	O
2	O
.	O
2	O
mM	O
,	O
respectively	O
.	O

The	O
corresponding	O
values	O
for	O
the	O
reaction	O
of	O
Ac	O
-	O
Leu	O
-	O
enk	O
were	O
0	O
.	O
5	O
nmol	O
/	O
min	O
/	O
50	O
ng	O
and	O
0	O
.	O
9	O
mM	O
.	O

Also	O
,	O
the	O
aminopeptidase	B-Protein
M	E-Protein
activity	O
on	O
Met	O
-	O
enk	O
can	O
be	O
inhibited	O
in	O
the	O
presence	O
of	O
Ac	O
-	O
Met	O
-	O
enk	O
,	O
which	O
acts	O
as	O
a	O
mixed	O
-	O
type	O
inhibitor	O
with	O
the	O
inhibition	O
constant	O
(	O
K	O
(	O
i	O
)	O
)	O
of	O
I	O
x	O
10	O
(	O
-	O
3	O
)	O
M	O
.	O

Evidence	O
for	O
involvement	O
of	O
polymorphic	O
CYP2C19	S-Protein
and	O
2C9	S-Protein
in	O
the	O
N	O
-	O
demethylation	O
of	O
sertraline	O
in	O
human	O
liver	O
microsomes	O
.	O

AIMS	O
:	O
The	O
present	O
study	O
was	O
designed	O
to	O
define	O
the	O
kinetic	O
behaviour	O
of	O
sertraline	O
N	O
-	O
demethylation	O
in	O
human	O
liver	O
microsomes	O
and	O
to	O
identify	O
the	O
isoforms	O
of	O
cytochrome	O
P450	O
involved	O
in	O
this	O
metabolic	O
pathway	O
.	O

METHODS	O
:	O
The	O
kinetics	O
of	O
the	O
formation	O
of	O
N	O
-	O
demethylsertraline	O
were	O
determined	O
in	O
human	O
liver	O
microsomes	O
from	O
six	O
genotyped	O
CYP2C19	S-Protein
extensive	O
(	O
EM	O
)	O
and	O
three	O
poor	O
metabolisers	O
(	O
PM	O
)	O
.	O

Selective	O
inhibitors	O
of	O
and	O
specific	O
monoclonal	O
antibodies	O
to	O
various	O
cytochrome	O
P450	O
isoforms	O
were	O
also	O
employed	O
.	O

RESULTS	O
:	O
The	O
kinetics	O
of	O
N	O
-	O
demethylsertraline	O
formation	O
in	O
all	O
EM	O
liver	O
microsomes	O
were	O
fitted	O
by	O
a	O
two	O
-	O
enzyme	O
Michaelis	O
-	O
Menten	O
equation	O
,	O
whereas	O
the	O
kinetics	O
in	O
all	O
PM	O
liver	O
microsomes	O
were	O
best	O
described	O
by	O
a	O
single	O
-	O
enzyme	O
Michaelis	O
-	O
Menten	O
equation	O
similar	O
to	O
the	O
low	O
-	O
affinity	O
component	O
found	O
in	O
EM	O
microsomes	O
.	O

Mean	O
apparent	O
Km	O
values	O
for	O
the	O
high	O
-	O
and	O
low	O
-	O
affinity	O
components	O
were	O
1	O
.	O
9	O
and	O
88	O
microm	O
and	O
V	O
max	O
values	O
were	O
33	O
and	O
554	O
pmol	O
min	O
-	O
1	O
mg	O
-	O
1	O
protein	O
,	O
respectively	O
,	O
in	O
the	O
EM	O
liver	O
microsomes	O
.	O

Omeprazole	O
(	O
a	O
CYP2C19	S-Protein
substrate	O
)	O
at	O
high	O
concentrations	O
and	O
sulphaphenazole	O
(	O
a	O
selective	O
inhibitor	O
of	O
CYP2C9	S-Protein
)	O
substantially	O
inhibited	O
N	O
-	O
demethylsertraline	O
formation	O
.	O

Of	O
five	O
monoclonal	O
antibodies	O
to	O
various	O
cytochrome	O
P450	O
forms	O
tested	O
,	O
only	O
anti	O
-	O
CYP2C8	S-Protein
/	O
9	S-Protein
/	O
19	S-Protein
had	O
any	O
inhibitory	O
effect	O
on	O
this	O
reaction	O
.	O

The	O
inhibition	O
of	O
sertraline	O
N	O
-	O
demethylation	O
by	O
anti	O
-	O
CYP2C8	S-Protein
/	O
9	S-Protein
/	O
19	S-Protein
was	O
greater	O
in	O
EM	O
livers	O
than	O
in	O
PM	O
livers	O
at	O
both	O
low	O
and	O
high	O
substrate	O
concentrations	O
.	O

However	O
,	O
anti	O
-	O
CYP2C8	S-Protein
/	O
9	S-Protein
/	O
19	S-Protein
did	O
not	O
abolish	O
the	O
formation	O
of	O
N	O
-	O
demethylsertraline	O
in	O
the	O
microsomes	O
from	O
any	O
of	O
the	O
livers	O
.	O

CONCLUSIONS	O
:	O
The	O
polymorphic	O
enzyme	O
CYP2C19	S-Protein
catalyses	O
the	O
high	O
-	O
affinity	O
N	O
-	O
demethylation	O
of	O
sertraline	O
,	O
while	O
CYP2C9	S-Protein
is	O
one	O
of	O
the	O
low	O
-	O
affinity	O
components	O
of	O
this	O
metabolic	O
pathway	O
.	O

Modulation	O
of	O
keratan	O
sulfate	O
synthesis	O
on	O
lumican	S-Protein
by	O
the	O
action	O
of	O
cytokines	O
on	O
human	O
articular	O
chondrocytes	O
.	O

Adult	O
human	O
articular	O
chondrocytes	O
were	O
used	O
to	O
investigate	O
why	O
keratan	O
sulfate	O
/	O
polylactosamine	O
chains	O
are	O
deficient	O
on	O
the	O
lumican	S-Protein
residing	O
in	O
the	O
matrix	O
of	O
adult	O
articular	O
cartilage	O
,	O
whereas	O
they	O
are	O
present	O
on	O
the	O
lumican	S-Protein
residing	O
in	O
the	O
matrix	O
of	O
juvenile	O
cartilage	O
.	O

Under	O
serum	O
-	O
free	O
conditions	O
with	O
either	O
monolayer	O
cultures	O
,	O
agarose	O
cultures	O
,	O
or	O
micromass	O
cultures	O
,	O
the	O
adult	O
chondrocytes	O
synthesized	O
a	O
form	O
of	O
lumican	S-Protein
possessing	O
keratan	O
sulfate	O
/	O
polylactosamine	O
chains	O
.	O

Thus	O
,	O
the	O
adult	O
chondrocytes	O
are	O
capable	O
of	O
producing	O
a	O
proteoglycan	O
form	O
of	O
lumican	S-Protein
and	O
this	O
appears	O
to	O
be	O
the	O
default	O
synthesis	O
preference	O
.	O

The	O
micromass	O
culture	O
system	O
proved	O
useful	O
for	O
demonstrating	O
that	O
growth	O
factors	O
/	O
cytokines	O
present	O
in	O
the	O
extracellular	O
milieu	O
are	O
capable	O
of	O
influencing	O
the	O
structure	O
of	O
the	O
keratan	O
sulfate	O
/	O
polylactosamine	O
chains	O
on	O
the	O
secreted	O
lumican	S-Protein
.	O

Of	O
particular	O
note	O
was	O
the	O
ability	O
of	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
to	O
promote	O
the	O
secretion	O
of	O
a	O
form	O
of	O
lumican	S-Protein
deficient	O
in	O
keratan	O
sulfate	O
/	O
polylactosamine	O
chains	O
,	O
whereas	O
with	O
bFGF	S-Protein
,	O
IGF	B-Protein
-	I-Protein
1	E-Protein
and	O
TGFbeta	O
keratan	O
sulfate	O
/	O
polylactosamine	O
chains	O
were	O
present	O
,	O
though	O
their	O
size	O
or	O
degree	O
of	O
substitution	O
varied	O
.	O

Thus	O
,	O
growth	O
factors	O
/	O
cytokines	O
are	O
able	O
to	O
modulate	O
the	O
molecular	O
form	O
of	O
lumican	S-Protein
.	O

Furthermore	O
,	O
additional	O
studies	O
showed	O
that	O
this	O
modulation	O
was	O
not	O
due	O
to	O
the	O
degradation	O
of	O
keratan	O
sulfate	O
/	O
polylactosamine	O
chains	O
following	O
proteoglycan	O
secretion	O
,	O
but	O
represented	O
a	O
direct	O
effect	O
on	O
synthesis	O
.	O

Dephosphorylation	O
of	O
p53	S-Protein
at	O
Ser20	O
after	O
cellular	O
exposure	O
to	O
low	O
levels	O
of	O
non	O
-	O
ionizing	O
radiation	O
.	O

Induction	O
of	O
the	O
transactivation	O
function	O
of	O
p53	S-Protein
after	O
cellular	O
irradiation	O
was	O
studied	O
under	O
conditions	O
in	O
which	O
upstream	O
signaling	O
events	O
modulating	O
p53	S-Protein
activation	O
were	O
uncoupled	O
from	O
those	O
regulating	O
stabilization	O
.	O

This	O
investigation	O
prompted	O
the	O
discovery	O
of	O
a	O
novel	O
radiation	O
-	O
responsive	O
kinase	O
pathway	O
targeting	O
Ser20	O
that	O
results	O
in	O
the	O
masking	O
of	O
the	O
DO	O
-	O
1	O
epitope	O
in	O
undamaged	O
cells	O
.	O

Unmasking	O
of	O
the	O
DO	O
-	O
1	O
epitope	O
via	O
dephosphorylation	O
occurs	O
in	O
response	O
to	O
low	O
doses	O
of	O
non	O
-	O
ionizing	O
radiation	O
.	O

Our	O
data	O
show	O
that	O
phosphorylation	O
at	O
Ser20	O
reduces	O
binding	O
of	O
the	O
mdm2	S-Protein
protein	O
,	O
suggesting	O
that	O
a	O
function	O
of	O
the	O
Ser20	O
-	O
kinase	O
pathway	O
may	O
be	O
to	O
produce	O
a	O
stable	O
pool	O
of	O
inactive	O
p53	S-Protein
in	O
undamaged	O
cells	O
which	O
can	O
be	O
readily	O
activated	O
after	O
cellular	O
injury	O
.	O

Phospho	O
-	O
specific	O
monoclonal	O
antibodies	O
were	O
used	O
to	O
determine	O
whether	O
the	O
Ser20	O
signaling	O
pathway	O
is	O
coupled	O
to	O
the	O
Ser15	O
and	O
Ser392	O
radiation	O
-	O
responsive	O
kinase	O
pathways	O
.	O

These	O
results	O
demonstrated	O
that	O
:	O
(	O
1	O
)	O
dephosphorylation	O
at	O
Ser20	O
is	O
co	O
-	O
ordinated	O
with	O
an	O
increased	O
steady	O
-	O
state	O
phosphorylation	O
at	O
Ser392	O
after	O
irradiation	O
,	O
without	O
p53	S-Protein
protein	O
stabilization	O
,	O
and	O
(	O
2	O
)	O
stabilization	O
of	O
p53	S-Protein
protein	O
can	O
occur	O
without	O
Ser15	O
phosphorylation	O
at	O
higher	O
doses	O
of	O
radiation	O
.	O

These	O
data	O
show	O
that	O
the	O
Ser20	O
and	O
Ser392	O
phosphorylation	O
sites	O
are	O
both	O
targeted	O
by	O
an	O
integrated	O
network	O
of	O
signaling	O
pathways	O
which	O
is	O
acutely	O
sensitive	O
to	O
radiation	O
injury	O
.	O

Molecular	O
mechanism	O
for	O
silencing	O
virally	O
transduced	O
genes	O
involves	O
histone	S-Protein
deacetylation	O
and	O
chromatin	O
condensation	O
.	O

Virally	O
transduced	O
genes	O
are	O
often	O
silenced	O
after	O
integration	O
into	O
the	O
host	O
genome	O
.	O

Chromatin	O
immunoprecipitation	O
and	O
nuclease	O
sensitivity	O
experiments	O
now	O
demonstrate	O
that	O
silencing	O
of	O
the	O
transgene	O
is	O
characterized	O
by	O
deacetylation	O
of	O
histone	B-Protein
H4	E-Protein
lysines	O
and	O
chromatin	O
condensation	O
.	O

Trichostatin	O
A	O
treatment	O
results	O
in	O
dramatic	O
reactivation	O
of	O
gene	O
expression	O
that	O
is	O
preceded	O
by	O
histone	S-Protein
acetylation	O
and	O
chromatin	O
decondensation	O
.	O

Analysis	O
of	O
individual	O
histone	B-Protein
H4	E-Protein
lysines	O
demonstrate	O
that	O
chromatin	O
domain	O
opening	O
is	O
coincident	O
with	O
rapid	O
acetylation	O
of	O
histone	B-Protein
H4	E-Protein
K5	O
,	O
K12	O
,	O
and	O
K16	O
and	O
that	O
maintenance	O
of	O
the	O
open	O
domain	O
is	O
correlated	O
with	O
acetylation	O
of	O
histone	B-Protein
H4	E-Protein
K8	O
.	O

Removal	O
of	O
trichostatin	O
A	O
results	O
in	O
rapid	O
deacetylation	O
of	O
histone	B-Protein
H4	E-Protein
K8	O
,	O
chromatin	O
condensation	O
,	O
and	O
transcription	O
silencing	O
.	O

The	O
results	O
suggest	O
that	O
deacetylation	O
of	O
histone	B-Protein
H4	E-Protein
lysines	O
and	O
coincident	O
chromatin	O
condensation	O
are	O
critically	O
involved	O
in	O
the	O
silencing	O
of	O
virally	O
transduced	O
genes	O
.	O

Kinins	O
in	O
humans	O
.	O

The	O
kinin	O
peptide	O
system	O
in	O
humans	O
is	O
complex	O
.	O

Whereas	O
plasma	O
kallikrein	O
generates	O
bradykinin	S-Protein
peptides	O
,	O
glandular	O
kallikrein	O
generates	O
kallidin	S-Protein
peptides	O
.	O

Moreover	O
,	O
a	O
proportion	O
of	O
kinin	O
peptides	O
is	O
hydroxylated	O
on	O
proline	O
(	O
3	O
)	O
of	O
the	O
bradykinin	S-Protein
sequence	O
.	O

We	O
established	O
HPLC	O
-	O
based	O
radioimmunoassays	O
for	O
nonhydroxylated	O
and	O
hydroxylated	O
bradykinin	S-Protein
and	O
kallidin	S-Protein
peptides	O
and	O
their	O
metabolites	O
in	O
blood	O
and	O
urine	O
.	O

Both	O
nonhydroxylated	O
and	O
hydroxylated	O
bradykinin	S-Protein
and	O
kallidin	S-Protein
peptides	O
were	O
identified	O
in	O
human	O
blood	O
and	O
urine	O
,	O
although	O
the	O
levels	O
in	O
blood	O
were	O
often	O
below	O
the	O
assay	O
detection	O
limit	O
.	O

Whereas	O
kallidin	S-Protein
peptides	O
were	O
more	O
abundant	O
than	O
bradykinin	S-Protein
peptides	O
in	O
urine	O
,	O
bradykinin	S-Protein
peptides	O
were	O
more	O
abundant	O
in	O
blood	O
.	O

Bradykinin	S-Protein
and	O
kallidin	S-Protein
peptide	O
levels	O
were	O
higher	O
in	O
venous	O
than	O
arterial	O
blood	O
.	O

Angiotensin	B-Protein
-	I-Protein
converting	I-Protein
enzyme	E-Protein
inhibition	O
increased	O
blood	O
levels	O
of	O
bradykinin	S-Protein
,	O
but	O
not	O
kallidin	S-Protein
,	O
peptides	O
.	O

Reactive	O
hyperemia	O
had	O
no	O
effect	O
on	O
antecubital	O
venous	O
levels	O
of	O
bradykinin	S-Protein
or	O
kallidin	S-Protein
peptide	O
levels	O
.	O

These	O
studies	O
demonstrate	O
differential	O
regulation	O
of	O
the	O
bradykinin	S-Protein
and	O
kallidin	S-Protein
peptide	O
systems	O
,	O
and	O
indicate	O
that	O
blood	O
levels	O
of	O
bradykinin	S-Protein
peptides	O
are	O
more	O
responsive	O
to	O
angiotensin	B-Protein
-	I-Protein
converting	I-Protein
enzyme	E-Protein
inhibition	O
than	O
blood	O
levels	O
of	O
kallidin	S-Protein
peptides	O
.	O

Polarized	O
secretion	O
of	O
the	O
regulated	O
secretory	O
protein	O
chromogranin	B-Protein
A	E-Protein
.	O

Bovine	O
chromogranin	B-Protein
A	E-Protein
(	O
CgA	S-Protein
)	O
,	O
together	O
with	O
secreted	O
alkaline	O
phosphatase	O
(	O
SEAP	O
)	O
as	O
an	O
external	O
control	O
for	O
apical	O
secretion	O
were	O
expressed	O
in	O
MDCK	O
cells	O
to	O
test	O
if	O
CgA	S-Protein
contains	O
sorting	O
signals	O
for	O
polarized	O
secretion	O
.	O

CgA	S-Protein
,	O
SEAP	O
,	O
and	O
the	O
endogenous	O
apical	O
marker	O
GP80	S-Protein
were	O
secreted	O
75	O
-	O
80	O
%	O
apically	O
.	O

Basolateral	O
secretion	O
of	O
SEAP	O
was	O
inhibited	O
40	O
%	O
by	O
ammonium	O
chloride	O
.	O

Sulfate	O
labeling	O
and	O
digestion	O
with	O
chondroitinase	B-Protein
ABC	E-Protein
revealed	O
a	O
120	O
kDa	O
proteoglycan	O
-	O
CgA	S-Protein
and	O
75	O
kDa	O
CgA	S-Protein
.	O

Inhibition	O
of	O
proteoglycan	O
synthesis	O
did	O
not	O
affect	O
apical	O
secretion	O
of	O
CgA	S-Protein
.	O

As	O
CgA	S-Protein
is	O
not	O
N	O
-	O
glycosylated	O
,	O
we	O
used	O
tunicamycin	O
to	O
test	O
if	O
cellular	O
N	O
-	O
glycosylation	O
is	O
required	O
for	O
apical	O
sorting	O
.	O

Tunicamycin	O
reversed	O
the	O
polarity	O
of	O
secretion	O
of	O
CgA	S-Protein
to	O
the	O
basolateral	O
side	O
.	O

These	O
results	O
suggest	O
that	O
CgA	S-Protein
contains	O
dominant	O
apical	O
and	O
recessive	O
basolateral	O
sorting	O
information	O
.	O

Hypoxic	O
induction	O
of	O
prolyl	B-Protein
4	I-Protein
-	I-Protein
hydroxylase	I-Protein
alpha	I-Protein
(	I-Protein
I	I-Protein
)	E-Protein
in	O
cultured	O
cells	O
.	O

Accumulated	O
evidence	O
indicates	O
that	O
hypoxia	O
activates	O
collagen	O
synthesis	O
in	O
tissues	O
.	O

To	O
explore	O
the	O
molecular	O
mechanism	O
of	O
activation	O
,	O
we	O
screened	O
genes	O
that	O
are	O
up	O
-	O
regulated	O
or	O
down	O
-	O
regulated	O
by	O
hypoxia	O
.	O

Fibroblasts	O
isolated	O
from	O
fetal	O
rat	O
lung	O
were	O
cultured	O
under	O
hypoxia	O
.	O

Differential	O
display	O
technique	O
showed	O
that	O
the	O
mRNA	O
level	O
of	O
prolyl	B-Protein
4	I-Protein
-	I-Protein
hydroxylase	I-Protein
(	I-Protein
PH	I-Protein
)	I-Protein
alpha	I-Protein
(	I-Protein
I	I-Protein
)	E-Protein
,	O
an	O
active	O
subunit	O
that	O
catalyzes	O
the	O
oxygen	O
-	O
dependent	O
hydroxylation	O
of	O
proline	O
residue	O
in	O
procollagen	O
,	O
increased	O
2	O
-	O
3	O
-	O
fold	O
after	O
an	O
8	O
-	O
h	O
exposure	O
to	O
hypoxia	O
.	O

This	O
elevated	O
level	O
was	O
maintained	O
over	O
40	O
h	O
and	O
returned	O
to	O
the	O
basal	O
level	O
after	O
reoxygenation	O
.	O

The	O
transcription	O
rate	O
,	O
protein	O
level	O
,	O
and	O
hydroxyproline	O
content	O
(	O
an	O
indicator	O
of	O
the	O
prolyl	O
hydroxylation	O
)	O
were	O
all	O
elevated	O
by	O
hypoxic	O
culture	O
.	O

Analysis	O
of	O
the	O
promotor	O
region	O
of	O
PHalpha	B-Protein
(	I-Protein
I	I-Protein
)	E-Protein
gene	O
indicated	O
that	O
a	O
motif	O
similar	O
to	O
hypoxia	O
-	O
responsive	O
element	O
(	O
HRE	O
)	O
of	O
hypoxia	O
-	O
inducible	O
genes	O
such	O
as	O
erythropoietin	S-Protein
,	O
was	O
identified	O
within	O
a	O
120	O
-	O
base	O
pair	O
sequence	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

Luciferase	S-Protein
reporter	O
assay	O
and	O
mutational	O
analysis	O
showed	O
that	O
a	O
site	O
similar	O
to	O
the	O
HRE	O
in	O
this	O
motif	O
is	O
functionally	O
essential	O
to	O
hypoxic	O
response	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
revealed	O
that	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
was	O
stimulated	O
and	O
bound	O
to	O
the	O
PHalpha	B-Protein
(	I-Protein
I	I-Protein
)	E-Protein
HRE	O
upon	O
hypoxic	O
challenge	O
.	O

Our	O
results	O
indicate	O
that	O
PHalpha	B-Protein
(	I-Protein
I	I-Protein
)	E-Protein
,	O
an	O
essential	O
enzyme	O
for	O
collagen	O
synthesis	O
,	O
is	O
a	O
target	O
gene	O
for	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
.	O

Methylation	O
and	O
silencing	O
of	O
the	O
retinoic	B-Protein
acid	I-Protein
receptor	I-Protein
-	I-Protein
beta2	E-Protein
gene	O
in	O
breast	O
cancer	O
.	O

BACKGROUND	O
:	O
A	O
growing	O
body	O
of	O
evidence	O
supports	O
the	O
hypotheses	O
that	O
the	O
retinoic	B-Protein
acid	I-Protein
receptor	I-Protein
beta2	E-Protein
(	O
RAR	B-Protein
-	I-Protein
beta2	E-Protein
)	O
gene	O
is	O
a	O
tumor	O
suppressor	O
gene	O
and	O
that	O
the	O
chemopreventive	O
effects	O
of	O
retinoids	O
are	O
due	O
to	O
induction	O
of	O
RAR	B-Protein
-	I-Protein
beta2	E-Protein
.	O

RAR	B-Protein
-	I-Protein
beta2	E-Protein
expression	O
is	O
reduced	O
in	O
many	O
malignant	O
tumors	O
,	O
and	O
we	O
examined	O
whether	O
methylation	O
of	O
RAR	B-Protein
-	I-Protein
beta2	E-Protein
could	O
be	O
responsible	O
for	O
this	O
silencing	O
.	O

METHODS	O
:	O
RAR	B-Protein
-	I-Protein
beta2	E-Protein
expression	O
was	O
studied	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
in	O
eight	O
breast	O
cancer	O
cell	O
lines	O
that	O
were	O
either	O
treated	O
with	O
the	O
demethylating	O
agent	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
and	O
subsequently	O
with	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
or	O
left	O
untreated	O
.	O

Sodium	O
bisulfite	O
genomic	O
sequencing	O
was	O
used	O
to	O
determine	O
the	O
locations	O
of	O
5	O
-	O
methylcytosines	O
in	O
the	O
RAR	B-Protein
-	I-Protein
beta2	E-Protein
genes	O
of	O
three	O
of	O
these	O
cell	O
lines	O
.	O

In	O
16	O
breast	O
cancer	O
biopsy	O
specimens	O
and	O
non	O
-	O
neoplastic	O
breast	O
tissue	O
,	O
methylation	O
-	O
specific	O
PCR	O
was	O
used	O
to	O
determine	O
the	O
methylation	O
status	O
of	O
RAR	B-Protein
-	I-Protein
beta2	E-Protein
,	O
and	O
,	O
in	O
13	O
of	O
the	O
specimens	O
,	O
RT	O
-	O
PCR	O
analysis	O
was	O
used	O
to	O
detect	O
RAR	B-Protein
-	I-Protein
beta2	E-Protein
expression	O
.	O

RESULTS	O
:	O
Cell	O
lines	O
SK	O
-	O
BR	O
-	O
3	O
,	O
T	O
-	O
47D	O
,	O
ZR	O
-	O
75	O
-	O
1	O
,	O
and	O
MCF7	O
exhibited	O
expression	O
of	O
RAR	B-Protein
-	I-Protein
beta2	E-Protein
only	O
after	O
demethylation	O
and	O
treatment	O
with	O
ATRA	O
.	O

The	O
first	O
exon	O
expressed	O
in	O
the	O
RAR	B-Protein
-	I-Protein
beta2	E-Protein
transcript	O
was	O
methylated	O
in	O
cell	O
lines	O
ZR	O
-	O
75	O
-	O
1	O
and	O
SK	O
-	O
BR	O
-	O
3	O
.	O

Six	O
breast	O
cancer	O
specimens	O
showed	O
methylation	O
in	O
the	O
same	O
region	O
of	O
the	O
gene	O
.	O

No	O
expression	O
of	O
RAR	B-Protein
-	I-Protein
beta2	E-Protein
was	O
found	O
in	O
any	O
grade	O
III	O
lesion	O
.	O

An	O
inverse	O
association	O
between	O
methylation	O
and	O
gene	O
expression	O
was	O
found	O
in	O
all	O
grade	O
II	O
lesions	O
.	O

The	O
RAR	B-Protein
-	I-Protein
beta2	E-Protein
gene	O
from	O
non	O
-	O
neoplastic	O
breast	O
tissue	O
was	O
unmethylated	O
and	O
expressed	O
.	O

CONCLUSIONS	O
:	O
Methylation	O
of	O
the	O
RAR	B-Protein
-	I-Protein
beta2	E-Protein
gene	O
may	O
be	O
an	O
initial	O
step	O
in	O
breast	O
carcinogenesis	O
;	O
treatment	O
of	O
cancer	O
patients	O
with	O
demethylating	O
agents	O
followed	O
by	O
retinoic	O
acid	O
may	O
offer	O
a	O
new	O
therapeutic	O
modality	O
.	O

Etiology	O
of	O
the	O
metabolic	O
syndrome	O
:	O
potential	O
role	O
of	O
insulin	S-Protein
resistance	O
,	O
leptin	S-Protein
resistance	O
,	O
and	O
other	O
players	O
.	O

Obesity	O
and	O
Type	O
2	O
diabetes	O
are	O
now	O
major	O
public	O
health	O
issues	O
in	O
developed	O
nations	O
and	O
have	O
reached	O
epidemic	O
proportions	O
in	O
many	O
developing	O
nations	O
,	O
as	O
well	O
as	O
disadvantaged	O
groups	O
in	O
developed	O
countries	O
,	O
e	O
.	O
g	O
.	O
,	O
Mexican	O
-	O
Americans	O
,	O
African	O
-	O
Americans	O
,	O
and	O
Australian	O
Aborigines	O
.	O

These	O
groups	O
all	O
show	O
hyperinsulinemia	O
and	O
insulin	S-Protein
resistance	O
,	O
which	O
have	O
been	O
demonstrated	O
to	O
be	O
future	O
predictors	O
of	O
Type	O
2	O
diabetes	O
and	O
have	O
also	O
been	O
suggested	O
as	O
key	O
factors	O
in	O
the	O
etiology	O
of	O
the	O
Metabolic	O
Syndrome	O
.	O

It	O
is	O
now	O
increasingly	O
recognized	O
that	O
Type	O
2	O
diabetes	O
is	O
part	O
of	O
a	O
cluster	O
of	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
risk	O
factors	O
comprising	O
the	O
Metabolic	O
Syndrome	O
.	O

This	O
group	O
is	O
at	O
very	O
high	O
risk	O
of	O
atherosclerosis	O
because	O
each	O
of	O
the	O
risk	O
factors	O
in	O
the	O
Metabolic	O
Syndrome	O
cluster	O
in	O
its	O
own	O
right	O
is	O
an	O
important	O
CVD	O
risk	O
factor	O
.	O

They	O
also	O
contribute	O
cumulatively	O
to	O
atherosclerosis	O
.	O

A	O
key	O
strategy	O
in	O
reducing	O
macrovascular	O
disease	O
lies	O
in	O
the	O
better	O
understanding	O
of	O
the	O
Metabolic	O
Syndrome	O
-	O
-	O
glucose	O
intolerance	O
,	O
hypertension	O
,	O
hyperlipidemia	O
,	O
and	O
central	O
obesity	O
.	O

Although	O
it	O
has	O
been	O
suggested	O
that	O
hyperinsulinemia	O
/	O
insulin	S-Protein
resistance	O
is	O
the	O
central	O
etiological	O
factor	O
for	O
the	O
Metabolic	O
Syndrome	O
,	O
epidemiological	O
data	O
do	O
not	O
support	O
the	O
idea	O
that	O
this	O
can	O
account	O
for	O
all	O
of	O
the	O
cluster	O
abnormalities	O
.	O

We	O
have	O
animal	O
and	O
human	O
data	O
suggesting	O
that	O
hyperleptinemia	O
rather	O
than	O
,	O
or	O
synergistically	O
with	O
,	O
hyperinsulinemia	O
may	O
play	O
a	O
central	O
role	O
in	O
the	O
genesis	O
of	O
the	O
CVD	O
risk	O
factor	O
cluster	O
that	O
constitutes	O
the	O
syndrome	O
.	O

Studies	O
in	O
Psammomys	O
obesus	O
(	O
the	O
Israeli	O
sand	O
rat	O
)	O
suggest	O
hyperinsulinemia	O
/	O
insulin	S-Protein
resistance	O
is	O
an	O
early	O
metabolic	O
lesion	O
in	O
the	O
development	O
of	O
obesity	O
and	O
Type	O
2	O
diabetes	O
.	O

This	O
animal	O
also	O
develops	O
other	O
features	O
of	O
the	O
Metabolic	O
Syndrome	O
,	O
making	O
it	O
an	O
excellent	O
model	O
to	O
investigate	O
etiology	O
.	O

Psammomys	O
,	O
when	O
placed	O
on	O
an	O
ad	O
libitum	O
laboratory	O
diet	O
,	O
develops	O
hyperinsulinemia	O
,	O
insulin	S-Protein
resistance	O
,	O
impaired	O
glucose	O
tolerance	O
,	O
diabetes	O
,	O
and	O
dyslipidemia	O
.	O

It	O
also	O
develops	O
hyperleptinemia	O
and	O
leptin	S-Protein
insensitivity	O
,	O
and	O
hyperleptinemia	O
is	O
correlated	O
with	O
insulin	S-Protein
resistance	O
independent	O
of	O
changes	O
in	O
body	O
weight	O
.	O

It	O
is	O
likely	O
that	O
a	O
similar	O
sequence	O
occurs	O
in	O
the	O
transition	O
from	O
the	O
prediabetic	O
state	O
to	O
Type	O
2	O
diabetes	O
in	O
humans	O
.	O

More	O
recently	O
,	O
other	O
potential	O
players	O
in	O
the	O
etiology	O
of	O
the	O
Metabolic	O
Syndrome	O
have	O
been	O
suggested	O
including	O
endothelial	O
dysfunction	O
and	O
acetylation	O
-	O
stimulating	O
protein	O
(	O
ASP	O
)	O
.	O

It	O
has	O
been	O
suggested	O
that	O
endothelial	O
dysfunction	O
may	O
be	O
an	O
antecedent	O
for	O
both	O
Type	O
2	O
diabetes	O
and	O
the	O
Metabolic	O
Syndrome	O
.	O

In	O
addition	O
,	O
ASP	O
is	O
a	O
serious	O
new	O
candidate	O
for	O
an	O
important	O
role	O
in	O
insulin	S-Protein
resistance	O
.	O

The	O
ASP	O
pathway	O
plays	O
a	O
critical	O
role	O
in	O
fatty	O
acid	O
metabolism	O
and	O
storage	O
,	O
and	O
it	O
has	O
been	O
suggested	O
that	O
ineffective	O
storage	O
of	O
fatty	O
acids	O
by	O
adipocytes	O
due	O
to	O
a	O
defect	O
in	O
the	O
ASP	O
pathway	O
may	O
lead	O
to	O
insulin	S-Protein
resistance	O
and	O
Type	O
2	O
diabetes	O
.	O

Differences	O
in	O
the	O
ligand	O
specificity	O
between	O
CD1d	S-Protein
-	O
restricted	O
T	O
cells	O
with	O
limited	O
and	O
diverse	O
T	O
-	O
cell	O
receptor	O
repertoire	O
.	O

The	O
natural	O
killer	O
(	O
NK	O
)	O
T	O
-	O
lymphocyte	O
population	O
consists	O
of	O
two	O
subsets	O
utilizing	O
a	O
diverse	O
and	O
restricted	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
repertoire	O
,	O
respectively	O
.	O

Both	O
populations	O
have	O
been	O
shown	O
to	O
include	O
autoreactive	O
cells	O
.	O

NKT	O
cells	O
carrying	O
restricted	O
Valpha14	O
(	O
AV14S1	O
)	O
Jalpha281	O
/	O
Vbeta8	O
.	O
2	O
(	O
BV8S2A1	O
)	O
TCR	O
have	O
been	O
shown	O
to	O
recognize	O
alpha	O
-	O
galactosylceramide	O
(	O
alphaGalCer	O
)	O
presented	O
in	O
the	O
context	O
of	O
murine	O
CD1d	S-Protein
.	O

In	O
this	O
study	O
we	O
screened	O
a	O
set	O
of	O
murine	O
CD1d	S-Protein
-	O
autoreactive	O
T	O
-	O
cell	O
hybridomas	O
with	O
diverse	O
TCR	O
for	O
their	O
reactivity	O
with	O
several	O
glycosylated	O
variants	O
of	O
ceramide	O
,	O
including	O
alphaGalCer	O
.	O

These	O
hybridomas	O
showed	O
a	O
different	O
pattern	O
of	O
reactivity	O
to	O
CD1d	S-Protein
-	O
expressing	O
antigen	O
-	O
presenting	O
cells	O
(	O
APC	O
)	O
and	O
were	O
not	O
reactive	O
with	O
any	O
of	O
the	O
tested	O
variants	O
of	O
ceramide	O
.	O

A	O
second	O
set	O
of	O
hybridomas	O
had	O
been	O
selected	O
for	O
expression	O
of	O
Valpha14	O
and	O
Vbeta8	O
.	O
2	O
TCR	O
chains	O
.	O

These	O
cells	O
responded	O
to	O
alphaGalCer	O
presented	O
on	O
CD1d	S-Protein
,	O
but	O
were	O
only	O
weakly	O
reactive	O
to	O
syngeneic	O
splenocytes	O
or	O
CD1d	S-Protein
-	O
transfected	O
cells	O
.	O

Their	O
fine	O
specificity	O
in	O
the	O
response	O
to	O
glycosylation	O
variants	O
of	O
ceramide	O
demonstrated	O
a	O
homogenous	O
reactivity	O
pattern	O
,	O
including	O
reactivity	O
to	O
alpha	O
-	O
galactosylsphingosine	O
,	O
the	O
variant	O
of	O
alphaGalCer	O
with	O
truncated	O
fatty	O
acyl	O
chain	O
.	O

These	O
findings	O
underline	O
the	O
differences	O
in	O
ligand	O
specificity	O
between	O
the	O
two	O
subsets	O
of	O
CD1d	S-Protein
-	O
restricted	O
NKT	O
cells	O
,	O
and	O
demonstrate	O
a	O
similarity	O
in	O
reactivity	O
among	O
the	O
hybridomas	O
using	O
the	O
Valpha14	O
-	O
Jalpha281	O
/	O
Vbeta8	O
.	O
2	O
TCR	O
.	O

Methylation	O
of	O
the	O
ribosomal	O
proteins	O
in	O
Escherichia	O
coli	O
.	O

Nature	O
and	O
stoichiometry	O
of	O
the	O
methylated	O
amino	O
acids	O
in	O
50S	O
ribosomal	O
proteins	O
.	O

Methylated	O
ribosomal	O
proteins	O
from	O
Escherichia	O
coli	O
50S	O
subunit	O
are	O
localized	O
by	O
growing	O
cells	O
in	O
a	O
medium	O
containing	O
(	O
1	O
-	O
14C	O
)	O
methionine	O
and	O
(	O
3H	O
-	O
methyl	O
)	O
-	O
methionine	O
and	O
comparing	O
the	O
3H	O
/	O
14C	O
ratio	O
for	O
each	O
of	O
the	O
50S	O
ribosomal	O
proteins	O
.	O

The	O
following	O
proteins	O
are	O
methylated	O
:	O
L11	S-Protein
,	O
L1	S-Protein
,	O
L3	S-Protein
,	O
L5	S-Protein
,	O
L7	S-Protein
,	O
L8	O
,	O
L9	S-Protein
,	O
L12	S-Protein
,	O
L18	S-Protein
,	O
and	O
L33	S-Protein
.	O

The	O
nature	O
and	O
stoichiometry	O
of	O
the	O
methylated	O
amino	O
acid	O
(	O
s	O
)	O
in	O
each	O
of	O
the	O
methylated	O
proteins	O
are	O
determined	O
.	O

Protein	O
L11	S-Protein
is	O
the	O
most	O
heavily	O
methylated	O
of	O
all	O
the	O
50S	O
subunit	O
proteins	O
.	O

This	O
protein	O
has	O
previously	O
been	O
implicated	O
in	O
the	O
peptidyl	O
transferase	O
reaction	O
during	O
protein	O
synthesis	O
(	O
K	O
.	O
H	O
.	O
Nierhaus	O
and	O
V	O
.	O
Montejo	O
(	O
1973	O
)	O
,	O
Proc	O
.	O
Nat	O
.	O
Acad	O
.	O
Sci	O
.	O
U	O
.	O
S	O
.	O
47	O
,	O
1588	O
-	O
1602	O
)	O
.	O

Three	O
proteins	O
(	O
L1	S-Protein
,	O
L3	S-Protein
,	O
and	O
L5	S-Protein
)	O
have	O
intermediate	O
levels	O
of	O
methylation	O
and	O
contain	O
about	O
0	O
.	O
4	O
-	O
0	O
.	O
6	O
methyl	O
groups	O
each	O
per	O
molecule	O
of	O
protein	O
.	O

Five	O
other	O
proteins	O
(	O
L7	S-Protein
,	O
L8	O
,	O
L9	S-Protein
,	O
L12	S-Protein
,	O
and	O
L18	S-Protein
)	O
are	O
also	O
methylated	O
to	O
a	O
slight	O
extent	O
(	O
-	O
0	O
.	O
1	O
methyl	O
group	O
/	O
molecule	O
of	O
protein	O
)	O
.	O

One	O
unknown	O
methylated	O
neutral	O
amino	O
acid	O
was	O
detected	O
in	O
protein	O
L11	S-Protein
and	O
at	O
least	O
one	O
and	O
possibly	O
two	O
other	O
unidentified	O
methylated	O
amino	O
acids	O
appeared	O
to	O
be	O
present	O
in	O
protein	O
L33	S-Protein
.	O

N	O
-	O
glycosylation	O
site	O
occupancy	O
of	O
rat	O
alpha	B-Protein
-	I-Protein
1	I-Protein
,	I-Protein
3	I-Protein
-	I-Protein
fucosyltransferase	I-Protein
IV	E-Protein
and	O
the	O
effect	O
of	O
glycosylation	O
on	O
enzymatic	O
activity	O
.	O

All	O
mammalian	O
alpha	O
-	O
1	O
,	O
3	O
-	O
fucosyltransferases	O
(	O
Fuc	O
-	O
Ts	O
)	O
so	O
far	O
characterized	O
have	O
potential	O
N	O
-	O
glycosylation	O
sites	O
,	O
but	O
the	O
role	O
of	O
these	O
sites	O
in	O
enzymatic	O
activity	O
or	O
localization	O
has	O
not	O
been	O
investigated	O
.	O

When	O
one	O
member	O
of	O
this	O
family	O
,	O
rFuc	B-Protein
-	I-Protein
TIV	E-Protein
,	O
is	O
expressed	O
in	O
bacteria	O
,	O
the	O
unglycosylated	O
form	O
of	O
rFuc	B-Protein
-	I-Protein
TIV	E-Protein
has	O
no	O
detectable	O
enzymatic	O
activity	O
.	O

The	O
two	O
potential	O
N	O
-	O
glycosylation	O
sites	O
of	O
rFuc	B-Protein
-	I-Protein
TIV	E-Protein
were	O
mutated	O
to	O
determine	O
site	O
occupancy	O
and	O
the	O
effect	O
of	O
site	O
occupancy	O
on	O
enzyme	O
activity	O
and	O
targeting	O
of	O
this	O
enzyme	O
.	O

Results	O
obtained	O
with	O
singly	O
mutated	O
forms	O
of	O
rFuc	B-Protein
-	I-Protein
TIV	E-Protein
indicate	O
that	O
both	O
sites	O
are	O
occupied	O
in	O
mammalian	O
cells	O
.	O

Lack	O
of	O
glycosylation	O
at	O
sites	O
117	O
-	O
119	O
,	O
218	O
-	O
220	O
,	O
or	O
both	O
of	O
these	O
sites	O
,	O
decreased	O
enzyme	O
activity	O
to	O
approximately	O
64	O
%	O
,	O
5	O
%	O
or	O
1	O
%	O
,	O
respectively	O
,	O
of	O
that	O
seen	O
in	O
the	O
unmutated	O
enzyme	O
.	O

These	O
results	O
show	O
that	O
N	O
-	O
glycosylation	O
is	O
necessary	O
for	O
optimal	O
enzyme	O
activity	O
,	O
with	O
glycosylation	O
at	O
site	O
218	O
-	O
220	O
playing	O
the	O
major	O
role	O
.	O

However	O
,	O
N	O
-	O
glycosylation	O
does	O
not	O
appear	O
to	O
affect	O
the	O
major	O
intracellular	O
location	O
of	O
the	O
enzyme	O
,	O
as	O
immunocytochemistry	O
reveals	O
the	O
same	O
perinuclear	O
pattern	O
of	O
staining	O
for	O
the	O
unglycosylated	O
mutants	O
as	O
is	O
seen	O
for	O
the	O
wild	O
-	O
type	O
rFuc	B-Protein
-	I-Protein
TIV	E-Protein
in	O
transfected	O
cells	O
.	O

Seminal	O
plasma	O
glycodelin	S-Protein
and	O
fertilization	O
in	O
vitro	O
.	O

Endometrium	O
-	O
derived	O
glycodelin	B-Protein
-	I-Protein
A	E-Protein
inhibits	O
sperm	O
-	O
egg	O
binding	O
,	O
whereas	O
differentially	O
glycosylated	O
seminal	O
plasma	O
glycodelin	B-Protein
-	I-Protein
S	E-Protein
does	O
not	O
.	O

The	O
difference	O
has	O
been	O
ascribed	O
to	O
the	O
specific	O
type	O
of	O
glycosylation	O
of	O
glycodelin	B-Protein
-	I-Protein
A	E-Protein
.	O

We	O
studied	O
whether	O
the	O
total	O
glycodelin	S-Protein
concentration	O
or	O
the	O
relative	O
glycodelin	B-Protein
-	I-Protein
A	E-Protein
concentration	O
in	O
seminal	O
plasma	O
are	O
related	O
to	O
the	O
in	O
vitro	O
fertilization	O
rate	O
of	O
oocytes	O
.	O

We	O
found	O
that	O
total	O
glycodelin	S-Protein
levels	O
were	O
significantly	O
higher	O
in	O
a	O
quartile	O
of	O
men	O
with	O
the	O
lowest	O
in	O
vitro	O
fertilization	O
rate	O
compared	O
with	O
the	O
remaining	O
3	O
quartiles	O
combined	O
(	O
P	O
=	O
.	O
01	O
)	O
.	O

However	O
,	O
for	O
predicting	O
low	O
fertilization	O
capacity	O
of	O
sperm	O
,	O
combining	O
the	O
glycodelin	S-Protein
and	O
sperm	O
concentrations	O
by	O
logistic	O
regression	O
analysis	O
did	O
not	O
significantly	O
increase	O
the	O
information	O
obtained	O
from	O
sperm	O
concentration	O
alone	O
.	O

We	O
used	O
specific	O
lectin	O
-	O
immunoassays	O
to	O
determine	O
whether	O
increased	O
glycodelin	B-Protein
-	I-Protein
A	E-Protein
-	O
type	O
glycosylation	O
in	O
seminal	O
plasma	O
would	O
be	O
related	O
to	O
failure	O
to	O
fertilize	O
.	O

No	O
difference	O
was	O
found	O
between	O
the	O
groups	O
with	O
high	O
fertilization	O
and	O
no	O
fertilization	O
in	O
vitro	O
.	O

It	O
is	O
concluded	O
that	O
,	O
although	O
high	O
seminal	O
plasma	O
total	O
glycodelin	S-Protein
level	O
has	O
a	O
tendency	O
of	O
being	O
associated	O
with	O
a	O
lower	O
fertilization	O
rate	O
,	O
the	O
difference	O
has	O
limited	O
value	O
to	O
predict	O
fertilization	O
in	O
vitro	O
.	O

Fluorescent	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
for	O
DNA	O
-	O
based	O
detection	O
of	O
prostate	O
cancer	O
in	O
bodily	O
fluids	O
.	O

Promoter	O
hypermethylation	O
of	O
the	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
P1	E-Protein
gene	O
(	O
GSTP1	S-Protein
)	O
is	O
the	O
most	O
frequent	O
DNA	O
alteration	O
in	O
prostatic	O
carcinoma	O
.	O

Because	O
this	O
epigenetic	O
DNA	O
alteration	O
can	O
be	O
reliably	O
detected	O
by	O
methylation	O
-	O
specific	O
PCR	O
(	O
MSP	O
)	O
,	O
we	O
applied	O
this	O
new	O
technique	O
for	O
molecular	O
detection	O
of	O
prostate	O
cancer	O
in	O
various	O
human	O
bodily	O
fluids	O
.	O

We	O
investigated	O
GSTP1	S-Protein
promoter	O
hypermethylation	O
in	O
DNA	O
isolated	O
from	O
plasma	O
,	O
serum	O
,	O
ejaculate	O
,	O
and	O
urine	O
after	O
prostate	O
massage	O
and	O
from	O
prostate	O
carcinoma	O
tissues	O
from	O
33	O
patients	O
with	O
prostate	O
cancer	O
and	O
26	O
control	O
patients	O
with	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
.	O

Fluorescently	O
labeled	O
MSP	O
products	O
were	O
analyzed	O
on	O
an	O
automated	O
gene	O
sequencer	O
.	O

Whereas	O
GSTP1	S-Protein
promoter	O
hypermethylation	O
was	O
not	O
detectable	O
by	O
MSP	O
in	O
prostate	O
tissue	O
and	O
bodily	O
fluids	O
from	O
patients	O
with	O
BPH	O
,	O
we	O
found	O
it	O
in	O
94	O
%	O
of	O
tumors	O
(	O
16	O
of	O
17	O
)	O
,	O
72	O
%	O
of	O
plasma	O
or	O
serum	O
samples	O
(	O
23	O
of	O
32	O
)	O
,	O
50	O
%	O
of	O
ejaculate	O
(	O
4	O
of	O
8	O
)	O
and	O
36	O
%	O
of	O
urine	O
(	O
4	O
of	O
11	O
)	O
from	O
patients	O
with	O
prostate	O
cancer	O
.	O

Additionally	O
,	O
MSP	O
identified	O
circulating	O
tumor	O
cells	O
in	O
30	O
%	O
(	O
10	O
of	O
33	O
)	O
of	O
prostate	O
cancer	O
patients	O
.	O

Analysis	O
of	O
GSTP1	S-Protein
promoter	O
hypermethylation	O
by	O
MSP	O
thus	O
provides	O
a	O
specific	O
tool	O
for	O
molecular	O
diagnosis	O
of	O
prostate	O
cancer	O
in	O
bodily	O
fluids	O
.	O

Coexpression	O
of	O
alpha	O
and	O
beta	O
subunits	O
of	O
prolyl	O
4	O
-	O
hydroxylase	O
stabilizes	O
the	O
triple	O
helix	O
of	O
recombinant	O
human	O
type	B-Protein
X	I-Protein
collagen	E-Protein
.	O

We	O
have	O
reported	O
previously	O
on	O
the	O
expression	O
of	O
recombinant	O
human	O
type	B-Protein
X	I-Protein
collagen	E-Protein
(	O
hrColX	S-Protein
)	O
in	O
HEK	O
293	O
and	O
HT	O
1080	O
cells	O
by	O
using	O
the	O
eukaryotic	O
expression	O
vector	O
pCMVsis	O
(	O
in	O
which	O
CMV	O
stands	O
for	O
cytomegalovirus	O
)	O
.	O

Several	O
stably	O
transfected	O
clones	O
secreted	O
full	O
-	O
length	O
triple	O
-	O
helical	O
hrColX	S-Protein
molecules	O
in	O
large	O
amounts	O
,	O
but	O
the	O
secreted	O
collagen	O
was	O
underhydroxylated	O
,	O
with	O
a	O
hydroxyproline	O
-	O
to	O
-	O
proline	O
ratio	O
of	O
0	O
.	O
25	O
and	O
a	O
melting	O
temperature	O
(	O
T	O
(	O
m	O
)	O
)	O
of	O
31	O
degrees	O
C	O
.	O

By	O
comparison	O
,	O
native	O
chicken	O
type	B-Protein
X	I-Protein
procollagen	E-Protein
has	O
a	O
T	O
(	O
m	O
)	O
of	O
46	O
degrees	O
C	O
.	O

To	O
stabilize	O
the	O
triple	O
helix	O
of	O
hrColX	S-Protein
,	O
an	O
hrColX	S-Protein
-	O
expressing	O
clone	O
(	O
A6	O
/	O
16	O
)	O
was	O
co	O
-	O
transfected	O
with	O
both	O
alpha	O
and	O
beta	O
subunits	O
of	O
human	O
prolyl	O
4	O
-	O
hydroxylase	O
.	O

Clones	O
were	O
selected	O
that	O
secreted	O
proalpha1	B-Protein
(	I-Protein
X	I-Protein
)	I-Protein
collagen	E-Protein
chains	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
75	O
kDa	O
and	O
an	O
increased	O
hydroxyproline	O
-	O
to	O
-	O
proline	O
ratio	O
of	O
close	O
to	O
0	O
.	O
5	O
.	O

As	O
a	O
result	O
of	O
enhanced	O
prolyl	O
hydroxylation	O
,	O
the	O
T	O
(	O
m	O
)	O
of	O
the	O
hrColX	S-Protein
was	O
increased	O
to	O
41	O
degrees	O
C	O
as	O
measured	O
by	O
CD	O
analysis	O
at	O
various	O
temperatures	O
.	O

The	O
CD	O
spectra	O
indicated	O
a	O
minimum	O
ellipticity	O
at	O
198	O
nm	O
and	O
a	O
peak	O
at	O
225	O
nm	O
at	O
20	O
degrees	O
C	O
,	O
confirming	O
the	O
presence	O
of	O
a	O
triple	O
helix	O
.	O

The	O
same	O
T	O
(	O
m	O
)	O
of	O
41	O
degrees	O
C	O
was	O
measured	O
for	O
the	O
triple	O
-	O
helical	O
core	O
fragments	O
of	O
hrColX	S-Protein
of	O
60	O
-	O
65	O
kDa	O
that	O
were	O
retained	O
after	O
brief	O
digestion	O
with	O
chymotrypsin	O
/	O
trypsin	O
at	O
increasing	O
temperatures	O
.	O

This	O
shows	O
that	O
the	O
human	O
cell	O
line	O
HEK	O
-	O
293	O
is	O
suitable	O
for	O
the	O
simultaneous	O
expression	O
of	O
three	O
genes	O
and	O
the	O
stable	O
production	O
of	O
substantial	O
amounts	O
of	O
recombinant	O
,	O
fully	O
hydroxylated	O
type	B-Protein
X	I-Protein
collagen	E-Protein
over	O
several	O
years	O
.	O

Biochemical	O
properties	O
and	O
cDNa	O
cloning	O
of	O
two	O
new	O
lectins	O
from	O
the	O
plasma	O
of	O
Tachypleus	O
tridentatus	O
:	O
Tachypleus	O
plasma	B-Protein
lectin	I-Protein
1	E-Protein
and	O
2	B-Protein
+	E-Protein
.	O

A	O
Sepharose	O
CL	O
-	O
4B	O
-	O
binding	O
protein	O
,	O
Tachypleus	O
plasma	B-Protein
lectin	I-Protein
1	E-Protein
(	O
TPL	B-Protein
-	I-Protein
1	E-Protein
)	O
,	O
and	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
binding	O
protein	O
,	O
Tachypleus	O
plasma	B-Protein
lectin	I-Protein
-	I-Protein
2	E-Protein
(	O
TPL	B-Protein
-	I-Protein
2	E-Protein
)	O
,	O
have	O
been	O
isolated	O
from	O
the	O
plasma	O
of	O
Tachypleus	O
tridentatus	O
and	O
biochemically	O
characterized	O
.	O

Each	O
protein	O
is	O
coded	O
by	O
a	O
homologous	O
family	O
of	O
multigenes	O
.	O

TPL	B-Protein
-	I-Protein
1	E-Protein
binds	O
to	O
Sepharose	O
CL	O
-	O
4B	O
and	O
was	O
eluted	O
with	O
buffer	O
containing	O
0	O
.	O
4	O
m	O
GlcNAc	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
TPL	B-Protein
-	I-Protein
1	E-Protein
consisted	O
of	O
232	O
amino	O
acids	O
with	O
an	O
N	O
-	O
glycosylation	O
site	O
,	O
Asn	O
-	O
Gly	O
-	O
Ser	O
at	O
residues	O
74	O
-	O
76	O
.	O

It	O
shares	O
a	O
65	O
%	O
sequence	O
identity	O
and	O
similar	O
internal	O
repeats	O
of	O
about	O
20	O
amino	O
acid	O
motifs	O
with	O
tachylectin	B-Protein
-	I-Protein
1	E-Protein
.	O

Tachylectin	B-Protein
-	I-Protein
1	E-Protein
was	O
identified	O
as	O
a	O
lipopolysaccharide	O
-	O
agarose	O
binding	O
nonglycosylated	O
protein	O
from	O
the	O
amebocytes	O
of	O
T	O
.	O
tridentatus	O
.	O

TPL	B-Protein
-	I-Protein
2	E-Protein
was	O
eluted	O
from	O
the	O
LPS	O
-	O
Sepharose	O
CL	O
-	O
4B	O
affinity	O
column	O
in	O
buffer	O
containing	O
0	O
.	O
4	O
m	O
GlcNAc	O
and	O
2	O
m	O
KCl	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
TPL	B-Protein
-	I-Protein
2	E-Protein
consisted	O
of	O
128	O
amino	O
acids	O
with	O
an	O
N	O
-	O
glycosylation	O
site	O
,	O
Asn	O
-	O
Cys	O
-	O
Thr	O
,	O
at	O
positions	O
3	O
-	O
5	O
.	O

It	O
shares	O
an	O
80	O
%	O
sequence	O
identity	O
with	O
tachylectin	B-Protein
-	I-Protein
3	E-Protein
,	O
isolated	O
from	O
the	O
amebocytes	O
of	O
T	O
.	O
tridentatus	O
.	O

TPL	B-Protein
-	I-Protein
2	E-Protein
purified	O
by	O
LPS	O
-	O
affinity	O
column	O
from	O
the	O
plasma	O
predominantly	O
exists	O
as	O
a	O
dimer	O
of	O
a	O
glycoprotein	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
36	O
kDa	O
.	O

Tachylectin	B-Protein
-	I-Protein
3	E-Protein
is	O
an	O
intracellular	O
nonglycosylated	O
protein	O
that	O
also	O
exists	O
as	O
a	O
dimer	O
in	O
solution	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
29	O
kDa	O
.	O

It	O
recognizes	O
Gram	O
-	O
negative	O
bacteria	O
through	O
the	O
0	O
-	O
antigen	O
of	O
LPS	O
.	O

Western	O
blot	O
analyses	O
showed	O
that	O
,	O
in	O
the	O
plasma	O
,	O
TPL	B-Protein
-	I-Protein
1	E-Protein
and	O
TPL	B-Protein
-	I-Protein
2	E-Protein
exist	O
predominantly	O
as	O
oligomers	O
with	O
molecular	O
masses	O
above	O
60	O
kDa	O
.	O

They	O
both	O
bind	O
to	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacteria	O
,	O
and	O
this	O
binding	O
is	O
inhibited	O
by	O
GlcNAc	O
.	O

Possible	O
binding	O
site	O
of	O
TPL	B-Protein
-	I-Protein
1	E-Protein
and	O
TPL	B-Protein
-	I-Protein
2	E-Protein
to	O
the	O
bacteria	O
could	O
be	O
at	O
the	O
NAc	O
moiety	O
of	O
GlcNAc	O
-	O
MurNAc	O
of	O
the	O
peptidoglycan	O
.	O

The	O
physiological	O
function	O
of	O
TPL	B-Protein
-	I-Protein
1	E-Protein
and	O
TPL	B-Protein
-	I-Protein
2	E-Protein
is	O
most	O
likely	O
related	O
to	O
their	O
ability	O
to	O
form	O
a	O
cluster	O
of	O
interlocking	O
molecules	O
to	O
immobilize	O
and	O
entrap	O
invading	O
organisms	O
.	O

Carboxyl	O
-	O
methylation	O
of	O
prenylated	O
calmodulin	O
CaM53	S-Protein
is	O
required	O
for	O
efficient	O
plasma	O
membrane	O
targeting	O
of	O
the	O
protein	O
.	O

Prenylation	O
is	O
necessary	O
for	O
association	O
of	O
the	O
petunia	O
calmodulin	O
CaM53	S-Protein
with	O
the	O
plasma	O
membrane	O
.	O

To	O
determine	O
whether	O
post	O
-	O
prenylation	O
processing	O
of	O
the	O
protein	O
was	O
also	O
required	O
for	O
plasma	O
membrane	O
targeting	O
,	O
we	O
studied	O
the	O
subcellular	O
localization	O
of	O
a	O
GFP	S-Protein
-	O
labelled	O
CaM53	S-Protein
reporter	O
in	O
yeast	O
and	O
plant	O
cells	O
.	O

Blocking	O
of	O
carboxyl	O
-	O
methylation	O
of	O
prenylated	O
proteins	O
either	O
by	O
a	O
specific	O
inhibitor	O
or	O
in	O
mutant	O
yeast	O
cells	O
resulted	O
in	O
localization	O
of	O
green	O
fluorescence	O
to	O
what	O
appears	O
to	O
be	O
the	O
endomembrane	O
system	O
,	O
in	O
contrast	O
with	O
the	O
plasma	O
membrane	O
localization	O
observed	O
in	O
control	O
cells	O
.	O

We	O
show	O
that	O
a	O
prenyl	O
-	O
cysteine	O
methyltransferase	O
(	O
PCM	O
)	O
activity	O
that	O
carboxyl	O
-	O
methylates	O
prenylated	O
CaM53	S-Protein
also	O
exists	O
in	O
plant	O
cells	O
,	O
and	O
that	O
it	O
is	O
required	O
for	O
efficient	O
plasma	O
membrane	O
targeting	O
.	O

We	O
also	O
report	O
an	O
Arabidopsis	O
gene	O
with	O
homology	O
to	O
PCM	O
and	O
demonstrate	O
that	O
it	O
encodes	O
a	O
protein	O
with	O
PCM	O
activity	O
that	O
localizes	O
to	O
the	O
endomembrane	O
system	O
of	O
plant	O
cells	O
,	O
similar	O
to	O
prenylated	O
but	O
unmethylated	O
CaM53	S-Protein
.	O

Together	O
,	O
our	O
data	O
suggest	O
that	O
,	O
following	O
prenylation	O
,	O
CaM53	S-Protein
is	O
probably	O
associated	O
with	O
the	O
endomembrane	O
system	O
,	O
where	O
a	O
PCM	O
activity	O
methylates	O
the	O
prenylated	O
protein	O
prior	O
to	O
targeting	O
it	O
to	O
its	O
final	O
destination	O
in	O
the	O
plasma	O
membrane	O
.	O

Negative	O
regulation	O
of	O
T	O
-	O
cell	O
activation	O
and	O
autoimmunity	O
by	O
Mgat5	S-Protein
N	O
-	O
glycosylation	O
.	O

T	O
-	O
cell	O
activation	O
requires	O
clustering	O
of	O
a	O
threshold	O
number	O
of	O
T	O
-	O
cell	O
receptors	O
(	O
TCRs	O
)	O
at	O
the	O
site	O
of	O
antigen	O
presentation	O
,	O
a	O
number	O
that	O
is	O
reduced	O
by	O
CD28	S-Protein
co	O
-	O
receptor	O
recruitment	O
of	O
signalling	O
proteins	O
to	O
TCRs	O
.	O

Here	O
we	O
demonstrate	O
that	O
a	O
deficiency	O
in	O
beta1	B-Protein
,	I-Protein
6	I-Protein
N	I-Protein
-	I-Protein
acetylglucosaminyltransferase	I-Protein
V	E-Protein
(	O
Mgat5	S-Protein
)	O
,	O
an	O
enzyme	O
in	O
the	O
N	O
-	O
glycosylation	O
pathway	O
,	O
lowers	O
T	O
-	O
cell	O
activation	O
thresholds	O
by	O
directly	O
enhancing	O
TCR	O
clustering	O
.	O

Mgat5	S-Protein
-	O
deficient	O
mice	O
showed	O
kidney	O
autoimmune	O
disease	O
,	O
enhanced	O
delayed	O
-	O
type	O
hypersensitivity	O
,	O
and	O
increased	O
susceptibility	O
to	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

Recruitment	O
of	O
TCRs	O
to	O
agonist	O
-	O
coated	O
beads	O
,	O
TCR	O
signalling	O
,	O
actin	O
microfilament	O
re	O
-	O
organization	O
,	O
and	O
agonist	O
-	O
induced	O
proliferation	O
were	O
all	O
enhanced	O
in	O
Mgat5	S-Protein
-	O
/	O
-	O
T	O
cells	O
.	O

Mgat5	S-Protein
initiates	O
GlcNAc	O
beta1	O
,	O
6	O
branching	O
on	O
N	O
-	O
glycans	O
,	O
thereby	O
increasing	O
N	O
-	O
acetyllactosamine	O
,	O
the	O
ligand	O
for	O
galectins	O
,	O
which	O
are	O
proteins	O
known	O
to	O
modulate	O
T	O
-	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O

Indeed	O
,	O
galectin	B-Protein
-	I-Protein
3	E-Protein
was	O
associated	O
with	O
the	O
TCR	O
complex	O
at	O
the	O
cell	O
surface	O
,	O
an	O
interaction	O
dependent	O
on	O
Mgat5	S-Protein
.	O

Pre	O
-	O
treatment	O
of	O
wild	O
-	O
type	O
T	O
cells	O
with	O
lactose	O
to	O
compete	O
for	O
galectin	O
binding	O
produced	O
a	O
phenocopy	O
of	O
Mgat5	S-Protein
clustering	O
-	O
/	O
-	O
TCR	O
.	O

These	O
data	O
indicate	O
that	O
a	O
galectin	O
-	O
glycoprotein	O
lattice	O
strengthened	O
by	O
Mgat5	S-Protein
-	O
modified	O
glycans	O
restricts	O
TCR	O
recruitment	O
to	O
the	O
site	O
of	O
antigen	O
presentation	O
.	O

Dysregulation	O
of	O
Mgat5	S-Protein
in	O
humans	O
may	O
increase	O
susceptibility	O
to	O
autoimmune	O
diseases	O
,	O
such	O
as	O
multiple	O
sclerosis	O
.	O

Acetylation	O
of	O
TAF	B-Protein
(	I-Protein
I	I-Protein
)	I-Protein
68	E-Protein
,	O
a	O
subunit	O
of	O
TIF	O
-	O
IB	O
/	O
SL1	O
,	O
activates	O
RNA	O
polymerase	O
I	O
transcription	O
.	O

Mammalian	O
rRNA	O
genes	O
are	O
preceded	O
by	O
a	O
terminator	O
element	O
that	O
is	O
recognized	O
by	O
the	O
transcription	O
termination	O
factor	O
TTF	B-Protein
-	I-Protein
I	E-Protein
.	O

In	O
exploring	O
the	O
functional	O
significance	O
of	O
the	O
promoter	O
-	O
proximal	O
terminator	O
,	O
we	O
found	O
that	O
TTF	B-Protein
-	I-Protein
I	E-Protein
associates	O
with	O
the	O
p300	B-Protein
/	I-Protein
CBP	I-Protein
-	I-Protein
associated	I-Protein
factor	E-Protein
PCAF	S-Protein
,	O
suggesting	O
that	O
TTF	B-Protein
-	I-Protein
I	E-Protein
may	O
target	O
histone	S-Protein
acetyltransferase	O
to	O
the	O
rDNA	O
promoter	O
.	O

We	O
demonstrate	O
that	O
PCAF	S-Protein
acetylates	O
TAF	B-Protein
(	I-Protein
I	I-Protein
)	I-Protein
68	E-Protein
,	O
the	O
second	O
largest	O
subunit	O
of	O
the	O
TATA	O
box	O
-	O
binding	O
protein	O
(	O
TBP	O
)	O
-	O
containing	O
factor	O
TIF	O
-	O
IB	O
/	O
SL1	O
,	O
and	O
acetylation	O
enhances	O
binding	O
of	O
TAF	B-Protein
(	I-Protein
I	I-Protein
)	I-Protein
68	E-Protein
to	O
the	O
rDNA	O
promoter	O
.	O

Moreover	O
,	O
PCAF	S-Protein
stimulates	O
RNA	O
polymerase	O
I	O
(	O
Pol	O
I	O
)	O
transcription	O
in	O
a	O
reconstituted	O
in	O
vitro	O
system	O
.	O

Consistent	O
with	O
acetylation	O
of	O
TIF	O
-	O
IB	O
/	O
SL1	O
being	O
required	O
for	O
rDNA	O
transcription	O
,	O
the	O
NAD	O
(	O
+	O
)	O
-	O
dependent	O
histone	S-Protein
deacetylase	O
mSir2a	S-Protein
deacetylates	O
TAF	B-Protein
(	I-Protein
I	I-Protein
)	I-Protein
68	E-Protein
and	O
represses	O
Pol	O
I	O
transcription	O
.	O

The	O
results	O
demonstrate	O
that	O
acetylation	O
of	O
the	O
basal	O
Pol	O
I	O
transcription	O
machinery	O
has	O
functional	O
consequences	O
and	O
suggest	O
that	O
reversible	O
acetylation	O
of	O
TIF	O
-	O
IB	O
/	O
SL1	O
may	O
be	O
an	O
effective	O
means	O
to	O
regulate	O
rDNA	O
transcription	O
in	O
response	O
to	O
external	O
signals	O
.	O

Direct	O
acetylation	O
of	O
the	O
estrogen	B-Protein
receptor	I-Protein
alpha	E-Protein
hinge	O
region	O
by	O
p300	S-Protein
regulates	O
transactivation	O
and	O
hormone	O
sensitivity	O
.	O

Regulation	O
of	O
nuclear	O
receptor	O
gene	O
expression	O
involves	O
dynamic	O
and	O
coordinated	O
interactions	O
with	O
histone	S-Protein
acetyl	O
transferase	O
(	O
HAT	O
)	O
and	O
deacetylase	O
complexes	O
.	O

The	O
estrogen	B-Protein
receptor	E-Protein
(	O
ERalpha	S-Protein
)	O
contains	O
two	O
transactivation	O
domains	O
regulating	O
ligand	O
-	O
independent	O
and	O
-	O
dependent	O
gene	O
transcription	O
(	O
AF	O
-	O
1	O
and	O
AF	O
-	O
2	O
(	O
activation	O
functions	O
1	O
and	O
2	O
)	O
)	O
.	O

ERalpha	S-Protein
-	O
regulated	O
gene	O
expression	O
involves	O
interactions	O
with	O
cointegrators	O
(	O
e	O
.	O
g	O
.	O
p300	S-Protein
/	O
CBP	S-Protein
,	O
P	B-Protein
/	I-Protein
CAF	E-Protein
)	O
that	O
have	O
the	O
capacity	O
to	O
modify	O
core	O
histone	S-Protein
acetyl	O
groups	O
.	O

Here	O
we	O
show	O
that	O
the	O
ERalpha	S-Protein
is	O
acetylated	O
in	O
vivo	O
.	O

p300	S-Protein
,	O
but	O
not	O
P	B-Protein
/	I-Protein
CAF	E-Protein
,	O
selectively	O
and	O
directly	O
acetylated	O
the	O
ERalpha	S-Protein
at	O
lysine	O
residues	O
within	O
the	O
ERalpha	S-Protein
hinge	O
/	O
ligand	O
binding	O
domain	O
.	O

Substitution	O
of	O
these	O
residues	O
with	O
charged	O
or	O
polar	O
residues	O
dramatically	O
enhanced	O
ERalpha	S-Protein
hormone	O
sensitivity	O
without	O
affecting	O
induction	O
by	O
MAPK	O
signaling	O
,	O
suggesting	O
that	O
direct	O
ERalpha	S-Protein
acetylation	O
normally	O
suppresses	O
ligand	O
sensitivity	O
.	O

These	O
ERalpha	S-Protein
lysine	O
residues	O
also	O
regulated	O
transcriptional	O
activation	O
by	O
histone	S-Protein
deacetylase	O
inhibitors	O
and	O
p300	S-Protein
.	O

The	O
conservation	O
of	O
the	O
ERalpha	S-Protein
acetylation	O
motif	O
in	O
a	O
phylogenetic	O
subset	O
of	O
nuclear	O
receptors	O
suggests	O
that	O
direct	O
acetylation	O
of	O
nuclear	O
receptors	O
may	O
contribute	O
to	O
additional	O
signaling	O
pathways	O
involved	O
in	O
metabolism	O
and	O
development	O
.	O

Coactivator	O
p300	S-Protein
acetylates	O
the	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
-	I-Protein
2	E-Protein
in	O
U937	O
cells	O
following	O
phorbol	O
ester	O
treatment	O
.	O

Interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
-	I-Protein
2	E-Protein
(	O
IRF	B-Protein
-	I-Protein
2	E-Protein
)	O
is	O
a	O
transcription	O
factor	O
of	O
the	O
IRF	O
family	O
that	O
represses	O
interferon	O
-	O
mediated	O
gene	O
expression	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
human	O
monocytic	O
U937	O
cells	O
express	O
truncated	O
forms	O
of	O
IRF	B-Protein
-	I-Protein
2	E-Protein
containing	O
the	O
DNA	O
binding	O
domain	O
but	O
lacking	O
much	O
of	O
the	O
C	O
-	O
terminal	O
regulatory	O
domain	O
.	O

U937	O
cells	O
are	O
shown	O
to	O
respond	O
to	O
phorbol	O
ester	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
to	O
induce	O
expression	O
of	O
histone	S-Protein
acetylases	O
p300	S-Protein
and	O
p300	B-Protein
/	I-Protein
CBP	I-Protein
-	I-Protein
associated	I-Protein
factor	E-Protein
(	O
PCAF	S-Protein
)	O
.	O

In	O
addition	O
,	O
TPA	O
treatment	O
led	O
to	O
the	O
appearance	O
of	O
full	O
-	O
length	O
IRF	B-Protein
-	I-Protein
2	E-Protein
,	O
along	O
with	O
a	O
reduction	O
of	O
the	O
truncated	O
protein	O
.	O

Interestingly	O
,	O
full	O
-	O
length	O
IRF	B-Protein
-	I-Protein
2	E-Protein
in	O
TPA	O
-	O
treated	O
U937	O
cells	O
occurred	O
as	O
a	O
complex	O
with	O
p300	S-Protein
as	O
well	O
as	O
PCAF	S-Protein
and	O
was	O
itself	O
acetylated	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
recombinant	O
IRF	B-Protein
-	I-Protein
2	E-Protein
was	O
acetylated	O
by	O
p300	S-Protein
and	O
to	O
a	O
lesser	O
degree	O
by	O
PCAF	S-Protein
in	O
vitro	O
.	O

Another	O
IRF	O
member	O
,	O
IRF	B-Protein
-	I-Protein
1	E-Protein
,	O
an	O
activator	O
of	O
interferon	O
-	O
mediated	O
transcription	O
,	O
was	O
also	O
acetylated	O
in	O
vitro	O
by	O
these	O
acetylases	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
the	O
addition	O
of	O
IRF	B-Protein
-	I-Protein
2	E-Protein
but	O
not	O
IRF	B-Protein
-	I-Protein
1	E-Protein
inhibits	O
core	O
histone	S-Protein
acetylation	O
by	O
p300	S-Protein
in	O
vitro	O
.	O

The	O
addition	O
of	O
IRF	B-Protein
-	I-Protein
2	E-Protein
also	O
inhibited	O
acetylation	O
of	O
nucleosomal	O
histones	S-Protein
in	O
TPA	O
-	O
treated	O
U937	O
cells	O
.	O

Acetylated	O
IRF	B-Protein
-	I-Protein
2	E-Protein
may	O
affect	O
local	O
chromatin	O
structure	O
in	O
vivo	O
by	O
inhibiting	O
core	O
histone	S-Protein
acetylation	O
and	O
may	O
serve	O
as	O
a	O
mechanism	O
by	O
which	O
IRF	B-Protein
-	I-Protein
2	E-Protein
negatively	O
regulates	O
interferon	O
-	O
inducible	O
transcription	O
.	O

The	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
the	O
Trichoderma	O
reesei	O
family	O
12	O
endoglucanase	B-Protein
3	E-Protein
,	O
Cel12A	S-Protein
,	O
at	O
1	O
.	O
9	O
A	O
resolution	O
.	O

We	O
present	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
Trichoderma	O
reesei	O
endoglucanase	B-Protein
3	E-Protein
(	O
Cel12A	S-Protein
)	O
,	O
a	O
small	O
,	O
218	O
amino	O
acid	O
residue	O
(	O
24	O
.	O
5	O
kDa	O
)	O
,	O
neutral	O
pI	O
,	O
glycoside	O
hydrolase	O
family	O
12	O
cellulase	O
that	O
lacks	O
a	O
cellulose	O
-	O
binding	O
module	O
.	O

The	O
structure	O
has	O
been	O
determined	O
using	O
X	O
-	O
ray	O
crystallography	O
and	O
refined	O
to	O
1	O
.	O
9	O
A	O
resolution	O
.	O

The	O
asymmetric	O
unit	O
consists	O
of	O
six	O
non	O
-	O
crystallographic	O
symmetry	O
-	O
related	O
molecules	O
that	O
were	O
exploited	O
to	O
improve	O
initial	O
multiple	O
isomorphous	O
replacement	O
phasing	O
,	O
and	O
subsequent	O
structure	O
refinement	O
.	O

The	O
enzyme	O
contains	O
one	O
disulfide	O
bridge	O
and	O
is	O
glycosylated	O
at	O
Asp164	O
by	O
a	O
single	O
N	O
-	O
acetyl	O
glucosamine	O
residue	O
.	O

The	O
protein	O
has	O
the	O
expected	O
fold	O
for	O
a	O
glycoside	O
hydrolase	O
clan	O
-	O
C	O
family	O
12	O
enzyme	O
.	O

It	O
contains	O
two	O
beta	O
-	O
sheets	O
,	O
of	O
six	O
and	O
nine	O
strands	O
,	O
packed	O
on	O
top	O
of	O
one	O
another	O
,	O
and	O
one	O
alpha	O
-	O
helix	O
.	O

The	O
concave	O
surface	O
of	O
the	O
nine	O
-	O
stranded	O
beta	O
-	O
sheet	O
forms	O
a	O
large	O
substrate	O
-	O
binding	O
groove	O
in	O
which	O
the	O
active	O
-	O
site	O
residues	O
are	O
located	O
.	O

In	O
the	O
active	O
site	O
,	O
we	O
find	O
a	O
carboxylic	O
acid	O
trio	O
,	O
similar	O
to	O
that	O
of	O
glycoside	O
hydrolase	O
families	O
7	O
and	O
16	O
.	O

The	O
strictly	O
conserved	O
Asp99	O
hydrogen	O
bonds	O
to	O
the	O
nucleophile	O
,	O
the	O
invariant	O
Glu116	O
.	O

The	O
binding	O
crevice	O
is	O
lined	O
with	O
both	O
aromatic	O
and	O
polar	O
amino	O
acid	O
side	O
-	O
chains	O
which	O
may	O
play	O
a	O
role	O
in	O
substrate	O
binding	O
.	O

The	O
structure	O
of	O
the	O
fungal	O
family	O
12	O
enzyme	O
presented	O
here	O
allows	O
a	O
complete	O
structural	O
characterization	O
of	O
the	O
glycoside	O
hydrolase	O
-	O
C	O
clan	O
.	O

Determination	O
of	O
essential	O
amino	O
acids	O
involved	O
in	O
the	O
CD4	S-Protein
-	O
independent	O
tropism	O
of	O
the	O
X4	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
m7NDK	O
isolate	O
:	O
role	O
of	O
potential	O
N	O
glycosylations	O
in	O
the	O
C2	O
and	O
V3	O
regions	O
of	O
gp120	S-Protein
.	O

Seven	O
mutations	O
in	O
the	O
C2	O
,	O
V3	O
,	O
and	O
C3	O
regions	O
of	O
gp120	S-Protein
are	O
implicated	O
in	O
the	O
tropism	O
of	O
the	O
first	O
CD4	S-Protein
-	O
independent	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
isolate	O
,	O
m7NDK	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
revealed	O
that	O
three	O
amino	O
acids	O
are	O
essential	O
to	O
maintain	O
this	O
tropism	O
,	O
one	O
in	O
the	O
C2	O
region	O
and	O
two	O
in	O
the	O
V3	O
loop	O
.	O

Two	O
mutations	O
implied	O
N	O
glycosylation	O
modifications	O
.	O

Epigenetics	O
of	O
latent	O
Epstein	O
-	O
Barr	O
virus	O
genomes	O
:	O
high	O
resolution	O
methylation	O
analysis	O
of	O
the	O
bidirectional	O
promoter	O
region	O
of	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	E-Protein
and	O
2B	S-Protein
genes	O
.	O

We	O
analysed	O
the	O
methylation	O
patterns	O
of	O
CpG	O
dinucleotides	O
in	O
a	O
bidirectional	O
promoter	O
region	O
(	O
LRS	O
,	O
LMP	B-Protein
1	E-Protein
regulatory	O
sequences	O
)	O
of	O
latent	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
genomes	O
using	O
automated	O
fluorescent	O
genomic	O
sequencing	O
after	O
bisulfite	O
-	O
induced	O
modification	O
of	O
DNA	O
.	O

Transcripts	O
for	O
two	O
latent	O
membrane	O
proteins	O
,	O
LMP	B-Protein
1	E-Protein
(	O
a	O
transforming	O
protein	O
)	O
and	O
LMP	B-Protein
2B	E-Protein
,	O
are	O
initiated	O
in	O
this	O
region	O
in	O
opposite	O
directions	O
.	O

We	O
found	O
that	O
B	O
cell	O
lines	O
and	O
a	O
clone	O
expressing	O
LMP	B-Protein
1	E-Protein
carried	O
EBV	O
genomes	O
with	O
unmethylated	O
or	O
hypomethylated	O
LRS	O
,	O
while	O
highly	O
methylated	O
CpG	O
dinucleotides	O
were	O
present	O
at	O
each	O
position	O
or	O
at	O
discrete	O
sites	O
and	O
within	O
hypermethylated	O
regions	O
in	O
LMP	B-Protein
1	E-Protein
negative	O
cells	O
.	O

Comparison	O
of	O
high	O
resolution	O
methylation	O
maps	O
suggests	O
that	O
CpG	O
methylation	O
-	O
mediated	O
direct	O
interference	O
with	O
binding	O
of	O
nuclear	O
factors	O
LBF	B-Protein
2	E-Protein
,	O
3	S-Protein
,	O
7	S-Protein
,	O
AML1	S-Protein
/	O
LBF1	S-Protein
,	O
LBF5	S-Protein
and	O
LBF6	S-Protein
or	O
methylation	O
of	O
CpGs	O
within	O
an	O
E	O
-	O
box	O
sequence	O
(	O
where	O
activators	O
as	O
well	O
as	O
repressors	O
can	O
bind	O
)	O
is	O
not	O
the	O
major	O
mechanism	O
in	O
silencing	O
of	O
the	O
LMP	B-Protein
1	E-Protein
promoter	O
.	O

Although	O
a	O
role	O
for	O
CpG	O
methylation	O
within	O
binding	O
sites	O
of	O
Sp1	S-Protein
and	O
3	S-Protein
,	O
ATF	O
/	O
CRE	O
and	O
a	O
sis	O
-	O
inducible	O
factor	O
(	O
SIF	O
)	O
cannot	O
be	O
excluded	O
,	O
hypermethylation	O
of	O
LRS	O
or	O
regions	O
within	O
LRS	O
in	O
LMP	B-Protein
1	E-Protein
negative	O
cells	O
suggests	O
a	O
role	O
for	O
an	O
indirect	O
mechanism	O
,	O
via	O
methylcytosine	O
binding	O
proteins	O
,	O
in	O
silencing	O
of	O
the	O
LMP	B-Protein
1	E-Protein
promoter	O
.	O

Methyl	O
CpG	O
binding	O
proteins	O
:	O
coupling	O
chromatin	O
architecture	O
to	O
gene	O
regulation	O
.	O

A	O
correlation	O
between	O
DNA	O
methylation	O
and	O
transcriptional	O
silencing	O
has	O
existed	O
for	O
many	O
years	O
.	O

Recently	O
,	O
substantial	O
progress	O
has	O
been	O
reported	O
in	O
the	O
search	O
for	O
proteins	O
that	O
interpret	O
the	O
regulatory	O
information	O
inherent	O
in	O
DNA	O
methylation	O
and	O
translate	O
this	O
information	O
into	O
functional	O
states	O
,	O
resulting	O
in	O
the	O
identification	O
of	O
a	O
family	O
of	O
highly	O
conserved	O
proteins	O
,	O
the	O
MBD	O
family	O
.	O

Direct	O
connections	O
between	O
these	O
proteins	O
and	O
histone	S-Protein
modification	O
enzymes	O
have	O
emerged	O
as	O
a	O
common	O
theme	O
,	O
implying	O
that	O
DNA	O
methylation	O
exerts	O
its	O
effects	O
primarily	O
through	O
repressive	O
chromatin	O
architecture	O
.	O

Recent	O
structural	O
determinations	O
of	O
the	O
DNA	O
binding	O
domain	O
of	O
two	O
MBD	O
family	O
members	O
,	O
MeCP2	S-Protein
and	O
MBD1	S-Protein
,	O
provide	O
a	O
framework	O
to	O
model	O
the	O
interactions	O
of	O
this	O
family	O
with	O
DNA	O
.	O

Comparative	O
sequence	O
analysis	O
and	O
experimental	O
DNA	O
binding	O
data	O
can	O
be	O
interpreted	O
using	O
this	O
structural	O
framework	O
allowing	O
one	O
to	O
contrast	O
the	O
members	O
of	O
the	O
MBD	O
family	O
with	O
each	O
other	O
and	O
to	O
predict	O
the	O
properties	O
of	O
new	O
family	O
members	O
.	O

The	O
identification	O
of	O
mutations	O
in	O
MeCP2	S-Protein
,	O
the	O
founding	O
member	O
of	O
this	O
family	O
,	O
as	O
causal	O
for	O
the	O
neurological	O
developmental	O
disorder	O
Rett	O
Syndrome	O
provides	O
additional	O
information	O
regarding	O
amino	O
acid	O
residues	O
crucial	O
to	O
the	O
functions	O
of	O
this	O
interesting	O
protein	O
family	O
.	O

Independent	O
function	O
of	O
two	O
destruction	O
domains	O
in	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
alpha	O
chains	O
activated	O
by	O
prolyl	O
hydroxylation	O
.	O

Oxygen	O
-	O
dependent	O
proteolytic	O
destruction	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
alpha	O
(	O
HIF	O
-	O
alpha	O
)	O
subunits	O
plays	O
a	O
central	O
role	O
in	O
regulating	O
transcriptional	O
responses	O
to	O
hypoxia	O
.	O

Recent	O
studies	O
have	O
defined	O
a	O
key	O
function	O
for	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumour	I-Protein
suppressor	E-Protein
E3	O
ubiquitin	S-Protein
ligase	O
(	O
VHLE3	S-Protein
)	O
in	O
this	O
process	O
,	O
and	O
have	O
defined	O
an	O
interaction	O
with	O
HIF	B-Protein
-	I-Protein
1	I-Protein
alpha	E-Protein
that	O
is	O
regulated	O
by	O
prolyl	O
hydroxylation	O
.	O

Here	O
we	O
show	O
that	O
two	O
independent	O
regions	O
within	O
the	O
HIF	O
-	O
alpha	O
oxygen	O
-	O
dependent	O
degradation	O
domain	O
(	O
ODDD	O
)	O
are	O
targeted	O
for	O
ubiquitylation	O
by	O
VHLE3	S-Protein
in	O
a	O
manner	O
dependent	O
upon	O
prolyl	O
hydroxylation	O
.	O

In	O
a	O
series	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
assays	O
,	O
we	O
demonstrate	O
the	O
independent	O
and	O
non	O
-	O
redundant	O
operation	O
of	O
each	O
site	O
in	O
regulation	O
of	O
the	O
HIF	O
system	O
.	O

Both	O
sites	O
contain	O
a	O
common	O
core	O
motif	O
,	O
but	O
differ	O
both	O
in	O
overall	O
sequence	O
and	O
in	O
the	O
conditions	O
under	O
which	O
they	O
bind	O
to	O
the	O
VHLE3	S-Protein
ligase	O
complex	O
.	O

The	O
definition	O
of	O
two	O
independent	O
destruction	O
domains	O
implicates	O
a	O
more	O
complex	O
system	O
of	O
pVHL	S-Protein
-	O
HIF	O
-	O
alpha	O
interactions	O
,	O
but	O
reinforces	O
the	O
role	O
of	O
prolyl	O
hydroxylation	O
as	O
an	O
oxygen	O
-	O
dependent	O
destruction	O
signal	O
.	O

A	O
conserved	O
family	O
of	O
prolyl	O
-	O
4	O
-	O
hydroxylases	O
that	O
modify	O
HIF	O
.	O

Mammalian	O
cells	O
respond	O
to	O
changes	O
in	O
oxygen	O
availability	O
through	O
a	O
conserved	O
pathway	O
that	O
is	O
regulated	O
by	O
the	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
.	O

The	O
alpha	O
subunit	O
of	O
HIF	O
is	O
targeted	O
for	O
degradation	O
under	O
normoxic	O
conditions	O
by	O
a	O
ubiquitin	S-Protein
-	O
ligase	O
complex	O
that	O
recognizes	O
a	O
hydroxylated	O
proline	O
residue	O
in	O
HIF	O
.	O

We	O
identified	O
a	O
conserved	O
family	O
of	O
HIF	O
prolyl	O
hydoxylase	O
(	O
HPH	O
)	O
enzymes	O
that	O
appear	O
to	O
be	O
responsible	O
for	O
this	O
posttranslational	O
modification	O
.	O

In	O
cultured	O
mammalian	O
cells	O
,	O
inappropriate	O
accumulation	O
of	O
HIF	O
caused	O
by	O
forced	O
expression	O
of	O
the	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
subunit	O
under	O
normoxic	O
conditions	O
was	O
attenuated	O
by	O
coexpression	O
of	O
HPH	O
.	O

Suppression	O
of	O
HPH	O
in	O
cultured	O
Drosophila	O
melanogaster	O
cells	O
by	O
RNA	O
interference	O
resulted	O
in	O
elevated	O
expression	O
of	O
a	O
hypoxia	O
-	O
inducible	O
gene	O
(	O
LDH	S-Protein
,	O
encoding	O
lactate	B-Protein
dehydrogenase	E-Protein
)	O
under	O
normoxic	O
conditions	O
.	O

These	O
findings	O
indicate	O
that	O
HPH	O
is	O
an	O
essential	O
component	O
of	O
the	O
pathway	O
through	O
which	O
cells	O
sense	O
oxygen	O
.	O

Suppression	O
of	O
tumor	O
-	O
related	O
glycosylation	O
of	O
cell	O
surface	O
receptors	O
by	O
the	O
16	O
-	O
kDa	O
membrane	O
subunit	O
of	O
vacuolar	O
H	O
+	O
-	O
ATPase	O
.	O

The	O
glycosylation	O
of	O
integrins	O
and	O
other	O
cell	O
surface	O
receptors	O
is	O
altered	O
in	O
many	O
transformed	O
cells	O
.	O

Notably	O
,	O
an	O
increase	O
in	O
the	O
number	O
of	O
beta1	O
,	O
6	O
-	O
branched	O
N	O
-	O
linked	O
oligosaccharides	O
correlates	O
strongly	O
with	O
invasive	O
growth	O
of	O
cells	O
.	O

An	O
ectopic	O
expression	O
of	O
the	O
Golgi	O
enzyme	O
N	B-Protein
-	I-Protein
acetylglucosaminyltransferase	I-Protein
V	E-Protein
(	O
GlcNAc	B-Protein
-	I-Protein
TV	E-Protein
)	O
,	O
which	O
forms	O
beta1	O
,	O
6	O
linkages	O
,	O
promotes	O
metastasis	O
of	O
a	O
number	O
of	O
cell	O
types	O
.	O

It	O
is	O
shown	O
here	O
that	O
the	O
16	O
-	O
kDa	O
transmembrane	O
subunit	O
(	O
16K	O
)	O
of	O
vacuolar	O
H	O
(	O
+	O
)	O
-	O
ATPase	O
suppresses	O
beta1	O
,	O
6	O
branching	O
of	O
beta	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
integrin	E-Protein
and	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptor	E-Protein
.	O

Overexpression	O
of	O
16K	O
inhibits	O
cell	O
adhesion	O
and	O
invasion	O
.	O

16K	O
contains	O
four	O
hydrophobic	O
membrane	O
-	O
spanning	O
alpha	O
-	O
helices	O
,	O
and	O
its	O
ability	O
to	O
influence	O
glycosylation	O
is	O
localized	O
primarily	O
within	O
the	O
second	O
and	O
fourth	O
membrane	O
-	O
spanning	O
alpha	O
-	O
helices	O
.	O

16K	O
also	O
interacts	O
directly	O
with	O
the	O
transmembrane	O
domain	O
of	O
beta	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
integrin	E-Protein
,	O
but	O
its	O
effects	O
on	O
glycosylation	O
were	O
independent	O
of	O
its	O
binding	O
to	O
beta	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
integrin	E-Protein
.	O

These	O
data	O
link	O
cell	O
surface	O
tumor	O
-	O
related	O
glycosylation	O
to	O
a	O
component	O
of	O
the	O
enzyme	O
responsible	O
for	O
acidification	O
of	O
the	O
exocytic	O
pathway	O
.	O

Developmentally	O
regulated	O
glycosylation	O
of	O
the	O
CD8alphabeta	S-Protein
coreceptor	O
stalk	O
modulates	O
ligand	O
binding	O
.	O

The	O
functional	O
consequences	O
of	O
glycan	O
structural	O
changes	O
associated	O
with	O
cellular	O
differentiation	O
are	O
ill	O
defined	O
.	O

Herein	O
,	O
we	O
investigate	O
the	O
role	O
of	O
glycan	O
adducts	O
to	O
the	O
O	O
-	O
glycosylated	O
polypeptide	O
stalk	O
tethering	O
the	O
CD8alphabeta	S-Protein
coreceptor	O
to	O
the	O
thymocyte	O
surface	O
.	O

We	O
show	O
that	O
immature	O
CD4	S-Protein
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
double	O
-	O
positive	O
thymocytes	O
bind	O
MHCI	O
tetramers	O
more	O
avidly	O
than	O
mature	O
CD8	O
single	O
-	O
positive	O
thymocytes	O
,	O
and	O
that	O
this	O
differential	O
binding	O
is	O
governed	O
by	O
developmentally	O
programmed	O
O	O
-	O
glycan	O
modification	O
controlled	O
by	O
the	O
ST3Gal	B-Protein
-	I-Protein
I	E-Protein
sialyltransferase	O
.	O

ST3Gal	B-Protein
-	I-Protein
I	E-Protein
induction	O
and	O
attendant	O
core	O
1	O
sialic	O
acid	O
addition	O
to	O
CD8beta	S-Protein
on	O
mature	O
thymocytes	O
decreases	O
CD8alphabeta	S-Protein
-	O
MHCI	O
avidity	O
by	O
altering	O
CD8alphabeta	S-Protein
domain	O
-	O
domain	O
association	O
and	O
/	O
or	O
orientation	O
.	O

Hence	O
,	O
glycans	O
on	O
the	O
CD8beta	S-Protein
stalk	O
appear	O
to	O
modulate	O
the	O
ability	O
of	O
the	O
distal	O
binding	O
surface	O
of	O
the	O
dimeric	O
CD8	O
globular	O
head	O
domains	O
to	O
clamp	O
MHCI	O
.	O

Differentially	O
methylated	O
forms	O
of	O
histone	B-Protein
H3	E-Protein
show	O
unique	O
association	O
patterns	O
with	O
inactive	O
human	O
X	O
chromosomes	O
.	O

Studies	O
of	O
histone	S-Protein
methylation	O
have	O
shown	O
that	O
H3	S-Protein
can	O
be	O
methylated	O
at	O
lysine	O
4	O
(	O
Lys4	O
)	O
or	O
lysine	O
9	O
(	O
Lys9	O
)	O
.	O

Whereas	O
H3	S-Protein
-	O
Lys4	O
methylation	O
has	O
been	O
correlated	O
with	O
active	O
gene	O
expression	O
,	O
H3	S-Protein
-	O
Lys9	O
methylation	O
has	O
been	O
linked	O
to	O
gene	O
silencing	O
and	O
assembly	O
of	O
heterochromatin	O
in	O
mouse	O
and	O
Schizosaccharomyces	O
pombe	O
.	O

The	O
chromodomain	O
of	O
mouse	O
HP1	O
(	O
and	O
Swi6	S-Protein
in	O
S	O
.	O
pombe	O
)	O
binds	O
H3	S-Protein
methylated	O
at	O
Lys9	O
,	O
and	O
methylation	O
at	O
this	O
site	O
is	O
thought	O
to	O
mark	O
and	O
promote	O
heterochromatin	O
assembly	O
.	O

We	O
have	O
used	O
a	O
well	O
-	O
studied	O
model	O
of	O
mammalian	O
epigenetic	O
silencing	O
,	O
the	O
human	O
inactive	O
X	O
chromosome	O
,	O
to	O
show	O
that	O
enrichment	O
for	O
H3	S-Protein
methylated	O
at	O
Lys9	O
is	O
also	O
a	O
distinguishing	O
mark	O
of	O
facultative	O
heterochromatin	O
.	O

In	O
contrast	O
,	O
H3	S-Protein
methylated	O
at	O
Lys4	O
is	O
depleted	O
in	O
the	O
inactive	O
X	O
chromosome	O
,	O
except	O
in	O
three	O
'	O
hot	O
spots	O
'	O
of	O
enrichment	O
along	O
its	O
length	O
.	O

Chromatin	O
immunoprecipitation	O
analyses	O
further	O
show	O
that	O
Lys9	O
methylation	O
is	O
associated	O
with	O
promoters	O
of	O
inactive	O
genes	O
,	O
whereas	O
Lys4	O
methylation	O
is	O
associated	O
with	O
active	O
genes	O
on	O
the	O
X	O
chromosome	O
.	O

These	O
data	O
demonstrate	O
that	O
differential	O
methylation	O
at	O
two	O
distinct	O
sites	O
of	O
the	O
H3	S-Protein
amino	O
terminus	O
correlates	O
with	O
contrasting	O
gene	O
activities	O
and	O
may	O
be	O
part	O
of	O
a	O
'	O
histone	S-Protein
code	O
'	O
involved	O
in	O
establishing	O
and	O
maintaining	O
facultative	O
heterochromatin	O
.	O

Chromosomal	O
integration	O
of	O
retinoic	O
acid	O
response	O
elements	O
prevents	O
cooperative	O
transcriptional	O
activation	O
by	O
retinoic	O
acid	O
receptor	O
and	O
retinoid	O
X	O
receptor	O
.	O

All	O
-	O
trans	O
-	O
retinoic	O
acid	O
receptors	O
(	O
RAR	O
)	O
and	O
9	O
-	O
cis	O
-	O
retinoic	O
acid	O
receptors	O
(	O
RXR	O
)	O
are	O
nuclear	O
receptors	O
known	O
to	O
cooperatively	O
activate	O
transcription	O
from	O
retinoid	O
-	O
regulated	O
promoters	O
.	O

By	O
comparing	O
the	O
transactivating	O
properties	O
of	O
RAR	O
and	O
RXR	O
in	O
P19	O
cells	O
using	O
either	O
plasmid	O
or	O
chromosomal	O
reporter	O
genes	O
containing	O
the	O
mRAR	B-Protein
beta	I-Protein
2	E-Protein
gene	O
promoter	O
,	O
we	O
found	O
contrasting	O
patterns	O
of	O
transcriptional	O
regulation	O
in	O
each	O
setting	O
.	O

Cooperativity	O
between	O
RXR	O
and	O
RAR	O
occurred	O
at	O
all	O
times	O
with	O
transiently	O
introduced	O
promoters	O
,	O
but	O
was	O
restricted	O
to	O
a	O
very	O
early	O
stage	O
(	O
<	O
3	O
h	O
)	O
for	O
chromosomal	O
promoters	O
.	O

This	O
time	O
-	O
dependent	O
loss	O
of	O
cooperativity	O
was	O
specific	O
for	O
chromosomal	O
templates	O
containing	O
two	O
copies	O
of	O
a	O
retinoid	O
-	O
responsive	O
element	O
(	O
RARE	O
)	O
and	O
was	O
not	O
influenced	O
by	O
the	O
spacing	O
between	O
the	O
two	O
RAREs	O
.	O

This	O
loss	O
of	O
cooperativity	O
suggested	O
a	O
delayed	O
acquisition	O
of	O
RAR	O
full	O
transcriptional	O
competence	O
because	O
(	O
i	O
)	O
cooperativity	O
was	O
maintained	O
at	O
RAR	O
ligand	O
subsaturating	O
concentrations	O
,	O
(	O
ii	O
)	O
overexpression	O
of	O
SRC	B-Protein
-	I-Protein
1	E-Protein
led	O
to	O
loss	O
of	O
cooperativity	O
and	O
even	O
to	O
strong	O
repression	O
of	O
chromosomal	O
templates	O
activity	O
,	O
and	O
(	O
iii	O
)	O
loss	O
of	O
cooperativity	O
was	O
observed	O
when	O
additional	O
cis	O
-	O
acting	O
response	O
elements	O
were	O
activated	O
.	O

Surprisingly	O
,	O
histone	S-Protein
deacetylase	O
inhibitors	O
counteracted	O
this	O
loss	O
of	O
cooperativity	O
by	O
repressing	O
partially	O
RAR	O
-	O
mediated	O
activation	O
of	O
chromosomal	O
promoters	O
.	O

Loss	O
of	O
cooperativity	O
was	O
not	O
correlated	O
to	O
local	O
histone	S-Protein
hyperacetylation	O
or	O
to	O
alteration	O
of	O
constitutive	O
RNA	O
polymerase	O
II	O
(	O
RNAP	O
)	O
loading	O
at	O
the	O
promoter	O
region	O
.	O

Unexpectedly	O
,	O
RNAP	O
binding	O
to	O
transcribed	O
regions	O
was	O
correlated	O
to	O
the	O
RAR	O
activation	O
state	O
as	O
well	O
as	O
to	O
acetylation	O
levels	O
of	O
histones	B-Protein
H3	E-Protein
and	O
H4	S-Protein
,	O
suggesting	O
that	O
RAR	O
acts	O
at	O
the	O
mRAR	B-Protein
beta	E-Protein
promoter	O
by	O
triggering	O
the	O
switch	O
from	O
an	O
RNA	O
elongation	O
-	O
incompetent	O
RNAP	O
form	O
towards	O
an	O
RNA	O
elongation	O
-	O
competent	O
RNAP	O
.	O

Murine	O
retroviruses	O
activate	O
B	O
cells	O
via	O
interaction	O
with	O
toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
4	E-Protein
.	O

Although	O
most	O
retroviruses	O
require	O
activated	O
cells	O
as	O
their	O
targets	O
for	O
infection	O
,	O
it	O
is	O
not	O
known	O
how	O
this	O
is	O
achieved	O
in	O
vivo	O
.	O

A	O
candidate	O
protein	O
for	O
the	O
activation	O
of	O
B	O
cells	O
by	O
either	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
or	O
murine	O
leukemia	O
virus	O
is	O
the	O
toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
4	E-Protein
(	O
TLR4	S-Protein
)	O
,	O
a	O
component	O
of	O
the	O
innate	O
immune	O
system	O
.	O

MMTV	O
caused	O
B	O
cell	O
activation	O
in	O
C3H	O
/	O
HeN	O
mice	O
but	O
not	O
in	O
C3H	O
/	O
HeJ	O
or	O
BALB	O
/	O
c	O
(	O
C	O
.	O
C3H	O
Tlr4	S-Protein
(	O
lps	O
-	O
d	O
)	O
)	O
congenic	O
mice	O
,	O
both	O
of	O
which	O
have	O
a	O
mutant	O
TLR4	S-Protein
gene	O
.	O

This	O
activation	O
was	O
independent	O
of	O
viral	O
gene	O
expression	O
,	O
because	O
it	O
occurred	O
after	O
treatment	O
of	O
MMTV	O
with	O
ultraviolet	O
light	O
or	O
2	O
,	O
2	O
'	O
-	O
dithiodipyridine	O
and	O
in	O
azidothymidine	O
-	O
treated	O
mice	O
.	O

Nuclear	O
extracts	O
prepared	O
from	O
the	O
lymphocytes	O
of	O
MMTV	O
-	O
injected	O
C3H	O
/	O
HeN	O
but	O
not	O
C3H	O
/	O
HeJ	O
mice	O
showed	O
increased	O
nuclear	O
factor	O
kappaB	O
activity	O
.	O

Additionally	O
,	O
the	O
MMTV	O
-	O
and	O
Moloney	O
murine	O
leukemia	O
virus	O
envelope	O
proteins	O
coimmunoprecipitated	O
with	O
TLR4	S-Protein
when	O
expressed	O
in	O
293T	O
cells	O
.	O

The	O
MMTV	O
receptor	O
failed	O
to	O
coimmunoprecipitate	O
with	O
TLR4	S-Protein
,	O
suggesting	O
that	O
MMTV	O
/	O
TLR4	S-Protein
interaction	O
is	O
independent	O
of	O
virus	O
attachment	O
and	O
fusion	O
.	O

These	O
results	O
identify	O
retroviral	O
proteins	O
that	O
interact	O
with	O
a	O
mammalian	O
toll	O
receptor	O
and	O
show	O
that	O
direct	O
activation	O
by	O
such	O
viruses	O
may	O
initiate	O
in	O
vivo	O
infection	O
pathways	O
.	O

Geldanamycin	O
inhibits	O
trichostatin	O
A	O
-	O
induced	O
cell	O
death	O
and	O
histone	B-Protein
H4	E-Protein
hyperacetylation	O
in	O
COS	O
-	O
7	O
cells	O
.	O

As	O
widely	O
believed	O
treating	O
cells	O
with	O
trichostatin	O
A	O
(	O
TSA	O
)	O
,	O
an	O
inhibitor	O
of	O
histone	S-Protein
deacetylase	O
,	O
results	O
in	O
histone	B-Protein
H4	E-Protein
hyperacetylation	O
and	O
cell	O
cycle	O
arrest	O
.	O

This	O
compound	O
is	O
often	O
compared	O
with	O
other	O
potential	O
anticancer	O
drugs	O
in	O
cell	O
cycle	O
,	O
proliferation	O
and	O
differentiation	O
research	O
.	O

Furthermore	O
,	O
geldanamycin	O
(	O
GA	O
)	O
,	O
a	O
90	O
-	O
kDa	O
heat	O
shock	O
protein	O
(	O
HSP90	O
)	O
specific	O
inhibitor	O
,	O
is	O
a	O
well	O
-	O
known	O
potential	O
anticancer	O
agent	O
.	O

This	O
study	O
examines	O
whether	O
GA	O
can	O
affect	O
the	O
cellular	O
functions	O
induced	O
by	O
TSA	O
.	O

When	O
using	O
TSA	O
treatment	O
,	O
although	O
caused	O
COS	O
-	O
7	O
cell	O
death	O
,	O
pretreatment	O
of	O
0	O
.	O
5	O
microg	O
/	O
ml	O
GA	O
for	O
30	O
min	O
and	O
an	O
addition	O
of	O
50	O
ng	O
/	O
ml	O
TSA	O
(	O
GA	O
+	O
TSA	O
)	O
apparently	O
averted	O
cell	O
death	O
.	O

Our	O
results	O
indicated	O
that	O
the	O
cell	O
survival	O
rate	O
was	O
only	O
approximately	O
20	O
%	O
when	O
prolonged	O
treatment	O
was	O
undertaken	O
with	O
50	O
ng	O
/	O
ml	O
TSA	O
(	O
TSA	O
)	O
alone	O
for	O
24	O
h	O
.	O

In	O
contrast	O
,	O
the	O
cell	O
survival	O
rate	O
was	O
enhanced	O
by	O
two	O
folds	O
when	O
treating	O
with	O
GA	O
+	O
TSA	O
.	O

Furthermore	O
,	O
DNA	O
fragmentation	O
assay	O
revealed	O
that	O
fragmented	O
DNA	O
was	O
produced	O
8	O
h	O
after	O
prolonged	O
treatment	O
with	O
TSA	O
alone	O
.	O

Within	O
16	O
h	O
,	O
the	O
apoptotic	O
percentages	O
of	O
TSA	O
-	O
treated	O
cells	O
were	O
between	O
15	O
-	O
25	O
%	O
.	O

In	O
contrast	O
,	O
the	O
other	O
treatments	O
did	O
not	O
exceed	O
6	O
%	O
.	O

Furthermore	O
,	O
GA	O
inhibited	O
TSA	O
-	O
induced	O
histone	B-Protein
H4	E-Protein
hyperacetylation	O
.	O

Western	O
blotting	O
analysis	O
further	O
demonstrated	O
that	O
the	O
HSP70	O
levels	O
did	O
not	O
significantly	O
increase	O
in	O
TSA	O
-	O
treated	O
cells	O
.	O

However	O
,	O
the	O
accumulated	O
70	O
-	O
kDa	O
heat	O
shock	O
protein	O
(	O
HSP70	O
)	O
markedly	O
increased	O
up	O
to	O
2	O
to	O
3	O
folds	O
at	O
8	O
h	O
in	O
GA	O
-	O
and	O
GA	O
+	O
TSA	O
-	O
treated	O
cells	O
,	O
and	O
the	O
maximum	O
amount	O
up	O
to	O
5	O
to	O
7	O
folds	O
at	O
20	O
h	O
.	O

Conversely	O
,	O
HSP90	O
did	O
not	O
markedly	O
increase	O
in	O
all	O
treatments	O
.	O

Based	O
on	O
the	O
results	O
in	O
this	O
study	O
,	O
we	O
suggest	O
that	O
apoptosis	O
induced	O
by	O
TSA	O
can	O
be	O
prevented	O
by	O
GA	O
-	O
induced	O
increment	O
of	O
heat	O
shock	O
proteins	O
,	O
particularly	O
HSP70	O
.	O

Tissue	B-Protein
factor	E-Protein
is	O
the	O
receptor	O
for	O
plasminogen	S-Protein
type	O
1	O
on	O
1	O
-	O
LN	O
human	O
prostate	O
cancer	O
cells	O
.	O

Tissue	B-Protein
factor	E-Protein
(	O
TF	S-Protein
)	O
,	O
the	O
initiator	O
of	O
the	O
extrinsic	O
pathway	O
of	O
coagulation	O
,	O
binds	O
plasminogen	S-Protein
(	O
Pg	S-Protein
)	O
with	O
high	O
affinity	O
through	O
an	O
interaction	O
between	O
kringles	O
1	O
-	O
3	O
of	O
Pg	S-Protein
and	O
the	O
extracellular	O
domain	O
of	O
TF	S-Protein
.	O

We	O
investigated	O
the	O
binding	O
of	O
Pg	S-Protein
type	O
1	O
(	O
Pg	S-Protein
1	O
)	O
and	O
Pg	S-Protein
type	O
2	O
(	O
Pg	S-Protein
2	O
)	O
to	O
highly	O
invasive	O
,	O
TF	S-Protein
-	O
expressing	O
,	O
1	O
-	O
LN	O
human	O
prostate	O
tumor	O
cells	O
and	O
to	O
TF	S-Protein
isolated	O
from	O
1	O
-	O
LN	O
cell	O
membranes	O
.	O

Pg	S-Protein
1	O
,	O
containing	O
both	O
N	O
-	O
linked	O
and	O
O	O
-	O
linked	O
oligosaccharide	O
chains	O
,	O
bound	O
to	O
isolated	O
TF	S-Protein
with	O
high	O
affinity	O
,	O
whereas	O
Pg	S-Protein
2	O
,	O
containing	O
only	O
one	O
O	O
-	O
linked	O
oligosaccharide	O
chain	O
,	O
did	O
not	O
bind	O
to	O
TF	S-Protein
.	O

Although	O
Pg	S-Protein
1	O
and	O
Pg	S-Protein
2	O
bind	O
to	O
1	O
-	O
LN	O
cells	O
,	O
only	O
anti	O
-	O
TF	S-Protein
antibodies	O
inhibited	O
the	O
binding	O
of	O
Pg	S-Protein
1	O
,	O
suggesting	O
that	O
TF	S-Protein
functions	O
as	O
the	O
receptor	O
for	O
Pg	S-Protein
1	O
on	O
1	O
-	O
LN	O
cells	O
.	O

Binding	O
of	O
Pg	S-Protein
1	O
to	O
isolated	O
TF	S-Protein
was	O
inhibited	O
by	O
6	O
-	O
aminohexanoic	O
acid	O
and	O
alpha	O
-	O
methylmannoside	O
,	O
suggesting	O
that	O
Pg	S-Protein
1	O
L	O
-	O
lysine	O
binding	O
sites	O
and	O
the	O
biantennary	O
,	O
mannose	O
-	O
containing	O
N	O
-	O
linked	O
oligosaccharide	O
chain	O
are	O
involved	O
in	O
this	O
interaction	O
.	O

Binding	O
of	O
Pg	S-Protein
1	O
to	O
1	O
-	O
LN	O
cells	O
promoted	O
activation	O
by	O
receptor	O
-	O
bound	O
urinary	B-Protein
-	I-Protein
type	I-Protein
Pg	I-Protein
activator	E-Protein
(	O
u	B-Protein
-	I-Protein
PA	E-Protein
)	O
and	O
initiated	O
a	O
Ca	O
(	O
+	O
+	O
)	O
signaling	O
cascade	O
.	O

In	O
previous	O
studies	O
we	O
demonstrated	O
that	O
the	O
Pg	S-Protein
2	O
O	O
-	O
linked	O
carbohydrate	O
chain	O
is	O
essential	O
for	O
its	O
binding	O
to	O
CD26	S-Protein
on	O
1	O
-	O
LN	O
cells	O
.	O

The	O
current	O
studies	O
suggest	O
that	O
Pg	S-Protein
oligosaccharide	O
chains	O
regulate	O
the	O
binding	O
of	O
Pg	S-Protein
1	O
and	O
Pg	S-Protein
2	O
to	O
separate	O
receptors	O
on	O
the	O
cell	O
surface	O
.	O

The	O
use	O
of	O
dioxygen	O
by	O
HIF	O
prolyl	O
hydroxylase	O
(	O
PHD1	S-Protein
)	O
.	O

The	O
hypoxic	O
response	O
in	O
animals	O
is	O
mediated	O
by	O
hydroxylation	O
of	O
proline	O
residues	O
in	O
the	O
alpha	O
-	O
subunit	O
of	O
hypoxia	O
inducible	O
factor	O
(	O
HIF	O
)	O
.	O

Hydroxylation	O
is	O
catalysed	O
by	O
prolyl	O
-	O
4	O
-	O
hydroxylases	O
(	O
PHD	O
isozymes	O
in	O
humans	O
)	O
which	O
are	O
iron	O
(	O
II	O
)	O
and	O
2	O
-	O
oxoglutarate	O
dependent	O
oxygenases	O
.	O

Mutation	O
of	O
the	O
arginine	O
proposed	O
to	O
bind	O
2	O
-	O
oxoglutarate	O
and	O
of	O
the	O
2His	O
-	O
1	O
-	O
carboxylate	O
iron	O
(	O
II	O
)	O
binding	O
motif	O
in	O
PHD1	S-Protein
dramatically	O
reduces	O
its	O
activity	O
.	O

The	O
source	O
of	O
the	O
oxygen	O
of	O
the	O
product	O
alcohol	O
is	O
(	O
>	O
95	O
%	O
)	O
dioxygen	O
.	O

Cell	O
cycle	O
specific	O
changes	O
in	O
the	O
human	O
cyclin	B-Protein
B1	E-Protein
gene	O
regulatory	O
region	O
as	O
revealed	O
by	O
response	O
to	O
trichostatin	O
A	O
.	O

The	O
human	O
cyclin	B-Protein
Bl	E-Protein
gene	O
is	O
cell	O
cycle	O
regulated	O
with	O
maximal	O
activity	O
during	O
G	O
(	O
2	O
)	O
/	O
M	O
.	O

We	O
examined	O
the	O
role	O
of	O
histone	S-Protein
deacetylation	O
in	O
cyclin	B-Protein
Bl	E-Protein
regulation	O
using	O
the	O
histone	S-Protein
deacetylase	O
inhibitor	O
trichostatin	O
A	O
(	O
TSA	O
)	O
.	O

TSA	O
treatment	O
(	O
100	O
ng	O
/	O
ml	O
)	O
of	O
NIH3T3	O
cells	O
containing	O
the	O
luciferase	S-Protein
reporter	O
construct	O
pCycB	O
(	O
-	O
287	O
)	O
-	O
LUC	O
caused	O
an	O
increase	O
in	O
promoter	O
activity	O
in	O
G	O
(	O
0	O
)	O
and	O
G	O
(	O
1	O
)	O
but	O
no	O
significant	O
change	O
in	O
G	O
(	O
2	O
)	O
.	O

Removal	O
of	O
upstream	O
sequences	O
including	O
an	O
E	O
-	O
box	O
and	O
Sp1	S-Protein
site	O
eliminated	O
the	O
TSA	O
induced	O
increase	O
in	O
G	O
(	O
0	O
)	O
and	O
G	O
(	O
1	O
)	O
,	O
and	O
caused	O
a	O
decrease	O
in	O
promoter	O
activity	O
during	O
S	O
and	O
G	O
(	O
2	O
)	O
.	O

Promoter	O
activity	O
increased	O
only	O
2	O
-	O
fold	O
following	O
TSA	O
treatment	O
of	O
G	O
(	O
0	O
)	O
cells	O
containing	O
the	O
construct	O
pCycB	O
(	O
MUT	O
-	O
E	O
-	O
Box	O
)	O
-	O
LUC	O
with	O
an	O
E	O
-	O
box	O
mutation	O
,	O
and	O
a	O
decrease	O
in	O
activity	O
was	O
detected	O
during	O
G	O
(	O
2	O
)	O
.	O

We	O
conclude	O
that	O
histone	S-Protein
deacetylation	O
contributes	O
to	O
the	O
repression	O
of	O
cyclin	B-Protein
B1	E-Protein
expression	O
in	O
G	O
(	O
0	O
)	O
and	O
G	O
(	O
1	O
)	O
,	O
and	O
that	O
this	O
mechanism	O
requires	O
,	O
in	O
part	O
,	O
the	O
E	O
-	O
box	O
.	O

TSA	O
reduction	O
of	O
cyclin	B-Protein
B1	E-Protein
promoter	O
activity	O
in	O
G	O
(	O
2	O
)	O
,	O
however	O
,	O
involves	O
sequences	O
within	O
the	O
first	O
119	O
bp	O
.	O

A	O
working	O
model	O
for	O
cyclin	B-Protein
B1	E-Protein
regulation	O
is	O
provided	O
.	O

The	O
other	O
Topa	O
:	O
formation	O
of	O
3	O
,	O
4	O
,	O
5	O
-	O
trihydroxyphenylalanine	O
in	O
peptides	O
.	O

Hydroxylation	O
of	O
peptidyl	O
-	O
3	O
,	O
4	O
-	O
dihydroxyphenyl	O
-	O
l	O
-	O
alanine	O
(	O
Dopa	O
)	O
was	O
observed	O
during	O
tyrosinase	O
incubation	O
of	O
a	O
decapeptide	O
related	O
to	O
the	O
mussel	O
adhesive	O
protein	O
mefp1	S-Protein
.	O

The	O
reaction	O
was	O
carried	O
out	O
at	O
high	O
enzyme	O
concentrations	O
(	O
700	O
units	O
tyrosinase	O
/	O
micromol	O
of	O
tyrosine	O
)	O
.	O

The	O
hydroxylation	O
of	O
tyrosines	O
in	O
the	O
decapeptide	O
proceeds	O
sequentially	O
.	O

First	O
,	O
Tyr	O
-	O
9	O
is	O
hydroxylated	O
to	O
Dopa	O
,	O
followed	O
by	O
hydroxylation	O
of	O
Tyr	O
-	O
5	O
;	O
finally	O
,	O
Dopa	O
-	O
9	O
is	O
hydroxylated	O
to	O
Topa	O
.	O

Topa	O
was	O
identified	O
as	O
3	O
,	O
4	O
,	O
5	O
-	O
trihydroxyphenylalanine	O
(	O
3	O
,	O
4	O
,	O
5	O
-	O
Topa	O
)	O
by	O
comparison	O
to	O
known	O
standards	O
using	O
amino	O
acid	O
analysis	O
,	O
derivatization	O
with	O
phenylisothiocyanate	O
in	O
combination	O
with	O
Edman	O
sequencing	O
,	O
and	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
mass	O
spectrometry	O
with	O
time	O
-	O
of	O
-	O
flight	O
.	O

Two	O
other	O
peptides	O
,	O
not	O
related	O
to	O
mussel	O
proteins	O
,	O
were	O
also	O
found	O
to	O
form	O
peptidyl	O
-	O
Topa	O
upon	O
incubation	O
with	O
tyrosinase	S-Protein
.	O

Although	O
3	O
,	O
4	O
,	O
5	O
-	O
Topa	O
has	O
been	O
reported	O
in	O
the	O
primary	O
sequence	O
of	O
several	O
peptides	O
,	O
its	O
formation	O
in	O
vitro	O
from	O
tyrosine	O
-	O
containing	O
peptides	O
is	O
novel	O
.	O

The	O
formation	O
of	O
Topa	O
would	O
appear	O
to	O
be	O
a	O
function	O
of	O
tyrosinase	S-Protein
rather	O
than	O
the	O
nucleophilic	O
addition	O
of	O
water	O
to	O
dopaquinone	O
.	O

Ubiquitination	O
of	O
histone	B-Protein
H2B	E-Protein
by	O
Rad6	S-Protein
is	O
required	O
for	O
efficient	O
Dot1	S-Protein
-	O
mediated	O
methylation	O
of	O
histone	B-Protein
H3	E-Protein
lysine	O
79	O
.	O

Dot1	S-Protein
is	O
a	O
non	O
-	O
SET	O
domain	O
protein	O
that	O
methylates	O
histone	B-Protein
H3	E-Protein
at	O
lysine	O
79	O
,	O
a	O
surface	O
-	O
exposed	O
residue	O
that	O
lies	O
within	O
the	O
globular	O
domain	O
.	O

In	O
the	O
context	O
of	O
a	O
nucleosome	O
,	O
H3	S-Protein
lysine	O
79	O
is	O
located	O
in	O
close	O
proximity	O
with	O
lysine	O
123	O
of	O
histone	B-Protein
H2B	E-Protein
,	O
a	O
major	O
site	O
for	O
ubiquitination	O
by	O
Rad6	S-Protein
.	O

Here	O
we	O
show	O
that	O
Rad6	S-Protein
-	O
mediated	O
ubiquitination	O
of	O
H2B	S-Protein
lysine	O
123	O
is	O
important	O
for	O
efficient	O
methylation	O
of	O
lysine	O
79	O
,	O
but	O
not	O
lysine	O
36	O
,	O
of	O
histone	B-Protein
H3	E-Protein
.	O

In	O
contrast	O
,	O
lysine	O
79	O
methylation	O
of	O
H3	S-Protein
is	O
not	O
required	O
for	O
ubiquitination	O
of	O
H2B	S-Protein
.	O

Our	O
study	O
provides	O
a	O
new	O
example	O
of	O
trans	O
-	O
histone	O
regulation	O
between	O
modifications	O
on	O
different	O
histones	O
.	O

In	O
addition	O
,	O
it	O
suggests	O
that	O
Rad6	S-Protein
affects	O
telomeric	O
silencing	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
influencing	O
methylation	O
of	O
histone	B-Protein
H3	E-Protein
.	O

Sequence	O
determinants	O
in	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1alpha	E-Protein
for	O
hydroxylation	O
by	O
the	O
prolyl	O
hydroxylases	O
PHD1	S-Protein
,	O
PHD2	S-Protein
,	O
and	O
PHD3	S-Protein
.	O

Hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
is	O
a	O
heterodimeric	O
transcription	O
factor	O
induced	O
by	O
hypoxia	O
.	O

Under	O
normoxic	O
conditions	O
,	O
site	O
-	O
specific	O
proline	O
hydroxylation	O
of	O
the	O
alpha	O
subunits	O
of	O
HIF	O
allows	O
recognition	O
by	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumor	I-Protein
suppressor	E-Protein
protein	O
(	O
VHL	S-Protein
)	O
,	O
a	O
component	O
of	O
an	O
E3	O
ubiquitin	S-Protein
ligase	O
complex	O
that	O
targets	O
these	O
subunits	O
for	O
degradation	O
by	O
the	O
ubiquitin	S-Protein
-	O
proteasome	O
pathway	O
.	O

Under	O
hypoxic	O
conditions	O
,	O
this	O
hydroxylation	O
is	O
inhibited	O
,	O
allowing	O
the	O
alpha	O
subunits	O
of	O
HIF	O
to	O
escape	O
VHL	S-Protein
-	O
mediated	O
degradation	O
.	O

Three	O
enzymes	O
,	O
prolyl	B-Protein
hydroxylase	I-Protein
domain	I-Protein
-	I-Protein
containing	I-Protein
proteins	I-Protein
1	E-Protein
,	O
2	S-Protein
,	O
and	O
3	S-Protein
(	O
PHD1	S-Protein
,	O
-	B-Protein
2	E-Protein
,	O
and	O
-	B-Protein
3	E-Protein
;	O
also	O
known	O
as	O
HIF	B-Protein
prolyl	I-Protein
hydroxylase	I-Protein
3	E-Protein
,	O
2	S-Protein
,	O
and	O
1	S-Protein
,	O
respectively	O
)	O
,	O
have	O
recently	O
been	O
identified	O
that	O
catalyze	O
proline	O
hydroxylation	O
of	O
HIF	O
alpha	O
subunits	O
.	O

These	O
enzymes	O
hydroxylate	O
specific	O
prolines	O
in	O
HIF	O
alpha	O
subunits	O
in	O
the	O
context	O
of	O
a	O
strongly	O
conserved	O
LXXLAP	O
sequence	O
motif	O
(	O
where	O
X	O
indicates	O
any	O
amino	O
acid	O
and	O
P	O
indicates	O
the	O
hydroxylacceptor	O
proline	O
)	O
.	O

We	O
report	O
here	O
that	O
PHD2	S-Protein
has	O
the	O
highest	O
specific	O
activity	O
toward	O
the	O
primary	O
hydroxylation	O
site	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

Furthermore	O
,	O
and	O
unexpectedly	O
,	O
mutations	O
can	O
be	O
tolerated	O
at	O
the	O
-	O
5	O
,	O
-	O
2	O
,	O
and	O
-	O
1	O
positions	O
(	O
relative	O
to	O
proline	O
)	O
of	O
the	O
LXXLAP	O
motif	O
.	O

Thus	O
,	O
these	O
results	O
provide	O
evidence	O
that	O
the	O
only	O
obligatory	O
residue	O
for	O
proline	O
hydroxylation	O
in	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
is	O
the	O
hydroxylacceptor	O
proline	O
itself	O
.	O

Role	O
of	O
prolyl	O
hydroxylation	O
in	O
oncogenically	O
stabilized	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1alpha	E-Protein
.	O

Stabilization	O
of	O
the	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
(	O
HIF	O
-	O
1	O
)	O
protein	O
is	O
essential	O
for	O
its	O
role	O
as	O
a	O
regulator	O
of	O
gene	O
expression	O
under	O
low	O
oxygen	O
conditions	O
.	O

Here	O
,	O
employing	O
a	O
novel	O
hydroxylation	O
-	O
specific	O
antibody	O
,	O
we	O
directly	O
show	O
that	O
proline	O
564	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
and	O
proline	O
531	O
of	O
HIF	B-Protein
-	I-Protein
2alpha	E-Protein
are	O
hydroxylated	O
under	O
normoxia	O
.	O

Importantly	O
,	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
Pro	O
-	O
564	O
and	O
HIF	B-Protein
-	I-Protein
2alpha	E-Protein
Pro	O
-	O
531	O
hydroxylation	O
is	O
diminished	O
with	O
the	O
treatment	O
of	O
hypoxia	O
,	O
cobalt	O
chloride	O
,	O
desferrioxamine	O
,	O
or	O
dimethyloxalyglycine	O
,	O
regardless	O
of	O
the	O
E3	O
ubiquitin	S-Protein
ligase	O
activity	O
of	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
(	I-Protein
VHL	I-Protein
)	I-Protein
tumor	I-Protein
suppressor	E-Protein
gene	O
.	O

Furthermore	O
,	O
in	O
VHL	S-Protein
-	O
deficient	O
cells	O
,	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
Pro	O
-	O
564	O
and	O
HIF	B-Protein
-	I-Protein
2alpha	E-Protein
Pro	O
-	O
531	O
had	O
detectable	O
amounts	O
of	O
hydroxylation	O
following	O
transition	O
to	O
hypoxia	O
,	O
indicating	O
that	O
the	O
post	O
-	O
translational	O
modification	O
is	O
not	O
reversible	O
.	O

The	O
introduction	O
of	O
v	B-Protein
-	I-Protein
Src	E-Protein
or	O
RasV12	S-Protein
oncogenes	O
resulted	O
in	O
the	O
stabilization	O
of	O
normoxic	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
and	O
the	O
loss	O
of	O
hydroxylated	O
Pro	O
-	O
564	O
,	O
demonstrating	O
that	O
oncogene	O
-	O
induced	O
stabilization	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
is	O
signaled	O
through	O
the	O
inhibition	O
of	O
prolyl	O
hydroxylation	O
.	O

Conversely	O
,	O
a	O
constitutively	O
active	O
Akt	O
oncogene	O
stabilized	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
under	O
normoxia	O
independently	O
of	O
prolyl	O
hydroxylation	O
,	O
suggesting	O
an	O
alternative	O
mechanism	O
for	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
stabilization	O
.	O

Thus	O
,	O
these	O
results	O
indicate	O
distinct	O
pathways	O
for	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
stabilization	O
by	O
different	O
oncogenes	O
.	O

More	O
importantly	O
,	O
these	O
findings	O
link	O
oncogenesis	O
with	O
normoxic	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
expression	O
through	O
prolyl	O
hydroxylation	O
.	O

Topological	O
analysis	O
of	O
peripherin	S-Protein
/	O
rds	S-Protein
and	O
abnormal	O
glycosylation	O
of	O
the	O
pathogenic	O
Pro216	O
-	O
-	O
>	O
Leu	O
mutation	O
.	O

Peripherin	S-Protein
/	O
rds	S-Protein
is	O
an	O
integral	O
membrane	O
glycoprotein	O
found	O
in	O
the	O
rim	O
regions	O
of	O
vertebrate	O
photoreceptor	O
cell	O
discs	O
.	O

The	O
protein	O
is	O
believed	O
to	O
be	O
involved	O
in	O
both	O
formation	O
and	O
maintenance	O
of	O
the	O
characteristic	O
flattened	O
morphology	O
of	O
the	O
outer	O
segment	O
discs	O
and	O
its	O
essential	O
nature	O
is	O
demonstrated	O
by	O
the	O
wide	O
range	O
of	O
retinal	O
degenerative	O
disorders	O
in	O
which	O
the	O
protein	O
has	O
an	O
involvement	O
.	O

Little	O
structural	O
data	O
has	O
been	O
determined	O
for	O
peripherin	S-Protein
/	O
rds	S-Protein
,	O
but	O
a	O
topological	O
model	O
of	O
the	O
protein	O
has	O
been	O
proposed	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
the	O
first	O
direct	O
evidence	O
for	O
the	O
topology	O
of	O
the	O
protein	O
through	O
the	O
use	O
of	O
scanning	O
glycosylation	O
mutagenesis	O
.	O

Both	O
the	O
topological	O
data	O
and	O
the	O
observation	O
that	O
only	O
the	O
Asn	O
(	O
229	O
)	O
site	O
is	O
efficiently	O
glycosylated	O
in	O
this	O
in	O
vitro	O
transcription	O
/	O
translation	O
system	O
support	O
the	O
common	O
hypotheses	O
.	O

Additionally	O
,	O
expression	O
of	O
the	O
Pro	O
(	O
216	O
)	O
-	O
-	O
>	O
Leu	O
mutant	O
demonstrates	O
an	O
abnormal	O
glycosylation	O
pattern	O
,	O
which	O
may	O
explain	O
the	O
mechanism	O
by	O
which	O
this	O
mutation	O
precipitates	O
a	O
retinal	O
degenerative	O
phenotype	O
.	O

Association	O
of	O
class	O
II	O
histone	O
deacetylases	O
with	O
heterochromatin	O
protein	O
1	O
:	O
potential	O
role	O
for	O
histone	S-Protein
methylation	O
in	O
control	O
of	O
muscle	O
differentiation	O
.	O

Class	O
II	O
histone	B-Protein
deacetylases	I-Protein
(	I-Protein
HDACs	I-Protein
)	I-Protein
4	E-Protein
,	O
5	S-Protein
,	O
7	S-Protein
,	O
and	O
9	S-Protein
repress	O
muscle	O
differentiation	O
through	O
associations	O
with	O
the	O
myocyte	O
enhancer	O
factor	O
2	O
(	O
MEF2	O
)	O
transcription	O
factor	O
.	O

MEF2	B-Protein
-	I-Protein
interacting	I-Protein
transcription	I-Protein
repressor	E-Protein
(	O
MITR	S-Protein
)	O
is	O
an	O
amino	O
-	O
terminal	O
splice	O
variant	O
of	O
HDAC9	S-Protein
that	O
also	O
potently	O
inhibits	O
MEF2	O
transcriptional	O
activity	O
despite	O
lacking	O
a	O
catalytic	O
domain	O
.	O

Here	O
we	O
report	O
that	O
MITR	S-Protein
,	O
HDAC4	S-Protein
,	O
and	O
HDAC5	S-Protein
associate	O
with	O
heterochromatin	O
protein	O
1	O
(	O
HP1	O
)	O
,	O
an	O
adaptor	O
protein	O
that	O
recognizes	O
methylated	O
lysines	O
within	O
histone	S-Protein
tails	O
and	O
mediates	O
transcriptional	O
repression	O
by	O
recruiting	O
histone	O
methyltransferase	O
.	O

Promyogenic	O
signals	O
provided	O
by	O
calcium	O
/	O
calmodulin	O
-	O
dependent	O
kinase	O
(	O
CaMK	O
)	O
disrupt	O
the	O
interaction	O
of	O
MITR	S-Protein
and	O
HDACs	O
with	O
HP1	O
.	O

Since	O
the	O
histone	S-Protein
methyl	O
-	O
lysine	O
residues	O
recognized	O
by	O
HP1	O
also	O
serve	O
as	O
substrates	O
for	O
deacetylation	O
by	O
HDACs	O
,	O
the	O
interaction	O
of	O
MITR	S-Protein
and	O
HDACs	O
with	O
HP1	O
provides	O
an	O
efficient	O
mechanism	O
for	O
silencing	O
MEF2	O
target	O
genes	O
by	O
coupling	O
histone	S-Protein
deacetylation	O
and	O
methylation	O
.	O

Indeed	O
,	O
nucleosomal	O
histones	S-Protein
surrounding	O
a	O
MEF2	O
-	O
binding	O
site	O
in	O
the	O
myogenin	S-Protein
gene	O
promoter	O
are	O
highly	O
methylated	O
in	O
undifferentiated	O
myoblasts	O
,	O
when	O
the	O
gene	O
is	O
silent	O
,	O
and	O
become	O
acetylated	O
during	O
muscle	O
differentiation	O
,	O
when	O
the	O
myogenin	S-Protein
gene	O
is	O
expressed	O
at	O
high	O
levels	O
.	O

The	O
ability	O
of	O
MEF2	O
to	O
recruit	O
a	O
histone	O
methyltransferase	O
to	O
target	O
gene	O
promoters	O
via	O
HP1	O
-	O
MITR	S-Protein
and	O
HP1	O
-	O
HDAC	O
interactions	O
and	O
of	O
CaMK	O
signaling	O
to	O
disrupt	O
these	O
interactions	O
provides	O
an	O
efficient	O
mechanism	O
for	O
signal	O
-	O
dependent	O
regulation	O
of	O
the	O
epigenetic	O
events	O
controlling	O
muscle	O
differentiation	O
.	O

Non	O
-	O
phosphorylating	O
glyceraldehyde	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
phosphate	I-Protein
dehydrogenase	E-Protein
is	O
post	O
-	O
translationally	O
phosphorylated	O
in	O
heterotrophic	O
cells	O
of	O
wheat	O
(	O
Triticum	O
aestivum	O
)	O
.	O

In	O
wheat	O
,	O
non	O
-	O
phosphorylating	O
,	O
NADP	B-Protein
-	I-Protein
dependent	I-Protein
glyceraldehyde	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
phosphate	I-Protein
dehydrogenase	E-Protein
(	O
GAPN	S-Protein
)	O
was	O
found	O
to	O
be	O
encoded	O
by	O
one	O
gene	O
giving	O
rise	O
to	O
a	O
single	O
protein	O
.	O

However	O
,	O
Western	O
blots	O
revealed	O
two	O
different	O
subunits	O
of	O
about	O
58	O
and	O
60	O
kDa	O
in	O
endosperm	O
and	O
shoots	O
.	O

The	O
latter	O
was	O
attributed	O
to	O
in	O
vivo	O
phosphorylation	O
of	O
shoot	O
GAPN	S-Protein
.	O

No	O
modification	O
occurred	O
in	O
leaves	O
,	O
where	O
the	O
enzyme	O
is	O
composed	O
by	O
a	O
single	O
58	O
kDa	O
polypeptide	O
.	O

GAPN	S-Protein
partially	O
purified	O
from	O
shoots	O
and	O
endosperm	O
was	O
dephosphorylated	O
in	O
vitro	O
with	O
alkaline	B-Protein
phosphatase	E-Protein
.	O

Phosphorylated	O
GAPN	S-Protein
exhibited	O
similar	O
affinity	O
for	O
substrates	O
but	O
a	O
lower	O
V	O
(	O
max	O
)	O
compared	O
to	O
the	O
non	O
-	O
phosphorylated	O
enzyme	O
.	O

Results	O
suggest	O
that	O
reversible	O
phosphorylation	O
of	O
GAPN	S-Protein
could	O
regulate	O
NADPH	O
production	O
in	O
the	O
cytosol	O
of	O
heterotrophic	O
plant	O
cells	O
.	O

Protein	B-Protein
arginine	I-Protein
methyltransferase	I-Protein
I	E-Protein
:	O
substrate	O
specificity	O
and	O
role	O
in	O
hnRNP	O
assembly	O
.	O

Prmt1	S-Protein
,	O
the	O
major	O
protein	O
arginine	O
methyltransferase	O
in	O
mammalian	O
cells	O
,	O
has	O
been	O
implicated	O
in	O
signal	O
transduction	O
,	O
transcriptional	O
control	O
,	O
and	O
protein	O
trafficking	O
.	O

In	O
the	O
present	O
study	O
,	O
mouse	O
embryonic	O
stem	O
cells	O
homozygous	O
for	O
an	O
essentially	O
null	O
mutation	O
in	O
the	O
Prmt1	S-Protein
gene	O
were	O
used	O
to	O
examine	O
Prmt1	S-Protein
activity	O
and	O
substrate	O
specificity	O
,	O
which	O
by	O
several	O
criteria	O
appeared	O
to	O
be	O
highly	O
specific	O
.	O

First	O
,	O
other	O
methyltransferases	O
did	O
not	O
substitute	O
for	O
the	O
loss	O
of	O
Prmt1	S-Protein
activity	O
.	O

Second	O
,	O
almost	O
all	O
proteins	O
modified	O
by	O
recombinant	O
Prmt1	S-Protein
in	O
vitro	O
were	O
authentic	O
substrates	O
,	O
i	O
.	O
e	O
.	O
,	O
proteins	O
rendered	O
hypomethylated	O
by	O
Prmt1	S-Protein
gene	O
disruption	O
.	O

Finally	O
,	O
Prmt1	S-Protein
did	O
not	O
modify	O
the	O
substrates	O
of	O
other	O
methyltransferases	O
from	O
cells	O
treated	O
with	O
methyltransferase	O
inhibitors	O
.	O

Recombinant	O
proteins	O
corresponding	O
to	O
two	O
splice	O
-	O
variants	O
,	O
Prmt1	S-Protein
(	O
353	O
)	O
and	O
Prmt1	S-Protein
(	O
371	O
)	O
,	O
methylated	O
different	O
,	O
proteins	O
in	O
vitro	O
,	O
providing	O
the	O
first	O
evidence	O
for	O
functional	O
differences	O
between	O
the	O
two	O
isoforms	O
.	O

However	O
,	O
the	O
differences	O
in	O
substrate	O
specificity	O
were	O
lost	O
by	O
the	O
addition	O
of	O
an	O
N	O
-	O
terminal	O
His	O
(	O
6	O
)	O
tag	O
.	O

Loss	O
of	O
Prmt1	S-Protein
activity	O
(	O
and	O
hypomethylation	O
of	O
hnRNPs	O
)	O
has	O
no	O
obvious	O
effect	O
on	O
the	O
formation	O
or	O
composition	O
of	O
hnRNP	O
complexes	O
.	O

Finally	O
,	O
methylation	O
of	O
the	O
most	O
abundant	O
Prmt1	S-Protein
substrates	O
appeared	O
to	O
be	O
extensive	O
and	O
constitutive	O
throughout	O
the	O
cell	O
cycle	O
,	O
suggesting	O
the	O
modification	O
does	O
not	O
modulate	O
protein	O
function	O
under	O
normal	O
growth	O
conditions	O
.	O

Group	O
D	O
prothrombin	S-Protein
activators	O
from	O
snake	O
venom	O
are	O
structural	O
homologues	O
of	O
mammalian	O
blood	O
coagulation	B-Protein
factor	I-Protein
Xa	E-Protein
.	O

Procoagulant	O
venoms	O
of	O
several	O
Australian	O
elapids	O
contain	O
proteinases	O
that	O
specifically	O
activate	O
prothrombin	S-Protein
;	O
among	O
these	O
,	O
Group	O
D	O
activators	O
are	O
functionally	O
similar	O
to	O
coagulation	B-Protein
factor	I-Protein
Xa	E-Protein
(	O
FXa	S-Protein
)	O
.	O

Structural	O
information	O
on	O
this	O
class	O
of	O
prothrombin	S-Protein
activators	O
will	O
contribute	O
significantly	O
towards	O
understanding	O
the	O
mechanism	O
of	O
FXa	S-Protein
-	O
mediated	O
prothrombin	S-Protein
activation	O
.	O

Here	O
we	O
present	O
the	O
purification	O
of	O
Group	O
D	O
prothrombin	S-Protein
activators	O
from	O
three	O
Australian	O
snake	O
venoms	O
(	O
Hoplocephalus	O
stephensi	O
,	O
Notechis	O
scutatus	O
scutatus	O
and	O
Notechis	O
ater	O
niger	O
)	O
using	O
a	O
single	O
-	O
step	O
method	O
,	O
and	O
their	O
N	O
-	O
terminal	O
sequences	O
.	O

The	O
N	O
-	O
terminal	O
sequence	O
of	O
the	O
heavy	O
chain	O
of	O
hopsarin	B-Protein
D	E-Protein
(	O
H	O
.	O
stephensi	O
)	O
revealed	O
that	O
a	O
fully	O
conserved	O
Cys	O
-	O
7	O
was	O
substituted	O
with	O
a	O
Ser	O
residue	O
.	O

We	O
therefore	O
determined	O
the	O
complete	O
amino	O
acid	O
sequence	O
of	O
hopsarin	B-Protein
D	E-Protein
.	O

Hopsarin	B-Protein
D	E-Protein
shows	O
approximately	O
70	O
%	O
similarity	O
with	O
FXa	S-Protein
and	O
approximately	O
98	O
%	O
similarity	O
with	O
trocarin	B-Protein
D	E-Protein
,	O
a	O
Group	O
D	O
prothrombin	S-Protein
activator	O
from	O
Tropidechis	O
carinatus	O
.	O

It	O
possesses	O
the	O
characteristic	O
Gla	O
domain	O
,	O
two	O
epidermal	O
growth	O
factor	O
-	O
like	O
domains	O
and	O
a	O
serine	O
proteinase	O
domain	O
.	O

All	O
residues	O
important	O
for	O
catalysis	O
are	O
conserved	O
,	O
as	O
are	O
most	O
regions	O
involved	O
in	O
interactions	O
with	O
factor	B-Protein
Va	E-Protein
and	O
prothrombin	S-Protein
.	O

However	O
,	O
there	O
are	O
some	O
structural	O
differences	O
.	O

Unlike	O
FXa	S-Protein
,	O
hopsarin	B-Protein
D	E-Protein
is	O
glycosylated	O
in	O
both	O
its	O
chains	O
:	O
in	O
light	O
-	O
chain	O
residue	O
52	O
and	O
heavy	O
-	O
chain	O
residue	O
45	O
.	O

The	O
glycosylation	O
on	O
the	O
heavy	O
chain	O
is	O
a	O
large	O
carbohydrate	O
moiety	O
adjacent	O
to	O
the	O
active	O
-	O
site	O
pocket	O
.	O

Overall	O
,	O
hopsarin	B-Protein
D	E-Protein
is	O
structurally	O
and	O
functionally	O
similar	O
to	O
mammalian	O
coagulation	B-Protein
FXa	E-Protein
.	O

Resistance	O
to	O
the	O
macrolide	O
antibiotic	O
tylosin	O
is	O
conferred	O
by	O
single	O
methylations	O
at	O
23S	O
rRNA	O
nucleotides	O
G748	O
and	O
A2058	O
acting	O
in	O
synergy	O
.	O

The	O
macrolide	O
antibiotic	O
tylosin	O
has	O
been	O
used	O
extensively	O
in	O
veterinary	O
medicine	O
and	O
exerts	O
potent	O
antimicrobial	O
activity	O
against	O
Gram	O
-	O
positive	O
bacteria	O
.	O

Tylosin	O
-	O
synthesizing	O
strains	O
of	O
the	O
Gram	O
-	O
positive	O
bacterium	O
Streptomyces	O
fradiae	O
protect	O
themselves	O
from	O
their	O
own	O
product	O
by	O
differential	O
expression	O
of	O
four	O
resistance	O
determinants	O
,	O
tlrA	S-Protein
,	O
tlrB	S-Protein
,	O
tlrC	S-Protein
,	O
and	O
tlrD	S-Protein
.	O

The	O
tlrB	S-Protein
and	O
tlrD	S-Protein
genes	O
encode	O
methyltransferases	O
that	O
add	O
single	O
methyl	O
groups	O
at	O
23S	O
rRNA	O
nucleotides	O
G748	O
and	O
A2058	O
,	O
respectively	O
.	O

Here	O
we	O
show	O
that	O
methylation	O
by	O
neither	O
TlrB	S-Protein
nor	O
TlrD	S-Protein
is	O
sufficient	O
on	O
its	O
own	O
to	O
give	O
tylosin	O
resistance	O
,	O
and	O
resistance	O
is	O
conferred	O
by	O
the	O
G748	O
and	O
A2058	O
methylations	O
acting	O
together	O
in	O
synergy	O
.	O

This	O
synergistic	O
mechanism	O
of	O
resistance	O
is	O
specific	O
for	O
the	O
macrolides	O
tylosin	O
and	O
mycinamycin	O
that	O
possess	O
sugars	O
extending	O
from	O
the	O
5	O
-	O
and	O
14	O
-	O
positions	O
of	O
the	O
macrolactone	O
ring	O
and	O
is	O
not	O
observed	O
for	O
macrolides	O
,	O
such	O
as	O
carbomycin	O
,	O
spiramycin	O
,	O
and	O
erythromycin	O
,	O
that	O
have	O
different	O
constellations	O
of	O
sugars	O
.	O

The	O
manner	O
in	O
which	O
the	O
G748	O
and	O
A2058	O
methylations	O
coincide	O
with	O
the	O
glycosylation	O
patterns	O
of	O
tylosin	O
and	O
mycinamycin	O
reflects	O
unambiguously	O
how	O
these	O
macrolides	O
fit	O
into	O
their	O
binding	O
site	O
within	O
the	O
bacterial	O
50S	O
ribosomal	O
subunit	O
.	O

A	O
novel	O
interaction	O
of	O
outer	B-Protein
membrane	I-Protein
protein	I-Protein
A	E-Protein
with	O
C4b	S-Protein
binding	O
protein	O
mediates	O
serum	O
resistance	O
of	O
Escherichia	O
coli	O
K1	O
.	O

Escherichia	O
coli	O
is	O
an	O
important	O
pathogen	O
that	O
causes	O
meningitis	O
in	O
neonates	O
.	O

The	O
development	O
of	O
bacteremia	O
preceding	O
the	O
traversal	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
is	O
a	O
prerequisite	O
for	O
this	O
pathogen	O
that	O
obviously	O
must	O
survive	O
the	O
bactericidal	O
activity	O
of	O
serum	O
.	O

Here	O
we	O
report	O
that	O
outer	B-Protein
membrane	I-Protein
protein	I-Protein
A	E-Protein
(	O
OmpA	S-Protein
)	O
of	O
Escherichia	O
coli	O
contributes	O
to	O
serum	O
resistance	O
by	O
binding	O
to	O
C4b	S-Protein
binding	O
protein	O
(	O
C4bp	O
)	O
,	O
a	O
complement	O
fluid	O
phase	O
regulator	O
.	O

C4bp	O
contains	O
seven	O
identical	O
alpha	O
-	O
chains	O
and	O
one	O
beta	O
-	O
chain	O
linked	O
together	O
with	O
disulfide	O
bridges	O
.	O

We	O
found	O
that	O
OmpA	S-Protein
binds	O
the	O
alpha	O
-	O
chain	O
of	O
C4bp	O
,	O
which	O
is	O
composed	O
of	O
eight	O
homologous	O
complement	O
control	O
protein	O
(	O
CCP	O
)	O
modules	O
.	O

Binding	O
studies	O
using	O
mutants	O
of	O
recombinant	O
C4bp	O
that	O
lack	O
one	O
CCP	O
at	O
a	O
time	O
suggest	O
that	O
CCP3	O
is	O
the	O
major	O
site	O
of	O
interaction	O
with	O
OmpA	S-Protein
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
N	O
terminus	O
of	O
OmpA	S-Protein
interacts	O
with	O
C4bp	O
.	O

Binding	O
of	O
C4bp	O
to	O
OmpA	S-Protein
is	O
not	O
significantly	O
inhibited	O
in	O
the	O
presence	O
of	O
either	O
C4b	S-Protein
or	O
heparin	O
and	O
is	O
not	O
salt	O
sensitive	O
,	O
implying	O
that	O
it	O
is	O
hydrophobic	O
in	O
nature	O
,	O
suggesting	O
a	O
novel	O
interaction	O
between	O
OmpA	S-Protein
and	O
C4bp	O
.	O

A	O
compelling	O
observation	O
in	O
this	O
study	O
is	O
that	O
synthetic	O
peptides	O
corresponding	O
to	O
CCP3	O
sequences	O
block	O
the	O
binding	O
of	O
C4bp	O
to	O
OmpA	S-Protein
and	O
also	O
significantly	O
enhance	O
serum	O
bactericidal	O
activity	O
.	O

The	O
Golgi	O
GDPase	S-Protein
of	O
the	O
fungal	O
pathogen	O
Candida	O
albicans	O
affects	O
morphogenesis	O
,	O
glycosylation	O
,	O
and	O
cell	O
wall	O
properties	O
.	O

Cell	O
wall	O
mannoproteins	O
are	O
largely	O
responsible	O
for	O
the	O
adhesive	O
properties	O
and	O
immunomodulation	O
ability	O
of	O
the	O
fungal	O
pathogen	O
Candida	O
albicans	O
.	O

The	O
outer	O
chain	O
extension	O
of	O
yeast	O
mannoproteins	O
occurs	O
in	O
the	O
lumen	O
of	O
the	O
Golgi	O
apparatus	O
.	O

GDP	O
-	O
mannose	O
must	O
first	O
be	O
transported	O
from	O
the	O
cytosol	O
into	O
the	O
Golgi	O
lumen	O
,	O
where	O
mannose	O
is	O
transferred	O
to	O
mannans	O
.	O

GDP	O
is	O
hydrolyzed	O
by	O
a	O
GDPase	S-Protein
,	O
encoded	O
by	O
GDA1	S-Protein
,	O
to	O
GMP	O
,	O
which	O
then	O
exits	O
the	O
Golgi	O
lumen	O
in	O
a	O
coupled	O
,	O
equimolar	O
exchange	O
with	O
cytosolic	O
GDP	O
-	O
mannose	O
.	O

We	O
isolated	O
and	O
disrupted	O
the	O
C	O
.	O
albicans	O
homologue	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
GDA1	S-Protein
gene	O
in	O
order	O
to	O
investigate	O
its	O
role	O
in	O
protein	O
mannosylation	O
and	O
pathogenesis	O
.	O

CaGda1p	S-Protein
shares	O
four	O
apyrase	O
conserved	O
regions	O
with	O
other	O
nucleoside	O
diphosphatases	O
.	O

Membranes	O
prepared	O
from	O
the	O
C	O
.	O
albicans	O
disrupted	O
gda1	S-Protein
/	O
gda1	S-Protein
strain	O
had	O
a	O
90	O
%	O
decrease	O
in	O
the	O
ability	O
to	O
hydrolyze	O
GDP	O
compared	O
to	O
wild	O
type	O
.	O

The	O
gda1	S-Protein
/	O
gda1	S-Protein
mutants	O
showed	O
a	O
severe	O
defect	O
in	O
O	O
-	O
mannosylation	O
and	O
reduced	O
cell	O
wall	O
phosphate	O
content	O
.	O

Other	O
cell	O
wall	O
-	O
related	O
phenotypes	O
are	O
present	O
,	O
such	O
as	O
elevated	O
chitin	O
levels	O
and	O
increased	O
susceptibility	O
to	O
attack	O
by	O
beta	O
-	O
1	O
,	O
3	O
-	O
glucanases	O
.	O

Our	O
results	O
show	O
that	O
the	O
C	O
.	O
albicans	O
organism	O
contains	O
beta	O
-	O
mannose	O
at	O
their	O
nonreducing	O
end	O
,	O
differing	O
from	O
S	O
.	O
cerevisiae	O
,	O
which	O
has	O
only	O
alpha	O
-	O
linked	O
mannose	O
residues	O
in	O
its	O
O	O
-	O
glycans	O
.	O

Mutants	O
lacking	O
both	O
alleles	O
of	O
GDA1	S-Protein
grow	O
at	O
the	O
same	O
rate	O
as	O
the	O
wild	O
type	O
but	O
are	O
partially	O
blocked	O
in	O
hyphal	O
formation	O
in	O
Lee	O
solid	O
medium	O
and	O
during	O
induction	O
in	O
liquid	O
by	O
changes	O
in	O
temperature	O
and	O
pH	O
.	O

However	O
,	O
the	O
mutants	O
still	O
form	O
normal	O
hyphae	O
in	O
the	O
presence	O
of	O
serum	O
and	O
N	O
-	O
acetylglucosamine	O
and	O
do	O
not	O
change	O
their	O
adherence	O
to	O
HeLa	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
data	O
are	O
in	O
agreement	O
with	O
the	O
hypothesis	O
that	O
several	O
pathways	O
regulate	O
the	O
yeast	O
-	O
hypha	O
transition	O
.	O

Gda1	S-Protein
/	O
gda1	S-Protein
cells	O
offer	O
a	O
model	O
for	O
discriminating	O
among	O
them	O
.	O

Histidine	O
407	O
,	O
a	O
phantom	O
residue	O
in	O
the	O
E1	O
subunit	O
of	O
the	O
Escherichia	O
coli	O
pyruvate	O
dehydrogenase	O
complex	O
,	O
activates	O
reductive	O
acetylation	O
of	O
lipoamide	O
on	O
the	O
E2	O
subunit	O
.	O

An	O
explanation	O
for	O
conservation	O
of	O
active	O
sites	O
between	O
the	O
E1	O
subunit	O
and	O
transketolase	O
.	O

Least	O
squares	O
alignment	O
of	O
the	O
E	O
.	O
coli	O
pyruvate	B-Protein
dehydrogenase	I-Protein
multienzyme	I-Protein
complex	I-Protein
E1	I-Protein
subunit	E-Protein
and	O
yeast	O
transketolase	O
crystal	O
structures	O
indicates	O
a	O
general	O
structural	O
similarity	O
between	O
the	O
two	O
enzymes	O
and	O
provides	O
a	O
plausible	O
location	O
for	O
a	O
short	O
-	O
loop	O
region	O
in	O
the	O
E1	O
structure	O
that	O
was	O
unobserved	O
due	O
to	O
disorder	O
.	O

The	O
residue	O
H407	O
,	O
located	O
in	O
this	O
region	O
,	O
is	O
shown	O
to	O
be	O
able	O
to	O
penetrate	O
the	O
active	O
site	O
.	O

Suggested	O
by	O
this	O
comparison	O
,	O
the	O
H407A	O
E1	O
variant	O
was	O
created	O
,	O
and	O
H407	O
was	O
shown	O
to	O
participate	O
in	O
the	O
reductive	O
acetylation	O
of	O
both	O
an	O
independently	O
expressed	O
lipoyl	O
domain	O
and	O
the	O
intact	O
1	O
-	O
lipoyl	O
E2	O
subunit	O
.	O

While	O
the	O
H407A	O
substitution	O
only	O
modestly	O
affected	O
the	O
reaction	O
through	O
pyruvate	O
decarboxylation	O
(	O
ca	O
.	O
14	O
%	O
activity	O
compared	O
to	O
parental	O
E1	O
)	O
,	O
the	O
overall	O
complex	O
has	O
a	O
much	O
impaired	O
activity	O
,	O
at	O
most	O
0	O
.	O
15	O
%	O
compared	O
to	O
parental	O
E1	O
.	O

Isothermal	O
titration	O
calorimetry	O
measurements	O
show	O
that	O
the	O
binding	O
of	O
the	O
lipoyl	O
domain	O
to	O
the	O
H407A	O
E1	O
variant	O
is	O
much	O
weaker	O
than	O
that	O
to	O
parental	O
E1	O
.	O

At	O
the	O
same	O
time	O
,	O
mass	O
spectrometric	O
measurements	O
clearly	O
demonstrate	O
much	O
impaired	O
reductive	O
acetylation	O
of	O
the	O
independently	O
expressed	O
lipoyl	O
domain	O
and	O
of	O
the	O
intact	O
1	O
-	O
lipoyl	O
E2	O
by	O
the	O
H407A	O
variant	O
compared	O
to	O
the	O
parental	O
E1	O
.	O

A	O
proposal	O
is	O
presented	O
to	O
explain	O
the	O
remarkable	O
conservation	O
of	O
the	O
three	O
-	O
dimensional	O
structure	O
at	O
the	O
active	O
centers	O
of	O
the	O
E	O
.	O
coli	O
E1	O
subunit	O
and	O
transketolase	O
on	O
the	O
basis	O
of	O
the	O
parallels	O
in	O
the	O
ligation	O
-	O
type	O
reactions	O
carried	O
out	O
and	O
the	O
need	O
to	O
protonate	O
a	O
very	O
weak	O
acid	O
,	O
a	O
dithiolane	O
sulfur	O
atom	O
in	O
the	O
former	O
,	O
and	O
a	O
carbonyl	O
oxygen	O
atom	O
in	O
the	O
latter	O
.	O

Sorting	O
of	O
rat	O
SPNT	S-Protein
in	O
renal	O
epithelium	O
is	O
independent	O
of	O
N	O
-	O
glycosylation	O
.	O

PURPOSE	O
:	O
The	O
sodium	O
-	O
dependent	O
,	O
purine	O
-	O
selective	O
nucleoside	O
transporter	O
,	O
SPNT	S-Protein
,	O
has	O
a	O
unique	O
steady	O
-	O
state	O
expression	O
pattern	O
in	O
renal	O
epithelial	O
cells	O
.	O

In	O
comparison	O
with	O
the	O
concentrative	O
nucleoside	O
transporter	O
,	O
CNTI	S-Protein
,	O
which	O
is	O
confined	O
to	O
the	O
apical	O
membrane	O
,	O
SPNT	S-Protein
is	O
expressed	O
predominantly	O
on	O
the	O
apical	O
membrane	O
but	O
with	O
significant	O
expression	O
on	O
the	O
basolateral	O
membrane	O
as	O
well	O
.	O

Alternate	O
surface	O
expression	O
indicates	O
that	O
SPNT	S-Protein
likely	O
has	O
different	O
sorting	O
and	O
trafficking	O
mechanisms	O
from	O
CNTI	S-Protein
.	O

Because	O
glycosylation	O
has	O
been	O
reported	O
to	O
be	O
essential	O
for	O
apical	O
targeting	O
of	O
other	O
transporters	O
,	O
and	O
SPNT	S-Protein
contains	O
three	O
unique	O
glycosylation	O
sites	O
,	O
we	O
examined	O
the	O
importance	O
of	O
glycosylation	O
in	O
sorting	O
of	O
SPNT	S-Protein
.	O

Preliminary	O
studies	O
suggested	O
that	O
glycosylation	O
affects	O
surface	O
expression	O
of	O
SPNT	S-Protein
but	O
not	O
CNT1	S-Protein
.	O

METHODS	O
:	O
All	O
three	O
unique	O
glycosylation	O
sites	O
were	O
mutated	O
alone	O
and	O
in	O
tandem	O
.	O

Wild	O
-	O
type	O
and	O
mutant	O
SPNT	S-Protein
,	O
tagged	O
with	O
green	B-Protein
fluorescence	I-Protein
protein	E-Protein
,	O
were	O
stably	O
transfected	O
into	O
MDCK	O
.	O

Positive	O
clones	O
were	O
assayed	O
for	O
polarized	O
surface	O
expression	O
by	O
immunofluorescence	O
and	O
functional	O
analysis	O
.	O

RESULTS	O
:	O
Mutation	O
at	O
all	O
three	O
sites	O
alone	O
or	O
in	O
tandem	O
resulted	O
in	O
functional	O
proteins	O
.	O

Removal	O
of	O
sites	O
N606	O
and	O
N625	O
resulted	O
in	O
proteins	O
of	O
reduced	O
molecular	O
mass	O
.	O

None	O
of	O
the	O
unglycosylated	O
mutants	O
localized	O
differently	O
than	O
wild	O
-	O
type	O
SPNT	S-Protein
.	O

CONCLUSION	O
:	O
N	O
-	O
linked	O
glycosylation	O
is	O
not	O
essential	O
for	O
polarized	O
sorting	O
.	O

Methylation	O
of	O
p16	B-Protein
(	I-Protein
INK4a	I-Protein
)	E-Protein
promoters	O
occurs	O
in	O
vivo	O
in	O
histologically	O
normal	O
human	O
mammary	O
epithelia	O
.	O

Cultures	O
of	O
human	O
mammary	O
epithelial	O
cells	O
(	O
HMECs	O
)	O
contain	O
a	O
subpopulation	O
of	O
variant	O
cells	O
with	O
the	O
capacity	O
to	O
propagate	O
beyond	O
an	O
in	O
vitro	O
proliferation	O
barrier	O
.	O

These	O
variant	O
HMECs	O
,	O
which	O
contain	O
hypermethylated	O
and	O
silenced	O
p16	B-Protein
(	I-Protein
INK4a	I-Protein
)	E-Protein
(	O
p16	S-Protein
)	O
promoters	O
,	O
eventually	O
accumulate	O
multiple	O
chromosomal	O
changes	O
,	O
many	O
of	O
which	O
are	O
similar	O
to	O
those	O
detected	O
in	O
premalignant	O
and	O
malignant	O
lesions	O
of	O
breast	O
cancer	O
.	O

To	O
determine	O
the	O
origin	O
of	O
these	O
variant	O
HMECs	O
in	O
culture	O
,	O
we	O
used	O
Luria	O
-	O
Delbruck	O
fluctuation	O
analysis	O
and	O
found	O
that	O
variant	O
HMECs	O
exist	O
within	O
the	O
population	O
before	O
the	O
proliferation	O
barrier	O
,	O
thereby	O
raising	O
the	O
possibility	O
that	O
variant	O
HMECs	O
exist	O
in	O
vivo	O
before	O
cultivation	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
examined	O
mammary	O
tissue	O
from	O
normal	O
women	O
for	O
evidence	O
of	O
p16	S-Protein
promoter	O
hypermethylation	O
.	O

Here	O
we	O
show	O
that	O
epithelial	O
cells	O
with	O
methylation	O
of	O
p16	S-Protein
promoter	O
sequences	O
occur	O
in	O
focal	O
patches	O
of	O
histologically	O
normal	O
mammary	O
tissue	O
of	O
a	O
substantial	O
fraction	O
of	O
healthy	O
,	O
cancer	O
-	O
free	O
women	O
.	O

The	O
transcriptional	O
enhancer	O
of	O
the	O
pea	O
plastocyanin	S-Protein
gene	O
associates	O
with	O
the	O
nuclear	O
matrix	O
and	O
regulates	O
gene	O
expression	O
through	O
histone	S-Protein
acetylation	O
.	O

The	O
influence	O
of	O
the	O
transcriptional	O
enhancer	O
of	O
the	O
pea	O
plastocyanin	S-Protein
gene	O
(	O
PetE	S-Protein
)	O
on	O
the	O
acetylation	O
of	O
histones	S-Protein
was	O
examined	O
with	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
experiments	O
using	O
antibodies	O
that	O
recognize	O
acetylated	O
or	O
nonacetylated	O
histones	B-Protein
H3	E-Protein
and	O
H4	S-Protein
.	O

In	O
transgenic	O
tobacco	O
plants	O
containing	O
the	O
pea	O
PetE	S-Protein
promoter	O
fused	O
to	O
uidA	S-Protein
,	O
both	O
acetylated	O
and	O
nonacetylated	O
histones	B-Protein
H3	E-Protein
and	O
H4	S-Protein
were	O
present	O
on	O
the	O
integrated	O
transgene	O
.	O

Linking	O
the	O
PetE	S-Protein
enhancer	O
to	O
the	O
transgene	O
resulted	O
in	O
increased	O
beta	B-Protein
-	I-Protein
glucuronidase	E-Protein
activity	O
and	O
increased	O
amounts	O
of	O
acetylated	O
histones	B-Protein
H3	E-Protein
and	O
H4	S-Protein
present	O
on	O
the	O
promoter	O
,	O
suggesting	O
that	O
the	O
enhancer	O
may	O
increase	O
transcription	O
by	O
mediating	O
the	O
acetylation	O
of	O
histones	S-Protein
.	O

Trichostatin	O
A	O
and	O
sodium	O
butyrate	O
,	O
which	O
are	O
potent	O
inhibitors	O
of	O
histone	S-Protein
deacetylases	O
(	O
HDAs	O
)	O
,	O
activated	O
expression	O
from	O
the	O
PetE	S-Protein
promoter	O
by	O
fourfold	O
,	O
with	O
a	O
concomitant	O
increase	O
in	O
the	O
acetylation	O
states	O
of	O
histones	B-Protein
H3	E-Protein
and	O
H4	S-Protein
,	O
as	O
determined	O
by	O
ChIP	O
,	O
indicating	O
that	O
the	O
acetylation	O
of	O
histones	S-Protein
has	O
a	O
direct	O
positive	O
effect	O
on	O
transcription	O
.	O

The	O
HDA	O
inhibitors	O
did	O
not	O
increase	O
expression	O
from	O
the	O
PetE	S-Protein
promoter	O
when	O
it	O
was	O
linked	O
to	O
the	O
enhancer	O
,	O
consistent	O
with	O
preexisting	O
hyperacetylated	O
histones	S-Protein
on	O
the	O
transgene	O
.	O

Mapping	O
of	O
histone	S-Protein
acetylation	O
states	O
along	O
the	O
reporter	O
gene	O
indicated	O
that	O
the	O
histones	B-Protein
H3	E-Protein
and	O
H4	S-Protein
associated	O
with	O
the	O
promoter	O
and	O
the	O
5	O
'	O
region	O
of	O
uidA	S-Protein
were	O
hyperacetylated	O
in	O
the	O
presence	O
of	O
the	O
PetE	S-Protein
enhancer	O
.	O

The	O
PetE	S-Protein
enhancer	O
bound	O
to	O
isolated	O
tobacco	O
nuclear	O
matrices	O
in	O
vitro	O
and	O
was	O
associated	O
with	O
the	O
nuclear	O
matrix	O
in	O
nuclei	O
isolated	O
from	O
transgenic	O
tobacco	O
plants	O
.	O

These	O
results	O
suggest	O
that	O
the	O
pea	O
PetE	S-Protein
enhancer	O
activates	O
transcription	O
by	O
associating	O
with	O
the	O
nuclear	O
matrix	O
,	O
mediating	O
the	O
acetylation	O
of	O
histones	S-Protein
on	O
the	O
promoter	O
and	O
the	O
nearby	O
coding	O
region	O
and	O
resulting	O
in	O
an	O
altered	O
chromatin	O
structure	O
.	O

Role	O
of	O
calnexin	S-Protein
in	O
the	O
glycan	O
-	O
independent	O
quality	O
control	O
of	O
proteolipid	B-Protein
protein	E-Protein
.	O

The	O
endoplasmic	O
(	O
ER	O
)	O
quality	O
control	O
apparatus	O
ensures	O
that	O
misfolded	O
or	O
unassembled	O
proteins	O
are	O
not	O
deployed	O
within	O
the	O
cell	O
,	O
but	O
are	O
retained	O
in	O
the	O
ER	O
and	O
degraded	O
.	O

A	O
glycoprotein	O
-	O
specific	O
system	O
involving	O
the	O
ER	O
lectins	O
calnexin	S-Protein
and	O
calreticulin	S-Protein
is	O
well	O
documented	O
,	O
but	O
very	O
little	O
is	O
known	O
about	O
mechanisms	O
that	O
may	O
operate	O
for	O
non	O
-	O
glycosylated	O
proteins	O
.	O

We	O
have	O
used	O
a	O
folding	O
mutant	O
of	O
a	O
non	O
-	O
glycosylated	O
membrane	O
protein	O
,	O
proteolipid	B-Protein
protein	E-Protein
(	O
PLP	S-Protein
)	O
,	O
to	O
examine	O
the	O
quality	O
control	O
of	O
this	O
class	O
of	O
polypeptide	O
.	O

We	O
find	O
that	O
calnexin	S-Protein
associates	O
with	O
newly	O
synthesized	O
PLP	S-Protein
molecules	O
,	O
binding	O
stably	O
to	O
misfolded	O
PLP	S-Protein
.	O

Calnexin	S-Protein
also	O
binds	O
stably	O
to	O
an	O
isolated	O
transmembrane	O
domain	O
of	O
PLP	S-Protein
,	O
suggesting	O
that	O
this	O
chaperone	O
is	O
able	O
to	O
monitor	O
the	O
folding	O
and	O
assembly	O
of	O
domains	O
within	O
the	O
ER	O
membrane	O
.	O

Notably	O
,	O
this	O
glycan	O
-	O
independent	O
interaction	O
with	O
calnexin	S-Protein
significantly	O
retards	O
the	O
degradation	O
of	O
misfolded	O
PLP	S-Protein
.	O

We	O
propose	O
that	O
calnexin	S-Protein
contributes	O
to	O
the	O
quality	O
control	O
of	O
non	O
-	O
glycosylated	O
polytopic	O
membrane	O
proteins	O
by	O
binding	O
to	O
misfolded	O
or	O
unassembled	O
transmembrane	O
domains	O
,	O
and	O
discuss	O
our	O
findings	O
in	O
relation	O
to	O
the	O
role	O
of	O
calnexin	S-Protein
in	O
the	O
degradation	O
of	O
misfolded	O
proteins	O
.	O

N	O
-	O
linked	O
glycosylation	O
of	O
native	O
and	O
recombinant	O
cauliflower	O
xyloglucan	B-Protein
endotransglycosylase	I-Protein
16A	E-Protein
.	O

The	O
gene	O
encoding	O
a	O
XET	S-Protein
(	O
xyloglucan	B-Protein
endotransglycosylase	E-Protein
)	O
from	O
cauliflower	O
(	O
Brassica	O
oleracea	O
var	O
.	O
botrytis	O
)	O
florets	O
has	O
been	O
cloned	O
and	O
sequenced	O
.	O

Sequence	O
analysis	O
indicated	O
a	O
high	O
degree	O
of	O
similarity	O
to	O
other	O
XET	S-Protein
enzymes	O
belonging	O
to	O
glycosyl	B-Protein
hydrolase	I-Protein
family	I-Protein
16	E-Protein
(	O
GH16	S-Protein
)	O
.	O

In	O
addition	O
to	O
the	O
conserved	O
GH16	S-Protein
catalytic	O
sequence	O
motif	O
EIDFE	O
,	O
there	O
exists	O
one	O
potential	O
N	O
-	O
linked	O
glycosylation	O
site	O
,	O
which	O
is	O
also	O
highly	O
conserved	O
in	O
XET	S-Protein
enzymes	O
from	O
this	O
family	O
.	O

Purification	O
of	O
the	O
corresponding	O
protein	O
from	O
extracts	O
of	O
cauliflower	O
florets	O
allowed	O
the	O
fractionation	O
of	O
a	O
single	O
,	O
pure	O
glycoform	O
,	O
which	O
was	O
analysed	O
by	O
MS	O
techniques	O
.	O

Accurate	O
protein	O
mass	O
determination	O
following	O
the	O
enzymic	O
deglycosylation	O
of	O
this	O
glycoform	O
indicated	O
the	O
presence	O
of	O
a	O
high	O
-	O
mannose	O
-	O
type	O
glycan	O
of	O
the	O
general	O
structure	O
GlcNAc2Man6	O
.	O

LC	O
/	O
MS	O
and	O
MS	O
/	O
MS	O
(	O
tandem	O
MS	O
)	O
analysis	O
provided	O
supporting	O
evidence	O
for	O
this	O
structure	O
and	O
confirmed	O
that	O
the	O
glycosylation	O
site	O
(	O
underlined	O
)	O
was	O
situated	O
close	O
to	O
the	O
predicted	O
catalytic	O
residues	O
in	O
the	O
conserved	O
sequence	O
YLSSTNNEHDEIDFEFLGNRTGQPVILQTNVFTGGK	O
.	O

Heterologous	O
expression	O
in	O
Pichia	O
pastoris	O
produced	O
a	O
range	O
of	O
protein	O
glycoforms	O
,	O
which	O
were	O
,	O
on	O
average	O
,	O
more	O
highly	O
mannosylated	O
than	O
the	O
purified	O
native	O
enzyme	O
.	O

This	O
difference	O
in	O
glycosylation	O
did	O
not	O
influence	O
the	O
apparent	O
enzymic	O
activity	O
of	O
the	O
enzyme	O
significantly	O
.	O

However	O
,	O
the	O
removal	O
of	O
high	O
-	O
mannose	O
glycosylation	O
in	O
recombinant	O
cauliflower	O
XET	S-Protein
by	O
endoglycosidase	B-Protein
H	E-Protein
,	O
quantified	O
by	O
electrospray	O
-	O
ionization	O
MS	O
,	O
caused	O
a	O
40	O
%	O
decrease	O
in	O
the	O
transglycosylation	O
activity	O
of	O
the	O
enzyme	O
.	O

No	O
hydrolytic	O
activity	O
was	O
detected	O
in	O
native	O
or	O
heterologously	O
expressed	O
BobXET16A	S-Protein
,	O
even	O
when	O
almost	O
completely	O
deglycosylated	O
.	O

Characterization	O
of	O
protein	B-Protein
kinase	I-Protein
C	I-Protein
-	I-Protein
delta	E-Protein
in	O
mouse	O
oocytes	O
throughout	O
meiotic	O
maturation	O
and	O
following	O
egg	O
activation	O
.	O

Changes	O
in	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activity	O
influence	O
the	O
progression	O
of	O
meiosis	O
;	O
however	O
,	O
the	O
specific	O
function	O
of	O
the	O
various	O
PKC	O
isoforms	O
in	O
female	O
gametes	O
is	O
not	O
known	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
protein	O
expression	O
and	O
subcellular	O
distribution	O
profile	O
of	O
PKC	B-Protein
-	I-Protein
delta	E-Protein
(	O
PKC	B-Protein
-	I-Protein
delta	E-Protein
)	O
,	O
a	O
novel	O
isoform	O
of	O
the	O
PKC	O
family	O
,	O
was	O
determined	O
in	O
mouse	O
oocytes	O
undergoing	O
meiotic	O
maturation	O
and	O
following	O
egg	O
activation	O
.	O

The	O
full	O
-	O
length	O
protein	O
was	O
observed	O
as	O
a	O
doublet	O
(	O
76	O
and	O
78	O
kDa	O
)	O
on	O
Western	O
blot	O
analysis	O
.	O

A	O
smaller	O
(	O
47	O
kDa	O
)	O
carboxyl	O
-	O
terminal	O
fragment	O
,	O
presumably	O
the	O
truncated	O
catalytic	O
domain	O
of	O
PKC	B-Protein
-	I-Protein
delta	E-Protein
,	O
was	O
also	O
strongly	O
expressed	O
.	O

Both	O
the	O
full	O
-	O
length	O
protein	O
and	O
the	O
catalytic	O
fragment	O
became	O
phosphorylated	O
coincident	O
with	O
the	O
resumption	O
of	O
meiosis	O
and	O
remained	O
phosphorylated	O
throughout	O
metaphase	O
II	O
(	O
MII	O
)	O
arrest	O
.	O

Immunofluorescence	O
staining	O
showed	O
PKC	B-Protein
-	I-Protein
delta	E-Protein
distributed	O
diffusely	O
throughout	O
the	O
cytoplasm	O
of	O
oocytes	O
during	O
maturation	O
and	O
associated	O
with	O
the	O
spindle	O
apparatus	O
during	O
the	O
first	O
meiotic	O
division	O
.	O

Discrete	O
foci	O
of	O
the	O
protein	O
also	O
localized	O
with	O
the	O
chromosomes	O
in	O
some	O
mature	O
eggs	O
.	O

Following	O
the	O
completion	O
of	O
meiosis	O
,	O
PKC	B-Protein
-	I-Protein
delta	E-Protein
became	O
dephosphorylated	O
within	O
2	O
h	O
of	O
in	O
vitro	O
fertilization	O
or	O
parthenogenetic	O
activation	O
.	O

The	O
protein	O
also	O
accumulated	O
in	O
the	O
nuclei	O
of	O
early	O
embryos	O
and	O
was	O
phosphorylated	O
during	O
M	O
-	O
phase	O
of	O
the	O
initial	O
mitotic	O
cleavage	O
division	O
.	O

By	O
the	O
two	O
-	O
cell	O
stage	O
,	O
expression	O
of	O
the	O
truncated	O
catalytic	O
fragment	O
was	O
minimal	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
subcellular	O
distribution	O
and	O
posttranslational	O
modification	O
of	O
PKC	B-Protein
-	I-Protein
delta	E-Protein
is	O
cell	O
cycle	O
dependent	O
,	O
suggesting	O
that	O
its	O
activity	O
and	O
/	O
or	O
function	O
likely	O
vary	O
with	O
the	O
progression	O
of	O
meiosis	O
and	O
egg	O
activation	O
.	O

HIF	O
prolyl	O
and	O
asparaginyl	O
hydroxylases	O
in	O
the	O
biological	O
response	O
to	O
intracellular	O
O	O
(	O
2	O
)	O
levels	O
.	O

Hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
is	O
a	O
heterodimeric	O
transcription	O
factor	O
that	O
plays	O
a	O
crucial	O
role	O
in	O
mediating	O
cellular	O
responses	O
to	O
oxygen	O
.	O

Oxygen	O
availability	O
influences	O
multiple	O
steps	O
in	O
HIF	O
activation	O
and	O
recent	O
studies	O
have	O
indicated	O
that	O
at	O
least	O
two	O
steps	O
in	O
this	O
process	O
are	O
governed	O
by	O
a	O
novel	O
mode	O
of	O
signal	O
transduction	O
involving	O
enzymatic	O
hydroxylation	O
of	O
specific	O
amino	O
acid	O
residues	O
in	O
HIF	O
-	O
alpha	O
subunits	O
by	O
a	O
series	O
of	O
2	O
-	O
oxoglutarate	O
(	O
2	O
-	O
OG	O
)	O
-	O
dependent	O
oxygenases	O
.	O

These	O
enzymes	O
are	O
non	O
-	O
haem	O
iron	O
enzymes	O
that	O
use	O
dioxygen	O
in	O
the	O
hydroxylation	O
reaction	O
and	O
therefore	O
provide	O
a	O
direct	O
link	O
between	O
the	O
availability	O
of	O
molecular	O
oxygen	O
and	O
regulation	O
of	O
HIF	O
.	O

Prolyl	O
hydroxylation	O
regulates	O
proteolytic	O
destruction	O
of	O
HIF	O
-	O
alpha	O
by	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	E-Protein
ubiquitin	S-Protein
ligase	O
complex	O
,	O
whereas	O
HIF	O
-	O
alpha	O
asparaginyl	O
hydroxylation	O
regulates	O
recruitment	O
of	O
transcriptional	O
coactivators	O
.	O

The	O
involvement	O
of	O
at	O
least	O
two	O
distinct	O
types	O
of	O
2	O
-	O
OG	O
-	O
dependent	O
oxygenase	O
in	O
oxygen	O
-	O
regulated	O
transcription	O
suggests	O
that	O
these	O
enzymes	O
may	O
be	O
well	O
suited	O
to	O
a	O
role	O
in	O
cellular	O
oxygen	O
sensing	O
.	O

A	O
PCR	O
-	O
based	O
method	O
for	O
studying	O
DNA	O
methylation	O
.	O

DNA	O
methylation	O
is	O
a	O
mechanism	O
for	O
regulation	O
of	O
gene	O
expression	O
in	O
animals	O
(	O
1	O
-	O
3	O
)	O
.	O

The	O
addition	O
of	O
a	O
methyl	O
group	O
at	O
the	O
5	O
-	O
position	O
of	O
cytosine	O
bases	O
occurs	O
exclusively	O
at	O
CpG	O
dinucleotides	O
.	O

CpG	O
dinucleotides	O
in	O
the	O
vertebrate	O
genome	O
are	O
underrepresented	O
and	O
amount	O
to	O
1	O
%	O
of	O
the	O
genome	O
(	O
4	O
)	O
.	O

However	O
,	O
in	O
some	O
regions	O
of	O
the	O
genome	O
,	O
CpG	O
residues	O
amount	O
to	O
6	O
%	O
or	O
more	O
of	O
the	O
dinucleotides	O
in	O
the	O
genome	O
.	O

These	O
regions	O
,	O
known	O
as	O
CpG	O
islands	O
,	O
are	O
usually	O
associated	O
with	O
the	O
promoter	O
regions	O
of	O
housekeeping	O
genes	O
and	O
,	O
in	O
contrast	O
to	O
CpGs	O
throughout	O
the	O
genome	O
,	O
are	O
unmethylated	O
(	O
5	O
,	O
6	O
)	O
.	O

Methylation	O
of	O
CpG	O
islands	O
occurs	O
only	O
in	O
silenced	O
genes	O
on	O
the	O
inactive	O
X	O
chromosome	O
and	O
in	O
parentally	O
imprinted	O
genes	O
(	O
7	O
)	O
.	O

In	O
addition	O
,	O
CpG	O
islands	O
may	O
become	O
methylated	O
upon	O
oncogenic	O
transformation	O
.	O

These	O
alterations	O
in	O
the	O
methylation	O
profile	O
are	O
correlated	O
with	O
silencing	O
of	O
tumor	O
suppressor	O
genes	O
such	O
as	O
p15	S-Protein
,	O
p16	S-Protein
,	O
Rb	S-Protein
,	O
VHL	S-Protein
,	O
e	B-Protein
-	I-Protein
cadherin	E-Protein
,	O
ER	S-Protein
,	O
and	O
HIC1	S-Protein
(	O
8	O
)	O
.	O

Transposable	O
elements	O
:	O
targets	O
for	O
early	O
nutritional	O
effects	O
on	O
epigenetic	O
gene	O
regulation	O
.	O

Early	O
nutrition	O
affects	O
adult	O
metabolism	O
in	O
humans	O
and	O
other	O
mammals	O
,	O
potentially	O
via	O
persistent	O
alterations	O
in	O
DNA	O
methylation	O
.	O

With	O
viable	O
yellow	O
agouti	O
(	O
A	O
(	O
vy	O
)	O
)	O
mice	O
,	O
which	O
harbor	O
a	O
transposable	O
element	O
in	O
the	O
agouti	S-Protein
gene	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
the	O
metastable	O
methylation	O
status	O
of	O
specific	O
transposable	O
element	O
insertion	O
sites	O
renders	O
them	O
epigenetically	O
labile	O
to	O
early	O
methyl	O
donor	O
nutrition	O
.	O

Our	O
results	O
show	O
that	O
dietary	O
methyl	O
supplementation	O
of	O
a	O
/	O
a	O
dams	O
with	O
extra	O
folic	O
acid	O
,	O
vitamin	O
B	O
(	O
12	O
)	O
,	O
choline	O
,	O
and	O
betaine	O
alter	O
the	O
phenotype	O
of	O
their	O
A	O
(	O
vy	O
)	O
/	O
a	O
offspring	O
via	O
increased	O
CpG	O
methylation	O
at	O
the	O
A	O
(	O
vy	O
)	O
locus	O
and	O
that	O
the	O
epigenetic	O
metastability	O
which	O
confers	O
this	O
lability	O
is	O
due	O
to	O
the	O
A	O
(	O
vy	O
)	O
transposable	O
element	O
.	O

These	O
findings	O
suggest	O
that	O
dietary	O
supplementation	O
,	O
long	O
presumed	O
to	O
be	O
purely	O
beneficial	O
,	O
may	O
have	O
unintended	O
deleterious	O
influences	O
on	O
the	O
establishment	O
of	O
epigenetic	O
gene	O
regulation	O
in	O
humans	O
.	O

Lgl1	S-Protein
,	O
a	O
mesenchymal	O
modulator	O
of	O
early	O
lung	O
branching	O
morphogenesis	O
,	O
is	O
a	O
secreted	O
glycoprotein	O
imported	O
by	O
late	O
gestation	O
lung	O
epithelial	O
cells	O
.	O

Secreted	O
glycoproteins	O
serve	O
a	O
variety	O
of	O
functions	O
related	O
to	O
cell	O
-	O
cell	O
communication	O
in	O
developmental	O
systems	O
.	O

We	O
cloned	O
LGL1	S-Protein
,	O
a	O
novel	O
glucocorticoid	O
-	O
inducible	O
gene	O
in	O
foetal	O
lung	O
,	O
and	O
described	O
its	O
temporal	O
and	O
spatial	O
localization	O
in	O
the	O
rat	O
.	O

Disruption	O
of	O
foetal	O
mesenchyme	O
-	O
specific	O
LGL1	S-Protein
expression	O
using	O
antisense	O
oligodeoxynucleotides	O
,	O
which	O
was	O
associated	O
with	O
a	O
50	O
%	O
decrease	O
in	O
lgl1	S-Protein
protein	O
levels	O
,	O
inhibited	O
airway	O
epithelial	O
branching	O
in	O
foetal	O
rat	O
gestational	O
day	O
13	O
lung	O
buds	O
in	O
explant	O
culture	O
.	O

These	O
findings	O
suggested	O
that	O
lgl1	S-Protein
functions	O
as	O
a	O
secreted	O
signalling	O
molecule	O
.	O

We	O
now	O
provide	O
evidence	O
supporting	O
a	O
role	O
for	O
lgl1	S-Protein
in	O
mesenchymal	O
-	O
epithelial	O
interactions	O
that	O
govern	O
lung	O
organogenesis	O
.	O

Lgl1	S-Protein
is	O
a	O
secreted	O
glycoprotein	O
with	O
a	O
conserved	O
N	O
-	O
terminal	O
secretory	O
signal	O
peptide	O
.	O

Using	O
dual	O
immunofluorescence	O
,	O
intracellular	O
lgl1	S-Protein
was	O
found	O
to	O
co	O
-	O
localize	O
with	O
markers	O
of	O
the	O
Golgi	O
apparatus	O
and	O
endoplasmic	O
reticulum	O
,	O
consistent	O
with	O
its	O
association	O
with	O
secretory	O
vesicles	O
.	O

Using	O
pulse	O
-	O
chase	O
studies	O
,	O
we	O
show	O
that	O
lgl1	S-Protein
is	O
a	O
stable	O
protein	O
with	O
a	O
half	O
-	O
life	O
of	O
11	O
.	O
5	O
h	O
.	O

Furthermore	O
,	O
at	O
gestational	O
days	O
20	O
and	O
21	O
(	O
term	O
=	O
22	O
)	O
,	O
foetal	O
distal	O
lung	O
epithelial	O
cells	O
import	O
lgl1	S-Protein
protein	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
support	O
distinct	O
roles	O
for	O
lgl1	S-Protein
as	O
a	O
mediator	O
of	O
glucocorticoid	O
-	O
induced	O
mesenchymal	O
-	O
epithelial	O
interactions	O
in	O
early	O
and	O
late	O
foetal	O
lung	O
organogenesis	O
.	O

CD44s	S-Protein
adhesive	O
function	O
spontaneous	O
and	O
PMA	O
-	O
inducible	O
CD44	S-Protein
cleavage	O
are	O
regulated	O
at	O
post	O
-	O
translational	O
level	O
in	O
cells	O
of	O
melanocytic	O
lineage	O
.	O

Adhesion	O
between	O
the	O
CD44s	S-Protein
receptor	O
and	O
hyaluronic	O
acid	O
plays	O
an	O
important	O
role	O
in	O
cell	O
migration	O
,	O
tumour	O
growth	O
and	O
progression	O
.	O

Although	O
the	O
alternative	O
splicing	O
of	O
CD44	S-Protein
variant	O
exons	O
represents	O
the	O
principal	O
regulatory	O
mechanism	O
of	O
CD44	S-Protein
-	O
mediated	O
functions	O
,	O
CD44v	S-Protein
spliced	O
variants	O
are	O
scantily	O
expressed	O
in	O
melanoma	O
cells	O
.	O

For	O
this	O
reason	O
,	O
we	O
have	O
investigated	O
the	O
possibility	O
that	O
post	O
-	O
translational	O
modifications	O
of	O
the	O
CD44	S-Protein
standard	O
receptor	O
could	O
play	O
a	O
pivotal	O
role	O
in	O
regulating	O
CD44	S-Protein
-	O
mediated	O
functions	O
in	O
melanoma	O
.	O

Using	O
metabolic	O
inhibitors	O
of	O
N	O
-	O
and	O
O	O
-	O
glycosylation	O
,	O
as	O
well	O
as	O
melanoma	O
transfectants	O
expressing	O
CD44s	S-Protein
O	O
-	O
glycosylation	O
site	O
-	O
specific	O
mutants	O
,	O
we	O
performed	O
structural	O
and	O
functional	O
analysis	O
of	O
N	O
-	O
and	O
O	O
-	O
deglycosylated	O
CD44s	S-Protein
molecules	O
expressed	O
in	O
melanoma	O
cells	O
.	O

We	O
discovered	O
that	O
complete	O
N	O
-	O
and	O
O	O
-	O
glycosylation	O
is	O
not	O
required	O
by	O
CD44s	S-Protein
to	O
be	O
correctly	O
expressed	O
on	O
the	O
melanoma	O
cell	O
surface	O
.	O

Indeed	O
,	O
variably	O
glycosylated	O
and	O
functionally	O
different	O
CD44s	S-Protein
molecules	O
were	O
constitutively	O
expressed	O
in	O
primary	O
and	O
metastatic	O
lesions	O
.	O

Furthermore	O
,	O
we	O
observed	O
that	O
changes	O
in	O
N	O
-	O
and	O
O	O
-	O
glycosylation	O
of	O
CD44s	S-Protein
could	O
modulate	O
its	O
cleavage	O
.	O

In	O
fact	O
,	O
spontaneous	O
CD44s	S-Protein
shedding	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
partial	O
or	O
complete	O
O	O
-	O
glycosylation	O
of	O
four	O
serine	O
-	O
glycine	O
motifs	O
localized	O
in	O
the	O
membrane	O
-	O
proximal	O
CD44	S-Protein
ectodomain	O
.	O

Mutation	O
of	O
these	O
serine	O
residues	O
,	O
as	O
well	O
as	O
an	O
extensive	O
metabolic	O
O	O
-	O
deglycosylation	O
,	O
strongly	O
impaired	O
spontaneous	O
CD44	S-Protein
shedding	O
.	O

Furthermore	O
,	O
an	O
O	O
-	O
glycosylation	O
-	O
independent	O
mechanism	O
of	O
CD44	S-Protein
cleavage	O
has	O
been	O
identified	O
.	O

This	O
alternative	O
mechanism	O
of	O
receptor	O
cleavage	O
is	O
phorbol	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
inducible	O
,	O
mediated	O
by	O
metalloproteinase	O
and	O
requires	O
the	O
presence	O
of	O
N	O
-	O
linked	O
sugar	O
residues	O
.	O

Our	O
findings	O
demonstrate	O
that	O
the	O
post	O
-	O
translational	O
modification	O
of	O
CD44s	S-Protein
represents	O
the	O
principal	O
regulatory	O
mechanism	O
of	O
CD44s	S-Protein
-	O
mediated	O
functions	O
in	O
melanoma	O
.	O

SPARC	S-Protein
/	O
osteonectin	S-Protein
is	O
a	O
frequent	O
target	O
for	O
aberrant	O
methylation	O
in	O
pancreatic	O
adenocarcinoma	O
and	O
a	O
mediator	O
of	O
tumor	O
-	O
stromal	O
interactions	O
.	O

Deregulated	O
expression	O
of	O
SPARC	S-Protein
/	O
osteonectin	S-Protein
,	O
a	O
secreted	O
glycoprotein	O
with	O
multiple	O
biological	O
functions	O
,	O
has	O
been	O
associated	O
with	O
the	O
progression	O
of	O
various	O
cancers	O
.	O

Using	O
microarrays	O
,	O
we	O
previously	O
identified	O
SPARC	S-Protein
as	O
one	O
of	O
the	O
genes	O
induced	O
by	O
treatment	O
with	O
a	O
DNA	O
methylation	O
inhibitor	O
in	O
pancreatic	O
cancer	O
cells	O
.	O

We	O
therefore	O
analysed	O
the	O
expression	O
pattern	O
and	O
methylation	O
status	O
of	O
the	O
SPARC	S-Protein
gene	O
in	O
pancreatic	O
cancer	O
.	O

Gene	O
expression	O
profiling	O
by	O
oligonucleotide	O
microarray	O
and	O
reverse	O
transcription	O
-	O
PCR	O
analyses	O
demonstrated	O
that	O
SPARC	S-Protein
mRNA	O
was	O
expressed	O
in	O
non	O
-	O
neoplastic	O
pancreatic	O
ductal	O
epithelial	O
cells	O
,	O
but	O
was	O
not	O
expressed	O
in	O
a	O
majority	O
of	O
pancreatic	O
cancer	O
cell	O
lines	O
.	O

The	O
loss	O
of	O
SPARC	S-Protein
expression	O
was	O
associated	O
with	O
aberrant	O
hypermethylation	O
of	O
its	O
CpG	O
island	O
.	O

Immunohistochemical	O
labeling	O
revealed	O
that	O
the	O
SPARC	S-Protein
protein	O
was	O
overexpressed	O
in	O
the	O
stromal	O
fibroblasts	O
immediately	O
adjacent	O
to	O
the	O
neoplastic	O
epithelium	O
in	O
primary	O
pancreatic	O
cancers	O
,	O
but	O
rarely	O
expressed	O
in	O
the	O
cancers	O
themselves	O
.	O

Primary	O
fibroblasts	O
derived	O
from	O
pancreatic	O
cancer	O
strongly	O
expressed	O
SPARC	S-Protein
mRNA	O
and	O
secreted	O
SPARC	S-Protein
protein	O
into	O
the	O
conditioned	O
media	O
,	O
and	O
treatment	O
of	O
pancreatic	O
cancer	O
cells	O
with	O
exogenous	O
SPARC	S-Protein
resulted	O
in	O
growth	O
suppression	O
.	O

SPARC	S-Protein
expression	O
in	O
fibroblasts	O
from	O
noncancerous	O
pancreatic	O
tissue	O
was	O
augmented	O
by	O
coculture	O
with	O
pancreatic	O
cancer	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
SPARC	S-Protein
is	O
a	O
frequent	O
target	O
for	O
aberrant	O
methylation	O
in	O
pancreatic	O
cancer	O
and	O
that	O
SPARC	S-Protein
expression	O
in	O
fibroblasts	O
adjacent	O
to	O
pancreatic	O
cancer	O
cells	O
is	O
regulated	O
through	O
tumor	O
-	O
stromal	O
interactions	O
.	O

Acetylation	O
of	O
the	O
HIV	O
-	O
1	O
Tat	S-Protein
protein	O
:	O
an	O
in	O
vitro	O
study	O
.	O

In	O
the	O
last	O
few	O
years	O
,	O
the	O
understanding	O
of	O
lysine	O
acetylation	O
as	O
a	O
regulatory	O
post	O
-	O
translational	O
modification	O
of	O
proteins	O
in	O
cell	O
signalling	O
cascades	O
has	O
increased	O
.	O

It	O
is	O
now	O
known	O
that	O
not	O
only	O
histones	S-Protein
but	O
also	O
non	O
-	O
histone	S-Protein
factors	O
can	O
serve	O
as	O
substrates	O
of	O
different	O
acetyltransferase	O
enzymes	O
.	O

Acetylated	O
lysine	O
residues	O
in	O
non	O
-	O
histone	S-Protein
factors	O
are	O
often	O
identified	O
using	O
radioactive	O
labelling	O
experiments	O
and	O
immunochemical	O
analysis	O
of	O
synthetic	O
peptides	O
.	O

In	O
this	O
study	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV	O
-	O
1	O
)	O
Tat	S-Protein
protein	O
,	O
we	O
demonstrate	O
the	O
benefits	O
of	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionisation	O
mass	O
spectrometry	O
,	O
proteolytic	O
digestion	O
and	O
Edman	O
sequencing	O
for	O
the	O
mapping	O
of	O
acetylation	O
sites	O
.	O

We	O
confirmed	O
that	O
the	O
HIV	O
-	O
1	O
Tat	S-Protein
protein	O
is	O
acetylated	O
in	O
vitro	O
by	O
the	O
acetyltransferase	O
p300	S-Protein
at	O
a	O
specific	O
lysine	O
residue	O
at	O
position	O
50	O
in	O
its	O
RNA	O
binding	O
region	O
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
the	O
Tat	S-Protein
cysteine	O
-	O
rich	O
region	O
is	O
acetylated	O
at	O
multiple	O
cysteine	O
residues	O
in	O
the	O
absence	O
of	O
enzyme	O
.	O

Since	O
this	O
non	O
-	O
enzymatic	O
cysteine	O
acetylation	O
occurs	O
independently	O
from	O
the	O
surrounding	O
peptide	O
sequence	O
,	O
we	O
consider	O
the	O
presence	O
of	O
cysteine	O
residues	O
in	O
acetylated	O
peptides	O
an	O
important	O
factor	O
for	O
the	O
interpretation	O
of	O
in	O
vitro	O
acetylation	O
assays	O
in	O
general	O
.	O

BP75	S-Protein
,	O
bromodomain	O
-	O
containing	O
M	O
(	O
r	O
)	O
75	O
,	O
000	O
protein	O
,	O
binds	O
dishevelled	B-Protein
-	I-Protein
1	E-Protein
and	O
enhances	O
Wnt	O
signaling	O
by	O
inactivating	O
glycogen	B-Protein
synthase	I-Protein
kinase	I-Protein
-	I-Protein
3	I-Protein
beta	E-Protein
.	O

To	O
identify	O
novel	O
regulators	O
of	O
Wnt	O
signaling	O
,	O
we	O
performed	O
yeast	O
two	O
-	O
hybrid	O
analyses	O
with	O
Dvl	B-Protein
-	I-Protein
1	E-Protein
and	O
identified	O
BP75	S-Protein
as	O
a	O
candidate	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
BP75	S-Protein
directly	O
interacts	O
with	O
Dvl	B-Protein
-	I-Protein
1	E-Protein
in	O
mammalian	O
cells	O
and	O
enhances	O
TCF	O
-	O
dependent	O
gene	O
expression	O
induced	O
by	O
Dvl	B-Protein
-	I-Protein
1	E-Protein
.	O

In	O
support	O
of	O
these	O
results	O
,	O
BP75	S-Protein
in	O
cooperation	O
with	O
Dvl	B-Protein
-	I-Protein
1	E-Protein
was	O
found	O
to	O
facilitate	O
dephosphorylation	O
at	O
Tyr216	O
of	O
glycogen	B-Protein
synthase	I-Protein
kinase	I-Protein
-	I-Protein
3beta	E-Protein
and	O
consequently	O
inhibit	O
its	O
kinase	O
activity	O
.	O

Furthermore	O
,	O
the	O
nuclear	O
translocation	O
and	O
formation	O
of	O
vesicular	O
structures	O
of	O
beta	B-Protein
-	I-Protein
catenin	E-Protein
were	O
induced	O
by	O
BP75	S-Protein
and	O
Dvl	B-Protein
-	I-Protein
1	E-Protein
in	O
a	O
synergistic	O
manner	O
.	O

Collectively	O
,	O
these	O
results	O
provided	O
us	O
a	O
novel	O
mechanism	O
in	O
Wnt	O
signaling	O
where	O
BP75	S-Protein
plays	O
important	O
regulatory	O
roles	O
between	O
glycogen	B-Protein
synthase	I-Protein
kinase	I-Protein
-	I-Protein
3beta	E-Protein
and	O
Dvl	S-Protein
.	O

Highly	O
restricted	O
localization	O
of	O
RNA	O
polymerase	O
II	O
within	O
a	O
locus	O
control	O
region	O
of	O
a	O
tissue	O
-	O
specific	O
chromatin	O
domain	O
.	O

RNA	O
polymerase	O
II	O
(	O
Pol	O
II	O
)	O
can	O
associate	O
with	O
regulatory	O
elements	O
far	O
from	O
promoters	O
.	O

For	O
the	O
murine	O
beta	B-Protein
-	I-Protein
globin	E-Protein
locus	O
,	O
Pol	O
II	O
binds	O
the	O
beta	B-Protein
-	I-Protein
globin	E-Protein
locus	O
control	O
region	O
(	O
LCR	O
)	O
far	O
upstream	O
of	O
the	O
beta	B-Protein
-	I-Protein
globin	E-Protein
promoters	O
,	O
independent	O
of	O
recruitment	O
to	O
and	O
activation	O
of	O
the	O
betamajor	O
promoter	O
.	O

We	O
describe	O
here	O
an	O
analysis	O
of	O
where	O
Pol	O
II	O
resides	O
within	O
the	O
LCR	O
,	O
how	O
it	O
is	O
recruited	O
to	O
the	O
LCR	O
,	O
and	O
the	O
functional	O
consequences	O
of	O
recruitment	O
.	O

High	O
-	O
resolution	O
analysis	O
of	O
the	O
distribution	O
of	O
Pol	O
II	O
revealed	O
that	O
Pol	O
II	O
binding	O
within	O
the	O
LCR	O
is	O
restricted	O
to	O
the	O
hypersensitive	O
sites	O
.	O

Blocking	O
elongation	O
eliminated	O
the	O
synthesis	O
of	O
genic	O
and	O
extragenic	O
transcripts	O
and	O
eliminated	O
Pol	O
II	O
from	O
the	O
betamajor	O
open	O
reading	O
frame	O
.	O

However	O
,	O
the	O
elongation	O
blockade	O
did	O
not	O
redistribute	O
Pol	O
II	O
at	O
the	O
hypersensitive	O
sites	O
,	O
suggesting	O
that	O
Pol	O
II	O
is	O
recruited	O
to	O
these	O
sites	O
.	O

The	O
distribution	O
of	O
Pol	O
II	O
did	O
not	O
strictly	O
correlate	O
with	O
the	O
distributions	O
of	O
histone	S-Protein
acetylation	O
and	O
methylation	O
.	O

As	O
Pol	O
II	O
associates	O
with	O
histone	S-Protein
-	O
modifying	O
enzymes	O
,	O
Pol	O
II	O
tracking	O
might	O
be	O
critical	O
for	O
establishing	O
and	O
maintaining	O
broad	O
histone	O
modification	O
patterns	O
.	O

However	O
,	O
blocking	O
elongation	O
did	O
not	O
disrupt	O
the	O
histone	S-Protein
modification	O
pattern	O
of	O
the	O
beta	B-Protein
-	I-Protein
globin	E-Protein
locus	O
,	O
indicating	O
that	O
Pol	O
II	O
tracking	O
is	O
not	O
required	O
to	O
maintain	O
the	O
pattern	O
.	O

An	O
axial	O
gradient	O
of	O
transgene	O
methylation	O
in	O
murine	O
skeletal	O
muscle	O
:	O
genomic	O
imprint	O
of	O
rostrocaudal	O
position	O
.	O

We	O
previously	O
used	O
mice	O
bearing	O
a	O
myosin	B-Protein
light	I-Protein
chain	E-Protein
-	O
chloramphenicol	B-Protein
acetyltransferase	E-Protein
(	O
MLC1	S-Protein
-	O
CAT	S-Protein
)	O
transgene	O
to	O
show	O
that	O
adult	O
muscle	O
cells	O
bear	O
a	O
heritable	O
,	O
cell	O
autonomous	O
memory	O
of	O
their	O
rostrocaudal	O
position	O
.	O

CAT	S-Protein
mRNA	O
and	O
protein	O
are	O
expressed	O
in	O
a	O
>	O
100	O
-	O
fold	O
rostrocaudal	O
gradient	O
in	O
skeletal	O
muscles	O
of	O
developing	O
and	O
adult	O
MLC1	S-Protein
-	O
CAT	S-Protein
mice	O
(	O
Donoghue	O
,	O
M	O
.	O
J	O
.	O
,	O
Merlie	O
,	O
J	O
.	O
P	O
.	O
,	O
Rosenthal	O
,	O
N	O
.	O
and	O
Sanes	O
,	O
J	O
.	O
R	O
.	O
(	O
1991	O
)	O
.	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
88	O
,	O
5847	O
-	O
5851	O
;	O
Donoghue	O
,	O
M	O
.	O
J	O
.	O
,	O
Alvarez	O
,	O
J	O
.	O
D	O
.	O
,	O
Merlie	O
,	O
J	O
.	O
P	O
.	O
and	O
Sanes	O
,	O
J	O
.	O
R	O
.	O
(	O
1991	O
)	O
.	O
J	O
.	O
Cell	O
Biol	O
.	O
115	O
,	O
423	O
-	O
434	O
)	O
.	O

Moreover	O
,	O
both	O
in	O
primary	O
cultures	O
and	O
in	O
myogenic	O
cell	O
lines	O
prepared	O
from	O
individual	O
muscles	O
of	O
these	O
mice	O
,	O
CAT	S-Protein
levels	O
reflect	O
the	O
body	O
position	O
from	O
which	O
the	O
myoblasts	O
were	O
derived	O
(	O
Donoghue	O
,	O
M	O
.	O
J	O
.	O
,	O
Morris	O
-	O
Valero	O
,	O
R	O
.	O
,	O
Johnson	O
,	O
Y	O
.	O
R	O
.	O
,	O
Merlie	O
,	O
J	O
.	O
P	O
.	O
and	O
Sanes	O
,	O
J	O
.	O
R	O
.	O
(	O
1992	O
)	O
.	O
Cell	O
69	O
,	O
67	O
-	O
77	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
methylation	O
state	O
of	O
the	O
MLC1	S-Protein
-	O
CAT	S-Protein
transgene	O
in	O
skeletal	O
muscles	O
is	O
also	O
graded	O
along	O
the	O
rostrocaudal	O
axis	O
:	O
methylation	O
levels	O
decrease	O
and	O
expression	O
levels	O
increase	O
in	O
the	O
order	O
,	O
jaw	O
-	O
-	O
>	O
neck	O
-	O
-	O
>	O
chest	O
and	O
forelimb	O
-	O
-	O
>	O
hindlimb	O
.	O

Methylation	O
levels	O
are	O
also	O
approx	O
.	O
10	O
-	O
fold	O
higher	O
in	O
rostrally	O
derived	O
than	O
in	O
caudally	O
derived	O
myogenic	O
cell	O
lines	O
,	O
which	O
express	O
low	O
and	O
high	O
levels	O
of	O
CAT	S-Protein
,	O
respectively	O
.	O

Within	O
each	O
cell	O
line	O
,	O
undifferentiated	O
cells	O
(	O
myoblasts	O
)	O
,	O
which	O
do	O
not	O
express	O
the	O
transgene	O
,	O
and	O
differentiated	O
cells	O
(	O
myotubes	O
)	O
,	O
which	O
do	O
,	O
are	O
indistinguishable	O
in	O
methylation	O
state	O
.	O

Thus	O
,	O
differentiation	O
-	O
related	O
changes	O
in	O
transgene	O
expression	O
do	O
not	O
affect	O
position	O
-	O
related	O
levels	O
of	O
transgene	O
methylation	O
.	O

On	O
the	O
other	O
hand	O
,	O
treatment	O
of	O
rostrally	O
derived	O
lines	O
with	O
the	O
demethylating	O
agent	O
,	O
5	O
-	O
azacytidine	O
,	O
decreases	O
methylation	O
and	O
increases	O
expression	O
of	O
the	O
transgene	O
.	O

Thus	O
,	O
perturbation	O
of	O
methylation	O
affects	O
expression	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
methylation	O
provides	O
a	O
genomic	O
imprint	O
of	O
rostrocaudal	O
body	O
position	O
that	O
may	O
serve	O
as	O
a	O
component	O
of	O
the	O
positional	O
memory	O
that	O
mammalian	O
cells	O
retain	O
into	O
adulthood	O
.	O

Role	O
of	O
the	O
lysine	O
and	O
arginine	O
residues	O
of	O
vitellogenin	O
in	O
high	O
affinity	O
binding	O
to	O
vitellogenin	O
receptors	O
in	O
locust	O
oocyte	O
membranes	O
.	O

A	O
specific	O
cell	O
surface	O
receptor	O
mediates	O
the	O
endocytosis	O
of	O
the	O
yolk	O
protein	O
vitellogenin	O
(	O
VTG	O
)	O
,	O
a	O
lipoglycoprotein	O
,	O
into	O
growing	O
oocytes	O
of	O
the	O
insect	O
Locusta	O
migratoria	O
.	O

The	O
ability	O
of	O
the	O
VTG	B-Protein
receptor	E-Protein
to	O
recognize	O
VTG	O
was	O
analyzed	O
in	O
binding	O
tests	O
after	O
modification	O
by	O
five	O
lysine	O
-	O
specific	O
and	O
two	O
other	O
reagents	O
.	O

Progressive	O
chemical	O
modification	O
of	O
the	O
lysyl	O
and	O
arginyl	O
residues	O
resulted	O
in	O
reduction	O
or	O
loss	O
of	O
the	O
derivatized	O
VTG	O
to	O
compete	O
for	O
binding	O
to	O
the	O
VTG	B-Protein
receptor	E-Protein
with	O
unmodified	O
VTG	O
.	O

Although	O
the	O
precise	O
role	O
of	O
the	O
lysine	O
residues	O
in	O
receptor	O
binding	O
remains	O
to	O
be	O
defined	O
we	O
conclude	O
that	O
they	O
are	O
involved	O
in	O
expression	O
of	O
a	O
recognition	O
site	O
interacting	O
with	O
the	O
binding	O
domain	O
of	O
the	O
VTG	B-Protein
receptor	E-Protein
.	O

Sulfhydryl	O
groups	O
are	O
not	O
involved	O
in	O
the	O
conformation	O
of	O
the	O
recognition	O
site	O
or	O
binding	O
ability	O
of	O
VTG	O
.	O

The	O
axonally	O
secreted	O
cell	O
adhesion	O
molecule	O
,	O
axonin	B-Protein
-	I-Protein
1	E-Protein
.	O

Primary	O
structure	O
,	O
immunoglobulin	O
-	O
like	O
and	O
fibronectin	O
-	O
type	O
-	O
III	O
-	O
like	O
domains	O
and	O
glycosyl	O
-	O
phosphatidylinositol	O
anchorage	O
.	O

Axonin	B-Protein
-	I-Protein
1	E-Protein
is	O
an	O
axon	O
-	O
associated	O
cell	O
adhesion	O
molecule	O
(	O
AxCAM	O
)	O
of	O
the	O
chicken	O
,	O
which	O
promotes	O
neurite	O
outgrowth	O
by	O
interaction	O
with	O
the	O
AxCAM	O
L1	O
(	O
G4	O
)	O
of	O
the	O
neuritic	O
membrane	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
and	O
sequence	O
determination	O
of	O
a	O
cDNA	O
encoding	O
axonin	B-Protein
-	I-Protein
1	E-Protein
.	O

Peptides	O
generated	O
by	O
enzymatic	O
cleavage	O
showed	O
similarity	O
to	O
the	O
AxCAM	O
F11	S-Protein
.	O

Degenerated	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
primers	O
were	O
designed	O
and	O
an	O
axonin	B-Protein
-	I-Protein
1	E-Protein
fragment	O
was	O
amplified	O
from	O
mRNA	O
of	O
embryonic	O
retina	O
.	O

Screening	O
of	O
a	O
cDNA	O
library	O
from	O
embryonic	O
brain	O
resulted	O
in	O
the	O
isolation	O
of	O
a	O
4	O
.	O
0	O
-	O
kb	O
cDNA	O
insert	O
with	O
an	O
open	O
reading	O
frame	O
of	O
3108	O
nucleotides	O
.	O

The	O
deduced	O
polypeptide	O
of	O
1036	O
amino	O
acids	O
includes	O
a	O
putative	O
hydrophobic	O
N	O
-	O
terminal	O
signal	O
sequence	O
of	O
23	O
or	O
25	O
amino	O
acids	O
and	O
a	O
C	O
-	O
terminal	O
hydrophobic	O
sequence	O
of	O
29	O
amino	O
acids	O
which	O
is	O
suggestive	O
of	O
sequences	O
serving	O
as	O
signal	O
for	O
the	O
attachment	O
of	O
a	O
glycosyl	O
-	O
phosphatidylinositol	O
(	O
glycosyl	O
-	O
PtdIns	O
)	O
anchor	O
.	O

The	O
putative	O
mature	O
form	O
of	O
axonin	B-Protein
-	I-Protein
1	E-Protein
comprises	O
six	O
immunoglobulin	O
-	O
like	O
repeats	O
,	O
followed	O
by	O
four	O
fibronectin	O
-	O
type	O
III	O
repeats	O
.	O

Axonin	B-Protein
-	I-Protein
1	E-Protein
exhibits	O
75	O
%	O
amino	O
acid	O
identity	O
with	O
the	O
AxCAM	O
TAG	B-Protein
-	I-Protein
1	E-Protein
of	O
the	O
rat	O
,	O
suggesting	O
that	O
it	O
is	O
the	O
chicken	O
homologue	O
of	O
TAG	B-Protein
-	I-Protein
1	E-Protein
.	O

Like	O
TAG	B-Protein
-	I-Protein
1	E-Protein
,	O
axonin	B-Protein
-	I-Protein
1	E-Protein
is	O
glycosyl	O
-	O
PtdIns	O
-	O
anchored	O
to	O
the	O
neuronal	O
membrane	O
;	O
in	O
contrast	O
to	O
TAG	B-Protein
-	I-Protein
1	E-Protein
,	O
it	O
does	O
not	O
exhibit	O
an	O
Arg	O
-	O
Gly	O
-	O
Asp	O
sequence	O
.	O

Characterization	O
of	O
UDP	O
-	O
N	O
-	O
acetylglucosamine	O
:	O
glycoprotein	O
N	O
-	O
acetylglucosamine	O
-	O
1	O
-	O
phosphotransferase	O
from	O
Acanthamoeba	O
castellanii	O
.	O

The	O
kinetic	O
properties	O
of	O
UDP	O
-	O
N	O
-	O
acetylglucosamine	O
:	O
glycoprotein	O
N	O
-	O
acetylglucosamine	O
-	O
1	O
-	O
phosphotransferase	O
(	O
GlcNAc	O
-	O
phosphotransferase	O
)	O
partially	O
purified	O
from	O
the	O
soil	O
amoeba	O
Acanthamoeba	O
castellanii	O
have	O
been	O
studied	O
.	O

The	O
transferase	O
phosphorylated	O
the	O
lysosomal	O
enzymes	O
uteroferrin	S-Protein
and	O
cathepsin	B-Protein
D	E-Protein
3	O
-	O
90	O
-	O
fold	O
better	O
than	O
nonlysosomal	O
glycoproteins	O
and	O
16	O
-	O
83	O
-	O
fold	O
better	O
than	O
a	O
Man9GlcNAc	O
oligosaccharide	O
.	O

Deglycosylated	O
uteroferrin	S-Protein
was	O
a	O
potent	O
competitive	O
inhibitor	O
of	O
the	O
phosphorylation	O
of	O
intact	O
uteroferrin	S-Protein
(	O
Ki	O
of	O
48	O
microM	O
)	O
but	O
did	O
not	O
inhibit	O
the	O
phosphorylation	O
of	O
RNase	O
B	O
or	O
the	O
simple	O
sugar	O
alpha	O
-	O
methylmannoside	O
.	O

Deglycosylated	O
RNase	O
(	O
RNase	B-Protein
A	E-Protein
)	O
did	O
not	O
inhibit	O
the	O
phosphorylation	O
of	O
RNase	O
B	O
or	O
uteroferrin	S-Protein
.	O

These	O
results	O
indicate	O
that	O
purified	O
amoeba	O
GlcNAc	O
-	O
phosphotransferase	O
recognizes	O
a	O
protein	O
domain	O
present	O
on	O
lysosomal	O
enzymes	O
but	O
absent	O
in	O
most	O
nonlysosomal	O
glycoproteins	O
.	O

The	O
transferase	O
also	O
exhibited	O
a	O
marked	O
preference	O
for	O
oligosaccharides	O
containing	O
mannose	O
alpha	O
1	O
,	O
2	O
-	O
mannose	O
sequences	O
,	O
but	O
this	O
cannot	O
account	O
for	O
the	O
high	O
affinity	O
binding	O
to	O
lysosomal	O
enzymes	O
.	O

A	O
.	O
castellanii	O
extracts	O
do	O
not	O
contain	O
detectable	O
levels	O
of	O
N	B-Protein
-	I-Protein
acetylglucosamine	I-Protein
-	I-Protein
1	I-Protein
-	I-Protein
phosphodiester	I-Protein
alpha	I-Protein
-	I-Protein
N	I-Protein
-	I-Protein
acetylglucosaminidase	E-Protein
,	O
the	O
second	O
enzyme	O
in	O
the	O
biosynthetic	O
pathway	O
for	O
the	O
mannose	O
6	O
-	O
phosphate	O
recognition	O
marker	O
.	O

We	O
conclude	O
that	O
A	O
.	O
castellanii	O
does	O
not	O
utilize	O
the	O
phosphomannosyl	O
sorting	O
pathway	O
despite	O
expression	O
of	O
very	O
high	O
levels	O
of	O
GlcNAc	O
-	O
phosphotransferase	O
.	O

Regulated	O
expression	O
allows	O
high	O
level	O
production	O
and	O
secretion	O
of	O
HIV	O
-	O
1	O
gp120	S-Protein
envelope	O
glycoprotein	O
in	O
Drosophila	O
Schneider	O
cells	O
.	O

We	O
have	O
established	O
a	O
stable	O
,	O
continuous	O
culture	O
Drosophila	O
Schneider	O
2	O
cell	O
line	O
that	O
efficiently	O
expresses	O
a	O
secreted	O
,	O
truncated	O
form	O
of	O
the	O
HIV	O
envelope	O
gp120	S-Protein
protein	O
in	O
a	O
regulated	O
manner	O
.	O

The	O
Drosophila	O
produced	O
recombinant	O
gp120	S-Protein
protein	O
is	O
highly	O
glycosylated	O
,	O
is	O
recognized	O
by	O
gp120	S-Protein
-	O
specific	O
monoclonal	O
antibodies	O
,	O
binds	O
to	O
the	O
CD4	S-Protein
receptor	O
and	O
has	O
the	O
ability	O
to	O
inhibit	O
syncytia	O
formation	O
between	O
uninfected	O
CD4	S-Protein
+	O
cells	O
and	O
HIV	O
infected	O
cells	O
.	O

We	O
conclude	O
that	O
this	O
recombinant	O
Drosophila	O
envelope	O
protein	O
is	O
an	O
appropriate	O
mimic	O
of	O
the	O
authentic	O
viral	O
envelope	O
protein	O
.	O

Thus	O
,	O
the	O
Drosophila	O
cell	O
provides	O
a	O
continuous	O
,	O
stable	O
culture	O
system	O
for	O
the	O
efficient	O
expression	O
of	O
secreted	O
forms	O
of	O
complex	O
surface	O
glycoproteins	O
in	O
quantities	O
sufficient	O
for	O
detailed	O
analyses	O
.	O

Purification	O
,	O
biochemical	O
characterization	O
,	O
and	O
cDNA	O
cloning	O
of	O
a	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	E-Protein
from	O
the	O
red	O
imported	O
fire	O
ant	O
,	O
Solenopsis	O
invicta	O
.	O

A	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	E-Protein
(	O
GST	S-Protein
)	O
was	O
purified	O
266	O
-	O
fold	O
from	O
adult	O
workers	O
of	O
the	O
red	O
imported	O
fire	O
ant	O
,	O
Solenopsis	O
invicta	O
(	O
Hymenoptera	O
:	O
Formicidae	O
)	O
by	O
affinity	O
chromatography	O
and	O
preparative	O
isoelectric	O
focusing	O
.	O

The	O
purified	O
enzyme	O
appeared	O
as	O
a	O
single	O
band	O
on	O
SDS	O
-	O
PAGE	O
and	O
had	O
a	O
Mr	O
of	O
25	O
.	O
5	O
kDa	O
.	O

Steady	O
state	O
kinetics	O
assays	O
of	O
the	O
enzyme	O
with	O
1	O
-	O
chloro	O
-	O
2	O
,	O
4	O
-	O
dinitrobenzene	O
as	O
substrate	O
were	O
conducted	O
.	O

The	O
Vmax	O
,	O
Km	O
CDNB	O
,	O
Km	O
GSH	O
,	O
kcat	O
,	O
kcat	O
/	O
Km	O
CDNB	O
,	O
and	O
kcat	O
/	O
Km	O
GSH	O
for	O
the	O
purified	O
fire	O
ant	O
GST	O
were	O
87	O
.	O
4	O
micromol	O
/	O
min	O
/	O
mg	O
,	O
0	O
.	O
13	O
mM	O
,	O
0	O
.	O
84	O
mM	O
,	O
74	O
.	O
5	O
s	O
(	O
-	O
1	O
)	O
,	O
573	O
.	O
1	O
mM	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
,	O
and	O
88	O
.	O
7	O
mM	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
,	O
respectively	O
.	O

An	O
internal	O
fragment	O
of	O
the	O
enzyme	O
,	O
released	O
by	O
endoproteinase	O
Lys	B-Protein
-	I-Protein
C	E-Protein
digestion	O
,	O
was	O
sequenced	O
and	O
used	O
to	O
design	O
a	O
degenerate	O
oligonucleotide	O
primer	O
.	O

Purified	O
cDNA	O
from	O
a	O
lambda	O
-	O
phage	O
expression	O
library	O
produced	O
from	O
worker	O
fire	O
ants	O
was	O
used	O
as	O
template	O
to	O
amplify	O
a	O
fragment	O
of	O
the	O
GST	S-Protein
transcript	O
which	O
was	O
subsequently	O
cloned	O
and	O
sequenced	O
.	O

5	O
'	O
and	O
3	O
'	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
were	O
subsequently	O
conducted	O
after	O
cDNA	O
production	O
by	O
RT	O
-	O
PCR	O
of	O
mRNA	O
from	O
adult	O
worker	O
fire	O
ants	O
.	O

An	O
open	O
reading	O
frame	O
comprising	O
202	O
amino	O
acids	O
with	O
a	O
calculated	O
molecular	O
weight	O
of	O
23	O
,	O
433	O
and	O
a	O
theoretical	O
pI	O
of	O
7	O
.	O
84	O
was	O
located	O
within	O
the	O
transcript	O
beginning	O
at	O
nucleotide	O
85	O
and	O
terminating	O
in	O
a	O
stop	O
codon	O
at	O
nucleotide	O
691	O
.	O

The	O
transcript	O
contained	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
of	O
84	O
and	O
296	O
nucleotides	O
,	O
respectively	O
.	O

The	O
sequences	O
of	O
the	O
internal	O
fragments	O
from	O
the	O
purified	O
fire	O
ant	O
GST	S-Protein
were	O
identical	O
to	O
corresponding	O
translated	O
regions	O
of	O
the	O
transcript	O
(	O
nucleotides	O
214	O
-	O
258	O
,	O
and	O
457	O
-	O
477	O
)	O
.	O

Comparison	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
with	O
GSTs	O
from	O
other	O
species	O
revealed	O
that	O
the	O
enzyme	O
was	O
most	O
closely	O
related	O
to	O
sigma	O
class	O
GSTs	O
.	O

Down	O
-	O
regulation	O
of	O
Sp1	S-Protein
activity	O
through	O
modulation	O
of	O
O	O
-	O
glycosylation	O
by	O
treatment	O
with	O
a	O
low	O
glucose	O
mimetic	O
,	O
2	O
-	O
deoxyglucose	O
.	O

2	O
-	O
Deoxyglucose	O
(	O
2	O
-	O
DG	O
)	O
,	O
a	O
nonmetabolizable	O
glucose	O
analogue	O
,	O
blocks	O
glycolysis	O
at	O
the	O
phosphohexose	B-Protein
isomerase	E-Protein
step	O
and	O
has	O
been	O
frequently	O
used	O
as	O
a	O
glucose	O
starvation	O
mimetic	O
in	O
studies	O
of	O
a	O
wide	O
variety	O
of	O
physiological	O
dysfuctions	O
.	O

However	O
,	O
the	O
effect	O
of	O
2	O
-	O
DG	O
on	O
protein	O
glycosylation	O
and	O
related	O
signal	O
pathways	O
has	O
not	O
been	O
investigated	O
in	O
depth	O
.	O

In	O
HeLa	O
,	O
an	O
HPV18	O
-	O
positive	O
cervical	O
carcinoma	O
line	O
,	O
2	O
-	O
DG	O
treatment	O
down	O
-	O
regulates	O
human	O
papillomavirus	O
early	O
gene	O
transcription	O
.	O

This	O
down	O
-	O
regulation	O
was	O
also	O
achieved	O
by	O
low	O
glucose	O
supply	O
or	O
hypoxia	O
,	O
suggesting	O
that	O
this	O
is	O
a	O
response	O
commonly	O
modulated	O
by	O
cellular	O
glucose	O
or	O
energy	O
level	O
.	O

We	O
investigated	O
how	O
2	O
-	O
DG	O
and	O
low	O
glucose	O
affect	O
transcriptional	O
activity	O
.	O

Human	O
papillomavirus	O
gene	O
transcription	O
was	O
only	O
marginally	O
affected	O
by	O
the	O
inhibition	O
of	O
ATP	O
synthesis	O
or	O
the	O
supplementation	O
of	O
pyruvate	O
to	O
2	O
-	O
DG	O
-	O
treated	O
cells	O
,	O
suggesting	O
that	O
poor	O
ATP	O
generation	O
is	O
involved	O
only	O
to	O
a	O
limited	O
extent	O
.	O

2	O
-	O
DG	O
treatment	O
also	O
inhibited	O
activation	O
of	O
p21	S-Protein
WAF1	S-Protein
promoter	O
,	O
which	O
is	O
controlled	O
by	O
p53	S-Protein
and	O
/	O
or	O
Sp1	S-Protein
.	O

In	O
a	O
reporter	O
assay	O
using	O
p21	S-Protein
WAF1	S-Protein
promoter	O
constructs	O
,	O
2	O
-	O
DG	O
exerted	O
a	O
strong	O
inhibitory	O
effect	O
on	O
Sp1	S-Protein
activity	O
.	O

DNA	O
binding	O
activity	O
of	O
Sp1	S-Protein
in	O
2	O
-	O
DG	O
-	O
treated	O
HeLa	O
cells	O
was	O
intact	O
,	O
whereas	O
it	O
was	O
severely	O
impaired	O
in	O
cells	O
incubated	O
in	O
a	O
low	O
glucose	O
medium	O
or	O
in	O
hypoxic	O
condition	O
.	O

Unexpectedly	O
,	O
Sp1	S-Protein
was	O
heavily	O
modified	O
with	O
GlcNAc	O
in	O
2	O
-	O
DG	O
-	O
treated	O
cells	O
,	O
which	O
is	O
at	O
least	O
partially	O
attributed	O
to	O
the	O
inhibitory	O
effect	O
of	O
2	O
-	O
DG	O
on	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
D	O
-	O
glucosaminidase	O
activity	O
.	O

Our	O
results	O
suggest	O
that	O
2	O
-	O
DG	O
,	O
like	O
low	O
glucose	O
or	O
hypoxic	O
condition	O
,	O
down	O
-	O
regulates	O
Sp1	S-Protein
activity	O
,	O
but	O
through	O
hyper	O
-	O
GlcNAcylation	O
instead	O
of	O
hypo	O
-	O
GlcNAcylation	O
.	O

Independent	O
signals	O
determine	O
the	O
subcellular	O
localization	O
of	O
NEP	S-Protein
in	O
prostate	O
cancer	O
cells	O
.	O

NEP	S-Protein
(	O
Neutral	B-Protein
endopeptidase	I-Protein
24	I-Protein
.	I-Protein
11	E-Protein
)	O
is	O
a	O
cell	O
surface	O
enzyme	O
that	O
hydrolyzes	O
bioactive	O
neuropeptides	O
implicated	O
in	O
the	O
transition	O
from	O
androgen	O
-	O
dependent	O
prostate	O
cancer	O
(	O
PC	O
)	O
to	O
androgen	O
-	O
independent	O
PC	O
.	O

We	O
report	O
the	O
cloning	O
and	O
sequence	O
analyses	O
of	O
NEP	S-Protein
cDNAs	O
from	O
human	O
androgen	O
-	O
responsive	O
LNCaP	O
PC	O
cells	O
and	O
prostatic	O
stromal	O
cells	O
.	O

To	O
investigate	O
the	O
functional	O
role	O
of	O
a	O
nuclear	O
localization	O
sequence	O
(	O
NLS	O
)	O
detected	O
within	O
the	O
N	O
-	O
terminus	O
and	O
of	O
an	O
endoplasmic	O
reticulum	O
retention	O
signal	O
within	O
the	O
C	O
-	O
terminus	O
,	O
NEP	S-Protein
-	O
GFP	S-Protein
expression	O
vectors	O
were	O
constructed	O
containing	O
the	O
whole	O
NEP	S-Protein
gene	O
,	O
fragments	O
encoding	O
the	O
N	O
-	O
terminus	O
/	O
C	O
-	O
terminus	O
of	O
the	O
protein	O
(	O
5	O
(	O
'	O
)	O
NEP	S-Protein
-	O
GFP	S-Protein
/	O
3	O
(	O
'	O
)	O
NEP	S-Protein
-	O
GFP	S-Protein
)	O
,	O
and	O
5	O
(	O
'	O
)	O
NEP	S-Protein
-	O
GFP	S-Protein
constructs	O
lacking	O
the	O
NLS	O
.	O

3	O
(	O
'	O
)	O
NEP	S-Protein
-	O
GFP	S-Protein
transfected	O
cells	O
showed	O
plasma	O
membrane	O
/	O
cytoplasmic	O
fluorescence	O
whereas	O
the	O
5	O
(	O
'	O
)	O
NEP	S-Protein
-	O
GFP	S-Protein
fusion	O
protein	O
was	O
also	O
detected	O
in	O
the	O
nucleus	O
.	O

The	O
omission	O
of	O
the	O
NLS	O
resulted	O
in	O
no	O
reduction	O
in	O
nuclear	O
and	O
an	O
increase	O
in	O
cytoplasmic	O
staining	O
.	O

The	O
results	O
suggest	O
that	O
the	O
analyzed	O
structural	O
motifs	O
determine	O
the	O
subcellular	O
distribution	O
of	O
NEP	S-Protein
in	O
epithelial	O
LNCaP	O
PC	O
cells	O
and	O
stromal	O
prostatic	O
cells	O
and	O
therefore	O
could	O
be	O
responsible	O
for	O
the	O
altered	O
cellular	O
localization	O
of	O
NEP	S-Protein
observed	O
in	O
PC	O
.	O

Folic	O
acid	O
,	O
polymorphism	O
of	O
methyl	O
-	O
group	O
metabolism	O
genes	O
,	O
and	O
DNA	O
methylation	O
in	O
relation	O
to	O
GI	O
carcinogenesis	O
.	O

DNA	O
methylation	O
is	O
the	O
main	O
epigenetic	O
modification	O
after	O
replication	O
in	O
humans	O
.	O

DNA	O
(	O
cytosine	O
-	O
5	O
)	O
-	O
methyltransferase	O
(	O
DNMT	O
)	O
catalyzes	O
the	O
transfer	O
of	O
a	O
methyl	O
group	O
from	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
methionine	O
(	O
SAM	O
)	O
to	O
C5	O
of	O
cytosine	O
within	O
CpG	O
dinucleotide	O
sequences	O
in	O
the	O
genomic	O
DNA	O
of	O
higher	O
eukaryotes	O
.	O

There	O
is	O
considerable	O
evidence	O
that	O
aberrant	O
DNA	O
methylation	O
plays	O
an	O
integral	O
role	O
in	O
carcinogenesis	O
.	O

Folic	O
acid	O
or	O
folate	O
is	O
crucial	O
for	O
normal	O
DNA	O
synthesis	O
and	O
can	O
regulate	O
DNA	O
methylation	O
,	O
and	O
through	O
this	O
,	O
it	O
affects	O
cellular	O
SAM	O
levels	O
.	O

Folate	O
deficiency	O
results	O
in	O
DNA	O
hypomethylation	O
.	O

Epidemiological	O
studies	O
have	O
indicated	O
that	O
folic	O
acid	O
protects	O
against	O
gastrointestinal	O
(	O
GI	O
)	O
cancers	O
.	O

Methylene	B-Protein
-	I-Protein
tetrahydrofolate	I-Protein
reductase	E-Protein
(	O
MTHFR	S-Protein
)	O
and	O
methionine	B-Protein
synthase	E-Protein
(	O
MS	S-Protein
)	O
are	O
the	O
enzymes	O
involved	O
in	O
folate	O
metabolism	O
and	O
are	O
thought	O
to	O
influence	O
DNA	O
methylation	O
.	O

MTHFR	S-Protein
is	O
highly	O
polymorphic	O
,	O
and	O
the	O
variant	O
genotypes	O
result	O
in	O
decreased	O
MTHFR	S-Protein
enzyme	O
activity	O
and	O
lower	O
plasma	O
folate	O
level	O
.	O

Two	O
common	O
MTHFR	S-Protein
polymorphisms	O
,	O
677CT	O
(	O
or	O
677TT	O
)	O
and	O
A1298C	O
,	O
and	O
an	O
MS	S-Protein
polymorphism	O
,	O
A	O
-	O
-	O
>	O
G	O
at	O
2756	O
,	O
have	O
been	O
identified	O
.	O

Most	O
studies	O
support	O
an	O
inverse	O
association	O
between	O
folate	O
status	O
and	O
the	O
rate	O
of	O
colorectal	O
adenomas	O
and	O
carcinomas	O
.	O

During	O
human	O
GI	O
carcinogenesis	O
,	O
MTHFR	S-Protein
is	O
highly	O
polymorphic	O
,	O
and	O
the	O
variant	O
genotypes	O
result	O
in	O
decreased	O
MTHFR	S-Protein
enzyme	O
activity	O
and	O
lower	O
plasma	O
folate	O
level	O
,	O
as	O
well	O
as	O
aberrant	O
methylation	O
.	O

Regulation	O
of	O
beta1C	S-Protein
and	O
beta1A	B-Protein
integrin	E-Protein
expression	O
in	O
prostate	O
carcinoma	O
cells	O
.	O

beta	B-Protein
(	I-Protein
1C	I-Protein
)	E-Protein
and	O
beta	B-Protein
(	I-Protein
1A	I-Protein
)	I-Protein
integrins	E-Protein
are	O
two	O
splice	O
variants	O
of	O
the	O
human	O
beta	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
integrin	E-Protein
subfamily	O
that	O
act	O
as	O
an	O
inhibitor	O
and	O
a	O
stimulator	O
of	O
cell	O
proliferation	O
,	O
respectively	O
.	O

In	O
neoplastic	O
prostate	O
epithelium	O
,	O
both	O
these	O
variants	O
are	O
down	O
-	O
regulated	O
at	O
the	O
mRNA	O
level	O
,	O
but	O
only	O
beta	B-Protein
(	I-Protein
1C	I-Protein
)	E-Protein
protein	O
levels	O
are	O
reduced	O
.	O

We	O
used	O
an	O
experimental	O
model	O
consisting	O
of	O
PNT1A	O
,	O
a	O
normal	O
immortalized	O
prostate	O
cell	O
line	O
,	O
and	O
LNCaP	O
and	O
PC	O
-	O
3	O
,	O
two	O
prostate	O
carcinoma	O
cell	O
lines	O
,	O
to	O
investigate	O
both	O
the	O
transcription	O
/	O
post	O
-	O
transcription	O
and	O
translation	O
/	O
post	O
-	O
translation	O
processes	O
of	O
beta	B-Protein
(	I-Protein
1C	I-Protein
)	E-Protein
and	O
beta	B-Protein
(	I-Protein
1A	I-Protein
)	E-Protein
.	O

Transcriptional	O
regulation	O
played	O
the	O
key	O
role	O
for	O
the	O
reduction	O
in	O
beta	B-Protein
(	I-Protein
1C	I-Protein
)	E-Protein
and	O
beta	B-Protein
(	I-Protein
1A	I-Protein
)	E-Protein
mRNA	O
expression	O
in	O
cancer	O
cells	O
,	O
as	O
beta	B-Protein
(	I-Protein
1C	I-Protein
)	E-Protein
and	O
beta	B-Protein
(	I-Protein
1A	I-Protein
)	E-Protein
mRNA	O
half	O
-	O
lives	O
were	O
comparable	O
in	O
normal	O
and	O
cancer	O
cells	O
.	O

beta	B-Protein
(	I-Protein
1C	I-Protein
)	E-Protein
translation	O
rate	O
decreased	O
in	O
cancer	O
cells	O
in	O
agreement	O
with	O
the	O
decrease	O
in	O
mRNA	O
levels	O
,	O
whereas	O
beta	B-Protein
(	I-Protein
1A	I-Protein
)	E-Protein
translation	O
rate	O
increased	O
more	O
than	O
2	O
-	O
fold	O
,	O
despite	O
the	O
reduction	O
in	O
mRNA	O
levels	O
.	O

Both	O
beta	B-Protein
(	I-Protein
1C	I-Protein
)	E-Protein
and	O
beta	B-Protein
(	I-Protein
1A	I-Protein
)	E-Protein
proteins	O
were	O
degraded	O
more	O
rapidly	O
in	O
cancer	O
than	O
in	O
normal	O
cells	O
,	O
and	O
pulse	O
-	O
chase	O
experiments	O
showed	O
that	O
intermediates	O
and	O
/	O
or	O
rates	O
of	O
beta	B-Protein
(	I-Protein
1C	I-Protein
)	E-Protein
and	O
beta	B-Protein
(	I-Protein
1A	I-Protein
)	E-Protein
protein	O
maturation	O
differ	O
in	O
cancer	O
versus	O
normal	O
cells	O
.	O

Inhibition	O
of	O
either	O
calpain	O
-	O
or	O
lysosomal	O
-	O
mediated	O
proteolysis	O
increased	O
both	O
beta	B-Protein
(	I-Protein
1C	I-Protein
)	E-Protein
and	O
beta	B-Protein
(	I-Protein
1A	I-Protein
)	E-Protein
protein	O
levels	O
,	O
the	O
former	O
in	O
normal	O
but	O
not	O
in	O
cancer	O
cells	O
and	O
the	O
latter	O
in	O
both	O
cell	O
types	O
,	O
albeit	O
at	O
a	O
higher	O
extent	O
in	O
cancer	O
than	O
in	O
normal	O
cells	O
.	O

Interestingly	O
,	O
inhibition	O
of	O
the	O
ubiquitin	S-Protein
proteolytic	O
pathway	O
increased	O
expression	O
of	O
ubiquitinated	O
beta	B-Protein
(	I-Protein
1C	I-Protein
)	E-Protein
protein	O
without	O
affecting	O
beta	B-Protein
(	I-Protein
1A	I-Protein
)	E-Protein
protein	O
levels	O
in	O
cancer	O
cells	O
.	O

These	O
results	O
show	O
that	O
transcriptional	O
,	O
translational	O
,	O
and	O
post	O
-	O
translational	O
processes	O
,	O
the	O
last	O
involving	O
the	O
ubiquitin	S-Protein
proteolytic	O
pathway	O
,	O
contribute	O
to	O
the	O
selective	O
loss	O
of	O
beta	B-Protein
(	I-Protein
1C	I-Protein
)	I-Protein
integrin	E-Protein
,	O
a	O
very	O
efficient	O
inhibitor	O
of	O
cell	O
proliferation	O
,	O
in	O
prostate	O
malignant	O
transformation	O
.	O

Acetylation	O
of	O
androgen	B-Protein
receptor	E-Protein
enhances	O
coactivator	O
binding	O
and	O
promotes	O
prostate	O
cancer	O
cell	O
growth	O
.	O

Modification	O
by	O
acetylation	O
occurs	O
at	O
epsilon	O
-	O
amino	O
lysine	O
residues	O
of	O
histones	O
and	O
transcription	O
factors	O
.	O

Unlike	O
phosphorylation	O
,	O
a	O
direct	O
link	O
between	O
transcription	O
factor	O
acetylation	O
and	O
cellular	O
growth	O
or	O
apoptosis	O
has	O
not	O
been	O
established	O
.	O

We	O
show	O
that	O
the	O
nuclear	O
androgen	B-Protein
receptor	E-Protein
(	O
AR	S-Protein
)	O
,	O
a	O
DNA	O
-	O
binding	O
transcriptional	O
regulator	O
,	O
is	O
acetylated	O
in	O
vivo	O
.	O

The	O
acetylation	O
of	O
the	O
AR	S-Protein
is	O
induced	O
by	O
ligand	O
dihydrotestosterone	O
and	O
by	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitors	O
in	O
living	O
cells	O
.	O

Direct	O
AR	S-Protein
acetylation	O
augmented	O
p300	S-Protein
binding	O
in	O
vitro	O
.	O

Constructs	O
mimicking	O
neutral	O
polar	O
substitution	O
acetylation	O
(	O
AR	S-Protein
(	O
K630Q	O
)	O
,	O
AR	S-Protein
(	O
K630T	O
)	O
)	O
enhanced	O
p300	S-Protein
binding	O
and	O
reduced	O
N	O
-	O
CoR	O
/	O
HDAC	O
/	O
Smad3	S-Protein
corepressor	O
binding	O
,	O
whereas	O
charged	O
residue	O
substitution	O
(	O
AR	S-Protein
(	O
K630R	O
)	O
)	O
reduced	O
p300	S-Protein
binding	O
and	O
enhanced	O
corepressor	O
binding	O
.	O

The	O
AR	S-Protein
acetylation	O
mimics	O
promoted	O
cell	O
survival	O
and	O
growth	O
of	O
prostate	O
cancer	O
cells	O
in	O
soft	O
agar	O
and	O
in	O
nude	O
mice	O
and	O
augmented	O
transcription	O
of	O
a	O
subset	O
of	O
growth	O
control	O
target	O
gene	O
promoters	O
.	O

Thus	O
,	O
transcription	O
factor	O
acetylation	O
regulates	O
coactivator	O
/	O
corepressor	O
complex	O
binding	O
,	O
altering	O
expression	O
of	O
specific	O
growth	O
control	O
genes	O
to	O
promote	O
aberrant	O
cellular	O
growth	O
in	O
vivo	O
.	O

DNA	B-Protein
-	I-Protein
methyltransferase	I-Protein
1	E-Protein
mRNA	O
is	O
selectively	O
overexpressed	O
in	O
telencephalic	O
GABAergic	O
interneurons	O
of	O
schizophrenia	O
brains	O
.	O

A	O
down	O
-	O
regulation	O
of	O
reelin	S-Protein
and	O
glutamic	B-Protein
acid	I-Protein
decarboxylase	I-Protein
(	I-Protein
GAD	I-Protein
)	I-Protein
67	E-Protein
mRNAs	O
was	O
detected	O
in	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
ergic	O
cortical	O
interneurons	O
of	O
schizophrenia	O
(	O
SZ	O
)	O
postmortem	O
brains	O
(	O
10	O
)	O
,	O
suggesting	O
that	O
the	O
availability	O
of	O
GABA	O
and	O
reelin	S-Protein
may	O
be	O
decreased	O
in	O
SZ	O
cortex	O
.	O

In	O
situ	O
hybridization	O
of	O
the	O
mRNA	O
encoding	O
for	O
DNA	B-Protein
-	I-Protein
methyltransferase	I-Protein
1	E-Protein
,	O
which	O
catalyzes	O
the	O
methylation	O
of	O
promoter	O
CpG	O
islands	O
,	O
shows	O
that	O
the	O
expression	O
of	O
this	O
mRNA	O
is	O
increased	O
in	O
cortical	O
GABAergic	O
interneurons	O
but	O
not	O
in	O
pyramidal	O
neurons	O
of	O
SZ	O
brains	O
.	O

Counts	O
of	O
reelin	S-Protein
mRNA	O
-	O
positive	O
neurons	O
in	O
Brodmann	O
'	O
s	O
area	O
10	O
of	O
either	O
nonpsychiatric	O
subjects	O
or	O
SZ	O
patients	O
show	O
that	O
the	O
expression	O
of	O
reelin	S-Protein
mRNA	O
is	O
decreased	O
in	O
layer	O
-	O
I	O
,	O
-	O
II	O
,	O
and	O
-	O
IV	O
GABAergic	O
interneurons	O
of	O
SZ	O
patients	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
increase	O
of	O
DNA	B-Protein
-	I-Protein
methyltransferase	I-Protein
1	E-Protein
expression	O
in	O
telencephalic	O
GABAergic	O
interneurons	O
of	O
SZ	O
patients	O
causes	O
a	O
promoter	O
hypermethylation	O
of	O
reelin	S-Protein
and	O
GAD	B-Protein
(	I-Protein
67	I-Protein
)	E-Protein
and	O
perhaps	O
of	O
other	O
genes	O
expressed	O
in	O
these	O
interneurons	O
.	O

It	O
is	O
difficult	O
to	O
decide	O
whether	O
this	O
dysfunction	O
of	O
GABAergic	O
neurons	O
detected	O
in	O
SZ	O
is	O
responsible	O
for	O
this	O
disease	O
or	O
is	O
a	O
consequence	O
of	O
this	O
disorder	O
.	O

Although	O
at	O
present	O
we	O
cannot	O
differentiate	O
between	O
these	O
two	O
alternatives	O
,	O
it	O
is	O
important	O
to	O
consider	O
that	O
so	O
far	O
a	O
molecular	O
pathology	O
of	O
cortical	O
GABAergic	O
neurons	O
appears	O
to	O
be	O
the	O
most	O
consistent	O
finding	O
associated	O
with	O
SZ	O
morbidity	O
.	O

Substrate	O
requirements	O
of	O
the	O
oxygen	O
-	O
sensing	O
asparaginyl	O
hydroxylase	O
factor	B-Protein
-	I-Protein
inhibiting	I-Protein
hypoxia	I-Protein
-	I-Protein
inducible	I-Protein
factor	E-Protein
.	O

The	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
alpha	I-Protein
subunits	I-Protein
1	E-Protein
and	O
2	S-Protein
(	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
and	O
HIF	B-Protein
-	I-Protein
2alpha	E-Protein
)	O
are	O
subjected	O
to	O
oxygen	O
-	O
dependent	O
asparaginyl	O
hydroxylation	O
,	O
a	O
modification	O
that	O
represses	O
the	O
carboxyl	O
-	O
terminal	O
transactivation	O
domain	O
(	O
CAD	O
)	O
at	O
normoxia	O
by	O
preventing	O
recruitment	O
of	O
the	O
p300	S-Protein
/	O
cAMP	O
-	O
response	O
element	O
-	O
binding	O
protein	O
coactivators	O
.	O

This	O
hydroxylation	O
is	O
performed	O
by	O
the	O
novel	O
asparaginyl	O
hydroxylase	O
,	O
factor	B-Protein
-	I-Protein
inhibiting	I-Protein
HIF	I-Protein
-	I-Protein
1	E-Protein
'	O
(	O
FIH	B-Protein
-	I-Protein
1	E-Protein
)	O
,	O
of	O
which	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
and	O
HIF	B-Protein
-	I-Protein
2alpha	E-Protein
are	O
the	O
only	O
reported	O
substrates	O
.	O

Here	O
we	O
investigated	O
the	O
substrate	O
requirements	O
of	O
FIH	B-Protein
-	I-Protein
1	E-Protein
by	O
characterizing	O
its	O
subcellular	O
localization	O
and	O
by	O
examining	O
amino	O
acids	O
within	O
the	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
substrate	O
for	O
their	O
importance	O
in	O
recognition	O
and	O
catalysis	O
by	O
FIH	B-Protein
-	I-Protein
1	E-Protein
.	O

Using	O
immunohistochemistry	O
,	O
we	O
showed	O
that	O
both	O
endogenous	O
and	O
transfected	O
FIH	B-Protein
-	I-Protein
1	E-Protein
are	O
primarily	O
confined	O
to	O
the	O
cytoplasm	O
and	O
remain	O
there	O
under	O
normoxia	O
and	O
following	O
treatment	O
with	O
the	O
hypoxia	O
mimetic	O
,	O
dipyridyl	O
.	O

Individual	O
alanine	O
mutations	O
of	O
seven	O
conserved	O
amino	O
acids	O
flanking	O
the	O
hydroxylated	O
asparagine	O
in	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
revealed	O
the	O
importance	O
of	O
the	O
valine	O
(	O
Val	O
-	O
802	O
)	O
adjacent	O
to	O
the	O
targeted	O
asparagine	O
.	O

The	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
CAD	O
V802A	O
mutant	O
exhibited	O
a	O
4	O
-	O
fold	O
lower	O
V	O
(	O
max	O
)	O
in	O
enzyme	O
assays	O
,	O
whereas	O
all	O
other	O
mutants	O
were	O
hydroxylated	O
as	O
efficiently	O
as	O
the	O
wild	O
type	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
CAD	O
.	O

Furthermore	O
,	O
in	O
cell	O
-	O
based	O
assays	O
the	O
transcriptional	O
activity	O
of	O
V802A	O
was	O
constitutive	O
,	O
suggesting	O
negligible	O
normoxic	O
hydroxylation	O
in	O
HEK293T	O
cells	O
,	O
whereas	O
the	O
wild	O
type	O
and	O
other	O
mutants	O
were	O
repressed	O
under	O
normoxia	O
.	O

Molecular	O
modeling	O
of	O
the	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
CAD	O
V802A	O
in	O
complex	O
with	O
FIH	B-Protein
-	I-Protein
1	E-Protein
predicted	O
an	O
alteration	O
in	O
asparagine	O
positioning	O
compared	O
with	O
the	O
wild	O
type	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
CAD	O
,	O
providing	O
an	O
explanation	O
for	O
the	O
impaired	O
catalysis	O
observed	O
and	O
confirming	O
the	O
importance	O
of	O
Val	O
-	O
802	O
in	O
asparaginyl	O
hydroxylation	O
by	O
FIH	B-Protein
-	I-Protein
1	E-Protein
.	O

Histone	B-Protein
H3	E-Protein
lysine	O
9	O
methylation	O
is	O
required	O
for	O
DNA	O
elimination	O
in	O
developing	O
macronuclei	O
in	O
Tetrahymena	O
.	O

Genome	O
-	O
wide	O
DNA	O
elimination	O
accompanies	O
development	O
of	O
the	O
somatic	O
macronucleus	O
from	O
the	O
germ	O
-	O
line	O
micronucleus	O
during	O
the	O
sexual	O
process	O
of	O
conjugation	O
in	O
the	O
ciliated	O
protozoan	O
Tetrahymena	O
thermophila	O
.	O

Small	O
RNAs	O
,	O
referred	O
to	O
as	O
"	O
scan	O
RNAs	O
"	O
(	O
scnRNAs	O
)	O
,	O
that	O
accumulate	O
only	O
during	O
conjugation	O
are	O
highly	O
enriched	O
in	O
the	O
eliminated	O
sequences	O
,	O
and	O
mutations	O
that	O
prevent	O
DNA	O
elimination	O
also	O
affect	O
the	O
accumulation	O
of	O
scnRNAs	O
,	O
suggesting	O
that	O
an	O
RNA	O
interference	O
(	O
RNAi	O
)	O
-	O
like	O
mechanism	O
is	O
involved	O
in	O
DNA	O
elimination	O
.	O

Histone	B-Protein
H3	E-Protein
that	O
is	O
methylated	O
at	O
lysine	O
9	O
(	O
K9	O
)	O
is	O
a	O
hallmark	O
of	O
heterochromatin	O
and	O
,	O
in	O
Tetrahymena	O
,	O
is	O
found	O
only	O
in	O
developing	O
macronuclei	O
(	O
anlagen	O
)	O
in	O
association	O
with	O
chromatin	O
containing	O
the	O
sequences	O
undergoing	O
elimination	O
.	O

In	O
this	O
article	O
,	O
we	O
demonstrate	O
that	O
a	O
mutation	O
in	O
the	O
TWI1	S-Protein
gene	O
that	O
eliminates	O
the	O
accumulation	O
of	O
scnRNAs	O
also	O
abolishes	O
H3	S-Protein
methylation	O
at	O
K9	O
.	O

We	O
created	O
mutant	O
strains	O
of	O
Tetrahymena	O
in	O
which	O
the	O
only	O
major	O
H3	S-Protein
contained	O
a	O
K9Q	O
mutation	O
.	O

These	O
mutants	O
accumulated	O
scnRNAs	O
normally	O
during	O
conjugation	O
but	O
showed	O
dramatically	O
reduced	O
efficiency	O
of	O
DNA	O
elimination	O
.	O

These	O
results	O
provide	O
strong	O
genetic	O
evidence	O
linking	O
an	O
RNAi	O
-	O
like	O
pathway	O
,	O
H3	S-Protein
K9	O
methylation	O
,	O
and	O
DNA	O
elimination	O
in	O
Tetrahymena	O
.	O

Structural	O
characterization	O
of	O
macroH2A	S-Protein
containing	O
chromatin	O
.	O

MacroH2A	S-Protein
(	O
mH2A	S-Protein
)	O
is	O
one	O
of	O
the	O
most	O
recently	O
identified	O
members	O
of	O
the	O
heteromorphous	O
histone	S-Protein
variant	O
family	O
.	O

It	O
is	O
unique	O
among	O
the	O
members	O
of	O
this	O
group	O
because	O
it	O
contains	O
an	O
unusually	O
large	O
non	O
-	O
histone	S-Protein
C	O
-	O
terminal	O
end	O
,	O
from	O
where	O
its	O
name	O
derives	O
,	O
and	O
appears	O
to	O
be	O
restricted	O
to	O
subphylum	O
vertebrata	O
.	O

Although	O
a	O
concerted	O
effort	O
has	O
been	O
carried	O
out	O
in	O
order	O
to	O
characterize	O
the	O
physiological	O
relevance	O
of	O
mH2A	S-Protein
,	O
little	O
is	O
known	O
in	O
comparison	O
about	O
the	O
structural	O
importance	O
of	O
the	O
molecule	O
.	O

Elucidating	O
the	O
biophysical	O
and	O
conformational	O
proprieties	O
of	O
mH2A	S-Protein
in	O
chromatin	O
may	O
provide	O
clues	O
into	O
the	O
links	O
between	O
this	O
histone	S-Protein
variant	O
and	O
its	O
unique	O
function	O
(	O
s	O
)	O
.	O

In	O
this	O
paper	O
,	O
we	O
look	O
first	O
at	O
the	O
heterogeneous	O
tissue	O
-	O
specific	O
distribution	O
of	O
this	O
protein	O
in	O
different	O
vertebrate	O
classes	O
.	O

This	O
is	O
followed	O
by	O
a	O
structural	O
comparison	O
between	O
mH2A	S-Protein
and	O
H2A	S-Protein
protein	O
and	O
by	O
the	O
characterization	O
of	O
the	O
nucleosome	O
core	O
particles	O
with	O
which	O
these	O
histone	S-Protein
subtypes	O
are	O
associated	O
.	O

We	O
find	O
that	O
the	O
highly	O
alpha	O
-	O
helical	O
C	O
-	O
terminus	O
of	O
mH2A	S-Protein
confers	O
an	O
asymmetric	O
conformation	O
to	O
nucleosomes	O
and	O
that	O
this	O
variant	O
is	O
tightly	O
bound	O
to	O
chromatin	O
fragments	O
in	O
a	O
way	O
that	O
does	O
not	O
depend	O
on	O
the	O
overall	O
extent	O
of	O
acetylation	O
of	O
the	O
other	O
core	O
histones	S-Protein
.	O

Role	O
of	O
the	O
DNA	O
methyltransferase	O
variant	O
DNMT3b3	S-Protein
in	O
DNA	O
methylation	O
.	O

Several	O
alternatively	O
spliced	O
variants	O
of	O
DNA	B-Protein
methyltransferase	I-Protein
(	I-Protein
DNMT	I-Protein
)	I-Protein
3b	E-Protein
have	O
been	O
described	O
.	O

Here	O
,	O
we	O
identified	O
new	O
murine	O
Dnmt3b	S-Protein
mRNA	O
isoforms	O
and	O
found	O
that	O
mouse	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
expressed	O
only	O
Dnmt3b	S-Protein
transcripts	O
that	O
contained	O
exons	O
10	O
and	O
11	O
,	O
whereas	O
the	O
Dnmt3b	S-Protein
transcripts	O
in	O
somatic	O
cells	O
lacked	O
these	O
exons	O
,	O
suggesting	O
that	O
this	O
region	O
is	O
important	O
for	O
embryonic	O
development	O
.	O

DNMT3b2	S-Protein
and	O
3b3	S-Protein
were	O
the	O
major	O
isoforms	O
expressed	O
in	O
human	O
cell	O
lines	O
and	O
the	O
mRNA	O
levels	O
of	O
these	O
isoforms	O
closely	O
correlated	O
with	O
their	O
protein	O
levels	O
.	O

Although	O
DNMT3b3	S-Protein
may	O
be	O
catalytically	O
inactive	O
,	O
it	O
still	O
may	O
be	O
biologically	O
important	O
because	O
D4Z4	O
and	O
satellites	O
2	O
and	O
3	O
repeat	O
sequences	O
,	O
all	O
known	O
DNMT3b	S-Protein
target	O
sequences	O
,	O
were	O
methylated	O
in	O
cells	O
that	O
predominantly	O
expressed	O
DNMT3b3	S-Protein
.	O

Treatment	O
of	O
cells	O
with	O
the	O
mechanism	O
-	O
based	O
inhibitor	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
(	O
5	O
-	O
Aza	O
-	O
CdR	O
)	O
caused	O
a	O
complete	O
depletion	O
of	O
DNMT1	S-Protein
,	O
3a	S-Protein
,	O
3b1	S-Protein
,	O
and	O
3b2	S-Protein
proteins	O
.	O

Human	O
DNMT3b3	S-Protein
and	O
the	O
murine	O
Dnmt3b3	S-Protein
-	O
like	O
isoform	O
,	O
Dnmt3b6	S-Protein
,	O
were	O
also	O
depleted	O
although	O
less	O
efficiently	O
,	O
suggesting	O
that	O
DNMT3b3	S-Protein
also	O
may	O
be	O
capable	O
of	O
DNA	O
binding	O
.	O

Moreover	O
,	O
de	O
novo	O
methylation	O
of	O
D4Z4	O
in	O
T24	O
cancer	O
cells	O
after	O
5	O
-	O
Aza	O
-	O
CdR	O
treatment	O
only	O
occurred	O
when	O
DNMT3b3	S-Protein
was	O
expressed	O
,	O
reinforcing	O
its	O
role	O
as	O
a	O
contributing	O
factor	O
of	O
DNA	O
methylation	O
.	O

The	O
expression	O
of	O
either	O
DNMT3b2	S-Protein
or	O
3b3	S-Protein
,	O
however	O
,	O
was	O
not	O
sufficient	O
to	O
explain	O
the	O
abnormal	O
methylation	O
of	O
DNMT3b	S-Protein
target	O
sequences	O
in	O
human	O
cancers	O
,	O
which	O
may	O
therefore	O
be	O
dependent	O
on	O
factors	O
that	O
affect	O
DNMT3b	S-Protein
targeting	O
.	O

Methylation	O
analyses	O
of	O
immunodeficiency	O
,	O
chromosomal	O
instabilities	O
,	O
and	O
facial	O
abnormalities	O
cells	O
revealed	O
that	O
an	O
Alu	O
repeat	O
sequence	O
was	O
highly	O
methylated	O
,	O
suggesting	O
that	O
Alu	O
sequences	O
are	O
not	O
DNMT3b	S-Protein
targets	O
.	O

Collagen	O
prolyl	O
4	O
-	O
hydroxylase	O
tetramers	O
and	O
dimers	O
show	O
identical	O
decreases	O
in	O
Km	O
values	O
for	O
peptide	O
substrates	O
with	O
increasing	O
chain	O
length	O
:	O
mutation	O
of	O
one	O
of	O
the	O
two	O
catalytic	O
sites	O
in	O
the	O
tetramer	O
inactivates	O
the	O
enzyme	O
by	O
more	O
than	O
half	O
.	O

The	O
collagen	O
prolyl	O
4	O
-	O
hydroxylases	O
(	O
collagen	O
P4Hs	O
,	O
EC	O
1	O
.	O
14	O
.	O
11	O
.	O
2	O
)	O
play	O
a	O
key	O
role	O
in	O
the	O
synthesis	O
of	O
the	O
extracellular	O
matrix	O
.	O

The	O
vertebrate	O
enzymes	O
are	O
alpha	O
(	O
2	O
)	O
beta	O
(	O
2	O
)	O
tetramers	O
,	O
the	O
beta	O
subunit	O
being	O
identical	O
to	O
protein	B-Protein
disulfide	I-Protein
isomerase	E-Protein
(	O
PDI	S-Protein
)	O
.	O

The	O
main	O
Caenorhabditis	O
elegans	O
collagen	O
P4H	O
form	O
is	O
an	O
unusual	O
PHY	B-Protein
-	I-Protein
1	E-Protein
/	O
PHY	B-Protein
-	I-Protein
2	E-Protein
/	O
(	O
PDI	S-Protein
)	O
(	O
2	O
)	O
mixed	O
tetramer	O
consisting	O
of	O
two	O
types	O
of	O
catalytic	O
alpha	O
subunit	O
,	O
but	O
the	O
PHY	B-Protein
-	I-Protein
1	E-Protein
and	O
PHY	B-Protein
-	I-Protein
2	E-Protein
polypeptides	O
also	O
form	O
active	O
PHY	O
/	O
PDI	S-Protein
dimers	O
.	O

The	O
lengths	O
of	O
peptide	O
substrates	O
have	O
a	O
major	O
effect	O
on	O
their	O
interaction	O
with	O
the	O
P4H	O
tetramers	O
,	O
the	O
K	O
(	O
m	O
)	O
values	O
decreasing	O
markedly	O
with	O
increasing	O
chain	O
length	O
.	O

This	O
phenomenon	O
has	O
been	O
explained	O
in	O
terms	O
of	O
processive	O
binding	O
of	O
the	O
two	O
catalytic	O
subunits	O
to	O
long	O
peptides	O
.	O

We	O
determined	O
here	O
the	O
K	O
(	O
m	O
)	O
values	O
of	O
a	O
collagen	O
P4H	O
having	O
two	O
catalytic	O
sites	O
,	O
the	O
C	O
.	O
elegans	O
mixed	O
tetramer	O
,	O
and	O
a	O
form	O
having	O
only	O
one	O
such	O
site	O
,	O
the	O
PHY	B-Protein
-	I-Protein
1	E-Protein
/	O
PDI	S-Protein
dimer	O
,	O
for	O
peptides	O
of	O
varying	O
lengths	O
.	O

All	O
the	O
K	O
(	O
m	O
)	O
values	O
of	O
the	O
PHY	B-Protein
-	I-Protein
1	E-Protein
/	O
PDI	S-Protein
dimer	O
were	O
found	O
to	O
be	O
about	O
1	O
.	O
5	O
-	O
2	O
.	O
5	O
times	O
those	O
of	O
the	O
tetramer	O
,	O
but	O
increasing	O
peptide	O
length	O
led	O
to	O
identical	O
decreases	O
in	O
the	O
values	O
of	O
both	O
enzyme	O
forms	O
.	O

The	O
K	O
(	O
m	O
)	O
for	O
a	O
nonhydroxylated	O
collagen	O
fragment	O
with	O
33	O
-	O
X	O
-	O
Y	O
-	O
Gly	O
-	O
triplets	O
but	O
only	O
11	O
-	O
X	O
-	O
Pro	O
-	O
Gly	O
-	O
triplets	O
was	O
found	O
to	O
correspond	O
to	O
the	O
number	O
of	O
the	O
former	O
rather	O
than	O
the	O
latter	O
.	O

To	O
study	O
the	O
individual	O
roles	O
of	O
the	O
two	O
catalytic	O
sites	O
in	O
a	O
tetramer	O
,	O
we	O
produced	O
mutant	O
PHY	B-Protein
-	I-Protein
1	E-Protein
/	O
PHY	B-Protein
-	I-Protein
2	E-Protein
/	O
(	O
PDI	S-Protein
)	O
(	O
2	O
)	O
tetramers	O
in	O
which	O
binding	O
of	O
the	O
Fe	O
(	O
2	O
+	O
)	O
ion	O
or	O
2	O
-	O
oxoglutarate	O
to	O
one	O
of	O
the	O
two	O
catalytic	O
sites	O
was	O
prevented	O
.	O

The	O
activities	O
of	O
the	O
mutant	O
tetramers	O
decreased	O
to	O
markedly	O
less	O
than	O
50	O
%	O
of	O
that	O
of	O
the	O
wild	O
type	O
,	O
being	O
about	O
5	O
-	O
10	O
%	O
and	O
20	O
-	O
30	O
%	O
with	O
the	O
enzymes	O
having	O
one	O
of	O
the	O
two	O
Fe	O
(	O
2	O
+	O
)	O
-	O
binding	O
sites	O
or	O
2	O
-	O
oxoglutarate	O
-	O
binding	O
sites	O
inactivated	O
,	O
respectively	O
,	O
while	O
the	O
K	O
(	O
m	O
)	O
values	O
for	O
these	O
cosubstrates	O
or	O
peptide	O
substrates	O
were	O
not	O
affected	O
.	O

Our	O
data	O
thus	O
indicate	O
that	O
although	O
collagen	O
P4Hs	O
do	O
not	O
act	O
on	O
peptide	O
substrates	O
by	O
a	O
processive	O
mechanism	O
,	O
prevention	O
of	O
hydroxylation	O
at	O
one	O
of	O
the	O
two	O
catalytic	O
sites	O
in	O
the	O
tetramer	O
impairs	O
the	O
function	O
of	O
the	O
other	O
catalytic	O
site	O
.	O

Hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
(	O
HIF	O
-	O
1	O
)	O
promotes	O
its	O
degradation	O
by	O
induction	O
of	O
HIF	O
-	O
alpha	O
-	O
prolyl	O
-	O
4	O
-	O
hydroxylases	O
.	O

An	O
important	O
regulator	O
involved	O
in	O
oxygen	O
-	O
dependent	O
gene	O
expression	O
is	O
the	O
transcription	O
factor	O
HIF	O
(	O
hypoxia	O
-	O
inducible	O
factor	O
)	O
,	O
which	O
is	O
composed	O
of	O
an	O
oxygen	O
-	O
sensitive	O
alpha	O
-	O
subunit	O
(	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
or	O
HIF	B-Protein
-	I-Protein
2alpha	E-Protein
)	O
and	O
a	O
constitutively	O
expressed	O
beta	O
-	O
subunit	O
.	O

In	O
normoxia	O
,	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
is	O
destabilized	O
by	O
post	O
-	O
translational	O
hydroxylation	O
of	O
Pro	O
-	O
564	O
and	O
Pro	O
-	O
402	O
by	O
a	O
family	O
of	O
oxygen	O
-	O
sensitive	O
dioxygenases	O
.	O

The	O
three	O
HIF	O
-	O
modifying	O
human	O
enzymes	O
have	O
been	O
termed	O
prolyl	O
hydroxylase	O
domain	O
containing	O
proteins	O
(	O
PHD1	S-Protein
,	O
PHD2	S-Protein
and	O
PHD3	S-Protein
)	O
.	O

Prolyl	O
hydroxylation	O
leads	O
to	O
pVHL	S-Protein
(	O
von	B-Protein
-	I-Protein
Hippel	I-Protein
-	I-Protein
Lindau	E-Protein
protein	O
)	O
-	O
dependent	O
ubiquitination	O
and	O
rapid	O
proteasomal	O
degradation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
that	O
human	O
PHD2	S-Protein
and	O
PHD3	S-Protein
are	O
induced	O
by	O
hypoxia	O
in	O
primary	O
and	O
transformed	O
cell	O
lines	O
.	O

In	O
the	O
human	O
osteosarcoma	O
cell	O
line	O
,	O
U2OS	O
,	O
selective	O
suppression	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
expression	O
by	O
RNA	O
interference	O
resulted	O
in	O
a	O
complete	O
loss	O
of	O
hypoxic	O
induction	O
of	O
PHD2	S-Protein
and	O
PHD3	S-Protein
.	O

Induction	O
of	O
PHD2	S-Protein
by	O
hypoxia	O
was	O
lost	O
in	O
pVHL	S-Protein
-	O
deficient	O
RCC4	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
hypoxic	O
induction	O
of	O
PHD2	S-Protein
and	O
PHD3	S-Protein
is	O
critically	O
dependent	O
on	O
HIF	O
-	O
alpha	O
.	O

Using	O
a	O
VHL	O
capture	O
assay	O
,	O
we	O
demonstrate	O
that	O
HIF	O
-	O
alpha	O
prolyl	O
-	O
4	O
-	O
hydroxylase	O
capacity	O
of	O
cytoplasmic	O
and	O
nuclear	O
protein	O
extracts	O
was	O
enhanced	O
by	O
prolonged	O
exposure	O
to	O
hypoxia	O
.	O

Degradation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
after	O
reoxygenation	O
was	O
accelerated	O
,	O
which	O
demonstrates	O
functional	O
relevance	O
of	O
the	O
present	O
results	O
.	O

We	O
propose	O
a	O
direct	O
,	O
negative	O
regulatory	O
mechanism	O
,	O
which	O
limits	O
accumulation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
in	O
hypoxia	O
and	O
leads	O
to	O
accelerated	O
degradation	O
on	O
reoxygenation	O
after	O
long	O
-	O
term	O
hypoxia	O
.	O

Inhibitory	O
potency	O
of	O
some	O
isatin	O
analogues	O
on	O
human	O
monoamine	B-Protein
oxidase	I-Protein
A	E-Protein
and	O
B	S-Protein
.	O

Isatin	O
is	O
an	O
endogenous	O
compound	O
which	O
acts	O
as	O
a	O
selective	O
inhibitor	O
of	O
monoamine	B-Protein
oxidase	I-Protein
(	I-Protein
MAO	I-Protein
)	I-Protein
B	E-Protein
.	O

In	O
this	O
study	O
a	O
range	O
of	O
isatin	O
analogues	O
were	O
tested	O
for	O
their	O
in	O
vitro	O
inhibition	O
of	O
human	O
MAO	B-Protein
A	E-Protein
and	O
B	S-Protein
.	O

Most	O
of	O
the	O
analogues	O
were	O
less	O
potent	O
than	O
isatin	O
.	O

Hydroxylation	O
of	O
the	O
aromatic	O
ring	O
changed	O
the	O
inhibitory	O
potency	O
in	O
favour	O
of	O
MAO	B-Protein
A	E-Protein
,	O
with	O
5	O
-	O
hydroxyisatin	O
being	O
a	O
potent	O
and	O
selective	O
MAO	B-Protein
A	E-Protein
inhibitor	O
(	O
IC50	O
8	O
microM	O
)	O
.	O

Isatinic	O
acid	O
,	O
which	O
is	O
formed	O
reversibly	O
from	O
isatin	O
at	O
alkaline	O
pH	O
,	O
showed	O
no	O
inhibition	O
.	O

The	O
crystal	O
structure	O
of	O
xanthine	B-Protein
oxidoreductase	E-Protein
during	O
catalysis	O
:	O
implications	O
for	O
reaction	O
mechanism	O
and	O
enzyme	O
inhibition	O
.	O

Molybdenum	O
is	O
widely	O
distributed	O
in	O
biology	O
and	O
is	O
usually	O
found	O
as	O
a	O
mononuclear	O
metal	O
center	O
in	O
the	O
active	O
sites	O
of	O
many	O
enzymes	O
catalyzing	O
oxygen	O
atom	O
transfer	O
.	O

The	O
molybdenum	O
hydroxylases	O
are	O
distinct	O
from	O
other	O
biological	O
systems	O
catalyzing	O
hydroxylation	O
reactions	O
in	O
that	O
the	O
oxygen	O
atom	O
incorporated	O
into	O
the	O
product	O
is	O
derived	O
from	O
water	O
rather	O
than	O
molecular	O
oxygen	O
.	O

Here	O
,	O
we	O
present	O
the	O
crystal	O
structure	O
of	O
the	O
key	O
intermediate	O
in	O
the	O
hydroxylation	O
reaction	O
of	O
xanthine	B-Protein
oxidoreductase	E-Protein
with	O
a	O
slow	O
substrate	O
,	O
in	O
which	O
the	O
carbon	O
-	O
oxygen	O
bond	O
of	O
the	O
product	O
is	O
formed	O
,	O
yet	O
the	O
product	O
remains	O
complexed	O
to	O
the	O
molybdenum	O
.	O

This	O
intermediate	O
displays	O
a	O
stable	O
broad	O
charge	O
-	O
transfer	O
band	O
at	O
approximately	O
640	O
nm	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
complex	O
indicates	O
that	O
the	O
catalytically	O
labile	O
Mo	O
-	O
OH	O
oxygen	O
has	O
formed	O
a	O
bond	O
with	O
a	O
carbon	O
atom	O
of	O
the	O
substrate	O
.	O

In	O
addition	O
,	O
the	O
MoS	O
group	O
of	O
the	O
oxidized	O
enzyme	O
has	O
become	O
protonated	O
to	O
afford	O
Mo	O
-	O
SH	O
on	O
reduction	O
of	O
the	O
molybdenum	O
center	O
.	O

In	O
contrast	O
to	O
previous	O
assignments	O
,	O
we	O
find	O
this	O
last	O
ligand	O
at	O
an	O
equatorial	O
position	O
in	O
the	O
square	O
-	O
pyramidal	O
metal	O
coordination	O
sphere	O
,	O
not	O
the	O
apical	O
position	O
.	O

A	O
water	O
molecule	O
usually	O
seen	O
in	O
the	O
active	O
site	O
of	O
the	O
enzyme	O
is	O
absent	O
in	O
the	O
present	O
structure	O
,	O
which	O
probably	O
accounts	O
for	O
the	O
stability	O
of	O
this	O
intermediate	O
toward	O
ligand	O
displacement	O
by	O
hydroxide	O
.	O

HIV	O
-	O
1	O
acute	O
infection	O
env	S-Protein
glycomutants	O
designed	O
from	O
3D	O
model	O
:	O
effects	O
on	O
processing	O
,	O
antigenicity	O
,	O
and	O
neutralization	O
sensitivity	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
envelope	B-Protein
protein	E-Protein
(	O
Env	S-Protein
)	O
has	O
evolved	O
to	O
limit	O
its	O
overall	O
immunogenicity	O
by	O
extensive	O
glycosylation	O
.	O

Only	O
a	O
few	O
studies	O
dealing	O
with	O
glycosylation	O
sites	O
have	O
taken	O
into	O
account	O
available	O
3D	O
data	O
in	O
a	O
global	O
approach	O
.	O

We	O
compared	O
primary	O
env	S-Protein
sequences	O
from	O
patients	O
with	O
acute	O
HIV	O
-	O
1	O
infection	O
.	O

Conserved	O
N	O
-	O
glycosylation	O
sites	O
were	O
placed	O
on	O
the	O
gp120	S-Protein
-	O
3D	O
model	O
.	O

Based	O
on	O
vicinity	O
,	O
we	O
defined	O
glycosylation	O
clusters	O
.	O

According	O
to	O
these	O
clusters	O
,	O
we	O
engineered	O
plasmids	O
encoding	O
deglycosylated	O
gp160	S-Protein
mutants	O
.	O

We	O
also	O
constructed	O
mutants	O
corresponding	O
to	O
nonclustered	O
glycans	O
or	O
to	O
the	O
full	O
deglycosylation	O
of	O
the	O
V1	O
or	O
V2	O
loop	O
.	O

After	O
in	O
vitro	O
expression	O
,	O
mutants	O
were	O
tested	O
for	O
functionality	O
.	O

We	O
also	O
compared	O
the	O
inhibition	O
of	O
pseudotyped	O
particles	O
infection	O
by	O
human	O
-	O
neutralizing	O
sera	O
.	O

Generally	O
,	O
clustered	O
and	O
nonclustered	O
mutants	O
were	O
affected	O
similarly	O
.	O

Silencing	O
of	O
more	O
than	O
one	O
glycan	O
had	O
deleterious	O
effects	O
,	O
independently	O
of	O
the	O
type	O
of	O
sugar	O
removed	O
.	O

However	O
,	O
some	O
mutants	O
were	O
moderately	O
affected	O
by	O
glycans	O
removal	O
suggesting	O
a	O
distinct	O
role	O
for	O
these	O
N	O
-	O
glycans	O
.	O

Additionally	O
,	O
compared	O
to	O
the	O
wild	O
-	O
type	O
pseudovirus	O
,	O
two	O
of	O
these	O
mutants	O
were	O
neutralized	O
at	O
higher	O
sera	O
dilutions	O
strengthening	O
the	O
importance	O
of	O
the	O
location	O
of	O
specific	O
N	O
-	O
glycans	O
in	O
limiting	O
the	O
neutralizing	O
response	O
.	O

These	O
results	O
could	O
guide	O
the	O
selection	O
of	O
env	S-Protein
mutants	O
with	O
the	O
fewest	O
antigenic	O
and	O
functional	O
alterations	O
but	O
with	O
enhanced	O
neutralization	O
sensitivity	O
.	O

Hypermethylation	O
of	O
Syk	S-Protein
gene	O
in	O
promoter	O
region	O
associated	O
with	O
oncogenesis	O
and	O
metastasis	O
of	O
gastric	O
carcinoma	O
.	O

AIM	O
:	O
To	O
investigate	O
the	O
relationship	O
between	O
methylation	O
of	O
Syk	S-Protein
(	O
spleen	B-Protein
tyrosine	I-Protein
kinase	E-Protein
)	O
gene	O
in	O
promoter	O
region	O
and	O
oncogenesis	O
,	O
metastasis	O
of	O
gastric	O
carcinoma	O
.	O

The	O
relation	O
between	O
silencing	O
of	O
the	O
Syk	S-Protein
gene	O
and	O
methylation	O
of	O
Syk	S-Protein
promoter	O
region	O
was	O
also	O
studied	O
.	O

METHODS	O
:	O
By	O
using	O
methylation	O
-	O
specific	O
PCR	O
(	O
MSP	O
)	O
technique	O
,	O
the	O
methylation	O
of	O
Syk	S-Protein
promoter	O
region	O
in	O
specimens	O
from	O
61	O
gastric	O
cancer	O
patients	O
(	O
tumor	O
tissues	O
and	O
adjacent	O
normal	O
tissues	O
)	O
was	O
detected	O
.	O

Meanwhile	O
,	O
RT	O
-	O
PCR	O
was	O
used	O
to	O
analyse	O
syk	S-Protein
expression	O
exclusively	O
.	O

RESULTS	O
:	O
The	O
expression	O
of	O
the	O
Syk	S-Protein
gene	O
was	O
detected	O
in	O
all	O
normal	O
gastric	O
tissues	O
.	O

Syk	S-Protein
expression	O
in	O
gastric	O
carcinoma	O
was	O
lower	O
in	O
14	O
out	O
of	O
61	O
gastric	O
cancer	O
samples	O
than	O
in	O
adjacent	O
normal	O
tissues	O
(	O
chi	O
(	O
2	O
)	O
=	O
72	O
.	O
3	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

No	O
methylation	O
of	O
Syk	S-Protein
promoter	O
was	O
found	O
in	O
adjacent	O
normal	O
tissues	O
.	O
hypermethylation	O
of	O
Syk	S-Protein
gene	O
in	O
promoter	O
was	O
detected	O
21	O
cases	O
in	O
61	O
gastric	O
carcinoma	O
patients	O
.	O

The	O
rate	O
of	O
methylation	O
of	O
Syk	S-Protein
promoter	O
in	O
gastric	O
carcinoma	O
was	O
higher	O
than	O
that	O
in	O
adjacent	O
normal	O
tissues	O
(	O
chi	O
(	O
2	O
)	O
=	O
25	O
.	O
1	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
31	O
patients	O
with	O
lymph	O
node	O
metastasis	O
,	O
17	O
were	O
found	O
with	O
Syk	S-Protein
promoter	O
methylation	O
.	O

A	O
significant	O
difference	O
was	O
noted	O
between	O
two	O
groups	O
(	O
chi	O
(	O
2	O
)	O
=	O
11	O
.	O
4	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
Hypermethylation	O
leads	O
to	O
silencing	O
of	O
the	O
Syk	S-Protein
gene	O
in	O
human	O
gastric	O
carcinoma	O
.	O

Methylation	O
of	O
Syk	S-Protein
promoter	O
is	O
correlated	O
to	O
oncogenesis	O
and	O
metastasis	O
of	O
gastric	O
carcinoma	O
.	O

Syk	S-Protein
is	O
considered	O
to	O
be	O
a	O
potential	O
tumor	O
suppressor	O
and	O
anti	O
-	O
metastasis	O
gene	O
in	O
human	O
gastric	O
cancer	O
.	O

Structure	O
-	O
function	O
relationship	O
of	O
the	O
extracellular	B-Protein
calcium	I-Protein
-	I-Protein
sensing	I-Protein
receptor	E-Protein
.	O

The	O
extracellular	B-Protein
calcium	I-Protein
-	I-Protein
sensing	I-Protein
receptor	E-Protein
(	O
CaR	S-Protein
)	O
originally	O
cloned	O
from	O
bovine	O
parathyroid	O
gland	O
is	O
a	O
G	O
protein	O
-	O
coupled	O
receptor	O
.	O

The	O
physiological	O
relevance	O
of	O
the	O
cloned	O
CaR	S-Protein
for	O
sensing	O
and	O
regulating	O
the	O
extracellular	O
calcium	O
concentration	O
has	O
been	O
established	O
by	O
identifying	O
hyper	O
-	O
and	O
hypocalcemic	O
disorders	O
resulting	O
from	O
inactivating	O
and	O
activating	O
mutations	O
,	O
respectively	O
,	O
in	O
the	O
CaR	S-Protein
.	O

The	O
cloned	O
CaR	S-Protein
has	O
been	O
stably	O
or	O
transiently	O
expressed	O
in	O
human	O
embryonic	O
kidney	O
cells	O
and	O
significant	O
progress	O
has	O
been	O
made	O
in	O
elucidating	O
its	O
regulation	O
and	O
activation	O
process	O
using	O
physiological	O
,	O
biochemical	O
and	O
molecular	O
biological	O
methods	O
.	O

A	O
large	O
collection	O
of	O
naturally	O
occurring	O
CaR	S-Protein
mutations	O
offers	O
a	O
valuable	O
resource	O
for	O
studies	O
aimed	O
at	O
understanding	O
the	O
structure	O
-	O
function	O
relationships	O
of	O
the	O
receptor	O
,	O
including	O
functional	O
importance	O
of	O
CaR	S-Protein
dimerization	O
.	O

In	O
turn	O
,	O
characterization	O
of	O
these	O
naturally	O
occurring	O
mutations	O
has	O
clarified	O
the	O
pathogenesis	O
of	O
clinical	O
conditions	O
involving	O
abnormalities	O
in	O
the	O
CaR	S-Protein
,	O
such	O
as	O
familial	O
hypocalciuric	O
hypercalcemia	O
and	O
neonatal	O
severe	O
hyperparathyroidism	O
.	O

Correlation	O
between	O
the	O
DNA	O
global	O
methylation	O
status	O
and	O
progesterone	B-Protein
receptor	E-Protein
expression	O
in	O
normal	O
endometrium	O
,	O
endometrioid	O
adenocarcinoma	O
and	O
precursors	O
.	O

Endometrial	O
carcinomas	O
are	O
the	O
most	O
common	O
malignancy	O
of	O
the	O
female	O
genital	O
tract	O
and	O
the	O
third	O
most	O
common	O
cancer	O
in	O
women	O
.	O

Progesterone	S-Protein
and	O
oestrogen	B-Protein
receptors	E-Protein
(	O
PRs	S-Protein
,	O
ERs	S-Protein
)	O
are	O
the	O
most	O
widely	O
documented	O
prognostic	O
and	O
predictive	O
factors	O
in	O
endometrioid	O
adenocarcinoma	O
.	O

Besides	O
the	O
hormonal	O
pathway	O
involved	O
in	O
the	O
progression	O
of	O
preneoplastic	O
and	O
neoplastic	O
lesions	O
,	O
alterations	O
of	O
the	O
DNA	O
methylation	O
status	O
have	O
been	O
shown	O
to	O
be	O
an	O
early	O
signal	O
of	O
tumorigenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
in	O
normal	O
endometrium	O
,	O
during	O
the	O
proliferative	O
phase	O
,	O
DNA	O
methylation	O
and	O
PR	S-Protein
expression	O
are	O
high	O
,	O
with	O
a	O
significant	O
decline	O
towards	O
the	O
end	O
of	O
the	O
secretory	O
phase	O
and	O
a	O
gradual	O
increase	O
in	O
non	O
-	O
atypical	O
and	O
atypical	O
endometrial	O
hyperplasia	O
;	O
they	O
reach	O
their	O
highest	O
level	O
in	O
grade	O
I	O
,	O
then	O
decrease	O
significantly	O
in	O
grade	O
-	O
II	O
and	O
grade	O
-	O
III	O
endometrioid	O
adenocarcinomas	O
.	O

During	O
each	O
stage	O
,	O
a	O
significant	O
positive	O
correlation	O
is	O
observed	O
between	O
DNA	O
methylation	O
and	O
PR	S-Protein
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
strong	O
parallelism	O
between	O
DNA	O
methylation	O
and	O
PR	S-Protein
expression	O
precludes	O
establishing	O
a	O
precise	O
determination	O
regarding	O
the	O
timing	O
of	O
these	O
events	O
,	O
clearly	O
involved	O
in	O
the	O
genesis	O
of	O
endometrioid	O
adenocarcinoma	O
.	O

Human	O
PAD4	S-Protein
regulates	O
histone	S-Protein
arginine	O
methylation	O
levels	O
via	O
demethylimination	O
.	O

Methylation	O
of	O
arginine	O
(	O
Arg	O
)	O
and	O
lysine	O
residues	O
in	O
histones	S-Protein
has	O
been	O
correlated	O
with	O
epigenetic	O
forms	O
of	O
gene	O
regulation	O
.	O

Although	O
histone	O
methyltransferases	O
are	O
known	O
,	O
enzymes	O
that	O
demethylate	O
histones	S-Protein
have	O
not	O
been	O
identified	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
human	O
peptidylarginine	B-Protein
deiminase	I-Protein
4	E-Protein
(	O
PAD4	S-Protein
)	O
regulates	O
histone	S-Protein
Arg	O
methylation	O
by	O
converting	O
methyl	O
-	O
Arg	O
to	O
citrulline	O
and	O
releasing	O
methylamine	O
.	O

PAD4	S-Protein
targets	O
multiple	O
sites	O
in	O
histones	B-Protein
H3	E-Protein
and	O
H4	S-Protein
,	O
including	O
those	O
sites	O
methylated	O
by	O
coactivators	O
CARM1	S-Protein
(	O
H3	S-Protein
Arg17	O
)	O
and	O
PRMT1	S-Protein
(	O
H4	S-Protein
Arg3	O
)	O
.	O

A	O
decrease	O
of	O
histone	S-Protein
Arg	O
methylation	O
,	O
with	O
a	O
concomitant	O
increase	O
of	O
citrullination	O
,	O
requires	O
PAD4	S-Protein
activity	O
in	O
human	O
HL	O
-	O
60	O
granulocytes	O
.	O

Moreover	O
,	O
PAD4	S-Protein
activity	O
is	O
linked	O
with	O
the	O
transcriptional	O
regulation	O
of	O
estrogen	O
-	O
responsive	O
genes	O
in	O
MCF	O
-	O
7	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
PAD4	S-Protein
mediates	O
gene	O
expression	O
by	O
regulating	O
Arg	O
methylation	O
and	O
citrullination	O
in	O
histones	S-Protein
.	O

Increased	O
DNA	O
methylation	O
in	O
the	O
HoxA5	S-Protein
promoter	O
region	O
correlates	O
with	O
decreased	O
expression	O
of	O
the	O
gene	O
during	O
tumor	O
promotion	O
.	O

Promoter	O
-	O
region	O
DNA	O
methylation	O
inhibits	O
transcription	O
.	O

A	O
two	O
-	O
stage	O
SENCAR	O
(	O
sensitive	O
to	O
mouse	O
carcinogenesis	O
)	O
mouse	O
skin	O
carcinogenicity	O
model	O
was	O
used	O
to	O
examine	O
gene	O
-	O
specific	O
changes	O
in	O
methylation	O
during	O
skin	O
tumor	O
promotion	O
.	O

Analysis	O
was	O
performed	O
on	O
7	O
,	O
12	O
-	O
dimethylbenz	O
[	O
a	O
]	O
anthracene	O
(	O
DMBA	O
)	O
-	O
initiated	O
skin	O
promoted	O
with	O
9	O
,	O
18	O
,	O
27	O
,	O
or	O
36	O
mg	O
cigarette	O
smoke	O
condensate	O
(	O
CSC	O
)	O
for	O
9	O
wk	O
,	O
or	O
27	O
mg	O
CSC	O
for	O
9	O
wk	O
and	O
sacrificed	O
6	O
wk	O
afterwards	O
(	O
recovery	O
group	O
)	O
.	O

Additionally	O
,	O
tumors	O
arising	O
following	O
promotion	O
with	O
27	O
mg	O
CSC	O
for	O
29	O
wk	O
were	O
assessed	O
.	O

Gene	O
array	O
analysis	O
identified	O
differentially	O
expressed	O
genes	O
.	O

Expression	O
of	O
HoxA5	S-Protein
,	O
a	O
tumor	O
suppressor	O
gene	O
,	O
was	O
decreased	O
following	O
9	O
wk	O
of	O
treatment	O
with	O
27	O
mg	O
CSC	O
,	O
and	O
returned	O
to	O
control	O
levels	O
during	O
recovery	O
.	O

HoxA5	S-Protein
promoter	O
methylation	O
was	O
measured	O
with	O
the	O
enzymatic	O
regional	O
methylation	O
assay	O
(	O
ERMA	O
)	O
.	O

DNA	O
was	O
bisulfite	O
-	O
modified	O
,	O
PCR	O
-	O
amplified	O
with	O
primers	O
containing	O
dam	O
sites	O
,	O
incubated	O
with	O
[	O
14C	O
-	O
methyl	O
]	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
methionine	O
(	O
SAM	O
)	O
and	O
dam	O
methyltransferase	O
for	O
DNA	O
quantification	O
,	O
then	O
incubated	O
with	O
[	O
3H	O
-	O
methyl	O
]	O
SAM	O
and	O
SssI	B-Protein
methylase	E-Protein
to	O
quantify	O
methylation	O
status	O
.	O

Higher	O
3H	O
/	O
14C	O
ratios	O
indicate	O
increased	O
methylation	O
.	O

The	O
3H	O
/	O
14C	O
ratios	O
of	O
animals	O
promoted	O
with	O
27	O
or	O
36	O
mg	O
CSC	O
(	O
48	O
.	O
2	O
+	O
/	O
-	O
6	O
.	O
9	O
and	O
24	O
.	O
2	O
+	O
/	O
-	O
6	O
.	O
1	O
,	O
respectively	O
)	O
were	O
higher	O
than	O
the	O
control	O
or	O
recovery	O
group	O
ratios	O
(	O
12	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
1	O
and	O
12	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
3	O
,	O
respectively	O
)	O
;	O
sequence	O
analysis	O
supported	O
these	O
findings	O
.	O

Increased	O
methylation	O
of	O
p16	S-Protein
or	O
O6	B-Protein
methylguanine	I-Protein
methyltranferase	E-Protein
(	O
MGMT	S-Protein
)	O
was	O
detected	O
in	O
4	O
/	O
8	O
(	O
50	O
%	O
)	O
of	O
the	O
tumor	O
samples	O
from	O
mice	O
promoted	O
with	O
27	O
mg	O
CSC	O
.	O

These	O
data	O
suggest	O
that	O
increased	O
DNA	O
methylation	O
contributes	O
to	O
the	O
downregulation	O
of	O
HoxA5	S-Protein
,	O
and	O
combined	O
with	O
hypermethylation	O
of	O
p16	S-Protein
or	O
MGMT	S-Protein
,	O
this	O
might	O
facilitate	O
the	O
clonal	O
expansion	O
of	O
increasingly	O
aberrant	O
cells	O
during	O
promotion	O
.	O

Histone	S-Protein
modification	O
in	O
constitutive	O
heterochromatin	O
versus	O
unexpressed	O
euchromatin	O
in	O
human	O
cells	O
.	O

Histone	S-Protein
modifications	O
are	O
implicated	O
in	O
regulating	O
chromatin	O
condensation	O
but	O
it	O
is	O
unclear	O
how	O
they	O
differ	O
between	O
constitutive	O
heterochromatin	O
and	O
unexpressed	O
euchromatin	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
were	O
done	O
on	O
various	O
human	O
cell	O
populations	O
using	O
antibodies	O
specific	O
for	O
acetylated	O
or	O
methylated	O
forms	O
of	O
histone	B-Protein
H3	E-Protein
or	O
H4	S-Protein
.	O

Analysis	O
of	O
the	O
immunoprecipitates	O
was	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
or	O
semi	O
-	O
quantitative	O
PCR	O
(	O
SQ	O
-	O
PCR	O
)	O
.	O

Of	O
eight	O
tested	O
antibodies	O
,	O
the	O
one	O
for	O
histone	B-Protein
H4	E-Protein
acetylated	O
at	O
lysine	O
4	O
,	O
8	O
,	O
12	O
,	O
or	O
16	O
was	O
best	O
for	O
distinguishing	O
constitutive	O
heterochromatin	O
from	O
unexpressed	O
euchromatin	O
,	O
but	O
differences	O
in	O
the	O
extent	O
of	O
immunoprecipitation	O
of	O
these	O
two	O
types	O
of	O
chromatin	O
were	O
only	O
modest	O
,	O
although	O
highly	O
reproducible	O
.	O

With	O
this	O
antibody	O
,	O
there	O
was	O
an	O
average	O
of	O
2	O
.	O
5	O
-	O
fold	O
less	O
immunoprecipitation	O
of	O
three	O
constitutive	O
heterochromatin	O
regions	O
than	O
of	O
four	O
unexpressed	O
euchromatic	O
gene	O
regions	O
and	O
about	O
15	O
-	O
fold	O
less	O
immunoprecipitation	O
of	O
these	O
heterochromatin	O
standards	O
than	O
of	O
two	O
constitutively	O
expressed	O
gene	O
standards	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

We	O
also	O
analyzed	O
histone	S-Protein
acetylation	O
and	O
methylation	O
by	O
immunocytochemistry	O
with	O
antibodies	O
to	O
H4	S-Protein
acetylated	O
at	O
lysine	O
8	O
,	O
H3	S-Protein
trimethylated	O
at	O
lysine	O
9	O
,	O
and	O
H3	S-Protein
methylated	O
at	O
lysine	O
4	O
.	O

In	O
addition	O
,	O
immunocytochemical	O
analysis	O
was	O
done	O
with	O
an	O
antibody	O
to	O
heterochromatin	B-Protein
protein	I-Protein
1alpha	E-Protein
(	O
HP1alpha	S-Protein
)	O
,	O
whose	O
preferential	O
binding	O
to	O
heterochromatin	O
has	O
been	O
linked	O
to	O
trimethylation	O
of	O
H3	S-Protein
at	O
lysine	O
9	O
.	O

Our	O
combined	O
ChIP	O
and	O
immunocytochemical	O
results	O
suggest	O
that	O
factors	O
other	O
than	O
hypoacetylation	O
of	O
the	O
N	O
-	O
terminal	O
tails	O
of	O
H4	S-Protein
and	O
hypermethylation	O
of	O
H3	S-Protein
at	O
lysine	O
9	O
can	O
play	O
an	O
important	O
role	O
in	O
determining	O
whether	O
a	O
chromatin	O
sequence	O
in	O
mammalian	O
cells	O
is	O
constitutively	O
heterochromatic	O
.	O

Regioselectivity	O
of	O
taxoid	O
-	O
O	O
-	O
acetyltransferases	O
:	O
heterologous	O
expression	O
and	O
characterization	O
of	O
a	O
new	O
taxadien	O
-	O
5alpha	O
-	O
ol	O
-	O
O	O
-	O
acetyltransferase	O
.	O

In	O
addition	O
to	O
the	O
anticancer	O
drug	O
Taxol	O
,	O
yew	O
(	O
Taxus	O
)	O
species	O
produce	O
a	O
large	O
variety	O
of	O
other	O
taxane	O
diterpenoids	O
which	O
differ	O
mainly	O
in	O
the	O
type	O
of	O
acyl	O
and	O
aroyl	O
groups	O
appended	O
to	O
the	O
many	O
hydroxyl	O
functions	O
on	O
the	O
taxane	O
core	O
;	O
acetate	O
esters	O
are	O
particularly	O
common	O
.	O

Taxol	O
bears	O
an	O
acetate	O
at	O
C10	O
and	O
another	O
at	O
C4	O
thought	O
to	O
originate	O
by	O
intramolecular	O
migration	O
of	O
a	O
C5	O
acetate	O
function	O
in	O
the	O
process	O
of	O
oxetane	O
ring	O
formation	O
,	O
but	O
many	O
other	O
naturally	O
occurring	O
taxoids	O
bear	O
acetate	O
groups	O
at	O
C1	O
,	O
C2	O
,	O
C7	O
,	O
C9	O
,	O
and	O
C13	O
,	O
in	O
addition	O
to	O
C5	O
and	O
C10	O
.	O

cDNAs	O
encoding	O
a	O
taxoid	O
5alpha	O
-	O
O	O
-	O
acetyltransferase	O
(	O
taxadien	O
-	O
5alpha	O
-	O
ol	O
as	O
substrate	O
)	O
and	O
a	O
taxoid	O
10beta	O
-	O
O	O
-	O
acetyltransferase	O
(	O
10	O
-	O
deacetylbaccatin	O
III	O
as	O
substrate	O
)	O
have	O
been	O
acquired	O
from	O
a	O
recently	O
isolated	O
family	O
of	O
Taxus	O
acyl	O
/	O
aroyltransferase	O
clones	O
.	O

To	O
explore	O
the	O
origins	O
of	O
other	O
acetylated	O
taxoids	O
,	O
the	O
group	O
of	O
recombinant	O
Taxus	O
acyltransferases	O
was	O
investigated	O
with	O
a	O
range	O
of	O
polyhydroxylated	O
taxoids	O
as	O
substrates	O
.	O

From	O
this	O
survey	O
,	O
a	O
new	O
acetyltransferase	O
clone	O
(	O
denoted	O
TAX19	S-Protein
)	O
was	O
identified	O
that	O
was	O
capable	O
of	O
acetylating	O
taxadien	O
-	O
5alpha	O
-	O
ol	O
with	O
activity	O
comparable	O
to	O
that	O
of	O
the	O
previously	O
identified	O
5alpha	O
-	O
O	O
-	O
acetyltransferase	O
(	O
clone	O
TAX1	S-Protein
)	O
.	O

However	O
,	O
when	O
these	O
two	O
recombinant	O
enzymes	O
were	O
presented	O
with	O
taxadien	O
-	O
triol	O
and	O
tetraol	O
substrates	O
,	O
they	O
exhibited	O
different	O
regiospecificities	O
.	O

The	O
TAX1	S-Protein
enzyme	O
preferentially	O
acetylates	O
the	O
"	O
northern	O
"	O
hemisphere	O
hydroxyls	O
at	O
C9	O
and	O
C10	O
,	O
whereas	O
the	O
TAX19	S-Protein
enzyme	O
preferentially	O
acetylates	O
the	O
"	O
east	O
-	O
west	O
"	O
pole	O
positions	O
at	O
C5	O
and	O
C13	O
.	O

The	O
TAX1	S-Protein
enzyme	O
possesses	O
the	O
lowest	O
KM	O
value	O
with	O
taxadien	O
-	O
5alpha	O
-	O
ol	O
(	O
an	O
early	O
pathway	O
metabolite	O
)	O
as	O
substrate	O
,	O
with	O
much	O
higher	O
KM	O
values	O
for	O
the	O
polyhydroxylated	O
taxoid	O
substrates	O
,	O
whereas	O
the	O
TAX19	S-Protein
enzyme	O
possesses	O
lower	O
KM	O
values	O
(	O
than	O
the	O
TAX1	S-Protein
transferase	O
)	O
for	O
all	O
taxoid	O
substrates	O
tested	O
.	O

These	O
results	O
suggest	O
that	O
both	O
TAX1	S-Protein
and	O
TAX19	S-Protein
acyltransferases	O
may	O
function	O
at	O
the	O
early	O
C5	O
acetylation	O
step	O
of	O
taxoid	O
metabolism	O
,	O
and	O
that	O
the	O
TAX19	S-Protein
acyltransferase	O
,	O
because	O
of	O
its	O
broader	O
specificity	O
for	O
polyhydroxylated	O
taxoids	O
,	O
may	O
also	O
function	O
later	O
in	O
metabolism	O
and	O
be	O
responsible	O
for	O
the	O
production	O
of	O
many	O
other	O
acetylated	O
taxoids	O
.	O

An	O
insulator	O
blocks	O
spreading	O
of	O
histone	S-Protein
acetylation	O
and	O
interferes	O
with	O
RNA	O
polymerase	O
II	O
transfer	O
between	O
an	O
enhancer	O
and	O
gene	O
.	O

We	O
studied	O
the	O
mechanism	O
by	O
which	O
an	O
insulator	O
interrupts	O
enhancer	O
signaling	O
to	O
a	O
gene	O
using	O
stably	O
replicated	O
chromatin	O
templates	O
containing	O
the	O
human	O
beta	B-Protein
-	I-Protein
globin	E-Protein
locus	O
control	O
region	O
HS2	O
enhancer	O
and	O
a	O
target	O
globin	O
gene	O
.	O

The	O
chicken	O
beta	B-Protein
-	I-Protein
globin	E-Protein
5	O
'	O
HS4	O
(	O
cHS4	O
)	O
insulator	O
acted	O
as	O
a	O
positional	O
enhancer	O
blocker	O
,	O
inhibiting	O
promoter	O
remodeling	O
and	O
transcription	O
activation	O
only	O
when	O
placed	O
between	O
the	O
enhancer	O
and	O
gene	O
.	O

Enhancer	O
blocking	O
by	O
cHS4	O
reduced	O
histone	S-Protein
hyperacetylation	O
across	O
a	O
zone	O
extending	O
from	O
the	O
enhancer	O
to	O
the	O
gene	O
and	O
inhibited	O
recruitment	O
of	O
CBP	S-Protein
and	O
p300	S-Protein
to	O
HS2	O
.	O

Enhancer	O
blocking	O
also	O
led	O
to	O
accumulation	O
of	O
RNA	O
polymerase	O
II	O
at	O
HS2	O
and	O
within	O
cHS4	O
,	O
accompanied	O
by	O
its	O
diminution	O
at	O
the	O
gene	O
promoter	O
.	O

The	O
enhancer	O
blocking	O
effects	O
were	O
completely	O
attributable	O
to	O
the	O
CTCF	S-Protein
binding	O
site	O
in	O
cHS4	O
.	O

These	O
findings	O
provide	O
experimental	O
evidence	O
for	O
the	O
involvement	O
of	O
spreading	O
in	O
establishment	O
of	O
a	O
broad	O
zone	O
of	O
histone	S-Protein
modification	O
by	O
an	O
enhancer	O
,	O
as	O
well	O
as	O
for	O
blocking	O
by	O
an	O
insulator	O
of	O
the	O
transfer	O
of	O
RNA	O
polymerase	O
II	O
from	O
an	O
enhancer	O
to	O
a	O
promoter	O
.	O

Targeted	O
disruption	O
of	O
the	O
Walker	O
-	O
Warburg	O
syndrome	O
gene	O
Pomt1	S-Protein
in	O
mouse	O
results	O
in	O
embryonic	O
lethality	O
.	O

O	O
-	O
mannosylation	O
is	O
an	O
important	O
protein	O
modification	O
in	O
eukaryotes	O
that	O
is	O
initiated	O
by	O
an	O
evolutionarily	O
conserved	O
family	O
of	O
protein	O
O	O
-	O
mannosyltransferases	O
.	O

The	O
first	O
mammalian	O
protein	O
O	O
-	O
mannosyltransferase	O
gene	O
described	O
was	O
the	O
human	O
POMT1	S-Protein
.	O

Mutations	O
in	O
the	O
hPOMT1	S-Protein
gene	O
are	O
responsible	O
for	O
Walker	O
-	O
Warburg	O
syndrome	O
(	O
WWS	O
)	O
,	O
a	O
severe	O
recessive	O
congenital	O
muscular	O
dystrophy	O
associated	O
with	O
defects	O
in	O
neuronal	O
migration	O
that	O
produce	O
complex	O
brain	O
and	O
eye	O
abnormalities	O
.	O

During	O
embryogenesis	O
,	O
the	O
murine	O
Pomt1	S-Protein
gene	O
is	O
prominently	O
expressed	O
in	O
the	O
neural	O
tube	O
,	O
the	O
developing	O
eye	O
,	O
and	O
the	O
mesenchyme	O
.	O

These	O
sites	O
of	O
expression	O
correlate	O
with	O
those	O
in	O
which	O
the	O
main	O
tissue	O
alterations	O
are	O
observed	O
in	O
WWS	O
patients	O
.	O

We	O
have	O
inactivated	O
a	O
Pomt1	S-Protein
allele	O
by	O
gene	O
targeting	O
in	O
embryonic	O
stem	O
cells	O
and	O
produced	O
chimeras	O
transmitting	O
the	O
defect	O
allele	O
to	O
offspring	O
.	O

Although	O
heterozygous	O
mice	O
were	O
viable	O
and	O
fertile	O
,	O
the	O
total	O
absence	O
of	O
Pomt1	S-Protein
(	O
-	O
/	O
-	O
)	O
pups	O
in	O
the	O
progeny	O
of	O
heterozygous	O
intercrosses	O
indicated	O
that	O
this	O
genotype	O
is	O
embryonic	O
lethal	O
.	O

An	O
analysis	O
of	O
the	O
mutant	O
phenotype	O
revealed	O
that	O
homozygous	O
Pomt1	S-Protein
(	O
-	O
/	O
-	O
)	O
mice	O
suffer	O
developmental	O
arrest	O
around	O
embryonic	O
day	O
(	O
E	O
)	O
7	O
.	O
5	O
and	O
die	O
between	O
E7	O
.	O
5	O
and	O
E9	O
.	O
5	O
.	O

The	O
Pomt1	S-Protein
(	O
-	O
/	O
-	O
)	O
embryos	O
present	O
defects	O
in	O
the	O
formation	O
of	O
Reichert	O
'	O
s	O
membrane	O
,	O
the	O
first	O
basement	O
membrane	O
to	O
form	O
in	O
the	O
embryo	O
.	O

The	O
failure	O
of	O
this	O
membrane	O
to	O
form	O
appears	O
to	O
be	O
the	O
result	O
of	O
abnormal	O
glycosylation	O
and	O
maturation	O
of	O
dystroglycan	S-Protein
that	O
may	O
impair	O
recruitment	O
of	O
laminin	O
,	O
a	O
structural	O
component	O
required	O
for	O
the	O
formation	O
of	O
Reichert	O
'	O
s	O
membrane	O
in	O
rodents	O
.	O

The	O
targeted	O
disruption	O
of	O
mPomt1	S-Protein
represents	O
an	O
example	O
of	O
an	O
engineered	O
deletion	O
of	O
a	O
known	O
glycosyltransferase	O
involved	O
in	O
O	O
-	O
mannosyl	O
glycan	O
synthesis	O
.	O

A	O
novel	O
Kex2	S-Protein
enzyme	O
can	O
process	O
the	O
proregion	O
of	O
the	O
yeast	O
alpha	O
-	O
factor	O
leader	O
in	O
the	O
endoplasmic	O
reticulum	O
instead	O
of	O
in	O
the	O
Golgi	O
.	O

The	O
prepro	O
sequence	O
of	O
the	O
yeast	O
prepro	O
-	O
alpha	O
-	O
factor	O
,	O
usually	O
referred	O
to	O
as	O
the	O
alpha	O
-	O
factor	O
leader	O
,	O
has	O
often	O
been	O
used	O
for	O
the	O
efficient	O
secretion	O
of	O
heterologous	O
proteins	O
from	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
alpha	O
-	O
factor	O
leader	O
consists	O
of	O
a	O
19	O
-	O
amino	O
acid	O
N	O
-	O
terminal	O
pre	O
or	O
signal	O
sequence	O
followed	O
by	O
a	O
66	O
-	O
amino	O
acid	O
proregion	O
.	O

After	O
removal	O
of	O
the	O
signal	O
sequence	O
during	O
membrane	O
translocation	O
,	O
the	O
proregion	O
is	O
cleaved	O
from	O
the	O
precursor	O
protein	O
by	O
the	O
Kex2	S-Protein
endoprotease	O
only	O
in	O
a	O
late	O
Golgi	O
compartment	O
.	O

Here	O
we	O
report	O
that	O
a	O
modified	O
Kex2	S-Protein
enzyme	O
,	O
containing	O
at	O
the	O
C	O
-	O
terminus	O
the	O
HDEL	O
tetrapeptide	O
,	O
cleaves	O
the	O
proregion	O
from	O
the	O
alpha	O
-	O
factor	O
leader	O
-	O
-	O
human	O
insulin	B-Protein
like	I-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
1	E-Protein
fusion	O
protein	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O

The	O
processing	O
of	O
pro	O
-	O
proteins	O
earlier	O
in	O
the	O
secretion	O
pathway	O
could	O
be	O
helpful	O
in	O
defining	O
the	O
cellular	O
function	O
of	O
the	O
proregions	O
present	O
naturally	O
in	O
various	O
eucaryotic	O
precursor	O
proteins	O
.	O

Value	O
of	O
p16INK4a	S-Protein
and	O
RASSF1A	S-Protein
promoter	O
hypermethylation	O
in	O
prognosis	O
of	O
patients	O
with	O
resectable	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

The	O
p16INK4a	S-Protein
and	O
RASSF1A	S-Protein
are	O
tumor	O
suppressor	O
genes	O
frequently	O
inactivated	O
by	O
de	O
novo	O
promoter	O
hypermethylation	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

We	O
studied	O
119	O
patients	O
with	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
70	O
stage	O
I	O
/	O
II	O
and	O
49	O
stage	O
IIIA	O
)	O
who	O
had	O
undergone	O
surgery	O
with	O
curative	O
intent	O
.	O

The	O
p16INK4a	S-Protein
and	O
RASSF1A	S-Protein
promoter	O
methylation	O
statuses	O
were	O
determined	O
by	O
methylation	O
-	O
specific	O
PCR	O
.	O

Statistical	O
analyses	O
,	O
all	O
two	O
-	O
sided	O
,	O
were	O
performed	O
to	O
determine	O
the	O
prognostic	O
effect	O
of	O
hypermethylation	O
on	O
various	O
clinical	O
parameters	O
.	O

Hypermethylation	O
of	O
the	O
p16INK4a	S-Protein
and	O
RASSF1A	S-Protein
promoters	O
was	O
found	O
in	O
58	O
(	O
49	O
%	O
)	O
and	O
46	O
(	O
39	O
%	O
)	O
tumors	O
,	O
respectively	O
,	O
and	O
30	O
tumors	O
(	O
25	O
%	O
)	O
exhibited	O
hypermethylation	O
of	O
both	O
gene	O
promoters	O
.	O

In	O
patients	O
with	O
stage	O
I	O
/	O
II	O
tumors	O
,	O
only	O
p16INK4a	S-Protein
promoter	O
hypermethylation	O
was	O
associated	O
with	O
a	O
poor	O
5	O
-	O
year	O
overall	O
survival	O
rate	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

In	O
patients	O
with	O
stage	O
IIIA	O
disease	O
,	O
however	O
,	O
RASSF1A	S-Protein
promoter	O
hypermethylation	O
was	O
a	O
stronger	O
predictor	O
of	O
a	O
poor	O
5	O
-	O
year	O
overall	O
survival	O
rate	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
than	O
p16INK4a	S-Protein
promoter	O
hypermethylation	O
.	O

Among	O
the	O
49	O
patients	O
with	O
stage	O
IIIA	O
tumors	O
,	O
16	O
(	O
89	O
%	O
)	O
of	O
the	O
18	O
patients	O
whose	O
tumors	O
showed	O
RASSF1A	S-Protein
promoter	O
hypermethylation	O
died	O
within	O
3	O
years	O
after	O
surgery	O
,	O
as	O
compared	O
with	O
only	O
12	O
(	O
39	O
%	O
)	O
of	O
the	O
31	O
patients	O
whose	O
tumors	O
had	O
no	O
RASSF1A	S-Protein
promoter	O
hypermethylation	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Multivariate	O
analysis	O
indicated	O
that	O
RASSF1A	S-Protein
promoter	O
hypermethylation	O
was	O
the	O
stronger	O
independent	O
predictor	O
for	O
survival	O
in	O
patients	O
with	O
locally	O
advanced	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Our	O
results	O
indicate	O
that	O
p16INK4a	S-Protein
promoter	O
hypermethylation	O
predicts	O
a	O
poor	O
5	O
-	O
year	O
survival	O
rates	O
for	O
patients	O
with	O
resectable	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
,	O
particularly	O
for	O
those	O
with	O
early	O
stage	O
tumors	O
,	O
whereas	O
RASSF1A	S-Protein
promoter	O
hypermethylation	O
is	O
a	O
profound	O
prognostic	O
predictor	O
for	O
patients	O
with	O
locally	O
advanced	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
,	O
suggesting	O
an	O
important	O
role	O
of	O
RASSF1A	S-Protein
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
progression	O
.	O

The	O
glutamine	O
residue	O
of	O
the	O
conserved	O
GGQ	O
motif	O
in	O
Saccharomyces	O
cerevisiae	O
release	O
factor	O
eRF1	S-Protein
is	O
methylated	O
by	O
the	O
product	O
of	O
the	O
YDR140w	S-Protein
gene	O
.	O

Polypeptide	O
release	O
factors	O
from	O
eubacteria	O
and	O
eukaryotes	O
,	O
although	O
similar	O
in	O
function	O
,	O
belong	O
to	O
different	O
protein	O
families	O
.	O

They	O
share	O
one	O
sequence	O
motif	O
,	O
a	O
GGQ	O
tripeptide	O
that	O
is	O
vital	O
to	O
release	O
factor	O
(	O
RF	O
)	O
activity	O
in	O
both	O
kingdoms	O
.	O

In	O
bacteria	O
,	O
the	O
Gln	O
residue	O
of	O
the	O
motif	O
in	O
RF1	S-Protein
and	O
RF2	S-Protein
is	O
modified	O
to	O
N	O
(	O
5	O
)	O
-	O
methyl	O
-	O
Gln	O
by	O
the	O
S	O
-	O
adenosyl	O
l	O
-	O
methionine	O
-	O
dependent	O
methyltransferase	O
PrmC	S-Protein
and	O
the	O
absence	O
of	O
Gln	O
methylation	O
decreases	O
the	O
release	O
activity	O
of	O
Escherichia	O
coli	O
RF2	S-Protein
in	O
vitro	O
severalfold	O
.	O

We	O
show	O
here	O
that	O
the	O
same	O
modification	O
is	O
made	O
to	O
the	O
GGQ	O
motif	O
of	O
Saccharomyces	O
cerevisiae	O
release	O
factor	O
eRF1	S-Protein
,	O
the	O
first	O
time	O
that	O
N	O
(	O
5	O
)	O
-	O
methyl	O
-	O
Gln	O
has	O
been	O
found	O
outside	O
the	O
bacterial	O
kingdom	O
.	O

The	O
product	O
of	O
the	O
YDR140w	S-Protein
gene	O
is	O
required	O
for	O
the	O
methylation	O
of	O
eRF1	S-Protein
in	O
vivo	O
and	O
for	O
optimal	O
yeast	O
cell	O
growth	O
.	O

YDR140w	S-Protein
protein	O
has	O
significant	O
homology	O
to	O
PrmC	S-Protein
but	O
lacks	O
the	O
N	O
-	O
terminal	O
domain	O
thought	O
to	O
be	O
involved	O
in	O
the	O
recognition	O
of	O
the	O
bacterial	O
release	O
factors	O
.	O

Overproduced	O
in	O
S	O
.	O
cerevisiae	O
,	O
YDR140w	S-Protein
can	O
methylate	O
eRF1	S-Protein
from	O
yeast	O
or	O
man	O
in	O
vitro	O
using	O
S	O
-	O
adenosyl	O
l	O
-	O
methionine	O
as	O
methyl	O
donor	O
provided	O
that	O
eRF3	S-Protein
and	O
GTP	O
are	O
also	O
present	O
,	O
suggesting	O
that	O
the	O
natural	O
substrate	O
of	O
the	O
methyltransferase	O
YDR140w	S-Protein
is	O
the	O
ternary	O
complex	O
eRF1	S-Protein
.	O
eRF3	S-Protein
.	O
GTP	O
.	O

Hepatitis	B-Protein
delta	I-Protein
virus	I-Protein
antigen	E-Protein
is	O
methylated	O
at	O
arginine	O
residues	O
,	O
and	O
methylation	O
regulates	O
subcellular	O
localization	O
and	O
RNA	O
replication	O
.	O

Hepatitis	O
delta	O
virus	O
(	O
HDV	O
)	O
contains	O
a	O
circular	O
RNA	O
which	O
encodes	O
a	O
single	O
protein	O
,	O
hepatitis	B-Protein
delta	I-Protein
antigen	E-Protein
(	O
HDAg	S-Protein
)	O
.	O

HDAg	S-Protein
exists	O
in	O
two	O
forms	O
,	O
a	O
small	O
form	O
(	O
S	B-Protein
-	I-Protein
HDAg	E-Protein
)	O
and	O
a	O
large	O
form	O
(	O
L	B-Protein
-	I-Protein
HDAg	E-Protein
)	O
.	O

S	B-Protein
-	I-Protein
HDAg	E-Protein
can	O
transactivate	O
HDV	O
RNA	O
replication	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
posttranslational	O
modifications	O
,	O
such	O
as	O
phosphorylation	O
and	O
acetylation	O
,	O
of	O
S	B-Protein
-	I-Protein
HDAg	E-Protein
can	O
modulate	O
HDV	O
RNA	O
replication	O
.	O

Here	O
we	O
show	O
that	O
S	B-Protein
-	I-Protein
HDAg	E-Protein
can	O
be	O
methylated	O
by	O
protein	O
arginine	O
methyltransferase	O
(	O
PRMT1	S-Protein
)	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
major	O
methylation	O
site	O
is	O
at	O
arginine	O
-	O
13	O
(	O
R13	O
)	O
,	O
which	O
is	O
in	O
the	O
RGGR	O
motif	O
of	O
an	O
RNA	O
-	O
binding	O
domain	O
.	O

The	O
methylation	O
of	O
S	B-Protein
-	I-Protein
HDAg	E-Protein
is	O
essential	O
for	O
HDV	O
RNA	O
replication	O
,	O
especially	O
for	O
replication	O
of	O
the	O
antigenomic	O
RNA	O
strand	O
to	O
form	O
the	O
genomic	O
RNA	O
strand	O
.	O

An	O
R13A	O
mutation	O
in	O
S	B-Protein
-	I-Protein
HDAg	E-Protein
inhibited	O
HDV	O
RNA	O
replication	O
.	O

The	O
presence	O
of	O
a	O
methylation	O
inhibitor	O
,	O
S	O
-	O
adenosyl	O
-	O
homocysteine	O
,	O
also	O
inhibited	O
HDV	O
RNA	O
replication	O
.	O

We	O
further	O
found	O
that	O
the	O
methylation	O
of	O
S	B-Protein
-	I-Protein
HDAg	E-Protein
affected	O
its	O
subcellular	O
localization	O
.	O

Methylation	O
-	O
defective	O
HDAg	S-Protein
lost	O
the	O
ability	O
to	O
form	O
a	O
speckled	O
structure	O
in	O
the	O
nucleus	O
and	O
also	O
permeated	O
into	O
the	O
cytoplasm	O
.	O

These	O
results	O
thus	O
revealed	O
a	O
novel	O
posttranslational	O
modification	O
of	O
HDAg	S-Protein
and	O
indicated	O
its	O
importance	O
for	O
HDV	O
RNA	O
replication	O
.	O

This	O
and	O
other	O
results	O
further	O
showed	O
that	O
,	O
unlike	O
replication	O
of	O
the	O
HDV	O
genomic	O
RNA	O
strand	O
,	O
replication	O
of	O
the	O
antigenomic	O
RNA	O
strand	O
requires	O
multiple	O
types	O
of	O
posttranslational	O
modification	O
,	O
including	O
the	O
phosphorylation	O
and	O
methylation	O
of	O
HDAg	S-Protein
.	O

Deglycosylation	O
of	O
the	O
NS1	S-Protein
protein	O
of	O
dengue	O
2	O
virus	O
,	O
strain	O
16681	O
:	O
construction	O
and	O
characterization	O
of	O
mutant	O
viruses	O
.	O

The	O
dengue	O
2	O
virus	O
(	O
DENV	O
-	O
2	O
)	O
NS1	S-Protein
glycoprotein	O
contains	O
two	O
potential	O
sites	O
for	O
N	O
-	O
linked	O
glycosylation	O
at	O
Asn	O
-	O
130	O
and	O
Asn	O
-	O
207	O
.	O

NS1	S-Protein
produced	O
in	O
infected	O
cells	O
is	O
glycosylated	O
at	O
both	O
of	O
these	O
sites	O
.	O

We	O
used	O
site	O
-	O
directed	O
mutagenesis	O
of	O
a	O
DENV	O
-	O
2	O
,	O
strain	O
16681	O
,	O
full	O
length	O
infectious	O
clone	O
to	O
create	O
mutant	O
viruses	O
lacking	O
the	O
Asn	O
-	O
130	O
,	O
Asn	O
-	O
207	O
or	O
both	O
of	O
these	O
NS1	S-Protein
glycosylation	O
sites	O
in	O
order	O
to	O
investigate	O
the	O
effects	O
of	O
deglycosylation	O
.	O

Ablation	O
of	O
both	O
NS1	S-Protein
glycosylation	O
sites	O
resulted	O
in	O
unstable	O
viruses	O
that	O
acquired	O
numerous	O
additional	O
mutations	O
;	O
these	O
viruses	O
were	O
not	O
further	O
characterized	O
.	O

Viruses	O
altered	O
at	O
the	O
Asn	O
-	O
130	O
site	O
exhibited	O
growth	O
characteristics	O
similar	O
to	O
the	O
wild	O
-	O
type	O
(	O
WT	O
)	O
16681	O
virus	O
in	O
LLC	O
-	O
MK	O
(	O
2	O
)	O
cells	O
and	O
reduced	O
growth	O
in	O
C6	O
/	O
36	O
cells	O
.	O

Viruses	O
mutated	O
at	O
the	O
Asn	O
-	O
207	O
site	O
achieved	O
similar	O
titers	O
in	O
LLC	O
-	O
MK	O
(	O
2	O
)	O
cells	O
compared	O
to	O
WT	O
,	O
however	O
,	O
the	O
appearance	O
of	O
cytopathic	O
effect	O
was	O
delayed	O
and	O
growth	O
of	O
these	O
viruses	O
in	O
C6	O
/	O
36	O
cells	O
was	O
also	O
reduced	O
compared	O
to	O
WT	O
virus	O
.	O

The	O
plaque	O
size	O
of	O
mutant	O
viruses	O
altered	O
at	O
the	O
Asn	O
-	O
130	O
site	O
did	O
not	O
differ	O
from	O
that	O
of	O
the	O
WT	O
virus	O
,	O
while	O
mutants	O
altered	O
at	O
the	O
Asn	O
-	O
207	O
site	O
exhibited	O
a	O
reduced	O
and	O
mixed	O
plaque	O
size	O
.	O

Temperature	O
sensitivity	O
studies	O
comparing	O
the	O
growth	O
of	O
the	O
viruses	O
at	O
37	O
degrees	O
C	O
and	O
39	O
degrees	O
C	O
showed	O
no	O
significant	O
differences	O
compared	O
to	O
the	O
WT	O
virus	O
.	O

Immunofluorescent	O
antibody	O
staining	O
of	O
infected	O
cells	O
showed	O
that	O
for	O
WT	O
16681	O
virus	O
or	O
the	O
Asn	O
-	O
130	O
site	O
mutant	O
viruses	O
NS1	S-Protein
was	O
located	O
throughout	O
the	O
cytoplasm	O
,	O
however	O
,	O
Asn	O
-	O
207	O
site	O
mutant	O
virus	O
NS1	S-Protein
protein	O
appeared	O
to	O
be	O
localized	O
to	O
the	O
perinuclear	O
region	O
.	O

Viruses	O
deglycosylated	O
at	O
either	O
site	O
exhibited	O
a	O
significant	O
reduction	O
in	O
mouse	O
neurovirulence	O
compared	O
to	O
the	O
WT	O
virus	O
.	O

The	O
results	O
of	O
our	O
studies	O
indicate	O
that	O
glycosylation	O
of	O
the	O
DENV	O
-	O
2	O
virus	O
NS1	S-Protein
protein	O
may	O
influence	O
NS1	S-Protein
protein	O
processing	O
/	O
transport	O
as	O
well	O
as	O
the	O
pathogenicity	O
of	O
the	O
virus	O
.	O

Epigenetic	O
status	O
and	O
aberrant	O
expression	O
of	O
the	O
maspin	S-Protein
gene	O
in	O
human	O
hepato	O
-	O
biliary	O
tract	O
carcinomas	O
.	O

We	O
examined	O
expression	O
of	O
maspin	S-Protein
and	O
the	O
epigenetic	O
status	O
of	O
its	O
gene	O
in	O
40	O
primary	O
hepato	O
-	O
biliary	O
tract	O
carcinomas	O
and	O
11	O
cell	O
lines	O
originating	O
from	O
hepato	O
-	O
pancreatico	O
-	O
biliary	O
tract	O
carcinomas	O
.	O

Aberrant	O
maspin	S-Protein
expression	O
was	O
frequently	O
observed	O
immunohistochemically	O
in	O
biliary	O
tract	O
carcinomas	O
(	O
22	O
/	O
25	O
,	O
88	O
%	O
)	O
but	O
not	O
in	O
hepatocellular	O
carcinomas	O
(	O
HCCs	O
)	O
(	O
0	O
/	O
15	O
,	O
0	O
%	O
)	O
.	O

Aberrant	O
maspin	S-Protein
expression	O
by	O
five	O
pancreatico	O
-	O
biliary	O
tract	O
carcinoma	O
cell	O
lines	O
was	O
closely	O
associated	O
with	O
demethylation	O
at	O
the	O
maspin	S-Protein
promoter	O
.	O

Five	O
of	O
six	O
HCC	O
cell	O
lines	O
were	O
maspin	S-Protein
-	O
negative	O
and	O
exhibited	O
extensive	O
hypomethylation	O
and	O
hypoacetylation	O
at	O
the	O
maspin	S-Protein
promoter	O
.	O

Treatment	O
with	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
did	O
not	O
activate	O
maspin	S-Protein
expression	O
in	O
these	O
five	O
maspin	S-Protein
-	O
negative	O
HCC	O
cell	O
lines	O
,	O
whereas	O
treatment	O
with	O
Trichostatin	O
A	O
(	O
TSA	O
)	O
activated	O
maspin	S-Protein
expression	O
in	O
two	O
of	O
them	O
.	O

Treatment	O
with	O
TSA	O
increased	O
histone	S-Protein
acetylation	O
in	O
some	O
HCC	O
cell	O
lines	O
.	O

These	O
results	O
suggest	O
that	O
aberrant	O
maspin	S-Protein
expression	O
in	O
biliary	O
tract	O
carcinomas	O
is	O
closely	O
associated	O
with	O
demethylation	O
at	O
the	O
promoter	O
region	O
,	O
but	O
that	O
some	O
HCC	O
cell	O
lines	O
additionally	O
require	O
histone	S-Protein
acetylation	O
.	O

In	O
addition	O
,	O
the	O
fact	O
that	O
maspin	S-Protein
-	O
negative	O
HCC	O
cell	O
lines	O
remain	O
after	O
treatment	O
with	O
TSA	O
suggests	O
the	O
existence	O
of	O
other	O
repressive	O
factors	O
controlling	O
maspin	S-Protein
expression	O
.	O

Toward	O
the	O
insulin	S-Protein
-	O
IGF	B-Protein
-	I-Protein
I	E-Protein
intermediate	O
structures	O
:	O
functional	O
and	O
structural	O
properties	O
of	O
the	O
[	O
TyrB25NMePheB26	O
]	O
insulin	S-Protein
mutant	O
.	O

The	O
origins	O
of	O
differentiation	O
of	O
insulin	S-Protein
from	O
insulin	B-Protein
-	I-Protein
like	I-Protein
growth	I-Protein
factor	I-Protein
I	E-Protein
(	O
IGF	B-Protein
-	I-Protein
I	E-Protein
)	O
are	O
still	O
unknown	O
.	O

To	O
address	O
the	O
problem	O
of	O
a	O
structural	O
and	O
biological	O
switch	O
from	O
the	O
mostly	O
metabolic	O
hormonal	O
activity	O
of	O
insulin	S-Protein
to	O
the	O
predominant	O
growth	O
factor	O
activities	O
of	O
IGF	B-Protein
-	I-Protein
I	E-Protein
,	O
an	O
insulin	S-Protein
analogue	O
with	O
IGF	B-Protein
-	I-Protein
I	E-Protein
-	O
like	O
structural	O
features	O
has	O
been	O
synthesized	O
.	O

Insulin	S-Protein
residues	O
Phe	O
(	O
B25	O
)	O
and	O
Tyr	O
(	O
B26	O
)	O
have	O
been	O
swapped	O
with	O
the	O
IGF	B-Protein
-	I-Protein
I	E-Protein
-	O
like	O
Tyr	O
(	O
24	O
)	O
and	O
Phe	O
(	O
25	O
)	O
sequence	O
with	O
a	O
simultaneous	O
methylation	O
of	O
the	O
peptide	O
nitrogen	O
of	O
residue	O
Phe	O
(	O
B26	O
)	O
.	O

These	O
modifications	O
were	O
expected	O
to	O
introduce	O
a	O
substantial	O
kink	O
in	O
the	O
main	O
chain	O
,	O
as	O
observed	O
at	O
residue	O
Phe	O
(	O
25	O
)	O
in	O
the	O
IGF	B-Protein
-	I-Protein
I	E-Protein
crystal	O
structure	O
.	O

These	O
alterations	O
should	O
provide	O
insight	O
into	O
the	O
structural	O
origins	O
of	O
insulin	S-Protein
-	O
IGF	B-Protein
-	I-Protein
I	E-Protein
structural	O
and	O
functional	O
divergence	O
.	O

The	O
[	O
Tyr	O
(	O
B25	O
)	O
NMePhe	O
(	O
B26	O
)	O
]	O
mutant	O
has	O
been	O
characterized	O
,	O
and	O
its	O
crystal	O
structure	O
has	O
been	O
determined	O
.	O

Surprisingly	O
,	O
all	O
of	O
these	O
changes	O
are	O
well	O
accommodated	O
within	O
an	O
insulin	S-Protein
R6	O
hexamer	O
.	O

Only	O
one	O
molecule	O
of	O
each	O
dimer	O
in	O
the	O
hexamer	O
responds	O
to	O
the	O
structural	O
alterations	O
,	O
the	O
other	O
remaining	O
very	O
similar	O
to	O
wild	O
-	O
type	O
insulin	S-Protein
.	O

All	O
alterations	O
,	O
modest	O
in	O
their	O
scale	O
,	O
cumulate	O
in	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
B	O
-	O
chain	O
(	O
residues	O
B23	O
-	O
B30	O
)	O
,	O
which	O
moves	O
toward	O
the	O
core	O
of	O
the	O
insulin	S-Protein
molecule	O
and	O
is	O
associated	O
with	O
a	O
significant	O
shift	O
of	O
the	O
A1	O
helix	O
toward	O
the	O
C	O
-	O
terminus	O
of	O
the	O
B	O
-	O
chain	O
.	O

These	O
changes	O
do	O
not	O
produce	O
the	O
expected	O
bend	O
of	O
the	O
main	O
chain	O
,	O
but	O
the	O
fold	O
of	O
the	O
mutant	O
does	O
reflect	O
some	O
structural	O
characteristics	O
of	O
IGF	B-Protein
-	I-Protein
1	E-Protein
,	O
and	O
in	O
addition	O
establishes	O
the	O
CO	O
(	O
A19	O
)	O
-	O
NH	O
(	O
B25	O
)	O
hydrogen	O
bond	O
,	O
which	O
is	O
normally	O
characteristic	O
of	O
T	O
-	O
state	O
insulin	S-Protein
.	O

Identification	O
of	O
17	O
,	O
20beta	O
,	O
21	O
-	O
trihydroxy	O
-	O
4	O
-	O
pregnen	O
-	O
3	O
-	O
one	O
as	O
an	O
oocyte	O
maturation	O
-	O
inducing	O
steroid	O
in	O
black	O
porgy	O
,	O
Acanthopagrus	O
schlegeli	O
.	O

The	O
identity	O
of	O
the	O
maturation	O
-	O
inducing	O
steroid	O
(	O
MIS	O
)	O
in	O
black	O
porgy	O
,	O
Acanthopagrus	O
schlegeli	O
,	O
a	O
marine	O
protandrous	O
teleost	O
,	O
is	O
unknown	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
two	O
teleost	O
MISs	O
,	O
the	O
progestins	O
17	O
,	O
20beta	O
,	O
21	O
-	O
trihydroxy	O
-	O
4	O
-	O
pregnen	O
-	O
3	O
-	O
one	O
(	O
20beta	O
-	O
S	O
)	O
and	O
17	O
,	O
20beta	O
-	O
dihydroxy	O
-	O
4	O
-	O
pregnen	O
-	O
3	O
-	O
one	O
(	O
DHP	O
)	O
can	O
induce	O
maturation	O
of	O
black	O
porgy	O
oocytes	O
in	O
vitro	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
identify	O
the	O
major	O
progestin	O
produced	O
during	O
oocyte	O
maturation	O
(	O
OM	O
)	O
in	O
black	O
porgy	O
and	O
investigate	O
whether	O
its	O
secretion	O
increases	O
during	O
this	O
process	O
.	O

Females	O
were	O
injected	O
twice	O
with	O
a	O
LHRH	S-Protein
analog	O
to	O
induce	O
OM	O
.	O

Ovarian	O
follicles	O
undergoing	O
OM	O
were	O
incubated	O
in	O
vitro	O
with	O
tritiated	O
[	O
3H	O
]	O
pregnenolone	O
precursor	O
and	O
the	O
tritiated	O
products	O
were	O
extracted	O
,	O
purified	O
,	O
and	O
identified	O
by	O
HPLC	O
,	O
TLC	O
,	O
acetylation	O
,	O
and	O
recrystallization	O
.	O

Significant	O
amounts	O
of	O
tritiated	O
products	O
were	O
biosynthesized	O
from	O
[	O
3H	O
]	O
pregnenolone	O
that	O
co	O
-	O
migrated	O
with	O
20beta	O
-	O
S	O
but	O
not	O
with	O
DHP	O
on	O
HPLC	O
and	O
TLC	O
.	O

Similar	O
TLC	O
profiles	O
were	O
obtained	O
with	O
the	O
tritiated	O
products	O
isolated	O
from	O
the	O
HPLC	O
/	O
TLC	O
20beta	O
-	O
S	O
fraction	O
and	O
standard	O
20beta	O
-	O
S	O
after	O
the	O
acetylation	O
reaction	O
.	O

The	O
identity	O
of	O
the	O
tritiated	O
products	O
as	O
20beta	O
-	O
S	O
was	O
confirmed	O
by	O
recrystallization	O
.	O

20beta	O
-	O
S	O
had	O
a	O
slightly	O
higher	O
potency	O
than	O
DHP	O
in	O
the	O
inducing	O
in	O
vitro	O
final	O
oocyte	O
maturation	O
.	O

Plasma	O
20beta	O
-	O
S	O
concentrations	O
increased	O
significantly	O
during	O
the	O
oocyte	O
maturation	O
after	O
injection	O
with	O
a	O
LHRH	S-Protein
analog	O
.	O

The	O
present	O
data	O
suggest	O
that	O
20beta	O
-	O
S	O
is	O
the	O
MIS	O
in	O
black	O
porgy	O
.	O

Human	O
papillomavirus	O
oncoprotein	O
E7	S-Protein
targets	O
the	O
promyelocytic	B-Protein
leukemia	E-Protein
protein	O
and	O
circumvents	O
cellular	O
senescence	O
via	O
the	O
Rb	S-Protein
and	O
p53	S-Protein
tumor	O
suppressor	O
pathways	O
.	O

Cellular	O
senescence	O
can	O
be	O
triggered	O
by	O
a	O
variety	O
of	O
signals	O
,	O
including	O
loss	O
of	O
telomeric	O
integrity	O
or	O
intense	O
oncogenic	O
signaling	O
,	O
and	O
is	O
considered	O
a	O
potent	O
,	O
natural	O
tumor	O
suppressor	O
mechanism	O
.	O

Previously	O
,	O
it	O
was	O
shown	O
that	O
the	O
promyelocytic	B-Protein
leukemia	E-Protein
protein	O
(	O
PML	S-Protein
)	O
induces	O
cellular	O
senescence	O
when	O
overexpressed	O
in	O
primary	O
human	O
fibroblasts	O
.	O

The	O
mechanism	O
by	O
which	O
the	O
PML	S-Protein
IV	O
isoform	O
elicits	O
this	O
irreversible	O
growth	O
arrest	O
is	O
believed	O
to	O
involve	O
activation	O
of	O
the	O
tumor	O
suppressor	O
pathways	O
p21	S-Protein
/	O
p53	S-Protein
and	O
p16	S-Protein
/	O
Rb	S-Protein
;	O
however	O
,	O
a	O
requirement	O
for	O
either	O
pathway	O
has	O
not	O
been	O
demonstrated	O
unequivocally	O
.	O

To	O
investigate	O
the	O
individual	O
contributions	O
of	O
p53	S-Protein
and	O
Rb	S-Protein
to	O
PML	S-Protein
-	O
induced	O
senescence	O
,	O
we	O
used	O
oncoproteins	O
E6	S-Protein
and	O
E7	S-Protein
from	O
human	O
papillomaviruses	O
(	O
HPVs	O
)	O
,	O
which	O
predominantly	O
target	O
p53	S-Protein
and	O
Rb	S-Protein
.	O

We	O
show	O
that	O
E7	S-Protein
,	O
but	O
not	O
E6	S-Protein
,	O
circumvents	O
PML	S-Protein
-	O
induced	O
senescence	O
.	O

Using	O
different	O
E7	S-Protein
mutant	O
proteins	O
,	O
dominant	O
negative	O
cyclin	B-Protein
-	I-Protein
dependent	I-Protein
kinase	I-Protein
4	E-Protein
,	O
and	O
p16	S-Protein
RNA	O
interference	O
,	O
we	O
demonstrate	O
that	O
Rb	S-Protein
-	O
related	O
and	O
Rb	S-Protein
-	O
independent	O
mechanisms	O
of	O
E7	S-Protein
are	O
necessary	O
for	O
subversion	O
of	O
PML	S-Protein
-	O
induced	O
senescence	O
and	O
we	O
identify	O
PML	S-Protein
as	O
a	O
novel	O
target	O
for	O
E7	S-Protein
.	O

Interaction	O
between	O
E7	S-Protein
and	O
a	O
functional	O
prosenescence	O
complex	O
composed	O
of	O
PML	S-Protein
,	O
p53	S-Protein
,	O
and	O
CBP	S-Protein
perturbs	O
transcriptional	O
activation	O
of	O
p53	S-Protein
,	O
thus	O
highlighting	O
a	O
significant	O
effect	O
also	O
on	O
the	O
p53	S-Protein
tumor	O
suppressor	O
pathway	O
.	O

Given	O
the	O
importance	O
of	O
HPV	O
in	O
the	O
pathogenesis	O
of	O
cervical	O
cancer	O
,	O
our	O
results	O
warrant	O
a	O
more	O
detailed	O
analyses	O
of	O
PML	S-Protein
in	O
HPV	O
infections	O
.	O

Dehydroepiandrosterone	O
and	O
its	O
7	O
-	O
hydroxylated	O
metabolites	O
do	O
not	O
interfere	O
with	O
the	O
transactivation	O
and	O
cellular	O
trafficking	O
of	O
the	O
glucocorticoid	B-Protein
receptor	E-Protein
.	O

The	O
human	O
brain	O
is	O
a	O
target	O
tissue	O
for	O
glucocorticoids	O
(	O
GC	O
)	O
.	O

Dehydroepiandrosterone	O
(	O
DHEA	O
)	O
is	O
a	O
neurosteroid	O
produced	O
in	O
the	O
brain	O
where	O
it	O
is	O
transformed	O
into	O
7alpha	O
-	O
hydroxy	O
-	O
DHEA	O
and	O
7beta	O
-	O
hydroxy	O
-	O
DHEA	O
.	O

The	O
antiglucocorticoid	O
effects	O
of	O
both	O
7	O
-	O
hydroxylated	O
metabolites	O
have	O
been	O
investigated	O
with	O
evidence	O
in	O
mice	O
that	O
neither	O
form	O
of	O
DHEA	O
interfered	O
with	O
the	O
binding	O
of	O
GC	O
to	O
its	O
glucocorticoid	B-Protein
receptor	E-Protein
(	O
GR	S-Protein
)	O
,	O
but	O
contributed	O
to	O
a	O
decreased	O
nuclear	O
uptake	O
of	O
the	O
activated	O
GR	S-Protein
.	O

Our	O
objective	O
was	O
to	O
use	O
COS	O
-	O
7	O
cell	O
culture	O
to	O
research	O
DHEA	O
,	O
7alpha	O
-	O
hydroxy	O
-	O
DHEA	O
and	O
7beta	O
-	O
hydroxy	O
-	O
DHEA	O
interferences	O
with	O
GR	S-Protein
trafficking	O
.	O

These	O
cells	O
did	O
not	O
carry	O
out	O
the	O
7alpha	O
-	O
hydroxylation	O
of	O
DHEA	O
and	O
the	O
oxidation	O
of	O
cortisol	O
into	O
cortisone	O
.	O

The	O
cDNA	O
of	O
the	O
human	O
GR	S-Protein
was	O
inserted	O
into	O
pcDNA3	O
for	O
a	O
transient	O
transfection	O
of	O
COS	O
-	O
7	O
cells	O
.	O

Human	O
GR	S-Protein
transactivation	O
activity	O
was	O
measured	O
from	O
a	O
luciferase	S-Protein
-	O
MMTV	O
reporter	O
gene	O
.	O

The	O
transfected	O
COS	O
-	O
7	O
cells	O
were	O
cultured	O
using	O
10	O
(	O
-	O
12	O
)	O
to	O
10	O
(	O
-	O
5	O
)	O
M	O
dexamethasone	O
(	O
DEX	O
)	O
or	O
cortisol	O
,	O
which	O
triggered	O
the	O
reporter	O
expression	O
.	O

Treatment	O
with	O
10	O
(	O
-	O
12	O
)	O
to	O
10	O
(	O
-	O
5	O
)	O
M	O
DHEA	O
,	O
7alpha	O
-	O
hydroxy	O
-	O
DHEA	O
and	O
7beta	O
-	O
hydroxy	O
-	O
DHEA	O
caused	O
no	O
change	O
in	O
the	O
GC	O
-	O
induced	O
GR	S-Protein
transactivation	O
.	O

A	O
reconstruction	O
of	O
the	O
process	O
associated	O
EGFP	S-Protein
to	O
the	O
human	O
GR	S-Protein
cDNA	O
.	O

Confocal	O
microscopic	O
examination	O
of	O
COS	O
-	O
7	O
cells	O
transiently	O
expressing	O
the	O
fusion	O
protein	O
EGFP	S-Protein
-	O
GR	S-Protein
showed	O
nuclear	O
fluorescence	O
60	O
min	O
after	O
incubation	O
with	O
10	O
(	O
-	O
8	O
)	O
M	O
DEX	O
or	O
cortisol	O
.	O

The	O
addition	O
of	O
10	O
(	O
-	O
5	O
)	O
M	O
DHEA	O
,	O
7alpha	O
-	O
hydroxy	O
-	O
DHEA	O
or	O
7beta	O
-	O
hydroxy	O
-	O
DHEA	O
did	O
not	O
change	O
its	O
kinesis	O
and	O
intensity	O
.	O

These	O
results	O
contribute	O
to	O
the	O
knowledge	O
of	O
DHEA	O
,	O
7alpha	O
-	O
hydroxy	O
-	O
DHEA	O
and	O
7beta	O
-	O
hydroxy	O
-	O
DHEA	O
,	O
in	O
relation	O
to	O
antiglucocorticoid	O
activity	O
.	O

We	O
conclude	O
that	O
direct	O
interference	O
with	O
GR	S-Protein
trafficking	O
can	O
be	O
discounted	O
in	O
the	O
case	O
of	O
these	O
hormones	O
,	O
therefore	O
proposing	O
new	O
possibilities	O
of	O
investigation	O
.	O

Myeloid	O
antigens	O
in	O
childhood	O
lymphoblastic	O
leukemia	O
:	O
clinical	O
data	O
point	O
to	O
regulation	O
of	O
CD66c	S-Protein
distinct	O
from	O
other	O
myeloid	O
antigens	O
.	O

BACKGROUND	O
:	O
Aberrant	O
expression	O
of	O
myeloid	O
antigens	O
(	O
MyAgs	O
)	O
on	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
cells	O
is	O
a	O
well	O
-	O
documented	O
phenomenon	O
,	O
although	O
its	O
regulating	O
mechanisms	O
are	O
unclear	O
.	O

MyAgs	O
in	O
ALL	O
are	O
interpreted	O
e	O
.	O
g	O
.	O
as	O
hallmarks	O
of	O
early	O
differentiation	O
stage	O
and	O
/	O
or	O
lineage	O
indecisiveness	O
.	O

Granulocytic	O
marker	O
CD66c	S-Protein
-	O
-	O
Carcinoembryonic	B-Protein
antigen	I-Protein
-	I-Protein
related	I-Protein
cell	I-Protein
adhesion	I-Protein
molecule	I-Protein
6	E-Protein
(	O
CEACAM6	S-Protein
)	O
is	O
aberrantly	O
expressed	O
on	O
ALL	O
with	O
strong	O
correlation	O
to	O
genotype	O
(	O
negative	O
in	O
TEL	S-Protein
/	O
AML1	S-Protein
and	O
MLL	S-Protein
/	O
AF4	S-Protein
,	O
positive	O
in	O
BCR	S-Protein
/	O
ABL	S-Protein
and	O
hyperdiploid	O
cases	O
)	O
.	O

METHODS	O
:	O
In	O
a	O
cohort	O
of	O
365	O
consecutively	O
diagnosed	O
Czech	O
B	O
-	O
precursor	O
ALL	O
patients	O
,	O
we	O
analyze	O
distribution	O
of	O
MyAg	O
+	O
cases	O
and	O
mutual	O
relationship	O
among	O
CD13	S-Protein
,	O
CD15	S-Protein
,	O
CD33	S-Protein
,	O
CD65	O
and	O
CD66c	S-Protein
.	O

The	O
most	O
frequent	O
MyAg	O
(	O
CD66c	S-Protein
)	O
is	O
studied	O
further	O
regarding	O
its	O
stability	O
from	O
diagnosis	O
to	O
relapse	O
,	O
prognostic	O
significance	O
and	O
regulation	O
of	O
surface	O
expression	O
.	O

For	O
the	O
latter	O
,	O
flow	O
cytometry	O
,	O
Western	O
blot	O
and	O
quantitative	O
RT	O
-	O
PCR	O
on	O
sorted	O
cells	O
is	O
used	O
.	O

RESULTS	O
:	O
We	O
show	O
CD66c	S-Protein
is	O
expressed	O
in	O
43	O
%	O
patients	O
,	O
which	O
is	O
more	O
frequent	O
than	O
other	O
MyAgs	O
studied	O
.	O

In	O
addition	O
,	O
CD66c	S-Protein
expression	O
negatively	O
correlates	O
with	O
CD13	S-Protein
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
,	O
CD33	S-Protein
(	O
p	O
=	O
0	O
.	O
002	O
)	O
and	O
/	O
or	O
CD65	O
(	O
p	O
=	O
0	O
.	O
029	O
)	O
.	O

Our	O
data	O
show	O
that	O
different	O
myeloid	O
antigens	O
often	O
differ	O
in	O
biological	O
importance	O
,	O
which	O
may	O
be	O
obscured	O
by	O
combining	O
them	O
into	O
"	O
MyAg	O
positive	O
ALL	O
"	O
.	O

We	O
show	O
that	O
unlike	O
other	O
MyAgs	O
,	O
CD66c	S-Protein
expression	O
is	O
not	O
shifted	O
from	O
the	O
onset	O
of	O
ALL	O
to	O
relapse	O
(	O
n	O
=	O
39	O
,	O
time	O
to	O
relapse	O
0	O
.	O
3	O
-	O
5	O
.	O
3	O
years	O
)	O
.	O

Although	O
opposite	O
has	O
previously	O
been	O
suggested	O
,	O
we	O
show	O
that	O
CEACAM6	S-Protein
transcription	O
is	O
invariably	O
followed	O
by	O
surface	O
expression	O
(	O
by	O
quantitative	O
RT	O
-	O
PCR	O
on	O
sorted	O
cells	O
)	O
and	O
that	O
malignant	O
cells	O
containing	O
CD66c	S-Protein
in	O
cytoplasm	O
without	O
surface	O
expression	O
are	O
not	O
found	O
by	O
flow	O
cytometry	O
nor	O
by	O
Western	O
blot	O
in	O
vivo	O
.	O

We	O
report	O
no	O
prognostic	O
significance	O
of	O
CD66c	S-Protein
,	O
globally	O
or	O
separately	O
in	O
genotype	O
subsets	O
of	O
B	O
-	O
precursor	O
ALL	O
,	O
nor	O
an	O
association	O
with	O
known	O
risk	O
factors	O
(	O
n	O
=	O
254	O
)	O
.	O

CONCLUSION	O
:	O
In	O
contrast	O
to	O
general	O
notion	O
we	O
show	O
that	O
different	O
MyAgs	O
in	O
lymphoblastic	O
leukemia	O
represent	O
different	O
biological	O
circumstances	O
.	O

We	O
chose	O
the	O
most	O
frequent	O
and	O
tightly	O
genotype	O
-	O
associated	O
MyAg	O
CD66c	S-Protein
to	O
show	O
its	O
stabile	O
expression	O
in	O
patients	O
from	O
diagnosis	O
to	O
relapse	O
,	O
which	O
differs	O
from	O
what	O
is	O
known	O
on	O
the	O
other	O
MyAgs	O
.	O

Surface	O
expression	O
of	O
CD66c	S-Protein
is	O
regulated	O
at	O
the	O
gene	O
transcription	O
level	O
,	O
in	O
contrast	O
to	O
previous	O
reports	O
.	O

Methylation	O
of	O
NMDA	O
receptor	O
NR2B	S-Protein
gene	O
as	O
a	O
function	O
of	O
age	O
in	O
the	O
mouse	O
brain	O
.	O

We	O
have	O
previously	O
reported	O
that	O
there	O
is	O
an	O
up	O
-	O
regulation	O
of	O
the	O
NR2B	S-Protein
gene	O
expression	O
in	O
the	O
adult	O
cortex	O
and	O
cultured	O
fetal	O
cortical	O
neurons	O
of	O
mice	O
following	O
chronic	O
ethanol	O
treatment	O
due	O
to	O
demethylation	O
of	O
cytosine	O
residues	O
in	O
the	O
NR2B	S-Protein
gene	O
CpG	O
island	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
methylation	O
pattern	O
of	O
the	O
NR2B	S-Protein
CpG	O
island	O
as	O
a	O
function	O
of	O
the	O
mouse	O
age	O
by	O
digesting	O
the	O
cortex	O
genomic	O
DNA	O
with	O
HpaII	S-Protein
enzyme	O
,	O
amplifying	O
the	O
interested	O
regions	O
by	O
performing	O
PCR	O
and	O
detecting	O
the	O
methylated	O
regions	O
by	O
Southern	O
hybridization	O
so	O
as	O
to	O
determine	O
whether	O
age	O
affects	O
the	O
methylation	O
process	O
.	O

We	O
observed	O
demethylation	O
of	O
various	O
regions	O
of	O
NR2B	S-Protein
gene	O
(	O
5227	O
-	O
5567	O
)	O
,	O
(	O
5647	O
-	O
6003	O
)	O
,	O
(	O
6091	O
-	O
6445	O
)	O
,	O
(	O
6424	O
-	O
7024	O
)	O
of	O
adult	O
mouse	O
cortex	O
.	O

Our	O
results	O
indicate	O
that	O
methylation	O
of	O
NR2B	S-Protein
gene	O
in	O
the	O
mouse	O
brain	O
is	O
age	O
-	O
dependent	O
phenomenon	O
.	O

Molecular	O
forms	O
and	O
microheterogeneity	O
of	O
the	O
oligosaccharide	O
chains	O
of	O
pregnancy	O
-	O
associated	O
CA125	S-Protein
antigen	O
.	O

BACKGROUND	O
:	O
The	O
cancer	O
antigen	O
CA125	S-Protein
has	O
a	O
very	O
complex	O
molecular	O
architecture	O
in	O
terms	O
of	O
both	O
protein	O
backbone	O
and	O
oligosaccharide	O
chains	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
molecular	O
forms	O
and	O
microheterogeneity	O
of	O
oligosaccharide	O
chains	O
of	O
pregnancy	O
-	O
associated	O
CA125	S-Protein
,	O
as	O
a	O
first	O
step	O
towards	O
gaining	O
an	O
insight	O
into	O
its	O
possible	O
involvement	O
as	O
a	O
ligand	O
in	O
carbohydrate	O
-	O
dependent	O
interactions	O
.	O

The	O
glycobiochemical	O
properties	O
of	O
CA125	S-Protein
may	O
be	O
of	O
diagnostic	O
and	O
biomedical	O
importance	O
as	O
specific	O
markers	O
of	O
physiological	O
and	O
pathological	O
conditions	O
of	O
early	O
pregnancy	O
,	O
as	O
well	O
as	O
targets	O
in	O
different	O
therapeutic	O
procedures	O
.	O

METHODS	O
:	O
Pregnancy	O
-	O
associated	O
CA125	S-Protein
was	O
characterized	O
by	O
gel	O
filtration	O
and	O
ion	O
-	O
exchange	O
chromatography	O
,	O
followed	O
by	O
lectin	O
-	O
affinity	O
chromatography	O
with	O
a	O
panel	O
of	O
plant	O
lectins	O
as	O
ligands	O
.	O

RESULTS	O
:	O
CA125	S-Protein
antigen	O
isolated	O
from	O
first	O
trimester	O
placental	O
extract	O
was	O
found	O
to	O
be	O
heterogeneous	O
in	O
respect	O
to	O
molecular	O
mass	O
and	O
the	O
existence	O
of	O
different	O
glyco	O
-	O
isoforms	O
.	O

Thus	O
,	O
elution	O
profiles	O
from	O
the	O
lectin	O
-	O
affinity	O
columns	O
demonstrated	O
molecular	O
subpopulations	O
bound	O
with	O
low	O
,	O
intermediate	O
and	O
high	O
affinity	O
.	O

Under	O
the	O
applied	O
experimental	O
conditions	O
,	O
CA125	S-Protein
bound	O
most	O
strongly	O
to	O
Triticum	O
vulgaris	O
agglutinin	O
(	O
WGA	O
)	O
and	O
Ricinus	O
communis	O
agglutinin	S-Protein
(	O
RCA	S-Protein
)	O
,	O
but	O
low	O
affinity	O
interactions	O
occurred	O
with	O
the	O
other	O
lectins	O
tested	O
.	O

CONCLUSIONS	O
:	O
The	O
assessment	O
of	O
the	O
carbohydrate	O
composition	O
of	O
N	O
-	O
and	O
O	O
-	O
glycans	O
of	O
pregnancy	O
-	O
associated	O
CA125	S-Protein
was	O
in	O
general	O
agreement	O
with	O
available	O
data	O
on	O
CA125	S-Protein
of	O
cancer	O
origin	O
.	O

The	O
main	O
difference	O
was	O
observed	O
in	O
reactivity	O
to	O
Canavalia	O
ensiformis	O
agglutinin	S-Protein
(	O
ConA	S-Protein
)	O
and	O
Phaseolus	O
vulgaris	O
erythroagglutinin	S-Protein
(	O
PHA	B-Protein
-	I-Protein
E	E-Protein
)	O
binding	O
.	O

COOH	O
-	O
terminal	O
methylation	O
of	O
lamin	B-Protein
B	E-Protein
and	O
inhibition	O
of	O
methylation	O
by	O
farnesylated	O
peptides	O
corresponding	O
to	O
lamin	B-Protein
B	E-Protein
and	O
other	O
CAAX	O
motif	O
proteins	O
.	O

Previous	O
reports	O
from	O
this	O
laboratory	O
have	O
demonstrated	O
that	O
lamin	B-Protein
B	E-Protein
is	O
reversibly	O
methylesterified	O
in	O
a	O
cell	O
cycle	O
-	O
dependent	O
manner	O
.	O

The	O
site	O
of	O
this	O
methylation	O
,	O
however	O
,	O
was	O
not	O
identified	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
single	O
major	O
methylated	O
product	O
obtained	O
following	O
reversed	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatographic	O
analysis	O
of	O
peptides	O
generated	O
by	O
proteolytic	O
digestion	O
of	O
lamin	B-Protein
B	E-Protein
from	O
rat	O
liver	O
nuclear	O
envelopes	O
.	O

This	O
peptide	O
was	O
retained	O
on	O
a	O
lamin	B-Protein
B	E-Protein
COOH	O
-	O
terminal	O
-	O
specific	O
antibody	O
-	O
affinity	O
column	O
,	O
and	O
COOH	O
-	O
terminal	O
localization	O
was	O
confirmed	O
by	O
amino	O
acid	O
sequencing	O
.	O

Two	O
other	O
COOH	O
-	O
terminal	O
peptides	O
were	O
found	O
but	O
were	O
not	O
methylated	O
and	O
differed	O
in	O
sequence	O
by	O
at	O
least	O
a	O
single	O
residue	O
from	O
the	O
methylated	O
peptide	O
,	O
indicating	O
the	O
existence	O
of	O
two	O
lamin	O
B	O
gene	O
products	O
.	O

Tetrapeptides	O
,	O
representing	O
the	O
putative	O
mature	O
COOH	O
termini	O
of	O
lamin	B-Protein
B	E-Protein
,	O
K	B-Protein
-	I-Protein
ras	I-Protein
-	I-Protein
2A	E-Protein
,	O
and	O
unprocessed	O
lamin	B-Protein
A	E-Protein
,	O
were	O
synthesized	O
with	O
or	O
without	O
farnesyl	O
modification	O
of	O
the	O
COOH	O
-	O
terminal	O
cysteines	O
.	O

All	O
three	O
farnesylated	O
peptides	O
served	O
as	O
substrates	O
for	O
the	O
partially	O
purified	O
lamin	O
B	O
methyltransferase	O
with	O
apparent	O
Km	O
values	O
of	O
4	O
.	O
5	O
,	O
0	O
.	O
69	O
,	O
and	O
21	O
microM	O
,	O
respectively	O
.	O

Nonfarnesylated	O
peptides	O
were	O
not	O
substrates	O
for	O
the	O
enzyme	O
.	O

The	O
three	O
farnesylated	O
peptides	O
were	O
also	O
effective	O
to	O
varying	O
degrees	O
at	O
inhibiting	O
the	O
methylation	O
of	O
lamin	B-Protein
B	E-Protein
and	O
other	O
cellular	O
proteins	O
in	O
cell	O
lysates	O
.	O

In	O
nucleo	O
enzymatic	O
assays	O
for	O
the	O
identification	O
and	O
characterization	O
of	O
histone	S-Protein
modifying	O
activities	O
.	O

The	O
impact	O
of	O
histone	S-Protein
phosphorylation	O
,	O
acetylation	O
,	O
and	O
methylation	O
onto	O
transcription	O
and	O
various	O
other	O
cellular	O
DNA	O
-	O
mediated	O
processes	O
is	O
now	O
well	O
established	O
.	O

Numerous	O
histone	S-Protein
modification	O
marks	O
,	O
specific	O
sites	O
carrying	O
particular	O
post	O
-	O
translational	O
modifications	O
,	O
have	O
been	O
described	O
and	O
analyzed	O
in	O
detail	O
.	O

Whereas	O
,	O
many	O
methods	O
for	O
the	O
study	O
of	O
histone	S-Protein
post	O
-	O
translational	O
modifications	O
involve	O
sophisticated	O
equipment	O
and	O
techniques	O
,	O
we	O
describe	O
the	O
revival	O
of	O
a	O
very	O
simple	O
procedure	O
for	O
the	O
analysis	O
of	O
histone	S-Protein
modifications	O
and	O
histone	S-Protein
modifying	O
enzymes	O
,	O
which	O
is	O
derived	O
from	O
experiments	O
first	O
carried	O
out	O
several	O
decades	O
ago	O
.	O

This	O
method	O
is	O
based	O
on	O
the	O
isolation	O
of	O
cell	O
nuclei	O
containing	O
intact	O
chromatin	O
structures	O
that	O
are	O
then	O
incubated	O
with	O
defined	O
enzymatic	O
substrates	O
of	O
histone	S-Protein
modifying	O
enzymes	O
.	O

We	O
provide	O
quick	O
protocols	O
for	O
the	O
isolation	O
of	O
nuclei	O
from	O
yeast	O
and	O
mammalian	O
cells	O
and	O
give	O
basic	O
procedures	O
for	O
the	O
phosphorylation	O
,	O
acetylation	O
,	O
and	O
methylation	O
of	O
histones	S-Protein
(	O
and	O
other	O
proteins	O
)	O
using	O
these	O
subcellular	O
sources	O
that	O
can	O
be	O
carried	O
out	O
in	O
any	O
laboratory	O
.	O

Simple	O
methods	O
for	O
the	O
analysis	O
of	O
histone	S-Protein
modifications	O
using	O
these	O
assays	O
are	O
discussed	O
.	O

Effective	O
therapy	O
of	O
human	O
lymphoma	O
xenografts	O
with	O
a	O
novel	O
recombinant	O
ribonuclease	O
/	O
anti	O
-	O
CD74	S-Protein
humanized	O
IgG4	O
antibody	O
immunotoxin	O
.	O

Ranpirnase	S-Protein
(	O
Rap	S-Protein
)	O
is	O
a	O
cytotoxic	O
ribonuclease	O
(	O
RNase	O
)	O
isolated	O
from	O
frog	O
oocytes	O
.	O

Here	O
we	O
describe	O
high	O
antitumor	O
activity	O
of	O
a	O
novel	O
immunotoxin	O
,	O
2L	O
-	O
Rap	S-Protein
-	O
hLL1	O
-	O
gamma4P	O
,	O
composed	O
of	O
2	O
Rap	S-Protein
molecules	O
,	O
each	O
fused	O
to	O
the	O
N	O
terminus	O
of	O
the	O
light	O
chain	O
of	O
hLL1	O
,	O
an	O
internalizing	O
anti	O
-	O
CD74	S-Protein
humanized	O
antibody	O
.	O

To	O
reduce	O
unwanted	O
side	O
effects	O
,	O
the	O
constant	O
region	O
of	O
hLL1	O
was	O
changed	O
from	O
gamma1	O
to	O
gamma4	O
and	O
further	O
to	O
gamma4P	O
by	O
replacing	O
serine228	O
to	O
proline	O
to	O
prevent	O
the	O
formation	O
of	O
a	O
half	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
common	O
for	O
IgG4	O
.	O

In	O
vitro	O
,	O
2L	O
-	O
Rap	S-Protein
-	O
hLL1	O
-	O
gamma4P	O
retained	O
RNase	O
activity	O
,	O
specific	O
binding	O
to	O
CD74	S-Protein
,	O
and	O
was	O
significantly	O
more	O
potent	O
against	O
CD74	S-Protein
+	O
cell	O
lines	O
(	O
Daudi	O
,	O
Raji	O
,	O
and	O
MC	O
/	O
CAR	O
)	O
than	O
naked	O
hLL1	O
.	O

In	O
vivo	O
,	O
the	O
pharmacokinetic	O
profile	O
of	O
2L	O
-	O
Rap	S-Protein
-	O
hLL1	O
-	O
gamma4P	O
was	O
similar	O
to	O
that	O
of	O
naked	O
hLL1	O
.	O

The	O
maximum	O
tolerated	O
dose	O
of	O
2L	O
-	O
Rap	S-Protein
-	O
hLL1	O
-	O
gamma4P	O
in	O
severe	O
combined	O
immunodeficient	O
mice	O
(	O
SCID	O
)	O
or	O
BALB	O
/	O
c	O
mice	O
was	O
50	O
microg	O
per	O
mouse	O
.	O

In	O
Raji	O
and	O
Daudi	O
Burkitt	O
lymphoma	O
xenograft	O
models	O
,	O
treatment	O
with	O
a	O
single	O
5	O
to	O
50	O
microg	O
dose	O
of	O
2L	O
-	O
Rap	S-Protein
-	O
hLL1	O
-	O
gamma4P	O
,	O
given	O
as	O
early	O
or	O
delayed	O
treatment	O
,	O
resulted	O
in	O
cures	O
of	O
most	O
animals	O
.	O

Treatment	O
with	O
2L	O
-	O
Rap	S-Protein
-	O
hLL1	O
-	O
gamma4P	O
was	O
significantly	O
better	O
than	O
all	O
controls	O
,	O
including	O
saline	O
,	O
naked	O
hLL1	O
,	O
and	O
nonspecific	O
immunotoxin	O
.	O

In	O
conclusion	O
,	O
2L	O
-	O
Rap	S-Protein
-	O
hLL1	O
-	O
gamma4P	O
demonstrated	O
excellent	O
in	O
vitro	O
and	O
in	O
vivo	O
efficacy	O
and	O
thus	O
merits	O
further	O
consideration	O
as	O
a	O
therapeutic	O
for	O
CD74	S-Protein
+	O
tumors	O
.	O

E2F	O
-	O
HDAC	O
complexes	O
negatively	O
regulate	O
the	O
tumor	O
suppressor	O
gene	O
ARHI	S-Protein
in	O
breast	O
cancer	O
.	O

ARHI	S-Protein
is	O
a	O
maternally	O
imprinted	O
tumor	O
suppressor	O
gene	O
whose	O
expression	O
is	O
markedly	O
downregulated	O
in	O
breast	O
cancer	O
.	O

Reactivation	O
of	O
ARHI	S-Protein
expression	O
in	O
breast	O
cancer	O
cells	O
is	O
associated	O
with	O
increased	O
histone	B-Protein
H3	E-Protein
acetylation	O
and	O
decreased	O
lysine	O
9	O
methylation	O
of	O
histone	B-Protein
H3	E-Protein
.	O

An	O
ARHI	S-Protein
promoter	O
segment	O
that	O
spanned	O
bases	O
-	O
420	O
to	O
+	O
58	O
(	O
designated	O
the	O
P2	O
region	O
)	O
exhibits	O
significantly	O
higher	O
promoter	O
activity	O
in	O
normal	O
cells	O
than	O
in	O
cancer	O
cells	O
.	O

To	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
contributing	O
to	O
this	O
differential	O
transcriptional	O
activity	O
,	O
we	O
sought	O
to	O
identify	O
transcription	O
factors	O
that	O
bind	O
to	O
the	O
P2	O
region	O
of	O
the	O
ARHI	S-Protein
promoter	O
and	O
regulate	O
its	O
activity	O
.	O

Sequence	O
analysis	O
and	O
oligonucleotide	O
competition	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
identified	O
an	O
A2	O
fragment	O
containing	O
an	O
E2F	O
-	O
binding	O
site	O
.	O

Using	O
specific	O
antibodies	O
in	O
supershift	O
assays	O
,	O
we	O
have	O
shown	O
that	O
anti	O
-	O
E2F1	S-Protein
and	O
4	S-Protein
antibodies	O
can	O
supershift	O
the	O
A2	O
-	O
protein	O
complexes	O
,	O
whereas	O
anti	O
-	O
E2F2	S-Protein
and	O
6	S-Protein
antibodies	O
cannot	O
,	O
demonstrating	O
that	O
the	O
A2	O
fragment	O
interacts	O
with	O
specific	O
members	O
of	O
the	O
E2F	O
family	O
proteins	O
.	O

When	O
compared	O
with	O
normal	O
breast	O
epithelial	O
cells	O
,	O
breast	O
cancer	O
cells	O
have	O
significantly	O
elevated	O
expression	O
of	O
E2F1	S-Protein
,	O
4	S-Protein
and	O
increased	O
E2F	O
DNA	O
-	O
binding	O
activity	O
.	O

Moreover	O
,	O
chromatin	O
immunoprecipitation	O
experiments	O
revealed	O
that	O
both	O
E2F1	S-Protein
and	O
4	S-Protein
bind	O
to	O
the	O
ARHI	S-Protein
promoter	O
in	O
breast	O
cancer	O
cells	O
in	O
vivo	O
.	O

This	O
binding	O
was	O
reduced	O
when	O
the	O
cells	O
were	O
treated	O
with	O
the	O
histone	S-Protein
deacetylase	O
(	O
HDAC	O
)	O
inhibitor	O
-	O
-	O
trichostatin	O
A	O
(	O
TSA	O
)	O
.	O

When	O
SKBr3	O
cells	O
were	O
cotransfected	O
with	O
an	O
ARHI	S-Protein
/	O
luciferase	S-Protein
reporter	O
and	O
E2F	O
-	O
expression	O
vectors	O
,	O
E2F1	S-Protein
and	O
4	S-Protein
reduced	O
ARHI	S-Protein
promoter	O
activity	O
2	O
-	O
3	O
-	O
fold	O
,	O
and	O
this	O
reduction	O
could	O
be	O
reversed	O
by	O
TSA	O
treatment	O
.	O

The	O
negative	O
regulation	O
by	O
E2F	O
-	O
HDAC	O
complexes	O
could	O
also	O
be	O
reduced	O
by	O
small	O
interfering	O
RNA	O
of	O
E2F1	S-Protein
and	O
4	S-Protein
.	O

While	O
the	O
retinoblastoma	O
protein	O
,	O
pRB	S-Protein
,	O
alone	O
had	O
no	O
effect	O
on	O
ARHI	S-Protein
promoter	O
activity	O
,	O
repression	O
by	O
E2F1	S-Protein
,	O
but	O
not	O
E2F4	S-Protein
,	O
was	O
enhanced	O
by	O
the	O
coexpression	O
of	O
pRB	S-Protein
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
E2F1	S-Protein
,	O
4	S-Protein
and	O
their	O
complexes	O
with	O
HDAC	O
play	O
an	O
important	O
role	O
in	O
downregulating	O
the	O
expression	O
of	O
the	O
tumor	O
suppressor	O
gene	O
ARHI	S-Protein
in	O
breast	O
cancer	O
cells	O
.	O

A	O
novel	O
approach	O
for	O
N	O
-	O
glycosylation	O
studies	O
using	O
detergent	O
extracted	O
microsomes	O
.	O

Recently	O
,	O
it	O
has	O
become	O
apparent	O
that	O
asparagine	O
-	O
linked	O
(	O
N	O
-	O
linked	O
)	O
oligosaccharide	O
at	O
an	O
early	O
stage	O
of	O
processing	O
can	O
play	O
an	O
important	O
role	O
in	O
quality	O
control	O
of	O
the	O
secretory	O
pathway	O
.	O

Here	O
,	O
we	O
have	O
developed	O
a	O
system	O
for	O
better	O
understanding	O
of	O
the	O
N	O
-	O
glycosylation	O
machinery	O
and	O
its	O
involvement	O
in	O
quality	O
control	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

Rough	O
microsomes	O
(	O
RM	O
)	O
treated	O
with	O
0	O
.	O
18	O
%	O
Tx	O
-	O
100	O
(	O
TxRM	O
)	O
preserved	O
translocation	O
activities	O
to	O
a	O
similar	O
extent	O
detected	O
in	O
RM	O
.	O

TxRM	O
were	O
depleted	O
of	O
many	O
soluble	O
proteins	O
including	O
glucosidase	O
II	O
,	O
BiP	S-Protein
and	O
Erp72	S-Protein
,	O
but	O
maintained	O
approximately	O
80	O
%	O
of	O
calnexin	S-Protein
,	O
a	O
membrane	O
protein	O
.	O

More	O
importantly	O
,	O
TxRM	O
revealed	O
insufficient	O
glycosylation	O
of	O
T	B-Protein
cell	I-Protein
receptor	I-Protein
-	I-Protein
alpha	E-Protein
(	O
TCR	B-Protein
-	I-Protein
alpha	E-Protein
)	O
,	O
suggesting	O
that	O
a	O
factor	O
or	O
factors	O
extracted	O
with	O
0	O
.	O
18	O
%	O
Tx	O
-	O
100	O
is	O
responsible	O
for	O
facilitating	O
the	O
transfer	O
of	O
oligosaccharides	O
to	O
the	O
protein	O
.	O

In	O
addition	O
,	O
the	O
top	O
band	O
of	O
TCR	B-Protein
-	I-Protein
alpha	E-Protein
translated	O
in	O
TxRM	O
migrated	O
slower	O
than	O
that	O
in	O
RM	O
,	O
but	O
faster	O
than	O
that	O
in	O
RM	O
treated	O
with	O
castanospermine	O
(	O
CST	O
)	O
,	O
an	O
inhibitor	O
of	O
glucosidase	B-Protein
I	E-Protein
/	O
II	O
.	O

This	O
suggests	O
that	O
the	O
trimming	O
of	O
the	O
inner	O
two	O
glucose	O
sugars	O
is	O
impaired	O
by	O
the	O
loss	O
of	O
glucosidase	O
II	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
TCR	B-Protein
-	I-Protein
alpha	E-Protein
coprecipitated	O
with	O
calnexin	S-Protein
migrated	O
between	O
unglucosylated	O
and	O
diglucosylated	O
forms	O
on	O
SDS	O
-	O
PAGE	O
.	O

Thus	O
,	O
the	O
treatment	O
of	O
RM	O
with	O
low	O
concentration	O
of	O
detergent	O
is	O
a	O
very	O
powerful	O
method	O
for	O
elucidating	O
not	O
only	O
N	O
-	O
glycosylation	O
processes	O
but	O
also	O
other	O
biological	O
functions	O
such	O
as	O
quality	O
control	O
in	O
the	O
ER	O
.	O

OCH1	S-Protein
encodes	O
a	O
novel	O
membrane	O
bound	O
mannosyltransferase	O
:	O
outer	O
chain	O
elongation	O
of	O
asparagine	O
-	O
linked	O
oligosaccharides	O
.	O

The	O
Saccharomyces	O
cerevisiae	O
och1	S-Protein
mutant	O
shows	O
a	O
deficiency	O
in	O
the	O
mannose	O
outer	O
chain	O
elongation	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
.	O

We	O
have	O
cloned	O
the	O
OCH1	S-Protein
gene	O
by	O
complementation	O
of	O
temperature	O
sensitive	O
(	O
ts	O
)	O
phenotype	O
for	O
growth	O
.	O

The	O
integrant	O
of	O
OCH1	S-Protein
gene	O
in	O
the	O
yeast	O
chromosome	O
can	O
complement	O
the	O
ts	O
phenotype	O
and	O
shows	O
the	O
same	O
mapping	O
position	O
as	O
that	O
of	O
the	O
och1	S-Protein
mutation	O
,	O
indicating	O
that	O
the	O
cloned	O
gene	O
is	O
the	O
true	O
gene	O
for	O
mutation	O
.	O

The	O
OCH1	S-Protein
gene	O
disruptant	O
is	O
not	O
lethal	O
but	O
ts	O
for	O
cell	O
growth	O
,	O
and	O
lacks	O
mannose	O
outer	O
chains	O
.	O

The	O
OCH1	S-Protein
gene	O
sequence	O
predicts	O
a	O
55	O
kDa	O
protein	O
consisting	O
of	O
480	O
amino	O
acids	O
.	O

It	O
contains	O
four	O
potential	O
asparagine	O
-	O
linked	O
(	O
N	O
-	O
linked	O
)	O
glycosylation	O
sites	O
and	O
a	O
single	O
transmembrane	O
region	O
near	O
the	O
N	O
-	O
terminus	O
.	O

In	O
vitro	O
translation	O
/	O
translocation	O
analysis	O
revealed	O
that	O
the	O
large	O
C	O
-	O
terminal	O
region	O
of	O
the	O
OCH1	S-Protein
protein	O
is	O
located	O
at	O
the	O
lumenal	O
side	O
of	O
microsomal	O
membranes	O
with	O
some	O
sugar	O
modification	O
,	O
indicating	O
a	O
type	O
II	O
membrane	O
topology	O
.	O

The	O
OCH1	S-Protein
protein	O
was	O
detected	O
in	O
yeast	O
membrane	O
fractions	O
as	O
four	O
forms	O
of	O
58	O
-	O
66	O
kDa	O
,	O
which	O
correspond	O
to	O
the	O
size	O
of	O
a	O
glycoprotein	O
containing	O
four	O
N	O
-	O
linked	O
sugar	O
chains	O
the	O
length	O
of	O
which	O
is	O
almost	O
the	O
same	O
or	O
slightly	O
larger	O
than	O
the	O
inner	O
core	O
(	O
Man8GlcNAc2	O
)	O
formed	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

Finally	O
,	O
the	O
OCH1	S-Protein
gene	O
was	O
found	O
to	O
encode	O
a	O
novel	O
mannosyltransferase	O
which	O
specifically	O
transfers	O
[	O
14C	O
]	O
mannose	O
to	O
the	O
unique	O
acceptor	O
,	O
the	O
core	O
-	O
like	O
oligosaccharide	O
of	O
cell	O
wall	O
mannan	O
accumulated	O
in	O
the	O
och1	S-Protein
disruptant	O
.	O

Nucleotide	O
sequence	O
and	O
transcriptional	O
analysis	O
of	O
a	O
gene	O
encoding	O
gp41	S-Protein
,	O
a	O
structural	O
glycoprotein	O
of	O
the	O
baculovirus	O
Autographa	O
californica	O
nuclear	O
polyhedrosis	O
virus	O
.	O

We	O
have	O
identified	O
and	O
sequenced	O
a	O
region	O
of	O
the	O
Autographa	O
californica	O
nuclear	O
polyhedrosis	O
virus	O
(	O
AcMNPV	O
)	O
genome	O
encoding	O
the	O
major	O
polyhedron	O
-	O
derived	O
virus	O
structural	O
glycoprotein	O
gp41	S-Protein
.	O

The	O
open	O
reading	O
frame	O
is	O
located	O
entirely	O
within	O
the	O
AcMNPV	O
SstII	O
-	O
M	O
fragment	O
.	O

The	O
protein	O
sequence	O
does	O
not	O
have	O
hydrophobic	O
regions	O
characteristic	O
of	O
integral	O
membrane	O
proteins	O
and	O
contains	O
a	O
putative	O
O	O
-	O
linked	O
GlcNAc	O
glycosylation	O
site	O
.	O

gp41	S-Protein
is	O
expressed	O
as	O
a	O
late	O
gene	O
,	O
with	O
transcripts	O
starting	O
within	O
two	O
consensus	O
late	O
transcription	O
start	O
sites	O
(	O
TAAG	O
)	O
located	O
immediately	O
upstream	O
of	O
the	O
first	O
methionine	O
codon	O
.	O

A	O
major	O
transcription	O
termination	O
signal	O
is	O
bypassed	O
,	O
possibly	O
generating	O
a	O
bicistronic	O
message	O
.	O

Finally	O
,	O
the	O
nucleotide	O
and	O
protein	O
sequences	O
of	O
AcMNPV	O
and	O
Bombyx	O
mori	O
nuclear	O
polyhedrosis	O
virus	O
are	O
highly	O
conserved	O
.	O

Inositol	O
deacylation	O
by	O
Bst1p	S-Protein
is	O
required	O
for	O
the	O
quality	O
control	O
of	O
glycosylphosphatidylinositol	O
-	O
anchored	O
proteins	O
.	O

Misfolded	O
proteins	O
are	O
recognized	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
,	O
transported	O
back	O
to	O
the	O
cytosol	O
,	O
and	O
degraded	O
by	O
the	O
proteasome	O
.	O

A	O
number	O
of	O
proteins	O
are	O
processed	O
and	O
modified	O
by	O
a	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
anchor	O
in	O
the	O
ER	O
,	O
but	O
the	O
quality	O
control	O
mechanisms	O
of	O
GPI	O
-	O
anchored	O
proteins	O
remain	O
unclear	O
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
quality	O
control	O
mechanism	O
of	O
misfolded	O
GPI	O
-	O
anchored	O
proteins	O
.	O

We	O
have	O
constructed	O
a	O
mutant	O
form	O
of	O
the	O
beta	O
-	O
1	O
,	O
3	O
-	O
glucanosyltransferase	O
Gas1p	S-Protein
(	O
Gas1	S-Protein
*	O
p	O
)	O
as	O
a	O
model	O
misfolded	O
GPI	O
-	O
anchored	O
protein	O
.	O

Gas1	S-Protein
*	O
p	O
was	O
modified	O
with	O
a	O
GPI	O
anchor	O
but	O
retained	O
in	O
the	O
ER	O
and	O
was	O
degraded	O
rapidly	O
via	O
the	O
proteasome	O
.	O

Disruption	O
of	O
BST1	S-Protein
,	O
which	O
encodes	O
GPI	O
inositol	O
deacylase	O
,	O
caused	O
a	O
delay	O
in	O
the	O
degradation	O
of	O
Gas1	S-Protein
*	O
p	O
.	O

This	O
delay	O
was	O
because	O
of	O
an	O
effect	O
on	O
the	O
deacylation	O
activity	O
of	O
Bst1p	S-Protein
.	O

Disruption	O
of	O
genes	O
involved	O
in	O
GPI	O
-	O
anchored	O
protein	O
concentration	O
and	O
N	O
-	O
glycan	O
processing	O
caused	O
different	O
effects	O
on	O
the	O
degradation	O
of	O
Gas1	S-Protein
*	O
p	O
and	O
a	O
soluble	O
misfolded	O
version	O
of	O
carboxypeptidase	B-Protein
Y	E-Protein
.	O

Furthermore	O
,	O
Gas1	B-Protein
*	I-Protein
p	E-Protein
associated	O
with	O
both	O
Bst1p	S-Protein
and	O
BiP	S-Protein
/	O
Kar2p	S-Protein
,	O
a	O
molecular	O
chaperone	O
,	O
in	O
vivo	O
.	O

Our	O
data	O
suggest	O
that	O
GPI	O
inositol	O
deacylation	O
plays	O
important	O
roles	O
in	O
the	O
quality	O
control	O
and	O
ER	O
-	O
associated	O
degradation	O
of	O
GPI	O
-	O
anchored	O
proteins	O
.	O

Promoter	O
methylation	O
reduces	O
C	B-Protein
/	I-Protein
EBPdelta	E-Protein
(	O
CEBPD	S-Protein
)	O
gene	O
expression	O
in	O
the	O
SUM	O
-	O
52PE	O
human	O
breast	O
cancer	O
cell	O
line	O
and	O
in	O
primary	O
breast	O
tumors	O
.	O

CCAAT	O
/	O
Enhancer	O
Binding	O
Proteins	O
(	O
C	O
/	O
EBPs	O
)	O
are	O
a	O
highly	O
conserved	O
family	O
of	O
leucine	O
zipper	O
proteins	O
that	O
regulate	O
cell	O
growth	O
and	O
differentiation	O
.	O

C	B-Protein
/	I-Protein
EBPdelta	E-Protein
functions	O
in	O
the	O
initiation	O
and	O
maintenance	O
of	O
mammary	O
epithelial	O
cell	O
G	O
(	O
0	O
)	O
growth	O
arrest	O
and	O
'	O
loss	O
of	O
function	O
'	O
alterations	O
in	O
C	B-Protein
/	I-Protein
EBPdelta	E-Protein
gene	O
expression	O
have	O
been	O
reported	O
in	O
human	O
breast	O
cancer	O
and	O
in	O
rodent	O
carcinogen	O
-	O
induced	O
mammary	O
tumors	O
.	O

The	O
molecular	O
mechanism	O
underlying	O
reduced	O
C	B-Protein
/	I-Protein
EBPdelta	E-Protein
gene	O
expression	O
in	O
mammary	O
tumorigenesis	O
,	O
however	O
,	O
is	O
unknown	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
C	B-Protein
/	I-Protein
EBPdelta	E-Protein
gene	O
expression	O
is	O
undetectable	O
in	O
the	O
SUM	O
-	O
52PE	O
human	O
breast	O
cancer	O
cell	O
line	O
and	O
that	O
silencing	O
of	O
SUM	O
-	O
52PE	O
C	B-Protein
/	I-Protein
EBPdelta	E-Protein
gene	O
expression	O
is	O
due	O
to	O
epigenetic	O
promoter	O
hypermethylation	O
(	O
26	O
/	O
27	O
CpGs	O
methylated	O
)	O
.	O

The	O
hypermethylated	O
SUM	O
-	O
52PE	O
C	B-Protein
/	I-Protein
EBPdelta	E-Protein
gene	O
promoter	O
is	O
associated	O
with	O
reduced	O
levels	O
of	O
acetylated	O
Histone	B-Protein
H4	E-Protein
,	O
consistent	O
with	O
a	O
closed	O
,	O
transcriptionally	O
inactive	O
chromatin	O
conformation	O
.	O

Treatment	O
with	O
5	O
'	O
-	O
aza	O
-	O
cytidine	O
and	O
trichostatin	O
A	O
(	O
TSA	O
)	O
re	O
-	O
activates	O
cytokine	O
-	O
induced	O
SUM	O
-	O
52PE	O
C	B-Protein
/	I-Protein
EBPdelta	E-Protein
gene	O
expression	O
.	O

C	B-Protein
/	I-Protein
EBPdelta	E-Protein
gene	O
expression	O
is	O
reduced	O
to	O
virtually	O
undetectable	O
levels	O
in	O
32	O
%	O
(	O
18	O
/	O
57	O
)	O
of	O
primary	O
human	O
breast	O
tumors	O
.	O

Site	O
-	O
specific	O
CpG	O
methylation	O
was	O
observed	O
in	O
33	O
%	O
(	O
6	O
/	O
18	O
)	O
of	O
the	O
low	O
C	B-Protein
/	I-Protein
EBPdelta	E-Protein
expressing	O
primary	O
breast	O
tumors	O
.	O

CpG	O
methylation	O
adjacent	O
to	O
the	O
C	B-Protein
/	I-Protein
EBPdelta	E-Protein
proximal	O
promoter	O
Sp1	S-Protein
site	O
was	O
associated	O
with	O
reduced	O
C	B-Protein
/	I-Protein
EBPdelta	E-Protein
expression	O
in	O
a	O
primary	O
breast	O
cancer	O
sample	O
.	O

Electromobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
demonstrated	O
a	O
significant	O
reduction	O
in	O
binding	O
to	O
oligos	O
containing	O
the	O
CpG	O
methylation	O
5	O
'	O
to	O
the	O
Sp1	S-Protein
binding	O
site	O
.	O

These	O
results	O
demonstrate	O
a	O
direct	O
link	O
between	O
C	B-Protein
/	I-Protein
EBPdelta	E-Protein
gene	O
promoter	O
hyper	O
-	O
and	O
site	O
specific	O
-	O
methylation	O
and	O
reduced	O
C	B-Protein
/	I-Protein
EBPdelta	E-Protein
gene	O
expression	O
in	O
breast	O
cancer	O
cell	O
lines	O
and	O
primary	O
breast	O
tumors	O
.	O

Peripheral	O
nerve	O
dysfunction	O
in	O
experimental	O
diabetes	O
is	O
mediated	O
by	O
cyclooxygenase	B-Protein
-	I-Protein
2	E-Protein
and	O
oxidative	O
stress	O
.	O

Glucose	O
-	O
mediated	O
oxidative	O
stress	O
and	O
alterations	O
in	O
cyclooxygenase	O
(	O
COX	O
)	O
pathway	O
activity	O
with	O
secondary	O
deficits	O
of	O
endoneurial	O
perfusion	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
experimental	O
diabetic	O
neuropathy	O
(	O
EDN	O
)	O
.	O

We	O
have	O
previously	O
reported	O
that	O
activation	O
of	O
the	O
COX	B-Protein
-	I-Protein
2	E-Protein
pathway	O
is	O
an	O
important	O
mediator	O
of	O
neurochemical	O
and	O
neurovascular	O
defects	O
in	O
EDN	O
in	O
a	O
rat	O
model	O
.	O

Considering	O
that	O
chemical	O
COX	O
inhibition	O
may	O
exert	O
other	O
pharmacological	O
effects	O
in	O
addition	O
to	O
inhibition	O
of	O
COX	O
activity	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
role	O
of	O
COX	B-Protein
-	I-Protein
2	E-Protein
in	O
experimental	O
diabetic	O
neuropathy	O
,	O
using	O
a	O
COX	B-Protein
-	I-Protein
2	E-Protein
knockout	O
mouse	O
model	O
.	O

Here	O
we	O
provide	O
evidence	O
that	O
COX	B-Protein
-	I-Protein
2	E-Protein
inactivation	O
had	O
a	O
protective	O
effect	O
against	O
diabetes	O
-	O
induced	O
motor	O
and	O
sensory	O
nerve	O
conduction	O
slowing	O
and	O
impaired	O
nerve	O
antioxidative	O
defense	O
that	O
were	O
clearly	O
manifest	O
in	O
the	O
wild	O
-	O
type	O
(	O
COX	O
-	O
2	O
(	O
+	O
/	O
+	O
)	O
)	O
diabetic	O
mice	O
.	O

These	O
preliminary	O
data	O
support	O
the	O
role	O
of	O
the	O
activation	O
of	O
the	O
COX	B-Protein
-	I-Protein
2	E-Protein
pathway	O
in	O
mediating	O
sensory	O
and	O
motor	O
nerve	O
conduction	O
velocity	O
deficits	O
in	O
EDN	O
.	O

These	O
findings	O
also	O
suggest	O
that	O
the	O
COX	B-Protein
-	I-Protein
2	E-Protein
pathway	O
seems	O
to	O
be	O
an	O
important	O
modulator	O
of	O
oxidative	O
stress	O
in	O
EDN	O
.	O

Active	O
-	O
site	O
characterization	O
of	O
S1	B-Protein
nuclease	E-Protein
.	O

I	O
.	O

Affinity	O
purification	O
and	O
influence	O
of	O
amino	O
-	O
group	O
modification	O
.	O

A	O
simple	O
procedure	O
,	O
involving	O
heat	O
-	O
treatment	O
,	O
DEAE	O
-	O
Sephadex	O
,	O
AMP	O
-	O
Sepharose	O
and	O
Bio	O
-	O
Gel	O
P	O
-	O
60	O
chromatography	O
,	O
was	O
developed	O
for	O
the	O
purification	O
of	O
S1	B-Protein
nuclease	E-Protein
to	O
homogeneity	O
from	O
commercially	O
available	O
Takadiastase	O
powder	O
.	O

Chemical	O
modification	O
of	O
the	O
amino	O
groups	O
of	O
purified	O
S1	B-Protein
nuclease	E-Protein
revealed	O
that	O
lysine	O
is	O
essential	O
for	O
single	O
-	O
stranded	O
DNAase	O
,	O
RNAase	O
and	O
phosphomonoesterase	O
activities	O
associated	O
with	O
the	O
enzyme	O
.	O

The	O
kinetics	O
of	O
inactivation	O
suggested	O
the	O
involvement	O
of	O
a	O
single	O
lysine	O
residue	O
in	O
the	O
active	O
site	O
of	O
the	O
enzyme	O
.	O

Additionally	O
,	O
lysine	O
modification	O
was	O
accompanied	O
by	O
a	O
concomitant	O
loss	O
of	O
all	O
the	O
activities	O
of	O
the	O
enzyme	O
,	O
indicating	O
the	O
presence	O
of	O
a	O
common	O
catalytic	O
site	O
responsible	O
for	O
the	O
hydrolysis	O
of	O
single	O
-	O
stranded	O
DNA	O
,	O
RNA	O
and	O
3	O
'	O
-	O
AMP	O
.	O

Substrate	O
-	O
protection	O
and	O
inhibitor	O
-	O
binding	O
studies	O
on	O
enzyme	O
modified	O
with	O
2	O
,	O
4	O
,	O
6	O
-	O
trinitrobenzenesulphonic	O
acid	O
showed	O
that	O
lysine	O
may	O
be	O
involved	O
in	O
the	O
substrate	O
binding	O
.	O

Prion	S-Protein
protein	O
-	O
related	O
proteins	O
from	O
zebrafish	O
are	O
complex	O
glycosylated	O
and	O
contain	O
a	O
glycosylphosphatidylinositol	O
anchor	O
.	O

A	O
hallmark	O
of	O
prion	S-Protein
diseases	O
in	O
mammals	O
is	O
a	O
conformational	O
transition	O
of	O
the	O
cellular	O
prion	B-Protein
protein	E-Protein
(	O
PrP	B-Protein
(	I-Protein
C	I-Protein
)	E-Protein
)	O
into	O
a	O
pathogenic	O
isoform	O
termed	O
PrP	B-Protein
(	I-Protein
Sc	I-Protein
)	E-Protein
.	O

PrP	B-Protein
(	I-Protein
C	I-Protein
)	E-Protein
is	O
highly	O
conserved	O
in	O
mammals	O
,	O
moreover	O
,	O
genes	O
of	O
PrP	S-Protein
-	O
related	O
proteins	O
have	O
been	O
recently	O
identified	O
in	O
fish	O
.	O

While	O
there	O
is	O
only	O
little	O
sequence	O
homology	O
to	O
mammalian	O
PrP	S-Protein
,	O
PrP	S-Protein
-	O
related	O
fish	O
proteins	O
were	O
predicted	O
to	O
be	O
modified	O
with	O
N	O
-	O
linked	O
glycans	O
and	O
a	O
C	O
-	O
terminal	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
anchor	O
.	O

We	O
biochemically	O
characterized	O
two	O
PrP	S-Protein
-	O
related	O
proteins	O
from	O
zebrafish	O
in	O
cultured	O
cells	O
and	O
show	O
that	O
both	O
zePrP1	S-Protein
and	O
zeSho2	S-Protein
are	O
imported	O
into	O
the	O
endoplasmic	O
reticulum	O
and	O
are	O
post	O
-	O
translationally	O
modified	O
with	O
complex	O
glycans	O
and	O
a	O
C	O
-	O
terminal	O
GPI	O
anchor	O
.	O

Nur77	S-Protein
is	O
differentially	O
modified	O
in	O
PC12	O
cells	O
upon	O
membrane	O
depolarization	O
and	O
growth	O
factor	O
treatment	O
.	O

The	O
rat	O
pheochromocytoma	O
cell	O
line	O
PC12	O
can	O
be	O
induced	O
by	O
growth	O
factors	O
to	O
undergo	O
proliferation	O
and	O
neuronal	O
differentiation	O
.	O

These	O
cells	O
also	O
have	O
excitable	O
membranes	O
that	O
can	O
be	O
depolarized	O
by	O
neurotransmitters	O
or	O
elevated	O
levels	O
of	O
extracellular	O
KCl	O
.	O

Treatment	O
of	O
PC12	O
cells	O
with	O
growth	O
factors	O
or	O
membrane	O
-	O
depolarizing	O
agents	O
rapidly	O
activates	O
the	O
expression	O
of	O
specific	O
genes	O
whose	O
products	O
are	O
thought	O
to	O
mediate	O
the	O
subsequent	O
biological	O
responses	O
.	O

One	O
such	O
gene	O
,	O
nur77	S-Protein
,	O
is	O
a	O
member	O
of	O
the	O
steroid	O
and	O
thyroid	O
hormone	O
receptor	O
gene	O
superfamily	O
.	O

We	O
have	O
identified	O
the	O
Nur77	S-Protein
protein	O
and	O
shown	O
that	O
it	O
is	O
synthesized	O
rapidly	O
and	O
transiently	O
in	O
PC12	O
cells	O
following	O
stimulation	O
,	O
has	O
a	O
short	O
half	O
-	O
life	O
of	O
30	O
to	O
40	O
min	O
,	O
and	O
is	O
located	O
in	O
both	O
the	O
nucleus	O
and	O
the	O
cytoplasm	O
.	O

Nur77	S-Protein
is	O
posttranslationally	O
modified	O
,	O
primarily	O
by	O
phosphorylation	O
on	O
serine	O
residues	O
.	O

Phosphopeptide	O
analysis	O
reveals	O
that	O
Nur77	S-Protein
is	O
modified	O
differently	O
upon	O
membrane	O
depolarization	O
than	O
after	O
treatment	O
with	O
growth	O
factors	O
.	O

We	O
hypothesize	O
that	O
the	O
activity	O
of	O
Nur77	S-Protein
is	O
regulated	O
by	O
both	O
differential	O
gene	O
expression	O
and	O
posttranslational	O
modification	O
and	O
that	O
these	O
modes	O
of	O
regulation	O
contribute	O
to	O
distinct	O
downstream	O
responses	O
specific	O
to	O
membrane	O
depolarization	O
and	O
growth	O
factor	O
treatment	O
.	O

Mass	O
spectrometric	O
characterization	O
of	O
human	O
histone	B-Protein
H3	E-Protein
:	O
a	O
bird	O
'	O
s	O
eye	O
view	O
.	O

The	O
modification	O
of	O
H3	S-Protein
in	O
asynchronous	O
HeLa	O
cells	O
was	O
profiled	O
using	O
Top	O
Down	O
Mass	O
Spectrometry	O
.	O

A	O
broad	O
distribution	O
of	O
species	O
differing	O
by	O
14	O
Da	O
and	O
containing	O
less	O
than	O
3	O
%	O
unmodified	O
protein	O
was	O
observed	O
for	O
all	O
three	O
variants	O
.	O

Species	O
of	O
up	O
to	O
+	O
168	O
Da	O
were	O
observed	O
for	O
H3	B-Protein
.	I-Protein
1	E-Protein
,	O
and	O
fragmentation	O
of	O
all	O
species	O
by	O
Electron	O
Capture	O
Dissociation	O
(	O
ECD	O
)	O
revealed	O
approximately	O
5	O
%	O
methylation	O
of	O
K4	O
and	O
approximately	O
50	O
%	O
dimethylation	O
of	O
K9	O
.	O

K14	O
and	O
K23	O
were	O
major	O
sites	O
of	O
acetylation	O
.	O

H3	B-Protein
.	I-Protein
3	E-Protein
was	O
slightly	O
hypermodified	O
with	O
the	O
apex	O
of	O
the	O
distribution	O
shifted	O
by	O
approximately	O
+	O
14	O
Da	O
compared	O
to	O
H3	B-Protein
.	I-Protein
1	E-Protein
.	O

H3	B-Protein
.	I-Protein
1	E-Protein
(	O
50	O
%	O
and	O
15	O
%	O
)	O
from	O
colchicine	O
-	O
treated	O
cells	O
was	O
monophosphorylated	O
and	O
diphosphorylated	O
,	O
respectively	O
,	O
with	O
equivalent	O
modification	O
of	O
S10	O
and	O
S28	O
.	O

Precise	O
characterization	O
of	O
human	O
histones	S-Protein
in	O
the	O
H2A	S-Protein
gene	O
family	O
by	O
top	O
down	O
mass	O
spectrometry	O
.	O

Top	O
Down	O
analysis	O
revealed	O
that	O
at	O
least	O
fourteen	O
genes	O
encoding	O
histone	B-Protein
H2A	E-Protein
are	O
coexpressed	O
in	O
HeLa	O
cells	O
.	O

Characterization	O
of	O
these	O
species	O
revealed	O
that	O
all	O
except	O
H2A	B-Protein
.	I-Protein
Z	E-Protein
and	O
H2A	B-Protein
.	I-Protein
F	I-Protein
/	I-Protein
Z	E-Protein
were	O
alpha	O
-	O
N	O
-	O
acetylated	O
,	O
H2A	B-Protein
.	I-Protein
O	E-Protein
and	O
H2A	B-Protein
.	I-Protein
C	E-Protein
,	O
D	S-Protein
,	O
I	S-Protein
,	O
N	S-Protein
,	O
P	S-Protein
were	O
the	O
most	O
abundant	O
,	O
and	O
those	O
exceeding	O
approximately	O
10	O
%	O
abundance	O
lacked	O
post	O
-	O
translational	O
modifications	O
.	O

This	O
unequivocal	O
identification	O
of	O
H2A	S-Protein
forms	O
illustrates	O
the	O
advantages	O
of	O
Top	O
Down	O
Mass	O
Spectrometry	O
and	O
provides	O
a	O
global	O
perspective	O
of	O
H2A	S-Protein
regulation	O
through	O
the	O
cell	O
cycle	O
.	O

Molecular	O
analysis	O
of	O
the	O
loss	O
of	O
somatic	O
instability	O
in	O
the	O
bz2	S-Protein
:	O
:	O
mu1	O
allele	O
of	O
maize	O
.	O

Multiple	O
genetic	O
and	O
epigenetic	O
changes	O
were	O
detected	O
within	O
one	O
plant	O
generation	O
at	O
the	O
bz2	S-Protein
:	O
:	O
mu1	O
mutable	O
allele	O
in	O
a	O
population	O
of	O
118	O
plants	O
.	O

Loss	O
of	O
somatic	O
instability	O
in	O
bz2	S-Protein
:	O
:	O
mu1	O
was	O
usually	O
correlated	O
with	O
methylation	O
of	O
the	O
Mu1	O
transposable	O
element	O
;	O
in	O
6	O
plants	O
,	O
somatic	O
instability	O
was	O
lost	O
as	O
a	O
result	O
of	O
mutations	O
in	O
bz2	S-Protein
:	O
:	O
mu1	O
.	O

This	O
is	O
a	O
surprisingly	O
high	O
frequency	O
of	O
mutation	O
per	O
allele	O
(	O
2	O
.	O
5	O
%	O
)	O
for	O
the	O
Mutator	O
family	O
,	O
for	O
which	O
germinal	O
revertants	O
occur	O
at	O
a	O
frequency	O
of	O
about	O
10	O
(	O
-	O
4	O
)	O
per	O
gamete	O
.	O

One	O
germinal	O
excision	O
event	O
was	O
found	O
that	O
contained	O
an	O
8	O
bp	O
deletion	O
,	O
frameshift	O
mutation	O
in	O
Bronze	B-Protein
-	I-Protein
2	E-Protein
.	O

The	O
three	O
other	O
mutants	O
described	O
occurred	O
as	O
a	O
result	O
of	O
abortive	O
transposition	O
,	O
in	O
which	O
75	O
-	O
77	O
bp	O
deletions	O
were	O
generated	O
at	O
the	O
junction	O
between	O
Bronze	B-Protein
-	I-Protein
2	E-Protein
and	O
Mu1	O
.	O

We	O
discuss	O
the	O
possible	O
mechanisms	O
,	O
and	O
the	O
role	O
of	O
host	O
factors	O
in	O
abortive	O
transposition	O
in	O
maize	O
.	O

Characterization	O
of	O
hARD2	S-Protein
,	O
a	O
processed	O
hARD1	S-Protein
gene	O
duplicate	O
,	O
encoding	O
a	O
human	O
protein	O
N	O
-	O
alpha	O
-	O
acetyltransferase	O
.	O

BACKGROUND	O
:	O
Protein	O
acetylation	O
is	O
increasingly	O
recognized	O
as	O
an	O
important	O
mechanism	O
regulating	O
a	O
variety	O
of	O
cellular	O
functions	O
.	O

Several	O
human	O
protein	O
acetyltransferases	O
have	O
been	O
characterized	O
,	O
most	O
of	O
them	O
catalyzing	O
epsilon	O
-	O
acetylation	O
of	O
histones	S-Protein
and	O
transcription	O
factors	O
.	O

We	O
recently	O
described	O
the	O
human	O
protein	O
acetyltransferase	O
hARD1	S-Protein
(	O
human	O
Arrest	B-Protein
Defective	I-Protein
1	E-Protein
)	O
.	O

hARD1	S-Protein
interacts	O
with	O
NATH	S-Protein
(	O
N	O
-	O
Acetyl	O
Transferase	O
Human	O
)	O
forming	O
a	O
complex	O
expressing	O
protein	O
N	O
-	O
terminal	O
alpha	O
-	O
acetylation	O
activity	O
.	O

RESULTS	O
:	O
We	O
here	O
describe	O
a	O
human	O
protein	O
,	O
hARD2	S-Protein
,	O
with	O
81	O
%	O
sequence	O
identity	O
to	O
hARD1	S-Protein
.	O

The	O
gene	O
encoding	O
hARD2	S-Protein
most	O
likely	O
originates	O
from	O
a	O
eutherian	O
mammal	O
specific	O
retrotransposition	O
event	O
.	O

hARD2	S-Protein
mRNA	O
and	O
protein	O
are	O
expressed	O
in	O
several	O
human	O
cell	O
lines	O
.	O

Immunoprecipitation	O
experiments	O
show	O
that	O
hARD2	S-Protein
protein	O
potentially	O
interacts	O
with	O
NATH	S-Protein
,	O
suggesting	O
that	O
hARD2	S-Protein
-	O
NATH	S-Protein
complexes	O
may	O
be	O
responsible	O
for	O
protein	O
N	O
-	O
alpha	O
-	O
acetylation	O
in	O
human	O
cells	O
.	O

In	O
NB4	O
cells	O
undergoing	O
retinoic	O
acid	O
mediated	O
differentiation	O
,	O
the	O
level	O
of	O
endogenous	O
hARD1	S-Protein
and	O
NATH	S-Protein
protein	O
decreases	O
while	O
the	O
level	O
of	O
hARD2	S-Protein
protein	O
is	O
stable	O
.	O

CONCLUSION	O
:	O
A	O
human	O
protein	O
N	O
-	O
alpha	O
-	O
acetyltransferase	O
is	O
herein	O
described	O
.	O

ARD2	S-Protein
potentially	O
complements	O
the	O
functions	O
of	O
ARD1	S-Protein
,	O
adding	O
more	O
flexibility	O
and	O
complexity	O
to	O
protein	O
N	O
-	O
alpha	O
-	O
acetylation	O
in	O
human	O
cells	O
as	O
compared	O
to	O
lower	O
organisms	O
which	O
only	O
have	O
one	O
ARD	O
.	O

Cardiomyopathy	O
associated	O
with	O
noninsulin	S-Protein
-	O
dependent	O
diabetes	O
.	O

Cardiovascular	O
disease	O
represents	O
the	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
noninsulin	S-Protein
-	O
dependent	O
diabetic	O
patients	O
.	O

While	O
it	O
was	O
once	O
thought	O
that	O
atherosclerotic	O
vascular	O
disease	O
was	O
responsible	O
for	O
all	O
of	O
these	O
adverse	O
effects	O
,	O
recent	O
studies	O
support	O
the	O
notion	O
that	O
one	O
of	O
the	O
major	O
adverse	O
complications	O
of	O
diabetes	O
is	O
the	O
development	O
of	O
a	O
diabetic	O
cardiomyopathy	O
characterized	O
by	O
defects	O
in	O
both	O
diastolic	O
and	O
systolic	O
function	O
.	O

Contributing	O
to	O
the	O
development	O
of	O
the	O
cardiomyopathy	O
is	O
a	O
shift	O
in	O
myosin	O
isozyme	O
content	O
in	O
favor	O
of	O
the	O
least	O
active	O
V3	O
form	O
.	O

Also	O
defective	O
in	O
the	O
noninsulin	S-Protein
-	O
dependent	O
diabetic	O
heart	O
is	O
regulation	O
of	O
calcium	O
homeostasis	O
.	O

While	O
transport	O
of	O
calcium	O
by	O
the	O
sarcolemmal	O
and	O
sarcoplasmic	O
reticular	O
calcium	O
pumps	O
are	O
minimally	O
affected	O
by	O
noninsulin	S-Protein
-	O
dependent	O
diabetes	O
,	O
significant	O
impairment	O
occurs	O
in	O
sarcolemmal	O
Na	O
(	O
+	O
)	O
-	O
Ca2	O
+	O
exchanger	O
activity	O
.	O

This	O
defect	O
limits	O
the	O
ability	O
of	O
of	O
the	O
diabetic	O
heart	O
to	O
extrude	O
calcium	O
,	O
contributing	O
to	O
an	O
elevation	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
.	O

Also	O
promoting	O
the	O
accumulation	O
of	O
calcium	O
by	O
the	O
diabetic	O
cell	O
is	O
a	O
decrease	O
in	O
Na	O
+	O
,	O
K	O
+	O
ATPase	O
activity	O
,	O
which	O
is	O
known	O
to	O
increase	O
[	O
Ca2	O
+	O
]	O
i	O
secondary	O
to	O
a	O
rise	O
in	O
[	O
Na	O
+	O
]	O
i	O
.	O

In	O
addition	O
,	O
calcium	O
influx	O
via	O
the	O
calcium	O
channel	O
is	O
stimulated	O
.	O

Although	O
the	O
molecular	O
mechanisms	O
underlying	O
these	O
defects	O
are	O
presently	O
unknown	O
,	O
the	O
possibility	O
that	O
they	O
may	O
be	O
related	O
to	O
aberrations	O
in	O
glucose	O
or	O
lipid	O
metabolism	O
are	O
considered	O
.	O

The	O
evidence	O
suggests	O
that	O
classical	O
theories	O
of	O
glucose	O
toxicity	O
,	O
such	O
as	O
excessive	O
polyol	O
production	O
or	O
glycosylation	O
,	O
appear	O
to	O
be	O
insignificant	O
factors	O
in	O
heart	O
.	O

Also	O
insignificant	O
are	O
defects	O
in	O
lipid	O
metabolism	O
leading	O
to	O
accumulation	O
of	O
toxic	O
lipid	O
amphiphiles	O
or	O
triacylglycerol	O
.	O

Rather	O
,	O
the	O
major	O
defects	O
involve	O
membrane	O
changes	O
,	O
such	O
as	O
phosphatidylethanolamine	O
N	O
-	O
methylation	O
and	O
protein	O
phosphorylation	O
,	O
which	O
can	O
be	O
attributed	O
to	O
the	O
state	O
of	O
insulin	S-Protein
resistance	O
.	O

Self	O
-	O
aggregation	O
of	O
fibrillar	O
collagens	O
I	O
and	O
II	S-Protein
involves	O
lysine	O
side	O
chains	O
.	O

Several	O
properties	O
of	O
fibrillar	O
collagens	O
depend	O
on	O
abundance	O
and	O
position	O
of	O
ionic	O
amino	O
acids	O
.	O

We	O
recently	O
demonstrated	O
that	O
N	O
-	O
methylation	O
and	O
N	O
-	O
acetylation	O
of	O
Lys	O
/	O
Hyl	O
amino	O
group	O
did	O
not	O
significantly	O
alter	O
the	O
thermal	O
stability	O
of	O
the	O
triple	O
helical	O
conformation	O
and	O
that	O
the	O
binding	O
of	O
modified	O
collagens	O
I	O
and	O
II	S-Protein
to	O
decorin	S-Protein
is	O
lost	O
only	O
on	O
N	O
-	O
acetylation	O
.	O

The	O
positive	O
charge	O
at	O
physiological	O
pH	O
of	O
Lys	O
/	O
Hyl	O
side	O
chains	O
is	O
preserved	O
only	O
by	O
N	O
-	O
methylation	O
.	O

We	O
report	O
here	O
the	O
new	O
aspect	O
of	O
the	O
influence	O
of	O
the	O
same	O
modifications	O
on	O
collagen	O
self	O
-	O
aggregation	O
in	O
neutral	O
conditions	O
.	O

Three	O
collagen	O
preparations	O
are	O
very	O
differently	O
affected	O
by	O
N	O
-	O
methylation	O
:	O
acid	O
-	O
soluble	O
type	O
I	O
collagen	O
maintains	O
the	O
ability	O
to	O
form	O
banded	O
fibrils	O
with	O
67	O
-	O
nm	O
periodicity	O
,	O
whereas	O
almost	O
no	O
structured	O
aggregates	O
were	O
detected	O
for	O
pepsin	O
-	O
soluble	O
type	O
I	O
collagen	O
;	O
pepsin	O
-	O
soluble	O
type	B-Protein
II	I-Protein
collagen	E-Protein
forms	O
a	O
very	O
different	O
supramolecular	O
species	O
,	O
known	O
as	O
segment	O
long	O
spacing	O
(	O
SLS	O
)	O
.	O

N	O
-	O
acetylation	O
blocks	O
the	O
formation	O
of	O
banded	O
fibrils	O
in	O
neutral	O
conditions	O
(	O
as	O
did	O
all	O
other	O
chemical	O
modifications	O
reported	O
in	O
the	O
literature	O
)	O
,	O
demonstrating	O
that	O
the	O
positive	O
charge	O
of	O
Lys	O
/	O
Hyl	O
amino	O
groups	O
is	O
essential	O
for	O
self	O
-	O
aggregation	O
.	O

Kinetic	O
measurements	O
by	O
turbidimetry	O
showed	O
a	O
sizeable	O
increase	O
of	O
absorbance	O
only	O
for	O
the	O
two	O
N	O
-	O
methylated	O
samples	O
forming	O
specific	O
supramolecular	O
aggregates	O
;	O
however	O
,	O
the	O
derivatization	O
affects	O
aggregation	O
kinetics	O
by	O
increasing	O
lag	O
time	O
and	O
decreasing	O
maximum	O
slope	O
of	O
absorbance	O
variation	O
,	O
and	O
lowers	O
aggregation	O
competency	O
.	O

We	O
discuss	O
that	O
the	O
effects	O
of	O
N	O
-	O
methylation	O
on	O
self	O
-	O
aggregation	O
are	O
caused	O
by	O
fewer	O
or	O
weaker	O
salt	O
bridges	O
and	O
by	O
decrease	O
of	O
hydrogen	O
bonding	O
potential	O
and	O
conclude	O
that	O
protonated	O
Lys	O
side	O
chains	O
are	O
involved	O
in	O
the	O
fibril	O
formation	O
process	O
.	O

A	O
PHD	O
finger	O
of	O
NURF	O
couples	O
histone	B-Protein
H3	E-Protein
lysine	O
4	O
trimethylation	O
with	O
chromatin	O
remodelling	O
.	O

Lysine	O
methylation	O
of	O
histones	S-Protein
is	O
recognized	O
as	O
an	O
important	O
component	O
of	O
an	O
epigenetic	O
indexing	O
system	O
demarcating	O
transcriptionally	O
active	O
and	O
inactive	O
chromatin	O
domains	O
.	O

Trimethylation	O
of	O
histone	B-Protein
H3	E-Protein
lysine	O
4	O
(	O
H3K4me3	S-Protein
)	O
marks	O
transcription	O
start	O
sites	O
of	O
virtually	O
all	O
active	O
genes	O
.	O

Recently	O
,	O
we	O
reported	O
that	O
the	O
WD40	O
-	O
repeat	O
protein	O
WDR5	S-Protein
is	O
important	O
for	O
global	O
levels	O
of	O
H3K4me3	S-Protein
and	O
control	O
of	O
HOX	O
gene	O
expression	O
.	O

Here	O
we	O
show	O
that	O
a	O
plant	O
homeodomain	O
(	O
PHD	O
)	O
finger	O
of	O
nucleosome	O
remodelling	O
factor	O
(	O
NURF	O
)	O
,	O
an	O
ISWI	O
-	O
containing	O
ATP	O
-	O
dependent	O
chromatin	O
-	O
remodelling	O
complex	O
,	O
mediates	O
a	O
direct	O
preferential	O
association	O
with	O
H3K4me3	S-Protein
tails	O
.	O

Depletion	O
of	O
H3K4me3	S-Protein
causes	O
partial	O
release	O
of	O
the	O
NURF	O
subunit	O
,	O
BPTF	S-Protein
(	O
bromodomain	B-Protein
and	I-Protein
PHD	I-Protein
finger	I-Protein
transcription	I-Protein
factor	E-Protein
)	O
,	O
from	O
chromatin	O
and	O
defective	O
recruitment	O
of	O
the	O
associated	O
ATPase	O
,	O
SNF2L	S-Protein
(	O
also	O
known	O
as	O
ISWI	S-Protein
and	O
SMARCA1	S-Protein
)	O
,	O
to	O
the	O
HOXC8	S-Protein
promoter	O
.	O

Loss	O
of	O
BPTF	S-Protein
in	O
Xenopus	O
embryos	O
mimics	O
WDR5	S-Protein
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
,	O
and	O
compromises	O
spatial	O
control	O
of	O
Hox	O
gene	O
expression	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
WDR5	S-Protein
and	O
NURF	O
function	O
in	O
a	O
common	O
biological	O
pathway	O
in	O
vivo	O
,	O
and	O
that	O
NURF	O
-	O
mediated	O
ATP	O
-	O
dependent	O
chromatin	O
remodelling	O
is	O
directly	O
coupled	O
to	O
H3K4	S-Protein
trimethylation	O
to	O
maintain	O
Hox	O
gene	O
expression	O
patterns	O
during	O
development	O
.	O

We	O
also	O
identify	O
a	O
previously	O
unknown	O
function	O
for	O
the	O
PHD	O
finger	O
as	O
a	O
highly	O
specialized	O
methyl	O
-	O
lysine	O
-	O
binding	O
domain	O
.	O

The	O
colR4	O
and	O
colR15	O
beta	O
-	O
tubulin	O
mutations	O
in	O
Chlamydomonas	O
reinhardtii	O
confer	O
altered	O
sensitivities	O
to	O
microtubule	O
inhibitors	O
and	O
herbicides	O
by	O
enhancing	O
microtubule	O
stability	O
.	O

The	O
colR4	O
and	O
colR15	O
beta	O
2	O
-	O
tubulin	O
missense	O
mutations	O
for	O
lysine	O
-	O
350	O
in	O
Chlamydomonas	O
reinhardtii	O
(	O
Lee	O
and	O
Huang	O
,	O
1990	O
)	O
were	O
originally	O
isolated	O
by	O
selection	O
for	O
resistance	O
to	O
the	O
growth	O
inhibitory	O
effects	O
of	O
colchicine	O
.	O

The	O
colR4	O
and	O
colR15	O
mutants	O
have	O
been	O
found	O
to	O
be	O
cross	O
resistant	O
to	O
vinblastine	O
and	O
several	O
classes	O
of	O
antimitotic	O
herbicides	O
,	O
including	O
the	O
dinitroanilines	O
(	O
oryzalin	O
,	O
trifluralin	O
,	O
profluralin	O
,	O
and	O
ethafluralin	O
)	O
;	O
the	O
phosphoric	O
amide	O
amiprophos	O
methyl	O
;	O
and	O
the	O
dimethyl	O
propynl	O
benzamide	O
pronamide	O
.	O

Like	O
colchicine	O
and	O
vinblastine	O
,	O
the	O
antimitotic	O
effects	O
of	O
these	O
plant	O
-	O
specific	O
herbicides	O
have	O
been	O
associated	O
with	O
the	O
depolymerization	O
of	O
microtubules	O
.	O

In	O
contrast	O
to	O
their	O
resistance	O
to	O
microtubule	O
-	O
depolymerizing	O
drugs	O
,	O
the	O
mutants	O
have	O
an	O
increased	O
sensitivity	O
to	O
taxol	O
,	O
a	O
drug	O
which	O
enhances	O
the	O
polymerization	O
and	O
stability	O
of	O
microtubules	O
.	O

This	O
pattern	O
of	O
altered	O
sensitivity	O
to	O
different	O
microtubule	O
inhibitors	O
was	O
found	O
to	O
cosegregate	O
and	O
corevert	O
with	O
the	O
beta	B-Protein
-	I-Protein
tubulin	E-Protein
mutations	O
providing	O
the	O
first	O
genetic	O
evidence	O
that	O
the	O
in	O
vivo	O
herbicidal	O
effects	O
of	O
the	O
dinitroanilines	O
,	O
amiprophos	O
methyl	O
,	O
and	O
pronamide	O
are	O
related	O
to	O
microtubule	O
function	O
.	O

Although	O
wild	O
-	O
type	O
like	O
in	O
their	O
growth	O
characteristics	O
,	O
the	O
colR4	O
and	O
colR15	O
mutants	O
were	O
found	O
to	O
have	O
an	O
altered	O
pattern	O
of	O
microtubules	O
containing	O
acetylated	O
alpha	O
-	O
tubulin	O
,	O
a	O
posttranslational	O
modification	O
that	O
has	O
been	O
associated	O
with	O
stable	O
subsets	O
of	O
microtubules	O
found	O
in	O
a	O
variety	O
of	O
cells	O
.	O

Microtubules	O
in	O
the	O
interphase	O
cytoplasm	O
and	O
those	O
of	O
the	O
intranuclear	O
spindle	O
of	O
mitotic	O
cells	O
,	O
which	O
in	O
wild	O
-	O
type	O
Chlamydomonas	O
cells	O
do	O
not	O
contain	O
acetylated	O
alpha	O
-	O
tubulin	O
,	O
were	O
found	O
to	O
be	O
acetylated	O
in	O
the	O
mutants	O
.	O

These	O
data	O
taken	O
together	O
suggest	O
that	O
the	O
colR4	O
and	O
colR15	O
missense	O
mutations	O
increase	O
the	O
stability	O
of	O
the	O
microtubules	O
into	O
which	O
the	O
mutant	O
beta	B-Protein
-	I-Protein
tubulins	E-Protein
are	O
incorporated	O
and	O
that	O
the	O
altered	O
drug	O
sensitivities	O
of	O
the	O
mutants	O
are	O
a	O
consequence	O
of	O
this	O
enhanced	O
microtubule	O
stability	O
.	O

Trimethylation	O
of	O
histone	B-Protein
H3	E-Protein
lysine	O
4	O
by	O
Set1	S-Protein
in	O
the	O
lytic	O
infection	O
of	O
human	O
herpes	O
simplex	O
virus	O
1	O
.	O

Human	O
herpes	O
simplex	O
virus	O
1	O
(	O
HSV	O
-	O
1	O
)	O
is	O
a	O
double	O
-	O
stranded	O
DNA	O
virus	O
that	O
causes	O
facial	O
,	O
ocular	O
,	O
and	O
encephalitic	O
disease	O
in	O
humans	O
.	O

Previous	O
work	O
showed	O
that	O
the	O
genome	O
of	O
HSV	O
-	O
1	O
is	O
associated	O
with	O
acetylated	O
and	O
methylated	O
histones	S-Protein
during	O
lytic	O
infection	O
.	O

However	O
,	O
the	O
physiological	O
role	O
of	O
histone	S-Protein
modifications	O
in	O
lytic	O
infection	O
of	O
HSV	O
-	O
1	O
is	O
unclear	O
.	O

We	O
examined	O
the	O
role	O
of	O
protein	O
methylation	O
in	O
lytic	O
infection	O
of	O
HSV	O
-	O
1	O
using	O
a	O
protein	O
methylation	O
inhibitor	O
,	O
5	O
'	O
-	O
deoxy	O
-	O
5	O
'	O
-	O
methylthioadenosine	O
(	O
MTA	O
)	O
.	O

We	O
found	O
that	O
MTA	O
strongly	O
reduces	O
the	O
transcription	O
and	O
replication	O
of	O
HSV	O
-	O
1	O
.	O

Moreover	O
,	O
MTA	O
treatment	O
decreases	O
the	O
level	O
of	O
trimethylation	O
of	O
lysine	O
4	O
in	O
histone	B-Protein
H3	E-Protein
(	O
H3K4me3	S-Protein
)	O
on	O
the	O
HSV	O
-	O
1	O
genome	O
.	O

These	O
results	O
suggest	O
that	O
protein	O
methylation	O
,	O
and	O
in	O
particular	O
,	O
histone	S-Protein
methylation	O
,	O
is	O
involved	O
in	O
the	O
lytic	O
infection	O
of	O
HSV	O
-	O
1	O
.	O

To	O
delineate	O
the	O
underlying	O
mechanism	O
,	O
we	O
investigated	O
the	O
role	O
of	O
two	O
H3K4	S-Protein
methyltransferases	O
,	O
Set1	S-Protein
and	O
Set7	B-Protein
/	I-Protein
9	E-Protein
,	O
in	O
the	O
lytic	O
infection	O
of	O
HSV	O
-	O
1	O
.	O

Using	O
small	O
interference	O
RNA	O
,	O
we	O
found	O
that	O
the	O
reduction	O
of	O
Set1	S-Protein
,	O
but	O
not	O
Set7	B-Protein
/	I-Protein
9	E-Protein
,	O
reduces	O
the	O
transcription	O
and	O
replication	O
of	O
HSV	O
-	O
1	O
and	O
specifically	O
decreases	O
H3K4me3	S-Protein
on	O
the	O
virus	O
genome	O
.	O

These	O
results	O
indicate	O
that	O
H3K4me3	S-Protein
mediated	O
by	O
Set1	S-Protein
is	O
required	O
for	O
optimal	O
gene	O
expression	O
and	O
replication	O
of	O
HSV	O
-	O
1	O
during	O
lytic	O
infection	O
and	O
suggest	O
that	O
this	O
pathway	O
could	O
be	O
a	O
potential	O
point	O
of	O
pharmacological	O
intervention	O
during	O
HSV	O
-	O
1	O
infection	O
.	O

Peroxynitrite	O
as	O
an	O
alternative	O
donor	O
of	O
oxygen	O
in	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
proline	O
hydroxylation	O
under	O
low	O
oxygen	O
availability	O
.	O

In	O
the	O
last	O
years	O
,	O
nitric	O
oxide	O
(	O
NO	O
)	O
mediated	O
signaling	O
became	O
an	O
integral	O
component	O
in	O
understanding	O
physiological	O
and	O
pathophysiological	O
processes	O
of	O
cell	O
proliferation	O
,	O
death	O
or	O
cellular	O
adaptation	O
.	O

Among	O
other	O
activities	O
,	O
NO	O
affects	O
multiple	O
targets	O
that	O
allow	O
regulation	O
of	O
gene	O
expression	O
.	O

Recently	O
,	O
NO	O
was	O
found	O
to	O
attenuate	O
accumulation	O
of	O
hypoxia	B-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1alpha	E-Protein
(	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
)	O
under	O
hypoxic	O
conditions	O
because	O
of	O
several	O
mechanisms	O
:	O
redistribution	O
of	O
oxygen	O
toward	O
non	O
-	O
respiratory	O
oxygen	O
-	O
dependent	O
targets	O
(	O
like	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
proline	O
hydroxylases	O
-	O
-	O
PHDs	O
,	O
which	O
perform	O
hydroxylation	O
of	O
Pro402	O
/	O
564	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
leading	O
to	O
its	O
proteasomal	O
degradation	O
)	O
;	O
in	O
addition	O
,	O
peroxynitrite	O
formed	O
during	O
interactions	O
between	O
NO	O
and	O
mitochondria	O
derived	O
superoxide	O
leads	O
to	O
an	O
increase	O
in	O
cytosolic	O
iron	O
/	O
2	O
-	O
oxoglutarate	O
(	O
2	O
-	O
OG	O
)	O
,	O
which	O
required	O
for	O
PHD	O
activation	O
.	O

Here	O
,	O
we	O
propose	O
a	O
hypothesis	O
that	O
peroxynitrite	O
,	O
formed	O
in	O
the	O
cells	O
upon	O
exposure	O
to	O
NO	O
under	O
low	O
oxygen	O
availability	O
,	O
serves	O
as	O
an	O
alternative	O
donor	O
of	O
oxygen	O
for	O
activated	O
PHDs	O
so	O
they	O
can	O
perform	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
proline	O
hydroxylation	O
to	O
de	O
-	O
accumulate	O
the	O
protein	O
.	O

Isolation	O
and	O
characterization	O
of	O
low	O
sulfated	O
heparan	O
sulfate	O
sequences	O
with	O
affinity	O
for	O
lipoprotein	B-Protein
lipase	E-Protein
.	O

Lipoprotein	B-Protein
lipase	E-Protein
(	O
LPL	S-Protein
)	O
,	O
which	O
is	O
an	O
important	O
enzyme	O
in	O
lipid	O
metabolism	O
,	O
binds	O
to	O
heparan	O
sulfate	O
(	O
HS	O
)	O
proteoglycans	O
.	O

This	O
interaction	O
is	O
crucial	O
for	O
several	O
aspects	O
of	O
LPL	S-Protein
function	O
,	O
such	O
as	O
intracellular	O
/	O
extracellular	O
transport	O
and	O
high	O
capacity	O
attachment	O
to	O
cell	O
surfaces	O
.	O

Retention	O
of	O
LPL	S-Protein
on	O
the	O
capillary	O
walls	O
,	O
and	O
elsewhere	O
,	O
via	O
HS	O
chains	O
is	O
most	O
likely	O
affected	O
by	O
the	O
quality	O
and	O
quantity	O
of	O
HS	O
present	O
.	O

Earlier	O
studies	O
have	O
demonstrated	O
that	O
LPL	S-Protein
interacts	O
with	O
highly	O
sulfated	O
HS	O
and	O
heparin	O
oligosaccharides	O
.	O

Since	O
such	O
structures	O
are	O
relatively	O
rare	O
in	O
endothelial	O
HS	O
,	O
we	O
have	O
re	O
-	O
addressed	O
the	O
question	O
of	O
physiological	O
ligand	O
structures	O
for	O
LPL	S-Protein
by	O
affinity	O
purification	O
of	O
end	O
-	O
labeled	O
oligosaccharides	O
originating	O
from	O
heparin	O
and	O
HS	O
on	O
immobilized	O
LPL	S-Protein
.	O

By	O
a	O
combination	O
of	O
chemical	O
modification	O
and	O
fragmentation	O
of	O
the	O
bound	O
material	O
we	O
identified	O
that	O
the	O
bound	O
fraction	O
contained	O
modestly	O
sulfated	O
oligosaccharides	O
with	O
an	O
average	O
sulfation	O
of	O
one	O
O	O
-	O
sulfate	O
per	O
disaccharide	O
unit	O
and	O
tolerates	O
N	O
-	O
acetylated	O
glucosamine	O
residues	O
.	O

Therefore	O
LPL	S-Protein
,	O
containing	O
several	O
clusters	O
of	O
positive	O
charges	O
on	O
each	O
subunit	O
,	O
may	O
constitute	O
an	O
ideal	O
structure	O
for	O
a	O
protein	O
that	O
needs	O
to	O
bind	O
with	O
reasonable	O
affinity	O
to	O
a	O
variety	O
of	O
modestly	O
sulfated	O
sequences	O
of	O
the	O
type	O
that	O
is	O
abundant	O
in	O
HS	O
chains	O
.	O

Structural	O
characterization	O
of	O
Set1	S-Protein
RNA	O
recognition	O
motifs	O
and	O
their	O
role	O
in	O
histone	B-Protein
H3	E-Protein
lysine	O
4	O
methylation	O
.	O

The	O
yeast	O
Set1	S-Protein
histone	B-Protein
H3	E-Protein
lysine	O
4	O
(	O
H3K4	O
)	O
methyltransferase	O
contains	O
,	O
in	O
addition	O
to	O
its	O
catalytic	O
SET	O
domain	O
,	O
a	O
conserved	O
RNA	O
recognition	O
motif	O
(	O
RRM1	O
)	O
.	O

We	O
present	O
here	O
the	O
crystal	O
structure	O
and	O
the	O
secondary	O
structure	O
assignment	O
in	O
solution	O
of	O
the	O
Set1	S-Protein
RRM1	O
.	O

Although	O
RRM1	O
has	O
the	O
expected	O
betaalphabetabetaalphabeta	O
RRM	O
-	O
fold	O
,	O
it	O
lacks	O
the	O
typical	O
RNA	O
-	O
binding	O
features	O
of	O
these	O
modules	O
.	O

RRM1	O
is	O
not	O
able	O
to	O
bind	O
RNA	O
by	O
itself	O
in	O
vitro	O
,	O
but	O
a	O
construct	O
combining	O
RRM1	O
with	O
a	O
newly	O
identified	O
downstream	O
RRM2	O
specifically	O
binds	O
RNA	O
.	O

In	O
vivo	O
,	O
H3K4	S-Protein
methylation	O
is	O
not	O
affected	O
by	O
a	O
point	O
mutation	O
in	O
RRM2	O
that	O
preserves	O
Set1	S-Protein
stability	O
but	O
affects	O
RNA	O
binding	O
in	O
vitro	O
.	O

In	O
contrast	O
mutating	O
RRM1	O
destabilizes	O
Set1	S-Protein
and	O
leads	O
to	O
an	O
increase	O
of	O
dimethylation	O
of	O
H3K4	S-Protein
at	O
the	O
5	O
'	O
-	O
coding	O
region	O
of	O
active	O
genes	O
at	O
the	O
expense	O
of	O
trimethylation	O
,	O
whereas	O
both	O
,	O
dimethylation	O
decreases	O
at	O
the	O
3	O
'	O
-	O
coding	O
region	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
Set1	S-Protein
RRMs	O
bind	O
RNA	O
,	O
but	O
Set1	S-Protein
RNA	O
-	O
binding	O
activity	O
is	O
not	O
linked	O
to	O
H3K4	S-Protein
methylation	O
.	O

Enhancement	O
of	O
CD8	O
T	O
-	O
cell	O
function	O
through	O
modifying	O
surface	O
glycoproteins	O
in	O
young	O
and	O
old	O
mice	O
.	O

Previous	O
work	O
from	O
our	O
laboratory	O
has	O
shown	O
that	O
modifying	O
cell	O
surface	O
glycosylation	O
with	O
either	O
a	O
Clostridium	O
perfringens	O
-	O
derived	O
sialidase	O
(	O
CP	O
-	O
Siase	O
)	O
,	O
or	O
an	O
O	O
-	O
linked	O
glycoprotein	O
endopeptidase	O
(	O
OSGE	O
)	O
can	O
enhance	O
the	O
function	O
of	O
CD4	S-Protein
T	O
cells	O
from	O
both	O
young	O
and	O
old	O
mice	O
at	O
multiple	O
levels	O
.	O

Here	O
we	O
have	O
re	O
-	O
assessed	O
the	O
effect	O
of	O
age	O
on	O
CD8	O
T	O
-	O
cell	O
function	O
,	O
and	O
examined	O
the	O
outcome	O
of	O
enzymatic	O
treatment	O
with	O
CP	O
-	O
Siase	O
and	O
OSGE	O
on	O
its	O
different	O
aspects	O
.	O

Pre	O
-	O
treatment	O
of	O
CD8	O
T	O
cells	O
with	O
either	O
CP	O
-	O
Siase	O
or	O
OSGE	O
led	O
to	O
a	O
significant	O
increase	O
in	O
anti	O
-	O
CD3	O
-	O
mediated	O
Ca2	O
+	O
response	O
in	O
both	O
young	O
and	O
old	O
mice	O
.	O

Pre	O
-	O
treated	O
CD8	O
T	O
cells	O
from	O
both	O
age	O
groups	O
also	O
displayed	O
a	O
significant	O
increase	O
in	O
activation	O
-	O
induced	O
CD69	S-Protein
and	O
CD25	S-Protein
expression	O
,	O
and	O
produced	O
significantly	O
higher	O
amounts	O
of	O
interleukin	B-Protein
-	I-Protein
2	E-Protein
and	O
interferon	B-Protein
-	I-Protein
gamma	E-Protein
in	O
comparison	O
to	O
their	O
untreated	O
counterparts	O
.	O

Furthermore	O
,	O
pretreatment	O
with	O
either	O
enzyme	O
enhanced	O
granzyme	B-Protein
B	E-Protein
expression	O
in	O
CD8	O
T	O
cells	O
,	O
and	O
increased	O
their	O
cytolytic	O
activity	O
in	O
vitro	O
.	O

These	O
data	O
support	O
the	O
notion	O
that	O
glycosylated	O
surface	O
proteins	O
hinder	O
CD8	O
T	O
-	O
cell	O
activation	O
and	O
function	O
in	O
both	O
young	O
and	O
old	O
mice	O
,	O
and	O
raise	O
the	O
possibility	O
of	O
significantly	O
improving	O
CD8	O
T	O
cell	O
function	O
in	O
older	O
individuals	O
through	O
enzymatic	O
alteration	O
of	O
surface	O
glycoproteins	O
.	O

Inhibition	O
of	O
histone	S-Protein
deacetylation	O
protects	O
wild	O
-	O
type	O
but	O
not	O
gelsolin	S-Protein
-	O
deficient	O
neurons	O
from	O
oxygen	O
/	O
glucose	O
deprivation	O
.	O

Histone	S-Protein
acetylation	O
and	O
deacetylation	O
participate	O
in	O
the	O
epigenetic	O
regulation	O
of	O
gene	O
expression	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
pre	O
-	O
treatment	O
with	O
the	O
histone	S-Protein
deacetylation	O
inhibitor	O
trichostatin	O
A	O
(	O
TSA	O
)	O
enhances	O
histone	S-Protein
acetylation	O
in	O
primary	O
cortical	O
neurons	O
and	O
protects	O
against	O
oxygen	O
/	O
glucose	O
deprivation	O
,	O
a	O
model	O
for	O
ischaemic	O
cell	O
death	O
in	O
vitro	O
.	O

The	O
actin	O
-	O
binding	O
protein	O
gelsolin	S-Protein
was	O
identified	O
as	O
a	O
mediator	O
of	O
neuroprotection	O
by	O
TSA	O
.	O

TSA	O
enhanced	O
histone	S-Protein
acetylation	O
of	O
the	O
gelsolin	S-Protein
promoter	O
region	O
,	O
and	O
up	O
-	O
regulated	O
gelsolin	S-Protein
messenger	O
RNA	O
and	O
protein	O
expression	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Double	O
-	O
label	O
confocal	O
immunocytochemistry	O
visualized	O
the	O
up	O
-	O
regulation	O
of	O
gelsolin	S-Protein
and	O
histone	S-Protein
acetylation	O
within	O
the	O
same	O
neuron	O
.	O

Together	O
with	O
gelsolin	S-Protein
up	O
-	O
regulation	O
,	O
TSA	O
pre	O
-	O
treatment	O
decreased	O
levels	O
of	O
filamentous	O
actin	O
.	O

The	O
neuroprotective	O
effect	O
of	O
TSA	O
was	O
completely	O
abolished	O
in	O
neurons	O
lacking	O
gelsolin	S-Protein
gene	O
expression	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
the	O
enhancement	O
of	O
gelsolin	S-Protein
gene	O
expression	O
correlates	O
with	O
neuroprotection	O
induced	O
by	O
the	O
inhibition	O
of	O
histone	S-Protein
deacetylation	O
.	O

Genetic	O
or	O
epigenetic	O
silencing	O
of	O
low	B-Protein
density	I-Protein
lipoprotein	I-Protein
receptor	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
1B	E-Protein
expression	O
in	O
oral	O
squamous	O
cell	O
carcinoma	O
.	O

Previously	O
,	O
we	O
have	O
reported	O
frequent	O
silencing	O
of	O
the	O
expression	O
of	O
LRP1B	S-Protein
by	O
genetic	O
and	O
epigenetic	O
mechanisms	O
in	O
esophageal	O
squamous	O
cell	O
carcinoma	O
.	O

As	O
the	O
same	O
events	O
might	O
be	O
involved	O
in	O
the	O
development	O
/	O
progression	O
of	O
OSCC	O
,	O
we	O
examined	O
intragenic	O
homozygous	O
deletions	O
,	O
expression	O
levels	O
,	O
and	O
methylation	O
status	O
in	O
the	O
CpG	O
island	O
of	O
this	O
gene	O
.	O

Homozygous	O
deletion	O
was	O
detected	O
in	O
only	O
1	O
of	O
18	O
(	O
5	O
.	O
6	O
%	O
)	O
OSCC	O
lines	O
,	O
whereas	O
the	O
expression	O
of	O
LRP1B	S-Protein
mRNA	O
was	O
silenced	O
in	O
8	O
of	O
17	O
(	O
47	O
.	O
1	O
%	O
)	O
OSCC	O
lines	O
without	O
homozygous	O
deletion	O
.	O

An	O
inverse	O
correlation	O
between	O
mRNA	O
expression	O
and	O
methylation	O
status	O
of	O
the	O
LRP1B	S-Protein
CpG	O
island	O
was	O
clearly	O
observed	O
in	O
OSCC	O
lines	O
,	O
and	O
LRP1B	S-Protein
mRNA	O
expression	O
was	O
restored	O
by	O
treatment	O
with	O
5	O
-	O
aza	O
-	O
dCyd	O
.	O

Frequent	O
methylation	O
of	O
the	O
LRP1B	S-Protein
promoter	O
was	O
also	O
observed	O
in	O
primary	O
OSCC	O
.	O

Taken	O
together	O
,	O
the	O
results	O
suggested	O
that	O
frequent	O
inactivation	O
of	O
LRP1B	S-Protein
mainly	O
occurs	O
by	O
means	O
of	O
epigenetic	O
mechanisms	O
in	O
OSCC	O
,	O
which	O
might	O
play	O
an	O
important	O
role	O
in	O
oral	O
tumorigenesis	O
.	O

Pronuclear	O
stage	O
porcine	O
embryos	O
do	O
not	O
possess	O
a	O
strict	O
asymmetric	O
distribution	O
of	O
lysine	O
9	O
dimethylation	O
of	O
histone	B-Protein
H3	E-Protein
based	O
solely	O
on	O
parental	O
origin	O
.	O

Epigenetic	O
modification	O
of	O
core	O
histone	S-Protein
proteins	O
plays	O
an	O
important	O
role	O
in	O
gene	O
transcription	O
and	O
chromatin	O
structure	O
.	O

It	O
is	O
known	O
that	O
the	O
methylation	O
status	O
of	O
the	O
lysine	O
9	O
residue	O
of	O
histone	B-Protein
H3	E-Protein
(	O
H3K9	S-Protein
)	O
is	O
closely	O
linked	O
with	O
repression	O
of	O
transcription	O
and	O
heterochromatin	O
formation	O
.	O

It	O
has	O
been	O
reported	O
that	O
a	O
strict	O
asymmetric	O
distribution	O
of	O
the	O
dimethylated	O
form	O
of	O
H3K9	S-Protein
exists	O
between	O
the	O
two	O
parental	O
genomes	O
in	O
murine	O
embryos	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
H3K9	S-Protein
dimethylation	O
pattern	O
in	O
cleavage	O
stage	O
porcine	O
embryos	O
.	O

Indirect	O
immunocytochemical	O
analysis	O
showed	O
that	O
this	O
modification	O
is	O
present	O
throughout	O
the	O
nuclei	O
of	O
pronuclear	O
,	O
2	O
-	O
cell	O
,	O
4	O
-	O
cell	O
and	O
blastocyst	O
stage	O
porcine	O
embryos	O
.	O

However	O
,	O
at	O
the	O
pronuclear	O
stage	O
the	O
pronuclei	O
within	O
in	O
vitro	O
-	O
fertilized	O
porcine	O
embryos	O
possessed	O
an	O
asymmetric	O
distribution	O
of	O
the	O
dimethylated	O
form	O
of	O
H3K9	S-Protein
;	O
this	O
distribution	O
was	O
not	O
based	O
solely	O
on	O
the	O
parent	O
-	O
of	O
-	O
origin	O
.	O

These	O
results	O
show	O
that	O
dimethylation	O
of	O
H3K9	S-Protein
is	O
differentially	O
regulated	O
in	O
pronuclear	O
stage	O
porcine	O
embryos	O
.	O

RIZ1	S-Protein
repression	O
is	O
associated	O
with	O
insulin	B-Protein
-	I-Protein
like	I-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
1	E-Protein
signaling	O
activation	O
in	O
chronic	O
myeloid	O
leukemia	O
cell	O
lines	O
.	O

RIZ1	S-Protein
is	O
a	O
histone	S-Protein
methyltransferase	O
whose	O
expression	O
and	O
activity	O
are	O
reduced	O
in	O
many	O
cancers	O
.	O

In	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
,	O
blastic	O
transformation	O
is	O
associated	O
with	O
loss	O
of	O
heterozygosity	O
in	O
the	O
region	O
where	O
RIZ1	S-Protein
is	O
located	O
and	O
with	O
decreased	O
RIZ1	S-Protein
expression	O
.	O

Forced	O
RIZ1	S-Protein
expression	O
in	O
model	O
CML	O
blast	O
crisis	O
(	O
BC	O
)	O
cell	O
lines	O
decreases	O
proliferation	O
,	O
increases	O
apoptosis	O
and	O
enhances	O
differentiation	O
.	O

We	O
characterized	O
molecular	O
mechanisms	O
that	O
may	O
contribute	O
to	O
potential	O
CML	O
tumor	O
suppressor	O
properties	O
of	O
RIZ1	S-Protein
.	O

Several	O
RIZ1	S-Protein
-	O
regulated	O
genes	O
involved	O
in	O
insulin	B-Protein
-	I-Protein
like	I-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
1	E-Protein
(	O
IGF	B-Protein
-	I-Protein
1	E-Protein
)	O
signaling	O
were	O
identified	O
using	O
cDNA	O
microarrays	O
.	O

RIZ1	S-Protein
was	O
shown	O
to	O
associate	O
with	O
promoter	O
regions	O
of	O
IGF	B-Protein
-	I-Protein
1	E-Protein
and	O
to	O
increase	O
histone	B-Protein
H3	E-Protein
lysine	O
9	O
methylation	O
using	O
chromatin	O
immunoprecipitation	O
assays	O
.	O

IGF	B-Protein
-	I-Protein
1	E-Protein
-	O
blocking	O
antibody	O
was	O
used	O
to	O
demonstrate	O
the	O
importance	O
of	O
autocrine	O
IGF	B-Protein
-	I-Protein
1	E-Protein
signaling	O
in	O
CML	O
-	O
BC	O
cell	O
line	O
viability	O
.	O

Forced	O
RIZ1	S-Protein
expression	O
in	O
CML	O
-	O
BC	O
cell	O
lines	O
decreases	O
IGF	B-Protein
-	I-Protein
1	I-Protein
receptor	E-Protein
activation	O
and	O
activation	O
of	O
downstream	O
signaling	O
components	O
extracellular	B-Protein
signal	I-Protein
-	I-Protein
regulated	I-Protein
kinase	I-Protein
1	E-Protein
/	O
2	S-Protein
and	O
AKT	O
.	O

These	O
results	O
highlight	O
the	O
therapeutic	O
potential	O
of	O
inhibiting	O
IGF	B-Protein
-	I-Protein
1	E-Protein
pathway	O
in	O
the	O
acute	O
phase	O
of	O
CML	O
.	O

[	O
Comparative	O
analysis	O
of	O
N	O
-	O
acetylation	O
polymorphism	O
in	O
humans	O
as	O
determined	O
by	O
phenotyping	O
and	O
genotyping	O
]	O

The	O
N	O
-	O
acetylation	O
polymorphisms	O
of	O
volunteers	O
from	O
the	O
Moscow	O
population	O
analyzed	O
by	O
phenotyping	O
and	O
genotyping	O
have	O
been	O
compared	O
.	O

The	O
ratios	O
between	O
the	O
proportions	O
of	O
fast	O
acetylators	O
(	O
FAs	O
)	O
and	O
slow	O
acetylators	O
(	O
SAs	O
)	O
estimated	O
by	O
phenotyping	O
and	O
genotyping	O
do	O
not	O
differ	O
significantly	O
from	O
each	O
other	O
(	O
47	O
and	O
44	O
%	O
,	O
respectively	O
)	O
.	O

The	O
absolute	O
acetylation	O
rate	O
widely	O
varies	O
in	O
both	O
FAs	O
and	O
SAs	O
.	O

The	O
NAT2	S-Protein
genotype	O
and	O
allele	O
frequencies	O
in	O
the	O
population	O
sample	O
have	O
been	O
calculated	O
.	O

The	O
most	O
frequent	O
alleles	O
are	O
NAT2	S-Protein
*	O
4	O
(	O
a	O
"	O
fast	O
"	O
allele	O
)	O
,	O
NAT2	S-Protein
*	O
5	O
,	O
and	O
NAT2	S-Protein
*	O
6	O
(	O
"	O
slow	O
"	O
alleles	O
)	O
;	O
the	O
most	O
frequent	O
genotypes	O
are	O
NAT2	S-Protein
*	O
5	O
/	O
*	O
5	O
,	O
NAT2	S-Protein
*	O
4	O
/	O
*	O
6	O
,	O
and	O
NAT2	S-Protein
*	O
4	O
/	O
*	O
5	O
.	O

Comparative	O
analysis	O
of	O
N	O
-	O
acetylation	O
polymorphism	O
estimated	O
by	O
phenotyping	O
and	O
genotyping	O
in	O
the	O
same	O
subjects	O
has	O
shown	O
a	O
complete	O
concordance	O
between	O
the	O
phenotype	O
and	O
genotype	O
in	O
only	O
62	O
out	O
of	O
75	O
subjects	O
(	O
87	O
%	O
)	O
.	O

Comparative	O
characteristics	O
and	O
presumed	O
applications	O
of	O
the	O
two	O
approaches	O
(	O
quantitative	O
estimation	O
of	O
acetylation	O
rate	O
and	O
qualitative	O
determination	O
of	O
the	O
acetylator	O
genotype	O
)	O
to	O
the	O
identification	O
of	O
individual	O
acetylation	O
status	O
are	O
presented	O
.	O

[	O
Expression	O
of	O
DNA	O
methyltransferases	O
in	O
salivary	O
adenoid	O
cystic	O
carcinoma	O
and	O
its	O
association	O
with	O
the	O
CpG	O
islands	O
methylation	O
of	O
tumor	O
suppressor	O
genes	O
]	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
role	O
of	O
DNA	O
methyltransferases	O
(	O
DNMT	O
)	O
in	O
carcinogenesis	O
and	O
development	O
of	O
salivary	O
adenoid	O
cystic	O
carcinoma	O
(	O
ACC	O
)	O
by	O
detection	O
the	O
expression	O
of	O
DNMT	O
in	O
ACC	O
and	O
to	O
assess	O
its	O
correlation	O
to	O
methylation	O
of	O
tumor	O
suppressor	O
genes	O
and	O
biological	O
behavior	O
of	O
ACC	O
.	O

METHODS	O
:	O
The	O
protein	O
expression	O
of	O
DNMT1	S-Protein
and	O
DNMT3b	S-Protein
were	O
examined	O
by	O
immunohistochemistry	O
in	O
paraffin	O
-	O
embedded	O
tissues	O
of	O
ACC	O
from	O
60	O
patients	O
.	O

The	O
association	O
between	O
the	O
positive	O
staining	O
of	O
DNMT1	S-Protein
and	O
DNMT3b	S-Protein
microscopically	O
and	O
the	O
CpG	O
islands	O
methylation	O
status	O
of	O
some	O
tumor	O
suppressor	O
genes	O
,	O
tumor	O
grade	O
and	O
stage	O
was	O
analysed	O
by	O
Fisher	O
exact	O
test	O
.	O

RESULTS	O
:	O
The	O
number	O
of	O
DNMT1	S-Protein
positive	O
cells	O
was	O
much	O
more	O
than	O
that	O
of	O
DNMT3b	S-Protein
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
positive	O
expression	O
of	O
DNMT1	S-Protein
was	O
increased	O
concomitantly	O
to	O
the	O
amounts	O
of	O
methylation	O
of	O
tumor	O
suppressor	O
genes	O
occurred	O
in	O
ACC	O
and	O
was	O
significantly	O
correlated	O
to	O
the	O
methylation	O
status	O
of	O
RASSF1A	S-Protein
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
difference	O
was	O
found	O
between	O
the	O
more	O
and	O
less	O
methylation	O
of	O
tumor	O
suppressor	O
genes	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
The	O
increased	O
positive	O
expression	O
of	O
DNMT1	S-Protein
correlated	O
to	O
the	O
tumor	O
grade	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
stage	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

It	O
was	O
much	O
more	O
expressed	O
in	O
the	O
lower	O
grade	O
or	O
more	O
advanced	O
stage	O
cases	O
.	O

The	O
correlation	O
between	O
the	O
expression	O
of	O
DNMT3b	S-Protein
and	O
the	O
methylation	O
of	O
tumor	O
suppressor	O
genes	O
,	O
tumor	O
grade	O
and	O
stage	O
was	O
not	O
found	O
.	O

CONCLUSIONS	O
:	O
DNMT1	S-Protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
maintenance	O
of	O
methylation	O
of	O
tumor	O
suppressor	O
genes	O
in	O
ACC	O
and	O
was	O
related	O
correlated	O
to	O
the	O
methylation	O
of	O
RASSF1A	S-Protein
,	O
tumor	O
grade	O
and	O
stage	O
,	O
which	O
implied	O
that	O
DNMT1	S-Protein
may	O
contribute	O
to	O
the	O
carcinogenesis	O
and	O
development	O
of	O
ACC	O
and	O
was	O
likely	O
to	O
be	O
a	O
molecular	O
marker	O
for	O
evaluating	O
the	O
prognosis	O
of	O
patients	O
with	O
ACC	O
.	O

Multiple	O
factors	O
affecting	O
cellular	O
redox	O
status	O
and	O
energy	O
metabolism	O
modulate	O
hypoxia	O
-	O
inducible	O
factor	O
prolyl	O
hydroxylase	O
activity	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Prolyl	O
hydroxylation	O
of	O
hypoxible	O
-	O
inducible	O
factor	O
alpha	O
(	O
HIF	O
-	O
alpha	O
)	O
proteins	O
is	O
essential	O
for	O
their	O
recognition	O
by	O
pVHL	S-Protein
containing	O
ubiquitin	S-Protein
ligase	O
complexes	O
and	O
subsequent	O
degradation	O
in	O
oxygen	O
(	O
O	O
(	O
2	O
)	O
)	O
-	O
replete	O
cells	O
.	O

Therefore	O
,	O
HIF	O
prolyl	O
hydroxylase	O
(	O
PHD	O
)	O
enzymatic	O
activity	O
is	O
critical	O
for	O
the	O
regulation	O
of	O
cellular	O
responses	O
to	O
O	O
(	O
2	O
)	O
deprivation	O
(	O
hypoxia	O
)	O
.	O

Using	O
a	O
fusion	O
protein	O
containing	O
the	O
human	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
O	O
(	O
2	O
)	O
-	O
dependent	O
degradation	O
domain	O
(	O
ODD	O
)	O
,	O
we	O
monitored	O
PHD	O
activity	O
both	O
in	O
vivo	O
and	O
in	O
cell	O
-	O
free	O
systems	O
.	O

This	O
novel	O
assay	O
allows	O
the	O
simultaneous	O
detection	O
of	O
both	O
hydroxylated	O
and	O
nonhydroxylated	O
PHD	O
substrates	O
in	O
cells	O
and	O
during	O
in	O
vitro	O
reactions	O
.	O

Importantly	O
,	O
the	O
ODD	O
fusion	O
protein	O
is	O
regulated	O
with	O
kinetics	O
identical	O
to	O
endogenous	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
during	O
cellular	O
hypoxia	O
and	O
reoxygenation	O
.	O

Using	O
in	O
vitro	O
assays	O
,	O
we	O
demonstrated	O
that	O
the	O
levels	O
of	O
iron	O
(	O
Fe	O
)	O
,	O
ascorbate	O
,	O
and	O
various	O
tricarboxylic	O
acid	O
(	O
TCA	O
)	O
cycle	O
intermediates	O
affect	O
PHD	O
activity	O
.	O

The	O
intracellular	O
levels	O
of	O
these	O
factors	O
also	O
modulate	O
PHD	O
function	O
and	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
accumulation	O
in	O
vivo	O
.	O

Furthermore	O
,	O
cells	O
treated	O
with	O
mitochondrial	O
inhibitors	O
,	O
such	O
as	O
rotenone	O
and	O
myxothiazol	O
,	O
provided	O
direct	O
evidence	O
that	O
PHDs	O
remain	O
active	O
in	O
hypoxic	O
cells	O
lacking	O
functional	O
mitochondria	O
.	O

Our	O
results	O
suggest	O
that	O
multiple	O
mitochondrial	O
products	O
,	O
including	O
TCA	O
cycle	O
intermediates	O
and	O
reactive	O
oxygen	O
species	O
,	O
can	O
coordinate	O
PHD	O
activity	O
,	O
HIF	O
stabilization	O
,	O
and	O
cellular	O
responses	O
to	O
O	O
(	O
2	O
)	O
depletion	O
.	O

Direct	O
correlation	O
between	O
methylation	O
status	O
and	O
expression	O
of	O
the	O
human	O
O	B-Protein
-	I-Protein
6	I-Protein
-	I-Protein
methylguanine	I-Protein
DNA	I-Protein
methyltransferase	E-Protein
gene	O
.	O

To	O
assess	O
the	O
role	O
of	O
DNA	O
cytosine	O
methylation	O
in	O
the	O
expression	O
of	O
the	O
O	B-Protein
-	I-Protein
6	I-Protein
-	I-Protein
methylguanine	I-Protein
DNA	I-Protein
methyltransferase	E-Protein
(	O
MGMT	S-Protein
)	O
gene	O
,	O
the	O
methylation	O
status	O
of	O
selected	O
CpG	O
-	O
containing	O
dinucleotides	O
in	O
and	O
surrounding	O
the	O
coding	O
regions	O
of	O
the	O
gene	O
were	O
examined	O
and	O
correlated	O
with	O
steady	O
state	O
expression	O
of	O
MGMT	S-Protein
mRNA	O
in	O
13	O
human	O
cell	O
lines	O
.	O

Additionally	O
,	O
tumor	O
cells	O
which	O
exhibited	O
very	O
high	O
levels	O
of	O
MGMT	S-Protein
expression	O
were	O
chronically	O
exposed	O
to	O
5	O
-	O
azacytidine	O
to	O
assess	O
the	O
effects	O
of	O
changes	O
in	O
gene	O
methylation	O
on	O
MGMT	S-Protein
expression	O
.	O

Results	O
of	O
these	O
studies	O
demonstrate	O
that	O
the	O
degree	O
of	O
methylation	O
of	O
multiple	O
MGMT	S-Protein
gene	O
regions	O
correlates	O
with	O
gene	O
expression	O
,	O
but	O
in	O
a	O
direct	O
rather	O
than	O
an	O
inverse	O
fashion	O
,	O
and	O
that	O
5	O
-	O
azacytidine	O
-	O
induced	O
demethylation	O
of	O
the	O
MGMT	S-Protein
gene	O
correlates	O
with	O
a	O
significant	O
reduction	O
,	O
rather	O
than	O
induction	O
,	O
of	O
MGMT	S-Protein
steady	O
-	O
state	O
mRNA	O
expression	O
.	O

These	O
results	O
suggest	O
a	O
unique	O
,	O
potentially	O
alterable	O
methylation	O
-	O
related	O
regulatory	O
mechanism	O
for	O
the	O
MGMT	S-Protein
gene	O
.	O

The	O
C	O
-	O
type	O
lectin	O
MGL	O
expressed	O
by	O
dendritic	O
cells	O
detects	O
glycan	O
changes	O
on	O
MUC1	S-Protein
in	O
colon	O
carcinoma	O
.	O

The	O
epithelial	O
mucin	O
MUC1	S-Protein
is	O
a	O
high	O
molecular	O
weight	O
membrane	O
glycoprotein	O
frequently	O
overexpressed	O
and	O
aberrantly	O
glycosylated	O
in	O
adenocarcinoma	O
.	O

Mucins	O
normally	O
contain	O
high	O
amounts	O
of	O
O	O
-	O
linked	O
carbohydrate	O
structures	O
that	O
may	O
influence	O
immune	O
reactions	O
to	O
this	O
antigen	O
.	O

During	O
malignant	O
transformation	O
,	O
certain	O
glyco	O
-	O
epitopes	O
of	O
MUC1	S-Protein
,	O
such	O
as	O
Tn	O
-	O
antigen	O
,	O
TF	O
-	O
antigen	O
and	O
their	O
sialylated	O
forms	O
become	O
exposed	O
.	O

The	O
role	O
of	O
these	O
glycan	O
structures	O
in	O
tumor	O
biology	O
is	O
unknown	O
,	O
but	O
their	O
presence	O
is	O
known	O
to	O
correlate	O
with	O
poor	O
prognosis	O
in	O
several	O
adenocarcinomas	O
.	O

We	O
analyzed	O
the	O
potency	O
of	O
MUC1	S-Protein
containing	O
Tn	O
-	O
antigens	O
(	O
MUC1	S-Protein
-	O
Tn	O
)	O
to	O
target	O
C	O
-	O
type	O
lectins	O
that	O
function	O
as	O
carbohydrate	O
recognition	O
and	O
uptake	O
molecules	O
on	O
dendritic	O
cells	O
(	O
DC	O
)	O
.	O

We	O
identified	O
the	O
macrophage	O
galactose	O
type	O
C	O
-	O
type	O
lectin	O
(	O
MGL	O
)	O
,	O
expressed	O
by	O
both	O
DC	O
and	O
macrophages	O
,	O
as	O
the	O
receptor	O
for	O
recognition	O
and	O
binding	O
of	O
MUC1	S-Protein
-	O
Tn	O
.	O

To	O
validate	O
the	O
occurrence	O
of	O
MGL	O
-	O
MUC1	S-Protein
interactions	O
in	O
situ	O
,	O
we	O
studied	O
the	O
binding	O
of	O
MGL	O
to	O
MUC1	S-Protein
in	O
primary	O
colon	O
carcinoma	O
tissue	O
.	O

Isolation	O
of	O
MUC1	S-Protein
out	O
of	O
colon	O
carcinoma	O
tissue	O
showed	O
strong	O
binding	O
activity	O
to	O
MGL	O
.	O

Interestingly	O
,	O
MGL	O
binding	O
to	O
MUC1	S-Protein
was	O
highly	O
correlated	O
to	O
binding	O
by	O
the	O
lectin	O
Helix	O
pomatia	O
agglutinin	S-Protein
(	O
HPA	S-Protein
)	O
,	O
which	O
is	O
associated	O
with	O
poor	O
prognosis	O
in	O
colorectal	O
cancer	O
.	O

The	O
detection	O
of	O
MGL	O
positive	O
cells	O
in	O
situ	O
at	O
the	O
tumor	O
site	O
together	O
with	O
the	O
modified	O
glycosylation	O
status	O
of	O
MUC1	S-Protein
to	O
target	O
MGL	O
on	O
DC	O
suggests	O
that	O
MGL	O
positive	O
antigen	O
presenting	O
cells	O
may	O
play	O
a	O
role	O
in	O
tumor	O
progression	O
.	O

Epigenetic	O
memory	O
at	O
malaria	O
virulence	O
genes	O
.	O

During	O
its	O
red	O
blood	O
cell	O
stage	O
,	O
the	O
malaria	O
parasite	O
Plasmodium	O
falciparum	O
can	O
switch	O
its	O
variant	O
surface	O
proteins	O
(	O
P	O
.	O
falciparum	O
erythrocyte	O
membrane	O
protein	O
1	O
)	O
to	O
evade	O
the	O
host	O
immune	O
response	O
.	O

The	O
var	O
gene	O
family	O
encodes	O
P	O
.	O
falciparum	O
erythrocyte	O
membrane	O
protein	O
1	O
,	O
different	O
versions	O
of	O
which	O
have	O
unique	O
binding	O
specificities	O
to	O
various	O
human	O
endothelial	O
surface	O
molecules	O
.	O

Individual	O
parasites	O
each	O
contain	O
approximately	O
60	O
var	O
genes	O
at	O
various	O
locations	O
within	O
their	O
chromosomes	O
;	O
however	O
,	O
parasite	O
isolates	O
contain	O
different	O
complements	O
of	O
var	O
genes	O
,	O
thus	O
,	O
the	O
gene	O
family	O
is	O
enormous	O
with	O
a	O
virtually	O
unlimited	O
number	O
of	O
members	O
.	O

A	O
single	O
var	O
gene	O
is	O
expressed	O
by	O
each	O
parasite	O
in	O
a	O
mutually	O
exclusive	O
manner	O
.	O

We	O
report	O
that	O
control	O
of	O
var	O
gene	O
transcription	O
and	O
antigenic	O
variation	O
is	O
associated	O
with	O
a	O
chromatin	O
memory	O
that	O
includes	O
methylation	O
of	O
histone	B-Protein
H3	E-Protein
at	O
lysine	O
K9	O
as	O
an	O
epigenetic	O
mark	O
.	O

We	O
also	O
discuss	O
how	O
gene	O
transcription	O
memory	O
may	O
affect	O
the	O
mechanism	O
of	O
pathogenesis	O
and	O
immune	O
evasion	O
.	O

Long	O
-	O
distance	O
combinatorial	O
linkage	O
between	O
methylation	O
and	O
acetylation	O
on	O
histone	B-Protein
H3	E-Protein
N	O
termini	O
.	O

Individual	O
posttranslational	O
modifications	O
(	O
PTMs	O
)	O
on	O
histones	S-Protein
have	O
well	O
established	O
roles	O
in	O
certain	O
biological	O
processes	O
,	O
notably	O
transcriptional	O
programming	O
.	O

Recent	O
genomewide	O
studies	O
describe	O
patterns	O
of	O
covalent	O
modifications	O
,	O
such	O
as	O
H3	S-Protein
methylation	O
and	O
acetylation	O
at	O
promoters	O
of	O
specific	O
target	O
genes	O
,	O
or	O
"	O
bivalent	O
domains	O
,	O
"	O
in	O
stem	O
cells	O
,	O
suggestive	O
of	O
a	O
possible	O
combinatorial	O
interplay	O
between	O
PTMs	O
on	O
the	O
same	O
histone	S-Protein
.	O

However	O
,	O
detection	O
of	O
long	O
-	O
range	O
PTM	O
associations	O
is	O
often	O
problematic	O
in	O
antibody	O
-	O
based	O
or	O
traditional	O
mass	O
spectrometric	O
-	O
based	O
analyses	O
.	O

Here	O
,	O
histone	B-Protein
H3	E-Protein
from	O
a	O
ciliate	O
model	O
was	O
analyzed	O
as	O
an	O
enriched	O
source	O
of	O
transcriptionally	O
active	O
chromatin	O
.	O

Using	O
a	O
recently	O
developed	O
mass	O
spectrometric	O
approach	O
,	O
combinatorial	O
modification	O
states	O
on	O
single	O
,	O
long	O
N	O
-	O
terminal	O
H3	S-Protein
fragments	O
(	O
residues	O
1	O
-	O
50	O
)	O
were	O
determined	O
.	O

The	O
entire	O
modification	O
status	O
of	O
intact	O
N	O
termini	O
was	O
obtained	O
and	O
indicated	O
correlations	O
between	O
K4	O
methylation	O
and	O
H3	S-Protein
acetylation	O
.	O

In	O
addition	O
,	O
K4	O
and	O
K27	O
methylation	O
were	O
identified	O
concurrently	O
on	O
one	O
H3	S-Protein
species	O
.	O

This	O
methodology	O
is	O
applicable	O
to	O
other	O
histones	S-Protein
and	O
larger	O
polypeptides	O
and	O
will	O
likely	O
be	O
a	O
valuable	O
tool	O
in	O
understanding	O
the	O
roles	O
of	O
combinatorial	O
patterns	O
of	O
PTMs	O
.	O

Posttranslational	O
modifications	O
in	O
human	O
plasma	O
MBL	S-Protein
and	O
human	O
recombinant	O
MBL	S-Protein
.	O

Mannan	B-Protein
-	I-Protein
binding	I-Protein
lectin	E-Protein
(	O
MBL	S-Protein
)	O
is	O
a	O
complex	O
serum	O
protein	O
that	O
plays	O
an	O
important	O
role	O
in	O
innate	O
immunity	O
.	O

In	O
addition	O
to	O
assuming	O
several	O
different	O
oligomeric	O
forms	O
,	O
the	O
polypeptide	O
itself	O
is	O
highly	O
heterogeneous	O
.	O

This	O
heterogeneity	O
is	O
due	O
to	O
post	O
-	O
translational	O
modifications	O
,	O
which	O
help	O
to	O
stabilize	O
the	O
intact	O
protein	O
in	O
its	O
active	O
conformation	O
.	O

For	O
the	O
first	O
time	O
,	O
positions	O
and	O
occupation	O
frequency	O
of	O
partial	O
hydroxylations	O
and	O
partial	O
glycosylations	O
are	O
reported	O
in	O
MBL	S-Protein
.	O

Hydroxylation	O
and	O
glycosylation	O
patterns	O
of	O
both	O
recombinant	O
and	O
plasma	O
derived	O
MBL	S-Protein
were	O
determined	O
,	O
using	O
a	O
combination	O
of	O
mass	O
spectrometry	O
on	O
reduced	O
MBL	S-Protein
and	O
on	O
enzyme	O
cleaved	O
MBL	S-Protein
.	O

Variations	O
in	O
the	O
degree	O
of	O
hydroxylation	O
and	O
glycosylation	O
seem	O
to	O
be	O
an	O
indigenous	O
characteristic	O
of	O
collectins	O
.	O

In	O
addition	O
to	O
these	O
already	O
known	O
modifications	O
,	O
a	O
new	O
post	O
-	O
translational	O
modification	O
was	O
identified	O
.	O

Cys	O
(	O
216	O
)	O
(	O
and	O
occasionally	O
also	O
Cys	O
(	O
202	O
)	O
)	O
was	O
modified	O
in	O
trace	O
amounts	O
to	O
dehydroalanine	O
,	O
as	O
detected	O
by	O
a	O
34	O
Da	O
mass	O
loss	O
.	O

This	O
impairs	O
the	O
formation	O
of	O
a	O
disulphide	O
bond	O
in	O
the	O
carbohydrate	O
recognition	O
domain	O
.	O

The	O
dehydroalanine	O
was	O
identified	O
in	O
similar	O
small	O
amounts	O
in	O
both	O
recombinant	O
and	O
plasma	O
-	O
derived	O
MBL	S-Protein
.	O

The	O
X	O
-	O
linked	O
mental	O
retardation	O
gene	O
SMCX	S-Protein
/	O
JARID1C	S-Protein
defines	O
a	O
family	O
of	O
histone	B-Protein
H3	E-Protein
lysine	O
4	O
demethylases	O
.	O

Histone	S-Protein
methylation	O
regulates	O
chromatin	O
structure	O
and	O
transcription	O
.	O

The	O
recently	O
identified	O
histone	S-Protein
demethylase	O
lysine	B-Protein
-	I-Protein
specific	I-Protein
demethylase	I-Protein
1	E-Protein
(	O
LSD1	S-Protein
)	O
is	O
chemically	O
restricted	O
to	O
demethylation	O
of	O
only	O
mono	O
-	O
and	O
di	O
-	O
but	O
not	O
trimethylated	O
histone	B-Protein
H3	E-Protein
lysine	O
4	O
(	O
H3K4me3	S-Protein
)	O
.	O

We	O
show	O
that	O
the	O
X	O
-	O
linked	O
mental	O
retardation	O
(	O
XLMR	O
)	O
gene	O
SMCX	S-Protein
(	O
JARID1C	S-Protein
)	O
,	O
which	O
encodes	O
a	O
JmjC	O
-	O
domain	O
protein	O
,	O
reversed	O
H3K4me3	S-Protein
to	O
di	O
-	O
and	O
mono	O
-	O
but	O
not	O
unmethylated	O
products	O
.	O

Other	O
SMCX	O
family	O
members	O
,	O
including	O
SMCY	S-Protein
,	O
RBP2	S-Protein
,	O
and	O
PLU	B-Protein
-	I-Protein
1	E-Protein
,	O
also	O
demethylated	O
H3K4me3	S-Protein
.	O

SMCX	S-Protein
bound	O
H3K9me3	S-Protein
via	O
its	O
N	O
-	O
terminal	O
PHD	O
(	O
plant	O
homeodomain	O
)	O
finger	O
,	O
which	O
may	O
help	O
coordinate	O
H3K4	S-Protein
demethylation	O
and	O
H3K9	S-Protein
methylation	O
in	O
transcriptional	O
repression	O
.	O

Significantly	O
,	O
several	O
XLMR	O
-	O
patient	O
point	O
mutations	O
reduced	O
SMCX	S-Protein
demethylase	O
activity	O
and	O
binding	O
to	O
H3K9me3	S-Protein
peptides	O
,	O
respectively	O
.	O

Importantly	O
,	O
studies	O
in	O
zebrafish	O
and	O
primary	O
mammalian	O
neurons	O
demonstrated	O
a	O
role	O
for	O
SMCX	S-Protein
in	O
neuronal	O
survival	O
and	O
dendritic	O
development	O
and	O
a	O
link	O
to	O
the	O
demethylase	O
activity	O
.	O

Our	O
findings	O
thus	O
identify	O
a	O
family	O
of	O
H3K4me3	S-Protein
demethylases	O
and	O
uncover	O
a	O
critical	O
link	O
between	O
histone	O
modifications	O
and	O
XLMR	O
.	O

Abnormal	O
prion	B-Protein
protein	E-Protein
in	O
the	O
pituitary	O
in	O
sporadic	O
and	O
variant	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
.	O

By	O
using	O
high	O
-	O
sensitivity	O
Western	O
blotting	O
and	O
immunohistochemistry	O
,	O
pituitary	O
glands	O
from	O
patients	O
with	O
sporadic	O
and	O
variant	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
(	O
sCJD	O
and	O
vCJD	O
,	O
respectively	O
)	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
the	O
protease	O
-	O
resistant	O
form	O
of	O
the	O
prion	B-Protein
protein	E-Protein
(	O
PrPres	S-Protein
)	O
.	O

PrPres	S-Protein
was	O
detected	O
in	O
a	O
greater	O
proportion	O
of	O
vCJD	O
pituitaries	O
than	O
sCJD	O
pituitaries	O
and	O
was	O
localized	O
predominantly	O
in	O
the	O
neurohypophysis	O
.	O

PrPres	S-Protein
was	O
also	O
detected	O
in	O
a	O
recurrent	O
pituitary	O
adenoma	O
from	O
an	O
sCJD	O
patient	O
.	O

Immunohistochemical	O
analysis	O
showed	O
sparse	O
positive	O
labelling	O
,	O
predominantly	O
in	O
folliculostellate	O
cells	O
,	O
in	O
vCJD	O
and	O
sCJD	O
adenohypophyses	O
.	O

The	O
PrPres	S-Protein
glycosylation	O
pattern	O
in	O
the	O
vCJD	O
neurohypophyses	O
showed	O
a	O
predominance	O
of	O
the	O
unglycosylated	O
band	O
,	O
which	O
differed	O
markedly	O
from	O
patterns	O
found	O
in	O
all	O
other	O
vCJD	O
tissues	O
.	O

The	O
presence	O
of	O
PrPres	S-Protein
in	O
the	O
pituitary	O
of	O
CJD	O
patients	O
at	O
autopsy	O
suggests	O
that	O
human	O
growth	B-Protein
hormone	E-Protein
-	O
related	O
iatrogenic	O
CJD	O
may	O
have	O
indeed	O
resulted	O
from	O
infectivity	O
in	O
collected	O
pituitaries	O
rather	O
than	O
necessarily	O
from	O
contamination	O
of	O
pituitary	O
pools	O
by	O
adjacent	O
brain	O
tissue	O
.	O

Anti	O
-	O
angiogenic	O
effect	O
of	O
tetraacetyl	O
-	O
phytosphingosine	O
.	O

In	O
a	O
search	O
for	O
the	O
wound	O
healing	O
accelerators	O
,	O
we	O
found	O
that	O
tetraacetyl	O
-	O
phytosphingosine	O
(	O
TAPS	O
)	O
,	O
a	O
sphingolipid	O
metabolite	O
produced	O
by	O
phytosphingosine	O
acetylation	O
,	O
has	O
significant	O
inhibitory	O
potential	O
on	O
healing	O
of	O
rabbit	O
ear	O
wound	O
.	O

As	O
angiogenesis	O
is	O
fundamental	O
to	O
proper	O
wound	O
healing	O
,	O
we	O
examined	O
the	O
effect	O
of	O
TAPS	O
on	O
angiogenesis	O
using	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
cultured	O
in	O
vitro	O
.	O

TAPS	O
markedly	O
decreased	O
vascular	B-Protein
endothelial	I-Protein
growth	I-Protein
factor	E-Protein
(	O
VEGF	S-Protein
)	O
-	O
induced	O
chemotactic	O
migration	O
and	O
capillary	O
-	O
like	O
tube	O
formation	O
.	O

Recognizing	O
its	O
inhibitory	O
potential	O
on	O
angiogenesis	O
,	O
we	O
further	O
investigated	O
the	O
action	O
mechanism	O
of	O
TAPS	O
.	O

TAPS	O
significantly	O
inhibited	O
VEGF	S-Protein
-	O
induced	O
proteolytic	O
enzyme	O
production	O
,	O
including	O
matrix	B-Protein
metalloproteinase	I-Protein
-	I-Protein
2	E-Protein
,	O
urokinase	B-Protein
-	I-Protein
type	I-Protein
plasminogen	I-Protein
activator	E-Protein
and	O
plasminogen	B-Protein
activator	I-Protein
inhibitor	I-Protein
-	I-Protein
1	E-Protein
.	O

TAPS	O
also	O
suppressed	O
VEGF	S-Protein
-	O
induced	O
phosphorylation	O
of	O
p42	S-Protein
/	O
44	S-Protein
extracellular	O
signal	O
-	O
regulated	O
kinase	O
and	O
c	B-Protein
-	I-Protein
Jun	E-Protein
N	O
-	O
terminal	O
kinase	O
.	O

In	O
addition	O
,	O
TAPS	O
abolished	O
VEGF	S-Protein
-	O
induced	O
intracellular	O
calcium	O
increase	O
,	O
measured	O
using	O
laser	O
scanning	O
confocal	O
microscopy	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
TAPS	O
exerts	O
its	O
inhibitory	O
action	O
on	O
angiogenesis	O
through	O
the	O
inhibition	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
activation	O
and	O
intracellular	O
calcium	O
increase	O
,	O
thereby	O
affecting	O
the	O
process	O
of	O
wound	O
healing	O
negatively	O
.	O

Mechanism	O
of	O
attenuation	O
of	O
angiotensin	B-Protein
-	I-Protein
II	E-Protein
-	O
induced	O
protein	O
degradation	O
by	O
insulin	B-Protein
-	I-Protein
like	I-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
I	E-Protein
(	O
IGF	B-Protein
-	I-Protein
I	E-Protein
)	O
.	O

Insulin	B-Protein
-	I-Protein
like	I-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
I	E-Protein
(	O
IGF	B-Protein
-	I-Protein
I	E-Protein
)	O
has	O
been	O
shown	O
to	O
attenuate	O
protein	O
degradation	O
in	O
murine	O
myotubes	O
induced	O
by	O
angiotensin	B-Protein
II	E-Protein
through	O
downregulation	O
of	O
the	O
ubiquitin	S-Protein
-	O
proteasome	O
pathway	O
,	O
although	O
the	O
mechanism	O
is	O
not	O
known	O
.	O

Angiotensin	B-Protein
II	E-Protein
is	O
known	O
to	O
upregulate	O
this	O
pathway	O
through	O
a	O
cellular	O
signalling	O
mechanism	O
involving	O
release	O
of	O
arachidonic	O
acid	O
,	O
activation	O
of	O
protein	B-Protein
kinase	I-Protein
Calpha	E-Protein
(	O
PKCalpha	S-Protein
)	O
,	O
degradation	O
of	O
inhibitor	O
-	O
kappaB	O
(	O
I	O
-	O
kappaB	O
)	O
and	O
nuclear	O
migration	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
and	O
all	O
of	O
these	O
events	O
were	O
attenuated	O
by	O
IGF	B-Protein
-	I-Protein
I	E-Protein
(	O
13	O
.	O
2	O
nM	O
)	O
.	O

Induction	O
of	O
the	O
ubiquitin	S-Protein
-	O
proteasome	O
pathway	O
has	O
been	O
linked	O
to	O
activation	O
of	O
the	O
RNA	O
-	O
activated	O
protein	O
kinase	O
(	O
PKR	O
)	O
,	O
since	O
an	O
inhibitor	O
of	O
PKR	O
attenuated	O
proteasome	O
expression	O
and	O
activity	O
in	O
response	O
to	O
angiotensin	B-Protein
II	E-Protein
and	O
prevented	O
the	O
decrease	O
in	O
the	O
myofibrillar	O
protein	O
myosin	O
.	O

Angiotensin	B-Protein
II	E-Protein
induced	O
phosphorylation	O
of	O
PKR	O
and	O
of	O
the	O
eukaryotic	B-Protein
initiation	I-Protein
factor	I-Protein
-	I-Protein
2	E-Protein
(	O
eIF2	S-Protein
)	O
on	O
the	O
alpha	O
-	O
subunit	O
,	O
and	O
this	O
was	O
attenuated	O
by	O
IGF	B-Protein
-	I-Protein
I	E-Protein
,	O
by	O
induction	O
of	O
the	O
expression	O
of	O
protein	O
phosphatase	O
1	O
,	O
which	O
dephosphorylates	O
PKR	O
.	O

Release	O
of	O
arachidonic	O
acid	O
and	O
activation	O
of	O
PKCalpha	S-Protein
by	O
angiotensin	B-Protein
II	E-Protein
were	O
attenuated	O
by	O
an	O
inhibitor	O
of	O
PKR	O
and	O
IGF	B-Protein
-	I-Protein
I	E-Protein
,	O
and	O
the	O
effect	O
was	O
reversed	O
by	O
Salubrinal	O
(	O
15	O
muM	O
)	O
,	O
an	O
inhibitor	O
of	O
eIF2alpha	S-Protein
dephosphorylation	O
,	O
as	O
was	O
activation	O
of	O
PKCalpha	S-Protein
.	O

In	O
addition	O
myotubes	O
transfected	O
with	O
a	O
dominant	O
-	O
negative	O
PKR	O
(	O
PKRDelta6	O
)	O
showed	O
no	O
release	O
of	O
arachidonate	O
in	O
response	O
to	O
Ang	B-Protein
II	E-Protein
,	O
and	O
no	O
activation	O
of	O
PKCalpha	S-Protein
.	O

These	O
results	O
suggest	O
that	O
phosphorylation	O
of	O
PKR	O
by	O
angiotensin	B-Protein
II	E-Protein
was	O
responsible	O
for	O
the	O
activation	O
of	O
the	O
PLA	O
(	O
2	O
)	O
/	O
PKC	O
pathway	O
leading	O
to	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
that	O
IGF	B-Protein
-	I-Protein
I	E-Protein
attenuates	O
protein	O
degradation	O
due	O
to	O
an	O
inhibitory	O
effect	O
on	O
activation	O
of	O
PKR	O
.	O

Arginine	O
methylation	O
of	O
the	O
HIV	O
-	O
1	O
nucleocapsid	B-Protein
protein	E-Protein
results	O
in	O
its	O
diminished	O
function	O
.	O

OBJECTIVE	O
:	O
The	O
HIV	O
-	O
1	O
nucleocapsid	B-Protein
protein	E-Protein
(	O
NC	S-Protein
)	O
is	O
involved	O
in	O
transfer	B-Protein
RNA3	E-Protein
annealing	O
to	O
the	O
primer	O
binding	O
site	O
of	O
viral	O
genomic	O
RNA	O
by	O
means	O
of	O
two	O
basic	O
regions	O
that	O
are	O
similar	O
to	O
the	O
N	O
-	O
terminal	O
portion	O
of	O
the	O
arginine	O
-	O
rich	O
motif	O
(	O
ARM	O
)	O
of	O
Tat	S-Protein
.	O

As	O
Tat	S-Protein
is	O
known	O
to	O
be	O
asymmetrically	O
arginine	O
dimethylated	O
by	O
protein	B-Protein
arginine	I-Protein
methyltransferase	I-Protein
6	E-Protein
(	O
PRMT6	S-Protein
)	O
in	O
its	O
ARM	O
,	O
we	O
investigated	O
whether	O
NC	S-Protein
could	O
also	O
act	O
as	O
a	O
substrate	O
for	O
this	O
enzyme	O
.	O

METHODS	O
:	O
Arginine	O
methylation	O
of	O
NC	S-Protein
was	O
demonstrated	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
sites	O
of	O
methylation	O
were	O
determined	O
by	O
mutational	O
analysis	O
.	O

The	O
impact	O
of	O
the	O
arginine	O
methylation	O
of	O
NC	S-Protein
was	O
measured	O
in	O
RNA	O
annealing	O
and	O
reverse	O
transcription	O
initiation	O
assays	O
.	O

An	O
arginine	O
methyltransferase	O
inhibitor	O
(	O
AMI	O
)	O
3	O
.	O
4	O
was	O
tested	O
for	O
its	O
effects	O
on	O
viral	O
infectivity	O
and	O
replication	O
in	O
vivo	O
.	O

RESULTS	O
:	O
NC	S-Protein
is	O
a	O
substrate	O
for	O
PRMT6	S-Protein
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

NC	S-Protein
possesses	O
arginine	O
dimethylation	O
sites	O
in	O
each	O
of	O
its	O
two	O
basic	O
regions	O
at	O
positions	O
R10	O
and	O
R32	O
,	O
and	O
methylated	O
NC	S-Protein
was	O
less	O
able	O
than	O
wild	O
-	O
type	O
to	O
promote	O
RNA	O
annealing	O
and	O
participate	O
in	O
the	O
initiation	O
of	O
reverse	O
transcription	O
.	O

Exposure	O
of	O
HIV	O
-	O
1	O
-	O
infected	O
MT2	O
and	O
primary	O
cord	O
blood	O
mononuclear	O
cells	O
to	O
AMI3	O
.	O
4	O
led	O
to	O
increased	O
viral	O
replication	O
,	O
whereas	O
viral	O
infectivity	O
was	O
not	O
significantly	O
affected	O
in	O
multinuclear	O
-	O
activation	O
galactosidase	O
indicator	O
assays	O
.	O

CONCLUSION	O
:	O
NC	S-Protein
is	O
an	O
in	O
-	O
vivo	O
target	O
of	O
PRMT6	S-Protein
,	O
and	O
arginine	O
methylation	O
of	O
NC	S-Protein
reduces	O
RNA	O
annealing	O
and	O
the	O
initiation	O
of	O
reverse	O
transcription	O
.	O

These	O
findings	O
may	O
lead	O
to	O
ways	O
of	O
driving	O
HIV	O
-	O
infected	O
cells	O
out	O
of	O
latency	O
with	O
drugs	O
that	O
inhibit	O
PRMT6	S-Protein
.	O

A	O
dual	O
role	O
of	O
EGFR	S-Protein
protein	O
tyrosine	O
kinase	O
signaling	O
in	O
ubiquitination	O
of	O
AAV2	O
capsids	O
and	O
viral	O
second	O
-	O
strand	O
DNA	O
synthesis	O
.	O

A	O
52	O
kd	O
cellular	O
protein	O
,	O
FK506	O
-	O
binding	O
protein	O
(	O
FKBP52	S-Protein
)	O
,	O
phosphorylated	O
at	O
tyrosine	O
residues	O
by	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptor	E-Protein
protein	O
tyrosine	O
kinase	O
(	O
EGFR	S-Protein
-	O
PTK	O
)	O
,	O
inhibits	O
adeno	O
-	O
associated	O
virus	O
2	O
(	O
AAV2	O
)	O
second	O
-	O
strand	O
DNA	O
synthesis	O
and	O
transgene	O
expression	O
.	O

FKBP52	S-Protein
is	O
dephosphorylated	O
at	O
tyrosine	O
residues	O
by	O
T	B-Protein
-	I-Protein
cell	I-Protein
protein	I-Protein
tyrosine	I-Protein
phosphatase	E-Protein
(	O
TC	B-Protein
-	I-Protein
PTP	E-Protein
)	O
,	O
and	O
TC	B-Protein
-	I-Protein
PTP	E-Protein
over	O
-	O
expression	O
leads	O
to	O
improved	O
viral	O
second	O
-	O
strand	O
DNA	O
synthesis	O
and	O
improved	O
transgene	O
expression	O
.	O

In	O
these	O
studies	O
,	O
we	O
observed	O
that	O
perturbation	O
of	O
EGFR	S-Protein
-	O
PTK	O
signaling	O
by	O
a	O
specific	O
inhibitor	O
,	O
Tyrphostin	O
23	O
(	O
Tyr23	O
)	O
,	O
augmented	O
the	O
transduction	O
efficiency	O
of	O
the	O
single	O
-	O
stranded	O
AAV	O
(	O
ssAAV	O
)	O
vector	O
as	O
well	O
as	O
the	O
self	O
-	O
complementary	O
AAV	O
(	O
scAAV	O
)	O
vector	O
.	O

Similarly	O
,	O
tyrosine	O
-	O
dephosphorylation	O
of	O
FKBP52	S-Protein
by	O
TC	B-Protein
-	I-Protein
PTP	E-Protein
resulted	O
in	O
increased	O
transduction	O
by	O
both	O
vectors	O
.	O

These	O
data	O
suggested	O
that	O
EGFR	S-Protein
-	O
PTK	O
signaling	O
also	O
affects	O
aspects	O
of	O
AAV	O
transduction	O
other	O
than	O
viral	O
second	O
-	O
strand	O
DNA	O
synthesis	O
.	O

We	O
document	O
that	O
inhibition	O
of	O
EGFR	S-Protein
-	O
PTK	O
signaling	O
leads	O
to	O
decreased	O
ubiquitination	O
of	O
AAV2	O
capsids	O
which	O
,	O
in	O
turn	O
,	O
facilitates	O
nuclear	O
transport	O
by	O
limiting	O
proteasome	O
-	O
mediated	O
degradation	O
of	O
AAV	O
vectors	O
.	O

We	O
also	O
document	O
that	O
Tyr23	O
-	O
mediated	O
increase	O
in	O
AAV2	O
transduction	O
efficiency	O
is	O
not	O
further	O
enhanced	O
by	O
a	O
specific	O
proteasome	O
inhibitor	O
,	O
MG132	O
.	O

Thus	O
,	O
EGFR	S-Protein
-	O
PTK	O
signaling	O
modulates	O
ubiquitin	S-Protein
(	O
Ub	S-Protein
)	O
/	O
proteasome	O
pathway	O
-	O
mediated	O
intracellular	O
trafficking	O
as	O
well	O
as	O
FKBP52	S-Protein
-	O
mediated	O
second	O
-	O
strand	O
DNA	O
synthesis	O
of	O
AAV2	O
vectors	O
.	O

This	O
has	O
implications	O
in	O
the	O
optimal	O
use	O
of	O
AAV	O
vectors	O
in	O
gene	O
therapy	O
.	O

Studies	O
of	O
the	O
in	O
vitro	O
Nalpha	O
-	O
acetyltransferase	O
activities	O
of	O
E	O
.	O
coli	O
RimL	S-Protein
protein	O
.	O

Although	O
the	O
Escherichia	O
coli	O
N	O
(	O
alpha	O
)	O
-	O
acetyltransferase	O
RimL	S-Protein
catalyzing	O
the	O
N	O
-	O
terminal	O
acetylation	O
of	O
L12	S-Protein
have	O
been	O
identified	O
through	O
mutant	O
analysis	O
,	O
little	O
is	O
known	O
about	O
its	O
enzymatic	O
activity	O
and	O
auxiliary	O
subunit	O
requirement	O
.	O

This	O
study	O
was	O
to	O
investigate	O
the	O
enzymatic	O
activities	O
of	O
RimL	S-Protein
and	O
its	O
substrate	O
specificity	O
.	O

RimL	S-Protein
,	O
its	O
substrate	O
L12	S-Protein
,	O
and	O
two	O
mutant	O
substrates	O
L12S1A	S-Protein
and	O
L12I2D	S-Protein
were	O
overexpressed	O
and	O
purified	O
from	O
E	O
.	O
coli	O
.	O

In	O
vitro	O
experimental	O
results	O
revealed	O
that	O
RimL	S-Protein
itself	O
can	O
convert	O
L12	S-Protein
to	O
L7	S-Protein
by	O
acetylation	O
of	O
the	O
N	O
-	O
terminal	O
serine	O
residue	O
.	O

The	O
K	O
(	O
m	O
)	O
value	O
for	O
L12	S-Protein
was	O
0	O
.	O
55	O
microM	O
and	O
the	O
V	O
(	O
max	O
)	O
was	O
25	O
.	O
71	O
min	O
(	O
-	O
1	O
)	O
as	O
determined	O
by	O
a	O
spectrophotometrical	O
method	O
.	O

We	O
also	O
found	O
that	O
RimL	S-Protein
acetylated	O
the	O
L12S1A	S-Protein
mutant	O
with	O
an	O
N	O
-	O
terminal	O
alanine	O
residue	O
instead	O
of	O
the	O
native	O
serine	O
residue	O
,	O
suggesting	O
RimL	S-Protein
can	O
acetylate	O
other	O
N	O
-	O
terminal	O
residues	O
.	O

Furthermore	O
,	O
when	O
the	O
second	O
N	O
-	O
terminal	O
residue	O
isoleucine	O
was	O
replaced	O
by	O
aspartic	O
acid	O
,	O
the	O
mutant	O
L12I2D	S-Protein
was	O
also	O
acetylated	O
by	O
RimL	S-Protein
but	O
under	O
a	O
much	O
lower	O
rate	O
.	O

Reptilian	O
transferrins	S-Protein
:	O
evolution	O
of	O
disulphide	O
bridges	O
and	O
conservation	O
of	O
iron	O
-	O
binding	O
center	O
.	O

Transferrins	S-Protein
,	O
found	O
in	O
invertebrates	O
and	O
vertebrates	O
,	O
form	O
a	O
physiologically	O
important	O
family	O
of	O
proteins	O
playing	O
a	O
major	O
role	O
in	O
iron	O
acquisition	O
and	O
transport	O
,	O
defense	O
against	O
microbial	O
pathogens	O
,	O
growth	O
and	O
differentiation	O
.	O

These	O
proteins	O
are	O
bilobal	O
in	O
structure	O
and	O
each	O
lobe	O
is	O
composed	O
of	O
two	O
domains	O
divided	O
by	O
a	O
cleft	O
harboring	O
an	O
iron	O
atom	O
.	O

Vertebrate	O
transferrins	O
comprise	O
of	O
serotransferrins	S-Protein
,	O
lactoferrins	S-Protein
and	O
ovotransferrins	S-Protein
.	O

In	O
mammals	O
serotransferrins	O
transport	O
iron	O
in	O
physiological	O
fluids	O
and	O
deliver	O
it	O
to	O
cells	O
,	O
while	O
lactoferrins	O
scavenge	O
iron	O
,	O
limiting	O
its	O
availability	O
to	O
invading	O
microbes	O
.	O

In	O
oviparous	O
vertebrates	O
there	O
is	O
only	O
one	O
transferrin	S-Protein
gene	O
,	O
expressed	O
either	O
in	O
the	O
liver	O
to	O
be	O
delivered	O
to	O
physiological	O
fluids	O
as	O
serotransferrin	S-Protein
,	O
or	O
in	O
the	O
oviduct	O
with	O
a	O
final	O
localization	O
in	O
egg	O
white	O
as	O
ovotransferrin	S-Protein
.	O

Being	O
products	O
of	O
one	O
gene	O
sero	B-Protein
-	E-Protein
and	O
ovotransferrin	S-Protein
are	O
identical	O
at	O
the	O
amino	O
-	O
acid	O
sequence	O
level	O
but	O
with	O
different	O
,	O
cell	O
specific	O
glycosylation	O
patterns	O
.	O

Our	O
knowledge	O
of	O
the	O
mechanisms	O
of	O
transferrin	S-Protein
iron	O
binding	O
and	O
release	O
is	O
based	O
on	O
sequence	O
and	O
structural	O
data	O
obtained	O
for	O
human	O
serotransferrin	S-Protein
and	O
hen	O
and	O
duck	O
ovotransferrins	S-Protein
.	O

No	O
sequence	O
information	O
about	O
other	O
ovotransferrins	S-Protein
was	O
available	O
until	O
our	O
recent	O
publication	O
of	O
turkey	O
,	O
ostrich	O
,	O
and	O
red	O
-	O
eared	O
turtle	O
(	O
TtrF	S-Protein
)	O
ovotransferrin	S-Protein
mRNA	O
sequences	O
[	O
Ciuraszkiewicz	O
,	O
J	O
.	O
,	O
Olczak	O
,	O
M	O
.	O
,	O
Watorek	O
,	O
W	O
.	O
,	O
2006	O
.	O
Isolation	O
,	O
cloning	O
and	O
sequencing	O
of	O
transferrins	S-Protein
from	O
red	O
-	O
eared	O
turtle	O
,	O
African	O
ostrich	O
and	O
turkey	O
.	O
Comp	O
.	O
Biochem	O
.	O
Physiol	O
.	O
143	O
B	O
,	O
301	O
-	O
310	O
]	O
.	O

In	O
the	O
present	O
paper	O
,	O
ten	O
new	O
reptilian	O
mRNA	O
transferrin	S-Protein
sequences	O
obtained	O
from	O
the	O
Nile	O
crocodile	O
(	O
NtrF	S-Protein
)	O
,	O
bearded	O
dragon	O
(	O
BtrF	S-Protein
)	O
,	O
Cuban	O
brown	O
anole	O
(	O
AtrF	S-Protein
)	O
,	O
veiled	O
and	O
Mediterranean	O
chameleons	O
(	O
VtrF	S-Protein
and	O
KtrF	S-Protein
)	O
,	O
sand	O
lizard	O
(	O
StrF	S-Protein
)	O
,	O
leopard	O
gecko	O
(	O
LtrF	S-Protein
)	O
,	O
Burmese	O
python	O
(	O
PtrF	S-Protein
)	O
,	O
African	O
house	O
snake	O
(	O
HtrF	S-Protein
)	O
,	O
and	O
grass	O
snake	O
(	O
GtrF	S-Protein
)	O
are	O
presented	O
and	O
analyzed	O
.	O

Nile	O
crocodile	O
and	O
red	O
-	O
eared	O
turtle	O
transferrins	O
have	O
a	O
disulphide	O
bridge	O
pattern	O
identical	O
to	O
known	O
bird	O
homologues	O
.	O

A	O
partially	O
different	O
disulphide	O
bridge	O
pattern	O
was	O
found	O
in	O
the	O
Squamata	O
(	O
snakes	O
and	O
lizards	O
)	O
.	O

The	O
possibility	O
of	O
a	O
unique	O
interdomain	O
disulphide	O
bridge	O
was	O
predicted	O
for	O
LtrF	S-Protein
.	O

Differences	O
were	O
found	O
in	O
iron	O
-	O
binding	O
centers	O
from	O
those	O
of	O
previously	O
known	O
transferrins	S-Protein
.	O

Substitutions	O
were	O
found	O
in	O
the	O
iron	O
-	O
chelating	O
residues	O
of	O
StrF	S-Protein
and	O
TtrF	S-Protein
and	O
in	O
the	O
synergistic	O
anion	O
-	O
binding	O
residues	O
of	O
NtrF	S-Protein
.	O

In	O
snakes	O
,	O
the	O
transferrin	S-Protein
(	O
PtrF	S-Protein
,	O
HtrF	S-Protein
and	O
GtrF	S-Protein
)	O
N	O
-	O
lobe	O
"	O
dilysine	O
trigger	O
"	O
occurring	O
in	O
all	O
other	O
known	O
transferrins	S-Protein
was	O
not	O
found	O
,	O
which	O
indicates	O
a	O
different	O
mechanism	O
of	O
iron	O
release	O
.	O

The	O
neutralizing	O
activity	O
of	O
anti	O
-	O
hepatitis	O
C	O
virus	O
antibodies	O
is	O
modulated	O
by	O
specific	O
glycans	O
on	O
the	O
E2	S-Protein
envelope	O
protein	O
.	O

Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
envelope	O
glycoproteins	O
are	O
highly	O
glycosylated	O
,	O
with	O
up	O
to	O
5	O
and	O
11	O
N	O
-	O
linked	O
glycans	O
on	O
E1	S-Protein
and	O
E2	S-Protein
,	O
respectively	O
.	O

Most	O
of	O
the	O
glycosylation	O
sites	O
on	O
HCV	O
envelope	O
glycoproteins	O
are	O
conserved	O
,	O
and	O
some	O
of	O
the	O
glycans	O
associated	O
with	O
these	O
proteins	O
have	O
been	O
shown	O
to	O
play	O
an	O
essential	O
role	O
in	O
protein	O
folding	O
and	O
HCV	O
entry	O
.	O

Such	O
a	O
high	O
level	O
of	O
glycosylation	O
suggests	O
that	O
these	O
glycans	O
can	O
limit	O
the	O
immunogenicity	O
of	O
HCV	O
envelope	O
proteins	O
and	O
restrict	O
the	O
binding	O
of	O
some	O
antibodies	O
to	O
their	O
epitopes	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
these	O
glycans	O
can	O
modulate	O
the	O
neutralizing	O
activity	O
of	O
anti	O
-	O
HCV	O
antibodies	O
.	O

HCV	O
pseudoparticles	O
(	O
HCVpp	O
)	O
bearing	O
wild	O
-	O
type	O
glycoproteins	O
or	O
mutants	O
at	O
individual	O
glycosylation	O
sites	O
were	O
evaluated	O
for	O
their	O
sensitivity	O
to	O
neutralization	O
by	O
antibodies	O
from	O
the	O
sera	O
of	O
infected	O
patients	O
and	O
anti	O
-	O
E2	S-Protein
monoclonal	O
antibodies	O
.	O

While	O
we	O
did	O
not	O
find	O
any	O
evidence	O
that	O
N	O
-	O
linked	O
glycans	O
of	O
E1	S-Protein
contribute	O
to	O
the	O
masking	O
of	O
neutralizing	O
epitopes	O
,	O
our	O
data	O
demonstrate	O
that	O
at	O
least	O
three	O
glycans	O
on	O
E2	S-Protein
(	O
denoted	O
E2N1	S-Protein
,	O
E2N6	S-Protein
,	O
and	O
E2N11	S-Protein
)	O
reduce	O
the	O
sensitivity	O
of	O
HCVpp	O
to	O
antibody	O
neutralization	O
.	O

Importantly	O
,	O
these	O
three	O
glycans	O
also	O
reduced	O
the	O
access	O
of	O
CD81	S-Protein
to	O
its	O
E2	S-Protein
binding	O
site	O
,	O
as	O
shown	O
by	O
using	O
a	O
soluble	O
form	O
of	O
the	O
extracellular	O
loop	O
of	O
CD81	S-Protein
in	O
inhibition	O
of	O
entry	O
.	O

These	O
data	O
suggest	O
that	O
glycans	O
E2N1	S-Protein
,	O
E2N6	S-Protein
,	O
and	O
E2N11	S-Protein
are	O
close	O
to	O
the	O
binding	O
site	O
of	O
CD81	S-Protein
and	O
modulate	O
both	O
CD81	S-Protein
and	O
neutralizing	O
antibody	O
binding	O
to	O
E2	S-Protein
.	O

In	O
conclusion	O
,	O
this	O
work	O
indicates	O
that	O
HCV	O
glycans	O
contribute	O
to	O
the	O
evasion	O
of	O
HCV	O
from	O
the	O
humoral	O
immune	O
response	O
.	O

L3MBTL1	S-Protein
,	O
a	O
histone	S-Protein
-	O
methylation	O
-	O
dependent	O
chromatin	O
lock	O
.	O

Distinct	O
histone	S-Protein
lysine	O
methylation	O
marks	O
are	O
involved	O
in	O
transcriptional	O
repression	O
linked	O
to	O
the	O
formation	O
and	O
maintenance	O
of	O
facultative	O
heterochromatin	O
,	O
although	O
the	O
underlying	O
mechanisms	O
remain	O
unclear	O
.	O

We	O
demonstrate	O
that	O
the	O
malignant	O
-	O
brain	O
-	O
tumor	O
(	O
MBT	O
)	O
protein	O
L3MBTL1	S-Protein
is	O
in	O
a	O
complex	O
with	O
core	O
histones	O
,	O
histone	B-Protein
H1b	E-Protein
,	O
HP1gamma	S-Protein
,	O
and	O
Rb	S-Protein
.	O

The	O
MBT	O
domain	O
is	O
structurally	O
related	O
to	O
protein	O
domains	O
that	O
directly	O
bind	O
methylated	O
histone	S-Protein
residues	O
.	O

Consistent	O
with	O
this	O
,	O
we	O
found	O
that	O
the	O
L3MBTL1	S-Protein
MBT	O
domains	O
compact	O
nucleosomal	O
arrays	O
dependent	O
on	O
mono	O
-	O
and	O
dimethylation	O
of	O
histone	B-Protein
H4	E-Protein
lysine	O
20	O
and	O
of	O
histone	B-Protein
H1b	E-Protein
lysine	O
26	O
.	O

The	O
MBT	O
domains	O
bind	O
at	O
least	O
two	O
nucleosomes	O
simultaneously	O
,	O
linking	O
repression	O
of	O
transcription	O
to	O
recognition	O
of	O
different	O
histone	O
marks	O
by	O
L3MBTL1	S-Protein
.	O

Consistently	O
,	O
L3MBTL1	S-Protein
was	O
found	O
to	O
negatively	O
regulate	O
the	O
expression	O
of	O
a	O
subset	O
of	O
genes	O
regulated	O
by	O
E2F	S-Protein
,	O
a	O
factor	O
that	O
interacts	O
with	O
Rb	S-Protein
.	O

Negative	O
regulation	O
of	O
the	O
SH2	B-Protein
-	I-Protein
homology	I-Protein
containing	I-Protein
protein	I-Protein
-	I-Protein
tyrosine	I-Protein
phosphatase	I-Protein
-	I-Protein
1	E-Protein
(	O
SHP	B-Protein
-	I-Protein
1	E-Protein
)	O
P2	O
promoter	O
by	O
the	O
HTLV	O
-	O
1	O
Tax	S-Protein
oncoprotein	O
.	O

Expression	O
of	O
SH	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
-	I-Protein
homology	I-Protein
-	I-Protein
containing	I-Protein
protein	I-Protein
-	I-Protein
tyrosine	I-Protein
phosphatase	I-Protein
-	I-Protein
1	E-Protein
(	O
SHP	B-Protein
-	I-Protein
1	E-Protein
)	O
,	O
a	O
candidate	O
tumor	O
suppressor	O
,	O
is	O
repressed	O
in	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
-	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
-	O
transformed	O
lymphocyte	O
cell	O
lines	O
,	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
cells	O
,	O
and	O
in	O
other	O
hematologic	O
malignancies	O
.	O

However	O
,	O
the	O
mechanisms	O
underlying	O
regulation	O
and	O
repression	O
of	O
SHP	B-Protein
-	I-Protein
1	E-Protein
remain	O
unclear	O
.	O

Herein	O
,	O
we	O
cloned	O
the	O
putative	O
full	O
-	O
length	O
,	O
hematopoietic	O
cell	O
-	O
specific	O
SHP	B-Protein
-	I-Protein
1	E-Protein
P2	O
promoter	O
and	O
identified	O
the	O
"	O
core	O
"	O
promoter	O
regions	O
.	O

HTLV	O
-	O
1	O
Tax	S-Protein
profoundly	O
represses	O
P2	O
promoter	O
activity	O
and	O
histone	B-Protein
deacetylase	I-Protein
-	I-Protein
1	E-Protein
(	O
HDAC1	S-Protein
)	O
potentiates	O
such	O
inhibition	O
.	O

NF	O
-	O
kappaB	O
was	O
implicated	O
as	O
both	O
a	O
rate	O
-	O
limiting	O
factor	O
for	O
basal	O
P2	O
promoter	O
activity	O
and	O
important	O
for	O
Tax	S-Protein
-	O
induced	O
promoter	O
silencing	O
(	O
TIPS	O
)	O
.	O

Chromatin	O
immunoprecipitation	O
studies	O
demonstrated	O
that	O
NF	O
-	O
kappaB	O
dissociates	O
from	O
the	O
SHP	B-Protein
-	I-Protein
1	E-Protein
P2	O
promoter	O
following	O
the	O
binding	O
of	O
Tax	S-Protein
and	O
HDAC1	S-Protein
.	O

This	O
is	O
in	O
agreement	O
with	O
coimmunoprecipitation	O
studies	O
where	O
NF	O
-	O
kappaB	O
competed	O
with	O
HDAC1	S-Protein
for	O
association	O
with	O
Tax	S-Protein
protein	O
.	O

We	O
propose	O
that	O
in	O
TIPS	O
,	O
Tax	S-Protein
recruits	O
HDAC1	S-Protein
to	O
the	O
SHP	B-Protein
-	I-Protein
1	E-Protein
P2	O
promoter	O
and	O
forms	O
an	O
inhibitory	O
complex	O
that	O
results	O
in	O
deacetylation	O
and	O
dissociation	O
of	O
NF	O
-	O
kappaB	O
from	O
the	O
promoter	O
and	O
attenuation	O
of	O
SHP	B-Protein
-	I-Protein
1	E-Protein
expression	O
.	O

TIPS	O
provides	O
a	O
possible	O
first	O
step	O
toward	O
HTLV	O
-	O
1	O
leukemogenesis	O
through	O
its	O
down	O
-	O
modulation	O
of	O
this	O
key	O
immediate	O
early	O
negative	O
regulator	O
of	O
IL	B-Protein
-	I-Protein
2	E-Protein
signaling	O
.	O

Methylation	O
of	O
CASP8	S-Protein
,	O
DCR2	S-Protein
,	O
and	O
HIN	B-Protein
-	I-Protein
1	E-Protein
in	O
neuroblastoma	O
is	O
associated	O
with	O
poor	O
outcome	O
.	O

PURPOSE	O
:	O
Epigenetic	O
aberrations	O
have	O
been	O
shown	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
most	O
cancers	O
.	O

To	O
investigate	O
the	O
clinical	O
significance	O
of	O
epigenetic	O
changes	O
in	O
neuroblastoma	O
,	O
we	O
evaluated	O
the	O
relationship	O
between	O
clinicopathologic	O
variables	O
and	O
the	O
pattern	O
of	O
gene	O
methylation	O
in	O
neuroblastoma	O
cell	O
lines	O
and	O
tumors	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Methylation	O
-	O
specific	O
PCR	O
was	O
used	O
to	O
evaluate	O
the	O
gene	O
methylation	O
status	O
of	O
19	O
genes	O
in	O
14	O
neuroblastoma	O
cell	O
lines	O
and	O
8	O
genes	O
in	O
70	O
primary	O
neuroblastoma	O
tumors	O
.	O

Associations	O
between	O
gene	O
methylation	O
,	O
established	O
prognostic	O
factors	O
,	O
and	O
outcome	O
were	O
evaluated	O
.	O

Log	O
-	O
rank	O
tests	O
were	O
used	O
to	O
identify	O
the	O
number	O
of	O
methylated	O
genes	O
that	O
was	O
most	O
predictive	O
of	O
overall	O
survival	O
.	O

RESULTS	O
:	O
Epigenetic	O
changes	O
were	O
detected	O
in	O
the	O
neuroblastoma	O
cell	O
lines	O
and	O
primary	O
tumors	O
,	O
although	O
the	O
pattern	O
of	O
methylation	O
varied	O
.	O

Eight	O
of	O
the	O
19	O
genes	O
analyzed	O
were	O
methylated	O
in	O
>	O
70	O
%	O
of	O
the	O
cell	O
lines	O
.	O

Epigenetic	O
changes	O
of	O
four	O
genes	O
were	O
detected	O
in	O
only	O
small	O
numbers	O
of	O
cell	O
lines	O
.	O

None	O
of	O
the	O
cell	O
lines	O
had	O
methylation	O
of	O
the	O
other	O
seven	O
genes	O
analyzed	O
.	O

In	O
primary	O
neuroblastoma	O
tumors	O
,	O
high	O
-	O
risk	O
disease	O
and	O
poor	O
outcome	O
were	O
associated	O
with	O
methylation	O
of	O
DCR2	S-Protein
,	O
CASP8	S-Protein
,	O
and	O
HIN	B-Protein
-	I-Protein
1	E-Protein
individually	O
.	O

Although	O
methylation	O
of	O
the	O
other	O
five	O
individual	O
genes	O
was	O
not	O
predictive	O
of	O
poor	O
outcome	O
,	O
a	O
trend	O
toward	O
decreased	O
survival	O
was	O
seen	O
in	O
patients	O
with	O
a	O
methylation	O
phenotype	O
,	O
defined	O
as	O
>	O
or	O
=	O
4	O
methylated	O
genes	O
(	O
P	O
=	O
0	O
.	O
055	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
study	O
indicates	O
that	O
clinically	O
aggressive	O
neuroblastoma	O
tumors	O
have	O
aberrant	O
methylation	O
of	O
multiple	O
genes	O
and	O
provides	O
a	O
rationale	O
for	O
exploring	O
treatment	O
strategies	O
that	O
include	O
demethylating	O
agents	O
.	O

Expression	O
of	O
the	O
Trichoderma	O
reesei	O
tyrosinase	B-Protein
2	E-Protein
in	O
Pichia	O
pastoris	O
:	O
isotopic	O
labeling	O
and	O
physicochemical	O
characterization	O
.	O

Trichoderma	O
reesei	O
tyrosinase	O
TYR2	S-Protein
has	O
been	O
demonstrated	O
to	O
be	O
able	O
to	O
oxidize	O
various	O
phenolic	O
compounds	O
and	O
also	O
peptide	O
and	O
protein	O
bound	O
tyrosine	O
,	O
and	O
thus	O
is	O
of	O
great	O
interest	O
for	O
different	O
biotechnological	O
applications	O
.	O

In	O
order	O
to	O
understand	O
the	O
reaction	O
mechanism	O
of	O
the	O
enzyme	O
it	O
would	O
be	O
essential	O
to	O
solve	O
its	O
three	O
dimensional	O
structure	O
.	O

Pichia	O
pastoris	O
is	O
a	O
suitable	O
expression	O
system	O
for	O
the	O
production	O
of	O
recombinant	O
enzymes	O
for	O
NMR	O
studies	O
and	O
therefore	O
we	O
expressed	O
TYR2	S-Protein
in	O
this	O
host	O
.	O

As	O
a	O
result	O
of	O
extensive	O
optimization	O
,	O
the	O
production	O
yield	O
of	O
active	O
histidine	O
tagged	O
tyrosinase	O
purified	O
from	O
P	O
.	O
pastoris	O
shake	O
flask	O
cultures	O
was	O
increased	O
from	O
2	O
.	O
5	O
to	O
24	O
mg	O
/	O
L	O
.	O

Correct	O
copper	O
concentration	O
in	O
the	O
growth	O
medium	O
was	O
critical	O
for	O
the	O
expression	O
of	O
this	O
copper	O
containing	O
enzyme	O
.	O

Our	O
analysis	O
showed	O
that	O
TYR2	S-Protein
expressed	O
in	O
P	O
.	O
pastoris	O
is	O
post	O
-	O
translationally	O
modified	O
;	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
153	O
amino	O
acids	O
of	O
the	O
protein	O
is	O
proteolytically	O
cleaved	O
off	O
from	O
the	O
catalytic	O
domain	O
and	O
the	O
only	O
potential	O
N	O
-	O
glycosylation	O
site	O
is	O
glycosylated	O
.	O

The	O
activities	O
of	O
TYR2	S-Protein
expressed	O
in	O
P	O
.	O
pastoris	O
and	O
T	O
.	O
reesei	O
on	O
diphenolic	O
L	O
-	O
dopa	O
and	O
monophenolic	O
L	O
-	O
tyrosine	O
were	O
rather	O
similar	O
.	O

The	O
TYR2	S-Protein
expressed	O
in	O
P	O
.	O
pastoris	O
showed	O
the	O
same	O
physicochemical	O
properties	O
in	O
CD	O
and	O
unfolding	O
assays	O
as	O
the	O
native	O
TYR2	S-Protein
enzyme	O
.	O

Uniform	O
isotopic	O
(	O
15	O
)	O
N	O
-	O
labeling	O
of	O
TYR2	S-Protein
was	O
carried	O
out	O
with	O
(	O
15	O
)	O
NH	O
(	O
4	O
)	O
SO	O
(	O
4	O
)	O
in	O
minimal	O
medium	O
to	O
assess	O
the	O
suitability	O
of	O
the	O
expression	O
system	O
for	O
investigation	O
by	O
NMR	O
spectroscopy	O
.	O

Asparaginyl	O
hydroxylation	O
of	O
the	O
Notch	O
ankyrin	O
repeat	O
domain	O
by	O
factor	B-Protein
inhibiting	I-Protein
hypoxia	I-Protein
-	I-Protein
inducible	I-Protein
factor	E-Protein
.	O

The	O
stability	O
and	O
activity	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
are	O
regulated	O
by	O
the	O
post	O
-	O
translational	O
hydroxylation	O
of	O
specific	O
prolyl	O
and	O
asparaginyl	O
residues	O
.	O

We	O
show	O
that	O
the	O
HIF	B-Protein
asparaginyl	I-Protein
hydroxylase	E-Protein
,	O
factor	B-Protein
inhibiting	I-Protein
HIF	E-Protein
(	O
FIH	S-Protein
)	O
,	O
also	O
catalyzes	O
hydroxylation	O
of	O
highly	O
conserved	O
asparaginyl	O
residues	O
within	O
ankyrin	O
repeat	O
(	O
AR	O
)	O
domains	O
(	O
ARDs	O
)	O
of	O
endogenous	O
Notch	O
receptors	O
.	O

AR	O
hydroxylation	O
decreases	O
the	O
extent	O
of	O
ARD	O
binding	O
to	O
FIH	S-Protein
while	O
not	O
affecting	O
signaling	O
through	O
the	O
canonical	O
Notch	O
pathway	O
.	O

ARD	O
proteins	O
were	O
found	O
to	O
efficiently	O
compete	O
with	O
HIF	O
for	O
FIH	S-Protein
-	O
dependent	O
hydroxylation	O
.	O

Crystallographic	O
analyses	O
of	O
the	O
hydroxylated	O
Notch	O
ARD	O
(	O
2	O
.	O
35A	O
)	O
and	O
of	O
Notch	O
peptides	O
bound	O
to	O
FIH	O
(	O
2	O
.	O
4	O
-	O
2	O
.	O
6A	O
)	O
reveal	O
the	O
stereochemistry	O
of	O
hydroxylation	O
on	O
the	O
AR	O
and	O
imply	O
that	O
significant	O
conformational	O
changes	O
are	O
required	O
in	O
the	O
ARD	O
fold	O
in	O
order	O
to	O
enable	O
hydroxylation	O
at	O
the	O
FIH	S-Protein
active	O
site	O
.	O

We	O
propose	O
that	O
ARD	O
proteins	O
function	O
as	O
natural	O
inhibitors	O
of	O
FIH	S-Protein
and	O
that	O
the	O
hydroxylation	O
status	O
of	O
these	O
proteins	O
provides	O
another	O
oxygen	O
-	O
dependent	O
interface	O
that	O
modulates	O
HIF	O
signaling	O
.	O

Mutational	O
analysis	O
of	O
the	O
myxovirescin	O
biosynthetic	O
gene	O
cluster	O
reveals	O
novel	O
insights	O
into	O
the	O
functional	O
elaboration	O
of	O
polyketide	O
backbones	O
.	O

It	O
has	O
been	O
proposed	O
that	O
two	O
acyl	O
carrier	O
proteins	O
(	O
ACPs	O
)	O
-	O
TaB	S-Protein
and	O
TaE	S-Protein
-	O
-	O
and	O
two	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
synthases	O
(	O
HMGSs	O
)	O
-	O
-	O
TaC	S-Protein
and	O
TaF	S-Protein
-	O
-	O
could	O
constitute	O
two	O
functional	O
ACP	O
-	O
HMGS	O
pairs	O
(	O
TaB	S-Protein
/	O
TaC	S-Protein
and	O
TaE	S-Protein
/	O
TaF	S-Protein
)	O
responsible	O
for	O
the	O
incorporation	O
of	O
acetate	O
and	O
propionate	O
units	O
into	O
the	O
myxovirescin	O
A	O
scaffold	O
,	O
leading	O
to	O
the	O
formation	O
of	O
beta	O
-	O
methyl	O
and	O
beta	O
-	O
ethyl	O
groups	O
,	O
respectively	O
.	O

It	O
has	O
been	O
suggested	O
that	O
three	O
more	O
proteins	O
-	O
-	O
TaX	S-Protein
and	O
TaY	S-Protein
,	O
which	O
are	O
members	O
of	O
the	O
superfamily	O
of	O
enoyl	O
-	O
CoA	O
hydratases	O
(	O
ECHs	O
)	O
,	O
and	O
a	O
variant	O
ketosynthase	O
(	O
KS	O
)	O
TaK	S-Protein
-	O
-	O
are	O
shared	O
between	O
two	O
ACP	O
-	O
HMGS	O
pairs	O
,	O
to	O
give	O
the	O
complete	O
set	O
of	O
enzymes	O
required	O
to	O
perform	O
the	O
beta	O
-	O
alkylations	O
.	O

The	O
beta	O
-	O
methyl	O
branch	O
is	O
presumably	O
further	O
hydroxylated	O
(	O
by	O
TaH	S-Protein
)	O
and	O
methylated	O
to	O
produce	O
the	O
methoxymethyl	O
group	O
observed	O
in	O
myxovirescin	O
A	O
.	O

To	O
substantiate	O
this	O
hypothesis	O
,	O
a	O
series	O
of	O
gene	O
-	O
deletion	O
mutants	O
were	O
created	O
,	O
and	O
the	O
effects	O
of	O
these	O
mutations	O
on	O
myxovirescin	O
production	O
were	O
examined	O
.	O

As	O
predicted	O
,	O
DeltataB	S-Protein
and	O
DeltataE	S-Protein
ACP	O
mutants	O
revealed	O
similar	O
phenotypes	O
to	O
their	O
associated	O
HMGS	O
mutants	O
DeltataC	S-Protein
and	O
DeltataF	S-Protein
,	O
respectively	O
,	O
thus	O
providing	O
direct	O
evidence	O
for	O
the	O
role	O
of	O
TaE	S-Protein
/	O
TaF	S-Protein
in	O
the	O
formation	O
of	O
the	O
beta	O
-	O
ethyl	O
branch	O
and	O
implying	O
a	O
role	O
for	O
TaB	S-Protein
/	O
TaC	S-Protein
in	O
the	O
formation	O
of	O
the	O
beta	O
-	O
methyl	O
group	O
.	O

Production	O
of	O
myxovirescin	O
A	O
was	O
dramatically	O
reduced	O
in	O
a	O
DeltataK	S-Protein
mutant	O
and	O
abolished	O
in	O
both	O
the	O
DeltataX	S-Protein
and	O
the	O
DeltataY	S-Protein
mutant	O
backgrounds	O
.	O

Analysis	O
of	O
a	O
DeltataH	S-Protein
mutant	O
confirmed	O
the	O
role	O
of	O
the	O
cytochrome	O
P450	O
TaH	S-Protein
in	O
hydroxylation	O
of	O
the	O
beta	O
-	O
methyl	O
group	O
.	O

Taken	O
together	O
,	O
these	O
experiments	O
support	O
a	O
model	O
in	O
which	O
the	O
discrete	O
ACPs	O
TaB	S-Protein
and	O
TaE	S-Protein
are	O
compatible	O
only	O
with	O
their	O
associated	O
HMGSs	O
TaC	S-Protein
and	O
TaF	S-Protein
,	O
respectively	O
,	O
and	O
function	O
in	O
a	O
substrate	O
-	O
specific	O
manner	O
.	O

Both	O
TaB	S-Protein
and	O
TaC	S-Protein
are	O
essential	O
for	O
myxovirescin	O
production	O
,	O
and	O
the	O
TaB	S-Protein
/	O
TaC	S-Protein
pair	O
can	O
rescue	O
antibiotic	O
production	O
in	O
the	O
absence	O
of	O
either	O
TaE	S-Protein
or	O
TaF	S-Protein
.	O

Finally	O
,	O
the	O
reduced	O
level	O
of	O
myxovirescin	O
production	O
in	O
the	O
DeltataE	S-Protein
mutant	O
,	O
relative	O
to	O
the	O
DeltataF	S-Protein
strain	O
,	O
suggests	O
an	O
additional	O
function	O
of	O
the	O
TaE	S-Protein
ACP	O
.	O

Clinical	O
application	O
of	O
methylation	O
specific	O
-	O
polymerase	O
chain	O
reaction	O
in	O
serum	O
of	O
patients	O
with	O
gastric	O
cancer	O
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
We	O
previously	O
reported	O
that	O
aberrant	O
methylation	O
of	O
p16	S-Protein
and	O
/	O
or	O
E	B-Protein
-	I-Protein
cadherin	E-Protein
genes	O
in	O
serum	O
DNA	O
could	O
serve	O
together	O
as	O
a	O
tumor	O
marker	O
in	O
gastric	O
cancer	O
.	O

We	O
presently	O
investigated	O
whether	O
sensitivity	O
could	O
be	O
increased	O
by	O
consideration	O
of	O
a	O
third	O
gene	O
,	O
which	O
encodes	O
retinoic	B-Protein
acid	I-Protein
receptor	I-Protein
-	I-Protein
1	E-Protein
(	O
RARbeta	S-Protein
)	O
.	O

METHODOLOGY	O
:	O
We	O
performed	O
a	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
MSP	O
)	O
in	O
serum	O
DNA	O
to	O
detect	O
aberrant	O
methylation	O
of	O
RARbeta	S-Protein
from	O
109	O
preoperative	O
gastric	O
cancer	O
patients	O
,	O
in	O
which	O
the	O
first	O
two	O
genes	O
had	O
been	O
characterized	O
.	O

We	O
also	O
examined	O
all	O
three	O
genes	O
in	O
sera	O
from	O
10	O
outpatients	O
during	O
postgastrectomy	O
follow	O
-	O
up	O
.	O

RESULTS	O
:	O
Aberrant	O
methylation	O
of	O
RARbeta	S-Protein
was	O
demonstrated	O
in	O
26	O
preoperative	O
patients	O
(	O
24	O
%	O
)	O
.	O

Considering	O
this	O
with	O
previous	O
results	O
,	O
52	O
patients	O
(	O
48	O
%	O
)	O
of	O
the	O
109	O
preoperative	O
showed	O
hypermethylation	O
of	O
at	O
least	O
one	O
gene	O
(	O
p16	S-Protein
,	O
E	B-Protein
-	I-Protein
cadherin	E-Protein
,	O
and	O
/	O
or	O
RARbeta	S-Protein
)	O
.	O

No	O
aberrant	O
methylation	O
was	O
detected	O
in	O
control	O
sera	O
.	O

In	O
the	O
follow	O
-	O
up	O
group	O
,	O
aberrant	O
methylation	O
was	O
demonstrated	O
in	O
2	O
of	O
the	O
3	O
patients	O
who	O
had	O
definite	O
radiologic	O
evidence	O
of	O
recurrences	O
.	O

One	O
of	O
the	O
patients	O
showing	O
promoter	O
hypermethylation	O
without	O
definite	O
findings	O
of	O
recurrence	O
at	O
the	O
time	O
of	O
analysis	O
developed	O
peritoneal	O
recurrence	O
6	O
months	O
later	O
.	O

CONCLUSIONS	O
:	O
Including	O
the	O
MSP	O
assay	O
in	O
conventional	O
follow	O
-	O
up	O
could	O
facilitate	O
early	O
detection	O
of	O
recurrent	O
disease	O
in	O
gastric	O
cancer	O
patients	O
.	O

Site	O
-	O
specific	O
N	O
-	O
glycan	O
characterization	O
of	O
human	O
complement	B-Protein
factor	I-Protein
H	E-Protein
.	O

Human	O
complement	B-Protein
factor	I-Protein
H	E-Protein
(	O
CFH	S-Protein
)	O
is	O
a	O
plasma	O
glycoprotein	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
alternative	O
pathway	O
of	O
the	O
complement	O
system	O
.	O

A	O
deficiency	O
in	O
CFH	S-Protein
is	O
a	O
cause	O
of	O
severe	O
pathologies	O
like	O
atypical	O
haemolytic	O
uraemic	O
syndrome	O
(	O
aHUS	O
)	O
.	O

CFH	S-Protein
is	O
a	O
155	O
-	O
kDa	O
glycoprotein	O
containing	O
nine	O
potential	O
N	O
-	O
glycosylation	O
sites	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
present	O
a	O
quantitative	O
glycosylation	O
analysis	O
of	O
CFH	S-Protein
using	O
capillary	O
electrophoresis	O
and	O
a	O
complete	O
site	O
-	O
specific	O
N	O
-	O
glycan	O
characterization	O
using	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
(	O
MALDI	O
-	O
TOF	O
)	O
and	O
liquid	O
chromatography	O
-	O
electrospray	O
ionization	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
ESIMS	O
/	O
MS	O
)	O
.	O

A	O
17	O
.	O
9	O
-	O
kDa	O
mass	O
decrease	O
,	O
observed	O
after	O
glycosidase	O
treatment	O
,	O
indicated	O
that	O
N	O
-	O
glycosylation	O
is	O
the	O
major	O
post	O
-	O
translational	O
modification	O
of	O
CFH	S-Protein
.	O

This	O
mass	O
difference	O
is	O
consistent	O
with	O
CFH	S-Protein
glycosylation	O
by	O
diantennary	O
disialylated	O
glycans	O
of	O
2204	O
Da	O
on	O
eight	O
sites	O
.	O

CFH	S-Protein
was	O
not	O
sensitive	O
to	O
endoglycosidase	B-Protein
H	E-Protein
(	O
Endo	B-Protein
H	E-Protein
)	O
deglycosylation	O
,	O
indicating	O
the	O
absence	O
of	O
hybrid	O
and	O
oligomannose	O
structures	O
.	O

Quantitative	O
analysis	O
showed	O
that	O
CFH	S-Protein
is	O
mainly	O
glycosylated	O
by	O
complex	O
,	O
diantennary	O
disialylated	O
,	O
non	O
-	O
fucosylated	O
glycans	O
.	O

Disialylated	O
fucosylated	O
and	O
monosialylated	O
non	O
-	O
fucosylated	O
oligosaccharides	O
were	O
also	O
identified	O
.	O

MS	O
analysis	O
allowed	O
complete	O
characterization	O
of	O
the	O
protein	O
backbone	O
,	O
verification	O
of	O
the	O
glycosylation	O
sites	O
and	O
site	O
-	O
specific	O
N	O
-	O
glycan	O
identification	O
.	O

The	O
absence	O
of	O
glycosylation	O
at	O
Asn199	O
of	O
the	O
NGSP	O
sequence	O
of	O
CFH	S-Protein
is	O
shown	O
.	O

Asn511	O
,	O
Asn700	O
,	O
Asn784	O
,	O
Asn804	O
,	O
Asn864	O
,	O
Asn893	O
,	O
Asn1011	O
and	O
Asn1077	O
are	O
glycosylated	O
essentially	O
by	O
diantennary	O
disialylated	O
structures	O
with	O
a	O
relative	O
distribution	O
varying	O
between	O
45	O
%	O
for	O
Asn804	O
and	O
75	O
%	O
for	O
Asn864	O
.	O

Diantennary	O
monosialylated	O
glycans	O
and	O
triantennary	O
trisialylated	O
fucosylated	O
and	O
non	O
-	O
fucosylated	O
structures	O
have	O
also	O
been	O
identified	O
.	O

Interestingly	O
,	O
the	O
sialylation	O
level	O
along	O
with	O
the	O
amount	O
of	O
triantennary	O
structures	O
decreases	O
from	O
the	O
N	O
-	O
to	O
the	O
C	O
-	O
terminal	O
side	O
of	O
the	O
protein	O
.	O

Epigenetic	O
regulation	O
of	O
microRNA	B-Protein
-	I-Protein
370	E-Protein
by	O
interleukin	B-Protein
-	I-Protein
6	E-Protein
in	O
malignant	O
human	O
cholangiocytes	O
.	O

Interleukin	B-Protein
-	I-Protein
6	E-Protein
(	O
IL	B-Protein
-	I-Protein
6	E-Protein
)	O
is	O
overexpressed	O
and	O
contributes	O
to	O
tumor	O
cell	O
growth	O
in	O
cholangiocarcinoma	O
.	O

Enforced	O
IL	B-Protein
-	I-Protein
6	E-Protein
production	O
can	O
alter	O
the	O
expression	O
of	O
specific	O
microRNAs	O
(	O
miRNAs	O
)	O
involved	O
in	O
tumor	O
growth	O
,	O
and	O
moreover	O
can	O
modulate	O
expression	O
of	O
methylation	O
-	O
dependent	O
genes	O
.	O

Thus	O
,	O
we	O
assessed	O
the	O
methylation	O
-	O
dependent	O
regulation	O
of	O
miRNA	O
expression	O
in	O
human	O
malignant	O
cholangiocytes	O
stably	O
transfected	O
to	O
overexpress	O
IL	B-Protein
-	I-Protein
6	E-Protein
.	O

The	O
expression	O
of	O
the	O
methyltransferases	O
DNA	B-Protein
methyltransferase	I-Protein
enzyme	I-Protein
-	I-Protein
1	E-Protein
and	O
HASJ4442	S-Protein
was	O
increased	O
by	O
IL	B-Protein
-	I-Protein
6	E-Protein
overexpression	O
,	O
but	O
was	O
decreased	O
by	O
the	O
methylation	O
inhibitor	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
(	O
5	O
-	O
aza	O
-	O
CdR	O
)	O
.	O

Expression	O
profiling	O
identified	O
seven	O
miRNAs	O
that	O
were	O
significantly	O
downregulated	O
by	O
IL	B-Protein
-	I-Protein
6	E-Protein
overexpression	O
(	O
<	O
0	O
.	O
4	O
-	O
fold	O
)	O
and	O
upregulated	O
(	O
>	O
2	O
-	O
fold	O
)	O
by	O
5	O
-	O
aza	O
-	O
CdR	O
.	O

One	O
of	O
these	O
,	O
miR	B-Protein
-	I-Protein
370	E-Protein
,	O
is	O
embedded	O
in	O
a	O
CpG	O
island	O
.	O

Although	O
5	O
-	O
aza	O
-	O
CdR	O
increased	O
miR	B-Protein
-	I-Protein
370	E-Protein
expression	O
by	O
2	O
.	O
1	O
-	O
fold	O
in	O
malignant	O
cells	O
,	O
the	O
expression	O
in	O
nonmalignant	O
cells	O
was	O
unchanged	O
.	O

The	O
oncogene	O
mitogen	B-Protein
-	I-Protein
activated	I-Protein
protein	I-Protein
kinase	I-Protein
kinase	I-Protein
kinase	I-Protein
8	E-Protein
(	O
MAP3K8	S-Protein
)	O
was	O
identified	O
as	O
a	O
target	O
of	O
miR	B-Protein
-	I-Protein
370	E-Protein
,	O
and	O
its	O
expression	O
was	O
decreased	O
by	O
5	O
-	O
aza	O
-	O
CdR	O
in	O
cholangiocarcinoma	O
cells	O
.	O

Overexpression	O
of	O
IL	B-Protein
-	I-Protein
6	E-Protein
reduced	O
miR	B-Protein
-	I-Protein
370	E-Protein
expression	O
and	O
reinstated	O
MAP3K8	S-Protein
expression	O
in	O
vitro	O
as	O
well	O
as	O
in	O
tumor	O
cell	O
xenografts	O
in	O
vivo	O
.	O

Thus	O
,	O
IL	B-Protein
-	I-Protein
6	E-Protein
may	O
contribute	O
to	O
tumor	O
growth	O
by	O
modulation	O
of	O
expression	O
of	O
selected	O
miRNAs	O
,	O
such	O
as	O
miR	B-Protein
-	I-Protein
370	E-Protein
.	O

These	O
studies	O
define	O
a	O
mechanism	O
by	O
which	O
inflammation	O
-	O
associated	O
cytokines	O
can	O
epigenetically	O
modulate	O
gene	O
expression	O
and	O
directly	O
contribute	O
to	O
tumor	O
biology	O
.	O

Rpn10	S-Protein
-	O
mediated	O
degradation	O
of	O
ubiquitinated	O
proteins	O
is	O
essential	O
for	O
mouse	O
development	O
.	O

Rpn10	S-Protein
is	O
a	O
subunit	O
of	O
the	O
26S	O
proteasome	O
that	O
recognizes	O
polyubiquitinated	O
proteins	O
.	O

The	O
importance	O
of	O
Rpn10	S-Protein
in	O
ubiquitin	S-Protein
-	O
mediated	O
proteolysis	O
is	O
debatable	O
,	O
since	O
a	O
deficiency	O
of	O
Rpn10	S-Protein
causes	O
different	O
phenotypes	O
in	O
different	O
organisms	O
.	O

To	O
date	O
,	O
the	O
role	O
of	O
mammalian	O
Rpn10	S-Protein
has	O
not	O
been	O
examined	O
genetically	O
.	O

Moreover	O
,	O
vertebrates	O
have	O
five	O
splice	O
variants	O
of	O
Rpn10	S-Protein
whose	O
expressions	O
are	O
developmentally	O
regulated	O
,	O
but	O
their	O
biological	O
significance	O
is	O
not	O
understood	O
.	O

To	O
address	O
these	O
issues	O
,	O
we	O
generated	O
three	O
kinds	O
of	O
Rpn10	S-Protein
mutant	O
mice	O
.	O

Rpn10	S-Protein
knockout	O
resulted	O
in	O
early	O
-	O
embryonic	O
lethality	O
,	O
demonstrating	O
the	O
essential	O
role	O
of	O
Rpn10	S-Protein
in	O
mouse	O
development	O
.	O

Rpn10a	S-Protein
knock	O
-	O
in	O
mice	O
,	O
which	O
exclusively	O
expressed	O
the	O
constitutive	O
type	O
of	O
Rpn10	S-Protein
and	O
did	O
not	O
express	O
vertebrate	O
-	O
specific	O
variants	O
,	O
grew	O
normally	O
,	O
indicating	O
that	O
Rpn10	S-Protein
diversity	O
is	O
not	O
essential	O
for	O
conventional	O
development	O
.	O

Mice	O
expressing	O
the	O
N	O
-	O
terminal	O
portion	O
of	O
Rpn10	S-Protein
,	O
which	O
contained	O
a	O
von	O
Willebrand	O
factor	O
A	O
(	O
VWA	O
)	O
domain	O
but	O
lacked	O
ubiquitin	O
-	O
interacting	O
motifs	O
(	O
Rpn10DeltaUIM	S-Protein
)	O
,	O
also	O
exhibited	O
embryonic	O
lethality	O
,	O
suggesting	O
the	O
important	O
contribution	O
of	O
UIM	O
domains	O
to	O
viability	O
,	O
but	O
survived	O
longer	O
than	O
Rpn10	S-Protein
-	O
null	O
mice	O
,	O
consistent	O
with	O
a	O
"	O
facilitator	O
"	O
function	O
of	O
the	O
VWA	O
domain	O
.	O

Biochemical	O
analysis	O
of	O
the	O
Rpn10DeltaUIM	S-Protein
liver	O
showed	O
specific	O
impairment	O
of	O
degradation	O
of	O
ubiquitinated	O
proteins	O
.	O

Our	O
results	O
demonstrate	O
that	O
Rpn10	S-Protein
-	O
mediated	O
degradation	O
of	O
ubiquitinated	O
proteins	O
,	O
catalyzed	O
by	O
UIMs	O
,	O
is	O
indispensable	O
for	O
mammalian	O
life	O
.	O

Induction	O
of	O
histone	S-Protein
acetylation	O
on	O
the	O
CRBPII	S-Protein
gene	O
in	O
perinatal	O
rat	O
small	O
intestine	O
.	O

The	O
expression	O
of	O
genes	O
associated	O
with	O
lipid	O
and	O
vitamin	O
A	O
metabolism	O
is	O
elevated	O
when	O
the	O
small	O
intestinal	O
mucosa	O
is	O
maturing	O
rapidly	O
during	O
the	O
perinatal	O
period	O
.	O

We	O
have	O
previously	O
reported	O
that	O
cellular	B-Protein
retinol	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
type	I-Protein
II	E-Protein
(	O
CRBPII	S-Protein
)	O
mRNA	O
levels	O
rise	O
abruptly	O
in	O
the	O
rat	O
small	O
intestine	O
during	O
this	O
period	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
the	O
acetylation	O
of	O
histones	B-Protein
H3	E-Protein
and	O
H4	S-Protein
is	O
involved	O
in	O
the	O
intestinal	O
expression	O
of	O
CRBPII	S-Protein
during	O
the	O
perinatal	O
stage	O
.	O

The	O
expression	O
of	O
cyclin	B-Protein
D1	E-Protein
and	O
cyclin	B-Protein
B1	E-Protein
genes	O
,	O
which	O
are	O
markers	O
of	O
cell	O
proliferation	O
,	O
decreased	O
markedly	O
during	O
the	O
perinatal	O
period	O
,	O
whereas	O
expression	O
of	O
CRBPII	S-Protein
as	O
well	O
as	O
villin	S-Protein
,	O
a	O
marker	O
of	O
intestinal	O
maturation	O
,	O
increased	O
rapidly	O
.	O

Using	O
a	O
ChIP	O
assay	O
,	O
we	O
showed	O
rapid	O
induction	O
of	O
acetylation	O
of	O
the	O
histones	B-Protein
H3	E-Protein
and	O
H4	S-Protein
which	O
interacted	O
with	O
the	O
promoter	O
/	O
enhancer	O
region	O
of	O
the	O
CRBPII	S-Protein
gene	O
at	O
this	O
time	O
.	O

The	O
binding	O
of	O
CBP	S-Protein
and	O
p300	S-Protein
,	O
which	O
have	O
histone	S-Protein
acetyltransferase	O
activity	O
,	O
as	O
well	O
as	O
binding	O
of	O
retinoid	B-Protein
X	I-Protein
receptor	I-Protein
alpha	E-Protein
(	O
RXRalpha	S-Protein
)	O
increased	O
on	O
the	O
CRBPII	S-Protein
promoter	O
/	O
enhancer	O
region	O
during	O
the	O
perinatal	O
period	O
.	O

These	O
results	O
suggest	O
that	O
CRBPII	S-Protein
gene	O
expression	O
during	O
the	O
perinatal	O
period	O
is	O
associated	O
with	O
abrupt	O
acetylation	O
of	O
histones	B-Protein
H3	E-Protein
and	O
H4	S-Protein
followed	O
by	O
the	O
binding	O
of	O
CBP	S-Protein
/	O
p300	S-Protein
and	O
RXRalpha	S-Protein
.	O

An	O
endoplasmic	O
reticulum	O
transmembrane	O
prolyl	O
4	O
-	O
hydroxylase	O
is	O
induced	O
by	O
hypoxia	O
and	O
acts	O
on	O
hypoxia	O
-	O
inducible	O
factor	O
alpha	O
.	O

Prolyl	O
4	O
-	O
hydroxylases	O
(	O
P4Hs	O
)	O
act	O
on	O
collagens	O
(	O
C	O
-	O
P4Hs	O
)	O
and	O
the	O
oxygen	O
-	O
dependent	O
degradation	O
domains	O
(	O
ODDDs	O
)	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
alpha	O
subunits	O
(	O
HIF	O
-	O
P4Hs	O
)	O
leading	O
to	O
degradation	O
of	O
the	O
latter	O
.	O

We	O
report	O
data	O
on	O
a	O
human	O
P4H	O
possessing	O
a	O
transmembrane	O
domain	O
(	O
P4H	O
-	O
TM	O
)	O
.	O

Its	O
gene	O
is	O
also	O
found	O
in	O
zebrafish	O
but	O
not	O
in	O
flies	O
and	O
nematodes	O
.	O

Its	O
sequence	O
more	O
closely	O
resembles	O
those	O
of	O
the	O
C	O
-	O
P4Hs	O
than	O
the	O
HIF	O
-	O
P4Hs	O
,	O
but	O
it	O
lacks	O
the	O
peptide	O
substrate	O
-	O
binding	O
domain	O
of	O
the	O
C	O
-	O
P4Hs	O
.	O

P4H	O
-	O
TM	O
levels	O
in	O
cultured	O
cells	O
are	O
increased	O
by	O
hypoxia	O
,	O
and	O
P4H	O
-	O
TM	O
is	O
N	O
-	O
glycosylated	O
and	O
is	O
located	O
in	O
endoplasmic	O
reticulum	O
membranes	O
with	O
its	O
catalytic	O
site	O
inside	O
the	O
lumen	O
,	O
a	O
location	O
differing	O
from	O
those	O
of	O
the	O
HIF	O
-	O
P4Hs	O
.	O

Despite	O
this	O
,	O
P4H	O
-	O
TM	O
overexpression	O
in	O
cultured	O
neuroblastoma	O
cells	O
reduced	O
HIF	O
-	O
alpha	O
ODDD	O
reporter	O
construct	O
levels	O
,	O
and	O
its	O
small	O
interfering	O
RNA	O
increased	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
protein	O
level	O
,	O
in	O
the	O
same	O
way	O
as	O
those	O
of	O
HIF	O
-	O
P4Hs	O
.	O

Furthermore	O
,	O
recombinant	O
P4H	O
-	O
TM	O
hydroxylated	O
the	O
two	O
critical	O
prolines	O
in	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
ODDD	O
in	O
vitro	O
,	O
with	O
a	O
preference	O
for	O
the	O
C	O
-	O
terminal	O
proline	O
,	O
whereas	O
it	O
did	O
not	O
hydroxylate	O
any	O
prolines	O
in	O
recombinant	O
type	O
I	O
procollagen	O
chains	O
.	O

Critical	O
DNA	O
binding	O
interactions	O
of	O
the	O
insulator	O
protein	O
CTCF	S-Protein
:	O
a	O
small	O
number	O
of	O
zinc	O
fingers	O
mediate	O
strong	O
binding	O
,	O
and	O
a	O
single	O
finger	O
-	O
DNA	O
interaction	O
controls	O
binding	O
at	O
imprinted	O
loci	O
.	O

The	O
DNA	O
-	O
binding	O
protein	O
CTCF	S-Protein
(	O
CCCTC	B-Protein
binding	I-Protein
factor	E-Protein
)	O
mediates	O
enhancer	O
blocking	O
insulation	O
at	O
sites	O
throughout	O
the	O
genome	O
and	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
allele	O
-	O
specific	O
expression	O
at	O
the	O
Igf2	S-Protein
/	O
H19	S-Protein
locus	O
and	O
at	O
other	O
imprinted	O
loci	O
.	O

Evidence	O
is	O
also	O
accumulating	O
that	O
CTCF	S-Protein
is	O
involved	O
in	O
large	O
scale	O
organization	O
of	O
genomic	O
chromatin	O
.	O

Although	O
CTCF	S-Protein
has	O
11	O
zinc	O
fingers	O
,	O
we	O
show	O
here	O
that	O
only	O
4	O
of	O
these	O
are	O
essential	O
to	O
strong	O
binding	O
and	O
that	O
they	O
recognize	O
a	O
core	O
12	O
-	O
bp	O
DNA	O
sequence	O
common	O
to	O
most	O
CTCF	S-Protein
sites	O
.	O

By	O
deleting	O
individual	O
fingers	O
and	O
mutating	O
individual	O
sites	O
,	O
we	O
determined	O
the	O
orientation	O
of	O
binding	O
.	O

Furthermore	O
,	O
we	O
were	O
able	O
to	O
identify	O
the	O
specific	O
finger	O
and	O
its	O
point	O
of	O
DNA	O
interaction	O
that	O
are	O
responsible	O
for	O
the	O
loss	O
of	O
CTCF	S-Protein
binding	O
when	O
CpG	O
residues	O
are	O
methylated	O
in	O
the	O
imprinted	O
Igf2	S-Protein
/	O
H19	S-Protein
locus	O
.	O

This	O
single	O
interaction	O
appears	O
to	O
be	O
critical	O
for	O
allele	O
-	O
specific	O
binding	O
and	O
insulation	O
by	O
CTCF	S-Protein
.	O

Promoter	O
methylation	O
status	O
of	O
multiple	O
genes	O
in	O
uveal	O
melanoma	O
.	O

PURPOSE	O
:	O
Aberrant	O
promoter	O
hypermethylation	O
of	O
CpG	O
islands	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
inactivation	O
of	O
tumor	O
-	O
suppressor	O
genes	O
(	O
TSGs	O
)	O
in	O
cancer	O
.	O

Studies	O
of	O
cutaneous	O
melanoma	O
have	O
reported	O
a	O
high	O
methylation	O
rate	O
for	O
MGMT	S-Protein
,	O
DAPK	S-Protein
,	O
RAR	B-Protein
-	I-Protein
b2	E-Protein
,	O
and	O
RASSF1A	S-Protein
.	O

In	O
colon	O
cancer	O
,	O
SOCS	B-Protein
-	I-Protein
1	E-Protein
,	O
IGF	B-Protein
-	I-Protein
2	E-Protein
,	O
RUNX3	S-Protein
,	O
NEUROG1	S-Protein
,	O
and	O
CACNA1G	S-Protein
are	O
commonly	O
inactivated	O
.	O

The	O
concomitant	O
methylation	O
of	O
at	O
least	O
three	O
of	O
these	O
genes	O
may	O
represent	O
a	O
distinct	O
trait	O
,	O
the	O
CpG	O
island	O
methylator	O
phenotype	O
(	O
CIMP	O
)	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
epigenetic	O
inactivation	O
of	O
multiple	O
genes	O
in	O
uveal	O
melanoma	O
.	O

METHODS	O
:	O
Twenty	O
samples	O
of	O
uveal	O
melanoma	O
were	O
analyzed	O
for	O
the	O
methylation	O
status	O
of	O
nine	O
candidate	O
cancer	O
-	O
related	O
genes	O
:	O
MGMT	S-Protein
,	O
DAPK	S-Protein
,	O
RAR	B-Protein
-	I-Protein
b2	E-Protein
,	O
RASSF1A	S-Protein
,	O
SOCS	B-Protein
-	I-Protein
1	E-Protein
,	O
IGF	B-Protein
-	I-Protein
2	E-Protein
,	O
RUNX3	S-Protein
,	O
NEUROG1	S-Protein
,	O
and	O
CACNA1G	S-Protein
,	O
using	O
real	O
-	O
time	O
quantitative	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
after	O
sodium	O
bisulfite	O
modification	O
.	O

RESULTS	O
:	O
Methylation	O
rates	O
of	O
the	O
genes	O
commonly	O
inactivated	O
in	O
cutaneous	O
melanoma	O
were	O
70	O
%	O
for	O
RASSFIA	S-Protein
,	O
5	O
%	O
for	O
MGMT	S-Protein
and	O
DAPK	S-Protein
,	O
and	O
0	O
for	O
RAR	B-Protein
-	I-Protein
b2	E-Protein
.	O

The	O
rates	O
for	O
the	O
CIMP	O
-	O
related	O
genes	O
were	O
25	O
%	O
for	O
RUNX3	S-Protein
,	O
5	O
%	O
for	O
NEUROG1	S-Protein
and	O
CACNA1G	S-Protein
,	O
and	O
0	O
for	O
SOCS	B-Protein
-	I-Protein
1	E-Protein
and	O
IGF	B-Protein
-	I-Protein
2	E-Protein
.	O

None	O
of	O
the	O
samples	O
was	O
CIMP	O
-	O
positive	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
study	O
uveal	O
melanoma	O
was	O
negative	O
for	O
CIMP	O
,	O
with	O
hypermethylation	O
of	O
RASSF1A	S-Protein
.	O

The	O
negative	O
CIMP	O
phenotype	O
and	O
frequent	O
RASSF1A	S-Protein
methylation	O
in	O
uveal	O
melanoma	O
is	O
in	O
accord	O
with	O
its	O
known	O
lack	O
of	O
BRAF	S-Protein
mutations	O
.	O

Given	O
that	O
mutations	O
in	O
genes	O
of	O
the	O
RAS	O
pathway	O
are	O
rarely	O
observed	O
in	O
uveal	O
melanoma	O
,	O
epigenetic	O
inactivation	O
of	O
RASSF1A	S-Protein
may	O
be	O
an	O
alternative	O
mechanism	O
of	O
tumorigenesis	O
.	O

The	O
low	O
frequency	O
of	O
promoter	O
methylation	O
of	O
TSGs	O
commonly	O
inactivated	O
in	O
cutaneous	O
melanoma	O
further	O
stratifies	O
the	O
different	O
tumorigenesis	O
pathway	O
in	O
cutaneous	O
and	O
uveal	O
melanoma	O
.	O

Characterization	O
of	O
protein	O
arginine	O
methyltransferases	O
in	O
porcine	O
brain	O
.	O

Protein	O
arginine	O
methylation	O
is	O
a	O
posttranslational	O
modification	O
involved	O
in	O
various	O
cellular	O
functions	O
including	O
cell	O
signaling	O
,	O
protein	O
subcellular	O
localization	O
and	O
transcriptional	O
regulation	O
.	O

We	O
analyze	O
the	O
protein	O
arginine	O
methyltransferases	O
(	O
PRMTs	O
)	O
that	O
catalyze	O
the	O
formation	O
of	O
methylarginines	O
in	O
porcine	O
brain	O
.	O

We	O
fractionated	O
the	O
brain	O
extracts	O
and	O
determined	O
the	O
PRMT	O
activities	O
as	O
well	O
as	O
the	O
distribution	O
of	O
different	O
PRMT	O
proteins	O
in	O
subcellular	O
fractions	O
of	O
porcine	O
brain	O
.	O

The	O
majority	O
of	O
the	O
type	O
I	O
methyltransferase	O
activities	O
that	O
catalyze	O
the	O
formation	O
of	O
asymmetric	O
dimethylarginines	O
was	O
in	O
the	O
cytosolic	O
S3	O
fraction	O
.	O

High	O
specific	O
activity	O
of	O
the	O
methyltransferase	O
was	O
detected	O
in	O
the	O
S4	O
fraction	O
(	O
high	O
-	O
salt	O
stripping	O
of	O
the	O
ultracentrifugation	O
precipitant	O
P3	O
fraction	O
)	O
,	O
indicating	O
that	O
part	O
of	O
the	O
PRMT	O
was	O
peripherally	O
associated	O
with	O
membrane	O
and	O
ribosomal	O
fractions	O
.	O

The	O
amount	O
and	O
distribution	O
of	O
PRMT1	S-Protein
are	O
consistent	O
with	O
the	O
catalytic	O
activity	O
.	O

The	O
elution	O
patterns	O
from	O
gel	O
filtration	O
and	O
anion	O
exchange	O
chromatography	O
also	O
indicate	O
that	O
the	O
type	O
I	O
activity	O
in	O
S3	O
and	O
S4	O
are	O
mostly	O
from	O
PRMT1	S-Protein
.	O

Our	O
results	O
suggest	O
that	O
part	O
of	O
the	O
type	O
I	O
arginine	O
methyltransferases	O
in	O
brains	O
,	O
mainly	O
PRMT1	S-Protein
,	O
are	O
sequestered	O
in	O
an	O
inactive	O
form	O
as	O
they	O
associated	O
with	O
membranes	O
or	O
large	O
subcellular	O
complexes	O
.	O

Our	O
biochemical	O
analyses	O
confirmed	O
the	O
complex	O
distribution	O
of	O
different	O
PRMTs	O
and	O
implicate	O
their	O
regulation	O
and	O
catalytic	O
activities	O
in	O
brain	O
.	O

A	O
novel	O
class	O
of	O
prolyl	O
hydroxylase	O
inhibitors	O
induces	O
angiogenesis	O
and	O
exerts	O
organ	O
protection	O
against	O
ischemia	O
.	O

OBJECTIVE	O
:	O
Hypoxia	O
inducible	O
factor	O
(	O
HIF	O
)	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
adaptation	O
to	O
ischemic	O
conditions	O
.	O

Its	O
activity	O
is	O
modulated	O
by	O
an	O
oxygen	O
-	O
dependent	O
hydroxylation	O
of	O
proline	O
residues	O
by	O
prolyl	O
hydroxylases	O
(	O
PHD	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
discovered	O
2	O
unique	O
compounds	O
(	O
TM6008	O
and	O
TM6089	O
)	O
,	O
which	O
inhibited	O
PHD	O
and	O
stabilized	O
HIF	O
activity	O
in	O
vitro	O
.	O

Our	O
docking	O
simulation	O
studies	O
based	O
on	O
the	O
3	O
-	O
dimensional	O
structure	O
of	O
human	O
PHD2	S-Protein
disclosed	O
that	O
they	O
preferentially	O
bind	O
to	O
the	O
active	O
site	O
of	O
PHD	O
.	O

Whereas	O
PHD	O
inhibitors	O
previously	O
reported	O
inhibit	O
PHD	O
activity	O
via	O
iron	O
chelation	O
,	O
TM6089	O
does	O
not	O
share	O
an	O
iron	O
chelating	O
motif	O
and	O
is	O
devoid	O
of	O
iron	O
chelating	O
activity	O
.	O

In	O
vitro	O
Matrigel	O
assays	O
and	O
in	O
vivo	O
sponge	O
assays	O
demonstrated	O
enhancement	O
of	O
angiogenesis	O
by	O
local	O
administration	O
of	O
TM6008	O
and	O
TM6089	O
.	O

Their	O
oral	O
administration	O
stimulated	O
HIF	O
activity	O
in	O
various	O
organs	O
of	O
transgenic	O
rats	O
expressing	O
a	O
hypoxia	O
-	O
responsive	O
reporter	O
vector	O
.	O

No	O
acute	O
toxicity	O
was	O
observed	O
up	O
to	O
2	O
weeks	O
after	O
a	O
single	O
oral	O
dose	O
of	O
2000	O
mg	O
/	O
kg	O
for	O
TM6008	O
.	O

Oral	O
administration	O
of	O
TM6008	O
protected	O
neurons	O
in	O
a	O
model	O
of	O
cerebrovascular	O
disease	O
.	O

The	O
protection	O
was	O
associated	O
with	O
amelioration	O
of	O
apoptosis	O
but	O
independent	O
of	O
enhanced	O
angiogenesis	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
uncovered	O
beneficial	O
effects	O
of	O
novel	O
PHD	O
inhibitors	O
preferentially	O
binding	O
to	O
the	O
active	O
site	O
of	O
PHD	O
.	O

CHD8	S-Protein
associates	O
with	O
human	O
Staf	S-Protein
and	O
contributes	O
to	O
efficient	O
U6	O
RNA	O
polymerase	O
III	O
transcription	O
.	O

Chromatin	O
remodeling	O
and	O
histone	S-Protein
modification	O
are	O
essential	O
for	O
eukaryotic	O
transcription	O
regulation	O
,	O
but	O
little	O
is	O
known	O
about	O
chromatin	O
-	O
modifying	O
activities	O
acting	O
on	O
RNA	O
polymerase	O
III	O
(	O
Pol	O
III	O
)	O
-	O
transcribed	O
genes	O
.	O

The	O
human	O
U6	O
small	O
nuclear	O
RNA	O
promoter	O
,	O
located	O
5	O
'	O
of	O
the	O
transcription	O
start	O
site	O
,	O
consists	O
of	O
a	O
core	O
region	O
directing	O
basal	O
transcription	O
and	O
an	O
activating	O
region	O
that	O
recruits	O
the	O
transcription	O
factors	O
Oct	B-Protein
-	I-Protein
1	E-Protein
and	O
Staf	S-Protein
(	O
ZNF143	S-Protein
)	O
.	O

Oct	B-Protein
-	I-Protein
1	E-Protein
activates	O
transcription	O
in	O
part	O
by	O
helping	O
recruit	O
core	O
binding	O
factors	O
,	O
but	O
nothing	O
is	O
known	O
about	O
the	O
mechanisms	O
of	O
transcription	O
activation	O
by	O
Staf	S-Protein
.	O

We	O
show	O
that	O
Staf	S-Protein
activates	O
U6	O
transcription	O
from	O
a	O
preassembled	O
chromatin	O
template	O
in	O
vitro	O
and	O
associates	O
with	O
several	O
proteins	O
linked	O
to	O
chromatin	O
modification	O
,	O
among	O
them	O
chromodomain	B-Protein
-	I-Protein
helicase	I-Protein
-	I-Protein
DNA	I-Protein
binding	I-Protein
protein	I-Protein
8	E-Protein
(	O
CHD8	S-Protein
)	O
.	O

CHD8	S-Protein
binds	O
to	O
histone	B-Protein
H3	E-Protein
di	O
-	O
and	O
trimethylated	O
on	O
lysine	O
4	O
.	O

It	O
resides	O
on	O
the	O
human	O
U6	O
promoter	O
as	O
well	O
as	O
the	O
mRNA	O
IRF3	S-Protein
promoter	O
in	O
vivo	O
and	O
contributes	O
to	O
efficient	O
transcription	O
from	O
both	O
these	O
promoters	O
.	O

Thus	O
,	O
Pol	O
III	O
transcription	O
from	O
type	O
3	O
promoters	O
uses	O
some	O
of	O
the	O
same	O
factors	O
used	O
for	O
chromatin	O
remodeling	O
at	O
Pol	O
II	O
promoters	O
.	O

Protein	B-Protein
arginine	I-Protein
methyltransferase	I-Protein
1	E-Protein
:	O
positively	O
charged	O
residues	O
in	O
substrate	O
peptides	O
distal	O
to	O
the	O
site	O
of	O
methylation	O
are	O
important	O
for	O
substrate	O
binding	O
and	O
catalysis	O
.	O

Protein	O
arginine	O
methyltransferases	O
(	O
PRMTs	O
)	O
are	O
a	O
group	O
of	O
eukaryotic	O
enzymes	O
that	O
catalyze	O
the	O
methylation	O
of	O
Arg	O
residues	O
in	O
a	O
variety	O
of	O
proteins	O
(	O
e	O
.	O
g	O
.	O
,	O
histones	B-Protein
H3	E-Protein
and	O
H4	S-Protein
)	O
,	O
and	O
their	O
activities	O
influence	O
a	O
wide	O
range	O
of	O
cellular	O
processes	O
,	O
including	O
cell	O
growth	O
,	O
RNA	O
splicing	O
,	O
differentiation	O
,	O
and	O
transcriptional	O
regulation	O
.	O

Dysregulation	O
of	O
these	O
enzymes	O
has	O
been	O
linked	O
to	O
heart	O
disease	O
and	O
cancer	O
,	O
suggesting	O
this	O
enzyme	O
family	O
as	O
a	O
novel	O
therapeutic	O
target	O
.	O

To	O
aid	O
the	O
development	O
of	O
PRMT	O
inhibitors	O
,	O
we	O
characterized	O
the	O
substrate	O
specificity	O
of	O
both	O
the	O
rat	O
and	O
human	O
PRMT1	S-Protein
orthologues	O
using	O
histone	O
based	O
peptide	O
substrates	O
.	O

N	O
-	O
and	O
C	O
-	O
terminal	O
truncations	O
to	O
identify	O
a	O
minimal	O
peptide	O
substrate	O
indicate	O
that	O
long	O
-	O
range	O
interactions	O
between	O
enzyme	O
and	O
substrate	O
are	O
important	O
for	O
high	O
rates	O
of	O
substrate	O
capture	O
.	O

The	O
importance	O
of	O
these	O
long	O
-	O
range	O
interactions	O
to	O
substrate	O
capture	O
were	O
confirmed	O
by	O
"	O
mutagenesis	O
"	O
experiments	O
on	O
a	O
minimal	O
peptide	O
substrate	O
.	O

Inhibition	O
studies	O
on	O
S	O
-	O
adenosyl	O
-	O
homocysteine	O
,	O
thioadenosine	O
,	O
methylthioadenosine	O
,	O
homocysteine	O
,	O
and	O
sinefungin	O
suggest	O
that	O
potent	O
and	O
selective	O
bisubstrate	O
analogue	O
inhibitor	O
(	O
s	O
)	O
for	O
PRMT1	S-Protein
can	O
be	O
developed	O
by	O
linking	O
a	O
histone	O
based	O
peptide	O
substrate	O
to	O
homocysteine	O
or	O
sinefungin	O
.	O

Additionally	O
,	O
we	O
present	O
evidence	O
that	O
PRMT1	S-Protein
utilizes	O
a	O
partially	O
processive	O
mechanism	O
to	O
dimethylate	O
its	O
substrates	O
.	O

Calcineurin	O
promotes	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
1alpha	E-Protein
expression	O
by	O
dephosphorylating	O
RACK1	S-Protein
and	O
blocking	O
RACK1	S-Protein
dimerization	O
.	O

Oxygen	O
homeostasis	O
represents	O
an	O
essential	O
organizing	O
principle	O
of	O
metazoan	O
evolution	O
and	O
biology	O
.	O

Hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
1	E-Protein
(	O
HIF	B-Protein
-	I-Protein
1	E-Protein
)	O
is	O
a	O
master	O
regulator	O
of	O
transcriptional	O
responses	O
to	O
changes	O
in	O
O2	O
concentration	O
.	O

HIF	O
-	O
1	O
is	O
a	O
heterodimer	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
and	O
HIF	B-Protein
-	I-Protein
1beta	E-Protein
subunits	O
.	O

O2	O
-	O
dependent	O
degradation	O
of	O
the	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
subunit	O
is	O
mediated	O
by	O
prolyl	O
hydroxylase	O
,	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
protein	E-Protein
(	O
VHL	S-Protein
)	O
/	O
Elongin	B-Protein
-	I-Protein
C	E-Protein
E3	O
ubiquitin	S-Protein
ligase	O
,	O
and	O
the	O
proteasome	O
.	O

O2	O
-	O
independent	O
degradation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
is	O
regulated	O
by	O
the	O
competition	O
of	O
RACK1	S-Protein
and	O
HSP90	S-Protein
for	O
binding	O
to	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

RACK1	S-Protein
binding	O
results	O
in	O
the	O
recruitment	O
of	O
the	O
Elongin	B-Protein
-	I-Protein
C	E-Protein
E3	O
ubiquitin	S-Protein
ligase	O
,	O
leading	O
to	O
VHL	S-Protein
-	O
independent	O
ubiquitination	O
and	O
degradation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
calcineurin	O
inhibits	O
the	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

Calcineurin	O
is	O
a	O
serine	O
/	O
threonine	O
phosphatase	O
that	O
is	O
activated	O
by	O
calcium	O
and	O
calmodulin	S-Protein
.	O

The	O
phosphatase	O
activity	O
of	O
calcineurin	O
is	O
required	O
for	O
its	O
regulation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

RACK1	S-Protein
binds	O
to	O
the	O
catalytic	O
domain	O
of	O
calcineurin	O
and	O
is	O
required	O
for	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
degradation	O
induced	O
by	O
the	O
calcineurin	O
inhibitor	O
cyclosporine	O
A	O
.	O

Elongin	B-Protein
-	I-Protein
C	E-Protein
and	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
each	O
bind	O
to	O
RACK1	S-Protein
and	O
dimerization	O
of	O
RACK1	S-Protein
is	O
required	O
to	O
recruit	O
Elongin	B-Protein
-	I-Protein
C	E-Protein
to	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

Phosphorylation	O
of	O
RACK1	S-Protein
promotes	O
its	O
dimerization	O
and	O
dephosphorylation	O
by	O
calcineurin	O
inhibits	O
dimerization	O
.	O

Serine	O
146	O
within	O
the	O
dimerization	O
domain	O
is	O
phosphorylated	O
and	O
mutation	O
of	O
serine	O
146	O
impairs	O
RACK1	S-Protein
dimerization	O
and	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
degradation	O
.	O

These	O
results	O
indicate	O
that	O
intracellular	O
calcium	O
levels	O
can	O
regulate	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
expression	O
by	O
modulating	O
calcineurin	O
activity	O
and	O
RACK1	S-Protein
dimerization	O
.	O

Flavonoids	O
-	O
induced	O
accumulation	O
of	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
(	I-Protein
HIF	I-Protein
)	I-Protein
-	I-Protein
1alpha	E-Protein
/	O
2alpha	S-Protein
is	O
mediated	O
through	O
chelation	O
of	O
iron	O
.	O

Hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1	I-Protein
alpha	E-Protein
(	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
)	O
is	O
the	O
regulatory	O
subunit	O
of	O
the	O
heterodimeric	O
transcription	O
factor	O
HIF	O
-	O
1	O
that	O
is	O
the	O
key	O
regulator	O
of	O
cellular	O
response	O
to	O
low	O
oxygen	O
tension	O
.	O

Under	O
normoxic	O
conditions	O
,	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
is	O
continuously	O
degraded	O
by	O
the	O
ubiquitin	S-Protein
-	O
proteasome	O
pathway	O
through	O
pVHL	S-Protein
(	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumor	I-Protein
suppressor	I-Protein
protein	E-Protein
)	O
.	O

Under	O
hypoxic	O
conditions	O
,	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
is	O
stabilized	O
and	O
induces	O
the	O
transcription	O
of	O
HIF	O
-	O
1	O
target	O
genes	O
.	O

Quercetin	O
,	O
a	O
flavonoid	O
with	O
anti	O
-	O
oxidant	O
,	O
anti	O
-	O
inflammatory	O
,	O
and	O
kinase	O
modulating	O
properties	O
,	O
has	O
been	O
found	O
to	O
induce	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
accumulation	O
and	O
VEGF	S-Protein
secretion	O
in	O
normoxia	O
.	O

In	O
this	O
study	O
,	O
the	O
molecular	O
mechanisms	O
of	O
quercetin	O
-	O
mediated	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
accumulation	O
were	O
investigated	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
,	O
in	O
addition	O
to	O
being	O
induced	O
by	O
hypoxia	O
,	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
can	O
be	O
induced	O
through	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
/	O
Akt	O
and	O
p53	S-Protein
signaling	O
pathways	O
.	O

But	O
our	O
study	O
revealed	O
,	O
through	O
p53	S-Protein
mutant	O
-	O
type	O
as	O
well	O
as	O
p53	S-Protein
null	O
cell	O
lines	O
,	O
that	O
neither	O
the	O
PI3K	O
/	O
Akt	O
nor	O
the	O
p53	S-Protein
signaling	O
pathway	O
is	O
required	O
for	O
quercetin	O
-	O
induced	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
accumulation	O
.	O

And	O
we	O
observed	O
that	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
accumulated	O
by	O
quercetin	O
is	O
not	O
ubiquitinated	O
and	O
the	O
interaction	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
with	O
pVHL	S-Protein
is	O
reduced	O
,	O
compared	O
with	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
accumulated	O
by	O
the	O
proteasome	O
inhibitor	O
MG132	O
.	O

The	O
use	O
of	O
quercetin	O
'	O
s	O
analogues	O
showed	O
that	O
only	O
quercetin	O
and	O
galangin	O
induce	O
HIF	B-Protein
-	I-Protein
1	E-Protein
/	O
2alpha	S-Protein
accumulation	O
and	O
this	O
effect	O
is	O
completely	O
reversed	O
by	O
additional	O
iron	O
ions	O
.	O

This	O
is	O
because	O
quercetin	O
and	O
galangin	O
are	O
able	O
to	O
chelate	O
cellular	O
iron	O
ions	O
that	O
are	O
cofactors	O
of	O
HIF	B-Protein
-	I-Protein
1	E-Protein
/	O
2alpha	S-Protein
proline	O
hydroxylase	O
(	O
PHD	O
)	O
.	O

These	O
data	O
suggest	O
that	O
quercetin	O
inhibits	O
the	O
ubiquitination	O
of	O
HIF	B-Protein
-	I-Protein
1	E-Protein
/	O
2alpha	S-Protein
in	O
normoxia	O
by	O
hindering	O
PHD	O
through	O
chelating	O
iron	O
ions	O
.	O

Synthesis	O
of	O
human	O
angiotensinogen	S-Protein
(	O
1	O
-	O
17	O
)	O
containing	O
one	O
of	O
the	O
putative	O
glycosylation	O
binding	O
sites	O
and	O
its	O
hydrolysis	O
by	O
human	O
renin	S-Protein
and	O
porcine	O
pepsin	O
.	O

The	O
N	O
-	O
terminal	O
heptadecapeptide	O
of	O
human	O
angiotensinogen	S-Protein
(	O
Asp	O
-	O
Arg	O
-	O
Val	O
-	O
Tyr	O
-	O
Ile	O
-	O
His	O
-	O
Pro	O
-	O
Phe	O
-	O
His	O
-	O
Leu	O
-	O
Val	O
-	O
Ile	O
-	O
His	O
-	O
Asn	O
-	O
Glu	O
-	O
Ser	O
-	O
Thr	O
-	O
NH2	O
)	O
,	O
with	O
the	O
C	O
-	O
terminal	O
carboxyl	O
group	O
amidated	O
,	O
was	O
synthesized	O
in	O
order	O
to	O
study	O
the	O
role	O
of	O
Asn	O
-	O
Glu	O
-	O
Ser	O
,	O
a	O
putative	O
carbohydrate	O
binding	O
site	O
,	O
on	O
the	O
hydrolysis	O
by	O
human	O
renin	S-Protein
.	O

The	O
synthesis	O
was	O
performed	O
by	O
fragment	O
condensation	O
using	O
the	O
Honzl	O
and	O
Rudinger	O
azide	O
procedure	O
.	O

In	O
our	O
conditions	O
for	O
azide	O
segment	O
condensation	O
,	O
histidine	O
racemization	O
was	O
demonstrated	O
to	O
be	O
negligible	O
for	O
most	O
of	O
the	O
condensation	O
reactions	O
.	O

Human	O
renin	S-Protein
liberates	O
angiotensin	B-Protein
I	E-Protein
from	O
h	O
-	O
angiotensinogen	S-Protein
(	O
1	O
-	O
17	O
)	O
-	O
NH2	O
with	O
a	O
Km	O
value	O
of	O
3	O
.	O
4	O
x	O
10	O
(	O
-	O
5	O
)	O
M	O
,	O
at	O
pH	O
7	O
.	O
3	O
and	O
37	O
degrees	O
being	O
similar	O
to	O
h	O
-	O
angiotensinogen	S-Protein
(	O
1	O
-	O
13	O
)	O
,	O
an	O
analog	O
without	O
the	O
carbohydrate	O
binding	O
site	O
.	O

However	O
,	O
the	O
Vmax	O
value	O
of	O
4	O
.	O
1	O
x	O
10	O
(	O
-	O
9	O
)	O
mol	O
/	O
G	O
.	O
U	O
.	O
min	O
is	O
one	O
order	O
of	O
magnitude	O
higher	O
.	O

Porcine	O
pepsin	O
was	O
demonstrated	O
to	O
cleave	O
preferentially	O
Leu10	O
-	O
Val11	O
bond	O
and	O
,	O
surprisingly	O
,	O
His9	O
-	O
Leu10	O
as	O
well	O
.	O

Down	O
-	O
regulation	O
of	O
Pkc1	S-Protein
-	O
mediated	O
signaling	O
by	O
the	O
deubiquitinating	O
enzyme	O
Ubp3	S-Protein
.	O

Regulated	O
ubiquitination	O
and	O
degradation	O
of	O
signaling	O
proteins	O
have	O
emerged	O
as	O
key	O
mechanisms	O
for	O
modulating	O
the	O
strength	O
and	O
duration	O
of	O
signaling	O
pathways	O
.	O

The	O
reversible	O
nature	O
of	O
the	O
ubiquitination	O
process	O
as	O
well	O
as	O
the	O
large	O
number	O
and	O
diversity	O
of	O
the	O
deubiquitinating	O
enzymes	O
raise	O
the	O
possibility	O
that	O
signaling	O
pathways	O
might	O
be	O
modulated	O
by	O
specific	O
deubiquitinating	O
enzyme	O
(	O
s	O
)	O
.	O

Here	O
we	O
provide	O
evidence	O
that	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
the	O
Pkc1	S-Protein
-	O
mediated	O
signaling	O
pathway	O
that	O
controls	O
the	O
cell	O
wall	O
integrity	O
is	O
negatively	O
regulated	O
by	O
the	O
deubiquitinating	O
enzyme	O
Ubp3	S-Protein
.	O

Disruption	O
of	O
the	O
UBP3	S-Protein
gene	O
leads	O
to	O
an	O
enhanced	O
activation	O
of	O
the	O
cell	O
wall	O
integrity	O
pathway	O
MAPK	O
Slt2	S-Protein
when	O
cells	O
are	O
challenged	O
with	O
a	O
variety	O
of	O
pathway	O
activation	O
agents	O
such	O
as	O
pheromone	O
and	O
Congo	O
red	O
.	O

The	O
ubp3	S-Protein
deletion	O
mutants	O
accumulate	O
high	O
levels	O
of	O
Pkc1	S-Protein
,	O
suggesting	O
potential	O
regulation	O
of	O
Pkc1	S-Protein
by	O
Ubp3	S-Protein
.	O

Consistent	O
with	O
this	O
,	O
Pkc1	S-Protein
and	O
Ubp3	S-Protein
interact	O
in	O
vivo	O
,	O
and	O
the	O
stability	O
of	O
Pkc1	S-Protein
is	O
markedly	O
increased	O
in	O
the	O
ubp3	S-Protein
deletion	O
mutants	O
.	O

Moreover	O
,	O
disruption	O
of	O
the	O
PKC1	S-Protein
gene	O
,	O
but	O
not	O
the	O
genes	O
that	O
encode	O
components	O
downstream	O
of	O
Pkc1	S-Protein
,	O
completely	O
suppresses	O
other	O
phenotypes	O
displayed	O
by	O
the	O
ubp3	S-Protein
deletion	O
mutants	O
such	O
as	O
hyperactivation	O
of	O
the	O
pheromone	O
-	O
responsive	O
MAPK	O
Fus3	S-Protein
(	O
Wang	O
,	O
Y	O
.	O
,	O
and	O
Dohlman	O
,	O
H	O
.	O
G	O
.	O
(	O
2002	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
277	O
,	O
15766	O
-	O
15772	O
)	O
.	O

These	O
findings	O
demonstrate	O
that	O
Ubp3	S-Protein
can	O
regulate	O
Pkc1	S-Protein
by	O
facilitating	O
its	O
destruction	O
and	O
provide	O
the	O
initial	O
evidence	O
that	O
Pkc1	S-Protein
plays	O
a	O
positive	O
role	O
in	O
modulating	O
the	O
parallel	O
pheromone	O
-	O
signaling	O
pathway	O
.	O

The	O
IRAK	O
-	O
catalysed	O
activation	O
of	O
the	O
E3	O
ligase	O
function	O
of	O
Pellino	O
isoforms	O
induces	O
the	O
Lys63	O
-	O
linked	O
polyubiquitination	O
of	O
IRAK1	S-Protein
.	O

The	O
protein	O
kinases	O
IRAK	B-Protein
[	I-Protein
IL	I-Protein
-	I-Protein
1	I-Protein
(	I-Protein
interleukin	I-Protein
1	I-Protein
)	I-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
kinase	I-Protein
]	I-Protein
1	E-Protein
and	O
4	S-Protein
play	O
key	O
roles	O
in	O
a	O
signalling	O
pathway	O
by	O
which	O
bacterial	O
infection	O
or	O
IL	O
-	O
1	O
trigger	O
the	O
production	O
of	O
inflammatory	O
mediators	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
IRAK1	S-Protein
and	O
IRAK4	S-Protein
phosphorylate	O
Pellino	O
isoforms	O
in	O
vitro	O
and	O
that	O
phosphorylation	O
greatly	O
enhances	O
Pellino	O
'	O
s	O
E3	O
ubiquitin	O
ligase	O
activity	O
.	O

We	O
show	O
that	O
,	O
in	O
vitro	O
,	O
Pellino	B-Protein
1	E-Protein
can	O
combine	O
with	O
the	O
E2	O
conjugating	O
complex	O
Ubc13	S-Protein
(	O
ubiquitin	B-Protein
-	I-Protein
conjugating	I-Protein
enzyme	I-Protein
13	E-Protein
)	O
-	O
Uev1a	S-Protein
(	O
ubiquitin	B-Protein
E2	I-Protein
variant	I-Protein
1a	E-Protein
)	O
to	O
catalyse	O
the	O
formation	O
of	O
K63	O
-	O
pUb	S-Protein
(	O
Lys63	O
-	O
linked	O
polyubiquitin	S-Protein
)	O
chains	O
,	O
with	O
UbcH3	S-Protein
to	O
catalyse	O
the	O
formation	O
of	O
K48	O
-	O
pUb	S-Protein
chains	O
and	O
with	O
UbcH4	S-Protein
,	O
UbcH5a	S-Protein
or	O
UbcH5b	S-Protein
to	O
catalyse	O
the	O
formation	O
of	O
pUb	S-Protein
-	O
chains	O
linked	O
mainly	O
via	O
Lys11	O
and	O
Lys48	O
of	O
ubiquitin	S-Protein
.	O

In	O
IRAK1	S-Protein
-	O
/	O
-	O
cells	O
,	O
the	O
co	O
-	O
transfection	O
of	O
DNA	O
encoding	O
wild	O
-	O
type	O
IRAK1	S-Protein
and	O
Pellino	B-Protein
2	E-Protein
,	O
but	O
not	O
inactive	O
mutants	O
of	O
these	O
proteins	O
,	O
induces	O
the	O
formation	O
of	O
K63	O
-	O
pUb	S-Protein
-	O
IRAK1	S-Protein
and	O
its	O
interaction	O
with	O
the	O
NEMO	S-Protein
[	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
(	I-Protein
nuclear	I-Protein
factor	I-Protein
kappaB	I-Protein
)	I-Protein
essential	I-Protein
modifier	E-Protein
]	O
regulatory	O
subunit	O
of	O
the	O
IKK	O
(	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
kinase	O
)	O
complex	O
,	O
a	O
K63	O
-	O
pUb	S-Protein
-	O
binding	O
protein	O
.	O

These	O
studies	O
suggest	O
that	O
Pellino	O
isoforms	O
may	O
be	O
the	O
E3	O
ubiquitin	S-Protein
ligases	O
that	O
mediate	O
the	O
IL	O
-	O
1	O
-	O
stimulated	O
formation	O
of	O
K63	O
-	O
pUb	S-Protein
-	O
IRAK1	S-Protein
in	O
cells	O
,	O
which	O
may	O
contribute	O
to	O
the	O
activation	O
of	O
IKKbeta	S-Protein
and	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
as	O
well	O
as	O
other	O
signalling	O
pathways	O
dependent	O
on	O
IRAK1	S-Protein
/	O
4	S-Protein
.	O

In	O
vitro	O
reconstitution	O
of	O
plant	O
Atg8	S-Protein
and	O
Atg12	S-Protein
conjugation	O
systems	O
essential	O
for	O
autophagy	O
.	O

Genetic	O
and	O
biochemical	O
analyses	O
using	O
yeast	O
Saccharomyces	O
cerevisiae	O
showed	O
that	O
two	O
ubiquitin	S-Protein
-	O
like	O
conjugation	O
systems	O
,	O
the	O
Atg8	S-Protein
and	O
Atg12	S-Protein
systems	O
,	O
exist	O
and	O
play	O
essential	O
roles	O
in	O
autophagy	O
,	O
the	O
bulk	O
degradation	O
system	O
conserved	O
in	O
yeast	O
and	O
mammals	O
.	O

These	O
conjugation	O
systems	O
are	O
also	O
conserved	O
in	O
Arabidopsis	O
thaliana	O
;	O
however	O
,	O
further	O
detailed	O
study	O
of	O
plant	O
ATG	O
(	O
autophagy	O
-	O
related	O
)	O
conjugation	O
systems	O
in	O
relation	O
to	O
those	O
in	O
yeast	O
and	O
mammals	O
is	O
needed	O
.	O

Here	O
,	O
we	O
describe	O
the	O
in	O
vitro	O
reconstitution	O
of	O
Arabidopsis	O
thaliana	O
ATG8	S-Protein
and	O
ATG12	S-Protein
(	O
AtATG8	S-Protein
and	O
AtATG12	S-Protein
)	O
conjugation	O
systems	O
using	O
purified	O
recombinant	O
proteins	O
.	O

AtATG12b	S-Protein
was	O
conjugated	O
to	O
AtATG5	S-Protein
in	O
a	O
manner	O
dependent	O
on	O
AtATG7	S-Protein
,	O
AtATG10	S-Protein
,	O
and	O
ATP	O
,	O
whereas	O
AtATG8a	S-Protein
was	O
conjugated	O
to	O
phosphatidylethanolamine	O
(	O
PE	O
)	O
in	O
a	O
manner	O
dependent	O
on	O
AtATG7	S-Protein
,	O
AtATG3	S-Protein
,	O
and	O
ATP	O
.	O

Other	O
AtATG8	S-Protein
homologs	O
(	O
AtATG8b	S-Protein
-	O
8i	S-Protein
)	O
were	O
similarly	O
conjugated	O
to	O
PE	O
.	O

The	O
AtATG8	S-Protein
conjugates	O
were	O
deconjugated	O
by	O
AtATG4a	S-Protein
and	O
AtATG4b	S-Protein
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
ATG	O
conjugation	O
systems	O
in	O
Arabidopsis	O
are	O
very	O
similar	O
to	O
those	O
in	O
yeast	O
and	O
mammals	O
.	O

Intriguingly	O
,	O
in	O
vitro	O
analyses	O
showed	O
that	O
AtATG12	S-Protein
-	O
AtATG5	S-Protein
conjugates	O
accelerated	O
the	O
formation	O
of	O
AtATG8	S-Protein
-	O
PE	O
,	O
whereas	O
AtATG3	S-Protein
inhibited	O
the	O
formation	O
of	O
AtATG12	S-Protein
-	O
AtATG5	S-Protein
conjugates	O
.	O

The	O
in	O
vitro	O
conjugation	O
systems	O
reported	O
here	O
will	O
afford	O
a	O
tool	O
with	O
which	O
to	O
investigate	O
the	O
cross	O
-	O
talk	O
mechanism	O
between	O
two	O
conjugation	O
systems	O
.	O

Histone	S-Protein
crosstalk	O
between	O
H2B	S-Protein
monoubiquitination	O
and	O
H3	S-Protein
methylation	O
mediated	O
by	O
COMPASS	O
.	O

COMPASS	O
,	O
the	O
yeast	O
homolog	O
of	O
the	O
mammalian	O
MLL	O
complex	O
,	O
is	O
a	O
histone	B-Protein
H3	E-Protein
lysine	O
4	O
(	O
H3K4	S-Protein
)	O
methylase	O
consisting	O
of	O
Set1	S-Protein
(	O
KMT2	S-Protein
)	O
and	O
seven	O
other	O
polypeptides	O
,	O
including	O
Cps35	S-Protein
,	O
the	O
only	O
essential	O
subunit	O
.	O

Histone	B-Protein
H2B	E-Protein
monoubiquitination	O
by	O
Rad6	S-Protein
/	O
Bre1	S-Protein
is	O
required	O
for	O
both	O
H3K4	S-Protein
methylation	O
by	O
COMPASS	O
,	O
and	O
H3K79	S-Protein
methylation	O
by	O
Dot1	S-Protein
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
for	O
such	O
histone	S-Protein
crosstalk	O
is	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
histone	B-Protein
H2B	E-Protein
monoubiquitination	O
controls	O
the	O
binding	O
of	O
Cps35	S-Protein
with	O
COMPASS	O
complex	O
.	O

Cps	B-Protein
35	E-Protein
is	O
required	O
for	O
COMPASS	O
'	O
catalytic	O
activity	O
in	O
vivo	O
,	O
and	O
the	O
addition	O
of	O
exogenous	O
purified	O
Cps35	S-Protein
to	O
COMPASS	O
purified	O
from	O
a	O
Deltarad6	S-Protein
background	O
results	O
in	O
the	O
generation	O
of	O
a	O
methylation	O
competent	O
COMPASS	O
.	O

Cps35	S-Protein
associates	O
with	O
the	O
chromatin	O
of	O
COMPASS	O
-	O
regulated	O
genes	O
in	O
a	O
H2BK123	S-Protein
monoubiquitination	O
-	O
dependent	O
but	O
Set1	S-Protein
-	O
independent	O
manner	O
.	O

Cps35	S-Protein
is	O
also	O
required	O
for	O
proper	O
H3K79	S-Protein
trimethylation	O
.	O

These	O
findings	O
offer	O
insight	O
into	O
the	O
molecular	O
role	O
of	O
Cps35	S-Protein
in	O
translating	O
the	O
H2B	S-Protein
monoubiquitination	O
signal	O
into	O
H3	S-Protein
methylation	O
.	O

The	O
Rsp5	S-Protein
E3	O
ligase	O
mediates	O
turnover	O
of	O
low	O
affinity	O
phosphate	O
transporters	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

In	O
an	O
effort	O
to	O
identify	O
novel	O
components	O
of	O
the	O
PHO	O
regulon	O
in	O
Saccharomyces	O
cerevisiae	O
,	O
we	O
have	O
isolated	O
and	O
characterized	O
suppressors	O
of	O
the	O
Pho	O
(	O
-	O
)	O
phenotype	O
associated	O
with	O
deletion	O
of	O
the	O
Pho4	S-Protein
transcriptional	O
activator	O
.	O

Here	O
we	O
report	O
that	O
either	O
a	O
defective	O
form	O
of	O
the	O
Rsp5	S-Protein
E3	O
ubiquitin	S-Protein
ligase	O
or	O
deletion	O
of	O
the	O
End3	S-Protein
component	O
of	O
the	O
endocytic	O
pathway	O
restores	O
growth	O
of	O
the	O
pho4	S-Protein
Delta	O
mutant	O
in	O
the	O
presence	O
of	O
limiting	O
inorganic	O
phosphate	O
(	O
P	O
i	O
)	O
.	O

The	O
spa1	O
-	O
1	O
suppressor	O
allele	O
of	O
RSP5	S-Protein
encodes	O
a	O
phenylalanine	O
-	O
to	O
-	O
valine	O
replacement	O
at	O
position	O
748	O
(	O
F748V	O
)	O
within	O
the	O
catalytic	O
HECT	O
domain	O
of	O
Rsp5	S-Protein
.	O

Consistent	O
with	O
suppression	O
due	O
to	O
impaired	O
ubiquitin	S-Protein
ligase	O
activity	O
,	O
the	O
heat	O
-	O
sensitive	O
growth	O
defect	O
of	O
the	O
spa1	O
-	O
1	O
mutant	O
is	O
suppressed	O
either	O
by	O
overexpression	O
of	O
ubiquitin	S-Protein
or	O
by	O
osmotic	O
stabilization	O
.	O

Western	O
blot	O
analyses	O
revealed	O
that	O
the	O
cellular	O
levels	O
of	O
the	O
Pho87	S-Protein
and	O
Pho91	S-Protein
low	O
affinity	O
P	O
i	O
are	O
markedly	O
increased	O
in	O
the	O
spa1	O
-	O
1	O
mutant	O
,	O
yet	O
Pho84	S-Protein
high	O
affinity	O
P	O
i	O
transporter	O
levels	O
are	O
unaffected	O
.	O

Furthermore	O
,	O
Pho87	S-Protein
and	O
Pho91	S-Protein
are	O
ubiquitinated	O
in	O
vivo	O
in	O
an	O
Rsp5	S-Protein
-	O
dependent	O
manner	O
,	O
and	O
the	O
Pho	O
+	O
phenotype	O
of	O
the	O
spa1	O
-	O
1	O
suppressor	O
is	O
dependent	O
upon	O
Pho87	S-Protein
and	O
Pho91	S-Protein
.	O

We	O
conclude	O
that	O
turnover	O
of	O
the	O
low	O
affinity	O
P	O
i	O
transporters	O
is	O
initiated	O
by	O
Rsp5	S-Protein
-	O
mediated	O
ubiquitination	O
followed	O
by	O
internalization	O
and	O
degradation	O
by	O
the	O
endocytic	O
pathway	O
.	O

Deubiquitylation	O
of	O
histone	B-Protein
H2A	E-Protein
activates	O
transcriptional	O
initiation	O
via	O
trans	O
-	O
histone	O
cross	O
-	O
talk	O
with	O
H3K4	S-Protein
di	O
-	O
and	O
trimethylation	O
.	O

Transcriptional	O
initiation	O
is	O
a	O
key	O
step	O
in	O
the	O
control	O
of	O
mRNA	O
synthesis	O
and	O
is	O
intimately	O
related	O
to	O
chromatin	O
structure	O
and	O
histone	S-Protein
modification	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
ubiquitylation	O
of	O
H2A	S-Protein
(	O
ubH2A	S-Protein
)	O
correlates	O
with	O
silent	O
chromatin	O
and	O
regulates	O
transcriptional	O
initiation	O
.	O

The	O
levels	O
of	O
ubH2A	S-Protein
vary	O
during	O
hepatocyte	O
regeneration	O
,	O
and	O
based	O
on	O
microarray	O
expression	O
data	O
from	O
regenerating	O
liver	O
,	O
we	O
identified	O
USP21	S-Protein
,	O
a	O
ubiquitin	S-Protein
-	O
specific	O
protease	O
that	O
catalyzes	O
the	O
hydrolysis	O
of	O
ubH2A	S-Protein
.	O

When	O
chromatin	O
is	O
assembled	O
in	O
vitro	O
,	O
ubH2A	S-Protein
,	O
but	O
not	O
H2A	S-Protein
,	O
specifically	O
represses	O
the	O
di	O
-	O
and	O
trimethylation	O
of	O
H3K4	S-Protein
.	O

USP21	S-Protein
relieves	O
this	O
ubH2A	S-Protein
-	O
specific	O
repression	O
.	O

In	O
addition	O
,	O
in	O
vitro	O
transcription	O
analysis	O
revealed	O
that	O
ubH2A	S-Protein
represses	O
transcriptional	O
initiation	O
,	O
but	O
not	O
transcriptional	O
elongation	O
,	O
by	O
inhibiting	O
H3K4	S-Protein
methylation	O
.	O

Notably	O
,	O
ubH2A	S-Protein
-	O
mediated	O
repression	O
was	O
not	O
observed	O
when	O
H3	S-Protein
Lys	O
4	O
was	O
changed	O
to	O
arginine	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
USP21	S-Protein
in	O
the	O
liver	O
up	O
-	O
regulates	O
a	O
gene	O
that	O
is	O
normally	O
down	O
-	O
regulated	O
during	O
hepatocyte	O
regeneration	O
.	O

Our	O
studies	O
revealed	O
a	O
novel	O
mode	O
of	O
trans	O
-	O
histone	S-Protein
cross	O
-	O
talk	O
,	O
in	O
which	O
H2A	S-Protein
ubiquitylation	O
controls	O
the	O
di	O
-	O
and	O
trimethylation	O
of	O
H3K4	S-Protein
,	O
resulting	O
in	O
regulation	O
of	O
transcriptional	O
initiation	O
.	O

Arabidopsis	O
UEV1D	S-Protein
promotes	O
Lysine	O
-	O
63	O
-	O
linked	O
polyubiquitination	O
and	O
is	O
involved	O
in	O
DNA	O
damage	O
response	O
.	O

DNA	O
damage	O
tolerance	O
(	O
DDT	O
)	O
in	O
budding	O
yeast	O
requires	O
Lys	O
-	O
63	O
-	O
linked	O
polyubiquitination	O
of	O
the	O
proliferating	B-Protein
cell	I-Protein
nuclear	I-Protein
antigen	E-Protein
.	O

The	O
ubiquitin	S-Protein
-	O
conjugating	O
enzyme	O
Ubc13	S-Protein
and	O
the	O
Ubc	O
enzyme	O
variant	O
(	O
Uev	O
)	O
methyl	B-Protein
methanesulfonate2	E-Protein
(	O
Mms2	S-Protein
)	O
are	O
required	O
for	O
this	O
process	O
.	O

Mms2	S-Protein
homologs	O
have	O
been	O
found	O
in	O
all	O
eukaryotic	O
genomes	O
examined	O
;	O
however	O
,	O
their	O
roles	O
in	O
multicellular	O
eukaryotes	O
have	O
not	O
been	O
elucidated	O
.	O

We	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
four	O
UEV1	O
genes	O
from	O
Arabidopsis	O
thaliana	O
.	O

All	O
four	O
Uev1	O
proteins	O
can	O
form	O
a	O
stable	O
complex	O
with	O
At	O
Ubc13	S-Protein
or	O
with	O
Ubc13	S-Protein
from	O
yeast	O
or	O
human	O
and	O
can	O
promote	O
Ubc13	S-Protein
-	O
mediated	O
Lys	O
-	O
63	O
polyubiquitination	O
.	O

All	O
four	O
Uev1	O
proteins	O
can	O
replace	O
yeast	O
MMS2	S-Protein
DDT	O
functions	O
in	O
vivo	O
.	O

Although	O
these	O
genes	O
are	O
ubiquitously	O
expressed	O
in	O
most	O
tissues	O
,	O
UEV1D	S-Protein
appears	O
to	O
express	O
at	O
a	O
much	O
higher	O
level	O
in	O
germinating	O
seeds	O
and	O
in	O
pollen	O
.	O

We	O
obtained	O
and	O
characterized	O
two	O
uev1d	S-Protein
null	O
mutant	O
T	O
-	O
DNA	O
insertion	O
lines	O
.	O

Compared	O
with	O
wild	O
-	O
type	O
plants	O
,	O
seeds	O
from	O
uev1d	S-Protein
null	O
plants	O
germinated	O
poorly	O
when	O
treated	O
with	O
a	O
DNA	O
-	O
damaging	O
agent	O
.	O

Those	O
that	O
germinated	O
grew	O
slower	O
,	O
and	O
the	O
majority	O
ceased	O
growth	O
within	O
2	O
weeks	O
.	O

Pollen	O
from	O
uev1d	S-Protein
plants	O
also	O
displayed	O
a	O
moderate	O
but	O
significant	O
decrease	O
in	O
germination	O
in	O
the	O
presence	O
of	O
DNA	O
damage	O
.	O

This	O
report	O
links	O
Ubc13	S-Protein
-	O
Uev	O
with	O
functions	O
in	O
DNA	O
damage	O
response	O
in	O
Arabidopsis	O
.	O

SAGA	O
-	O
mediated	O
H2B	S-Protein
deubiquitination	O
controls	O
the	O
development	O
of	O
neuronal	O
connectivity	O
in	O
the	O
Drosophila	O
visual	O
system	O
.	O

Nonstop	S-Protein
,	O
which	O
has	O
previously	O
been	O
shown	O
to	O
have	O
homology	O
to	O
ubiquitin	S-Protein
proteases	O
,	O
is	O
required	O
for	O
proper	O
termination	O
of	O
axons	O
R1	O
-	O
R6	O
in	O
the	O
optic	O
lobe	O
of	O
the	O
developing	O
Drosophila	O
eye	O
.	O

Herein	O
,	O
we	O
establish	O
that	O
Nonstop	S-Protein
actually	O
functions	O
as	O
an	O
ubiquitin	O
protease	O
to	O
control	O
the	O
levels	O
of	O
ubiquitinated	O
histone	B-Protein
H2B	E-Protein
in	O
flies	O
.	O

We	O
further	O
establish	O
that	O
Nonstop	S-Protein
is	O
the	O
functional	O
homolog	O
of	O
yeast	O
Ubp8	S-Protein
,	O
and	O
can	O
substitute	O
for	O
Ubp8	S-Protein
function	O
in	O
yeast	O
cells	O
.	O

In	O
yeast	O
,	O
Ubp8	S-Protein
activity	O
requires	O
Sgf11	S-Protein
.	O

We	O
show	O
that	O
in	O
Drosophila	O
,	O
loss	O
of	O
Sgf11	S-Protein
function	O
causes	O
similar	O
photoreceptor	O
axon	O
-	O
targeting	O
defects	O
as	O
loss	O
of	O
Nonstop	S-Protein
.	O

Ubp8	S-Protein
and	O
Sgf11	S-Protein
are	O
components	O
of	O
the	O
yeast	O
SAGA	O
complex	O
,	O
suggesting	O
that	O
Nonstop	S-Protein
function	O
might	O
be	O
mediated	O
through	O
the	O
Drosophila	O
SAGA	O
complex	O
.	O

Indeed	O
,	O
we	O
find	O
that	O
Nonstop	S-Protein
does	O
associate	O
with	O
SAGA	O
components	O
in	O
flies	O
,	O
and	O
mutants	O
in	O
other	O
SAGA	O
subunits	O
display	O
nonstop	S-Protein
phenotypes	O
,	O
indicating	O
that	O
SAGA	O
complex	O
is	O
required	O
for	O
accurate	O
axon	O
guidance	O
in	O
the	O
optic	O
lobe	O
.	O

Candidate	O
genes	O
regulated	O
by	O
SAGA	O
that	O
may	O
be	O
required	O
for	O
correct	O
axon	O
targeting	O
were	O
identified	O
by	O
microarray	O
analysis	O
of	O
gene	O
expression	O
in	O
SAGA	O
mutants	O
.	O

Coordinated	O
activation	O
of	O
the	O
nuclear	O
ubiquitin	S-Protein
ligase	O
Cul3	S-Protein
-	O
SPOP	S-Protein
by	O
the	O
generation	O
of	O
phosphatidylinositol	O
5	O
-	O
phosphate	O
.	O

Phosphoinositide	O
signaling	O
pathways	O
regulate	O
numerous	O
processes	O
in	O
eukaryotic	O
cells	O
,	O
including	O
migration	O
,	O
proliferation	O
,	O
and	O
survival	O
.	O

The	O
regulatory	O
lipid	O
phosphatidylinositol	O
4	O
,	O
5	O
-	O
bisphosphate	O
is	O
synthesized	O
by	O
two	O
distinct	O
classes	O
of	O
phosphatidylinositol	O
phosphate	O
kinases	O
(	O
PIPKs	O
)	O
,	O
the	O
type	O
I	O
and	O
II	O
PIPKs	O
.	O

Although	O
numerous	O
physiological	O
functions	O
have	O
been	O
identified	O
for	O
type	O
I	O
PIPKs	O
,	O
little	O
is	O
known	O
about	O
the	O
functions	O
and	O
regulation	O
of	O
type	O
II	O
PIPK	O
.	O

Using	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
,	O
we	O
identified	O
an	O
interaction	O
between	O
the	O
type	B-Protein
IIbeta	I-Protein
PIPK	E-Protein
isoform	O
(	O
PIPKIIbeta	S-Protein
)	O
and	O
SPOP	S-Protein
(	O
speckle	B-Protein
-	I-Protein
type	I-Protein
POZ	I-Protein
domain	I-Protein
protein	E-Protein
)	O
,	O
a	O
nuclear	O
speckle	O
-	O
associated	O
protein	O
that	O
recruits	O
substrates	O
to	O
Cul3	S-Protein
-	O
based	O
ubiquitin	S-Protein
ligases	O
.	O

PIPKIIbeta	S-Protein
and	O
SPOP	S-Protein
interact	O
and	O
co	O
-	O
localize	O
at	O
nuclear	O
speckles	O
in	O
mammalian	O
cells	O
,	O
and	O
SPOP	S-Protein
mediates	O
the	O
ubiquitylation	O
of	O
PIPKIIbeta	S-Protein
by	O
Cul3	S-Protein
-	O
based	O
ubiquitin	S-Protein
ligases	O
.	O

Additionally	O
,	O
stimulation	O
of	O
the	O
p38	O
MAPK	O
pathway	O
enhances	O
the	O
ubiquitin	S-Protein
ligase	O
activity	O
of	O
Cul3	S-Protein
-	O
SPOP	S-Protein
toward	O
multiple	O
substrate	O
proteins	O
.	O

Finally	O
,	O
a	O
kinase	O
-	O
dead	O
PIPKIIbeta	S-Protein
mutant	O
enhanced	O
ubiquitylation	O
of	O
Cul3	S-Protein
-	O
SPOP	S-Protein
substrates	O
.	O

The	O
kinase	O
-	O
dead	O
PIPKIIbeta	S-Protein
mutant	O
increases	O
the	O
cellular	O
content	O
of	O
its	O
substrate	O
lipid	O
phosphatidylinositol	O
5	O
-	O
phosphate	O
(	O
PI5P	O
)	O
,	O
suggesting	O
that	O
PI5P	O
may	O
stimulate	O
Cul3	S-Protein
-	O
SPOP	S-Protein
activity	O
through	O
a	O
p38	O
-	O
dependent	O
signaling	O
pathway	O
.	O

Expression	O
of	O
phosphatidylinositol	O
-	O
4	O
,	O
5	O
-	O
bisphosphate	O
4	O
-	O
phosphatases	O
that	O
generate	O
PI5P	O
dramatically	O
stimulated	O
Cul3	S-Protein
-	O
SPOP	S-Protein
activity	O
and	O
was	O
blocked	O
by	O
the	O
p38	O
inhibitor	O
SB203580	O
.	O

Taken	O
together	O
,	O
these	O
data	O
define	O
a	O
novel	O
mechanism	O
whereby	O
the	O
phosphoinositide	O
PI5P	O
leads	O
to	O
stimulation	O
of	O
Cul3	S-Protein
-	O
SPOP	S-Protein
ubiquitin	S-Protein
ligase	O
activity	O
and	O
also	O
implicate	O
PIPKIIbeta	S-Protein
as	O
a	O
key	O
regulator	O
of	O
this	O
signaling	O
pathway	O
through	O
its	O
association	O
with	O
the	O
Cul3	S-Protein
-	O
SPOP	S-Protein
complex	O
.	O

HOP	S-Protein
/	O
OB1	S-Protein
/	O
NECC1	S-Protein
promoter	O
DNA	O
is	O
frequently	O
hypermethylated	O
and	O
involved	O
in	O
tumorigenic	O
ability	O
in	O
esophageal	O
squamous	O
cell	O
carcinoma	O
.	O

Promoter	O
DNA	O
hypermethylation	O
with	O
gene	O
silencing	O
is	O
a	O
common	O
feature	O
of	O
human	O
cancer	O
,	O
and	O
cancer	O
-	O
prone	O
methylation	O
is	O
believed	O
to	O
be	O
a	O
landmark	O
of	O
tumor	O
suppressor	O
genes	O
(	O
TSG	O
)	O
.	O

Identification	O
of	O
novel	O
methylated	O
genes	O
would	O
not	O
only	O
aid	O
in	O
the	O
development	O
of	O
tumor	O
markers	O
but	O
also	O
elucidate	O
the	O
biological	O
behavior	O
of	O
human	O
cancers	O
.	O

We	O
identified	O
several	O
epigenetically	O
silenced	O
candidate	O
TSGs	O
by	O
pharmacologic	O
unmasking	O
of	O
esophageal	O
squamous	O
cell	O
carcinoma	O
(	O
ESCC	O
)	O
cell	O
lines	O
by	O
demethylating	O
agents	O
(	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycitidine	O
and	O
trichostatin	O
A	O
)	O
combined	O
with	O
ESCC	O
expression	O
profiles	O
using	O
expression	O
microarray	O
.	O

HOP	S-Protein
/	O
OB1	S-Protein
/	O
NECC1	S-Protein
was	O
identified	O
as	O
an	O
epigenetically	O
silenced	O
candidate	O
TSG	O
and	O
further	O
examined	O
for	O
(	O
a	O
)	O
expression	O
status	O
,	O
(	O
b	O
)	O
methylation	O
status	O
,	O
and	O
(	O
c	O
)	O
functional	O
involvement	O
in	O
cancer	O
cell	O
lines	O
.	O

(	O
a	O
)	O
The	O
HOP	S-Protein
gene	O
encodes	O
two	O
putative	O
promoters	O
(	O
promoters	O
A	O
and	O
B	O
)	O
associated	O
with	O
two	O
open	O
reading	O
frames	O
(	O
HOPalpha	S-Protein
and	O
HOPbeta	S-Protein
,	O
respectively	O
)	O
,	O
and	O
HOPalpha	S-Protein
and	O
HOPbeta	S-Protein
were	O
both	O
down	O
-	O
regulated	O
in	O
ESCC	O
independently	O
.	O

(	O
b	O
)	O
Promoter	O
B	O
harbors	O
dense	O
CpG	O
islands	O
,	O
in	O
which	O
we	O
found	O
dense	O
methylation	O
in	O
a	O
cancer	O
-	O
prone	O
manner	O
(	O
55	O
%	O
in	O
tumor	O
tissues	O
by	O
TaqMan	O
methylation	O
-	O
specific	O
PCR	O
)	O
,	O
whereas	O
promoter	O
A	O
does	O
not	O
harbor	O
CpG	O
islands	O
.	O

HOPbeta	S-Protein
silencing	O
was	O
associated	O
with	O
DNA	O
methylation	O
of	O
promoter	O
B	O
in	O
nine	O
ESCC	O
cell	O
lines	O
tested	O
,	O
and	O
reactivated	O
by	O
optimal	O
conditions	O
of	O
demethylating	O
agents	O
,	O
whereas	O
HOPalpha	S-Protein
silencing	O
was	O
not	O
reactivated	O
by	O
such	O
treatments	O
.	O

Forced	O
expression	O
of	O
HOP	S-Protein
suppressed	O
tumorigenesis	O
in	O
soft	O
agar	O
in	O
four	O
different	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
.	O

More	O
convincingly	O
,	O
RNA	O
interference	O
knockdown	O
of	O
HOP	S-Protein
in	O
TE2	O
cells	O
showed	O
drastic	O
restoration	O
of	O
the	O
oncogenic	O
phenotype	O
.	O

In	O
conclusion	O
,	O
HOP	S-Protein
is	O
a	O
putative	O
TSG	O
that	O
harbors	O
tumor	O
inhibitory	O
activity	O
,	O
and	O
we	O
for	O
the	O
first	O
time	O
showed	O
that	O
the	O
final	O
shutdown	O
process	O
of	O
HOP	S-Protein
expression	O
is	O
linked	O
to	O
promoter	O
DNA	O
hypermethylation	O
under	O
the	O
double	O
control	O
of	O
the	O
discrete	O
promoter	O
regions	O
in	O
cancer	O
.	O

The	O
activation	O
of	O
p53	S-Protein
mediated	O
by	O
Epstein	O
-	O
Barr	O
virus	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	E-Protein
in	O
SV40	O
large	B-Protein
T	I-Protein
-	I-Protein
antigen	E-Protein
transformed	O
cells	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
encoded	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	E-Protein
(	O
LMP1	S-Protein
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
carcinogenesis	O
of	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
.	O

The	O
tumor	O
suppressor	O
p53	S-Protein
is	O
an	O
important	O
transcription	O
factor	O
.	O

The	O
mutation	O
of	O
the	O
p53	S-Protein
gene	O
is	O
the	O
frequent	O
alteration	O
in	O
most	O
of	O
tumors	O
,	O
but	O
nearly	O
100	O
%	O
wild	O
-	O
type	O
p53	S-Protein
gene	O
is	O
found	O
in	O
NPC	O
biopsy	O
.	O

Here	O
,	O
our	O
study	O
testified	O
that	O
SV40	O
T	B-Protein
-	I-Protein
antigen	E-Protein
transformed	O
nasopharyngeal	O
epithelial	O
cells	O
contained	O
free	O
,	O
wild	O
-	O
type	O
p53	S-Protein
.	O

Moreover	O
,	O
LMP1	S-Protein
regulated	O
p53	S-Protein
both	O
at	O
transcriptional	O
and	O
translational	O
level	O
.	O

Furthermore	O
,	O
the	O
mechanism	O
of	O
p53	S-Protein
accumulation	O
mediated	O
by	O
LMP1	S-Protein
from	O
post	O
-	O
translational	O
level	O
-	O
phosphorylation	O
and	O
ubiquitination	O
were	O
determined	O
.	O

Therefore	O
,	O
the	O
effects	O
of	O
EBV	O
LMP1	S-Protein
on	O
p53	S-Protein
may	O
potentially	O
contribute	O
to	O
EBV	O
-	O
associated	O
pathogenesis	O
.	O

Ribosomal	B-Protein
protein	I-Protein
S6	I-Protein
kinase	I-Protein
1	E-Protein
interacts	O
with	O
and	O
is	O
ubiquitinated	O
by	O
ubiquitin	S-Protein
ligase	O
ROC1	S-Protein
.	O

Ribosomal	O
protein	O
S6	O
kinase	O
(	O
S6K	O
)	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
growth	O
and	O
cellular	O
metabolism	O
.	O

The	O
activation	O
of	O
S6K	O
in	O
response	O
to	O
diverse	O
extracellular	O
stimuli	O
is	O
mediated	O
by	O
multiple	O
phosphorylations	O
coordinated	O
by	O
the	O
mTOR	S-Protein
and	O
PI3K	O
signaling	O
pathways	O
.	O

We	O
have	O
recently	O
found	O
that	O
both	O
forms	O
of	O
S6K	O
are	O
modified	O
by	O
ubiquitination	O
.	O

Following	O
these	O
findings	O
,	O
we	O
demonstrate	O
here	O
for	O
the	O
first	O
time	O
that	O
S6K1	S-Protein
associates	O
specifically	O
with	O
ubiquitin	S-Protein
ligase	O
ROC1	S-Protein
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
interaction	O
was	O
initially	O
identified	O
in	O
the	O
yeast	O
two	O
-	O
hybrid	O
screening	O
and	O
further	O
confirmed	O
by	O
pull	O
-	O
down	O
and	O
co	O
-	O
immunoprecipitation	O
assays	O
.	O

Furthermore	O
,	O
the	O
overexpression	O
of	O
ROC1	S-Protein
leads	O
to	O
an	O
increase	O
in	O
S6K1	S-Protein
ubiquitination	O
.	O

Consistent	O
with	O
this	O
observation	O
,	O
we	O
showed	O
that	O
the	O
steady	O
-	O
state	O
level	O
of	O
S6K1	S-Protein
is	O
regulated	O
by	O
ROC1	S-Protein
,	O
since	O
downregulation	O
of	O
ROC1	S-Protein
by	O
specific	O
siRNA	O
promotes	O
stabilization	O
of	O
S6K1	S-Protein
protein	O
.	O

The	O
results	O
suggest	O
the	O
involvement	O
of	O
ROC1	S-Protein
in	O
S6K1	S-Protein
ubiquitination	O
and	O
subsequent	O
proteasomal	O
degradation	O
.	O

Regulation	O
of	O
ribosomal	O
protein	O
S6	O
kinases	O
by	O
ubiquitination	O
.	O

Ribosomal	O
protein	O
S6	O
kinase	O
(	O
S6K	O
)	O
is	O
a	O
key	O
player	O
in	O
the	O
regulation	O
of	O
cell	O
growth	O
and	O
energy	O
metabolism	O
via	O
the	O
mTOR	S-Protein
and	O
PI3K	O
signalling	O
pathways	O
.	O

The	O
activity	O
and	O
subcellular	O
localization	O
of	O
S6K	O
are	O
regulated	O
by	O
multiple	O
S	O
/	O
T	O
phosphorylations	O
in	O
response	O
to	O
diverse	O
extracellular	O
stimuli	O
.	O

Downregulation	O
of	O
S6K	O
signalling	O
occurs	O
through	O
the	O
action	O
of	O
S	O
/	O
T	O
phosphatases	O
(	O
PP2A	O
and	O
PP1	O
)	O
and	O
tumor	O
suppressors	O
(	O
TSC1	S-Protein
/	O
2	S-Protein
and	O
PTEN	S-Protein
)	O
.	O

We	O
report	O
here	O
that	O
,	O
in	O
addition	O
to	O
phosphorylation	O
,	O
S6Ks	O
are	O
ubiquitinated	O
in	O
cells	O
.	O

The	O
pattern	O
of	O
ubiquitination	O
and	O
the	O
effect	O
of	O
proteasomal	O
inhibitors	O
on	O
the	O
steady	O
-	O
state	O
level	O
of	O
transiently	O
overexpressed	O
and	O
endogenous	O
S6Ks	O
point	O
to	O
proteasome	O
-	O
mediated	O
degradation	O
of	O
ubiquitinated	O
S6Ks	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
site	O
(	O
s	O
)	O
of	O
ubiquitination	O
are	O
located	O
in	O
the	O
kinase	O
domain	O
and	O
that	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
regulatory	O
regions	O
modulate	O
the	O
efficiency	O
of	O
S6K	O
ubiquitination	O
.	O

This	O
study	O
suggests	O
that	O
S6K	O
signalling	O
also	O
could	O
be	O
regulated	O
through	O
the	O
proteasome	O
-	O
mediated	O
turnover	O
of	O
S6Ks	O
.	O

Serological	O
reactivity	O
and	O
biochemical	O
characterization	O
of	O
methylated	O
and	O
unmethylated	O
forms	O
of	O
a	O
recombinant	O
protein	O
fragment	O
derived	O
from	O
outer	B-Protein
membrane	I-Protein
protein	I-Protein
B	E-Protein
of	O
Rickettsia	O
typhi	O
.	O

Rickettsia	O
typhi	O
,	O
an	O
obligate	O
intracellular	O
bacterium	O
that	O
causes	O
murine	O
typhus	O
,	O
possesses	O
a	O
heavily	O
methylated	O
outer	B-Protein
membrane	I-Protein
protein	I-Protein
B	E-Protein
(	O
OmpB	S-Protein
)	O
antigen	O
.	O

This	O
immunodominant	O
antigen	O
is	O
responsible	O
for	O
serological	O
reactions	O
and	O
is	O
capable	O
of	O
eliciting	O
protective	O
immune	O
responses	O
with	O
a	O
guinea	O
pig	O
model	O
.	O

Western	O
blot	O
analysis	O
of	O
partially	O
digested	O
OmpB	S-Protein
with	O
patient	O
sera	O
revealed	O
that	O
most	O
of	O
the	O
reactive	O
fragments	O
are	O
larger	O
than	O
20	O
kDa	O
.	O

One	O
of	O
these	O
fragments	O
,	O
which	O
is	O
located	O
at	O
the	O
N	O
terminus	O
(	O
amino	O
acids	O
33	O
to	O
273	O
)	O
,	O
fragment	O
A	O
(	O
At	O
)	O
,	O
has	O
been	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
expressed	O
protein	O
(	O
rAt	O
)	O
was	O
purified	O
by	O
chromatography	O
and	O
properly	O
refolded	O
by	O
sequential	O
dialysis	O
.	O

The	O
refolded	O
rAt	O
protein	O
was	O
recognized	O
by	O
at	O
least	O
87	O
%	O
of	O
the	O
typhus	O
group	O
patient	O
sera	O
as	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

However	O
,	O
the	O
titers	O
were	O
lower	O
than	O
those	O
obtained	O
with	O
OmpB	S-Protein
of	O
R	O
.	O
typhi	O
.	O

Since	O
native	O
OmpB	S-Protein
is	O
hypermethylated	O
at	O
lysine	O
residues	O
,	O
we	O
chemically	O
methylated	O
the	O
lysine	O
residues	O
in	O
rAt	O
.	O

The	O
methylation	O
was	O
confirmed	O
by	O
amino	O
acid	O
composition	O
analysis	O
,	O
and	O
the	O
methylation	O
pattern	O
of	O
the	O
methylated	O
rAt	O
(	O
mrAt	O
)	O
protein	O
was	O
similar	O
to	O
that	O
of	O
native	O
At	O
from	O
OmpB	S-Protein
,	O
as	O
revealed	O
by	O
liquid	O
chromatography	O
-	O
mass	O
spectrometry	O
analysis	O
.	O

Both	O
rAt	O
and	O
mrAt	O
were	O
evaluated	O
in	O
an	O
ELISA	O
for	O
their	O
serological	O
reactivity	O
with	O
patient	O
sera	O
.	O

Among	O
patient	O
sera	O
tested	O
,	O
83	O
%	O
exhibited	O
higher	O
titers	O
with	O
mrAt	O
than	O
with	O
rAt	O
.	O

These	O
results	O
suggest	O
that	O
rAt	O
,	O
with	O
or	O
without	O
methylation	O
,	O
can	O
potentially	O
replace	O
rickettsia	O
-	O
derived	O
OmpB	S-Protein
or	O
whole	O
-	O
cell	O
antigen	O
for	O
the	O
diagnosis	O
of	O
R	O
.	O
typhi	O
infection	O
.	O

E3	O
ubiquitin	S-Protein
ligase	O
E6AP	S-Protein
-	O
mediated	O
TSC2	S-Protein
turnover	O
in	O
the	O
presence	O
and	O
absence	O
of	O
HPV16	O
E6	S-Protein
.	O

We	O
previously	O
found	O
that	O
HPV16	O
E6	S-Protein
causes	O
the	O
degradation	O
of	O
the	O
tumor	O
suppressor	O
protein	O
TSC2	S-Protein
,	O
resulting	O
in	O
the	O
phosphorylation	O
of	O
S6	O
kinase	O
and	O
S6	S-Protein
even	O
in	O
the	O
absence	O
of	O
insulin	S-Protein
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
E6	S-Protein
-	O
associated	O
protein	O
(	O
E6AP	S-Protein
)	O
in	O
HPV16	O
E6	S-Protein
-	O
induced	O
TSC2	S-Protein
degradation	O
.	O

Our	O
results	O
demonstrated	O
that	O
TSC2	S-Protein
was	O
targeted	O
for	O
degradation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
HPV16	O
E6	S-Protein
.	O

Over	O
-	O
expression	O
of	O
E6AP	S-Protein
enhanced	O
the	O
degradation	O
of	O
TSC2	S-Protein
by	O
HPV16	O
E6	S-Protein
,	O
while	O
expression	O
of	O
a	O
dominant	O
negative	O
E6AP	S-Protein
(	O
C833A	O
)	O
inhibited	O
the	O
E6	S-Protein
-	O
induced	O
degradation	O
.	O

Additionally	O
,	O
by	O
using	O
shRNAs	O
to	O
block	O
E6AP	S-Protein
expression	O
in	O
HPV16	O
positive	O
and	O
negative	O
cells	O
,	O
we	O
found	O
a	O
significantly	O
prolonged	O
TSC2	S-Protein
half	O
-	O
life	O
.	O

An	O
in	O
vivo	O
ubiquitination	O
assay	O
was	O
done	O
to	O
reveal	O
that	O
E6AP	S-Protein
promoted	O
the	O
ubiquitination	O
of	O
TSC2	S-Protein
independent	O
of	O
HPV16	O
E6	S-Protein
.	O

We	O
further	O
found	O
that	O
TSC2	S-Protein
bound	O
E6AP	S-Protein
in	O
the	O
presence	O
as	O
well	O
as	O
in	O
the	O
absence	O
of	O
HPV16	O
E6	S-Protein
.	O

The	O
binding	O
regions	O
on	O
E6AP	S-Protein
and	O
TSC2	S-Protein
have	O
been	O
identified	O
as	O
amino	O
acid	O
(	O
aa	O
)	O
260	O
-	O
316	O
,	O
aa	O
428	O
-	O
500	O
and	O
aa	O
1	O
-	O
175	O
,	O
aa	O
1251	O
-	O
1807	O
,	O
respectively	O
.	O

Taken	O
together	O
,	O
degradation	O
of	O
TSC2	S-Protein
is	O
mediated	O
by	O
E6AP	S-Protein
ubiquitin	S-Protein
ligase	O
.	O

Pam	S-Protein
(	O
Protein	B-Protein
associated	I-Protein
with	I-Protein
Myc	E-Protein
)	O
functions	O
as	O
an	O
E3	O
ubiquitin	S-Protein
ligase	O
and	O
regulates	O
TSC	O
/	O
mTOR	S-Protein
signaling	O
.	O

The	O
tumor	O
suppressor	O
tuberin	S-Protein
,	O
encoded	O
by	O
the	O
Tuberous	O
Sclerosis	O
Complex	O
(	O
TSC	O
)	O
gene	O
TSC2	S-Protein
,	O
negatively	O
regulates	O
the	O
mammalian	B-Protein
target	I-Protein
of	I-Protein
rapamycin	E-Protein
(	O
mTOR	S-Protein
)	O
pathway	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
control	O
of	O
cell	O
growth	O
and	O
proliferation	O
.	O

In	O
addition	O
to	O
naturally	O
occurring	O
mutations	O
,	O
several	O
kinases	O
including	O
Akt	O
,	O
RSK1	S-Protein
,	O
and	O
ERK	O
are	O
known	O
to	O
phosphorylate	O
and	O
inactivate	O
tuberin	S-Protein
.	O

We	O
demonstrate	O
a	O
novel	O
mechanism	O
of	O
tuberin	S-Protein
inactivation	O
through	O
ubiquitination	O
by	O
Pam	S-Protein
,	O
a	O
putative	O
RING	O
finger	O
-	O
containing	O
E3	O
ubiquitin	S-Protein
(	O
Ub	S-Protein
)	O
ligase	O
in	O
mammalian	O
cells	O
.	O

We	O
show	O
that	O
Pam	S-Protein
associates	O
with	O
E2	O
ubiquitin	S-Protein
-	O
conjugating	O
enzymes	O
,	O
and	O
tuberin	S-Protein
can	O
be	O
ubiquitinated	O
by	O
Pam	S-Protein
through	O
its	O
RING	O
finger	O
domain	O
.	O

Tuberin	S-Protein
ubiquitination	O
is	O
independent	O
of	O
its	O
phosphorylation	O
by	O
Akt	O
,	O
RSK1	S-Protein
,	O
and	O
ERK	O
kinases	O
.	O

Pam	S-Protein
is	O
also	O
self	O
-	O
ubiquitinated	O
through	O
its	O
RING	O
finger	O
domain	O
.	O

Moreover	O
,	O
the	O
TSC1	S-Protein
protein	O
hamartin	S-Protein
,	O
which	O
forms	O
a	O
heterodimer	O
with	O
tuberin	S-Protein
,	O
protects	O
tuberin	S-Protein
from	O
ubiquitination	O
by	O
Pam	S-Protein
.	O

However	O
,	O
TSC1	S-Protein
fails	O
to	O
protect	O
a	O
disease	O
-	O
associated	O
missense	O
mutant	O
of	O
TSC2	S-Protein
from	O
ubiquitination	O
by	O
Pam	S-Protein
.	O

Furthermore	O
,	O
Pam	S-Protein
knockdown	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
in	O
rat	O
primary	O
neurons	O
elevates	O
the	O
level	O
of	O
tuberin	S-Protein
,	O
and	O
subsequently	O
inhibits	O
the	O
mTOR	S-Protein
pathway	O
.	O

Our	O
results	O
provide	O
novel	O
evidence	O
that	O
Pam	S-Protein
can	O
function	O
as	O
an	O
E3	O
Ub	O
ligase	O
toward	O
tuberin	S-Protein
and	O
regulate	O
mTOR	S-Protein
signaling	O
,	O
suggesting	O
that	O
Pam	S-Protein
can	O
in	O
turn	O
regulate	O
cell	O
growth	O
and	O
proliferation	O
as	O
well	O
as	O
neuronal	O
function	O
through	O
the	O
TSC	O
/	O
mTOR	S-Protein
pathway	O
in	O
mammalian	O
cells	O
.	O

Proteolysis	O
of	O
AKAP121	S-Protein
regulates	O
mitochondrial	O
activity	O
during	O
cellular	O
hypoxia	O
and	O
brain	O
ischaemia	O
.	O

A	B-Protein
-	I-Protein
kinase	I-Protein
anchor	I-Protein
protein	I-Protein
121	E-Protein
(	O
AKAP121	S-Protein
)	O
assembles	O
a	O
multivalent	O
signalling	O
complex	O
on	O
the	O
outer	O
mitochondrial	O
membrane	O
that	O
controls	O
persistence	O
and	O
amplitude	O
of	O
cAMP	O
and	O
src	S-Protein
signalling	O
to	O
mitochondria	O
,	O
and	O
plays	O
an	O
essential	O
role	O
in	O
oxidative	O
metabolism	O
and	O
cell	O
survival	O
.	O

Here	O
,	O
we	O
show	O
that	O
AKAP121	S-Protein
levels	O
are	O
regulated	O
post	O
-	O
translationally	O
by	O
the	O
ubiquitin	S-Protein
/	O
proteasome	O
pathway	O
.	O

Seven	B-Protein
In	I-Protein
-	I-Protein
Absentia	I-Protein
Homolog	I-Protein
2	E-Protein
(	O
Siah2	S-Protein
)	O
,	O
an	O
E3	O
-	O
ubiquitin	S-Protein
ligase	O
whose	O
expression	O
is	O
induced	O
in	O
hypoxic	O
conditions	O
,	O
formed	O
a	O
complex	O
and	O
degraded	O
AKAP121	S-Protein
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
Siah2	S-Protein
or	O
oxygen	O
and	O
glucose	O
deprivation	O
(	O
OGD	O
)	O
promotes	O
Siah2	S-Protein
-	O
mediated	O
ubiquitination	O
and	O
proteolysis	O
of	O
AKAP121	S-Protein
.	O

Upregulation	O
of	O
Siah2	S-Protein
,	O
by	O
modulation	O
of	O
the	O
cellular	O
levels	O
of	O
AKAP121	S-Protein
,	O
significantly	O
affects	O
mitochondrial	O
activity	O
assessed	O
as	O
mitochondrial	O
membrane	O
potential	O
and	O
oxidative	O
capacity	O
.	O

Also	O
during	O
cerebral	O
ischaemia	O
,	O
AKAP121	S-Protein
is	O
degraded	O
in	O
a	O
Siah2	S-Protein
-	O
dependent	O
manner	O
.	O

These	O
findings	O
reveal	O
a	O
novel	O
mechanism	O
of	O
attenuation	O
of	O
cAMP	O
/	O
PKA	O
signaling	O
,	O
which	O
occurs	O
at	O
the	O
distal	O
sites	O
of	O
signal	O
generation	O
mediated	O
by	O
proteolysis	O
of	O
an	O
AKAP	O
scaffold	O
protein	O
.	O

By	O
regulating	O
the	O
stability	O
of	O
AKAP121	S-Protein
-	O
signalling	O
complex	O
at	O
mitochondria	O
,	O
cells	O
efficiently	O
and	O
rapidly	O
adapt	O
oxidative	O
metabolism	O
to	O
fluctuations	O
in	O
oxygen	O
availability	O
.	O

T3	O
-	O
mediated	O
expression	O
of	O
PGC	B-Protein
-	I-Protein
1alpha	E-Protein
via	O
a	O
far	O
upstream	O
located	O
thyroid	O
hormone	O
response	O
element	O
.	O

Thyroid	O
hormone	O
(	O
T3	O
)	O
has	O
a	O
profound	O
influence	O
on	O
normal	O
development	O
,	O
differentiation	O
and	O
metabolism	O
.	O

T3	O
induces	O
complex	O
gene	O
expression	O
patterns	O
raises	O
the	O
question	O
of	O
how	O
these	O
expression	O
patterns	O
might	O
be	O
regulated	O
.	O

Since	O
the	O
transcriptional	O
coactivator	O
peroxisome	B-Protein
proliferator	I-Protein
-	I-Protein
activated	I-Protein
receptor	I-Protein
gamma	I-Protein
coactivator	I-Protein
-	I-Protein
1alpha	E-Protein
(	O
PGC	B-Protein
-	I-Protein
1alpha	E-Protein
)	O
induces	O
very	O
similar	O
cellular	O
energy	O
metabolic	O
pathways	O
,	O
we	O
investigated	O
the	O
molecular	O
mechanism	O
of	O
T3	O
regulation	O
of	O
PGC	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

PGC	B-Protein
-	I-Protein
1alpha	E-Protein
is	O
rapidly	O
regulated	O
by	O
T3	O
,	O
both	O
in	O
vivo	O
and	O
in	O
cell	O
culture	O
.	O

Transient	O
transfection	O
experiments	O
demonstrated	O
binding	O
of	O
the	O
thyroid	O
hormone	O
receptor	O
(	O
TR	O
)	O
to	O
a	O
response	O
element	O
located	O
at	O
-	O
4kb	O
upstream	O
of	O
the	O
transcriptional	O
start	O
site	O
within	O
the	O
PGC	B-Protein
-	I-Protein
1alpha	E-Protein
gene	O
.	O

Introducing	O
of	O
a	O
single	O
copy	O
of	O
the	O
-	O
4kb	O
TRE	O
in	O
a	O
heterologous	O
promoter	O
context	O
is	O
sufficient	O
to	O
maintain	O
T3	O
responsiveness	O
.	O

Chromatin	O
immunoprecipitation	O
analysis	O
revealed	O
increased	O
histone	S-Protein
acetylation	O
upon	O
stimulation	O
of	O
T3	O
.	O

Finally	O
,	O
TR	O
binds	O
the	O
-	O
4kb	O
TRE	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
identifying	O
PGC	B-Protein
-	I-Protein
1alpha	E-Protein
as	O
a	O
direct	O
target	O
of	O
TR	O
action	O
.	O

Since	O
T3	O
directly	O
regulates	O
PGC	B-Protein
-	I-Protein
1alpha	E-Protein
and	O
PGC	B-Protein
-	I-Protein
1alpha	E-Protein
coactivates	O
liganded	O
TR	O
,	O
we	O
suggest	O
an	O
autoregulatory	O
feed	O
-	O
forward	O
loop	O
of	O
PGC	B-Protein
-	I-Protein
1alpha	E-Protein
activation	O
upon	O
T3	O
treatment	O
.	O

Monoubiquitinated	O
H2B	S-Protein
is	O
associated	O
with	O
the	O
transcribed	O
region	O
of	O
highly	O
expressed	O
genes	O
in	O
human	O
cells	O
.	O

Histone	S-Protein
modifications	O
have	O
emerged	O
as	O
important	O
regulators	O
of	O
transcription	O
.	O

Histone	B-Protein
H2B	E-Protein
monoubiquitination	O
has	O
also	O
been	O
implicated	O
in	O
transcription	O
;	O
however	O
,	O
better	O
understanding	O
of	O
the	O
biological	O
significance	O
of	O
this	O
modification	O
in	O
mammalian	O
cells	O
has	O
been	O
hindered	O
by	O
the	O
lack	O
of	O
suitable	O
reagents	O
,	O
particularly	O
antibodies	O
capable	O
of	O
specifically	O
recognizing	O
ubiquitinated	O
H2B	S-Protein
(	O
ubH2B	S-Protein
)	O
.	O

Here	O
,	O
we	O
report	O
the	O
generation	O
of	O
anti	O
-	O
ubH2B	S-Protein
monoclonal	O
antibodies	O
using	O
a	O
branched	O
peptide	O
as	O
immunogen	O
.	O

These	O
antibodies	O
provide	O
a	O
powerful	O
tool	O
for	O
exploring	O
the	O
biochemical	O
functions	O
of	O
H2B	S-Protein
monoubiquitination	O
at	O
both	O
a	O
genome	O
-	O
wide	O
and	O
gene	O
-	O
specific	O
level	O
.	O

Application	O
of	O
these	O
antibodies	O
in	O
high	O
resolution	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
-	O
chip	O
experiments	O
in	O
human	O
cells	O
,	O
using	O
tiling	O
arrays	O
,	O
revealed	O
preferential	O
association	O
of	O
ubiquitinated	O
H2B	S-Protein
with	O
the	O
transcribed	O
regions	O
of	O
highly	O
expressed	O
genes	O
.	O

Unlike	O
dimethylated	O
H3K4	S-Protein
,	O
ubH2B	S-Protein
was	O
not	O
associated	O
with	O
distal	O
promoter	O
regions	O
.	O

Furthermore	O
,	O
experimental	O
modulation	O
of	O
the	O
transcriptional	O
activity	O
of	O
the	O
tumour	O
suppressor	O
p53	S-Protein
was	O
accompanied	O
by	O
rapid	O
changes	O
in	O
the	O
H2B	S-Protein
ubiquitination	O
status	O
of	O
its	O
p21	S-Protein
target	O
gene	O
,	O
attesting	O
to	O
the	O
dynamic	O
nature	O
of	O
this	O
process	O
.	O

It	O
has	O
recently	O
been	O
demonstrated	O
that	O
the	O
apparent	O
extent	O
of	O
gene	O
expression	O
often	O
reflects	O
elongation	O
rather	O
than	O
initiation	O
rates	O
;	O
thus	O
,	O
our	O
findings	O
suggest	O
that	O
H2B	S-Protein
ubiquitination	O
is	O
intimately	O
linked	O
with	O
global	O
transcriptional	O
elongation	O
in	O
mammalian	O
cells	O
.	O

Identification	O
of	O
major	O
lysine	O
residues	O
of	O
S	B-Protein
(	I-Protein
3	I-Protein
)	I-Protein
-	I-Protein
RNase	E-Protein
of	O
Petunia	O
inflata	O
involved	O
in	O
ubiquitin	S-Protein
-	O
26S	O
proteasome	O
-	O
mediated	O
degradation	O
in	O
vitro	O
.	O

S	O
-	O
RNase	O
-	O
based	O
self	O
-	O
incompatibility	O
has	O
been	O
identified	O
in	O
three	O
flowering	O
plant	O
families	O
,	O
including	O
the	O
Solanaceae	O
,	O
and	O
this	O
self	O
/	O
non	O
-	O
self	O
recognition	O
mechanism	O
between	O
pollen	O
and	O
pistil	O
is	O
controlled	O
by	O
two	O
polymorphic	O
genes	O
at	O
the	O
S	O
-	O
locus	O
,	O
S	O
-	O
RNase	O
and	O
S	O
-	O
locus	O
F	O
-	O
box	O
(	O
SLF	O
)	O
.	O

S	O
-	O
RNase	O
is	O
produced	O
in	O
the	O
pistil	O
and	O
taken	O
up	O
by	O
pollen	O
tubes	O
in	O
a	O
non	O
-	O
S	O
-	O
haplotype	O
-	O
specific	O
manner	O
.	O

How	O
an	O
allelic	O
product	O
of	O
SLF	O
interacts	O
with	O
self	O
and	O
non	O
-	O
self	O
S	O
-	O
RNases	O
to	O
result	O
in	O
growth	O
inhibition	O
of	O
self	O
pollen	O
tubes	O
is	O
not	O
completely	O
understood	O
.	O

One	O
model	O
predicts	O
that	O
SLF	O
targets	O
non	O
-	O
self	O
S	O
-	O
RNases	O
for	O
ubiquitin	S-Protein
/	O
26S	O
proteasome	O
-	O
mediated	O
degradation	O
,	O
thereby	O
only	O
allowing	O
self	O
S	O
-	O
RNase	O
to	O
exert	O
cytotoxic	O
activity	O
inside	O
a	O
pollen	O
tube	O
.	O

To	O
test	O
this	O
model	O
,	O
we	O
studied	O
whether	O
any	O
of	O
the	O
20	O
lysine	O
residues	O
in	O
S	B-Protein
(	I-Protein
3	I-Protein
)	I-Protein
-	I-Protein
RNase	E-Protein
of	O
Petunia	O
inflata	O
might	O
be	O
targets	O
for	O
ubiquitination	O
.	O

We	O
identified	O
six	O
lysines	O
near	O
the	O
C	O
-	O
terminus	O
for	O
which	O
mutation	O
to	O
arginine	O
significantly	O
reduced	O
ubiquitination	O
and	O
degradation	O
of	O
the	O
mutant	O
S	B-Protein
(	I-Protein
3	I-Protein
)	I-Protein
-	I-Protein
RNase	E-Protein
,	O
GST	O
:	O
S	B-Protein
(	I-Protein
3	I-Protein
)	I-Protein
-	I-Protein
RNase	E-Protein
(	O
K141	O
-	O
164R	O
)	O
in	O
pollen	O
tube	O
extracts	O
.	O

We	O
further	O
showed	O
that	O
GST	O
:	O
S	B-Protein
(	I-Protein
3	I-Protein
)	I-Protein
-	I-Protein
RNase	E-Protein
(	O
K141	O
-	O
164R	O
)	O
and	O
GST	O
:	O
S	B-Protein
(	I-Protein
3	I-Protein
)	I-Protein
-	I-Protein
RNase	E-Protein
had	O
similar	O
RNase	O
activity	O
,	O
suggesting	O
that	O
their	O
degradation	O
was	O
probably	O
not	O
caused	O
by	O
an	O
ER	O
-	O
associated	O
protein	O
degradation	O
pathway	O
that	O
removes	O
mis	O
-	O
folded	O
proteins	O
.	O

Finally	O
,	O
we	O
showed	O
that	O
PiSBP1	S-Protein
(	O
P	O
.	O
inflata	O
S	B-Protein
-	I-Protein
RNase	I-Protein
binding	I-Protein
protein	I-Protein
1	E-Protein
)	O
,	O
a	O
potential	O
RING	O
-	O
HC	O
subunit	O
of	O
the	O
PiSLF	O
(	O
P	O
.	O
inflata	O
SLF	O
)	O
-	O
containing	O
E3	O
-	O
like	O
complex	O
,	O
could	O
target	O
S	O
-	O
RNase	O
for	O
ubiquitination	O
in	O
vitro	O
.	O

All	O
these	O
results	O
suggest	O
that	O
ubiquitin	S-Protein
/	O
26S	O
proteasome	O
-	O
dependent	O
degradation	O
of	O
S	O
-	O
RNase	O
may	O
be	O
an	O
integral	O
part	O
of	O
the	O
S	O
-	O
RNase	O
-	O
based	O
self	O
-	O
incompatibility	O
mechanism	O
.	O

PHDs	O
overactivation	O
during	O
chronic	O
hypoxia	O
"	O
desensitizes	O
"	O
HIFalpha	O
and	O
protects	O
cells	O
from	O
necrosis	O
.	O

Cell	O
adaptation	O
to	O
changes	O
in	O
oxygen	O
(	O
O	O
(	O
2	O
)	O
)	O
availability	O
is	O
controlled	O
by	O
two	O
subfamilies	O
of	O
O	O
(	O
2	O
)	O
-	O
dependent	O
enzymes	O
:	O
the	O
hypoxia	O
inducible	O
factor	O
(	O
HIF	O
)	O
-	O
prolyl	O
and	O
asparaginyl	O
hydroxylases	O
[	O
prolyl	O
hydroxylases	O
domain	O
(	O
PHDs	O
)	O
and	O
factor	B-Protein
inhibiting	I-Protein
HIF	E-Protein
(	O
FIH	S-Protein
)	O
]	O
.	O

These	O
oxygen	O
sensors	O
regulate	O
the	O
activity	O
of	O
the	O
HIF	O
,	O
a	O
transcriptional	O
complex	O
central	O
in	O
O	O
(	O
2	O
)	O
homeostasis	O
.	O

In	O
well	O
oxygenated	O
cells	O
,	O
PHDs	O
hydroxylate	O
the	O
HIFalpha	O
subunits	O
,	O
thereby	O
targeting	O
them	O
for	O
proteasomal	O
degradation	O
.	O

In	O
contrast	O
,	O
acute	O
hypoxia	O
inhibits	O
PHDs	O
,	O
leading	O
to	O
HIFalpha	O
stabilisation	O
.	O

However	O
,	O
here	O
we	O
show	O
that	O
chronic	O
hypoxia	O
induces	O
HIF1	B-Protein
/	I-Protein
2alpha	E-Protein
"	O
desensitization	O
"	O
in	O
cellulo	O
and	O
in	O
mice	O
.	O

At	O
the	O
basis	O
of	O
this	O
general	O
adaptative	O
mechanism	O
,	O
we	O
demonstrate	O
that	O
chronic	O
hypoxia	O
not	O
only	O
increases	O
the	O
pool	O
of	O
PHDs	O
but	O
also	O
overactivates	O
the	O
three	O
PHD	O
isoforms	O
.	O

This	O
overactivation	O
appears	O
to	O
be	O
mediated	O
by	O
an	O
increase	O
in	O
intracellular	O
O	O
(	O
2	O
)	O
availability	O
consequent	O
to	O
the	O
inhibition	O
of	O
mitochondrial	O
respiration	O
.	O

By	O
using	O
in	O
cellulo	O
and	O
in	O
vivo	O
siRNA	O
,	O
we	O
found	O
that	O
the	O
PHDs	O
are	O
the	O
key	O
enzymes	O
triggering	O
HIFalpha	O
desensitization	O
,	O
a	O
feedback	O
mechanism	O
required	O
to	O
protect	O
cells	O
against	O
necrotic	O
cell	O
death	O
and	O
thus	O
to	O
adapt	O
them	O
across	O
a	O
chronic	O
hypoxia	O
.	O

Hence	O
,	O
PHDs	O
serve	O
as	O
dual	O
enzymes	O
,	O
for	O
which	O
inactivation	O
and	O
later	O
overactivation	O
is	O
necessary	O
for	O
cell	O
survival	O
in	O
acute	O
or	O
chronic	O
hypoxia	O
,	O
respectively	O
.	O

Dependence	O
of	O
reactive	O
oxygen	O
species	O
and	O
FLICE	B-Protein
inhibitory	I-Protein
protein	E-Protein
on	O
lipofectamine	O
-	O
induced	O
apoptosis	O
in	O
human	O
lung	O
epithelial	O
cells	O
.	O

Cationic	O
liposomes	O
such	O
as	O
lipofectamine	O
(	O
LF	O
)	O
are	O
widely	O
used	O
as	O
nonviral	O
gene	O
delivery	O
vectors	O
;	O
however	O
,	O
their	O
clinical	O
application	O
is	O
limited	O
by	O
their	O
cytotoxicity	O
.	O

These	O
agents	O
have	O
been	O
shown	O
to	O
induce	O
apoptosis	O
as	O
the	O
primary	O
mode	O
of	O
cell	O
death	O
,	O
but	O
their	O
mechanism	O
of	O
action	O
is	O
not	O
well	O
understood	O
.	O

The	O
present	O
study	O
investigated	O
the	O
mechanism	O
of	O
LF	O
-	O
induced	O
apoptosis	O
and	O
examined	O
the	O
role	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
this	O
process	O
.	O

We	O
found	O
that	O
LF	O
induced	O
apoptosis	O
of	O
human	O
epithelial	O
H460	O
cells	O
through	O
a	O
mechanism	O
that	O
involves	O
caspase	O
activation	O
and	O
ROS	O
generation	O
.	O

Inhibition	O
of	O
caspase	O
activity	O
by	O
pan	O
-	O
caspase	O
inhibitor	O
(	O
z	O
-	O
VAD	O
-	O
fmk	O
)	O
or	O
by	O
specific	O
caspase	B-Protein
-	I-Protein
8	E-Protein
inhibitor	O
(	O
z	O
-	O
IETD	O
-	O
fmk	O
)	O
or	O
caspase	B-Protein
-	I-Protein
9	E-Protein
inhibitor	O
(	O
z	O
-	O
LEHD	O
-	O
fmk	O
)	O
inhibited	O
the	O
apoptotic	O
effect	O
of	O
LF	O
.	O

Overexpression	O
of	O
FLICE	B-Protein
-	I-Protein
inhibitory	I-Protein
protein	E-Protein
(	O
FLIP	S-Protein
)	O
or	O
B	O
-	O
cell	O
lymphoma	O
-	O
2	O
,	O
which	O
are	O
known	O
inhibitors	O
of	O
the	O
extrinsic	O
and	O
intrinsic	O
death	O
pathways	O
,	O
respectively	O
,	O
similarly	O
inhibited	O
apoptosis	O
by	O
LF	O
.	O

Induction	O
of	O
apoptosis	O
by	O
LF	O
was	O
shown	O
to	O
require	O
ROS	O
generation	O
because	O
its	O
inhibition	O
by	O
ROS	O
scavengers	O
or	O
by	O
ectopic	O
expression	O
of	O
antioxidant	O
enzyme	O
superoxide	O
dismutase	O
and	O
glutathione	O
peroxidase	O
strongly	O
inhibited	O
the	O
apoptotic	O
effect	O
of	O
LF	O
.	O

Electron	O
spin	O
resonance	O
studies	O
showed	O
that	O
LF	O
induced	O
multiple	O
ROS	O
;	O
however	O
,	O
superoxide	O
was	O
found	O
to	O
be	O
the	O
primary	O
ROS	O
responsible	O
for	O
LF	O
-	O
induced	O
apoptosis	O
.	O

The	O
mechanism	O
by	O
which	O
ROS	O
mediate	O
the	O
apoptotic	O
effect	O
of	O
LF	O
involves	O
down	O
-	O
regulation	O
of	O
FLIP	S-Protein
through	O
the	O
ubiquitination	O
pathway	O
.	O

In	O
demonstrating	O
the	O
role	O
of	O
FLIP	S-Protein
and	O
ROS	O
in	O
LF	O
death	O
signaling	O
,	O
we	O
document	O
a	O
novel	O
mechanism	O
of	O
apoptosis	O
regulation	O
that	O
may	O
be	O
exploited	O
to	O
decrease	O
cytotoxicity	O
and	O
increase	O
gene	O
transfection	O
efficiency	O
of	O
cationic	O
liposomes	O
.	O

Salmonella	B-Protein
secreted	I-Protein
factor	I-Protein
L	E-Protein
deubiquitinase	O
of	O
Salmonella	O
typhimurium	O
inhibits	O
NF	O
-	O
kappaB	O
,	O
suppresses	O
IkappaBalpha	S-Protein
ubiquitination	O
and	O
modulates	O
innate	O
immune	O
responses	O
.	O

Salmonella	O
enterica	O
translocates	O
virulent	O
factors	O
into	O
host	O
cells	O
using	O
type	O
III	O
secretion	O
systems	O
to	O
promote	O
host	O
colonization	O
,	O
intracellular	O
bacterial	O
replication	O
and	O
survival	O
,	O
and	O
disease	O
pathogenesis	O
.	O

Among	O
many	O
effectors	O
,	O
the	O
type	O
III	O
secretion	O
system	O
encoded	O
in	O
Salmonella	O
pathogenicity	O
island	O
2	O
translocates	O
a	O
Salmonella	O
-	O
specific	O
protein	O
,	O
designated	O
Salmonella	B-Protein
secreted	I-Protein
factor	I-Protein
L	E-Protein
(	O
SseL	S-Protein
)	O
,	O
a	O
putative	O
virulence	O
factor	O
possessing	O
deubiquitinase	O
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
attempt	O
to	O
elucidate	O
the	O
mechanism	O
and	O
the	O
function	O
of	O
SseL	S-Protein
in	O
vitro	O
,	O
in	O
primary	O
host	O
macrophages	O
and	O
in	O
vivo	O
in	O
infected	O
mice	O
.	O

Expression	O
of	O
SseL	S-Protein
in	O
mammalian	O
cells	O
suppresses	O
NF	O
-	O
kappaB	O
activation	O
downstream	O
of	O
IkappaBalpha	S-Protein
kinases	O
and	O
impairs	O
IkappaBalpha	S-Protein
ubiquitination	O
and	O
degradation	O
,	O
but	O
not	O
IkappaBalpha	S-Protein
phosphorylation	O
.	O

Disruption	O
of	O
the	O
gene	O
encoding	O
SseL	S-Protein
in	O
S	O
.	O
enterica	O
serovar	O
typhimurium	O
increases	O
IkappaBalpha	S-Protein
degradation	O
and	O
ubiquitination	O
,	O
as	O
well	O
as	O
NF	O
-	O
kappaB	O
activation	O
in	O
infected	O
macrophages	O
,	O
compared	O
with	O
wild	O
-	O
type	O
bacteria	O
.	O

Mice	O
infected	O
with	O
SseL	S-Protein
-	O
deficient	O
bacteria	O
mount	O
stronger	O
inflammatory	O
responses	O
,	O
associated	O
with	O
increased	O
production	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
cytokines	O
.	O

Thus	O
,	O
SseL	S-Protein
represents	O
one	O
of	O
the	O
first	O
bacterial	O
deubiquitinases	O
demonstrated	O
to	O
modulate	O
the	O
host	O
inflammatory	O
response	O
in	O
vivo	O
.	O

Members	O
of	O
the	O
E2D	O
(	O
UbcH5	O
)	O
family	O
mediate	O
the	O
ubiquitination	O
of	O
the	O
conserved	O
cysteine	O
of	O
Pex5p	S-Protein
,	O
the	O
peroxisomal	O
import	O
receptor	O
.	O

According	O
to	O
current	O
models	O
of	O
peroxisomal	O
biogenesis	O
,	O
newly	O
synthesized	O
peroxisomal	O
matrix	O
proteins	O
are	O
transported	O
into	O
the	O
organelle	O
by	O
Pex5p	S-Protein
.	O

Pex5p	S-Protein
recognizes	O
these	O
proteins	O
in	O
the	O
cytosol	O
,	O
mediates	O
their	O
membrane	O
translocation	O
,	O
and	O
is	O
exported	O
back	O
into	O
the	O
cytosol	O
in	O
an	O
ATP	O
-	O
dependent	O
manner	O
.	O

We	O
have	O
previously	O
shown	O
that	O
export	O
of	O
Pex5p	S-Protein
is	O
preceded	O
by	O
(	O
and	O
requires	O
)	O
monoubiquitination	O
of	O
a	O
conserved	O
cysteine	O
residue	O
present	O
at	O
its	O
N	O
terminus	O
.	O

In	O
yeasts	O
,	O
and	O
probably	O
also	O
in	O
plants	O
,	O
ubiquitination	O
of	O
Pex5p	S-Protein
is	O
mediated	O
by	O
a	O
specialized	O
ubiquitin	S-Protein
-	O
conjugating	O
enzyme	O
,	O
Pex4p	S-Protein
.	O

In	O
mammals	O
,	O
the	O
identity	O
of	O
this	O
enzyme	O
has	O
remained	O
unknown	O
for	O
many	O
years	O
.	O

Here	O
,	O
we	O
provide	O
evidence	O
suggesting	O
that	O
E2D1	S-Protein
/	O
2	S-Protein
/	O
3	S-Protein
(	O
UbcH5a	S-Protein
/	O
b	S-Protein
/	O
c	S-Protein
)	O
are	O
the	O
mammalian	O
functional	O
counterparts	O
of	O
yeast	O
/	O
plant	O
Pex4p	S-Protein
.	O

The	O
mechanistic	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
.	O

The	O
association	O
of	O
GSK3	B-Protein
beta	E-Protein
with	O
E2F1	S-Protein
facilitates	O
nerve	O
growth	O
factor	O
-	O
induced	O
neural	O
cell	O
differentiation	O
.	O

It	O
is	O
widely	O
acknowledged	O
that	O
E2F1	S-Protein
and	O
GSK3beta	S-Protein
are	O
both	O
involved	O
in	O
the	O
process	O
of	O
cell	O
differentiation	O
.	O

However	O
,	O
the	O
relationship	O
between	O
E2F1	S-Protein
and	O
GSK3beta	S-Protein
in	O
cell	O
differentiation	O
has	O
yet	O
to	O
be	O
discovered	O
.	O

Here	O
,	O
we	O
provide	O
evidence	O
that	O
in	O
the	O
differentiation	O
of	O
PC12	O
cells	O
induced	O
by	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
,	O
GSK3beta	S-Protein
was	O
increased	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
,	O
whereas	O
E2F1	S-Protein
at	O
these	O
two	O
levels	O
was	O
decreased	O
.	O

Both	O
wild	O
-	O
type	O
GSK3beta	S-Protein
and	O
its	O
kinase	O
-	O
defective	O
mutant	O
GSK3beta	S-Protein
KM	O
can	O
inhibit	O
E2F1	S-Protein
by	O
promoting	O
its	O
ubiquitination	O
through	O
physical	O
interaction	O
.	O

In	O
addition	O
,	O
the	O
colocalization	O
of	O
GSK3beta	S-Protein
and	O
E2F1	S-Protein
and	O
their	O
subcellular	O
distribution	O
,	O
regulated	O
by	O
NGF	O
,	O
were	O
observed	O
in	O
the	O
process	O
of	O
PC12	O
differentiation	O
.	O

At	O
the	O
tissue	O
level	O
,	O
GSK3beta	S-Protein
colocalized	O
and	O
interacted	O
with	O
E2F1	S-Protein
in	O
mouse	O
hippocampus	O
.	O

Furthermore	O
,	O
GSK3beta	S-Protein
facilitated	O
neurite	O
outgrowth	O
by	O
rescuing	O
the	O
promoter	O
activities	O
of	O
Cdk	S-Protein
inhibitors	O
p21	S-Protein
and	O
p15	S-Protein
from	O
the	O
inhibition	O
caused	O
by	O
E2F1	S-Protein
.	O

To	O
summarize	O
,	O
our	O
findings	O
suggest	O
that	O
GSK3beta	S-Protein
can	O
promote	O
the	O
ubiquitination	O
of	O
E2F1	S-Protein
via	O
physical	O
interaction	O
and	O
thus	O
inhibit	O
its	O
transcription	O
activity	O
in	O
a	O
kinase	O
activity	O
independent	O
manner	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
the	O
NGF	O
-	O
induced	O
PC12	O
differentiation	O
.	O

Synthetic	O
lethal	O
screens	O
identify	O
gene	O
silencing	O
processes	O
in	O
yeast	O
and	O
implicate	O
the	O
acetylated	O
amino	O
terminus	O
of	O
Sir3	S-Protein
in	O
recognition	O
of	O
the	O
nucleosome	O
core	O
.	O

Dot1	S-Protein
methylates	O
histone	B-Protein
H3	E-Protein
lysine	O
79	O
(	O
H3K79	S-Protein
)	O
on	O
the	O
nucleosome	O
core	O
and	O
is	O
involved	O
in	O
Sir	O
protein	O
-	O
mediated	O
silencing	O
.	O

Previous	O
studies	O
suggested	O
that	O
H3K79	S-Protein
methylation	O
within	O
euchromatin	O
prevents	O
nonspecific	O
binding	O
of	O
the	O
Sir	O
proteins	O
,	O
which	O
in	O
turn	O
facilitates	O
binding	O
of	O
the	O
Sir	O
proteins	O
in	O
unmethylated	O
silent	O
chromatin	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
the	O
Sir	O
protein	O
binding	O
is	O
influenced	O
by	O
this	O
modification	O
is	O
unclear	O
.	O

We	O
performed	O
genome	O
-	O
wide	O
synthetic	O
genetic	O
array	O
(	O
SGA	O
)	O
analysis	O
and	O
identified	O
interactions	O
of	O
DOT1	S-Protein
with	O
SIR1	S-Protein
and	O
POL32	S-Protein
.	O

The	O
synthetic	O
growth	O
defects	O
found	O
by	O
SGA	O
analysis	O
were	O
attributed	O
to	O
the	O
loss	O
of	O
mating	O
type	O
identity	O
caused	O
by	O
a	O
synthetic	O
silencing	O
defect	O
.	O

By	O
using	O
epistasis	O
analysis	O
,	O
DOT1	S-Protein
,	O
SIR1	S-Protein
,	O
and	O
POL32	S-Protein
could	O
be	O
placed	O
in	O
different	O
pathways	O
of	O
silencing	O
.	O

Dot1	S-Protein
shared	O
its	O
silencing	O
phenotypes	O
with	O
the	O
NatA	O
N	O
-	O
terminal	O
acetyltransferase	O
complex	O
and	O
the	O
conserved	O
N	O
-	O
terminal	O
bromo	O
adjacent	O
homology	O
(	O
BAH	O
)	O
domain	O
of	O
Sir3	S-Protein
(	O
a	O
substrate	O
of	O
NatA	O
)	O
.	O

We	O
classified	O
all	O
of	O
these	O
as	O
affecting	O
a	O
common	O
silencing	O
process	O
,	O
and	O
we	O
show	O
that	O
mutations	O
in	O
this	O
process	O
lead	O
to	O
nonspecific	O
binding	O
of	O
Sir3	S-Protein
to	O
chromatin	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
BAH	O
domain	O
of	O
Sir3	S-Protein
binds	O
to	O
histone	B-Protein
H3K79	E-Protein
and	O
that	O
acetylation	O
of	O
the	O
BAH	O
domain	O
is	O
required	O
for	O
the	O
binding	O
specificity	O
of	O
Sir3	S-Protein
for	O
nucleosomes	O
unmethylated	O
at	O
H3K79	S-Protein
.	O

Isoniazid	O
acetylating	O
phenotype	O
in	O
patients	O
with	O
paracoccidioidomycosis	O
and	O
its	O
relationship	O
with	O
serum	O
sulfadoxin	O
levels	O
,	O
glucose	B-Protein
-	I-Protein
6	I-Protein
-	I-Protein
phosphate	I-Protein
dehydrogenase	E-Protein
and	O
glutathione	B-Protein
reductase	E-Protein
activities	O
.	O

The	O
authors	O
evaluated	O
the	O
isoniazid	O
acetylating	O
phenotype	O
and	O
measured	O
hematocrit	O
,	O
hemoglobin	O
,	O
glucose	B-Protein
-	I-Protein
6	I-Protein
-	I-Protein
phosphate	I-Protein
dehydrogenase	E-Protein
and	O
glutathione	B-Protein
reductase	E-Protein
activities	O
plus	O
serum	O
sulfadoxin	O
levels	O
in	O
39	O
patients	O
with	O
paracoccidioidomycosis	O
(	O
33	O
males	O
and	O
6	O
females	O
)	O
aged	O
17	O
to	O
58	O
years	O
.	O

Twenty	O
one	O
(	O
53	O
.	O
84	O
%	O
)	O
of	O
the	O
patients	O
presented	O
a	O
slow	O
acetylating	O
phenotype	O
and	O
18	O
(	O
46	O
.	O
16	O
%	O
)	O
a	O
fast	O
acetylating	O
phenotype	O
.	O

Glucose	B-Protein
-	I-Protein
6	I-Protein
-	I-Protein
phosphate	I-Protein
-	I-Protein
dehydrogenase	E-Protein
(	O
G6PD	S-Protein
)	O
activity	O
was	O
decreased	O
in	O
5	O
(	O
23	O
.	O
80	O
%	O
)	O
slow	O
acetylators	O
and	O
in	O
4	O
(	O
22	O
.	O
22	O
%	O
)	O
fast	O
acetylators	O
.	O

Glutathione	B-Protein
reductase	E-Protein
activity	O
was	O
decreased	O
in	O
14	O
(	O
66	O
.	O
66	O
%	O
)	O
slow	O
acetylators	O
and	O
in	O
12	O
(	O
66	O
.	O
66	O
%	O
)	O
fast	O
acetylators	O
.	O

Serum	O
levels	O
of	O
free	O
and	O
total	O
sulfadoxin	O
were	O
higher	O
in	O
slow	O
acetylator	O
(	O
p	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

Analysis	O
of	O
the	O
results	O
permitted	O
us	O
to	O
conclude	O
that	O
serum	O
sulfadoxin	O
levels	O
are	O
related	O
to	O
the	O
acetylator	O
phenotype	O
.	O

Furthermore	O
,	O
sulfadoxin	O
levels	O
were	O
always	O
above	O
50	O
micrograms	O
/	O
ml	O
,	O
a	O
value	O
considered	O
therapeutic	O
.	O

Glutathione	B-Protein
reductase	E-Protein
deficiency	O
observed	O
in	O
66	O
%	O
of	O
patients	O
may	O
be	O
related	O
to	O
the	O
intestinal	O
malabsorption	O
of	O
nutrients	O
,	O
among	O
them	O
riboflavin	O
,	O
a	O
FAD	O
precursor	O
vitamin	O
,	O
in	O
patients	O
with	O
paracoceidioidomycosis	O
.	O

Evidence	O
against	O
posttranslational	O
glycosylation	O
of	O
rat	O
glucocorticoid	B-Protein
receptors	E-Protein
.	O

The	O
observed	O
M	O
(	O
r	O
)	O
of	O
the	O
rat	O
glucocorticoid	B-Protein
receptor	E-Protein
on	O
denaturing	O
polyacrylamide	O
gels	O
is	O
7	O
-	O
11	O
kDa	O
higher	O
than	O
that	O
deduced	O
from	O
the	O
cloned	O
cDNA	O
sequence	O
of	O
the	O
receptor	O
.	O

Posttranslational	O
modification	O
of	O
the	O
receptor	O
,	O
such	O
as	O
glycosylation	O
,	O
could	O
account	O
for	O
this	O
difference	O
in	O
mol	O
wt	O
.	O

Indeed	O
,	O
several	O
reports	O
have	O
appeared	O
in	O
the	O
literature	O
suggesting	O
that	O
glucocorticoid	B-Protein
receptors	E-Protein
contain	O
sugar	O
moieties	O
.	O

We	O
have	O
used	O
a	O
variety	O
of	O
methods	O
to	O
determine	O
whether	O
the	O
receptor	O
is	O
glycosylated	O
,	O
i	O
.	O
e	O
.	O
,	O
digestion	O
of	O
affinity	O
labeled	O
receptors	O
with	O
various	O
glycosidases	O
,	O
immunoadsorption	O
of	O
receptors	O
after	O
whole	O
cell	O
labeling	O
with	O
[	O
3H	O
]	O
D	O
-	O
glucosamine	O
,	O
and	O
ion	O
exchange	O
and	O
lectin	O
column	O
chromatography	O
of	O
affinity	O
labeled	O
receptors	O
.	O

With	O
each	O
of	O
these	O
methods	O
,	O
there	O
was	O
no	O
evidence	O
for	O
glycosylation	O
of	O
the	O
receptor	O
protein	O
.	O

We	O
therefore	O
conclude	O
that	O
there	O
is	O
no	O
significant	O
amount	O
of	O
either	O
N	O
-	O
linked	O
glycosylation	O
,	O
or	O
O	O
-	O
linked	O
glycosylation	O
with	O
D	O
-	O
glucosamine	O
,	O
of	O
the	O
rat	O
glucocorticoid	B-Protein
receptor	E-Protein
.	O

The	O
intramolecular	O
autoglucosylation	O
of	O
monomeric	O
glycogenin	S-Protein
.	O

The	O
ability	O
of	O
monomeric	O
glycogenin	S-Protein
to	O
autoglucosylate	O
by	O
an	O
intramolecular	O
mechanism	O
of	O
reaction	O
is	O
described	O
using	O
non	O
-	O
glucosylated	O
and	O
partially	O
glucosylated	O
recombinant	O
glycogenin	S-Protein
.	O

We	O
determined	O
that	O
monomer	O
glycogenin	S-Protein
exists	O
in	O
solution	O
at	O
concentration	O
below	O
0	O
.	O
60	O
-	O
0	O
.	O
85	O
microM	O
.	O

The	O
specific	O
autoglucosylation	O
rate	O
of	O
non	O
-	O
glucosylated	O
and	O
glucosylated	O
monomeric	O
glycogenin	S-Protein
represented	O
50	O
and	O
70	O
%	O
of	O
the	O
specific	O
rate	O
of	O
the	O
corresponding	O
dimeric	O
glycogenin	S-Protein
species	O
.	O

The	O
incorporation	O
of	O
a	O
unique	O
sugar	O
unit	O
into	O
the	O
tyrosine	O
hydroxyl	O
group	O
of	O
non	O
-	O
glucosylated	O
glycogenin	S-Protein
,	O
analyzed	O
by	O
autoxylosylation	O
,	O
occurred	O
at	O
a	O
lower	O
rate	O
than	O
the	O
incorporation	O
into	O
the	O
glucose	O
hydroxyl	O
group	O
of	O
the	O
glucosylated	O
enzyme	O
.	O

The	O
intramonomer	O
autoglucosylation	O
mechanism	O
here	O
described	O
for	O
the	O
first	O
time	O
,	O
confers	O
to	O
a	O
just	O
synthesized	O
glycogenin	S-Protein
molecule	O
the	O
capacity	O
to	O
produce	O
maltosaccharide	O
primer	O
for	O
glycogen	O
synthase	O
,	O
without	O
the	O
need	O
to	O
reach	O
the	O
concentration	O
required	O
for	O
association	O
into	O
the	O
more	O
efficient	O
autoglucosylating	O
dimer	O
.	O

The	O
monomeric	O
and	O
dimeric	O
interconversion	O
determining	O
the	O
different	O
autoglucosylation	O
rate	O
,	O
might	O
serve	O
as	O
a	O
modulation	O
mechanism	O
for	O
the	O
de	O
novo	O
biosynthesis	O
of	O
glycogen	O
at	O
the	O
initial	O
glucose	O
polymerization	O
step	O
.	O

Glycation	O
does	O
not	O
modify	O
bovine	O
serum	B-Protein
albumin	E-Protein
(	O
BSA	S-Protein
)	O
-	O
induced	O
reduction	O
of	O
rat	O
aortic	O
relaxation	O
:	O
the	O
response	O
to	O
glycated	O
and	O
nonglycated	O
BSA	S-Protein
is	O
lost	O
in	O
metabolic	O
syndrome	O
.	O

The	O
effects	O
of	O
nonglycated	O
bovine	O
serum	B-Protein
albumin	E-Protein
(	O
BSA	S-Protein
)	O
and	O
advanced	O
glycosylation	O
end	O
products	O
of	O
BSA	S-Protein
(	O
AGE	O
-	O
BSA	S-Protein
)	O
on	O
vascular	O
responses	O
of	O
control	O
and	O
metabolic	O
syndrome	O
(	O
MS	O
)	O
rats	O
characterized	O
by	O
hypertriglyceridemia	O
,	O
hypertension	O
,	O
hyperinsulinemia	O
,	O
and	O
insulin	S-Protein
resistance	O
were	O
studied	O
.	O

Albumin	S-Protein
and	O
in	O
vitro	O
prepared	O
AGE	O
-	O
BSA	S-Protein
have	O
vascular	O
effects	O
;	O
however	O
,	O
recent	O
studies	O
indicate	O
that	O
some	O
effects	O
of	O
in	O
vitro	O
prepared	O
AGEs	O
are	O
due	O
to	O
the	O
conditions	O
in	O
which	O
they	O
were	O
generated	O
.	O

We	O
produced	O
AGEs	O
by	O
incubating	O
glucose	O
with	O
BSA	S-Protein
for	O
60	O
days	O
under	O
sterile	O
conditions	O
in	O
darkness	O
and	O
at	O
37	O
degrees	O
C	O
.	O

To	O
develop	O
MS	O
rats	O
,	O
male	O
Wistar	O
animals	O
were	O
given	O
30	O
%	O
sucrose	O
in	O
drinking	O
water	O
since	O
weanling	O
.	O

Six	O
month	O
old	O
animals	O
were	O
used	O
.	O

Blood	O
pressure	O
,	O
insulin	S-Protein
,	O
triglycerides	O
,	O
and	O
serum	B-Protein
albumin	E-Protein
were	O
increased	O
in	O
MS	O
rats	O
.	O

Contraction	O
of	O
aortic	O
rings	O
elicited	O
with	O
norepinephrine	O
was	O
stronger	O
.	O

There	O
were	O
no	O
effects	O
of	O
nonglycated	O
BSA	O
or	O
AGE	O
-	O
BSA	S-Protein
on	O
contractions	O
in	O
control	O
or	O
MS	O
rats	O
;	O
however	O
,	O
both	O
groups	O
responded	O
to	O
L	O
-	O
NAME	O
,	O
an	O
inhibitor	O
of	O
nitric	O
oxide	O
synthesis	O
.	O

Arterial	O
relaxation	O
induced	O
using	O
acetylcholine	O
was	O
smaller	O
in	O
MS	O
rats	O
.	O

Nonglycated	O
BSA	S-Protein
and	O
AGE	O
-	O
BSA	S-Protein
significantly	O
diminished	O
relaxation	O
in	O
a	O
35	O
%	O
in	O
the	O
control	O
group	O
but	O
the	O
decrease	O
was	O
similar	O
when	O
using	O
nonglycated	O
BSA	S-Protein
and	O
AGE	O
-	O
BSA	S-Protein
.	O

This	O
decrease	O
was	O
not	O
present	O
in	O
the	O
MS	O
rats	O
and	O
was	O
not	O
due	O
to	O
increased	O
RAGEs	O
or	O
altered	O
biochemical	O
characteristics	O
of	O
BSA	S-Protein
.	O

In	O
conclusion	O
,	O
both	O
BSA	S-Protein
and	O
AGE	O
-	O
BSA	S-Protein
inhibit	O
vascular	O
relaxation	O
in	O
control	O
artic	O
rings	O
.	O

In	O
MS	O
rats	O
the	O
effect	O
is	O
lost	O
possibly	O
due	O
to	O
alterations	O
in	O
endothelial	O
cells	O
that	O
are	O
a	O
consequence	O
of	O
the	O
illness	O
.	O

USP22	S-Protein
,	O
an	O
hSAGA	O
subunit	O
and	O
potential	O
cancer	O
stem	O
cell	O
marker	O
,	O
reverses	O
the	O
polycomb	O
-	O
catalyzed	O
ubiquitylation	O
of	O
histone	B-Protein
H2A	E-Protein
.	O

Initial	O
studies	O
of	O
the	O
mammalian	O
hSAGA	O
transcriptional	O
coactivator	O
complex	O
identified	O
the	O
acetyltransferase	O
hGCN5	S-Protein
/	O
PCAF	S-Protein
as	O
the	O
only	O
known	O
enzymatic	O
subunit	O
.	O

Recently	O
we	O
demonstrated	O
that	O
the	O
ubiquitin	S-Protein
hydrolase	O
USP22	S-Protein
comprises	O
a	O
second	O
enzymatic	O
subunit	O
of	O
hSAGA	O
,	O
and	O
that	O
is	O
required	O
for	O
activator	O
-	O
driven	O
transcription	O
.	O

USP22	S-Protein
is	O
expressed	O
with	O
polycomb	O
ubiquitin	S-Protein
ligases	O
in	O
an	O
11	O
gene	O
signature	O
that	O
defines	O
therapy	O
-	O
resistant	O
tumors	O
.	O

At	O
the	O
biochemical	O
level	O
,	O
these	O
Polycomb	O
proteins	O
function	O
as	O
global	O
transcriptional	O
repressors	O
by	O
catalyzing	O
the	O
ubiquitylation	O
of	O
histone	B-Protein
H2A	E-Protein
.	O

In	O
yeast	O
,	O
the	O
USP22	S-Protein
homolog	O
functions	O
as	O
a	O
transcriptional	O
coactivator	O
by	O
removing	O
ubiquitin	S-Protein
from	O
a	O
distinct	O
core	O
histones	O
,	O
H2B	S-Protein
.	O

Given	O
that	O
USP22	S-Protein
is	O
expressed	O
in	O
cancer	O
as	O
part	O
of	O
an	O
11	O
gene	O
signature	O
that	O
includes	O
transcriptional	O
repressors	O
which	O
ubiquitylate	O
H2A	S-Protein
,	O
it	O
seemed	O
possible	O
that	O
USP22	S-Protein
might	O
activate	O
transcription	O
in	O
part	O
via	O
the	O
deubiquitylation	O
of	O
this	O
same	O
substrate	O
.	O

As	O
reported	O
here	O
,	O
biochemical	O
analysis	O
of	O
the	O
substrate	O
specificity	O
of	O
USP22	S-Protein
reveals	O
that	O
it	O
deubiquitylates	O
histone	B-Protein
H2A	E-Protein
in	O
addition	O
to	O
H2B	S-Protein
.	O

This	O
finding	O
supports	O
a	O
model	O
in	O
which	O
the	O
H2A	S-Protein
ubiquitin	S-Protein
hydrolase	O
USP22	S-Protein
is	O
coordinately	O
expressed	O
with	O
Polycomb	O
H2A	S-Protein
ubiquitin	S-Protein
ligases	O
in	O
order	O
that	O
the	O
transcription	O
of	O
certain	O
critical	O
transforming	O
genes	O
be	O
maintained	O
in	O
the	O
face	O
of	O
the	O
global	O
repression	O
mediated	O
by	O
Polycomb	O
.	O

Hydrogen	O
peroxide	O
prolongs	O
nuclear	O
localization	O
of	O
NF	O
-	O
kappaB	O
in	O
activated	O
cells	O
by	O
suppressing	O
negative	O
regulatory	O
mechanisms	O
.	O

NF	O
-	O
kappaB	O
transcription	O
factors	O
induce	O
pro	O
-	O
inflammatory	O
molecules	O
(	O
e	O
.	O
g	O
.	O
IL	B-Protein
-	I-Protein
8	E-Protein
)	O
in	O
response	O
to	O
cytokines	O
(	O
e	O
.	O
g	O
.	O
TNFalpha	S-Protein
,	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
)	O
or	O
other	O
stimuli	O
.	O

In	O
the	O
basal	O
state	O
,	O
they	O
are	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
inhibitory	O
IkappaB	O
proteins	O
.	O

Pro	O
-	O
inflammatory	O
signaling	O
triggers	O
polyubiquitination	O
of	O
intermediaries	O
(	O
e	O
.	O
g	O
.	O
RIP1	S-Protein
)	O
,	O
which	O
activate	O
IkappaB	O
kinases	O
that	O
trigger	O
Ser	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaBalpha	S-Protein
,	O
thereby	O
promoting	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
.	O

A	O
negative	O
feedback	O
loop	O
exists	O
whereby	O
NF	O
-	O
kappaB	O
drives	O
resynthesis	O
of	O
IkappaBalpha	S-Protein
,	O
which	O
promotes	O
export	O
of	O
NF	O
-	O
kappaB	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

This	O
process	O
relies	O
on	O
Cezanne	S-Protein
,	O
a	O
deubiquitinating	O
cysteine	O
protease	O
that	O
stabilizes	O
resynthesized	O
IkappaBalpha	S-Protein
by	O
removing	O
polyubiquitin	S-Protein
from	O
modified	O
intermediaries	O
.	O

H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
is	O
generated	O
during	O
inflammation	O
.	O

Here	O
we	O
examined	O
the	O
effects	O
of	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
on	O
NF	O
-	O
kappaB	O
dynamics	O
and	O
pro	O
-	O
inflammatory	O
activation	O
in	O
cultured	O
cells	O
co	O
-	O
stimulated	O
with	O
TNFalpha	S-Protein
or	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
.	O

Quantitative	O
reverse	O
transcription	O
-	O
PCR	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
revealed	O
that	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
enhanced	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
8	E-Protein
by	O
TNFalpha	S-Protein
or	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
.	O

We	O
demonstrated	O
by	O
using	O
assays	O
of	O
NF	O
-	O
kappaB	O
nuclear	O
localization	O
and	O
by	O
imaging	O
of	O
live	O
cells	O
expressing	O
a	O
fluorescent	O
form	O
of	O
NF	O
-	O
kappaB	O
that	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
prolonged	O
NF	O
-	O
kappaB	O
nuclear	O
localization	O
in	O
cells	O
co	O
-	O
stimulated	O
with	O
TNFalpha	S-Protein
or	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
by	O
suppressing	O
its	O
export	O
from	O
the	O
nucleus	O
.	O

We	O
provide	O
evidence	O
that	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
suppresses	O
NF	O
-	O
kappaB	O
export	O
by	O
prolonging	O
polyubiquitination	O
of	O
signaling	O
intermediaries	O
,	O
which	O
promotes	O
Ser	O
phosphorylation	O
and	O
destabilization	O
of	O
newly	O
synthesized	O
IkappaBalpha	S-Protein
proteins	O
.	O

Finally	O
,	O
we	O
observed	O
that	O
the	O
catalytic	O
activity	O
of	O
Cezanne	S-Protein
and	O
its	O
ability	O
to	O
suppress	O
RIP1	S-Protein
polyubiquitination	O
and	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
were	O
inhibited	O
by	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
.	O

We	O
conclude	O
that	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
prolongs	O
NF	O
-	O
kappaB	O
activation	O
in	O
co	O
-	O
stimulated	O
cells	O
by	O
suppressing	O
the	O
negative	O
regulatory	O
functions	O
of	O
Cezanne	O
and	O
IkappaBalpha	S-Protein
.	O

Regulators	O
of	O
cellular	O
levels	O
of	O
histone	S-Protein
acetylation	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Histone	S-Protein
acetylation	O
levels	O
are	O
regulated	O
through	O
the	O
opposing	O
activities	O
of	O
histone	S-Protein
acetyltransferases	O
(	O
HATs	O
)	O
and	O
deacetylases	O
(	O
HDACs	O
)	O
.	O

While	O
much	O
is	O
known	O
about	O
gene	O
-	O
specific	O
control	O
of	O
histone	S-Protein
acetylation	O
,	O
little	O
is	O
understood	O
about	O
how	O
total	O
or	O
cellular	O
levels	O
of	O
histone	S-Protein
acetylation	O
are	O
regulated	O
.	O

To	O
identify	O
regulators	O
of	O
cellular	O
levels	O
of	O
histone	S-Protein
acetylation	O
,	O
we	O
developed	O
an	O
immunofluorescence	O
-	O
based	O
approach	O
to	O
screen	O
the	O
single	O
-	O
gene	O
deletion	O
library	O
of	O
Saccharomyces	O
cerevisiae	O
for	O
strains	O
with	O
significant	O
reductions	O
in	O
cellular	O
histone	S-Protein
acetylation	O
levels	O
.	O

Of	O
the	O
4848	O
mutants	O
screened	O
,	O
we	O
identified	O
63	O
strains	O
with	O
considerable	O
cellular	O
hypoacetylation	O
of	O
N	O
-	O
terminal	O
lysines	O
in	O
histones	B-Protein
H3	E-Protein
and	O
H4	S-Protein
.	O

The	O
cellular	O
hypoacetylation	O
was	O
validated	O
for	O
subsets	O
of	O
the	O
identified	O
strains	O
through	O
secondary	O
screens	O
including	O
mass	O
spectrometric	O
analysis	O
of	O
individual	O
lysines	O
and	O
chromatin	O
immunoprecipitation	O
of	O
specific	O
genomic	O
loci	O
.	O

Among	O
the	O
identified	O
mutants	O
were	O
several	O
members	O
of	O
the	O
Ccr4	O
-	O
Not	O
complex	O
,	O
V	O
-	O
type	O
ATPases	O
,	O
and	O
vacuolar	O
protein	O
-	O
sorting	O
complexes	O
as	O
well	O
as	O
genes	O
with	O
unknown	O
functions	O
.	O

We	O
show	O
that	O
Gcn5	S-Protein
,	O
a	O
major	O
HAT	O
in	O
yeast	O
,	O
has	O
diminished	O
histone	S-Protein
acetyltransferase	O
activity	O
in	O
particular	O
mutants	O
,	O
providing	O
a	O
plausible	O
explanation	O
for	O
reduction	O
of	O
cellular	O
acetylation	O
levels	O
in	O
vivo	O
.	O

Our	O
findings	O
have	O
revealed	O
unexpected	O
and	O
novel	O
links	O
between	O
histone	S-Protein
acetylation	O
,	O
Gcn5	S-Protein
HAT	O
activity	O
,	O
and	O
diverse	O
processes	O
such	O
as	O
transcription	O
,	O
cellular	O
ion	O
homeostasis	O
,	O
and	O
protein	O
transport	O
.	O

Ubc4	B-Protein
/	I-Protein
5	E-Protein
and	O
c	B-Protein
-	I-Protein
Cbl	E-Protein
continue	O
to	O
ubiquitinate	O
EGF	B-Protein
receptor	E-Protein
after	O
internalization	O
to	O
facilitate	O
polyubiquitination	O
and	O
degradation	O
.	O

c	B-Protein
-	I-Protein
Cbl	E-Protein
is	O
the	O
E3	O
ubiquitin	S-Protein
ligase	O
that	O
ubiquitinates	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
(	I-Protein
EGF	I-Protein
)	I-Protein
receptor	E-Protein
(	O
EGFR	S-Protein
)	O
.	O

On	O
the	O
basis	O
of	O
localization	O
,	O
knockdown	O
,	O
and	O
in	O
vitro	O
activity	O
analyses	O
,	O
we	O
have	O
identified	O
the	O
E2	O
ubiquitin	S-Protein
-	O
conjugating	O
enzyme	O
that	O
cooperates	O
with	O
c	B-Protein
-	I-Protein
Cbl	E-Protein
as	O
Ubc4	B-Protein
/	I-Protein
5	E-Protein
.	O

Upon	O
EGF	S-Protein
stimulation	O
,	O
both	O
Ubc4	B-Protein
/	I-Protein
5	E-Protein
and	O
c	B-Protein
-	I-Protein
Cbl	E-Protein
were	O
relocated	O
to	O
the	O
plasma	O
membrane	O
and	O
then	O
to	O
Hrs	S-Protein
-	O
positive	O
endosomes	O
,	O
strongly	O
suggesting	O
that	O
EGFR	S-Protein
continues	O
to	O
be	O
ubiquitinated	O
after	O
internalization	O
.	O

Our	O
time	O
-	O
course	O
experiment	O
showed	O
that	O
EGFR	S-Protein
undergoes	O
polyubiquitination	O
,	O
which	O
seemed	O
to	O
be	O
facilitated	O
during	O
the	O
transport	O
to	O
Hrs	S-Protein
-	O
positive	O
endosomes	O
.	O

Use	O
of	O
a	O
conjugation	O
-	O
defective	O
ubiquitin	S-Protein
mutant	O
suggested	O
that	O
receptor	O
polyubiquitination	O
is	O
required	O
for	O
efficient	O
interaction	O
with	O
Hrs	S-Protein
and	O
subsequent	O
sorting	O
to	O
lysosomes	O
.	O

Abrupt	O
inhibition	O
of	O
the	O
EGFR	S-Protein
kinase	O
activity	O
resulted	O
in	O
dissociation	O
of	O
c	B-Protein
-	I-Protein
Cbl	E-Protein
from	O
EGFR	S-Protein
.	O

Concomitantly	O
,	O
EGFR	S-Protein
was	O
rapidly	O
deubiquitinated	O
and	O
its	O
degradation	O
was	O
delayed	O
.	O

We	O
propose	O
that	O
sustained	O
tyrosine	O
phosphorylation	O
of	O
EGFR	S-Protein
facilitates	O
its	O
polyubiquitination	O
in	O
endosomes	O
and	O
counteracts	O
rapid	O
deubiquitination	O
,	O
thereby	O
ensuring	O
Hrs	S-Protein
-	O
dependent	O
lysosomal	O
sorting	O
.	O

Genome	O
-	O
wide	O
analysis	O
reveals	O
MOF	S-Protein
as	O
a	O
key	O
regulator	O
of	O
dosage	O
compensation	O
and	O
gene	O
expression	O
in	O
Drosophila	O
.	O

Dosage	O
compensation	O
,	O
mediated	O
by	O
the	O
MSL	O
complex	O
,	O
regulates	O
X	O
-	O
chromosomal	O
gene	O
expression	O
in	O
Drosophila	O
.	O

Here	O
we	O
report	O
that	O
the	O
histone	B-Protein
H4	E-Protein
lysine	O
16	O
(	O
H4K16	S-Protein
)	O
specific	O
histone	S-Protein
acetyltransferase	O
MOF	S-Protein
displays	O
differential	O
binding	O
behavior	O
depending	O
on	O
whether	O
the	O
target	O
gene	O
is	O
located	O
on	O
the	O
X	O
chromosome	O
versus	O
the	O
autosomes	O
.	O

More	O
specifically	O
,	O
on	O
the	O
male	O
X	O
chromosome	O
,	O
where	O
MSL1	S-Protein
and	O
MSL3	S-Protein
are	O
preferentially	O
associated	O
with	O
the	O
3	O
'	O
end	O
of	O
dosage	O
compensated	O
genes	O
,	O
MOF	S-Protein
displays	O
a	O
bimodal	O
distribution	O
binding	O
to	O
promoters	O
and	O
the	O
3	O
'	O
ends	O
of	O
genes	O
.	O

In	O
contrast	O
,	O
on	O
MSL1	S-Protein
/	O
MSL3	S-Protein
independent	O
X	O
-	O
linked	O
genes	O
and	O
autosomal	O
genes	O
in	O
males	O
and	O
females	O
,	O
MOF	S-Protein
binds	O
primarily	O
to	O
promoters	O
.	O

Binding	O
of	O
MOF	S-Protein
to	O
autosomes	O
is	O
functional	O
,	O
as	O
H4K16	S-Protein
acetylation	O
and	O
the	O
transcription	O
levels	O
of	O
a	O
number	O
of	O
genes	O
are	O
affected	O
upon	O
MOF	S-Protein
depletion	O
.	O

Therefore	O
,	O
MOF	S-Protein
is	O
not	O
only	O
involved	O
in	O
the	O
onset	O
of	O
dosage	O
compensation	O
,	O
but	O
also	O
acts	O
as	O
a	O
regulator	O
of	O
gene	O
expression	O
in	O
the	O
Drosophila	O
genome	O
.	O

Methylated	O
NEUROD1	S-Protein
promoter	O
is	O
a	O
marker	O
for	O
chemosensitivity	O
in	O
breast	O
cancer	O
.	O

PURPOSE	O
:	O
Chemotherapy	O
can	O
be	O
an	O
integral	O
component	O
of	O
the	O
adjuvant	O
management	O
strategy	O
for	O
women	O
with	O
early	O
stage	O
breast	O
cancer	O
.	O

To	O
date	O
,	O
no	O
tool	O
is	O
available	O
to	O
predict	O
or	O
monitor	O
the	O
efficacy	O
of	O
these	O
therapies	O
.	O

The	O
aim	O
of	O
this	O
proof	O
-	O
of	O
-	O
principle	O
study	O
was	O
to	O
assess	O
whether	O
NEUROD1	S-Protein
DNA	O
methylation	O
is	O
able	O
to	O
predict	O
the	O
response	O
to	O
neoadjuvant	O
and	O
adjuvant	O
chemotherapy	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Recently	O
,	O
we	O
showed	O
that	O
NEUROD1	S-Protein
DNA	O
is	O
differentially	O
methylated	O
in	O
neoplastic	O
versus	O
nonneoplastic	O
breast	O
tissue	O
samples	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
MethyLight	O
and	O
analyzed	O
NEUROD1	S-Protein
methylation	O
in	O
(	O
a	O
)	O
74	O
breast	O
cancer	O
tissue	O
samples	O
,	O
(	O
b	O
)	O
two	O
independent	O
sets	O
of	O
pretreatment	O
core	O
biopsies	O
of	O
23	O
(	O
training	O
set	O
)	O
and	O
21	O
(	O
test	O
set	O
)	O
neoadjuvantly	O
treated	O
breast	O
cancer	O
patients	O
,	O
and	O
(	O
c	O
)	O
pretherapeutic	O
and	O
posttherapeutic	O
serum	O
samples	O
from	O
107	O
breast	O
cancer	O
patients	O
treated	O
with	O
adjuvant	O
chemotherapy	O
.	O

RESULTS	O
:	O
High	O
-	O
grade	O
tumors	O
showed	O
higher	O
NEUROD1	S-Protein
methylation	O
levels	O
.	O

Estrogen	B-Protein
receptor	E-Protein
-	O
negative	O
breast	O
cancers	O
with	O
high	O
NEUROD1	S-Protein
methylation	O
were	O
10	O
.	O
8	O
-	O
fold	O
more	O
likely	O
to	O
respond	O
with	O
a	O
complete	O
pathologic	O
response	O
following	O
neoadjuvant	O
chemotherapy	O
.	O

Patients	O
with	O
positive	O
serum	O
pretreatment	O
NEUROD1	S-Protein
methylation	O
,	O
which	O
persisted	O
after	O
chemotherapy	O
,	O
indicated	O
poor	O
relapse	O
-	O
free	O
and	O
overall	O
survival	O
in	O
univariate	O
and	O
multivariate	O
analyses	O
(	O
relative	O
risk	O
for	O
relapse	O
,	O
6	O
.	O
2	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
6	O
-	O
24	O
;	O
P	O
=	O
0	O
.	O
008	O
,	O
and	O
relative	O
risk	O
for	O
death	O
,	O
14	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
6	O
-	O
120	O
;	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
support	O
the	O
view	O
that	O
NEUROD1	S-Protein
methylation	O
is	O
a	O
chemosensitivity	O
marker	O
in	O
estrogen	B-Protein
receptor	E-Protein
-	O
negative	O
breast	O
cancer	O
.	O

Lysine	O
144	O
,	O
a	O
ubiquitin	S-Protein
attachment	O
site	O
in	O
HIV	O
-	O
1	O
Nef	S-Protein
,	O
is	O
required	O
for	O
Nef	S-Protein
-	O
mediated	O
CD4	S-Protein
down	O
-	O
regulation	O
.	O

Nef	S-Protein
is	O
a	O
HIV	O
-	O
1	O
accessory	O
protein	O
critical	O
for	O
the	O
replication	O
of	O
the	O
virus	O
and	O
the	O
development	O
of	O
AIDS	O
.	O

The	O
major	O
pathological	O
activity	O
of	O
Nef	S-Protein
is	O
the	O
down	O
-	O
regulation	O
of	O
CD4	S-Protein
,	O
the	O
primary	O
receptor	O
of	O
HIV	O
-	O
1	O
infection	O
.	O

The	O
mechanism	O
underlying	O
Nef	S-Protein
-	O
mediated	O
CD4	S-Protein
endocytosis	O
and	O
degradation	O
remains	O
incompletely	O
understood	O
.	O

Since	O
protein	O
ubiquitination	O
is	O
the	O
predominant	O
sorting	O
signal	O
in	O
receptor	O
endocytosis	O
,	O
we	O
investigated	O
whether	O
Nef	S-Protein
is	O
ubiquitinated	O
.	O

The	O
in	O
vivo	O
ubiquitination	O
assay	O
showed	O
that	O
both	O
HIV	O
-	O
1	O
and	O
SIV	O
Nef	S-Protein
proteins	O
expressed	O
in	O
Jurkat	O
T	O
cells	O
and	O
293T	O
cells	O
were	O
multiple	O
ubiquitinated	O
by	O
ubiquitin	S-Protein
-	O
His	O
.	O

The	O
lysine	O
-	O
free	O
HIV	O
-	O
1	O
Nef	S-Protein
mutant	O
(	O
Delta10K	O
)	O
generated	O
by	O
replacing	O
all	O
10	O
lysines	O
with	O
arginines	O
was	O
not	O
ubiquitinated	O
and	O
the	O
major	O
ubiquitin	S-Protein
-	O
His	O
attachment	O
sites	O
in	O
HIV	O
-	O
1	O
Nef	S-Protein
were	O
determined	O
to	O
be	O
lysine	O
144	O
(	O
di	O
-	O
ubiquitinated	O
)	O
and	O
lysine	O
204	O
(	O
mono	O
-	O
ubiquitinated	O
)	O
.	O

Lysine	O
-	O
free	O
HIV	O
-	O
1	O
Nef	S-Protein
was	O
completely	O
inactive	O
in	O
Nef	S-Protein
-	O
mediated	O
CD4	S-Protein
down	O
-	O
regulation	O
,	O
so	O
was	O
the	O
Nef	S-Protein
mutant	O
with	O
a	O
single	O
arginine	O
substitution	O
at	O
K144	O
but	O
not	O
at	O
K204	O
.	O

A	O
mutant	O
HIV	O
-	O
1	O
provirion	O
NL4	O
-	O
3	O
with	O
a	O
single	O
arginine	O
substitution	O
in	O
Nef	S-Protein
at	O
K144	O
was	O
also	O
inactive	O
in	O
Nef	S-Protein
-	O
mediated	O
CD4	S-Protein
down	O
-	O
regulation	O
.	O

Lysine	O
-	O
free	O
Nef	S-Protein
mutant	O
reintroduced	O
with	O
lysine	O
144	O
(	O
DeltaK10	O
+	O
K144	O
)	O
was	O
shown	O
active	O
in	O
CD4	S-Protein
down	O
-	O
regulation	O
.	O

These	O
data	O
suggest	O
that	O
ubiquitination	O
of	O
Nef	S-Protein
,	O
particularly	O
diubiquitination	O
of	O
the	O
lysine	O
144	O
,	O
is	O
necessary	O
for	O
Nef	S-Protein
-	O
mediated	O
CD4	S-Protein
down	O
-	O
regulation	O
.	O

Hydroxynitrile	O
glucosides	O
.	O

beta	O
-	O
and	O
gamma	O
-	O
Hydroxynitrile	O
glucosides	O
are	O
structurally	O
related	O
to	O
cyanogenic	O
glucosides	O
(	O
alpha	O
-	O
hydroxynitrile	O
glucosides	O
)	O
but	O
do	O
not	O
give	O
rise	O
to	O
hydrogen	O
cyanide	O
release	O
upon	O
hydrolysis	O
.	O

Structural	O
similarities	O
and	O
frequent	O
co	O
-	O
occurrence	O
suggest	O
that	O
the	O
biosynthetic	O
pathways	O
for	O
these	O
compounds	O
share	O
common	O
features	O
.	O

Based	O
on	O
available	O
literature	O
data	O
we	O
propose	O
that	O
oximes	O
produced	O
by	O
CYP79	S-Protein
orthologs	O
are	O
common	O
intermediates	O
and	O
that	O
their	O
conversion	O
into	O
beta	O
-	O
and	O
gamma	O
-	O
hydroxynitrile	O
glucosides	O
is	O
mediated	O
by	O
evolutionary	O
diversified	O
multifunctional	O
orthologs	O
to	O
CYP71E1	S-Protein
.	O

We	O
designate	O
these	O
as	O
CYP71	O
(	O
betagamma	O
)	O
and	O
CYP71	O
(	O
alphabetagamma	O
)	O
;	O
in	O
combination	O
with	O
the	O
classical	O
CYP71	O
(	O
alpha	O
)	O
(	O
CYP71E1	S-Protein
and	O
orthologs	O
)	O
these	O
are	O
able	O
to	O
hydroxylate	O
any	O
of	O
the	O
carbon	O
atoms	O
present	O
in	O
the	O
amino	O
acid	O
and	O
oxime	O
derived	O
nitriles	O
.	O

Subsequent	O
dehydration	O
reactions	O
and	O
hydroxylations	O
and	O
a	O
final	O
glycosylation	O
step	O
afford	O
the	O
unsaturated	O
beta	O
-	O
and	O
gamma	O
-	O
hydroxynitrile	O
glucosides	O
.	O

This	O
scheme	O
would	O
explain	O
the	O
distribution	O
patterns	O
of	O
alpha	O
-	O
,	O
beta	O
-	O
and	O
gamma	O
-	O
hydroxynitrile	O
glucosides	O
found	O
in	O
plants	O
.	O

The	O
possible	O
biological	O
functions	O
of	O
these	O
hydroxynitriles	O
are	O
discussed	O
.	O

The	O
CHD3	S-Protein
remodeler	O
PICKLE	S-Protein
promotes	O
trimethylation	O
of	O
histone	B-Protein
H3	E-Protein
lysine	O
27	O
.	O

CHD3	S-Protein
proteins	O
are	O
ATP	O
-	O
dependent	O
chromatin	O
remodelers	O
that	O
contribute	O
to	O
repression	O
of	O
developmentally	O
regulated	O
genes	O
in	O
both	O
animal	O
and	O
plant	O
systems	O
.	O

In	O
animals	O
,	O
this	O
repression	O
has	O
been	O
linked	O
to	O
a	O
multiple	O
subunit	O
complex	O
,	O
Mi	O
-	O
2	O
/	O
NuRD	O
,	O
whose	O
constituents	O
include	O
a	O
CHD3	S-Protein
protein	O
,	O
a	O
histone	S-Protein
deacetylase	O
,	O
and	O
a	O
methyl	O
-	O
CpG	O
-	O
binding	O
domain	O
protein	O
.	O

In	O
Arabidopsis	O
,	O
PICKLE	S-Protein
(	O
PKL	S-Protein
)	O
codes	O
for	O
a	O
CHD3	S-Protein
protein	O
that	O
acts	O
during	O
germination	O
to	O
repress	O
expression	O
of	O
seed	O
-	O
associated	O
genes	O
.	O

Repression	O
of	O
seed	O
-	O
associated	O
traits	O
is	O
promoted	O
in	O
pkl	O
seedlings	O
by	O
the	O
plant	O
growth	O
regulator	O
gibberellin	O
(	O
GA	O
)	O
.	O

We	O
undertook	O
a	O
microarray	O
analysis	O
to	O
determine	O
how	O
PKL	S-Protein
and	O
GA	O
act	O
to	O
promote	O
the	O
transition	O
from	O
seed	O
to	O
seedling	O
.	O

We	O
found	O
that	O
PKL	S-Protein
and	O
GA	O
act	O
in	O
separate	O
pathways	O
to	O
repress	O
expression	O
of	O
seed	O
-	O
specific	O
genes	O
.	O

Comparison	O
of	O
genomic	O
datasets	O
revealed	O
that	O
PKL	S-Protein
-	O
dependent	O
genes	O
are	O
enriched	O
for	O
trimethylation	O
of	O
histone	B-Protein
H3	E-Protein
lysine	O
27	O
(	O
H3K27me3	S-Protein
)	O
,	O
a	O
repressive	O
epigenetic	O
mark	O
.	O

Chromatin	O
immunoprecipitation	O
studies	O
demonstrate	O
that	O
PKL	S-Protein
promotes	O
H3K27me3	S-Protein
in	O
both	O
germinating	O
seedlings	O
and	O
in	O
adult	O
plants	O
but	O
do	O
not	O
identify	O
a	O
connection	O
between	O
PKL	S-Protein
-	O
dependent	O
expression	O
and	O
acetylation	O
levels	O
.	O

Taken	O
together	O
,	O
our	O
analyses	O
illuminate	O
a	O
new	O
pathway	O
by	O
which	O
CHD3	S-Protein
remodelers	O
contribute	O
to	O
repression	O
in	O
eukaryotes	O
.	O

HES1	S-Protein
is	O
a	O
novel	O
interactor	O
of	O
the	O
Fanconi	O
anemia	O
core	O
complex	O
.	O

Fanconi	O
anemia	O
(	O
FA	O
)	O
proteins	O
are	O
thought	O
to	O
play	O
a	O
role	O
in	O
chromosome	O
stability	O
and	O
repair	O
of	O
DNA	O
cross	O
-	O
links	O
;	O
however	O
,	O
these	O
functions	O
may	O
not	O
fully	O
explain	O
the	O
developmental	O
abnormalities	O
and	O
bone	O
marrow	O
failure	O
that	O
are	O
characteristic	O
of	O
FA	O
individuals	O
.	O

Here	O
we	O
associate	O
the	O
FA	O
proteins	O
with	O
the	O
Notch1	S-Protein
developmental	O
pathway	O
through	O
a	O
direct	O
protein	O
-	O
protein	O
interaction	O
between	O
the	O
FA	O
core	O
complex	O
and	O
the	O
hairy	B-Protein
enhancer	I-Protein
of	I-Protein
split	I-Protein
1	E-Protein
(	O
HES1	S-Protein
)	O
.	O

HES1	S-Protein
interaction	O
with	O
FA	O
core	O
complex	O
members	O
is	O
dependent	O
on	O
a	O
functional	O
FA	O
pathway	O
.	O

Cells	O
depleted	O
of	O
HES1	S-Protein
exhibit	O
an	O
FA	O
-	O
like	O
phenotype	O
that	O
includes	O
cellular	O
hypersensitivity	O
to	O
mitomycin	O
C	O
(	O
MMC	O
)	O
and	O
lack	O
of	O
FANCD2	S-Protein
monoubiquitination	O
and	O
foci	O
formation	O
.	O

HES1	S-Protein
is	O
also	O
required	O
for	O
proper	O
nuclear	O
localization	O
or	O
stability	O
of	O
some	O
members	O
of	O
the	O
core	O
complex	O
.	O

Our	O
results	O
suggest	O
that	O
HES1	S-Protein
is	O
a	O
novel	O
interacting	O
protein	O
of	O
the	O
FA	O
core	O
complex	O
.	O

Fluorescent	O
reporters	O
of	O
the	O
histone	S-Protein
acetyltransferase	O
.	O

Histone	S-Protein
acetyltransferases	O
(	O
HATs	O
)	O
are	O
important	O
chromatin	O
modifying	O
enzymes	O
that	O
catalyze	O
acetylation	O
of	O
specific	O
lysine	O
residues	O
in	O
histone	S-Protein
and	O
nonhistone	O
substrates	O
.	O

They	O
participate	O
in	O
multiple	O
cellular	O
processes	O
such	O
as	O
transcriptional	O
regulation	O
and	O
signal	O
transduction	O
.	O

Aberrant	O
expression	O
of	O
HATs	O
has	O
been	O
observed	O
in	O
various	O
disease	O
states	O
,	O
especially	O
cancer	O
.	O

However	O
,	O
current	O
strategies	O
used	O
for	O
studying	O
HAT	O
enzymatic	O
activity	O
and	O
inhibitor	O
discovery	O
are	O
quite	O
limited	O
.	O

We	O
report	O
here	O
a	O
novel	O
strategy	O
for	O
the	O
homogeneous	O
,	O
continuous	O
,	O
one	O
-	O
step	O
measurement	O
of	O
HAT	O
activity	O
.	O

A	O
series	O
of	O
fluorescent	O
reporters	O
based	O
on	O
the	O
amino	O
-	O
terminal	O
seqence	O
of	O
histone	B-Protein
H4	E-Protein
were	O
synthesized	O
and	O
evaluated	O
for	O
HAT	O
assay	O
.	O

Fluorescence	O
signals	O
change	O
effectively	O
in	O
response	O
to	O
the	O
acetylation	O
process	O
by	O
HAT	O
p300	S-Protein
.	O

Such	O
an	O
assay	O
should	O
thus	O
be	O
broadly	O
useful	O
for	O
assaying	O
HAT	O
activity	O
in	O
vitro	O
as	O
well	O
as	O
valuable	O
in	O
discovering	O
new	O
anticancer	O
drugs	O
based	O
on	O
the	O
modulation	O
of	O
the	O
HAT	O
targets	O
.	O

Rapid	O
histone	S-Protein
deacetylation	O
and	O
transient	O
HDAC	O
association	O
in	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
region	O
of	O
TSST	B-Protein
-	I-Protein
1	E-Protein
-	O
stimulated	O
T	O
cells	O
.	O

It	O
remains	O
unclear	O
how	O
superantigen	O
induces	O
unresponsiveness	O
in	O
stimulated	O
T	O
cells	O
.	O

We	O
analyzed	O
the	O
chromatin	O
status	O
of	O
the	O
interleukin	B-Protein
-	I-Protein
2	E-Protein
(	O
IL	B-Protein
-	I-Protein
2	E-Protein
)	O
promoter	O
region	O
in	O
T	O
cells	O
stimulated	O
with	O
toxic	B-Protein
shock	I-Protein
syndrome	I-Protein
toxin	I-Protein
-	I-Protein
1	E-Protein
(	O
TSST	B-Protein
-	I-Protein
1	E-Protein
)	O
superantigen	O
using	O
T	O
cell	O
receptor	O
-	O
transgenic	O
T	O
cells	O
responding	O
to	O
ovalbumin	S-Protein
(	O
OVA	S-Protein
)	O
and	O
TSST	B-Protein
-	I-Protein
1	E-Protein
.	O

Compared	O
to	O
OVA	S-Protein
stimulation	O
,	O
naive	O
T	O
cells	O
cultured	O
with	O
TSST	B-Protein
-	I-Protein
1	E-Protein
showed	O
lower	O
IL	B-Protein
-	I-Protein
2	E-Protein
expression	O
after	O
transient	O
enhancement	O
.	O

Coincidentally	O
,	O
the	O
acetylated	O
histone	B-Protein
H3	E-Protein
(	O
AcH3	S-Protein
)	O
level	O
at	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
region	O
was	O
first	O
enhanced	O
,	O
and	O
then	O
decreased	O
,	O
in	O
TSST	B-Protein
-	I-Protein
1	E-Protein
-	O
stimulated	O
T	O
cells	O
.	O

At	O
the	O
reduction	O
stage	O
of	O
AcH3	S-Protein
,	O
histone	B-Protein
deacetylase	I-Protein
-	I-Protein
1	E-Protein
(	O
HDAC1	S-Protein
)	O
was	O
markedly	O
associated	O
with	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
region	O
in	O
a	O
TSST	B-Protein
-	I-Protein
1	E-Protein
-	O
specific	O
manner	O
without	O
HDAC1	S-Protein
over	O
-	O
expression	O
.	O

The	O
enhancement	O
of	O
HDAC1	S-Protein
association	O
and	O
IL	B-Protein
-	I-Protein
2	E-Protein
suppression	O
was	O
prevented	O
by	O
pre	O
-	O
treatment	O
with	O
HDAC	O
inhibitor	O
,	O
but	O
not	O
once	O
the	O
anergy	O
status	O
was	O
established	O
.	O

These	O
results	O
suggest	O
that	O
recruitment	O
of	O
HDAC1	S-Protein
in	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
region	O
at	O
the	O
early	O
stimulation	O
stage	O
with	O
TSST	B-Protein
-	I-Protein
1	E-Protein
plays	O
a	O
pivotal	O
role	O
in	O
sAg	O
-	O
induced	O
anergy	O
.	O

H2B	S-Protein
ubiquitylation	O
plays	O
a	O
role	O
in	O
nucleosome	O
dynamics	O
during	O
transcription	O
elongation	O
.	O

The	O
monoubiquitylation	O
of	O
histone	B-Protein
H2B	E-Protein
has	O
been	O
associated	O
with	O
transcription	O
initiation	O
and	O
elongation	O
,	O
but	O
its	O
role	O
in	O
these	O
processes	O
is	O
poorly	O
understood	O
.	O

We	O
report	O
that	O
H2B	S-Protein
ubiquitylation	O
is	O
required	O
for	O
efficient	O
reassembly	O
of	O
nucleosomes	O
during	O
RNA	O
polymerase	O
II	O
(	O
Pol	O
II	O
)	O
-	O
mediated	O
transcription	O
elongation	O
in	O
yeast	O
.	O

This	O
role	O
is	O
carried	O
out	O
in	O
cooperation	O
with	O
the	O
histone	S-Protein
chaperone	O
Spt16	S-Protein
,	O
and	O
in	O
the	O
absence	O
of	O
H2B	S-Protein
ubiquitylation	O
and	O
functional	O
Spt16	S-Protein
,	O
chromatin	O
structure	O
is	O
not	O
properly	O
restored	O
in	O
the	O
wake	O
of	O
elongating	O
Pol	O
II	O
.	O

Moreover	O
,	O
H2B	S-Protein
ubiquitylation	O
and	O
Spt16	S-Protein
play	O
a	O
role	O
in	O
each	O
other	O
'	O
s	O
regulation	O
.	O

H2B	S-Protein
ubiquitylation	O
is	O
required	O
for	O
the	O
stable	O
accumulation	O
of	O
Spt16	S-Protein
at	O
the	O
GAL1	S-Protein
coding	O
region	O
,	O
and	O
Spt16	S-Protein
regulates	O
the	O
formation	O
of	O
ubiquitylated	O
H2B	S-Protein
both	O
globally	O
and	O
at	O
the	O
GAL1	S-Protein
gene	O
.	O

These	O
data	O
provide	O
a	O
mechanism	O
linking	O
H2B	S-Protein
ubiquitylation	O
to	O
Spt16	S-Protein
in	O
the	O
regulation	O
of	O
nucleosome	O
dynamics	O
during	O
transcription	O
elongation	O
.	O

Characterization	O
of	O
an	O
alpha	B-Protein
-	I-Protein
L	I-Protein
-	I-Protein
rhamnosidase	E-Protein
from	O
Aspergillus	O
kawachii	O
and	O
its	O
gene	O
.	O

An	O
alpha	B-Protein
-	I-Protein
L	I-Protein
-	I-Protein
rhamnosidase	E-Protein
was	O
purified	O
by	O
fractionating	O
a	O
culture	O
filtrate	O
of	O
Aspergillus	O
kawachii	O
grown	O
on	O
L	O
-	O
rhamnose	O
as	O
the	O
sole	O
carbon	O
source	O
.	O

The	O
alpha	B-Protein
-	I-Protein
L	I-Protein
-	I-Protein
rhamnosidase	E-Protein
had	O
a	O
molecular	O
mass	O
of	O
90	O
kDa	O
and	O
a	O
high	O
degree	O
of	O
N	O
-	O
glycosylation	O
of	O
approximately	O
22	O
%	O
.	O

The	O
enzyme	O
exhibited	O
optimal	O
activity	O
at	O
pH	O
4	O
.	O
0	O
and	O
temperature	O
of	O
50	O
degrees	O
C	O
.	O

Further	O
,	O
it	O
was	O
observed	O
to	O
be	O
thermostable	O
,	O
and	O
it	O
retained	O
more	O
than	O
80	O
%	O
of	O
its	O
original	O
activity	O
following	O
incubation	O
at	O
60	O
degrees	O
C	O
for	O
1	O
h	O
.	O

Its	O
T	O
(	O
50	O
)	O
value	O
was	O
determined	O
to	O
be	O
72	O
degrees	O
C	O
.	O

The	O
enzyme	O
was	O
able	O
to	O
hydrolyze	O
alpha	O
-	O
1	O
,	O
2	O
-	O
and	O
alpha	O
-	O
1	O
,	O
6	O
-	O
glycosidic	O
bonds	O
.	O

The	O
specific	O
activity	O
of	O
the	O
enzyme	O
was	O
higher	O
toward	O
naringin	O
than	O
toward	O
hesperidin	O
.	O

The	O
A	O
.	O
kawachii	O
alpha	B-Protein
-	I-Protein
L	I-Protein
-	I-Protein
rhamnosidase	E-Protein
-	O
encoding	O
gene	O
(	O
Ak	O
-	O
rhaA	S-Protein
)	O
codes	O
for	O
a	O
655	O
-	O
amino	O
-	O
acid	O
protein	O
.	O

Based	O
on	O
the	O
amino	O
acid	O
sequence	O
deduced	O
from	O
the	O
cDNA	O
,	O
the	O
protein	O
possessed	O
13	O
potential	O
N	O
-	O
glycosylation	O
recognition	O
sites	O
and	O
exhibited	O
a	O
high	O
degree	O
of	O
sequence	O
identity	O
(	O
up	O
to	O
75	O
%	O
)	O
with	O
the	O
alpha	B-Protein
-	I-Protein
L	I-Protein
-	I-Protein
rhamnosidases	E-Protein
belonging	O
to	O
the	O
glycoside	O
hydrolase	O
family	O
78	O
from	O
Aspergillus	O
aculeatus	O
and	O
with	O
hypothetical	O
Aspergillus	O
oryzae	O
and	O
Aspergillus	O
fumigatus	O
proteins	O
.	O

Targeting	O
WW	O
domains	O
linker	O
of	O
HECT	O
-	O
type	O
ubiquitin	S-Protein
ligase	O
Smurf1	S-Protein
for	O
activation	O
by	O
CKIP	B-Protein
-	I-Protein
1	E-Protein
.	O

E3	O
ubiquitin	S-Protein
ligases	O
are	O
final	O
effectors	O
of	O
the	O
enzyme	O
cascade	O
controlling	O
ubiquitylation	O
.	O

A	O
central	O
issue	O
in	O
understanding	O
their	O
regulation	O
is	O
to	O
decipher	O
mechanisms	O
of	O
their	O
assembly	O
and	O
activity	O
.	O

In	O
contrast	O
with	O
RING	O
-	O
type	O
E3s	O
,	O
fewer	O
mechanisms	O
are	O
known	O
for	O
regulation	O
of	O
HECT	O
-	O
type	O
E3s	O
.	O

Smad	B-Protein
ubiquitylation	I-Protein
regulatory	I-Protein
factor	I-Protein
1	E-Protein
(	O
Smurf1	S-Protein
)	O
,	O
a	O
C2	O
-	O
WW	O
-	O
HECT	O
-	O
domain	O
E3	O
,	O
is	O
crucial	O
for	O
bone	O
homeostasis	O
,	O
in	O
which	O
it	O
suppresses	O
osteoblast	O
activity	O
.	O

However	O
,	O
whether	O
and	O
how	O
its	O
activity	O
is	O
regulated	O
remains	O
unclear	O
.	O

Here	O
we	O
show	O
that	O
Smurf1	S-Protein
,	O
but	O
not	O
Smurf2	S-Protein
,	O
interacts	O
with	O
casein	B-Protein
kinase	I-Protein
-	I-Protein
2	I-Protein
interacting	I-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
(	O
CKIP	B-Protein
-	I-Protein
1	E-Protein
)	O
,	O
resulting	O
in	O
an	O
increase	O
in	O
its	O
E3	O
ligase	O
activity	O
.	O

Surprisingly	O
,	O
CKIP	B-Protein
-	I-Protein
1	E-Protein
targets	O
specifically	O
the	O
linker	O
region	O
between	O
the	O
WW	O
domains	O
of	O
Smurf1	S-Protein
,	O
thereby	O
augmenting	O
its	O
affinity	O
for	O
and	O
promoting	O
ubiquitylation	O
of	O
the	O
substrate	O
.	O

Moreover	O
,	O
CKIP	B-Protein
-	I-Protein
1	E-Protein
-	O
deficient	O
mice	O
undergo	O
an	O
age	O
-	O
dependent	O
increase	O
in	O
bone	O
mass	O
as	O
a	O
result	O
of	O
accelerated	O
osteogenesis	O
and	O
decreased	O
Smurf1	S-Protein
activity	O
.	O

These	O
findings	O
provide	O
evidence	O
that	O
the	O
WW	O
domains	O
linker	O
is	O
important	O
in	O
complex	O
assembly	O
and	O
in	O
regulating	O
activity	O
of	O
HECT	O
-	O
type	O
E3s	O
and	O
that	O
CKIP	B-Protein
-	I-Protein
1	E-Protein
functions	O
as	O
the	O
first	O
auxiliary	O
factor	O
to	O
enhance	O
the	O
activation	O
of	O
Smurf1	S-Protein
.	O

Regulation	O
of	O
acetylation	O
at	O
the	O
major	O
histocompatibility	O
complex	O
class	O
II	O
proximal	O
promoter	O
by	O
the	O
19S	O
proteasomal	O
ATPase	O
Sug1	S-Protein
.	O

Recent	O
studies	O
have	O
made	O
evident	O
the	O
fact	O
that	O
the	O
19S	O
regulatory	O
component	O
of	O
the	O
proteasome	O
has	O
functions	O
that	O
extend	O
beyond	O
degradation	O
,	O
particularly	O
in	O
the	O
regulation	O
of	O
transcription	O
.	O

Although	O
19S	O
ATPases	O
facilitate	O
chromatin	O
remodeling	O
and	O
acetylation	O
events	O
in	O
yeast	O
(	O
Saccharomyces	O
cerevisiae	O
)	O
,	O
it	O
is	O
unclear	O
if	O
they	O
play	O
similar	O
roles	O
in	O
mammalian	O
cells	O
.	O

We	O
have	O
recently	O
shown	O
that	O
the	O
19S	O
ATPase	O
Sug1	S-Protein
positively	O
regulates	O
the	O
transcription	O
of	O
the	O
critical	O
inflammatory	O
gene	O
for	O
major	O
histocompatibility	O
complex	O
class	O
II	O
(	O
MHC	O
-	O
II	O
)	O
by	O
stabilizing	O
enhanceosome	O
assembly	O
at	O
the	O
proximal	O
promoter	O
.	O

We	O
now	O
show	O
that	O
Sug1	S-Protein
is	O
crucial	O
for	O
regulating	O
histone	B-Protein
H3	E-Protein
acetylation	O
at	O
the	O
MHC	O
-	O
II	O
proximal	O
promoter	O
.	O

Sug1	S-Protein
binds	O
to	O
acetylated	O
histone	B-Protein
H3	E-Protein
and	O
,	O
in	O
the	O
absence	O
of	O
Sug1	S-Protein
,	O
histone	B-Protein
H3	E-Protein
acetylation	O
is	O
dramatically	O
decreased	O
at	O
the	O
proximal	O
promoter	O
,	O
with	O
a	O
preferential	O
loss	O
of	O
acetylation	O
at	O
H3	S-Protein
lysine	O
18	O
.	O

Sug1	S-Protein
also	O
binds	O
to	O
the	O
MHC	O
-	O
II	O
histone	O
acetyltransferase	O
CREB	B-Protein
-	I-Protein
binding	I-Protein
protein	E-Protein
(	O
CBP	S-Protein
)	O
and	O
is	O
critical	O
for	O
the	O
recruitment	O
of	O
CBP	S-Protein
to	O
the	O
MHC	O
-	O
II	O
proximal	O
promoter	O
.	O

Our	O
current	O
study	O
strongly	O
implicates	O
the	O
19S	O
ATPase	O
Sug1	S-Protein
in	O
modifying	O
histones	S-Protein
to	O
initiate	O
MHC	O
-	O
II	O
transcription	O
and	O
provides	O
novel	O
insights	O
into	O
the	O
role	O
of	O
the	O
proteasome	O
in	O
the	O
regulation	O
of	O
mammalian	O
transcription	O
.	O

Post	O
-	O
synthetic	O
acetylation	O
of	O
HMGB1	S-Protein
protein	O
modulates	O
its	O
interactions	O
with	O
supercoiled	O
DNA	O
.	O

High	B-Protein
mobility	I-Protein
group	I-Protein
box	I-Protein
(	I-Protein
HMGB	I-Protein
)	I-Protein
proteins	I-Protein
1	E-Protein
and	O
2	S-Protein
are	O
abundant	O
non	O
-	O
histone	S-Protein
nuclear	O
proteins	O
that	O
regulate	O
chromatin	O
structure	O
because	O
of	O
their	O
structure	O
-	O
specific	O
binding	O
to	O
DNA	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
how	O
the	O
post	O
-	O
synthetic	O
acetylation	O
of	O
HMGB1	S-Protein
affects	O
its	O
interaction	O
with	O
negatively	O
supercoiled	O
DNA	O
by	O
employing	O
monoacetylated	O
at	O
Lys2	O
protein	O
,	O
isolated	O
from	O
butyrate	O
-	O
treated	O
cells	O
.	O

Our	O
data	O
reveal	O
that	O
this	O
modification	O
enhances	O
three	O
reaction	O
parameters	O
:	O
binding	O
affinity	O
,	O
supercoiling	O
activity	O
and	O
capacity	O
to	O
protect	O
the	O
supercoiled	O
DNA	O
from	O
relaxation	O
by	O
topoisomerase	B-Protein
I	E-Protein
.	O

We	O
show	O
that	O
monoacetylation	O
at	O
Lys2	O
mimics	O
the	O
effect	O
of	O
acidic	O
tail	O
removal	O
but	O
to	O
a	O
lesser	O
extent	O
thus	O
demonstrating	O
that	O
in	O
vivo	O
acetylated	O
HMGB1	S-Protein
is	O
capable	O
of	O
modulating	O
its	O
interaction	O
with	O
negatively	O
supercoiled	O
DNA	O
.	O

IRF2	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
is	O
a	O
JDP2	S-Protein
ubiquitin	S-Protein
ligase	O
and	O
an	O
inhibitor	O
of	O
ATF2	S-Protein
-	O
dependent	O
transcription	O
.	O

Jun	B-Protein
-	I-Protein
dimerization	I-Protein
protein	I-Protein
2	E-Protein
(	O
JDP2	S-Protein
)	O
is	O
a	O
member	O
of	O
the	O
activating	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
family	O
of	O
transcription	O
factors	O
.	O

JDP2	S-Protein
dimerizes	O
with	O
other	O
AP	O
-	O
1	O
proteins	O
such	O
as	O
activating	B-Protein
transcription	I-Protein
factor	I-Protein
-	I-Protein
2	E-Protein
(	O
ATF2	S-Protein
)	O
and	O
Jun	S-Protein
to	O
repress	O
transcription	O
from	O
promoters	O
that	O
contain	O
a	O
cyclic	O
AMP	O
-	O
responsive	O
element	O
(	O
CRE	O
)	O
.	O

Interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
-	I-Protein
2	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
(	O
IRF2	B-Protein
-	I-Protein
BP1	E-Protein
)	O
,	O
which	O
is	O
reported	O
to	O
be	O
a	O
transcriptional	O
corepressor	O
of	O
IRF2	S-Protein
,	O
was	O
isolated	O
as	O
a	O
JDP2	S-Protein
-	O
binding	O
protein	O
using	O
an	O
epitope	O
-	O
tagging	O
method	O
.	O

As	O
anticipated	O
from	O
the	O
presence	O
of	O
a	O
RING	O
-	O
finger	O
domain	O
,	O
IRF2	B-Protein
-	I-Protein
BP1	E-Protein
enhanced	O
the	O
polyubiquitination	O
of	O
JDP2	S-Protein
.	O

Moreover	O
,	O
IRF2	B-Protein
-	I-Protein
BP1	E-Protein
repressed	O
ATF2	S-Protein
-	O
mediated	O
transcriptional	O
activation	O
from	O
a	O
CRE	O
-	O
containing	O
promoter	O
.	O

Prolyl	O
4	O
-	O
hydroxylation	O
regulates	O
Argonaute	B-Protein
2	E-Protein
stability	O
.	O

Human	O
Argonaute	O
(	O
Ago	O
)	O
proteins	O
are	O
essential	O
components	O
of	O
the	O
RNA	O
-	O
induced	O
silencing	O
complexes	O
(	O
RISCs	O
)	O
.	O

Argonaute	B-Protein
2	E-Protein
(	O
Ago2	S-Protein
)	O
has	O
a	O
P	O
-	O
element	O
-	O
induced	O
wimpy	O
testis	O
(	O
PIWI	O
)	O
domain	O
,	O
which	O
folds	O
like	O
RNase	O
H	O
and	O
is	O
responsible	O
for	O
target	O
RNA	O
cleavage	O
in	O
RNA	O
interference	O
.	O

Proteins	O
such	O
as	O
Dicer	S-Protein
,	O
TRBP	S-Protein
,	O
MOV10	S-Protein
,	O
RHA	S-Protein
,	O
RCK	S-Protein
/	O
p54	S-Protein
and	O
KIAA1093	S-Protein
associate	O
with	O
Ago	O
proteins	O
and	O
participate	O
in	O
small	O
RNA	O
processing	O
,	O
RISC	O
loading	O
and	O
localization	O
of	O
Ago	O
proteins	O
in	O
the	O
cytoplasmic	O
messenger	O
RNA	O
processing	O
bodies	O
.	O

However	O
,	O
mechanisms	O
that	O
regulate	O
RNA	O
interference	O
remain	O
obscure	O
.	O

Here	O
we	O
report	O
physical	O
interactions	O
between	O
Ago2	S-Protein
and	O
the	O
alpha	O
-	O
(	O
P4H	B-Protein
-	I-Protein
alpha	I-Protein
(	I-Protein
I	I-Protein
)	E-Protein
)	O
and	O
beta	O
-	O
(	O
P4H	B-Protein
-	I-Protein
beta	E-Protein
)	O
subunits	O
of	O
the	O
type	O
I	O
collagen	O
prolyl	O
-	O
4	O
-	O
hydroxylase	O
(	O
C	O
-	O
P4H	O
(	O
I	O
)	O
)	O
.	O

Mass	O
spectrometric	O
analysis	O
identified	O
hydroxylation	O
of	O
the	O
endogenous	O
Ago2	S-Protein
at	O
proline	O
700	O
.	O

In	O
vitro	O
,	O
both	O
Ago2	S-Protein
and	O
Ago4	S-Protein
seem	O
to	O
be	O
more	O
efficiently	O
hydroxylated	O
than	O
Ago1	S-Protein
and	O
Ago3	S-Protein
by	O
recombinant	O
human	O
C	O
-	O
P4H	O
(	O
I	O
)	O
.	O

Importantly	O
,	O
human	O
cells	O
depleted	O
of	O
P4H	B-Protein
-	I-Protein
alpha	I-Protein
(	I-Protein
I	I-Protein
)	E-Protein
or	O
P4H	B-Protein
-	I-Protein
beta	E-Protein
by	O
short	O
hairpin	O
RNA	O
and	O
P4H	B-Protein
-	I-Protein
alpha	I-Protein
(	I-Protein
I	I-Protein
)	E-Protein
null	O
mouse	O
embryonic	O
fibroblast	O
cells	O
showed	O
reduced	O
stability	O
of	O
Ago2	S-Protein
and	O
impaired	O
short	O
interfering	O
RNA	O
programmed	O
RISC	O
activity	O
.	O

Furthermore	O
,	O
mutation	O
of	O
proline	O
700	O
to	O
alanine	O
also	O
resulted	O
in	O
destabilization	O
of	O
Ago2	S-Protein
,	O
thus	O
linking	O
Ago2	S-Protein
P700	O
and	O
hydroxylation	O
at	O
this	O
residue	O
to	O
its	O
stability	O
regulation	O
.	O

These	O
findings	O
identify	O
hydroxylation	O
as	O
a	O
post	O
-	O
translational	O
modification	O
important	O
for	O
Ago2	S-Protein
stability	O
and	O
effective	O
RNA	O
interference	O
.	O

Deubiquitylation	O
regulates	O
activation	O
and	O
proteolytic	O
cleavage	O
of	O
ENaC	O
.	O

The	O
epithelial	O
sodium	O
channel	O
(	O
ENaC	O
)	O
is	O
critical	O
for	O
sodium	O
and	O
BP	O
homeostasis	O
.	O

ENaC	O
is	O
regulated	O
by	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
-	O
mediated	O
ubiquitylation	O
,	O
which	O
leads	O
to	O
its	O
internalization	O
;	O
this	O
process	O
can	O
be	O
reversed	O
by	O
deubiquitylation	O
,	O
which	O
is	O
regulated	O
by	O
the	O
aldosterone	O
-	O
induced	O
enzyme	O
Usp2	B-Protein
-	I-Protein
45	E-Protein
.	O

In	O
a	O
second	O
regulatory	O
pathway	O
,	O
ENaC	O
can	O
be	O
activated	O
by	O
luminal	O
serine	O
protease	O
-	O
mediated	O
cleavage	O
of	O
its	O
extracellular	O
loops	O
.	O

Whether	O
these	O
two	O
regulatory	O
processes	O
interact	O
,	O
however	O
,	O
is	O
unknown	O
.	O

Here	O
,	O
in	O
HEK293	O
cells	O
stably	O
transfected	O
with	O
ENaC	O
,	O
Usp2	B-Protein
-	I-Protein
45	E-Protein
interacted	O
with	O
ENaC	O
,	O
leading	O
to	O
deubiquitylation	O
of	O
the	O
channel	O
and	O
stimulation	O
of	O
ENaC	O
activity	O
>	O
20	O
-	O
fold	O
.	O

This	O
was	O
accompanied	O
by	O
a	O
modest	O
increase	O
in	O
cell	O
surface	O
expression	O
of	O
ENaC	O
and	O
by	O
proteolytic	O
cleavage	O
of	O
alphaENaC	S-Protein
and	O
gammaENaC	S-Protein
at	O
their	O
extracellular	O
loops	O
.	O

When	O
endocytosis	O
was	O
inhibited	O
with	O
dominant	O
negative	O
dynamin	S-Protein
(	O
DynK44R	S-Protein
)	O
,	O
channel	O
density	O
and	O
gammaENaC	S-Protein
cleavage	O
were	O
increased	O
,	O
but	O
alphaENaC	S-Protein
cleavage	O
and	O
ENaC	O
activity	O
were	O
not	O
augmented	O
.	O

When	O
Usp2	B-Protein
-	I-Protein
45	E-Protein
was	O
coexpressed	O
with	O
DynK44R	S-Protein
,	O
both	O
alphaENaC	S-Protein
cleavage	O
and	O
activity	O
were	O
recovered	O
.	O

In	O
summary	O
,	O
these	O
data	O
suggest	O
that	O
Usp2	B-Protein
-	I-Protein
45	E-Protein
deubiquitylation	O
of	O
ENaC	O
enhances	O
the	O
proteolytic	O
activation	O
of	O
both	O
alphaENaC	S-Protein
and	O
gammaENaC	S-Protein
,	O
possibly	O
by	O
inducing	O
a	O
conformational	O
change	O
and	O
by	O
interfering	O
with	O
endocytosis	O
,	O
respectively	O
.	O

Bivalirudin	O
decreases	O
NO	O
bioavailability	O
by	O
vascular	O
immobilization	O
of	O
myeloperoxidase	S-Protein
.	O

Bivalirudin	O
,	O
a	O
direct	O
thrombin	S-Protein
inhibitor	O
,	O
has	O
emerged	O
as	O
an	O
important	O
alternative	O
to	O
heparin	O
in	O
patients	O
undergoing	O
percutaneous	O
coronary	O
intervention	O
.	O

However	O
,	O
it	O
remains	O
elusive	O
if	O
potentially	O
adverse	O
extracoagulant	O
properties	O
are	O
responsible	O
for	O
the	O
fact	O
that	O
its	O
favorable	O
effects	O
in	O
clinical	O
studies	O
are	O
mainly	O
driven	O
by	O
a	O
reduction	O
in	O
bleeding	O
events	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
determine	O
the	O
effects	O
and	O
mechanisms	O
of	O
acute	O
treatment	O
with	O
bivalirudin	O
in	O
comparison	O
to	O
heparin	O
on	O
NO	O
bioavailability	O
,	O
an	O
important	O
factor	O
for	O
the	O
pathogenesis	O
of	O
ischemic	O
events	O
.	O

In	O
particular	O
,	O
we	O
studied	O
the	O
interaction	O
between	O
bivalirudin	O
and	O
myeloperoxidase	S-Protein
(	O
MPO	S-Protein
)	O
,	O
a	O
leukocyte	O
-	O
derived	O
enzyme	O
that	O
consumes	O
endothelial	O
-	O
derived	O
nitric	O
oxide	O
(	O
NO	O
)	O
,	O
modifies	O
a	O
variety	O
of	O
biological	O
targets	O
,	O
and	O
thus	O
affects	O
the	O
integrity	O
of	O
the	O
vessel	O
wall	O
.	O

In	O
patients	O
undergoing	O
elective	O
percutaneous	O
coronary	O
intervention	O
,	O
bivalirudin	O
,	O
in	O
contrast	O
to	O
heparin	O
,	O
exhibited	O
a	O
significant	O
decrease	O
in	O
plasma	O
MPO	S-Protein
levels	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
accompanied	O
by	O
a	O
deterioration	O
of	O
flow	O
-	O
mediated	O
dilation	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
,	O
a	O
surrogate	O
for	O
endothelial	O
NO	O
bioavailability	O
.	O

In	O
vitro	O
experiments	O
revealed	O
avid	O
binding	O
of	O
bivalirudin	O
to	O
both	O
bovine	O
aortic	O
endothelial	O
cells	O
(	O
BAEC	O
)	O
and	O
MPO	S-Protein
.	O

Methylation	O
of	O
bivalirudin	O
carboxyl	O
groups	O
at	O
the	O
carboxyl	O
-	O
terminal	O
end	O
revealed	O
the	O
specific	O
binding	O
site	O
of	O
bivalirudin	O
to	O
MPO	S-Protein
.	O

Bivalirudin	O
-	O
facilitated	O
binding	O
of	O
MPO	S-Protein
to	O
BAEC	O
resulted	O
also	O
in	O
functional	O
changes	O
in	O
terms	O
of	O
increased	O
NO	O
consumption	O
as	O
well	O
as	O
enhanced	O
MPO	S-Protein
-	O
mediated	O
redox	O
modifications	O
.	O

These	O
results	O
illustrate	O
dichotomous	O
extracoagulant	O
properties	O
of	O
heparins	O
and	O
thrombin	S-Protein
inhibitors	O
and	O
suggest	O
that	O
bivalirudin	O
acutely	O
impairs	O
endothelial	O
NO	O
bioavailability	O
,	O
thereby	O
underscoring	O
the	O
potentially	O
critical	O
role	O
of	O
MPO	S-Protein
as	O
a	O
mediator	O
of	O
vascular	O
function	O
.	O

Histone	B-Protein
H3	E-Protein
modifications	O
associated	O
with	O
differentiation	O
and	O
long	O
-	O
term	O
culture	O
of	O
mesenchymal	O
adipose	O
stem	O
cells	O
.	O

Long	O
-	O
term	O
culture	O
of	O
mesenchymal	O
stem	O
cells	O
leads	O
to	O
a	O
loss	O
of	O
differentiation	O
capacity	O
,	O
the	O
molecular	O
mechanism	O
of	O
which	O
remains	O
not	O
understood	O
.	O

We	O
show	O
here	O
that	O
expansion	O
of	O
adipose	O
stem	O
cells	O
(	O
ASCs	O
)	O
to	O
late	O
passage	O
(	O
replicative	O
senescence	O
)	O
is	O
associated	O
with	O
promoter	O
-	O
specific	O
and	O
global	O
changes	O
in	O
epigenetic	O
histone	O
modifications	O
.	O

In	O
undifferentiated	O
ASCs	O
,	O
inactive	O
adipogenic	O
and	O
myogenic	O
promoters	O
are	O
enriched	O
in	O
a	O
repressive	O
combination	O
of	O
trimethylated	O
H3K4	S-Protein
(	O
H3K4m3	S-Protein
)	O
and	O
H3K27m3	S-Protein
in	O
the	O
absence	O
of	O
H3K9m3	S-Protein
,	O
a	O
heterochromatin	O
mark	O
.	O

Sequential	O
chromatin	O
immunoprecipitation	O
assays	O
indicate	O
that	O
H3K4m3	S-Protein
and	O
H3K27m3	S-Protein
co	O
-	O
occupy	O
a	O
fraction	O
of	O
nucleosomes	O
on	O
some	O
but	O
not	O
all	O
lineage	O
-	O
specific	O
promoters	O
examined	O
.	O

However	O
in	O
cultured	O
primary	O
keratinocytes	O
,	O
adipogenic	O
and	O
myogenic	O
promoters	O
are	O
enriched	O
in	O
trimethylated	O
H3K4	S-Protein
,	O
K27	O
,	O
and	O
K9	O
,	O
illustrating	O
two	O
distinct	O
epigenetic	O
states	O
of	O
inactive	O
promoters	O
related	O
to	O
potential	O
for	O
activation	O
.	O

H3K4m3	S-Protein
and	O
H3K27m3	S-Protein
stably	O
mark	O
promoters	O
during	O
long	O
-	O
term	O
ASC	O
culture	O
indicating	O
that	O
loss	O
of	O
differentiation	O
capacity	O
is	O
not	O
due	O
to	O
alterations	O
in	O
these	O
histone	S-Protein
modifications	O
on	O
these	O
loci	O
.	O

Adipogenic	O
differentiation	O
in	O
early	O
passage	O
results	O
in	O
H3K27	S-Protein
demethylation	O
and	O
H3K9	S-Protein
acetylation	O
specifically	O
on	O
adipogenic	O
promoters	O
.	O

On	O
induction	O
of	O
differentiation	O
in	O
late	O
passage	O
,	O
however	O
,	O
transcriptional	O
upregulation	O
is	O
impaired	O
,	O
H3K27	S-Protein
trimethylation	O
is	O
maintained	O
and	O
H3K9	S-Protein
acetylation	O
is	O
inhibited	O
on	O
promoters	O
.	O

In	O
addition	O
,	O
the	O
polycomb	O
proteins	O
Ezh2	S-Protein
and	O
Bmi1	S-Protein
are	O
targeted	O
to	O
promoters	O
.	O

This	O
correlates	O
with	O
global	O
cellular	O
Ezh2	S-Protein
increase	O
and	O
H3K9	S-Protein
deacetylation	O
.	O

Promoter	O
targeting	O
by	O
Ezh2	S-Protein
and	O
Bmi1	S-Protein
in	O
late	O
passage	O
ASCs	O
suggests	O
the	O
establishment	O
of	O
a	O
polycomb	O
-	O
mediated	O
epigenetic	O
program	O
aiming	O
at	O
repressing	O
transcription	O
.	O

New	O
insights	O
into	O
NF	O
-	O
kappaB	O
regulation	O
and	O
function	O
.	O

NF	O
-	O
kappaB	O
(	O
nuclear	O
factor	O
-	O
kappaB	O
)	O
transcription	O
factors	O
have	O
multiple	O
critical	O
roles	O
in	O
the	O
regulation	O
of	O
immune	O
responses	O
.	O

In	O
unstimulated	O
cells	O
,	O
NF	O
-	O
kappaB	O
proteins	O
are	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
IkappaB	O
inhibitory	O
proteins	O
.	O

Various	O
immune	O
stimuli	O
induce	O
the	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
to	O
phosphorylate	O
IkappaBs	O
,	O
triggering	O
their	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
,	O
which	O
permits	O
nuclear	O
translocation	O
of	O
associated	O
NF	O
-	O
kappaB	O
subunits	O
and	O
activation	O
of	O
NF	O
-	O
kappaB	O
target	O
genes	O
.	O

Recent	O
studies	O
have	O
highlighted	O
the	O
importance	O
of	O
dynamic	O
ubiquitination	O
-	O
deubiquitination	O
events	O
in	O
regulating	O
this	O
canonical	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
.	O

Ubiquitination	O
additionally	O
plays	O
critical	O
roles	O
in	O
activation	O
of	O
the	O
noncanonical	O
pathway	O
that	O
regulates	O
NF	O
-	O
kappaB	O
via	O
signal	O
-	O
induced	O
processing	O
of	O
NF	B-Protein
-	I-Protein
kappaB2	E-Protein
p100	S-Protein
.	O

New	O
research	O
has	O
also	O
identified	O
several	O
novel	O
regulatory	O
proteins	O
that	O
control	O
the	O
transcriptional	O
activity	O
of	O
nuclear	O
NF	O
-	O
kappaB	O
.	O

A	O
C	O
-	O
terminal	O
fragment	O
of	O
Cyclin	B-Protein
E	E-Protein
,	O
generated	O
by	O
caspase	O
-	O
mediated	O
cleavage	O
,	O
is	O
degraded	O
in	O
the	O
absence	O
of	O
a	O
recognizable	O
phosphodegron	O
.	O

We	O
have	O
previously	O
shown	O
that	O
caspase	O
-	O
mediated	O
cleavage	O
of	O
Cyclin	B-Protein
E	E-Protein
generates	O
p18	O
-	O
Cyclin	B-Protein
E	E-Protein
in	O
hematopoietic	O
tumor	O
cells	O
.	O

Its	O
expression	O
can	O
induce	O
apoptosis	O
or	O
sensitize	O
to	O
apoptotic	O
stimuli	O
in	O
many	O
cell	O
types	O
.	O

However	O
,	O
p18	O
-	O
cyclin	B-Protein
E	E-Protein
has	O
a	O
much	O
shorter	O
half	O
-	O
life	O
than	O
Cyclin	B-Protein
E	E-Protein
,	O
being	O
more	O
effectively	O
ubiquitinated	O
and	O
degraded	O
by	O
the	O
26	O
S	O
proteasome	O
.	O

A	O
two	O
-	O
step	O
process	O
has	O
emerged	O
that	O
regulates	O
accelerated	O
degradation	O
of	O
Cyclin	B-Protein
E	E-Protein
,	O
with	O
a	O
caspase	O
-	O
mediated	O
cleavage	O
followed	O
by	O
enhanced	O
proteasome	O
-	O
mediated	O
degradation	O
.	O

We	O
show	O
that	O
recognition	O
of	O
p18	O
-	O
Cyclin	B-Protein
E	E-Protein
by	O
the	O
Skp1	S-Protein
-	O
Cul1	S-Protein
-	O
Fbw7	S-Protein
(	O
SCF	O
)	O
complex	O
and	O
its	O
interaction	O
with	O
the	O
Fbw7	S-Protein
protein	O
isoforms	O
can	O
take	O
place	O
independently	O
of	O
phosphorylation	O
of	O
p18	O
-	O
Cyclin	B-Protein
E	E-Protein
at	O
a	O
C	O
-	O
terminal	O
phosphodegron	O
.	O

In	O
addition	O
to	O
the	O
SCF	O
(	O
Fbw7	S-Protein
)	O
pathway	O
,	O
Ku70	S-Protein
binding	O
that	O
facilitates	O
Hdm2	S-Protein
recruitment	O
may	O
also	O
be	O
implicated	O
in	O
p18	O
-	O
Cyclin	B-Protein
E	E-Protein
ubiquitination	O
.	O

Blocking	O
p18	O
-	O
Cyclin	B-Protein
E	E-Protein
degradation	O
with	O
proteasome	O
inhibitors	O
increases	O
levels	O
of	O
p18	O
-	O
Cyclin	B-Protein
E	E-Protein
and	O
enhances	O
its	O
association	O
with	O
Ku70	S-Protein
,	O
thus	O
leading	O
to	O
Bax	S-Protein
release	O
,	O
its	O
activation	O
,	O
and	O
apoptosis	O
.	O

Moreover	O
,	O
cells	O
expressing	O
p18	O
-	O
Cyclin	B-Protein
E	E-Protein
are	O
more	O
sensitive	O
to	O
treatment	O
with	O
proteasome	O
inhibitors	O
,	O
such	O
as	O
Bortezomib	O
.	O

By	O
preventing	O
its	O
proteasomal	O
degradation	O
,	O
p18	O
-	O
Cyclin	B-Protein
E	E-Protein
,	O
but	O
not	O
Cyclin	B-Protein
E	E-Protein
,	O
may	O
become	O
an	O
effective	O
therapeutic	O
target	O
for	O
Bortezomib	O
and	O
apoptotic	O
effectors	O
in	O
hematopoietic	O
malignancies	O
.	O

Jade	B-Protein
-	I-Protein
1	E-Protein
inhibits	O
Wnt	O
signalling	O
by	O
ubiquitylating	O
beta	B-Protein
-	I-Protein
catenin	E-Protein
and	O
mediates	O
Wnt	O
pathway	O
inhibition	O
by	O
pVHL	S-Protein
.	O

The	O
von	O
Hippel	O
-	O
Lindau	O
protein	O
pVHL	S-Protein
suppresses	O
renal	O
tumorigenesis	O
in	O
part	O
by	O
promoting	O
the	O
degradation	O
of	O
hypoxia	O
-	O
inducible	O
HIF	B-Protein
-	I-Protein
alpha	E-Protein
transcription	O
factors	O
;	O
additional	O
mechanisms	O
have	O
been	O
proposed	O
.	O

pVHL	S-Protein
also	O
stabilizes	O
the	O
plant	O
homeodomain	O
protein	O
Jade	B-Protein
-	I-Protein
1	E-Protein
,	O
which	O
is	O
a	O
candidate	O
renal	O
tumour	O
suppressor	O
that	O
may	O
correlate	O
with	O
renal	O
cancer	O
risk	O
.	O

Here	O
we	O
show	O
that	O
Jade	B-Protein
-	I-Protein
1	E-Protein
binds	O
the	O
oncoprotein	O
beta	B-Protein
-	I-Protein
catenin	E-Protein
in	O
Wnt	O
-	O
responsive	O
fashion	O
.	O

Moreover	O
,	O
Jade	B-Protein
-	I-Protein
1	E-Protein
destabilizes	O
wild	O
-	O
type	O
beta	B-Protein
-	I-Protein
catenin	E-Protein
but	O
not	O
a	O
cancer	O
-	O
causing	O
form	O
of	O
beta	B-Protein
-	I-Protein
catenin	E-Protein
.	O

Whereas	O
the	O
well	O
-	O
established	O
beta	B-Protein
-	I-Protein
catenin	E-Protein
E3	O
ubiquitin	S-Protein
ligase	O
component	O
beta	B-Protein
-	I-Protein
TrCP	E-Protein
ubiquitylates	O
only	O
phosphorylated	O
beta	B-Protein
-	I-Protein
catenin	E-Protein
,	O
Jade	B-Protein
-	I-Protein
1	E-Protein
ubiquitylates	O
both	O
phosphorylated	O
and	O
non	O
-	O
phosphorylated	O
beta	B-Protein
-	I-Protein
catenin	E-Protein
and	O
therefore	O
regulates	O
canonical	O
Wnt	O
signalling	O
in	O
both	O
Wnt	O
-	O
off	O
and	O
Wnt	O
-	O
on	O
phases	O
.	O

Thus	O
,	O
the	O
different	O
characteristics	O
of	O
beta	B-Protein
-	I-Protein
TrCP	E-Protein
and	O
Jade	B-Protein
-	I-Protein
1	E-Protein
may	O
ensure	O
optimal	O
Wnt	O
pathway	O
regulation	O
.	O

Furthermore	O
,	O
pVHL	S-Protein
downregulates	O
beta	B-Protein
-	I-Protein
catenin	E-Protein
in	O
a	O
Jade	B-Protein
-	I-Protein
1	E-Protein
-	O
dependent	O
manner	O
and	O
inhibits	O
Wnt	O
signalling	O
,	O
supporting	O
a	O
role	O
for	O
Jade	B-Protein
-	I-Protein
1	E-Protein
and	O
Wnt	O
signalling	O
in	O
renal	O
tumorigenesis	O
.	O

The	O
pVHL	S-Protein
tumour	O
suppressor	O
and	O
the	O
Wnt	O
tumorigenesis	O
pathway	O
are	O
therefore	O
directly	O
linked	O
through	O
Jade	B-Protein
-	I-Protein
1	E-Protein
.	O

Inhibition	O
of	O
Siah	S-Protein
ubiquitin	S-Protein
ligase	O
function	O
.	O

Tumor	O
hypoxia	O
induces	O
the	O
upregulation	O
of	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
1alpha	E-Protein
(	O
Hif	B-Protein
-	I-Protein
1alpha	E-Protein
)	O
,	O
which	O
in	O
turn	O
induces	O
the	O
expression	O
of	O
genes	O
including	O
VEGF	S-Protein
to	O
recruit	O
new	O
blood	O
vessel	O
outgrowth	O
,	O
enabling	O
tumor	O
growth	O
and	O
metastasis	O
.	O

Interference	O
with	O
the	O
Hif	B-Protein
-	I-Protein
1	E-Protein
pathway	O
and	O
neoangiogenesis	O
is	O
an	O
attractive	O
antitumor	O
target	O
.	O

The	O
hydroxylation	O
of	O
Hif	B-Protein
-	I-Protein
1alpha	E-Protein
by	O
prolyl	O
-	O
hydroxylase	O
(	O
PHD	O
)	O
proteins	O
during	O
normoxia	O
serves	O
as	O
a	O
recognition	O
motif	O
for	O
its	O
proteasomal	O
degradation	O
.	O

However	O
,	O
under	O
hypoxic	O
conditions	O
,	O
hydroxylation	O
is	O
inhibited	O
and	O
furthermore	O
,	O
PHD	O
proteins	O
are	O
themselves	O
polyubiquitylated	O
and	O
degraded	O
by	O
Siah	S-Protein
ubiquitin	S-Protein
ligases	O
.	O

Our	O
data	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
inhibition	O
of	O
the	O
interaction	O
between	O
Siah	S-Protein
and	O
PHD	O
proteins	O
using	O
a	O
fragment	O
derived	O
from	O
a	O
Drosophila	O
protein	O
(	O
phyllopod	S-Protein
)	O
interferes	O
with	O
the	O
PHD	O
degradation	O
.	O

Furthermore	O
,	O
cells	O
stably	O
expressing	O
the	O
phyllopod	S-Protein
fragment	O
display	O
reduced	O
upregulation	O
of	O
Hif	B-Protein
-	I-Protein
1alpha	E-Protein
protein	O
levels	O
and	O
Hif	B-Protein
-	I-Protein
1	E-Protein
-	O
mediated	O
gene	O
expression	O
under	O
hypoxia	O
.	O

In	O
a	O
syngeneic	O
mouse	O
model	O
of	O
breast	O
cancer	O
,	O
the	O
phyllopod	S-Protein
fragment	O
reduced	O
tumor	O
growth	O
and	O
neoangiogenesis	O
and	O
prolonged	O
survival	O
of	O
the	O
mice	O
.	O

In	O
addition	O
,	O
levels	O
of	O
Hif	B-Protein
-	I-Protein
1alpha	E-Protein
and	O
its	O
target	O
Glut	B-Protein
-	I-Protein
1	E-Protein
are	O
reduced	O
in	O
tumors	O
expressing	O
the	O
phyllopod	S-Protein
fragment	O
.	O

These	O
data	O
show	O
,	O
in	O
a	O
proof	O
-	O
of	O
-	O
principle	O
study	O
,	O
that	O
Siah	S-Protein
protein	O
,	O
the	O
most	O
upstream	O
component	O
of	O
the	O
hypoxia	O
pathway	O
yet	O
identified	O
,	O
is	O
a	O
viable	O
drug	O
target	O
for	O
antitumor	O
therapies	O
.	O

Smurf2	S-Protein
induces	O
ubiquitin	S-Protein
-	O
dependent	O
degradation	O
of	O
Smurf1	S-Protein
to	O
prevent	O
migration	O
of	O
breast	O
cancer	O
cells	O
.	O

Ubiquitin	S-Protein
-	O
dependent	O
protein	O
degradation	O
is	O
involved	O
in	O
various	O
biological	O
processes	O
,	O
and	O
accumulating	O
evidence	O
suggests	O
that	O
E3	O
ubiquitin	S-Protein
ligases	O
play	O
important	O
roles	O
in	O
cancer	O
development	O
.	O

Smad	B-Protein
ubiquitin	I-Protein
regulatory	I-Protein
factor	I-Protein
1	E-Protein
(	O
Smurf1	S-Protein
)	O
and	O
Smurf2	S-Protein
are	O
E3	O
ubiquitin	S-Protein
ligases	O
,	O
which	O
suppress	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
family	O
signaling	O
through	O
degradation	O
of	O
Smads	O
and	O
receptors	O
for	O
TGF	O
-	O
beta	O
and	O
bone	O
morphogenetic	O
proteins	O
.	O

In	O
addition	O
,	O
Smurf1	S-Protein
has	O
been	O
reported	O
to	O
promote	O
RhoA	S-Protein
ubiquitination	O
and	O
degradation	O
and	O
regulate	O
cell	O
motility	O
,	O
suggesting	O
the	O
involvement	O
of	O
Smurf1	S-Protein
in	O
cancer	O
progression	O
.	O

However	O
,	O
the	O
regulation	O
and	O
biological	O
function	O
of	O
Smurf1	S-Protein
and	O
Smurf2	S-Protein
in	O
cancer	O
development	O
remain	O
to	O
be	O
elucidated	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
the	O
post	O
-	O
translational	O
regulation	O
of	O
Smurf1	S-Protein
by	O
Smurf2	S-Protein
and	O
the	O
functional	O
differences	O
between	O
Smurf1	S-Protein
and	O
Smurf2	S-Protein
in	O
the	O
progression	O
of	O
breast	O
cancer	O
cells	O
.	O

Smurf2	S-Protein
interacted	O
with	O
Smurf1	S-Protein
and	O
induced	O
its	O
ubiquitination	O
and	O
degradation	O
,	O
whereas	O
Smurf1	S-Protein
failed	O
to	O
induce	O
degradation	O
of	O
Smurf2	S-Protein
.	O

Knockdown	O
of	O
Smurf2	S-Protein
in	O
human	O
breast	O
cancer	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
resulted	O
in	O
increases	O
in	O
the	O
levels	O
of	O
Smurf1	S-Protein
protein	O
,	O
and	O
enhancement	O
of	O
cell	O
migration	O
in	O
vitro	O
and	O
bone	O
metastasis	O
in	O
vivo	O
.	O

Of	O
note	O
,	O
knockdown	O
of	O
Smurf1	S-Protein
,	O
but	O
not	O
of	O
Smurf2	S-Protein
,	O
enhanced	O
TGF	O
-	O
beta	O
signaling	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
,	O
suggesting	O
that	O
increased	O
an	O
protein	O
level	O
of	O
Smurf1	S-Protein
offsets	O
the	O
effect	O
of	O
Smurf2	S-Protein
knockdown	O
on	O
TGF	O
-	O
beta	O
signaling	O
.	O

These	O
results	O
indicate	O
that	O
two	O
related	O
E3	O
ubiquitin	S-Protein
ligases	O
,	O
Smurf1	S-Protein
and	O
Smurf2	S-Protein
,	O
act	O
in	O
the	O
same	O
direction	O
in	O
TGF	O
-	O
beta	O
family	O
signaling	O
but	O
play	O
opposite	O
roles	O
in	O
cell	O
migration	O
.	O

Histone	B-Protein
H2A	E-Protein
ubiquitination	O
in	O
transcriptional	O
regulation	O
and	O
DNA	O
damage	O
repair	O
.	O

The	O
precise	O
molecular	O
strategies	O
that	O
coordinate	O
patterns	O
of	O
transcriptional	O
response	O
to	O
specific	O
signals	O
is	O
central	O
for	O
understanding	O
normal	O
development	O
and	O
disease	O
.	O

Precise	O
control	O
of	O
transcriptional	O
programs	O
underlying	O
metazoan	O
development	O
is	O
modulated	O
by	O
enzymatically	O
active	O
coregulatory	O
complexes	O
,	O
coupled	O
with	O
epigenetic	O
strategies	O
.	O

Epigenetic	O
modifications	O
,	O
particularly	O
DNA	O
methylation	O
and	O
covalent	O
histone	S-Protein
modifications	O
,	O
for	O
instance	O
acetylation	O
,	O
methylation	O
,	O
phosphorylation	O
and	O
ubiquitination	O
,	O
play	O
an	O
essential	O
role	O
in	O
transcription	O
regulation	O
,	O
chromatin	O
remodeling	O
,	O
genome	O
instability	O
and	O
X	O
chromosome	O
inactivation	O
.	O

Recently	O
,	O
the	O
ubiquitinases	O
and	O
deubiquitinases	O
responsible	O
for	O
histone	B-Protein
H2A	E-Protein
ubiquitination	O
and	O
deubiquitination	O
have	O
been	O
identified	O
and	O
characterized	O
.	O

These	O
studies	O
suggest	O
that	O
histone	B-Protein
H2A	E-Protein
ubiquitination	O
play	O
important	O
roles	O
in	O
many	O
cellular	O
events	O
,	O
such	O
as	O
transcription	O
initiation	O
and	O
elongation	O
,	O
silencing	O
,	O
and	O
DNA	O
repair	O
.	O

Alteration	O
of	O
histone	B-Protein
H2A	E-Protein
ubiquitination	O
modifications	O
may	O
contribute	O
human	O
diseases	O
,	O
such	O
as	O
cancer	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
enzymes	O
involved	O
in	O
H2A	S-Protein
ubiquitination	O
/	O
deubiquitination	O
and	O
that	O
possible	O
molecular	O
mechanisms	O
underlying	O
histone	B-Protein
H2A	E-Protein
ubiquitination	O
/	O
deubiquitination	O
in	O
transcriptional	O
regulation	O
and	O
DNA	O
damage	O
repair	O
.	O

Proteasome	O
inhibition	O
induces	O
neurite	O
outgrowth	O
through	O
posttranslational	O
modification	O
of	O
TrkA	S-Protein
receptor	O
.	O

The	O
ubiquitin	S-Protein
-	O
proteasome	O
pathway	O
regulates	O
many	O
biological	O
processes	O
,	O
including	O
protein	O
degradation	O
,	O
receptor	O
endocytosis	O
,	O
protein	O
sorting	O
,	O
subnuclear	O
trafficking	O
and	O
neuronal	O
differentiation	O
.	O

While	O
proteasome	O
inhibition	O
is	O
known	O
to	O
induce	O
neurite	O
outgrowth	O
,	O
the	O
signaling	O
mechanisms	O
that	O
mediate	O
these	O
effects	O
have	O
not	O
been	O
defined	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
underlying	O
mechanisms	O
that	O
link	O
proteasome	O
inhibition	O
with	O
neurite	O
generation	O
.	O

We	O
found	O
that	O
the	O
proteasome	O
inhibitors	O
,	O
MG132	O
and	O
lactacystin	O
,	O
induced	O
neurite	O
outgrowth	O
and	O
also	O
activated	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
/	O
mitogen	O
activated	O
protein	O
kinase	O
and	O
phosphatidylinositol	O
-	O
3	O
-	O
kinase	O
/	O
AKT	O
pathways	O
.	O

These	O
proteasome	O
inhibitors	O
also	O
induced	O
phosphorylation	O
and	O
ubiquitination	O
of	O
TrkA	S-Protein
receptors	O
,	O
indicating	O
that	O
proteasome	O
inhibition	O
activates	O
the	O
major	O
pathways	O
of	O
TrkA	S-Protein
signaling	O
.	O

However	O
,	O
in	O
contrast	O
to	O
nerve	O
growth	O
factor	O
stimulation	O
,	O
which	O
induces	O
internalization	O
of	O
surface	O
TrkA	S-Protein
receptors	O
,	O
proteasome	O
inhibitor	O
-	O
induced	O
neurite	O
outgrowth	O
did	O
not	O
require	O
TrkA	S-Protein
receptor	O
internalization	O
.	O

These	O
results	O
indicate	O
that	O
the	O
ubiquitin	S-Protein
-	O
proteasome	O
system	O
regulates	O
neurite	O
formation	O
through	O
posttranslational	O
modification	O
of	O
TrkA	S-Protein
receptors	O
.	O

The	O
genomic	O
landscapes	O
of	O
histone	B-Protein
H3	E-Protein
-	O
Lys9	O
modifications	O
of	O
gene	O
promoter	O
regions	O
and	O
expression	O
profiles	O
in	O
human	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
.	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
of	O
nonembryonic	O
origins	O
possess	O
the	O
proliferation	O
and	O
multi	O
-	O
lineage	O
differentiation	O
potentials	O
.	O

It	O
has	O
been	O
established	O
that	O
epigenetic	O
mechanisms	O
could	O
be	O
critical	O
for	O
determining	O
the	O
fate	O
of	O
stem	O
cells	O
,	O
and	O
MSCs	O
derived	O
from	O
different	O
origins	O
exhibited	O
different	O
expression	O
profiles	O
individually	O
to	O
a	O
certain	O
extent	O
.	O

In	O
this	O
study	O
,	O
ChIP	O
-	O
on	O
-	O
chip	O
was	O
used	O
to	O
generate	O
genome	O
-	O
wide	O
histone	B-Protein
H3	E-Protein
-	O
Lys9	O
acetylation	O
and	O
dimethylation	O
profiles	O
at	O
gene	O
promoters	O
in	O
human	O
bone	O
marrow	O
MSCs	O
.	O

We	O
showed	O
that	O
modifications	O
of	O
histone	B-Protein
H3	E-Protein
-	O
Lys9	O
at	O
gene	O
promoters	O
correlated	O
well	O
with	O
mRNA	O
expression	O
in	O
human	O
bone	O
marrow	O
MSCs	O
.	O

Functional	O
analysis	O
revealed	O
that	O
many	O
key	O
cellular	O
pathways	O
in	O
human	O
bone	O
marrow	O
MSC	O
self	O
-	O
renewal	O
,	O
such	O
as	O
the	O
canonical	O
signaling	O
pathways	O
,	O
cell	O
cycle	O
pathways	O
and	O
cytokine	O
related	O
pathways	O
may	O
be	O
regulated	O
by	O
H3	S-Protein
-	O
Lys9	O
modifications	O
.	O

These	O
data	O
suggest	O
that	O
gene	O
activation	O
and	O
silencing	O
affected	O
by	O
H3	S-Protein
-	O
Lys9	O
acetylation	O
and	O
dimethylation	O
,	O
respectively	O
,	O
may	O
be	O
essential	O
to	O
the	O
maintenance	O
of	O
human	O
bone	O
marrow	O
MSC	O
self	O
-	O
renewal	O
and	O
multi	O
-	O
potency	O
.	O

Arginine	O
methylation	O
of	O
FOXO	O
transcription	O
factors	O
inhibits	O
their	O
phosphorylation	O
by	O
Akt	O
.	O

Forkhead	O
box	O
O	O
(	O
FOXO	O
)	O
transcription	O
factors	O
,	O
the	O
key	O
regulators	O
of	O
cell	O
survival	O
,	O
are	O
negatively	O
controlled	O
through	O
the	O
PI3K	O
-	O
Akt	O
signaling	O
pathway	O
.	O

Phosphorylation	O
of	O
FOXO	O
by	O
Akt	O
leads	O
to	O
cytoplasmic	O
localization	O
and	O
subsequent	O
degradation	O
via	O
the	O
ubiquitin	S-Protein
-	O
proteasome	O
system	O
.	O

Here	O
we	O
show	O
a	O
paradigm	O
of	O
FOXO1	S-Protein
regulation	O
by	O
the	O
protein	O
arginine	O
methyltransferase	O
PRMT1	S-Protein
.	O

PRMT1	S-Protein
methylated	O
FOXO1	S-Protein
at	O
conserved	O
Arg248	O
and	O
Arg250	O
within	O
a	O
consensus	O
motif	O
for	O
Akt	O
phosphorylation	O
;	O
this	O
methylation	O
directly	O
blocked	O
Akt	O
-	O
mediated	O
phosphorylation	O
of	O
FOXO1	S-Protein
at	O
Ser253	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Silencing	O
of	O
PRMT1	S-Protein
by	O
small	O
interfering	O
RNA	O
enhanced	O
nuclear	O
exclusion	O
,	O
polyubiquitination	O
,	O
and	O
proteasomal	O
degradation	O
of	O
FOXO1	S-Protein
.	O

PRMT1	S-Protein
knockdown	O
led	O
to	O
a	O
decrease	O
in	O
oxidative	O
-	O
stress	O
-	O
induced	O
apoptosis	O
depending	O
on	O
the	O
PI3K	O
-	O
Akt	O
signaling	O
pathway	O
.	O

Furthermore	O
,	O
stable	O
expression	O
of	O
enzymatic	O
inactive	O
PRMT1	S-Protein
mutant	O
increased	O
resistance	O
to	O
apoptosis	O
,	O
whereas	O
this	O
effect	O
was	O
reversed	O
by	O
expression	O
of	O
phosphorylation	O
-	O
deficient	O
FOXO1	S-Protein
.	O

Our	O
findings	O
predict	O
a	O
role	O
for	O
arginine	O
methylation	O
as	O
an	O
inhibitory	O
modification	O
against	O
Akt	O
-	O
mediated	O
phosphorylation	O
.	O

Suppression	O
of	O
microtubule	O
dynamic	O
instability	O
and	O
turnover	O
in	O
MCF7	O
breast	O
cancer	O
cells	O
by	O
sulforaphane	O
.	O

Sulforaphane	O
(	O
SFN	O
)	O
,	O
a	O
prominent	O
isothiocyanate	O
present	O
in	O
cruciferous	O
vegetables	O
,	O
is	O
believed	O
to	O
be	O
responsible	O
along	O
with	O
other	O
isothiocyanates	O
for	O
the	O
cancer	O
preventive	O
activity	O
of	O
such	O
vegetables	O
.	O

SFN	O
arrests	O
mitosis	O
,	O
possibly	O
by	O
affecting	O
spindle	O
microtubule	O
function	O
.	O

A	O
critical	O
property	O
of	O
microtubules	O
is	O
their	O
rapid	O
and	O
time	O
-	O
sensitive	O
growth	O
and	O
shortening	O
dynamics	O
(	O
dynamic	O
instability	O
)	O
,	O
and	O
suppression	O
of	O
dynamics	O
by	O
antimitotic	O
anticancer	O
drugs	O
(	O
e	O
.	O
g	O
.	O
taxanes	O
and	O
the	O
vinca	O
alkaloids	O
)	O
is	O
central	O
to	O
the	O
anticancer	O
mechanisms	O
of	O
such	O
drugs	O
.	O

We	O
found	O
that	O
at	O
concentrations	O
that	O
inhibited	O
proliferation	O
and	O
mitosis	O
of	O
MCF7	O
-	O
green	B-Protein
fluorescent	I-Protein
protein	E-Protein
-	O
alpha	O
-	O
tubulin	O
breast	O
tumor	O
cells	O
by	O
approximately	O
50	O
%	O
(	O
~	O
15	O
microM	O
)	O
,	O
SFN	O
significantly	O
modified	O
microtubule	O
organization	O
in	O
arrested	O
spindles	O
without	O
modulating	O
the	O
spindle	O
microtubule	O
mass	O
,	O
in	O
a	O
manner	O
similar	O
to	O
that	O
of	O
much	O
more	O
powerful	O
antimitotic	O
drugs	O
.	O

By	O
using	O
quantitative	O
fluorescence	O
video	O
microscopy	O
,	O
we	O
determined	O
that	O
at	O
its	O
mitotic	O
concentration	O
required	O
to	O
inhibit	O
mitosis	O
by	O
50	O
%	O
,	O
SFN	O
suppressed	O
the	O
dynamic	O
instability	O
of	O
the	O
interphase	O
microtubules	O
in	O
these	O
cells	O
,	O
strongly	O
reducing	O
the	O
rate	O
and	O
extent	O
of	O
growth	O
and	O
shortening	O
and	O
decreasing	O
microtubule	O
turnover	O
,	O
without	O
affecting	O
the	O
polymer	O
mass	O
.	O

SFN	O
suppressed	O
the	O
dynamics	O
of	O
purified	O
microtubules	O
in	O
a	O
similar	O
fashion	O
at	O
concentrations	O
well	O
below	O
those	O
required	O
to	O
depolymerize	O
microtubules	O
,	O
indicating	O
that	O
the	O
suppression	O
of	O
dynamic	O
instability	O
by	O
SFN	O
in	O
cells	O
is	O
due	O
to	O
a	O
direct	O
effect	O
on	O
the	O
microtubules	O
.	O

The	O
results	O
indicate	O
that	O
SFN	O
arrests	O
proliferation	O
and	O
mitosis	O
by	O
stabilizing	O
microtubules	O
in	O
a	O
manner	O
weaker	O
than	O
but	O
similar	O
to	O
more	O
powerful	O
clinically	O
used	O
antimitotic	O
anticancer	O
drugs	O
and	O
strongly	O
support	O
the	O
hypothesis	O
that	O
inhibition	O
of	O
mitosis	O
by	O
microtubule	O
stabilization	O
is	O
important	O
for	O
SFN	O
'	O
s	O
chemopreventive	O
activity	O
.	O

The	O
Air	S-Protein
noncoding	O
RNA	O
epigenetically	O
silences	O
transcription	O
by	O
targeting	O
G9a	S-Protein
to	O
chromatin	O
.	O

A	O
number	O
of	O
large	O
noncoding	O
RNAs	O
(	O
ncRNAs	O
)	O
epigenetically	O
silence	O
genes	O
through	O
unknown	O
mechanisms	O
.	O

The	O
Air	S-Protein
ncRNA	O
is	O
imprinted	O
-	O
-	O
monoallelically	O
expressed	O
from	O
the	O
paternal	O
allele	O
.	O

Air	S-Protein
is	O
required	O
for	O
allele	O
-	O
specific	O
silencing	O
of	O
the	O
cis	O
-	O
linked	O
Slc22a3	S-Protein
,	O
Slc22a2	S-Protein
,	O
and	O
Igf2r	S-Protein
genes	O
in	O
mouse	O
placenta	O
.	O

We	O
show	O
that	O
Air	S-Protein
interacts	O
with	O
the	O
Slc22a3	S-Protein
promoter	O
chromatin	O
and	O
the	O
H3K9	S-Protein
histone	S-Protein
methyltransferase	O
G9a	S-Protein
in	O
placenta	O
.	O

Air	S-Protein
accumulates	O
at	O
the	O
Slc22a3	S-Protein
promoter	O
in	O
correlation	O
with	O
localized	O
H3K9	S-Protein
methylation	O
and	O
transcriptional	O
repression	O
.	O

Genetic	O
ablation	O
of	O
G9a	S-Protein
results	O
in	O
nonimprinted	O
,	O
biallelic	O
transcription	O
of	O
Slc22a3	S-Protein
.	O

Truncated	O
Air	S-Protein
fails	O
to	O
accumulate	O
at	O
the	O
Slc22a3	S-Protein
promoter	O
,	O
which	O
results	O
in	O
reduced	O
G9a	S-Protein
recruitment	O
and	O
biallelic	O
transcription	O
.	O

Our	O
results	O
suggest	O
that	O
Air	S-Protein
,	O
and	O
potentially	O
other	O
large	O
ncRNAs	O
,	O
target	O
repressive	O
histone	S-Protein
-	O
modifying	O
activities	O
through	O
molecular	O
interaction	O
with	O
specific	O
chromatin	O
domains	O
to	O
epigenetically	O
silence	O
transcription	O
.	O

Processing	O
of	O
hemojuvelin	S-Protein
requires	O
retrograde	O
trafficking	O
to	O
the	O
Golgi	O
in	O
HepG2	O
cells	O
.	O

Hemojuvelin	S-Protein
(	O
HJV	S-Protein
)	O
was	O
recently	O
identified	O
as	O
a	O
critical	O
regulator	O
of	O
iron	O
homeostasis	O
.	O

It	O
is	O
either	O
associated	O
with	O
cell	O
membranes	O
through	O
a	O
glycosylphosphatidylinositol	O
anchor	O
or	O
released	O
as	O
a	O
soluble	O
form	O
.	O

Membrane	O
-	O
anchored	O
HJV	S-Protein
acts	O
as	O
a	O
coreceptor	O
for	O
bone	O
morphogenetic	O
proteins	O
and	O
activates	O
the	O
transcription	O
of	O
hepcidin	S-Protein
,	O
a	O
hormone	O
that	O
regulates	O
iron	O
efflux	O
from	O
cells	O
.	O

Soluble	O
HJV	S-Protein
antagonizes	O
bone	O
morphogenetic	O
protein	O
signaling	O
and	O
suppresses	O
hepcidin	S-Protein
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
trafficking	O
and	O
processing	O
of	O
HJV	S-Protein
.	O

Cellular	O
HJV	S-Protein
reached	O
the	O
plasma	O
membrane	O
without	O
obtaining	O
complex	O
oligosaccharides	O
,	O
indicating	O
that	O
HJV	S-Protein
avoided	O
Golgi	O
processing	O
.	O

Secreted	O
HJV	S-Protein
,	O
in	O
contrast	O
,	O
has	O
complex	O
oligosaccharides	O
and	O
can	O
be	O
derived	O
from	O
HJV	S-Protein
with	O
high	O
-	O
mannose	O
oligosaccharides	O
at	O
the	O
plasma	O
membrane	O
.	O

Our	O
results	O
support	O
a	O
model	O
in	O
which	O
retrograde	O
trafficking	O
of	O
HJV	S-Protein
before	O
cleavage	O
is	O
the	O
predominant	O
processing	O
pathway	O
.	O

Release	O
of	O
HJV	S-Protein
requires	O
it	O
to	O
bind	O
to	O
the	O
transmembrane	O
receptor	O
neogenin	S-Protein
.	O

Neogenin	S-Protein
does	O
not	O
,	O
however	O
,	O
play	O
a	O
role	O
in	O
HJV	S-Protein
trafficking	O
to	O
the	O
cell	O
surface	O
,	O
suggesting	O
that	O
it	O
could	O
be	O
involved	O
either	O
in	O
retrograde	O
trafficking	O
of	O
HJV	S-Protein
or	O
in	O
cleavage	O
leading	O
to	O
HJV	S-Protein
release	O
.	O

Drosophila	O
stem	O
cells	O
share	O
a	O
common	O
requirement	O
for	O
the	O
histone	B-Protein
H2B	E-Protein
ubiquitin	S-Protein
protease	O
scrawny	S-Protein
.	O

Stem	O
cells	O
within	O
diverse	O
tissues	O
share	O
the	O
need	O
for	O
a	O
chromatin	O
configuration	O
that	O
promotes	O
self	O
-	O
renewal	O
,	O
yet	O
few	O
chromatin	O
proteins	O
are	O
known	O
to	O
regulate	O
multiple	O
types	O
of	O
stem	O
cells	O
.	O

We	O
describe	O
a	O
Drosophila	O
gene	O
,	O
scrawny	S-Protein
(	O
scny	S-Protein
)	O
,	O
encoding	O
a	O
ubiquitin	S-Protein
-	O
specific	O
protease	O
,	O
which	O
is	O
required	O
in	O
germline	O
,	O
epithelial	O
,	O
and	O
intestinal	O
stem	O
cells	O
.	O

Like	O
its	O
yeast	O
relative	O
UBP10	S-Protein
,	O
Scrawny	S-Protein
deubiquitylates	O
histone	B-Protein
H2B	E-Protein
and	O
functions	O
in	O
gene	O
silencing	O
.	O

Consistent	O
with	O
previous	O
studies	O
of	O
this	O
conserved	O
pathway	O
of	O
chromatin	O
regulation	O
,	O
scny	S-Protein
mutant	O
cells	O
have	O
elevated	O
levels	O
of	O
ubiquitinylated	O
H2B	S-Protein
and	O
trimethylated	O
H3K4	S-Protein
.	O

Our	O
findings	O
suggest	O
that	O
inhibiting	O
H2B	S-Protein
ubiquitylation	O
through	O
scny	S-Protein
represents	O
a	O
common	O
mechanism	O
within	O
stem	O
cells	O
that	O
is	O
used	O
to	O
repress	O
the	O
premature	O
expression	O
of	O
key	O
differentiation	O
genes	O
,	O
including	O
Notch	O
target	O
genes	O
.	O

The	O
role	O
of	O
Rsp5	S-Protein
ubiquitin	S-Protein
ligase	O
in	O
regulation	O
of	O
diverse	O
processes	O
in	O
yeast	O
cells	O
.	O

Rsp5	S-Protein
is	O
a	O
conserved	O
ubiquitin	S-Protein
ligase	O
involved	O
in	O
regulation	O
of	O
numerous	O
cellular	O
processes	O
.	O

A	O
growing	O
number	O
of	O
publications	O
describing	O
new	O
functions	O
of	O
the	O
ligase	O
have	O
appeared	O
in	O
recent	O
years	O
.	O

Rsp5	S-Protein
was	O
shown	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
intracellular	O
trafficking	O
of	O
proteins	O
via	O
endocytosis	O
and	O
multivesicular	O
body	O
sorting	O
.	O

Moreover	O
,	O
nuclear	O
functions	O
of	O
Rsp5	S-Protein
in	O
response	O
to	O
various	O
stresses	O
have	O
been	O
discovered	O
.	O

Rsp5	S-Protein
is	O
also	O
involved	O
in	O
the	O
regulation	O
of	O
unsaturated	O
fatty	O
acid	O
and	O
sterol	O
synthesis	O
and	O
phospholipid	O
composition	O
.	O

Here	O
,	O
an	O
overview	O
of	O
Rsp5	S-Protein
functions	O
with	O
emphasis	O
on	O
its	O
involvement	O
in	O
the	O
regulation	O
of	O
lipid	O
biosynthesis	O
will	O
be	O
presented	O
.	O

Independent	O
assembly	O
and	O
secretion	O
of	O
a	O
dimeric	O
adhesive	O
domain	O
of	O
von	B-Protein
Willebrand	I-Protein
factor	E-Protein
containing	O
the	O
glycoprotein	O
Ib	O
-	O
binding	O
site	O
.	O

von	B-Protein
Willebrand	I-Protein
factor	E-Protein
(	O
vWF	S-Protein
)	O
is	O
a	O
multimeric	O
glycoprotein	O
that	O
supports	O
platelet	O
adhesion	O
on	O
thrombogenic	O
surfaces	O
as	O
part	O
of	O
the	O
normal	O
hemostatic	O
response	O
to	O
vascular	O
injury	O
.	O

We	O
have	O
employed	O
a	O
domain	O
-	O
specific	O
expression	O
strategy	O
to	O
analyze	O
the	O
biosynthetic	O
processing	O
steps	O
and	O
minimum	O
structural	O
requirements	O
for	O
assembly	O
of	O
the	O
platelet	O
receptor	O
glycoprotein	O
Ib	O
-	O
binding	O
domain	O
of	O
vWF	S-Protein
.	O

A	O
chimeric	O
cDNA	O
that	O
codes	O
for	O
the	O
vWF	S-Protein
signal	O
peptide	O
and	O
a	O
segment	O
of	O
vWF	S-Protein
internal	O
primary	O
sequence	O
,	O
residues	O
441	O
-	O
730	O
,	O
directs	O
the	O
secretion	O
of	O
a	O
functional	O
vWF	S-Protein
fragment	O
from	O
mammalian	O
cells	O
.	O

The	O
recombinant	O
molecule	O
intrinsically	O
assembles	O
through	O
intermolecular	O
disulfide	O
bond	O
formation	O
into	O
a	O
dimeric	O
adhesive	O
domain	O
without	O
contributions	O
from	O
other	O
regions	O
of	O
vWF	S-Protein
,	O
including	O
propeptide	O
,	O
previously	O
indicated	O
as	O
essential	O
for	O
vWF	S-Protein
multimer	O
assembly	O
.	O

Prevention	O
of	O
N	O
-	O
linked	O
glycosylation	O
on	O
the	O
recombinant	O
domain	O
does	O
not	O
impair	O
dimer	O
formation	O
or	O
the	O
ability	O
to	O
support	O
platelet	O
aggregation	O
.	O

These	O
results	O
identify	O
a	O
minimum	O
structural	O
element	O
for	O
vWF	S-Protein
subunit	O
assembly	O
and	O
provide	O
new	O
insights	O
into	O
the	O
processing	O
steps	O
to	O
produce	O
vWF	S-Protein
multimers	O
and	O
adhesive	O
domains	O
.	O

Genome	O
-	O
wide	O
histone	S-Protein
methylation	O
profile	O
for	O
heart	O
failure	O
.	O

Epigenetic	O
alterations	O
are	O
implicated	O
in	O
the	O
development	O
of	O
cardiac	O
hypertrophy	O
and	O
heart	O
failure	O
,	O
but	O
little	O
is	O
known	O
of	O
which	O
epigenetic	O
changes	O
in	O
which	O
regions	O
of	O
the	O
genome	O
play	O
such	O
a	O
role	O
.	O

We	O
now	O
show	O
that	O
trimethylation	O
of	O
histone	B-Protein
H3	E-Protein
on	O
lysine	O
-	O
4	O
(	O
K4TM	O
)	O
or	O
lysine	O
-	O
9	O
(	O
K9TM	O
)	O
is	O
markedly	O
affected	O
in	O
cardiomyocytes	O
in	O
association	O
with	O
the	O
development	O
of	O
heart	O
failure	O
in	O
a	O
rat	O
disease	O
model	O
.	O

High	O
-	O
throughput	O
pyrosequencing	O
performed	O
with	O
ChIP	O
products	O
for	O
K4TM	O
or	O
K9TM	O
prepared	O
from	O
human	O
left	O
ventricular	O
tissue	O
with	O
retained	O
or	O
damaged	O
function	O
also	O
revealed	O
that	O
protein	O
-	O
coding	O
genes	O
located	O
in	O
the	O
vicinity	O
of	O
K4TM	O
marks	O
differ	O
between	O
functional	O
and	O
disabled	O
myocytes	O
,	O
yet	O
both	O
sets	O
of	O
genes	O
encode	O
proteins	O
that	O
function	O
in	O
the	O
same	O
signal	O
transduction	O
pathways	O
for	O
cardiac	O
function	O
,	O
indicative	O
of	O
differential	O
K4TM	O
marking	O
during	O
the	O
development	O
of	O
heart	O
failure	O
.	O

However	O
,	O
K9TM	O
mark	O
-	O
profile	O
was	O
less	O
dependent	O
on	O
the	O
disease	O
status	O
compared	O
to	O
that	O
of	O
K4TM	O
.	O

Our	O
data	O
collectively	O
reveal	O
global	O
epigenetic	O
changes	O
in	O
cardiac	O
myocytes	O
associated	O
with	O
heart	O
failure	O
.	O

Asparagine	O
beta	O
-	O
hydroxylation	O
stabilizes	O
the	O
ankyrin	O
repeat	O
domain	O
fold	O
.	O

Ankyrin	O
repeats	O
(	O
ARs	O
)	O
are	O
one	O
of	O
the	O
most	O
common	O
structural	O
motifs	O
among	O
eukaryotic	O
proteins	O
.	O

Recent	O
analyses	O
have	O
shown	O
that	O
factor	B-Protein
inhibiting	I-Protein
hypoxia	I-Protein
-	I-Protein
inducible	I-Protein
factor	E-Protein
(	O
FIH	S-Protein
)	O
catalyses	O
the	O
hydroxylation	O
of	O
highly	O
conserved	O
Asn	O
-	O
residues	O
within	O
ankyrin	O
repeat	O
domains	O
(	O
ARDs	O
)	O
.	O

However	O
,	O
the	O
effect	O
of	O
Asn	O
-	O
hydroxylation	O
on	O
ARD	O
structure	O
is	O
unknown	O
.	O

Supporting	O
the	O
proposal	O
that	O
FIH	S-Protein
-	O
mediated	O
ARD	O
hydroxylation	O
is	O
ubiquitous	O
we	O
report	O
that	O
consensus	O
ARD	O
proteins	O
are	O
FIH	S-Protein
substrates	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

X	O
-	O
ray	O
diffraction	O
analyses	O
revealed	O
that	O
hydroxylation	O
does	O
not	O
alter	O
the	O
archetypical	O
ARD	O
conformation	O
in	O
the	O
crystalline	O
state	O
.	O

However	O
,	O
other	O
biophysical	O
analyses	O
revealed	O
that	O
hydroxylation	O
significantly	O
stabilizes	O
the	O
ARD	O
fold	O
in	O
solution	O
.	O

We	O
propose	O
that	O
intracellular	O
protein	O
hydroxylation	O
is	O
much	O
more	O
common	O
than	O
previously	O
thought	O
and	O
that	O
one	O
of	O
its	O
roles	O
is	O
stabilization	O
of	O
localized	O
regions	O
of	O
ARD	O
folds	O
.	O

Recessive	O
osteogenesis	O
imperfecta	O
caused	O
by	O
LEPRE1	S-Protein
mutations	O
:	O
clinical	O
documentation	O
and	O
identification	O
of	O
the	O
splice	O
form	O
responsible	O
for	O
prolyl	O
3	O
-	O
hydroxylation	O
.	O

BACKGROUND	O
:	O
Recessive	O
forms	O
of	O
osteogenesis	O
imperfecta	O
(	O
OI	O
)	O
may	O
be	O
caused	O
by	O
mutations	O
in	O
LEPRE1	S-Protein
,	O
encoding	O
prolyl	B-Protein
3	I-Protein
-	I-Protein
hydroxylase	I-Protein
-	I-Protein
1	E-Protein
(	O
P3H1	S-Protein
)	O
or	O
in	O
CRTAP	S-Protein
,	O
encoding	O
cartilage	O
associated	O
protein	O
.	O

These	O
proteins	O
constitute	O
together	O
with	O
cyclophilin	B-Protein
B	E-Protein
(	O
CyPB	S-Protein
)	O
the	O
prolyl	O
3	O
-	O
hydroxylation	O
complex	O
that	O
hydroxylates	O
the	O
Pro986	O
residue	O
in	O
both	O
the	O
type	B-Protein
I	E-Protein
and	O
type	B-Protein
II	I-Protein
collagen	I-Protein
alpha1	I-Protein
-	I-Protein
chains	E-Protein
.	O

METHODS	O
:	O
We	O
screened	O
LEPRE1	S-Protein
,	O
CRTAP	S-Protein
and	O
PPIB	S-Protein
(	O
encoding	O
CyPB	S-Protein
)	O
in	O
a	O
European	O
/	O
Middle	O
Eastern	O
cohort	O
of	O
20	O
lethal	O
/	O
severe	O
OI	O
patients	O
without	O
a	O
type	O
I	O
collagen	O
mutation	O
.	O

RESULTS	O
:	O
Four	O
novel	O
homozygous	O
and	O
compound	O
heterozygous	O
mutations	O
were	O
identified	O
in	O
LEPRE1	S-Protein
in	O
four	O
probands	O
.	O

Two	O
probands	O
survived	O
the	O
neonatal	O
period	O
,	O
including	O
one	O
patient	O
who	O
is	O
the	O
eldest	O
reported	O
patient	O
(	O
17	O
7	O
/	O
12	O
years	O
)	O
so	O
far	O
with	O
P3H1	S-Protein
deficiency	O
.	O

At	O
birth	O
,	O
clinical	O
and	O
radiologic	O
features	O
were	O
hardly	O
distinguishable	O
from	O
those	O
in	O
patients	O
with	O
autosomal	O
dominant	O
(	O
AD	O
)	O
severe	O
/	O
lethal	O
OI	O
.	O

Follow	O
-	O
up	O
data	O
reveal	O
that	O
the	O
longer	O
lived	O
patients	O
develop	O
a	O
severe	O
osteochondrodysplasia	O
that	O
overlaps	O
with	O
,	O
but	O
has	O
some	O
distinctive	O
features	O
from	O
,	O
AD	O
OI	O
.	O

A	O
new	O
splice	O
site	O
mutation	O
was	O
identified	O
in	O
two	O
of	O
the	O
four	O
probands	O
,	O
affecting	O
only	O
one	O
of	O
three	O
LEPRE1	S-Protein
mRNA	O
splice	O
forms	O
,	O
detected	O
in	O
this	O
study	O
.	O

The	O
affected	O
splice	O
form	O
encodes	O
a	O
736	O
amino	O
acid	O
(	O
AA	O
)	O
protein	O
with	O
a	O
"	O
KDEL	O
"	O
endoplasmic	O
reticulum	O
retention	O
signal	O
.	O

While	O
western	O
blotting	O
and	O
immunocytochemical	O
analysis	O
of	O
fibroblast	O
cultures	O
revealed	O
absence	O
of	O
this	O
P3H1	S-Protein
protein	O
,	O
mass	O
spectrometry	O
and	O
SDS	O
-	O
urea	O
-	O
PAGE	O
data	O
showed	O
severe	O
reduction	O
of	O
alpha1	O
(	O
I	O
)	O
Pro986	O
3	O
-	O
hydroxylation	O
and	O
overmodification	O
of	O
type	O
I	O
(	O
pro	O
)	O
collagen	O
chains	O
in	O
skin	O
fibroblasts	O
of	O
the	O
patients	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
3	O
-	O
hydroxylation	O
function	O
of	O
P3H1	S-Protein
is	O
restricted	O
to	O
the	O
736AA	O
splice	O
form	O
.	O

Suppression	O
of	O
the	O
deubiquitinating	O
enzyme	O
USP5	S-Protein
causes	O
the	O
accumulation	O
of	O
unanchored	O
polyubiquitin	S-Protein
and	O
the	O
activation	O
of	O
p53	S-Protein
.	O

Both	O
p53	S-Protein
and	O
its	O
repressor	O
Mdm2	S-Protein
are	O
subject	O
to	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
.	O

We	O
show	O
that	O
knockdown	O
of	O
the	O
deubiquitinating	O
enzyme	O
USP5	S-Protein
(	O
isopeptidase	B-Protein
T	E-Protein
)	O
results	O
in	O
an	O
increase	O
in	O
the	O
level	O
and	O
transcriptional	O
activity	O
of	O
p53	S-Protein
.	O

Suppression	O
of	O
USP5	S-Protein
stabilizes	O
p53	S-Protein
,	O
whereas	O
it	O
has	O
little	O
or	O
no	O
effect	O
on	O
the	O
stability	O
of	O
Mdm2	S-Protein
.	O

This	O
provides	O
a	O
mechanism	O
for	O
transcriptional	O
activation	O
of	O
p53	S-Protein
.	O

USP5	S-Protein
knockdown	O
interferes	O
with	O
the	O
degradation	O
of	O
ubiquitinated	O
p53	S-Protein
rather	O
than	O
attenuating	O
p53	S-Protein
ubiquitination	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
a	O
preferred	O
substrate	O
for	O
USP5	S-Protein
is	O
unanchored	O
polyubiquitin	S-Protein
.	O

Consistent	O
with	O
this	O
,	O
we	O
observed	O
for	O
the	O
first	O
time	O
in	O
a	O
mammalian	O
system	O
that	O
USP5	S-Protein
makes	O
a	O
major	O
contribution	O
to	O
Lys	O
-	O
48	O
-	O
linked	O
polyubiquitin	S-Protein
disassembly	O
and	O
that	O
suppression	O
of	O
USP5	S-Protein
results	O
in	O
the	O
accumulation	O
of	O
unanchored	O
polyubiquitin	S-Protein
chains	O
.	O

Ectopic	O
expression	O
of	O
a	O
C	O
-	O
terminal	O
mutant	O
of	O
ubiquitin	S-Protein
(	O
G75A	O
/	O
G76A	O
)	O
,	O
which	O
also	O
causes	O
the	O
accumulation	O
of	O
free	O
polyubiquitin	S-Protein
,	O
recapitulates	O
the	O
effects	O
of	O
USP5	S-Protein
knockdown	O
on	O
the	O
p53	S-Protein
pathway	O
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
p53	S-Protein
is	O
selectively	O
stabilized	O
because	O
the	O
unanchored	O
polyubiquitin	S-Protein
that	O
accumulates	O
after	O
USP5	S-Protein
knockdown	O
is	O
able	O
to	O
compete	O
with	O
ubiquitinated	O
p53	S-Protein
but	O
not	O
with	O
Mdm2	S-Protein
for	O
proteasomal	O
recognition	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
there	O
are	O
significant	O
differences	O
in	O
proteasomal	O
recognition	O
of	O
p53	S-Protein
and	O
Mdm2	S-Protein
.	O

These	O
differences	O
could	O
be	O
exploited	O
therapeutically	O
.	O

Our	O
study	O
reveals	O
a	O
novel	O
mechanism	O
for	O
regulation	O
of	O
p53	S-Protein
and	O
identifies	O
USP5	S-Protein
as	O
a	O
potential	O
target	O
for	O
p53	S-Protein
activating	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

Deubiquitination	O
of	O
CXCR4	S-Protein
by	O
USP14	S-Protein
is	O
critical	O
for	O
both	O
CXCL12	S-Protein
-	O
induced	O
CXCR4	S-Protein
degradation	O
and	O
chemotaxis	O
but	O
not	O
ERK	O
ativation	O
.	O

The	O
chemokine	O
receptor	O
CXCR4	S-Protein
plays	O
important	O
roles	O
in	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

Abnormal	O
expression	O
of	O
CXCR4	S-Protein
contributes	O
to	O
cancer	O
and	O
inflammatory	O
and	O
neurodegenerative	O
disorders	O
.	O

Although	O
ligand	O
-	O
dependent	O
CXCR4	S-Protein
ubiquitination	O
is	O
known	O
to	O
accelerate	O
CXCR4	S-Protein
degradation	O
,	O
little	O
is	O
known	O
about	O
counter	O
mechanisms	O
for	O
receptor	O
deubiquitination	O
.	O

CXCL12	S-Protein
,	O
a	O
CXCR4	S-Protein
agonist	O
,	O
induces	O
a	O
time	O
-	O
dependent	O
association	O
of	O
USP14	S-Protein
with	O
CXCR4	S-Protein
,	O
or	O
its	O
C	O
terminus	O
,	O
that	O
is	O
not	O
mimicked	O
by	O
USP2A	S-Protein
,	O
USP4	S-Protein
,	O
or	O
USP7	S-Protein
,	O
other	O
members	O
of	O
the	O
deubiquitination	O
catalytic	O
family	O
.	O

Co	O
-	O
localization	O
of	O
CXCR4	S-Protein
and	O
USP14	S-Protein
also	O
is	O
time	O
-	O
dependent	O
following	O
CXCL12	S-Protein
stimulation	O
.	O

The	O
physical	O
interaction	O
of	O
CXCR4	S-Protein
and	O
USP14	S-Protein
is	O
paralleled	O
by	O
USP14	S-Protein
-	O
catalyzed	O
deubiquitination	O
of	O
the	O
receptor	O
;	O
knockdown	O
of	O
endogenous	O
USP14	S-Protein
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
blocks	O
CXCR4	S-Protein
deubiquitination	O
,	O
whereas	O
overexpression	O
of	O
USP14	S-Protein
promotes	O
CXCR4	S-Protein
deubiquitination	O
.	O

We	O
also	O
observed	O
that	O
ubiquitination	O
of	O
CXCR4	S-Protein
facilitated	O
receptor	O
degradation	O
,	O
whereas	O
overexpression	O
of	O
USP14	S-Protein
or	O
RNAi	O
-	O
induced	O
knockdown	O
of	O
USP14	S-Protein
blocked	O
CXCL12	S-Protein
-	O
mediated	O
CXCR4	S-Protein
degradation	O
.	O

Most	O
interestingly	O
,	O
CXCR4	S-Protein
-	O
mediated	O
chemotactic	O
cell	O
migration	O
was	O
blocked	O
by	O
either	O
overexpression	O
or	O
RNAi	O
-	O
mediated	O
knockdown	O
of	O
USP14	S-Protein
,	O
implying	O
that	O
a	O
CXCR4	S-Protein
-	O
ubiquitin	S-Protein
cycle	O
on	O
the	O
receptor	O
,	O
rather	O
than	O
a	O
particular	O
ubiquitinated	O
state	O
of	O
the	O
receptor	O
,	O
is	O
critical	O
for	O
the	O
ligand	O
gradient	O
sensing	O
and	O
directed	O
motility	O
required	O
for	O
chemokine	O
-	O
mediated	O
chemotaxis	O
.	O

Our	O
observation	O
that	O
a	O
mutant	O
of	O
CXCR4	S-Protein
,	O
HA	O
-	O
3K	O
/	O
R	O
CXCR4	S-Protein
,	O
which	O
cannot	O
be	O
ubiquitinated	O
and	O
does	O
not	O
mediate	O
a	O
chemotactic	O
response	O
to	O
CXCL12	S-Protein
,	O
indicates	O
the	O
importance	O
of	O
this	O
covalent	O
modification	O
not	O
only	O
in	O
marking	O
receptors	O
for	O
degradation	O
but	O
also	O
for	O
permitting	O
CXCR4	S-Protein
-	O
mediated	O
signaling	O
.	O

Finally	O
,	O
the	O
indistinguishable	O
activation	O
of	O
ERK	O
by	O
wild	O
typeor	O
3K	O
/	O
R	O
-	O
CXCR4	S-Protein
suggests	O
that	O
chemotaxis	O
in	O
response	O
to	O
CXCL12	S-Protein
may	O
be	O
independent	O
of	O
the	O
ERK	O
cascade	O
.	O

Direct	O
and	O
continuous	O
assay	O
for	O
prolyl	B-Protein
4	I-Protein
-	I-Protein
hydroxylase	E-Protein
.	O

Prolyl	B-Protein
4	I-Protein
-	I-Protein
hydroxylase	E-Protein
(	O
P4H	S-Protein
)	O
is	O
a	O
nonheme	O
iron	O
dioxygenase	O
that	O
catalyzes	O
the	O
posttranslational	O
hydroxylation	O
of	O
(	O
2S	O
)	O
-	O
proline	O
(	O
Pro	O
)	O
residues	O
in	O
protocollagen	S-Protein
strands	O
.	O

The	O
resulting	O
(	O
2S	O
,	O
4R	O
)	O
-	O
4	O
-	O
hydroxyproline	O
(	O
Hyp	O
)	O
residues	O
are	O
essential	O
for	O
the	O
folding	O
,	O
secretion	O
,	O
and	O
stability	O
of	O
the	O
collagen	S-Protein
triple	O
helix	O
.	O

P4H	S-Protein
uses	O
alpha	O
-	O
ketoglutarate	O
and	O
O2	O
as	O
cosubstrates	O
,	O
and	O
forms	O
succinate	O
and	O
CO2	O
as	O
well	O
as	O
Hyp	O
.	O

Described	O
herein	O
is	O
the	O
first	O
assay	O
for	O
P4H	S-Protein
that	O
continuously	O
and	O
directly	O
detects	O
turnover	O
of	O
the	O
proline	O
-	O
containing	O
substrate	O
.	O

This	O
assay	O
is	O
based	O
on	O
(	O
2S	O
,	O
4S	O
)	O
-	O
4	O
-	O
fluoroproline	O
(	O
flp	O
)	O
,	O
a	O
proline	O
analogue	O
that	O
is	O
transformed	O
into	O
(	O
2S	O
)	O
-	O
4	O
-	O
ketoproline	O
(	O
Kep	O
)	O
and	O
inorganic	O
fluoride	O
by	O
P4H	S-Protein
.	O

The	O
fluoride	O
ion	O
,	O
and	O
thus	O
turnover	O
by	O
P4H	S-Protein
,	O
is	O
detected	O
by	O
a	O
fluoride	O
ion	O
-	O
selective	O
electrode	O
.	O

Using	O
this	O
assay	O
,	O
steady	O
-	O
state	O
kinetic	O
parameters	O
for	O
the	O
human	O
P4H	S-Protein
-	O
catalyzed	O
turnover	O
of	O
a	O
flp	O
-	O
containing	O
peptide	O
were	O
determined	O
and	O
found	O
to	O
be	O
comparable	O
to	O
those	O
obtained	O
with	O
a	O
discontinuous	O
HPLC	O
-	O
based	O
assay	O
.	O

In	O
addition	O
,	O
this	O
assay	O
can	O
be	O
used	O
to	O
characterize	O
P4H	S-Protein
variants	O
,	O
as	O
demonstrated	O
by	O
a	O
comparison	O
of	O
catalysis	O
by	O
D414A	O
P4H	S-Protein
and	O
the	O
wild	O
-	O
type	O
enzyme	O
.	O

Finally	O
,	O
the	O
use	O
of	O
the	O
assay	O
to	O
identify	O
small	O
-	O
molecule	O
inhibitors	O
of	O
P4H	S-Protein
was	O
verified	O
by	O
an	O
analysis	O
of	O
catalysis	O
in	O
the	O
presence	O
of	O
2	O
,	O
4	O
-	O
pyridine	O
dicarboxylate	O
,	O
an	O
analogue	O
of	O
alpha	O
-	O
ketoglutarate	O
.	O

Thus	O
,	O
the	O
assay	O
described	O
herein	O
could	O
facilitate	O
biochemical	O
analyses	O
of	O
this	O
essential	O
enzyme	O
.	O

The	O
ubiquitin	S-Protein
-	O
editing	O
enzyme	O
A20	S-Protein
requires	O
RNF11	S-Protein
to	O
downregulate	O
NF	O
-	O
kappaB	O
signalling	O
.	O

The	O
RING	O
domain	O
protein	O
RNF11	S-Protein
is	O
overexpressed	O
in	O
breast	O
cancers	O
and	O
promotes	O
tumour	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
signalling	O
.	O

RNF11	S-Protein
has	O
been	O
proposed	O
to	O
regulate	O
TGF	O
-	O
beta	O
signalling	O
by	O
interacting	O
with	O
HECT	O
-	O
and	O
SCF	O
-	O
type	O
E3	O
ligases	O
;	O
however	O
,	O
the	O
role	O
of	O
RNF11	S-Protein
in	O
other	O
signalling	O
pathways	O
is	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
demonstrate	O
a	O
novel	O
function	O
of	O
RNF11	S-Protein
as	O
a	O
negative	O
regulator	O
of	O
NF	O
-	O
kappaB	O
and	O
jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
signalling	O
pathways	O
.	O

Knockdown	O
of	O
RNF11	S-Protein
with	O
siRNA	O
resulted	O
in	O
persistent	O
tumour	B-Protein
necrosis	I-Protein
factor	E-Protein
(	O
TNF	S-Protein
)	O
-	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
mediated	O
NF	O
-	O
kappaB	O
and	O
JNK	O
signalling	O
.	O

RNF11	S-Protein
interacted	O
with	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
A20	S-Protein
and	O
its	O
regulatory	O
protein	O
TAX1BP1	S-Protein
in	O
a	O
stimulus	O
-	O
dependent	O
manner	O
.	O

RNF11	S-Protein
negatively	O
regulated	O
RIP1	S-Protein
and	O
TRAF6	S-Protein
ubiquitination	O
upon	O
stimulation	O
with	O
TNF	S-Protein
and	O
LPS	O
,	O
respectively	O
.	O

Furthermore	O
,	O
RNF11	S-Protein
was	O
required	O
for	O
A20	S-Protein
to	O
interact	O
with	O
and	O
inactivate	O
RIP1	S-Protein
to	O
inhibit	O
TNF	S-Protein
-	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
.	O

Our	O
studies	O
reveal	O
that	O
RNF11	S-Protein
,	O
together	O
with	O
TAX1BP1	S-Protein
and	O
Itch	S-Protein
,	O
is	O
an	O
essential	O
component	O
of	O
an	O
A20	S-Protein
ubiquitin	S-Protein
-	O
editing	O
protein	O
complex	O
that	O
ensures	O
transient	O
activation	O
of	O
inflammatory	O
signalling	O
pathways	O
.	O

Circadian	O
rhythm	O
transcription	O
factor	O
CLOCK	S-Protein
regulates	O
the	O
transcriptional	O
activity	O
of	O
the	O
glucocorticoid	B-Protein
receptor	E-Protein
by	O
acetylating	O
its	O
hinge	O
region	O
lysine	O
cluster	O
:	O
potential	O
physiological	O
implications	O
.	O

Glucocorticoids	O
,	O
end	O
products	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
,	O
influence	O
functions	O
of	O
virtually	O
all	O
organs	O
and	O
tissues	O
through	O
the	O
glucocorticoid	B-Protein
receptor	E-Protein
(	O
GR	S-Protein
)	O
.	O

Circulating	O
levels	O
of	O
glucocorticoids	O
fluctuate	O
naturally	O
in	O
a	O
circadian	O
fashion	O
and	O
regulate	O
the	O
transcriptional	O
activity	O
of	O
GR	S-Protein
in	O
target	O
tissues	O
.	O

The	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
protein	O
CLOCK	S-Protein
,	O
a	O
histone	S-Protein
acetyltransferase	O
(	O
HAT	O
)	O
,	O
and	O
its	O
heterodimer	O
partner	O
BMAL1	S-Protein
are	O
self	O
-	O
oscillating	O
transcription	O
factors	O
that	O
generate	O
circadian	O
rhythms	O
in	O
both	O
the	O
central	O
nervous	O
system	O
and	O
periphery	O
.	O

We	O
found	O
that	O
CLOCK	S-Protein
/	O
BMAL1	S-Protein
repressed	O
GR	S-Protein
-	O
induced	O
transcriptional	O
activity	O
in	O
a	O
HAT	O
-	O
activity	O
-	O
dependent	O
fashion	O
.	O

In	O
serum	O
-	O
shock	O
-	O
synchronized	O
cells	O
,	O
transactivational	O
activity	O
of	O
GR	S-Protein
,	O
accessed	O
by	O
mRNA	O
expression	O
of	O
an	O
endogenous	O
-	O
responsive	O
gene	O
,	O
fluctuated	O
spontaneously	O
in	O
a	O
circadian	O
fashion	O
in	O
reverse	O
phase	O
with	O
CLOCK	S-Protein
/	O
BMAL1	S-Protein
mRNA	O
expression	O
.	O

CLOCK	S-Protein
and	O
GR	S-Protein
interacted	O
with	O
each	O
other	O
physically	O
,	O
and	O
CLOCK	S-Protein
suppressed	O
binding	O
of	O
GR	S-Protein
to	O
its	O
DNA	O
recognition	O
sequences	O
by	O
acetylating	O
multiple	O
lysine	O
residues	O
located	O
in	O
its	O
hinge	O
region	O
.	O

These	O
findings	O
indicate	O
that	O
CLOCK	S-Protein
/	O
BMAL1	S-Protein
functions	O
as	O
a	O
reverse	O
-	O
phase	O
negative	O
regulator	O
of	O
glucocorticoid	O
action	O
in	O
target	O
tissues	O
,	O
possibly	O
by	O
antagonizing	O
biological	O
actions	O
of	O
diurnally	O
fluctuating	O
circulating	O
glucocorticoids	O
.	O

Further	O
,	O
these	O
results	O
suggest	O
that	O
a	O
peripheral	O
target	O
tissue	O
circadian	O
rhythm	O
indirectly	O
influences	O
the	O
functions	O
of	O
every	O
organ	O
and	O
tissue	O
inside	O
the	O
body	O
through	O
modulation	O
of	O
the	O
ubiquitous	O
and	O
diverse	O
actions	O
of	O
glucocorticoids	O
.	O

FKBP25	S-Protein
,	O
a	O
novel	O
regulator	O
of	O
the	O
p53	S-Protein
pathway	O
,	O
induces	O
the	O
degradation	O
of	O
MDM2	S-Protein
and	O
activation	O
of	O
p53	S-Protein
.	O

The	O
p53	S-Protein
tumour	O
suppressor	O
protein	O
is	O
tightly	O
controlled	O
by	O
the	O
E3	O
ubiquitin	S-Protein
ligase	O
,	O
mouse	B-Protein
double	I-Protein
minute	I-Protein
2	E-Protein
(	O
MDM2	S-Protein
)	O
,	O
but	O
maintains	O
MDM2	S-Protein
expression	O
as	O
part	O
of	O
a	O
negative	O
feedback	O
loop	O
.	O

We	O
have	O
identified	O
the	O
immunophilin	O
,	O
25kDa	B-Protein
FK506	I-Protein
-	I-Protein
binding	I-Protein
protein	E-Protein
(	O
FKBP25	S-Protein
)	O
,	O
previously	O
shown	O
to	O
be	O
regulated	O
by	O
p53	S-Protein
-	O
mediated	O
repression	O
,	O
as	O
an	O
MDM2	S-Protein
-	O
interacting	O
partner	O
.	O

We	O
show	O
that	O
FKBP25	S-Protein
stimulates	O
auto	O
-	O
ubiquitylation	O
and	O
proteasomal	O
degradation	O
of	O
MDM2	S-Protein
,	O
leading	O
to	O
the	O
induction	O
of	O
p53	S-Protein
.	O

Depletion	O
of	O
FKBP25	S-Protein
by	O
siRNA	O
leads	O
to	O
increased	O
levels	O
of	O
MDM2	S-Protein
and	O
a	O
corresponding	O
reduction	O
in	O
p53	S-Protein
and	O
p21	S-Protein
levels	O
.	O

These	O
data	O
are	O
consistent	O
with	O
the	O
idea	O
that	O
FKBP25	S-Protein
contributes	O
to	O
regulation	O
of	O
the	O
p53	S-Protein
-	O
MDM2	S-Protein
negative	O
feedback	O
loop	O
.	O

Tolerance	O
induction	O
using	O
lentiviral	O
gene	O
delivery	O
delays	O
onset	O
and	O
severity	O
of	O
collagen	B-Protein
II	E-Protein
arthritis	O
.	O

The	O
treatment	O
of	O
rheumatoid	O
arthritis	O
remains	O
suboptimal	O
;	O
thus	O
there	O
is	O
considerable	O
interest	O
in	O
the	O
development	O
of	O
strategies	O
that	O
mediate	O
tolerance	O
to	O
autoantigens	O
.	O

Using	O
lentiviral	O
gene	O
transfer	O
in	O
vivo	O
,	O
we	O
expressed	O
the	O
immunodominant	O
epitope	O
of	O
collagen	B-Protein
type	I-Protein
II	E-Protein
(	O
CII	S-Protein
)	O
on	O
major	O
histocompatibility	O
complex	O
class	O
II	O
molecules	O
(	O
MHC	O
II	O
)	O
in	O
a	O
mouse	O
model	O
of	O
destructive	O
arthritis	O
.	O

A	O
sequence	O
corresponding	O
to	O
amino	O
acids	O
259	O
-	O
270	O
of	O
CII	S-Protein
was	O
fused	O
into	O
the	O
class	B-Protein
II	I-Protein
-	I-Protein
associated	I-Protein
invariant	I-Protein
chain	I-Protein
peptide	E-Protein
(	O
CLIP	S-Protein
)	O
position	O
of	O
the	O
invariant	O
chain	O
to	O
achieve	O
efficient	O
binding	O
to	O
MHC	O
II	O
.	O

Transduction	O
of	O
cloned	O
cells	O
and	O
primary	O
antigen	O
-	O
presenting	O
cells	O
(	O
APCs	O
)	O
in	O
vitro	O
demonstrated	O
successful	O
presentation	O
of	O
the	O
peptide	O
on	O
MHC	O
II	O
,	O
and	O
a	O
physiological	O
glycosylation	O
pattern	O
.	O

Compared	O
with	O
controls	O
,	O
mice	O
intravenously	O
injected	O
with	O
lentiviral	O
vectors	O
encoding	O
this	O
epitope	O
displayed	O
significantly	O
less	O
frequent	O
,	O
less	O
severe	O
,	O
and	O
less	O
destructive	O
arthritis	O
,	O
decreased	O
lymphocyte	O
proliferation	O
in	O
response	O
to	O
restimulation	O
with	O
CII	S-Protein
,	O
and	O
lower	O
CII	S-Protein
-	O
specific	O
antibody	O
levels	O
.	O

This	O
was	O
associated	O
with	O
an	O
increased	O
production	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
in	O
vitro	O
.	O

We	O
suggest	O
that	O
overexpression	O
of	O
the	O
immunodominant	O
CII	S-Protein
epitope	O
on	O
MHC	O
II	O
induces	O
T	O
cell	O
production	O
of	O
TGF	O
-	O
beta	O
and	O
leads	O
to	O
inhibition	O
of	O
arthritis	O
by	O
means	O
of	O
both	O
antigen	O
-	O
specific	O
and	O
bystander	O
mechanisms	O
.	O

Thus	O
,	O
antigen	O
-	O
specific	O
tolerance	O
induction	O
using	O
lentiviral	O
gene	O
delivery	O
can	O
ameliorate	O
arthritis	O
.	O

O	O
-	O
linked	O
N	O
-	O
acetylglucosaminylation	O
of	O
Sp1	S-Protein
inhibits	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
promoter	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
gene	O
expression	O
and	O
replication	O
are	O
regulated	O
by	O
the	O
promoter	O
/	O
enhancer	O
located	O
in	O
the	O
U3	O
region	O
of	O
the	O
proviral	O
5	O
'	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

The	O
binding	O
of	O
cellular	O
transcription	O
factors	O
to	O
specific	O
regulatory	O
sites	O
in	O
the	O
5	O
'	O
LTR	O
is	O
a	O
key	O
event	O
in	O
the	O
replication	O
cycle	O
of	O
HIV	O
-	O
1	O
.	O

Since	O
transcriptional	O
activity	O
is	O
regulated	O
by	O
the	O
posttranslational	O
modification	O
of	O
transcription	O
factors	O
with	O
the	O
monosaccharide	O
O	O
-	O
linked	O
N	O
-	O
acetyl	O
-	O
D	O
-	O
glucosamine	O
(	O
O	O
-	O
GlcNAc	O
)	O
,	O
we	O
evaluated	O
whether	O
increased	O
O	O
-	O
GlcNAcylation	O
affects	O
HIV	O
-	O
1	O
transcription	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrate	O
that	O
treatment	O
of	O
HIV	O
-	O
1	O
-	O
infected	O
lymphocytes	O
with	O
the	O
O	O
-	O
GlcNAcylation	O
-	O
enhancing	O
agent	O
glucosamine	O
(	O
GlcN	O
)	O
repressed	O
viral	O
transcription	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Overexpression	O
of	O
O	B-Protein
-	I-Protein
GlcNAc	I-Protein
transferase	E-Protein
(	O
OGT	S-Protein
)	O
,	O
the	O
sole	O
known	O
enzyme	O
catalyzing	O
the	O
addition	O
of	O
O	O
-	O
GlcNAc	O
to	O
proteins	O
,	O
specifically	O
inhibited	O
the	O
activity	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
promoter	O
in	O
different	O
T	O
-	O
cell	O
lines	O
and	O
in	O
primary	O
CD4	S-Protein
(	O
+	O
)	O
T	O
lymphocytes	O
.	O

Inhibition	O
of	O
HIV	O
-	O
1	O
LTR	O
activity	O
in	O
infected	O
T	O
cells	O
was	O
most	O
efficient	O
(	O
>	O
95	O
%	O
)	O
when	O
OGT	S-Protein
was	O
recombinantly	O
overexpressed	O
prior	O
to	O
infection	O
.	O

O	O
-	O
GlcNAcylation	O
of	O
the	O
transcription	O
factor	O
Sp1	S-Protein
and	O
the	O
presence	O
of	O
Sp1	S-Protein
-	O
binding	O
sites	O
in	O
the	O
LTR	O
were	O
found	O
to	O
be	O
crucial	O
for	O
this	O
inhibitory	O
effect	O
.	O

From	O
this	O
study	O
,	O
we	O
conclude	O
that	O
O	O
-	O
GlcNAcylation	O
of	O
Sp1	S-Protein
inhibits	O
the	O
activity	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
promoter	O
.	O

Modulation	O
of	O
Sp1	S-Protein
O	O
-	O
GlcNAcylation	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
HIV	O
-	O
1	O
latency	O
and	O
activation	O
and	O
links	O
viral	O
replication	O
to	O
the	O
glucose	O
metabolism	O
of	O
the	O
host	O
cell	O
.	O

Hence	O
,	O
the	O
establishment	O
of	O
a	O
metabolic	O
treatment	O
might	O
supplement	O
the	O
repertoire	O
of	O
antiretroviral	O
therapies	O
against	O
AIDS	O
.	O

Macrosialin	S-Protein
,	O
a	O
macrophage	O
-	O
restricted	O
membrane	O
sialoprotein	O
differentially	O
glycosylated	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
.	O

Rat	O
monoclonal	O
antibody	O
FA	O
/	O
11	O
has	O
been	O
used	O
to	O
identify	O
macrosialin	S-Protein
,	O
a	O
sialoglycoprotein	O
confined	O
to	O
murine	O
mononuclear	O
phagocytes	O
and	O
related	O
cells	O
.	O

Originally	O
identified	O
as	O
a	O
macrophage	O
-	O
associated	O
glycoprotein	O
predominantly	O
localized	O
in	O
intracellular	O
membranes	O
(	O
Smith	O
,	O
M	O
.	O
J	O
.	O
,	O
and	O
G	O
.	O
L	O
.	O
E	O
.	O
Koch	O
.	O
1987	O
.	O
J	O
.	O
Cell	O
Sci	O
.	O
87	O
:	O
113	O
)	O
,	O
the	O
antigen	O
is	O
widely	O
expressed	O
on	O
tissue	O
macrophages	O
,	O
including	O
those	O
in	O
lymphoid	O
areas	O
,	O
and	O
is	O
expressed	O
at	O
low	O
levels	O
on	O
isolated	O
dendritic	O
cells	O
.	O

Immuno	O
-	O
adsorption	O
experiments	O
reported	O
here	O
show	O
that	O
macrosialin	S-Protein
is	O
identical	O
to	O
the	O
major	O
87	O
-	O
115	O
-	O
kD	O
sialoglycoprotein	O
previously	O
identified	O
by	O
lectin	O
blotting	O
in	O
exudate	O
but	O
not	O
resident	O
peritoneal	O
macrophages	O
(	O
Rabinowitz	O
,	O
S	O
.	O
,	O
and	O
S	O
.	O
Gordon	O
.	O
1989	O
.	O
J	O
.	O
Cell	O
Sci	O
.	O
93	O
:	O
623	O
)	O
.	O

Resident	O
peritoneal	O
macrophages	O
express	O
low	O
levels	O
of	O
macrosialin	S-Protein
antigen	O
in	O
a	O
glycoform	O
that	O
does	O
not	O
bind	O
125I	O
wheat	O
germ	O
agglutinin	O
or	O
125I	O
peanut	O
agglutinin	S-Protein
;	O
inflammatory	O
stimuli	O
upregulate	O
expression	O
of	O
this	O
antigen	O
(	O
up	O
to	O
17	O
-	O
fold	O
)	O
,	O
in	O
an	O
alternative	O
glycoform	O
that	O
is	O
detected	O
by	O
these	O
lectins	O
.	O

Pulse	O
-	O
chase	O
experiments	O
reveal	O
a	O
44	O
-	O
kD	O
core	O
peptide	O
that	O
initially	O
bears	O
high	O
-	O
mannose	O
chains	O
(	O
giving	O
Mr	O
66	O
kD	O
)	O
and	O
is	O
subsequently	O
processed	O
to	O
a	O
mature	O
protein	O
of	O
Mr	O
87	O
-	O
104	O
kD	O
.	O

Each	O
glycoform	O
contains	O
N	O
-	O
linked	O
glycan	O
,	O
as	O
well	O
as	O
O	O
-	O
linked	O
sugar	O
structures	O
that	O
show	O
alternative	O
processing	O
.	O

Poly	O
-	O
N	O
-	O
acetyllactosamine	O
structures	O
are	O
detected	O
in	O
the	O
exudate	O
cell	O
glycoform	O
only	O
.	O

This	O
new	O
marker	O
for	O
mononuclear	O
phagocytes	O
illustrates	O
two	O
strategies	O
by	O
which	O
macrophages	O
remodel	O
their	O
membranes	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
.	O

Its	O
predominantly	O
intracellular	O
location	O
and	O
restricted	O
cell	O
distribution	O
suggest	O
a	O
possible	O
role	O
in	O
membrane	O
fusion	O
or	O
antigen	O
processing	O
.	O

Protein	O
phosphatase	O
2A	O
contributes	O
to	O
the	O
cardiac	O
dysfunction	O
induced	O
by	O
endotoxemia	O
.	O

AIMS	O
:	O
Sepsis	O
-	O
associated	O
cardiac	O
dysfunction	O
represents	O
an	O
intrinsic	O
impairment	O
of	O
cardiomyocyte	O
function	O
due	O
in	O
part	O
to	O
a	O
decrease	O
in	O
myofilament	O
Ca	O
(	O
2	O
+	O
)	O
sensitivity	O
associated	O
with	O
a	O
sustained	O
increase	O
in	O
cardiac	B-Protein
troponin	I-Protein
I	E-Protein
(	O
cTnI	S-Protein
)	O
phosphorylation	O
at	O
Ser23	O
/	O
24	O
.	O

Dephosphorylation	O
of	O
cTnI	S-Protein
is	O
under	O
regulatory	O
control	O
.	O

Thus	O
,	O
muscarinic	O
and	O
adenosine	B-Protein
A	I-Protein
(	I-Protein
1	I-Protein
)	I-Protein
-	I-Protein
receptor	E-Protein
agonists	O
antagonize	O
beta	O
-	O
adrenergic	O
stimulation	O
via	O
activation	O
of	O
protein	O
phosphatase	O
2A	O
(	O
PP2A	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
modulation	O
of	O
PP2A	O
and	O
thus	O
cTnI	S-Protein
phosphorylation	O
could	O
improve	O
sepsis	O
-	O
induced	O
contractile	O
dysfunction	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Cardiomyocytes	O
were	O
isolated	O
from	O
control	O
or	O
septic	O
mice	O
16	O
-	O
18	O
h	O
after	O
an	O
injection	O
of	O
vehicle	O
or	O
lipopolysaccharide	O
(	O
LPS	O
;	O
9	O
mg	O
/	O
kg	O
ip	O
)	O
respectively	O
.	O

Protein	O
expression	O
and	O
phosphatase	O
activity	O
were	O
determined	O
in	O
homogenates	O
of	O
control	O
and	O
septic	O
hearts	O
.	O

Our	O
data	O
showed	O
that	O
LPS	O
significantly	O
increased	O
cTnI	S-Protein
phosphorylation	O
at	O
Ser23	O
/	O
24	O
in	O
cardiomyocytes	O
and	O
reduced	O
contraction	O
amplitude	O
without	O
affecting	O
Ca	O
(	O
2	O
+	O
)	O
-	O
transients	O
.	O

Treatment	O
of	O
cardiomyocytes	O
with	O
the	O
A	O
(	O
1	O
)	O
agonist	O
cyclopentyladenosine	O
(	O
CPA	O
)	O
or	O
the	O
protein	O
kinase	O
A	O
inhibitor	O
H89	O
significantly	O
attenuated	O
the	O
LPS	O
-	O
induced	O
contractile	O
dysfunction	O
without	O
effect	O
on	O
Ca	O
(	O
2	O
+	O
)	O
-	O
transients	O
.	O

Co	O
-	O
treatment	O
with	O
CPA	O
and	O
H89	O
completely	O
reversed	O
the	O
contractile	O
dysfunction	O
.	O

Increased	O
cTnI	S-Protein
phosphorylation	O
in	O
septic	O
hearts	O
was	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
the	O
protein	O
expression	O
of	O
both	O
the	O
catalytic	O
and	O
regulatory	O
subunits	O
(	O
B56	B-Protein
alpha	E-Protein
)	O
of	O
PP2A	O
and	O
a	O
decrease	O
in	O
PP2A	O
activity	O
.	O

CPA	O
treatment	O
of	O
septic	O
hearts	O
increased	O
PP2A	O
activity	O
.	O

An	O
increase	O
in	O
the	O
protein	O
expression	O
of	O
demethylated	O
PP2A	O
and	O
a	O
decrease	O
in	O
the	O
PP2A	O
-	O
methyltransferase	O
(	O
PPMT	O
;	O
the	O
methyltransferase	O
that	O
catalyses	O
this	O
reaction	O
)	O
were	O
also	O
observed	O
.	O

CONCLUSION	O
:	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
sustained	O
cTnI	S-Protein
phosphorylation	O
underlies	O
the	O
contractile	O
dysfunction	O
seen	O
in	O
sepsis	O
.	O

Erythrocytosis	O
-	O
associated	O
HIF	B-Protein
-	I-Protein
2alpha	E-Protein
mutations	O
demonstrate	O
a	O
critical	O
role	O
for	O
residues	O
C	O
-	O
terminal	O
to	O
the	O
hydroxylacceptor	O
proline	O
.	O

A	O
classic	O
physiologic	O
response	O
to	O
hypoxia	O
in	O
humans	O
is	O
the	O
up	O
-	O
regulation	O
of	O
the	O
ERYTHROPOIETIN	S-Protein
(	O
EPO	S-Protein
)	O
gene	O
,	O
which	O
is	O
the	O
central	O
regulator	O
of	O
red	O
blood	O
cell	O
mass	O
.	O

The	O
EPO	S-Protein
gene	O
,	O
in	O
turn	O
,	O
is	O
activated	O
by	O
hypoxia	O
inducible	O
factor	O
(	O
HIF	O
)	O
.	O

HIF	O
is	O
a	O
transcription	O
factor	O
consisting	O
of	O
an	O
alpha	O
subunit	O
(	O
HIF	O
-	O
alpha	O
)	O
and	O
a	O
beta	O
subunit	O
(	O
HIF	B-Protein
-	I-Protein
beta	E-Protein
)	O
.	O

Under	O
normoxic	O
conditions	O
,	O
prolyl	O
hydroxylase	O
domain	O
protein	O
(	O
PHD	O
,	O
also	O
known	O
as	O
HIF	O
prolyl	O
hydroxylase	O
and	O
egg	O
laying	O
-	O
defective	O
nine	O
protein	O
)	O
site	O
specifically	O
hydroxylates	O
HIF	O
-	O
alpha	O
in	O
a	O
conserved	O
LXXLAP	O
motif	O
(	O
where	O
underlining	O
indicates	O
the	O
hydroxylacceptor	O
proline	O
)	O
.	O

This	O
provides	O
a	O
recognition	O
motif	O
for	O
the	O
von	B-Protein
Hippel	I-Protein
Lindau	E-Protein
protein	O
,	O
a	O
component	O
of	O
an	O
E3	O
ubiquitin	S-Protein
ligase	O
complex	O
that	O
targets	O
hydroxylated	O
HIF	O
-	O
alpha	O
for	O
degradation	O
.	O

Under	O
hypoxic	O
conditions	O
,	O
this	O
inherently	O
oxygen	O
-	O
dependent	O
modification	O
is	O
arrested	O
,	O
thereby	O
stabilizing	O
HIF	O
-	O
alpha	O
and	O
allowing	O
it	O
to	O
activate	O
the	O
EPO	S-Protein
gene	O
.	O

We	O
previously	O
identified	O
and	O
characterized	O
an	O
erythrocytosis	O
-	O
associated	O
HIF2A	S-Protein
mutation	O
,	O
G537W	O
.	O

More	O
recently	O
,	O
we	O
reported	O
two	O
additional	O
erythrocytosis	O
-	O
associated	O
HIF2A	S-Protein
mutations	O
,	O
G537R	O
and	O
M535V	O
.	O

Here	O
,	O
we	O
describe	O
the	O
functional	O
characterization	O
of	O
these	O
two	O
mutants	O
as	O
well	O
as	O
a	O
third	O
novel	O
erythrocytosis	O
-	O
associated	O
mutation	O
,	O
P534L	O
.	O

These	O
mutations	O
affect	O
residues	O
C	O
-	O
terminal	O
to	O
the	O
LXXLAP	O
motif	O
.	O

We	O
find	O
that	O
all	O
result	O
in	O
impaired	O
degradation	O
and	O
thus	O
aberrant	O
stabilization	O
of	O
HIF	B-Protein
-	I-Protein
2alpha	E-Protein
.	O

However	O
,	O
each	O
exhibits	O
a	O
distinct	O
profile	O
with	O
respect	O
to	O
their	O
effects	O
on	O
PHD2	S-Protein
binding	O
and	O
von	B-Protein
Hippel	I-Protein
Lindau	E-Protein
interaction	O
.	O

These	O
findings	O
reinforce	O
the	O
importance	O
of	O
HIF	B-Protein
-	I-Protein
2alpha	E-Protein
in	O
human	O
EPO	S-Protein
regulation	O
,	O
demonstrate	O
heterogeneity	O
of	O
functional	O
defects	O
arising	O
from	O
these	O
mutations	O
,	O
and	O
point	O
to	O
a	O
critical	O
role	O
for	O
residues	O
C	O
-	O
terminal	O
to	O
the	O
LXXLAP	O
motif	O
in	O
HIF	O
-	O
alpha	O
.	O

K63	O
-	O
specific	O
deubiquitination	O
by	O
two	O
JAMM	O
/	O
MPN	O
+	O
complexes	O
:	O
BRISC	O
-	O
associated	O
Brcc36	S-Protein
and	O
proteasomal	O
Poh1	S-Protein
.	O

An	O
unusual	O
deubiquitinating	O
(	O
DUB	O
)	O
activity	O
exists	O
in	O
HeLa	O
cell	O
extracts	O
that	O
is	O
highly	O
specific	O
for	O
cleaving	O
K63	O
-	O
linked	O
but	O
not	O
K48	O
-	O
linked	O
polyubiquitin	S-Protein
chains	O
.	O

The	O
activity	O
is	O
insensitive	O
to	O
both	O
N	O
-	O
ethyl	O
-	O
maleimide	O
and	O
ubiquitin	S-Protein
aldehyde	O
,	O
indicating	O
that	O
it	O
lacks	O
an	O
active	O
site	O
cysteine	O
residue	O
,	O
and	O
gel	O
filtration	O
experiments	O
show	O
that	O
it	O
resides	O
in	O
a	O
high	O
molecular	O
weight	O
(	O
approximately	O
600	O
kDa	O
)	O
complex	O
.	O

Using	O
a	O
biochemical	O
approach	O
,	O
we	O
found	O
that	O
the	O
K63	O
-	O
specific	O
DUB	O
activity	O
co	O
-	O
fractionated	O
through	O
seven	O
chromatographic	O
steps	O
with	O
three	O
multisubunit	O
complexes	O
:	O
the	O
19S	O
(	O
PA700	O
)	O
portion	O
of	O
the	O
26S	O
proteasome	O
,	O
the	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
and	O
a	O
novel	O
complex	O
that	O
includes	O
the	O
JAMM	O
/	O
MPN	O
+	O
domain	O
-	O
containing	O
protein	O
Brcc36	S-Protein
.	O

When	O
we	O
analysed	O
the	O
individual	O
complexes	O
,	O
we	O
found	O
that	O
the	O
activity	O
was	O
intrinsic	O
to	O
PA700	O
and	O
the	O
Brcc36	S-Protein
isopeptidase	O
complex	O
(	O
BRISC	O
)	O
,	O
but	O
that	O
the	O
CSN	O
-	O
associated	O
activity	O
was	O
due	O
entirely	O
to	O
an	O
interaction	O
with	O
Brcc36	S-Protein
.	O

None	O
of	O
the	O
complexes	O
cleave	O
K6	O
,	O
K11	O
,	O
K29	O
,	O
K48	O
or	O
alpha	O
-	O
linked	O
polyubiquitin	S-Protein
,	O
but	O
they	O
do	O
cleave	O
K63	O
linkages	O
within	O
mixed	O
-	O
linkage	O
chains	O
.	O

Our	O
results	O
suggest	O
that	O
specificity	O
for	O
K63	O
-	O
linked	O
polyubiquitin	S-Protein
is	O
a	O
common	O
property	O
of	O
the	O
JAMM	O
/	O
MPN	O
+	O
family	O
of	O
DUBs	O
.	O

Disease	O
-	O
associated	O
mutant	O
ubiquitin	S-Protein
causes	O
proteasomal	O
impairment	O
and	O
enhances	O
the	O
toxicity	O
of	O
protein	O
aggregates	O
.	O

Protein	O
homeostasis	O
is	O
critical	O
for	O
cellular	O
survival	O
and	O
its	O
dysregulation	O
has	O
been	O
implicated	O
in	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
and	O
other	O
neurodegenerative	O
disorders	O
.	O

Despite	O
the	O
growing	O
appreciation	O
of	O
the	O
pathogenic	O
mechanisms	O
involved	O
in	O
familial	O
forms	O
of	O
AD	O
,	O
much	O
less	O
is	O
known	O
about	O
the	O
sporadic	O
cases	O
.	O

Aggregates	O
found	O
in	O
both	O
familial	O
and	O
sporadic	O
AD	O
often	O
include	O
proteins	O
other	O
than	O
those	O
typically	O
associated	O
with	O
the	O
disease	O
.	O

One	O
such	O
protein	O
is	O
a	O
mutant	O
form	O
of	O
ubiquitin	S-Protein
,	O
UBB	S-Protein
+	O
1	O
,	O
a	O
frameshift	O
product	O
generated	O
by	O
molecular	O
misreading	O
of	O
a	O
wild	O
-	O
type	O
ubiquitin	S-Protein
gene	O
.	O

UBB	S-Protein
+	O
1	O
has	O
been	O
associated	O
with	O
multiple	O
disorders	O
.	O

UBB	S-Protein
+	O
1	O
cannot	O
function	O
as	O
a	O
ubiquitin	S-Protein
molecule	O
,	O
and	O
it	O
is	O
itself	O
a	O
substrate	O
for	O
degradation	O
by	O
the	O
ubiquitin	S-Protein
/	O
proteasome	O
system	O
(	O
UPS	O
)	O
.	O

Accumulation	O
of	O
UBB	S-Protein
+	O
1	O
impairs	O
the	O
proteasome	O
system	O
and	O
enhances	O
toxic	O
protein	O
aggregation	O
,	O
ultimately	O
resulting	O
in	O
cell	O
death	O
.	O

Here	O
,	O
we	O
describe	O
a	O
novel	O
model	O
system	O
to	O
investigate	O
how	O
UBB	S-Protein
+	O
1	O
impairs	O
UPS	O
function	O
and	O
whether	O
it	O
plays	O
a	O
causal	O
role	O
in	O
protein	O
aggregation	O
.	O

We	O
expressed	O
a	O
protein	O
analogous	O
to	O
UBB	S-Protein
+	O
1	O
in	O
yeast	O
(	O
Ub	S-Protein
(	O
ext	O
)	O
)	O
and	O
demonstrated	O
that	O
it	O
caused	O
UPS	O
impairment	O
.	O

Blocking	O
ubiquitination	O
of	O
Ub	S-Protein
(	O
ext	O
)	O
or	O
weakening	O
its	O
interactions	O
with	O
other	O
ubiquitin	S-Protein
-	O
processing	O
proteins	O
reduced	O
the	O
UPS	O
impairment	O
.	O

Expression	O
of	O
Ub	S-Protein
(	O
ext	O
)	O
altered	O
the	O
conjugation	O
of	O
wild	O
-	O
type	O
ubiquitin	S-Protein
to	O
a	O
UPS	O
substrate	O
.	O

The	O
expression	O
of	O
Ub	S-Protein
(	O
ext	O
)	O
markedly	O
enhanced	O
cellular	O
susceptibility	O
to	O
toxic	O
protein	O
aggregates	O
but	O
,	O
surprisingly	O
,	O
did	O
not	O
induce	O
or	O
alter	O
nontoxic	O
protein	O
aggregates	O
in	O
yeast	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
Ub	S-Protein
(	O
ext	O
)	O
interacts	O
with	O
more	O
than	O
one	O
protein	O
to	O
elicit	O
impairment	O
of	O
the	O
UPS	O
and	O
affect	O
protein	O
aggregate	O
toxicity	O
.	O

Furthermore	O
,	O
we	O
suggest	O
a	O
model	O
whereby	O
chronic	O
UPS	O
impairment	O
could	O
inflict	O
deleterious	O
consequences	O
on	O
proper	O
protein	O
aggregate	O
sequestration	O
.	O

Regulation	O
of	O
DNA	O
damage	O
response	O
pathways	O
by	O
the	O
cullin	O
-	O
RING	O
ubiquitin	S-Protein
ligases	O
.	O

Eukaryotic	O
cells	O
repair	O
ultraviolet	O
light	O
(	O
UV	O
)	O
-	O
and	O
chemical	O
carcinogen	O
-	O
induced	O
DNA	O
strand	O
-	O
distorting	O
damage	O
through	O
the	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
pathway	O
.	O

Concurrent	O
activation	O
of	O
the	O
DNA	O
damage	O
checkpoints	O
is	O
also	O
required	O
to	O
arrest	O
the	O
cell	O
cycle	O
and	O
allow	O
time	O
for	O
NER	O
action	O
.	O

Recent	O
studies	O
uncovered	O
critical	O
roles	O
for	O
ubiquitin	S-Protein
-	O
mediated	O
post	O
-	O
translational	O
modifications	O
in	O
controlling	O
both	O
NER	O
and	O
checkpoint	O
functions	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
recent	O
progress	O
in	O
delineating	O
the	O
roles	O
of	O
cullin	O
-	O
RING	O
E3	O
ubiquitin	S-Protein
ligases	O
in	O
orchestrating	O
the	O
cellular	O
DNA	O
damage	O
response	O
through	O
ubiquitination	O
of	O
NER	O
factors	O
,	O
histones	S-Protein
,	O
and	O
checkpoint	O
effectors	O
.	O

Histone	S-Protein
modifications	O
dictate	O
specific	O
biological	O
readouts	O
.	O

The	O
basic	O
unit	O
of	O
chromatin	O
is	O
the	O
nucleosomal	O
core	O
particle	O
,	O
containing	O
147	O
bp	O
of	O
DNA	O
that	O
wraps	O
twice	O
around	O
an	O
octamer	O
of	O
core	O
histones	S-Protein
.	O

The	O
core	O
histones	S-Protein
bear	O
a	O
highly	O
dynamic	O
N	O
-	O
terminal	O
amino	O
acid	O
tail	O
around	O
20	O
-	O
35	O
residues	O
in	O
length	O
and	O
rich	O
in	O
basic	O
amino	O
acids	O
.	O

These	O
tails	O
extending	O
from	O
the	O
surface	O
of	O
nucleosome	O
play	O
an	O
important	O
role	O
in	O
folding	O
of	O
nucleosomal	O
arrays	O
into	O
higher	O
order	O
chromatin	O
structure	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
eukaryotic	O
gene	O
regulation	O
.	O

The	O
amino	O
terminal	O
tails	O
protruding	O
from	O
the	O
nuclesomes	O
get	O
modified	O
by	O
the	O
addition	O
of	O
small	O
groups	O
such	O
as	O
methyl	O
,	O
acetyl	O
and	O
phosphoryl	O
groups	O
.	O

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
these	O
complex	O
modification	O
patterns	O
and	O
their	O
biological	O
functions	O
.	O

Moreover	O
,	O
these	O
modifications	O
seem	O
to	O
be	O
part	O
of	O
a	O
complex	O
scheme	O
where	O
distinct	O
histone	S-Protein
modifications	O
act	O
in	O
a	O
sequential	O
manner	O
or	O
in	O
combination	O
to	O
form	O
a	O
"	O
histone	S-Protein
code	O
"	O
read	O
by	O
other	O
proteins	O
to	O
control	O
the	O
structure	O
and	O
/	O
or	O
function	O
of	O
the	O
chromatin	O
fiber	O
.	O

Errors	O
in	O
this	O
histone	S-Protein
code	O
may	O
be	O
involved	O
in	O
many	O
human	O
diseases	O
especially	O
cancer	O
,	O
the	O
nature	O
of	O
which	O
could	O
be	O
therapeutically	O
exploited	O
.	O

Increasing	O
evidence	O
suggests	O
that	O
many	O
proteins	O
bear	O
multiple	O
,	O
distinct	O
modifications	O
,	O
and	O
the	O
ability	O
of	O
one	O
modification	O
to	O
antagonize	O
or	O
synergize	O
the	O
deposition	O
of	O
another	O
can	O
have	O
significant	O
biological	O
consequences	O
.	O

Epstein	B-Protein
-	I-Protein
Barr	I-Protein
virus	I-Protein
nuclear	I-Protein
antigen	I-Protein
3C	E-Protein
augments	O
Mdm2	S-Protein
-	O
mediated	O
p53	S-Protein
ubiquitination	O
and	O
degradation	O
by	O
deubiquitinating	O
Mdm2	S-Protein
.	O

Epstein	B-Protein
-	I-Protein
Barr	I-Protein
virus	I-Protein
(	I-Protein
EBV	I-Protein
)	I-Protein
nuclear	I-Protein
antigen	I-Protein
3C	E-Protein
(	O
EBNA3C	S-Protein
)	O
is	O
one	O
of	O
the	O
essential	O
latent	O
antigens	O
for	O
primary	O
B	O
-	O
cell	O
transformation	O
.	O

Previous	O
studies	O
established	O
that	O
EBNA3C	S-Protein
facilitates	O
degradation	O
of	O
several	O
vital	O
cell	O
cycle	O
regulators	O
,	O
including	O
the	O
retinoblastoma	S-Protein
(	O
pRb	S-Protein
)	O
and	O
p27	S-Protein
(	O
KIP	S-Protein
)	O
proteins	O
,	O
by	O
recruitment	O
of	O
the	O
SCF	O
(	O
Skp2	S-Protein
)	O
E3	O
ubiquitin	S-Protein
ligase	O
complex	O
.	O

EBNA3C	S-Protein
was	O
also	O
shown	O
to	O
be	O
ubiquitinated	O
at	O
its	O
N	O
-	O
terminal	O
residues	O
.	O

Furthermore	O
,	O
EBNA3C	S-Protein
can	O
bind	O
to	O
and	O
be	O
degraded	O
in	O
vitro	O
by	O
purified	O
20S	O
proteasomes	O
.	O

Surprisingly	O
,	O
in	O
lymphoblastoid	O
cell	O
lines	O
,	O
EBNA3C	S-Protein
is	O
extremely	O
stable	O
,	O
and	O
the	O
mechanism	O
for	O
this	O
stability	O
is	O
unknown	O
.	O

In	O
this	O
report	O
we	O
show	O
that	O
EBNA3C	S-Protein
can	O
function	O
as	O
a	O
deubiquitination	O
enzyme	O
capable	O
of	O
deubiquitinating	O
itself	O
in	O
vitro	O
as	O
well	O
as	O
in	O
vivo	O
.	O

Functional	O
mapping	O
using	O
deletion	O
and	O
point	O
mutational	O
analysis	O
showed	O
that	O
both	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
domains	O
of	O
EBNA3C	S-Protein
contribute	O
to	O
the	O
deubiquitination	O
activity	O
.	O

We	O
also	O
show	O
that	O
EBNA3C	S-Protein
efficiently	O
deubiquitinates	O
Mdm2	S-Protein
,	O
an	O
important	O
cellular	O
proto	O
-	O
oncogene	O
,	O
which	O
is	O
known	O
to	O
be	O
overexpressed	O
in	O
several	O
human	O
cancers	O
.	O

The	O
data	O
presented	O
here	O
further	O
demonstrate	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
EBNA3C	S-Protein
can	O
bind	O
to	O
the	O
acidic	O
domain	O
of	O
Mdm2	S-Protein
.	O

Additionally	O
,	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
EBNA3C	S-Protein
strongly	O
stabilizes	O
Mdm2	S-Protein
.	O

Importantly	O
,	O
EBNA3C	S-Protein
simultaneously	O
binds	O
to	O
both	O
Mdm2	S-Protein
and	O
p53	S-Protein
and	O
can	O
form	O
a	O
stable	O
ternary	O
complex	O
;	O
however	O
,	O
in	O
the	O
presence	O
of	O
p53	S-Protein
the	O
binding	O
affinity	O
of	O
Mdm2	S-Protein
toward	O
EBNA3C	S-Protein
was	O
significantly	O
reduced	O
,	O
suggesting	O
that	O
p53	S-Protein
and	O
Mdm2	S-Protein
might	O
share	O
a	O
common	O
overlapping	O
domain	O
of	O
EBNA3C	S-Protein
.	O

We	O
also	O
showed	O
that	O
EBNA3C	S-Protein
enhances	O
the	O
intrinsic	O
ubiquitin	O
ligase	O
activity	O
of	O
Mdm2	S-Protein
toward	O
p53	S-Protein
,	O
which	O
in	O
turn	O
facilitated	O
p53	S-Protein
ubiquitination	O
and	O
degradation	O
.	O

Thus	O
,	O
manipulation	O
of	O
the	O
oncoprotein	O
Mdm2	S-Protein
by	O
EBNA3C	S-Protein
potentially	O
provides	O
a	O
favorable	O
environment	O
for	O
transformation	O
and	O
proliferation	O
of	O
EBV	O
-	O
infected	O
cells	O
.	O

Genome	O
-	O
wide	O
profiling	O
of	O
histone	B-Protein
h3	E-Protein
lysine	O
4	O
and	O
lysine	O
27	O
trimethylation	O
reveals	O
an	O
epigenetic	O
signature	O
in	O
prostate	O
carcinogenesis	O
.	O

BACKGROUND	O
:	O
Increasing	O
evidence	O
implicates	O
the	O
critical	O
roles	O
of	O
epigenetic	O
regulation	O
in	O
cancer	O
.	O

Very	O
recent	O
reports	O
indicate	O
that	O
global	O
gene	O
silencing	O
in	O
cancer	O
is	O
associated	O
with	O
specific	O
epigenetic	O
modifications	O
.	O

However	O
,	O
the	O
relationship	O
between	O
epigenetic	O
switches	O
and	O
more	O
dynamic	O
patterns	O
of	O
gene	O
activation	O
and	O
repression	O
has	O
remained	O
largely	O
unknown	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
Genome	O
-	O
wide	O
profiling	O
of	O
the	O
trimethylation	O
of	O
histone	B-Protein
H3	E-Protein
lysine	O
4	O
(	O
H3K4me3	S-Protein
)	O
and	O
lysine	O
27	O
(	O
H3K27me3	S-Protein
)	O
was	O
performed	O
using	O
chromatin	O
immunoprecipitation	O
coupled	O
with	O
whole	O
genome	O
promoter	O
microarray	O
(	O
ChIP	O
-	O
chip	O
)	O
techniques	O
.	O

Comparison	O
of	O
the	O
ChIP	O
-	O
chip	O
data	O
and	O
microarray	O
gene	O
expression	O
data	O
revealed	O
that	O
loss	O
and	O
/	O
or	O
gain	O
of	O
H3K4me3	S-Protein
and	O
/	O
or	O
H3K27me3	S-Protein
were	O
strongly	O
associated	O
with	O
differential	O
gene	O
expression	O
,	O
including	O
microRNA	O
expression	O
,	O
between	O
prostate	O
cancer	O
and	O
primary	O
cells	O
.	O

The	O
most	O
common	O
switches	O
were	O
gain	O
or	O
loss	O
of	O
H3K27me3	S-Protein
coupled	O
with	O
low	O
effect	O
on	O
gene	O
expression	O
.	O

The	O
least	O
prevalent	O
switches	O
were	O
between	O
H3K4me3	S-Protein
and	O
H3K27me3	S-Protein
coupled	O
with	O
much	O
higher	O
fractions	O
of	O
activated	O
and	O
silenced	O
genes	O
.	O

Promoter	O
patterns	O
of	O
H3K4me3	S-Protein
and	O
H3K27me3	S-Protein
corresponded	O
strongly	O
with	O
coordinated	O
expression	O
changes	O
of	O
regulatory	O
gene	O
modules	O
,	O
such	O
as	O
HOX	O
and	O
microRNA	O
genes	O
,	O
and	O
structural	O
gene	O
modules	O
,	O
such	O
as	O
desmosome	O
and	O
gap	O
junction	O
genes	O
.	O

A	O
number	O
of	O
epigenetically	O
switched	O
oncogenes	O
and	O
tumor	O
suppressor	O
genes	O
were	O
found	O
overexpressed	O
and	O
underexpressed	O
accordingly	O
in	O
prostate	O
cancer	O
cells	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
This	O
work	O
offers	O
a	O
dynamic	O
picture	O
of	O
epigenetic	O
switches	O
in	O
carcinogenesis	O
and	O
contributes	O
to	O
an	O
overall	O
understanding	O
of	O
coordinated	O
regulation	O
of	O
gene	O
expression	O
in	O
cancer	O
.	O

Our	O
data	O
indicate	O
an	O
H3K4me3	S-Protein
/	O
H3K27me3	S-Protein
epigenetic	O
signature	O
of	O
prostate	O
carcinogenesis	O
.	O

Monoubiquitylation	O
in	O
the	O
Fanconi	O
anemia	O
DNA	O
damage	O
response	O
pathway	O
.	O

The	O
hereditary	O
genetic	O
disorder	O
Fanconi	O
anemia	O
(	O
FA	O
)	O
belongs	O
to	O
the	O
heterogeneous	O
group	O
of	O
diseases	O
associated	O
with	O
defective	O
DNA	O
damage	O
repair	O
.	O

Recently	O
,	O
several	O
reviews	O
have	O
discussed	O
the	O
FA	O
pathway	O
and	O
its	O
molecular	O
players	O
in	O
the	O
context	O
of	O
genome	O
maintenance	O
and	O
tumor	O
suppression	O
mechanisms	O
[	O
H	O
.	O

Joenje	O
,	O
K	O
.	O
J	O
.	O

Patel	O
,	O
The	O
emerging	O
genetic	O
and	O
molecular	O
basis	O
of	O
Fanconi	O
anaemia	O
,	O
Nat	O
.	O

Rev	O
.	O

Genet	O
.	O

2	O
(	O
2001	O
)	O
446	O
-	O
457	O
;	O
W	O
.	O

Wang	O
,	O
Emergence	O
of	O
a	O
DNA	O
-	O
damage	O
response	O
network	O
consisting	O
of	O
Fanconi	O
anaemia	O
and	O
BRCA	O
proteins	O
,	O
Nat	O
.	O

Rev	O
.	O

Genet	O
.	O

8	O
(	O
2007	O
)	O
735	O
-	O
748	O
;	O
L	O
.	O
J	O
.	O

8	O
(	O
2007	O
)	O
735	O
-	O
748	O
;	O
L	O
.	O
J	O
.	O

Niedernhofer	O
,	O
A	O
.	O
S	O
.	O

Lalai	O
,	O
J	O
.	O
H	O
.	O

Hoeijmakers	O
,	O
Fanconi	O
anemia	O
(	O
cross	O
)	O
linked	O
to	O
DNA	O
repair	O
,	O
Cell	O
123	O
(	O
2005	O
)	O
1191	O
-	O
1198	O
;	O
K	O
.	O
J	O
.	O

Patel	O
,	O
Fanconi	O
anemia	O
and	O
breast	O
cancer	O
susceptibility	O
,	O
Nat	O
.	O

Genet	O
.	O

39	O
(	O
2007	O
)	O
142	O
-	O
143	O
]	O
.	O

This	O
review	O
assesses	O
the	O
influence	O
of	O
post	O
-	O
translational	O
modification	O
by	O
ubiquitin	S-Protein
.	O

We	O
review	O
and	O
extract	O
the	O
key	O
features	O
of	O
the	O
enzymatic	O
cascade	O
required	O
for	O
the	O
monoubiquitylation	O
of	O
the	O
FANCD2	S-Protein
/	O
FANCI	S-Protein
complex	O
and	O
attempt	O
to	O
include	O
recent	O
findings	O
into	O
a	O
coherent	O
mechanism	O
.	O

As	O
this	O
part	O
of	O
the	O
FA	O
pathway	O
is	O
still	O
far	O
from	O
fully	O
understood	O
,	O
we	O
raise	O
several	O
points	O
that	O
must	O
be	O
addressed	O
in	O
future	O
studies	O
.	O

Mutational	O
uncoupling	O
of	O
the	O
role	O
of	O
Sus1	S-Protein
in	O
nuclear	O
pore	O
complex	O
targeting	O
of	O
an	O
mRNA	O
export	O
complex	O
and	O
histone	B-Protein
H2B	E-Protein
deubiquitination	O
.	O

Sus1	S-Protein
is	O
an	O
evolutionary	O
conserved	O
protein	O
that	O
functions	O
both	O
in	O
transcription	O
and	O
mRNA	O
export	O
and	O
has	O
been	O
proposed	O
to	O
contribute	O
to	O
coupling	O
these	O
processes	O
in	O
yeast	O
.	O

Sus1	S-Protein
mediates	O
its	O
different	O
roles	O
as	O
a	O
component	O
of	O
both	O
the	O
histone	B-Protein
H2B	E-Protein
deubiquitinating	O
module	O
(	O
Sus1	S-Protein
-	O
Sgf11	S-Protein
-	O
Ubp8	S-Protein
-	O
Sgf73	S-Protein
)	O
of	O
the	O
SAGA	O
(	O
Spt	S-Protein
-	O
Ada	S-Protein
-	O
Gcn5	S-Protein
acetyltransferase	O
)	O
transcriptional	O
co	O
-	O
activator	O
and	O
the	O
mRNA	O
export	O
complex	O
,	O
TREX	O
-	O
2	O
(	O
Sus1	S-Protein
-	O
Sac3	S-Protein
-	O
Thp1	S-Protein
-	O
Cdc31	S-Protein
)	O
.	O

We	O
have	O
dissected	O
the	O
different	O
functions	O
of	O
Sus1	S-Protein
with	O
respect	O
to	O
its	O
partitioning	O
in	O
transcription	O
and	O
export	O
complexes	O
using	O
a	O
mutational	O
approach	O
.	O

Here	O
we	O
show	O
that	O
the	O
sus1	S-Protein
-	O
10	O
(	O
E18A	O
,	O
S19A	O
,	O
and	O
G20A	O
)	O
and	O
sus1	S-Protein
-	O
12	O
(	O
V73A	O
and	O
D75A	O
)	O
alleles	O
of	O
Sus1	S-Protein
can	O
be	O
dissociated	O
from	O
TREX	O
-	O
2	O
while	O
leaving	O
its	O
interaction	O
with	O
SAGA	O
largely	O
intact	O
.	O

Conversely	O
,	O
the	O
binding	O
to	O
both	O
TREX	O
-	O
2	O
and	O
SAGA	O
was	O
impaired	O
in	O
the	O
sus1	S-Protein
-	O
11	O
allele	O
(	O
G37A	O
and	O
W38A	O
)	O
,	O
in	O
which	O
two	O
highly	O
conserved	O
residues	O
were	O
mutated	O
.	O

In	O
vitro	O
experiments	O
demonstrated	O
that	O
dissociation	O
of	O
mutant	O
Sus1	S-Protein
from	O
its	O
partners	O
is	O
caused	O
by	O
a	O
reduced	O
affinity	O
toward	O
the	O
TREX	O
-	O
2	O
subunit	O
,	O
Sac3	S-Protein
,	O
and	O
the	O
SAGA	O
factor	O
,	O
Sgf11	S-Protein
,	O
respectively	O
.	O

Consistent	O
with	O
the	O
biochemical	O
data	O
,	O
these	O
sus1	S-Protein
mutant	O
alleles	O
showed	O
differential	O
genetic	O
relationships	O
with	O
SAGA	O
and	O
mRNA	O
export	O
mutants	O
.	O

In	O
vivo	O
,	O
all	O
three	O
sus1	S-Protein
mutants	O
were	O
impaired	O
in	O
targeting	O
TREX	O
-	O
2	O
(	O
i	O
.	O
e	O
.	O
Sac3	S-Protein
)	O
to	O
the	O
nuclear	O
pore	O
complexes	O
and	O
exhibited	O
nuclear	O
mRNA	O
export	O
defects	O
.	O

This	O
study	O
has	O
implications	O
for	O
how	O
Sus1	S-Protein
,	O
in	O
combination	O
with	O
distinct	O
interaction	O
partners	O
,	O
can	O
regulate	O
diverse	O
aspects	O
of	O
gene	O
expression	O
.	O

Ischemia	B-Protein
-	I-Protein
reperfusion	I-Protein
-	I-Protein
inducible	I-Protein
protein	E-Protein
modulates	O
cell	O
sensitivity	O
to	O
anticancer	O
drugs	O
by	O
regulating	O
activity	O
of	O
efflux	O
transporter	O
.	O

Human	O
ischemia	B-Protein
-	I-Protein
reperfusion	I-Protein
-	I-Protein
inducible	I-Protein
protein	E-Protein
(	O
hIRIP	S-Protein
)	O
or	O
hYrdC	S-Protein
belongs	O
to	O
the	O
SUA5	S-Protein
/	O
YrdC	S-Protein
/	O
YciO	S-Protein
protein	O
family	O
and	O
affects	O
activity	O
of	O
a	O
variety	O
of	O
cellular	O
transporters	O
.	O

We	O
observed	O
that	O
overexpression	O
of	O
wild	O
-	O
type	O
or	O
dominant	O
-	O
negative	O
mutant	O
of	O
hIRIP	S-Protein
protein	O
affects	O
the	O
cellular	O
sensitivity	O
to	O
anticancer	O
drugs	O
with	O
different	O
mechanisms	O
of	O
toxicity	O
.	O

Here	O
we	O
investigated	O
in	O
detail	O
the	O
effect	O
of	O
hIRIP	S-Protein
on	O
cell	O
sensitivity	O
to	O
doxorubicin	O
and	O
show	O
that	O
hIRIP	S-Protein
inhibits	O
the	O
drug	O
efflux	O
.	O

Multidrug	O
-	O
resistant	O
P	O
-	O
glycoprotein	O
was	O
identified	O
as	O
one	O
of	O
the	O
target	O
transporters	O
.	O

IRIP	S-Protein
does	O
not	O
influence	O
P	O
-	O
glycoprotein	O
biosynthesis	O
but	O
affects	O
its	O
processing	O
and	O
promotes	O
degradation	O
.	O

We	O
also	O
show	O
that	O
P	O
-	O
glycoprotein	O
is	O
associated	O
with	O
COP	B-Protein
-	I-Protein
alpha	E-Protein
,	O
one	O
of	O
the	O
proteins	O
of	O
the	O
COPI	O
complex	O
.	O

This	O
interaction	O
is	O
sensitive	O
to	O
the	O
level	O
of	O
hIRIP	S-Protein
expression	O
.	O

These	O
findings	O
suggest	O
that	O
hIRIP	S-Protein
expression	O
can	O
regulate	O
cargo	O
assembly	O
and	O
function	O
of	O
efflux	O
transporters	O
,	O
including	O
P	O
-	O
glycoprotein	O
,	O
which	O
mediates	O
one	O
of	O
the	O
most	O
common	O
mechanisms	O
of	O
the	O
multidrug	O
resistance	O
.	O

Protein	O
kinase	O
DYRK2	S-Protein
is	O
a	O
scaffold	O
that	O
facilitates	O
assembly	O
of	O
an	O
E3	O
ligase	O
.	O

Protein	O
kinases	O
have	O
central	O
functions	O
in	O
various	O
cellular	O
signal	O
transduction	O
pathways	O
through	O
their	O
substrate	O
phosphorylation	O
.	O

Here	O
we	O
show	O
that	O
a	O
protein	O
kinase	O
,	O
DYRK2	S-Protein
,	O
has	O
unexpected	O
role	O
as	O
a	O
scaffold	O
for	O
an	O
E3	O
ubiquitin	S-Protein
ligase	O
complex	O
.	O

DYRK2	S-Protein
associates	O
with	O
an	O
E3	O
ligase	O
complex	O
containing	O
EDD	S-Protein
,	O
DDB1	S-Protein
and	O
VPRBP	S-Protein
proteins	O
(	O
EDVP	O
complex	O
)	O
.	O

Strikingly	O
,	O
DYRK2	S-Protein
serves	O
as	O
a	O
scaffold	O
for	O
the	O
EDVP	O
complex	O
,	O
because	O
small	O
-	O
interfering	O
-	O
RNA	O
-	O
mediated	O
depletion	O
of	O
DYRK2	S-Protein
disrupts	O
the	O
formation	O
of	O
the	O
EDD	S-Protein
-	O
DDB1	S-Protein
-	O
VPRBP	S-Protein
complex	O
.	O

Although	O
the	O
kinase	O
activity	O
of	O
DYRK2	S-Protein
is	O
dispensable	O
for	O
its	O
ability	O
to	O
mediate	O
EDVP	O
complex	O
formation	O
,	O
it	O
is	O
required	O
for	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
its	O
downstream	O
substrate	O
,	O
katanin	B-Protein
p60	E-Protein
.	O

Collectively	O
,	O
our	O
results	O
reveal	O
a	O
new	O
type	O
of	O
E3	O
-	O
ubiquitin	S-Protein
ligase	O
complex	O
in	O
humans	O
that	O
depends	O
on	O
a	O
protein	O
kinase	O
for	O
complex	O
formation	O
as	O
well	O
as	O
for	O
the	O
subsequent	O
phosphorylation	O
,	O
ubiquitylation	O
and	O
degradation	O
of	O
their	O
substrates	O
.	O

Aberrant	O
histone	S-Protein
modifications	O
at	O
the	O
thyrotropin	B-Protein
-	I-Protein
releasing	I-Protein
hormone	E-Protein
gene	O
in	O
resistance	O
to	O
thyroid	O
hormone	O
:	O
analysis	O
of	O
F455S	O
mutant	O
thyroid	O
hormone	O
receptor	O
.	O

We	O
reported	O
a	O
novel	O
mutation	O
of	O
thyroid	B-Protein
hormone	I-Protein
receptor	I-Protein
(	I-Protein
TR	I-Protein
)	I-Protein
-	I-Protein
beta	E-Protein
,	O
F455S	O
,	O
in	O
a	O
patient	O
with	O
pituitary	O
resistance	O
to	O
thyroid	O
hormone	O
(	O
RTH	O
)	O
,	O
who	O
showed	O
impaired	O
release	O
of	O
nuclear	O
receptor	O
corepressor	O
and	O
abnormal	O
histone	S-Protein
deacetylation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
further	O
analyzed	O
the	O
histone	S-Protein
modifications	O
and	O
the	O
dynamics	O
of	O
TR	O
and	O
RNA	O
polymerase	O
II	O
on	O
the	O
TRH	S-Protein
gene	O
.	O

The	O
lysine	O
residues	O
9	O
(	O
H3K9	O
)	O
and	O
14	O
(	O
K14	O
)	O
of	O
the	O
histone	B-Protein
H3	E-Protein
were	O
acetylated	O
in	O
the	O
absence	O
of	O
thyroid	O
hormone	O
(	O
TH	O
)	O
,	O
and	O
addition	O
of	O
TH	O
caused	O
a	O
temporary	O
deacetylation	O
of	O
both	O
residues	O
.	O

Although	O
H3K4	S-Protein
was	O
di	O
-	O
and	O
trimethylated	O
in	O
the	O
absence	O
of	O
T	O
(	O
3	O
)	O
,	O
no	O
methylation	O
of	O
H3K9	S-Protein
or	O
K27	O
was	O
detected	O
.	O

Long	O
-	O
term	O
incubation	O
with	O
T	O
(	O
3	O
)	O
decreased	O
the	O
level	O
of	O
trimethylated	O
H3K4	S-Protein
,	O
the	O
amount	O
of	O
TR	O
,	O
and	O
the	O
level	O
of	O
phosphorylated	O
RNA	O
polymerase	O
II	O
but	O
not	O
dimethylated	O
H3K4	S-Protein
.	O

Treatment	O
with	O
an	O
inhibitor	O
for	O
H3K4	S-Protein
methyltransferase	O
,	O
5	O
'	O
-	O
deoxy	O
-	O
5	O
'	O
-	O
methylthioadenosine	O
,	O
decreased	O
basal	O
promoter	O
activity	O
but	O
did	O
not	O
affect	O
the	O
repression	O
by	O
TH	O
.	O

Conversely	O
,	O
overexpression	O
of	O
MLL	S-Protein
,	O
an	O
H3K4	S-Protein
-	O
specific	O
methyltransferase	O
,	O
caused	O
an	O
increase	O
in	O
basal	O
activity	O
.	O

In	O
the	O
presence	O
of	O
F455S	O
,	O
methylation	O
of	O
H3K4	S-Protein
and	O
the	O
dynamics	O
of	O
TR	O
were	O
intact	O
,	O
but	O
both	O
H3K9	S-Protein
and	O
H3K14	S-Protein
were	O
hyperacetylated	O
,	O
and	O
T	O
(	O
3	O
)	O
-	O
induced	O
deacetylation	O
was	O
impaired	O
,	O
resulting	O
in	O
a	O
high	O
transcriptional	O
level	O
.	O

These	O
findings	O
demonstrated	O
that	O
1	O
)	O
negative	O
regulation	O
of	O
the	O
TRH	S-Protein
gene	O
by	O
TH	O
involves	O
both	O
the	O
acetylation	O
and	O
methylation	O
of	O
specific	O
residues	O
of	O
histone	S-Protein
tails	O
and	O
changing	O
the	O
amount	O
of	O
TR	O
,	O
and	O
2	O
)	O
the	O
major	O
impairment	O
to	O
histone	S-Protein
modifications	O
in	O
F455S	O
was	O
hyperacetylation	O
of	O
the	O
specific	O
histone	S-Protein
tails	O
.	O

The	O
synovial	O
sarcoma	O
-	O
associated	O
SYT	S-Protein
-	O
SSX2	S-Protein
oncogene	O
antagonizes	O
the	O
polycomb	O
complex	O
protein	O
Bmi1	S-Protein
.	O

This	O
study	O
demonstrates	O
deregulation	O
of	O
polycomb	O
activity	O
by	O
the	O
synovial	O
sarcoma	O
-	O
associated	O
SYT	S-Protein
-	O
SSX2	S-Protein
oncogene	O
,	O
also	O
known	O
as	O
SS18	S-Protein
-	O
SSX2	S-Protein
.	O

Synovial	O
sarcoma	O
is	O
a	O
soft	O
tissue	O
cancer	O
associated	O
with	O
a	O
recurrent	O
t	O
(	O
X	O
:	O
18	O
)	O
translocation	O
event	O
that	O
generates	O
one	O
of	O
two	O
fusion	O
proteins	O
,	O
SYT	S-Protein
-	O
SSX1	S-Protein
or	O
SYT	S-Protein
-	O
SSX2	S-Protein
.	O

The	O
role	O
of	O
the	O
translocation	O
products	O
in	O
this	O
disease	O
is	O
poorly	O
understood	O
.	O

We	O
present	O
evidence	O
that	O
the	O
SYT	S-Protein
-	O
SSX2	S-Protein
fusion	O
protein	O
interacts	O
with	O
the	O
polycomb	O
repressive	O
complex	O
and	O
modulates	O
its	O
gene	O
silencing	O
activity	O
.	O

SYT	S-Protein
-	O
SSX2	S-Protein
causes	O
destabilization	O
of	O
the	O
polycomb	O
subunit	O
Bmi1	S-Protein
,	O
resulting	O
in	O
impairment	O
of	O
polycomb	O
-	O
associated	O
histone	B-Protein
H2A	E-Protein
ubiquitination	O
and	O
reactivation	O
of	O
polycomb	O
target	O
genes	O
.	O

Silencing	O
by	O
polycomb	O
complexes	O
plays	O
a	O
vital	O
role	O
in	O
numerous	O
physiological	O
processes	O
.	O

In	O
recent	O
years	O
,	O
numerous	O
reports	O
have	O
implicated	O
gain	O
of	O
polycomb	O
silencing	O
function	O
in	O
several	O
cancers	O
.	O

This	O
study	O
provides	O
evidence	O
that	O
,	O
in	O
the	O
appropriate	O
context	O
,	O
expression	O
of	O
the	O
SYT	S-Protein
-	O
SSX2	S-Protein
oncogene	O
leads	O
to	O
loss	O
of	O
polycomb	O
function	O
.	O

It	O
challenges	O
the	O
notion	O
that	O
cancer	O
is	O
solely	O
associated	O
with	O
an	O
increase	O
in	O
polycomb	O
function	O
and	O
suggests	O
that	O
any	O
imbalance	O
in	O
polycomb	O
activity	O
could	O
drive	O
the	O
cell	O
toward	O
oncogenesis	O
.	O

These	O
findings	O
provide	O
a	O
mechanism	O
by	O
which	O
the	O
SYT	S-Protein
-	O
SSX2	S-Protein
chimera	O
may	O
contribute	O
to	O
synovial	O
sarcoma	O
pathogenesis	O
.	O

Tobacco	O
smoke	O
induces	O
polycomb	O
-	O
mediated	O
repression	O
of	O
Dickkopf	B-Protein
-	I-Protein
1	E-Protein
in	O
lung	O
cancer	O
cells	O
.	O

Limited	O
information	O
is	O
available	O
about	O
epigenetic	O
mechanisms	O
by	O
which	O
cigarette	O
smoke	O
enhances	O
the	O
initiation	O
and	O
progression	O
of	O
lung	O
cancer	O
.	O

To	O
examine	O
this	O
issue	O
,	O
A549	O
and	O
Calu	O
-	O
6	O
lung	O
cancer	O
cells	O
were	O
cultured	O
in	O
normal	O
media	O
with	O
or	O
without	O
tobacco	O
smoke	O
condensate	O
(	O
TSC	O
)	O
under	O
clinically	O
relevant	O
exposure	O
conditions	O
.	O

Ten	O
-	O
day	O
TSC	O
exposure	O
dramatically	O
increased	O
the	O
tumorigenicity	O
of	O
lung	O
cancer	O
cells	O
in	O
nude	O
mice	O
.	O

Microarray	O
and	O
quantitative	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
experiments	O
revealed	O
that	O
this	O
phenomenon	O
coincided	O
with	O
diminished	O
expression	O
of	O
Dickkopf	B-Protein
-	I-Protein
1	E-Protein
(	O
Dkk	B-Protein
-	I-Protein
1	E-Protein
)	O
.	O

Western	O
blot	O
,	O
chromatin	O
immunoprecipitation	O
,	O
methylation	O
-	O
specific	O
PCR	O
,	O
and	O
pyrosequencing	O
experiments	O
showed	O
that	O
repression	O
of	O
Dkk	B-Protein
-	I-Protein
1	E-Protein
coincided	O
with	O
decreased	O
H4K16Ac	S-Protein
,	O
increased	O
H3K27me3	S-Protein
,	O
and	O
recruitment	O
of	O
SirT1	S-Protein
,	O
EZH2	S-Protein
,	O
SUZ12	S-Protein
,	O
and	O
Bmi1	S-Protein
without	O
DNA	O
hypermethylation	O
within	O
the	O
Dkk	B-Protein
-	I-Protein
1	E-Protein
promoter	O
despite	O
prolonged	O
TSC	O
exposures	O
.	O

Removal	O
of	O
TSC	O
from	O
culture	O
media	O
resulted	O
in	O
loss	O
of	O
promoter	O
-	O
associated	O
polycomb	O
repressor	O
complexes	O
and	O
reexpression	O
of	O
Dkk	B-Protein
-	I-Protein
1	E-Protein
.	O

siRNA	O
-	O
mediated	O
knockdown	O
of	O
EZH2	S-Protein
and	O
SirT1	S-Protein
partially	O
abrogated	O
TSC	O
-	O
mediated	O
inhibition	O
of	O
Dkk	B-Protein
-	I-Protein
1	E-Protein
expression	O
.	O

Western	O
blot	O
and	O
quantitative	O
RT	O
-	O
PCR	O
array	O
experiments	O
showed	O
that	O
TSC	O
exposure	O
as	O
well	O
as	O
knockdown	O
of	O
Dkk	B-Protein
-	I-Protein
1	E-Protein
activated	O
Wnt	O
signaling	O
and	O
significantly	O
up	O
-	O
regulated	O
Wnt5a	S-Protein
in	O
lung	O
cancer	O
cells	O
.	O

Knockdown	O
of	O
Dkk	B-Protein
-	I-Protein
1	E-Protein
recapitulated	O
the	O
dramatic	O
protumorigenic	O
effects	O
of	O
TSC	O
exposure	O
in	O
Calu	O
-	O
6	O
cells	O
.	O

Despite	O
the	O
transient	O
nature	O
of	O
Dkk	B-Protein
-	I-Protein
1	E-Protein
repression	O
following	O
TSC	O
exposure	O
in	O
vitro	O
,	O
Dkk	B-Protein
-	I-Protein
1	E-Protein
remained	O
silenced	O
in	O
tumor	O
xenografts	O
derived	O
from	O
TSC	O
-	O
treated	O
Calu	O
-	O
6	O
cells	O
.	O

Collectively	O
,	O
these	O
data	O
provide	O
evidence	O
that	O
cigarette	O
smoke	O
directly	O
engages	O
polycomb	O
machinery	O
to	O
activate	O
a	O
signaling	O
network	O
implicated	O
in	O
maintenance	O
of	O
cancer	O
stem	O
cells	O
.	O

TRIM44	S-Protein
interacts	O
with	O
and	O
stabilizes	O
terf	S-Protein
,	O
a	O
TRIM	O
ubiquitin	S-Protein
E3	O
ligase	O
.	O

Terf	S-Protein
/	O
TRIM17	S-Protein
is	O
a	O
member	O
of	O
the	O
TRIM	O
family	O
of	O
proteins	O
,	O
which	O
is	O
characterized	O
by	O
the	O
RING	O
finger	O
,	O
B	O
-	O
box	O
,	O
and	O
coiled	O
-	O
coil	O
domains	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
terf	S-Protein
interacts	O
with	O
TRIM44	S-Protein
.	O

Terf	S-Protein
underwent	O
ubiquitination	O
in	O
vitro	O
in	O
the	O
presence	O
of	O
the	O
E2	O
enzyme	O
UbcH6	S-Protein
;	O
this	O
suggests	O
that	O
terf	S-Protein
exhibits	O
E3	O
ubiquitin	S-Protein
ligase	O
activity	O
.	O

It	O
was	O
also	O
found	O
that	O
terf	S-Protein
was	O
conjugated	O
with	O
polyubiquitin	S-Protein
chains	O
and	O
stabilized	O
by	O
the	O
proteasome	O
inhibitor	O
in	O
mammalian	O
cells	O
;	O
this	O
suggested	O
that	O
terf	S-Protein
rendered	O
itself	O
susceptible	O
to	O
proteasomal	O
degradation	O
through	O
polyubiquitination	O
.	O

We	O
also	O
found	O
that	O
TRIM44	S-Protein
inhibited	O
ubiquitination	O
of	O
terf	S-Protein
,	O
and	O
thus	O
stabilized	O
the	O
protein	O
.	O

The	O
N	O
-	O
terminal	O
region	O
of	O
TRIM44	S-Protein
contains	O
a	O
zinc	O
-	O
finger	O
domain	O
found	O
in	O
ubiquitin	S-Protein
hydrolases	O
(	O
ZF	O
UBP	O
)	O
and	O
ubiquitin	S-Protein
specific	O
proteases	O
(	O
USPs	O
)	O
.	O

Thus	O
,	O
we	O
proposed	O
that	O
TRIM44	S-Protein
may	O
function	O
as	O
a	O
new	O
class	O
of	O
the	O
"	O
USP	O
-	O
like	O
-	O
TRIM	O
"	O
which	O
regulates	O
the	O
activity	O
of	O
associated	O
TRIM	O
proteins	O
.	O

Age	O
-	O
dependent	O
variations	O
of	O
the	O
biosyntheses	O
of	O
fibronectin	S-Protein
and	O
fibrous	O
collagens	O
in	O
mouse	O
skin	O
.	O

Skin	O
explant	O
cultures	O
from	O
hairless	O
mice	O
of	O
increasing	O
age	O
were	O
incubated	O
with	O
radioactive	O
precursors	O
in	O
order	O
to	O
determine	O
the	O
age	O
-	O
dependent	O
variations	O
of	O
the	O
biosyntheses	O
of	O
fibronectin	S-Protein
and	O
fibrous	O
collagens	O
(	O
types	O
I	O
and	O
III	O
)	O
.	O

Total	O
collagen	O
synthesis	O
expressed	O
as	O
a	O
percentage	O
of	O
total	O
protein	O
synthesis	O
did	O
not	O
vary	O
with	O
age	O
but	O
,	O
if	O
expressed	O
as	O
micrograms	O
hydroxyproline	O
per	O
mg	O
wet	O
weight	O
of	O
skin	O
,	O
decreased	O
by	O
about	O
30	O
%	O
between	O
2	O
and	O
22	O
months	O
of	O
age	O
.	O

Hydroxylation	O
of	O
collagen	O
,	O
expressed	O
as	O
the	O
ratio	O
of	O
3H	O
-	O
hypro	O
over	O
3H	O
(	O
pro	O
+	O
hypro	O
)	O
incorporated	O
in	O
freshly	O
synthesized	O
collagen	O
,	O
decreased	O
with	O
age	O
by	O
about	O
40	O
%	O
between	O
2	O
and	O
22	O
months	O
of	O
age	O
.	O

The	O
proportion	O
of	O
type	B-Protein
III	I-Protein
collagen	E-Protein
expressed	O
as	O
%	O
of	O
type	O
I	O
+	O
type	B-Protein
III	I-Protein
collagens	E-Protein
increased	O
progressively	O
with	O
age	O
by	O
about	O
25	O
%	O
at	O
12	O
months	O
to	O
60	O
%	O
at	O
22	O
months	O
of	O
age	O
.	O

Fibronectin	S-Protein
biosynthesis	O
,	O
determined	O
by	O
immunoprecipitation	O
of	O
35S	O
-	O
methionine	O
labeled	O
peptides	O
in	O
SDS	O
-	O
extracts	O
of	O
skin	O
increased	O
progressively	O
with	O
age	O
from	O
about	O
2	O
%	O
of	O
total	O
incorporated	O
radioactivity	O
in	O
fibronectin	S-Protein
at	O
2	O
months	O
to	O
4	O
%	O
at	O
22	O
months	O
.	O

Plasma	O
fibronectin	S-Protein
,	O
of	O
hepatic	O
origin	O
,	O
was	O
shown	O
already	O
to	O
increase	O
with	O
age	O
in	O
humans	O
.	O

It	O
appears	O
thus	O
that	O
the	O
expression	O
of	O
genes	O
coding	O
for	O
extracellular	O
matrix	O
macromolecules	O
is	O
under	O
age	O
-	O
dependent	O
regulation	O
.	O

This	O
regulation	O
appears	O
to	O
be	O
different	O
for	O
the	O
investigated	O
macromolecules	O
.	O

Beta	O
-	O
arrestin	O
-	O
dependent	O
signaling	O
and	O
trafficking	O
of	O
7	O
-	O
transmembrane	O
receptors	O
is	O
reciprocally	O
regulated	O
by	O
the	O
deubiquitinase	O
USP33	S-Protein
and	O
the	O
E3	O
ligase	O
Mdm2	S-Protein
.	O

Beta	O
-	O
arrestins	O
are	O
multifunctional	O
adaptors	O
that	O
mediate	O
the	O
desensitization	O
,	O
internalization	O
,	O
and	O
some	O
signaling	O
functions	O
of	O
seven	O
-	O
transmembrane	O
receptors	O
(	O
7TMRs	O
)	O
.	O

Agonist	O
-	O
stimulated	O
ubiquitination	O
of	O
beta	B-Protein
-	I-Protein
arrestin2	E-Protein
mediated	O
by	O
the	O
E3	O
ubiquitin	S-Protein
ligase	O
Mdm2	S-Protein
is	O
critical	O
for	O
rapid	O
beta	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
-	I-Protein
adrenergic	I-Protein
receptor	E-Protein
(	O
beta	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
AR	E-Protein
)	O
internalization	O
.	O

We	O
now	O
report	O
the	O
discovery	O
that	O
the	O
deubiquitinating	O
enzyme	O
ubiquitin	B-Protein
-	I-Protein
specific	I-Protein
protease	I-Protein
33	E-Protein
(	O
USP33	S-Protein
)	O
binds	O
beta	B-Protein
-	I-Protein
arrestin2	E-Protein
and	O
leads	O
to	O
the	O
deubiquitination	O
of	O
beta	O
-	O
arrestins	O
.	O

USP33	S-Protein
and	O
Mdm2	S-Protein
function	O
reciprocally	O
and	O
favor	O
respectively	O
the	O
stability	O
or	O
lability	O
of	O
the	O
receptor	O
beta	O
-	O
arrestin	O
complex	O
,	O
thus	O
regulating	O
the	O
longevity	O
and	O
subcellular	O
localization	O
of	O
receptor	O
signalosomes	O
.	O

Receptors	O
such	O
as	O
the	O
beta	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
AR	E-Protein
,	O
previously	O
shown	O
to	O
form	O
loose	O
complexes	O
with	O
beta	O
-	O
arrestin	O
(	O
"	O
class	O
A	O
"	O
)	O
promote	O
a	O
beta	O
-	O
arrestin	O
conformation	O
conducive	O
for	O
binding	O
to	O
the	O
deubiquitinase	O
,	O
whereas	O
the	O
vasopressin	B-Protein
V2R	E-Protein
,	O
which	O
forms	O
tight	O
beta	O
-	O
arrestin	O
complexes	O
(	O
"	O
class	O
B	O
"	O
)	O
,	O
promotes	O
a	O
distinct	O
beta	O
-	O
arrestin	O
conformation	O
that	O
favors	O
dissociation	O
of	O
the	O
enzyme	O
.	O

Thus	O
,	O
USP33	S-Protein
-	O
beta	O
-	O
arrestin	O
interaction	O
is	O
a	O
key	O
regulatory	O
step	O
in	O
7TMR	O
trafficking	O
and	O
signal	O
transmission	O
from	O
the	O
activated	O
receptors	O
to	O
downstream	O
effectors	O
.	O

Impairment	O
of	O
ubiquitylation	O
by	O
mutation	O
in	O
Drosophila	O
E1	O
promotes	O
both	O
cell	O
-	O
autonomous	O
and	O
non	O
-	O
cell	O
-	O
autonomous	O
Ras	O
-	O
ERK	O
activation	O
in	O
vivo	O
.	O

Ras	O
signaling	O
can	O
promote	O
proliferation	O
,	O
cell	O
survival	O
and	O
differentiation	O
.	O

Mutations	O
in	O
components	O
of	O
the	O
Ras	O
pathway	O
are	O
found	O
in	O
many	O
solid	O
tumors	O
and	O
are	O
associated	O
with	O
developmental	O
disorders	O
.	O

We	O
demonstrate	O
here	O
that	O
Drosophila	O
tissues	O
containing	O
hypomorphic	O
mutations	O
in	O
E1	O
,	O
the	O
most	O
upstream	O
enzyme	O
in	O
the	O
ubiquitin	S-Protein
pathway	O
,	O
display	O
cell	O
-	O
autonomous	O
upregulation	O
of	O
Ras	O
-	O
ERK	O
activity	O
and	O
Ras	O
-	O
dependent	O
ectopic	O
proliferation	O
.	O

Ubiquitylation	O
is	O
widely	O
accepted	O
to	O
regulate	O
receptor	O
tyrosine	O
kinase	O
(	O
RTK	O
)	O
endocytosis	O
upstream	O
of	O
Ras	O
.	O

However	O
,	O
although	O
the	O
ectopic	O
proliferation	O
of	O
E1	O
hypomorphs	O
is	O
dramatically	O
suppressed	O
by	O
removing	O
one	O
copy	O
of	O
Ras	O
,	O
removal	O
of	O
the	O
more	O
upstream	O
components	O
Egfr	S-Protein
,	O
Grb2	S-Protein
or	O
sos	S-Protein
shows	O
no	O
suppression	O
.	O

Thus	O
,	O
decreased	O
ubiquitylation	O
may	O
lead	O
to	O
growth	O
-	O
relevant	O
Ras	O
-	O
ERK	O
activation	O
by	O
failing	O
to	O
regulate	O
a	O
step	O
downstream	O
of	O
RTK	O
endocytosis	O
.	O

We	O
further	O
demonstrate	O
that	O
Drosophila	O
Ras	O
is	O
ubiquitylated	O
.	O

Our	O
findings	O
suggest	O
that	O
Ras	O
ubiquitylation	O
restricts	O
growth	O
and	O
proliferation	O
in	O
vivo	O
.	O

We	O
also	O
report	O
our	O
intriguing	O
observation	O
that	O
complete	O
inactivation	O
of	O
E1	O
causes	O
non	O
-	O
autonomous	O
activation	O
of	O
Ras	O
-	O
ERK	O
in	O
adjacent	O
tissue	O
,	O
mimicking	O
oncogenic	O
Ras	O
overexpression	O
.	O

We	O
demonstrate	O
that	O
maintaining	O
sufficient	O
E1	O
function	O
is	O
required	O
both	O
cell	O
autonomously	O
and	O
non	O
-	O
cell	O
autonomously	O
to	O
prevent	O
inappropriate	O
Ras	O
-	O
ERK	O
-	O
dependent	O
growth	O
and	O
proliferation	O
in	O
vivo	O
and	O
may	O
implicate	O
loss	O
of	O
Ras	O
ubiquitylation	O
in	O
developmental	O
disorders	O
and	O
cancer	O
.	O

HSP70	O
protects	O
BCL2L12	S-Protein
and	O
BCL2L12A	S-Protein
from	O
N	O
-	O
terminal	O
ubiquitination	O
-	O
mediated	O
proteasomal	O
degradation	O
.	O

BCL2L12	S-Protein
has	O
been	O
found	O
to	O
be	O
associated	O
with	O
favorable	O
prognosis	O
in	O
breast	O
cancer	O
patients	O
while	O
correlated	O
with	O
tumorigenesis	O
of	O
glioblastoma	O
and	O
colon	O
cancer	O
.	O

Here	O
,	O
we	O
report	O
that	O
BCL2L12	S-Protein
and	O
its	O
transcript	O
variant	O
BCL2L12A	S-Protein
are	O
degraded	O
through	O
ubiquitin	S-Protein
-	O
proteasome	O
system	O
(	O
UPS	O
)	O
.	O

Interestingly	O
,	O
the	O
ubiquitinations	O
and	O
degradations	O
of	O
BCL2L12	S-Protein
and	O
BCL2L12A	S-Protein
are	O
independent	O
of	O
the	O
internal	O
lysine	O
residues	O
but	O
the	O
first	O
N	O
-	O
terminal	O
residues	O
.	O

In	O
addition	O
,	O
HSP70	O
was	O
identified	O
to	O
interact	O
with	O
BCL2L12	S-Protein
and	O
BCL2L12A	S-Protein
and	O
protected	O
them	O
from	O
ubiquitinations	O
and	O
degradations	O
in	O
mammalian	O
cells	O
.	O

In	O
summary	O
,	O
HSP70	O
protects	O
BCL2L12	S-Protein
and	O
BCL2L12A	S-Protein
from	O
N	O
-	O
terminal	O
ubiquitination	O
-	O
mediated	O
proteasomal	O
degradation	O
.	O

Ubiquitylation	O
of	O
Fe65	S-Protein
adaptor	O
protein	O
by	O
neuronal	B-Protein
precursor	I-Protein
cell	I-Protein
expressed	I-Protein
developmentally	I-Protein
down	I-Protein
regulated	I-Protein
4	I-Protein
-	I-Protein
2	E-Protein
(	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
)	O
via	O
the	O
WW	O
domain	O
interaction	O
with	O
Fe65	S-Protein
.	O

Fe65	S-Protein
has	O
been	O
characterized	O
as	O
an	O
adaptor	O
protein	O
,	O
originally	O
identified	O
as	O
an	O
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
corresponding	O
to	O
an	O
mRNA	O
expressed	O
at	O
high	O
levels	O
in	O
the	O
rat	O
brain	O
.	O

It	O
contains	O
one	O
WW	O
domain	O
and	O
two	O
phosphotyrosine	O
interaction	O
/	O
phosphotyrosine	O
binding	O
domains	O
(	O
PID1	O
/	O
PID2	O
)	O
.	O

As	O
the	O
neuronal	B-Protein
precursor	I-Protein
cell	I-Protein
expressed	I-Protein
developmentally	I-Protein
down	I-Protein
regulated	I-Protein
4	I-Protein
-	I-Protein
2	E-Protein
(	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
)	O
has	O
a	O
putative	O
WW	O
domain	O
binding	O
motif	O
(	O
(	O
72	O
)	O
PPLP	O
(	O
75	O
)	O
)	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
,	O
we	O
hypothesized	O
that	O
Fe65	S-Protein
associates	O
with	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
through	O
a	O
WW	O
domain	O
interaction	O
,	O
which	O
has	O
the	O
characteristics	O
of	O
E3	O
ubiquitin	S-Protein
-	O
protein	O
ligase	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
evidence	O
for	O
the	O
interaction	O
between	O
Fe65	S-Protein
WW	O
domain	O
and	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
through	O
its	O
specific	O
motif	O
,	O
using	O
a	O
pull	O
down	O
approach	O
and	O
co	O
-	O
immunoprecipitation	O
.	O

Additionally	O
,	O
the	O
co	O
-	O
localization	O
of	O
Fe65	S-Protein
and	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
were	O
observed	O
via	O
confocal	O
microscopy	O
.	O

Co	O
-	O
localization	O
of	O
Fe65	S-Protein
and	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
was	O
disrupted	O
by	O
either	O
the	O
mutation	O
of	O
Fe65	S-Protein
WW	O
domain	O
or	O
its	O
putative	O
binding	O
motif	O
of	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
.	O

When	O
the	O
ubiquitin	S-Protein
assay	O
was	O
performed	O
,	O
the	O
interaction	O
of	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
(	O
wt	O
)	O
with	O
Fe65	S-Protein
is	O
required	O
for	O
the	O
cell	O
apoptosis	O
and	O
the	O
ubiquitylation	O
of	O
Fe65	S-Protein
.	O

We	O
also	O
observed	O
that	O
the	O
ubiquitylation	O
of	O
Fe65	S-Protein
(	O
wt	O
)	O
was	O
augmented	O
depending	O
on	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
expression	O
levels	O
,	O
whereas	O
the	O
Fe65	S-Protein
WW	O
domain	O
mutant	O
(	O
W243KP245K	O
)	O
or	O
the	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
AL	O
mutant	O
(	O
(	O
72	O
)	O
PPLP	O
(	O
75	O
)	O
was	O
changed	O
to	O
(	O
72	O
)	O
APLA	O
(	O
75	O
)	O
)	O
was	O
under	O
-	O
ubiquitinated	O
significantly	O
.	O

Thus	O
,	O
our	O
observations	O
implicated	O
that	O
the	O
protein	O
-	O
protein	O
interaction	O
between	O
the	O
WW	O
domain	O
of	O
Fe65	S-Protein
and	O
the	O
putative	O
binding	O
motif	O
of	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
down	O
-	O
regulates	O
Fe65	S-Protein
protein	O
stability	O
and	O
subcellular	O
localization	O
through	O
its	O
ubiquitylation	O
,	O
to	O
contribute	O
cell	O
apoptosis	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
assays	O
for	O
studying	O
histone	S-Protein
ubiquitination	O
and	O
deubiquitination	O
.	O

Posttranslational	O
histone	S-Protein
modifications	O
play	O
important	O
roles	O
in	O
regulating	O
chromatin	O
structure	O
and	O
function	O
(	O
Martin	O
and	O
Zhang	O
,	O
Nat	O
Rev	O
Mol	O
Cell	O
Biol	O
6	O
:	O
838	O
-	O
849	O
,	O
2005	O
;	O
Jenuwein	O
and	O
Allis	O
,	O
Science	O
293	O
:	O
1074	O
-	O
1080	O
,	O
2001	O
)	O
.	O

One	O
example	O
of	O
such	O
modifications	O
is	O
histone	S-Protein
ubiquitination	O
,	O
which	O
occurs	O
predominately	O
on	O
H2A	S-Protein
and	O
H2B	S-Protein
.	O

Recent	O
studies	O
have	O
highlighted	O
important	O
regulatory	O
roles	O
of	O
H2A	S-Protein
ubiquitination	O
in	O
Polycomb	O
group	O
proteins	O
-	O
mediated	O
gene	O
silencing	O
(	O
Wang	O
et	O
al	O
.	O
,	O
Nature	O
431	O
:	O
873	O
-	O
878	O
,	O
2004	O
;	O
Joo	O
et	O
al	O
.	O
,	O
Nature	O
449	O
:	O
1068	O
-	O
1072	O
,	O
2007	O
)	O
and	O
H2B	S-Protein
ubiquitination	O
in	O
transcription	O
,	O
H3	S-Protein
methylation	O
,	O
and	O
DNA	O
methylation	O
(	O
Zhang	O
,	O
Genes	O
Dev	O
17	O
:	O
2733	O
-	O
2740	O
,	O
2003	O
;	O
Sun	O
and	O
Allis	O
,	O
Nature	O
418	O
:	O
104	O
-	O
108	O
,	O
2002	O
;	O
Sridhar	O
et	O
al	O
.	O
,	O
Nature	O
447	O
:	O
735	O
-	O
738	O
,	O
2007	O
)	O
.	O

Here	O
we	O
describe	O
methods	O
for	O
in	O
vitro	O
histone	S-Protein
ubiquitination	O
and	O
deubiquitination	O
assays	O
.	O

We	O
also	O
describe	O
approaches	O
to	O
investigate	O
the	O
in	O
vivo	O
function	O
of	O
a	O
putative	O
histone	S-Protein
ubiquitin	S-Protein
ligase	O
and	O
deubiquitinase	O
.	O

These	O
experimental	O
procedures	O
are	O
largely	O
based	O
on	O
our	O
studies	O
in	O
mammalian	O
cells	O
.	O

These	O
methods	O
should	O
provide	O
useful	O
tools	O
for	O
studying	O
this	O
bulky	O
histone	S-Protein
modification	O
.	O

Kinetic	O
analysis	O
of	O
human	O
protein	B-Protein
arginine	I-Protein
N	I-Protein
-	I-Protein
methyltransferase	I-Protein
2	E-Protein
:	O
formation	O
of	O
monomethyl	O
-	O
and	O
asymmetric	O
dimethyl	O
-	O
arginine	O
residues	O
on	O
histone	B-Protein
H4	E-Protein
.	O

Protein	O
arginine	O
N	O
-	O
methyltransferases	O
(	O
PRMTs	O
)	O
methylate	O
arginine	O
residues	O
within	O
proteins	O
using	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
methionine	O
(	O
AdoMet	O
)	O
to	O
form	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
homocysteine	O
and	O
methylarginine	O
residues	O
.	O

All	O
PRMTs	O
produce	O
omega	O
-	O
NG	O
-	O
monomethylarginine	O
(	O
MMA	O
)	O
residues	O
and	O
either	O
asymmetric	O
omega	O
-	O
N	O
(	O
G	O
)	O
,	O
N	O
(	O
G	O
)	O
-	O
dimethylarginine	O
(	O
aDMA	O
)	O
or	O
symmetric	O
omega	O
-	O
N	O
(	O
G	O
)	O
,	O
N	O
'	O
(	O
G	O
)	O
-	O
dimethylarginine	O
(	O
sDMA	O
)	O
residues	O
,	O
referred	O
to	O
as	O
Type	O
I	O
or	O
Type	O
II	O
activity	O
respectively	O
.	O

Here	O
we	O
report	O
methylation	O
activity	O
from	O
PRMT2	S-Protein
and	O
compare	O
it	O
with	O
PRMT1	S-Protein
activity	O
using	O
UPLC	O
-	O
MS	O
/	O
MS	O
(	O
ultra	O
-	O
performance	O
liquid	O
chromatography	O
-	O
tandem	O
MS	O
)	O
,	O
gel	O
electrophoresis	O
,	O
and	O
thin	O
-	O
layer	O
chromatography	O
.	O

We	O
show	O
that	O
PRMT2	S-Protein
is	O
a	O
Type	O
I	O
enzyme	O
and	O
that	O
the	O
ratio	O
of	O
aDMA	O
to	O
MMA	O
produced	O
by	O
PRMTs	B-Protein
1	E-Protein
and	O
2	S-Protein
is	O
dependent	O
on	O
the	O
substrate	O
,	O
regardless	O
of	O
rate	O
or	O
K	O
(	O
m	O
)	O
,	O
suggesting	O
that	O
the	O
reactions	O
for	O
both	O
enzymes	O
are	O
distributive	O
rather	O
than	O
processive	O
.	O

Using	O
UPLC	O
-	O
MS	O
/	O
MS	O
we	O
find	O
that	O
,	O
for	O
PRMT2	S-Protein
,	O
the	O
dissociation	O
constant	O
(	O
KAs	O
)	O
and	O
K	O
(	O
m	O
)	O
of	O
AdoMet	O
and	O
the	O
Km	O
of	O
histone	B-Protein
H4	E-Protein
are	O
similar	O
to	O
values	O
for	O
PRMT1	S-Protein
,	O
whereas	O
the	O
PRMT2	S-Protein
k	O
(	O
cat	O
)	O
is	O
800	O
-	O
fold	O
less	O
than	O
the	O
PRMT1	S-Protein
k	O
(	O
cat	O
)	O
.	O

Although	O
PRMT2	S-Protein
activity	O
is	O
substantially	O
lower	O
than	O
PRMT1	S-Protein
in	O
vitro	O
,	O
the	O
fact	O
that	O
both	O
enzymes	O
selectively	O
methylate	O
histone	B-Protein
H4	E-Protein
suggest	O
that	O
PRMT2	S-Protein
,	O
like	O
PRMT1	S-Protein
,	O
may	O
act	O
as	O
a	O
transcription	O
co	O
-	O
activator	O
through	O
this	O
modification	O
.	O

The	O
transcription	O
-	O
independent	O
mitochondrial	O
p53	S-Protein
program	O
is	O
a	O
major	O
contributor	O
to	O
nutlin	O
-	O
induced	O
apoptosis	O
in	O
tumor	O
cells	O
.	O

Strategies	O
to	O
induce	O
p53	S-Protein
activation	O
in	O
tumors	O
that	O
retain	O
wild	O
-	O
type	O
p53	S-Protein
are	O
promising	O
for	O
cancer	O
therapy	O
.	O

Nutlin	O
is	O
a	O
potent	O
and	O
selective	O
pharmacological	O
MDM2	S-Protein
inhibitor	O
that	O
competitively	O
binds	O
to	O
its	O
p53	S-Protein
-	O
binding	O
pocket	O
,	O
thereby	O
leading	O
to	O
non	O
-	O
genotoxic	O
p53	S-Protein
stabilization	O
and	O
activation	O
of	O
growth	O
arrest	O
and	O
apoptosis	O
pathways	O
.	O

Nutlin	O
-	O
induced	O
apoptosis	O
is	O
thought	O
to	O
occur	O
via	O
p53	S-Protein
'	O
s	O
transcriptional	O
program	O
.	O

Here	O
we	O
report	O
that	O
the	O
transcription	O
-	O
independent	O
mitochondrial	O
p53	S-Protein
program	O
plays	O
an	O
important	O
role	O
in	O
Nutlin	O
-	O
induced	O
p53	S-Protein
-	O
mediated	O
tumor	O
cell	O
death	O
.	O

Aside	O
from	O
nuclear	O
stabilization	O
,	O
Nutlin	O
causes	O
cytoplasmic	O
p53	S-Protein
accumulation	O
and	O
translocation	O
to	O
mitochondria	O
.	O

Monoubiquitinated	O
p53	S-Protein
,	O
originating	O
from	O
a	O
distinct	O
cytoplasmic	O
pool	O
,	O
is	O
the	O
preferred	O
p53	S-Protein
species	O
that	O
translocates	O
to	O
mitochondria	O
in	O
response	O
to	O
stress	O
.	O

Nutlin	O
does	O
not	O
interfere	O
with	O
MDM2	S-Protein
'	O
s	O
ability	O
to	O
monoubiquitinate	O
p53	S-Protein
,	O
due	O
to	O
the	O
fact	O
that	O
MDM2	S-Protein
-	O
p53	S-Protein
complexes	O
are	O
only	O
partially	O
disrupted	O
and	O
that	O
Nutlin	O
-	O
stabilized	O
MDM2	S-Protein
retains	O
its	O
E3	O
ubiquitin	S-Protein
ligase	O
activity	O
.	O

Nutlin	O
-	O
induced	O
mitochondrial	O
p53	S-Protein
translocation	O
is	O
rapid	O
and	O
associated	O
with	O
cytochrome	B-Protein
C	E-Protein
release	O
that	O
precedes	O
induction	O
of	O
p53	S-Protein
target	O
genes	O
.	O

Specific	O
inhibition	O
of	O
mitochondrial	O
p53	S-Protein
translocation	O
by	O
Pifithrin	O
mu	O
reduces	O
the	O
apoptotic	O
Nutlin	O
response	O
by	O
2	O
.	O
5	O
-	O
fold	O
,	O
underlining	O
the	O
significance	O
of	O
p53	S-Protein
'	O
s	O
mitochondrial	O
program	O
in	O
Nutlin	O
-	O
induced	O
apoptosis	O
.	O

Surprisingly	O
,	O
blocking	O
the	O
transcriptional	O
arm	O
of	O
p53	S-Protein
,	O
either	O
via	O
alpha	B-Protein
-	I-Protein
Amanitin	E-Protein
or	O
the	O
p53	S-Protein
-	O
specific	O
transcriptional	O
inhibitor	O
Pifithrin	O
alpha	O
,	O
not	O
only	O
fails	O
to	O
inhibit	O
,	O
but	O
greatly	O
potentiates	O
Nutlin	O
-	O
induced	O
apoptosis	O
.	O

In	O
sum	O
,	O
the	O
direct	O
mitochondrial	O
program	O
is	O
a	O
major	O
mechanism	O
in	O
Nutlin	O
-	O
induced	O
p53	S-Protein
-	O
mediated	O
apoptosis	O
.	O

Moreover	O
,	O
at	O
least	O
in	O
some	O
tumors	O
the	O
transcriptional	O
p53	S-Protein
activities	O
in	O
net	O
balance	O
not	O
only	O
are	O
dispensable	O
for	O
the	O
apoptotic	O
Nutlin	O
response	O
,	O
but	O
appear	O
to	O
actively	O
block	O
its	O
therapeutic	O
effect	O
.	O

Biochemical	O
characterization	O
of	O
the	O
prolyl	B-Protein
3	I-Protein
-	I-Protein
hydroxylase	I-Protein
1	E-Protein
.	O
cartilage	B-Protein
-	I-Protein
associated	I-Protein
protein	E-Protein
.	O
cyclophilin	B-Protein
B	E-Protein
complex	O
.	O

The	O
rough	O
endoplasmic	O
reticulum	O
-	O
resident	O
protein	O
complex	O
consisting	O
of	O
prolyl	B-Protein
3	I-Protein
-	I-Protein
hydroxylase	I-Protein
1	E-Protein
(	O
P3H1	S-Protein
)	O
,	O
cartilage	B-Protein
-	I-Protein
associated	I-Protein
protein	E-Protein
(	O
CRTAP	S-Protein
)	O
,	O
and	O
cyclophilin	B-Protein
B	E-Protein
(	O
CypB	S-Protein
)	O
can	O
be	O
isolated	O
from	O
chick	O
embryos	O
on	O
a	O
gelatin	O
-	O
Sepharose	O
column	O
,	O
indicating	O
some	O
involvement	O
in	O
the	O
biosynthesis	O
of	O
procollagens	O
.	O

Prolyl	B-Protein
3	I-Protein
-	I-Protein
hydroxylase	I-Protein
1	E-Protein
modifies	O
a	O
single	O
proline	O
residue	O
in	O
the	O
alpha	O
chains	O
of	O
type	O
I	O
,	O
II	S-Protein
,	O
and	O
III	B-Protein
collagens	E-Protein
to	O
(	O
3S	O
)	O
-	O
hydroxyproline	O
.	O

The	O
peptidyl	O
-	O
prolyl	O
cis	O
-	O
trans	O
isomerase	O
activity	O
of	O
cyclophilin	B-Protein
B	E-Protein
was	O
shown	O
previously	O
to	O
catalyze	O
the	O
rate	O
of	O
triple	O
helix	O
formation	O
.	O

Here	O
we	O
show	O
that	O
cyclophilin	B-Protein
B	E-Protein
in	O
the	O
complex	O
shows	O
peptidyl	O
-	O
prolyl	O
cis	O
-	O
trans	O
isomerase	O
activity	O
and	O
that	O
the	O
P3H1	S-Protein
.	O
CRTAP	S-Protein
.	O
CypB	S-Protein
complex	O
has	O
another	O
important	O
function	O
:	O
it	O
acts	O
as	O
a	O
chaperone	O
molecule	O
when	O
tested	O
with	O
two	O
classical	O
chaperone	O
assays	O
.	O

The	O
P3H1	S-Protein
.	O
CRTAP	S-Protein
.	O
CypB	S-Protein
complex	O
inhibited	O
the	O
thermal	O
aggregation	O
of	O
citrate	B-Protein
synthase	E-Protein
and	O
was	O
active	O
in	O
the	O
denatured	O
rhodanese	O
refolding	O
and	O
aggregation	O
assay	O
.	O

The	O
chaperone	O
activity	O
of	O
the	O
complex	O
was	O
higher	O
than	O
that	O
of	O
protein	O
-	O
disulfide	O
isomerase	O
,	O
a	O
well	O
characterized	O
chaperone	O
.	O

The	O
P3H1	S-Protein
.	O
CRTAP	S-Protein
.	O
CypB	S-Protein
complex	O
also	O
delayed	O
the	O
in	O
vitro	O
fibril	O
formation	O
of	O
type	O
I	O
collagen	O
,	O
indicating	O
that	O
this	O
complex	O
is	O
also	O
able	O
to	O
interact	O
with	O
triple	O
helical	O
collagen	O
and	O
acts	O
as	O
a	O
collagen	O
chaperone	O
.	O

GSK3beta	S-Protein
affects	O
apical	O
-	O
basal	O
polarity	O
and	O
cell	O
-	O
cell	O
adhesion	O
by	O
regulating	O
aPKC	S-Protein
levels	O
.	O

The	O
dynamic	O
rearrangement	O
of	O
cell	O
-	O
cell	O
contacts	O
is	O
required	O
for	O
the	O
establishment	O
of	O
functional	O
epithelial	O
cell	O
sheets	O
.	O

However	O
,	O
the	O
signaling	O
pathways	O
and	O
cellular	O
mechanisms	O
that	O
initiate	O
and	O
maintain	O
this	O
polarity	O
are	O
not	O
well	O
understood	O
.	O

We	O
show	O
that	O
loss	O
of	O
the	O
Wnt	O
signaling	O
component	O
GSK3	B-Protein
beta	E-Protein
results	O
in	O
increased	O
levels	O
of	O
aPKC	S-Protein
and	O
leads	O
to	O
defects	O
in	O
apical	O
-	O
basal	O
polarity	O
.	O

We	O
find	O
that	O
GSK3	B-Protein
beta	E-Protein
directly	O
phosphorylates	O
aPKC	S-Protein
,	O
which	O
likely	O
promotes	O
its	O
ubiquitin	S-Protein
-	O
mediated	O
proteosomal	O
degradation	O
.	O

aPKC	S-Protein
increases	O
the	O
levels	O
of	O
Armadillo	O
and	O
stabilizes	O
adherens	O
junctions	O
.	O

These	O
results	O
suggest	O
that	O
the	O
Wnt	O
pathway	O
component	O
GSK3	B-Protein
beta	E-Protein
regulates	O
the	O
polarity	O
determinant	O
aPKC	S-Protein
,	O
which	O
in	O
turn	O
affects	O
cell	O
-	O
cell	O
contacts	O
during	O
the	O
development	O
of	O
polarized	O
tissues	O
.	O

Cj1123c	S-Protein
(	O
PglD	S-Protein
)	O
,	O
a	O
multifaceted	O
acetyltransferase	O
from	O
Campylobacter	O
jejuni	O
.	O

Campylobacter	O
jejuni	O
produces	O
both	O
N	O
-	O
and	O
O	O
-	O
glycosylated	O
proteins	O
.	O

Because	O
protein	O
glycosylation	O
contributes	O
to	O
bacterial	O
virulence	O
,	O
a	O
thorough	O
characterization	O
of	O
the	O
enzymes	O
involved	O
in	O
protein	O
glycosylation	O
is	O
warranted	O
to	O
assess	O
their	O
potential	O
use	O
as	O
therapeutic	O
targets	O
and	O
as	O
glyco	O
-	O
engineering	O
tools	O
.	O

We	O
performed	O
a	O
detailed	O
biochemical	O
analysis	O
of	O
the	O
molecular	O
determinants	O
of	O
the	O
substrate	O
and	O
acyl	O
-	O
donor	O
specificities	O
of	O
Cj1123c	S-Protein
(	O
also	O
known	O
as	O
PglD	S-Protein
)	O
,	O
an	O
acetyltransferase	O
of	O
the	O
HexAT	O
superfamily	O
involved	O
in	O
N	O
-	O
glycosylation	O
of	O
proteins	O
.	O

We	O
show	O
that	O
Cj1123c	S-Protein
has	O
acetyl	O
-	O
CoA	O
-	O
dependent	O
N	O
-	O
acetyltransferase	O
activity	O
not	O
only	O
on	O
the	O
UDP	O
-	O
4	O
-	O
amino	O
-	O
4	O
,	O
6	O
-	O
dideoxy	O
-	O
GlcNAc	O
intermediate	O
of	O
the	O
N	O
-	O
glycosylation	O
pathway	O
but	O
also	O
on	O
the	O
UDP	O
-	O
4	O
-	O
amino	O
-	O
4	O
,	O
6	O
-	O
dideoxy	O
-	O
AltNAc	O
intermediate	O
of	O
the	O
O	O
-	O
glycosylation	O
pathway	O
,	O
implying	O
functional	O
redundancy	O
between	O
both	O
pathways	O
.	O

We	O
further	O
demonstrate	O
that	O
,	O
despite	O
its	O
somewhat	O
relaxed	O
substrate	O
specificity	O
for	O
N	O
-	O
acetylation	O
,	O
Cj1123c	S-Protein
cannot	O
acetylate	O
aminoglycosides	O
,	O
indicating	O
a	O
preference	O
for	O
sugar	O
-	O
nucleotide	O
substrates	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
Cj1123c	S-Protein
can	O
O	O
-	O
acetylate	O
UDP	O
-	O
GlcNAc	O
and	O
that	O
Cj1123c	S-Protein
is	O
very	O
versatile	O
in	O
terms	O
of	O
acyl	O
-	O
CoA	O
donors	O
as	O
it	O
can	O
use	O
propionyl	O
-	O
and	O
butyryl	O
-	O
CoA	O
instead	O
of	O
acetyl	O
-	O
CoA	O
.	O

Finally	O
,	O
using	O
structural	O
information	O
available	O
for	O
Cj1123c	S-Protein
and	O
related	O
enzymes	O
,	O
we	O
identify	O
three	O
residues	O
(	O
H125	O
,	O
G143	O
,	O
and	O
G173	O
)	O
involved	O
in	O
catalysis	O
and	O
(	O
or	O
)	O
acyl	O
-	O
donor	O
specificity	O
,	O
opening	O
up	O
possibilities	O
of	O
tailoring	O
the	O
specificity	O
of	O
Cj1123c	S-Protein
for	O
the	O
synthesis	O
of	O
novel	O
sugars	O
.	O

A	O
role	O
for	O
ubiquitin	S-Protein
in	O
selective	O
autophagy	O
.	O

Ubiquitination	O
is	O
the	O
hallmark	O
of	O
protein	O
degradation	O
by	O
the	O
26S	O
proteasome	O
.	O

However	O
,	O
the	O
proteasome	O
is	O
limited	O
in	O
its	O
capacity	O
to	O
degrade	O
oligomeric	O
and	O
aggregated	O
proteins	O
.	O

Removal	O
of	O
harmful	O
protein	O
aggregates	O
is	O
mediated	O
by	O
autophagy	O
,	O
a	O
mechanism	O
by	O
which	O
the	O
cell	O
sequesters	O
cytosolic	O
cargo	O
and	O
delivers	O
it	O
for	O
degradation	O
by	O
the	O
lysosome	O
.	O

Identification	O
of	O
autophagy	O
receptors	O
,	O
such	O
as	O
p62	S-Protein
/	O
SQSTM1	S-Protein
and	O
NBR1	S-Protein
,	O
which	O
simultaneously	O
bind	O
both	O
ubiquitin	S-Protein
and	O
autophagy	O
-	O
specific	O
ubiquitin	S-Protein
-	O
like	O
modifiers	O
,	O
LC3	O
/	O
GABARAP	S-Protein
,	O
has	O
provided	O
a	O
molecular	O
link	O
between	O
ubiquitination	O
and	O
autophagy	O
.	O

This	O
review	O
explores	O
the	O
hypothesis	O
that	O
ubiquitin	S-Protein
represents	O
a	O
selective	O
degradation	O
signal	O
suitable	O
for	O
targeting	O
various	O
types	O
of	O
cargo	O
,	O
ranging	O
from	O
protein	O
aggregates	O
to	O
membrane	O
-	O
bound	O
organelles	O
and	O
microbes	O
.	O

Estradiol	O
down	O
regulates	O
the	O
binding	O
activity	O
of	O
an	O
avian	O
vitellogenin	O
gene	O
repressor	O
(	O
MDBP	B-Protein
-	I-Protein
2	E-Protein
)	O
and	O
triggers	O
a	O
gradual	O
demethylation	O
of	O
the	O
mCpG	O
pair	O
of	O
its	O
DNA	O
binding	O
site	O
.	O

A	O
negative	O
regulating	O
protein	O
(	O
MDBP	B-Protein
-	I-Protein
2	E-Protein
)	O
from	O
rooster	O
liver	O
nuclear	O
extracts	O
binds	O
preferentially	O
to	O
a	O
methylated	O
promoter	O
region	O
5	O
'	O
TTCACCTTmCGCTATGAGGGGGATCATACTGG3	O
'	O
of	O
the	O
avian	O
vitellogenin	B-Protein
II	E-Protein
gene	O
(	O
Nucleic	O
Acids	O
Res	O
.	O
19	O
,	O
1029	O
-	O
1034	O
,	O
1991	O
)	O
.	O

Treatment	O
of	O
adult	O
and	O
immature	O
roosters	O
with	O
estradiol	O
results	O
in	O
a	O
90	O
%	O
decrease	O
in	O
the	O
binding	O
activity	O
of	O
MDBP	B-Protein
-	I-Protein
2	E-Protein
within	O
three	O
days	O
.	O

This	O
corresponds	O
to	O
the	O
level	O
found	O
in	O
egg	O
laying	O
hens	O
.	O

The	O
decrease	O
in	O
the	O
binding	O
activity	O
of	O
MDBP	B-Protein
-	I-Protein
2	E-Protein
precedes	O
the	O
onset	O
of	O
vitellogenin	O
gene	O
transcription	O
.	O

At	O
the	O
same	O
time	O
,	O
there	O
is	O
a	O
two	O
-	O
fold	O
increase	O
in	O
the	O
binding	O
activity	O
of	O
NHP	B-Protein
-	I-Protein
1	E-Protein
(	O
tested	O
with	O
the	O
same	O
oligonucleotide	O
as	O
for	O
MDBP	B-Protein
-	I-Protein
2	E-Protein
)	O
,	O
a	O
protein	O
thought	O
to	O
be	O
involved	O
in	O
the	O
active	O
demethylation	O
of	O
DNA	O
.	O

The	O
methylated	O
oligonucleotide	O
binds	O
either	O
MDBP	B-Protein
-	I-Protein
2	E-Protein
or	O
NHP	B-Protein
-	I-Protein
1	E-Protein
and	O
there	O
is	O
no	O
complex	O
formation	O
between	O
the	O
two	O
proteins	O
and	O
DNA	O
.	O

Estradiol	O
treatment	O
does	O
not	O
change	O
the	O
equilibrium	O
binding	O
constant	O
of	O
MDBP	B-Protein
-	I-Protein
2	E-Protein
which	O
is	O
about	O
10	O
(	O
-	O
9	O
)	O
M	O
for	O
the	O
methylated	O
oligonucleotide	O
.	O

The	O
early	O
kinetics	O
of	O
demethylation	O
of	O
the	O
mCpG	O
pair	O
in	O
the	O
binding	O
site	O
of	O
MDBP	B-Protein
-	I-Protein
2	E-Protein
was	O
studied	O
by	O
means	O
of	O
genomic	O
sequencing	O
.	O

A	O
low	O
level	O
of	O
demethylation	O
of	O
mCpG	O
starts	O
gradually	O
on	O
both	O
DNA	O
strands	O
already	O
4	O
hours	O
after	O
estradiol	O
treatment	O
during	O
the	O
lag	O
phase	O
of	O
vitellogenin	O
mRNA	O
synthesis	O
.	O

It	O
is	O
concluded	O
that	O
the	O
lowering	O
of	O
the	O
binding	O
activity	O
of	O
MDBP	B-Protein
-	I-Protein
2	E-Protein
may	O
have	O
a	O
stronger	O
effect	O
on	O
the	O
derepression	O
of	O
the	O
gene	O
than	O
the	O
slow	O
demethylation	O
of	O
MDBP	B-Protein
-	I-Protein
2	E-Protein
DNA	O
binding	O
site	O
.	O

The	O
role	O
of	O
the	O
methylated	O
CpG	O
is	O
to	O
assure	O
a	O
high	O
binding	O
affinity	O
of	O
the	O
repressor	O
to	O
DNA	O
.	O

Hepatitis	O
C	O
virus	O
-	O
core	B-Protein
protein	E-Protein
facilitates	O
the	O
degradation	O
of	O
Ku70	S-Protein
and	O
reduces	O
DNA	O
-	O
PK	O
activity	O
in	O
hepatocytes	O
.	O

We	O
have	O
established	O
monoclonal	O
antibodies	O
(	O
MoAbs	O
)	O
that	O
are	O
directed	O
against	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
-	O
expressing	O
cells	O
.	O

They	O
showed	O
enhanced	O
tumorigenicity	O
after	O
passage	O
in	O
culture	O
for	O
more	O
than	O
44	O
days	O
(	O
RzM6	O
-	O
44d	O
cells	O
)	O
.	O

To	O
address	O
the	O
mechanism	O
underlying	O
this	O
phenomenon	O
,	O
we	O
characterized	O
the	O
MoAbs	O
,	O
and	O
found	O
that	O
one	O
of	O
the	O
clones	O
recognized	O
a	O
molecule	O
that	O
was	O
down	O
-	O
regulated	O
in	O
the	O
RzM6	O
-	O
44d	O
cells	O
.	O

This	O
molecule	O
was	O
purified	O
and	O
identified	O
as	O
the	O
70	O
-	O
kDa	O
thyroid	O
autoantigen	O
Ku70	S-Protein
.	O

Moreover	O
,	O
expression	O
of	O
the	O
full	O
-	O
length	O
HCV	O
genome	O
or	O
HCV	O
-	O
core	B-Protein
protein	E-Protein
sequence	O
in	O
WRL68	O
human	O
embryonic	O
liver	O
cells	O
reduced	O
the	O
level	O
of	O
Ku70	S-Protein
protein	O
,	O
enhanced	O
the	O
ubiquitination	O
of	O
Ku70	S-Protein
,	O
and	O
decreased	O
the	O
activity	O
of	O
DNA	O
-	O
activated	O
protein	O
kinase	O
(	O
DNA	O
-	O
PK	O
)	O
.	O

Therefore	O
,	O
it	O
appears	O
that	O
the	O
HCV	O
-	O
core	O
protein	O
facilitates	O
the	O
degradation	O
of	O
Ku70	S-Protein
and	O
reduces	O
DNA	O
-	O
PK	O
activity	O
in	O
noncancerous	O
liver	O
cells	O
.	O

Occludin	S-Protein
phosphorylation	O
and	O
ubiquitination	O
regulate	O
tight	O
junction	O
trafficking	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
induced	O
permeability	O
.	O

Vascular	B-Protein
endothelial	I-Protein
growth	I-Protein
factor	E-Protein
(	O
VEGF	S-Protein
)	O
alters	O
tight	O
junctions	O
(	O
TJs	O
)	O
and	O
promotes	O
vascular	O
permeability	O
in	O
many	O
retinal	O
and	O
brain	O
diseases	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
of	O
barrier	O
regulation	O
are	O
poorly	O
understood	O
.	O

Here	O
we	O
demonstrate	O
that	O
occludin	S-Protein
phosphorylation	O
and	O
ubiquitination	O
regulate	O
VEGF	S-Protein
-	O
induced	O
TJ	O
protein	O
trafficking	O
and	O
concomitant	O
vascular	O
permeability	O
.	O

VEGF	S-Protein
treatment	O
induced	O
TJ	O
fragmentation	O
and	O
occludin	O
trafficking	O
from	O
the	O
cell	O
border	O
to	O
early	O
and	O
late	O
endosomes	O
,	O
concomitant	O
with	O
increased	O
occludin	S-Protein
phosphorylation	O
on	O
Ser	O
-	O
490	O
and	O
ubiquitination	O
.	O

Furthermore	O
,	O
both	O
co	O
-	O
immunoprecipitation	O
and	O
immunocytochemistry	O
demonstrated	O
that	O
VEGF	S-Protein
treatment	O
increased	O
the	O
interaction	O
between	O
occludin	S-Protein
and	O
modulators	O
of	O
intracellular	O
trafficking	O
that	O
contain	O
the	O
ubiquitin	S-Protein
interacting	O
motif	O
,	O
including	O
Epsin	B-Protein
-	I-Protein
1	E-Protein
,	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
pathway	I-Protein
substrate	I-Protein
15	E-Protein
(	O
Eps15	S-Protein
)	O
,	O
and	O
hepatocyte	B-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
regulated	I-Protein
tyrosine	I-Protein
kinase	I-Protein
substrate	E-Protein
(	O
Hrs	S-Protein
)	O
.	O

Inhibiting	O
occludin	S-Protein
phosphorylation	O
by	O
mutating	O
Ser	O
-	O
490	O
to	O
Ala	O
suppressed	O
VEGF	S-Protein
-	O
induced	O
ubiquitination	O
,	O
inhibited	O
trafficking	O
of	O
TJ	O
proteins	O
,	O
and	O
prevented	O
the	O
increase	O
in	O
endothelial	O
permeability	O
.	O

In	O
addition	O
,	O
an	O
occludin	S-Protein
-	O
ubiquitin	S-Protein
chimera	O
disrupted	O
TJs	O
and	O
increased	O
permeability	O
without	O
VEGF	S-Protein
.	O

These	O
data	O
demonstrate	O
a	O
novel	O
mechanism	O
of	O
VEGF	S-Protein
-	O
induced	O
occludin	S-Protein
phosphorylation	O
and	O
ubiquitination	O
that	O
contributes	O
to	O
TJ	O
trafficking	O
and	O
subsequent	O
vascular	O
permeability	O
.	O

Parkin	S-Protein
promotes	O
intracellular	O
Abeta1	S-Protein
-	O
42	O
clearance	O
.	O

Alzheimer	O
'	O
s	O
disease	O
and	O
Parkinson	O
'	O
s	O
disease	O
are	O
common	O
neurodegenerative	O
diseases	O
that	O
may	O
share	O
some	O
underlying	O
mechanisms	O
of	O
pathogenesis	O
.	O

Abeta	S-Protein
(	O
1	O
-	O
42	O
)	O
fragments	O
are	O
found	O
intracellularly	O
,	O
and	O
extracellularly	O
as	O
amyloid	O
plaques	O
,	O
in	O
Alzheimer	O
'	O
s	O
disease	O
and	O
in	O
dementia	O
with	O
Lewy	O
Bodies	O
.	O

Parkin	S-Protein
is	O
an	O
E3	O
-	O
ubiquitin	S-Protein
ligase	O
involved	O
in	O
proteasomal	O
degradation	O
of	O
intracellular	O
proteins	O
.	O

Mutations	O
in	O
parkin	S-Protein
,	O
which	O
result	O
in	O
loss	O
of	O
parkin	S-Protein
function	O
,	O
lead	O
to	O
early	O
onset	O
Parkinsonism	O
.	O

Here	O
we	O
tested	O
whether	O
the	O
ubiquitin	S-Protein
ligase	O
activity	O
of	O
parkin	S-Protein
could	O
lead	O
to	O
reduction	O
in	O
intracellular	O
human	O
Abeta	S-Protein
(	O
1	O
-	O
42	O
)	O
.	O

Lentiviral	O
constructs	O
encoding	O
either	O
human	O
parkin	S-Protein
or	O
human	O
Abeta	S-Protein
(	O
1	O
-	O
42	O
)	O
were	O
used	O
to	O
infect	O
M17	O
neuroblastoma	O
cells	O
.	O

Parkin	S-Protein
expression	O
resulted	O
in	O
reduction	O
of	O
intracellular	O
human	O
Abeta	S-Protein
(	O
1	O
-	O
42	O
)	O
levels	O
and	O
protected	O
against	O
its	O
toxicity	O
in	O
M17	O
cells	O
.	O

Co	O
-	O
injection	O
of	O
lentiviral	O
constructs	O
into	O
control	O
rat	O
primary	O
motor	O
cortex	O
demonstrated	O
that	O
parkin	S-Protein
co	O
-	O
expression	O
reduced	O
human	O
Abeta	S-Protein
(	O
1	O
-	O
42	O
)	O
levels	O
and	O
Abeta	S-Protein
(	O
1	O
-	O
42	O
)	O
-	O
induced	O
neuronal	O
degeneration	O
in	O
vivo	O
.	O

Parkin	S-Protein
increased	O
proteasomal	O
activity	O
,	O
and	O
proteasomal	O
inhibition	O
blocked	O
the	O
effects	O
of	O
parkin	S-Protein
on	O
reducing	O
Abeta	S-Protein
(	O
1	O
-	O
42	O
)	O
levels	O
.	O

Incubation	O
of	O
Abeta	S-Protein
(	O
1	O
-	O
42	O
)	O
cell	O
lysates	O
with	O
ubiquitin	S-Protein
,	O
in	O
the	O
presence	O
of	O
parkin	S-Protein
,	O
demonstrated	O
the	O
generation	O
of	O
Abeta	S-Protein
-	O
ubiquitin	S-Protein
complexes	O
.	O

These	O
data	O
indicate	O
that	O
parkin	S-Protein
promotes	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
of	O
intracellular	O
Abeta	S-Protein
(	O
1	O
-	O
42	O
)	O
and	O
demonstrate	O
a	O
protective	O
effect	O
in	O
neurodegenerative	O
diseases	O
with	O
Abeta	S-Protein
deposits	O
.	O

Characterization	O
of	O
seminoma	O
-	O
derived	O
placental	B-Protein
-	I-Protein
like	I-Protein
alkaline	I-Protein
phosphatase	E-Protein
.	O

Characteristics	O
of	O
placental	B-Protein
-	I-Protein
like	I-Protein
alkaline	I-Protein
phosphatase	E-Protein
(	O
PLAP	B-Protein
-	I-Protein
like	E-Protein
enzyme	O
)	O
in	O
seminoma	O
was	O
studied	O
.	O

By	O
use	O
of	O
lectin	O
affinity	O
chromatography	O
,	O
PLAP	B-Protein
-	I-Protein
like	E-Protein
enzyme	O
in	O
seminoma	O
revealed	O
extra	O
sugar	O
chains	O
compared	O
to	O
placental	B-Protein
alkaline	I-Protein
phosphatase	E-Protein
(	O
PLAP	S-Protein
)	O
,	O
indicating	O
heterogeneity	O
of	O
the	O
carbohydrate	O
moiety	O
.	O

However	O
,	O
the	O
glycosylation	O
patterns	O
were	O
found	O
to	O
be	O
essentially	O
similar	O
between	O
seminoma	O
and	O
normal	O
testis	O
.	O

On	O
isoelectric	O
focusing	O
,	O
differences	O
in	O
migration	O
patterns	O
were	O
revealed	O
between	O
seminoma	O
-	O
derived	O
and	O
normal	O
testis	O
-	O
derived	O
PLAP	B-Protein
-	I-Protein
like	E-Protein
enzyme	O
as	O
well	O
as	O
between	O
PLAP	B-Protein
-	I-Protein
like	E-Protein
enzyme	O
and	O
PLAP	S-Protein
.	O

The	O
differences	O
in	O
charge	O
were	O
mainly	O
due	O
to	O
differences	O
in	O
sialylation	O
of	O
the	O
molecules	O
.	O

The	O
complex	O
pattern	O
of	O
PLAP	B-Protein
-	I-Protein
like	E-Protein
enzyme	O
from	O
seminoma	O
on	O
isoelectric	O
focusing	O
was	O
not	O
altered	O
by	O
neuraminidase	O
treatment	O
,	O
indicating	O
a	O
considerable	O
charge	O
heterogeneity	O
within	O
the	O
population	O
of	O
the	O
enzyme	O
molecules	O
from	O
the	O
tumor	O
.	O

Role	O
of	O
glycosylation	O
in	O
conformational	O
stability	O
,	O
activity	O
,	O
macromolecular	O
interaction	O
and	O
immunogenicity	O
of	O
recombinant	O
human	O
factor	B-Protein
VIII	E-Protein
.	O

Factor	B-Protein
VIII	E-Protein
(	O
FVIII	S-Protein
)	O
is	O
a	O
multi	O
-	O
domain	O
glycoprotein	O
that	O
is	O
an	O
essential	O
cofactor	O
in	O
the	O
blood	O
coagulation	O
cascade	O
.	O

Its	O
deficiency	O
or	O
dysfunction	O
causes	O
hemophilia	O
A	O
,	O
a	O
bleeding	O
disorder	O
.	O

Replacement	O
using	O
exogenous	O
recombinant	O
human	O
factor	B-Protein
VIII	E-Protein
(	O
rFVIII	S-Protein
)	O
is	O
the	O
first	O
line	O
of	O
therapy	O
for	O
hemophilia	O
A	O
.	O

The	O
role	O
of	O
glycosylation	O
on	O
the	O
activity	O
,	O
stability	O
,	O
protein	O
-	O
lipid	O
interaction	O
,	O
and	O
immunogenicity	O
of	O
FVIII	S-Protein
is	O
not	O
known	O
.	O

In	O
order	O
to	O
investigate	O
the	O
role	O
of	O
glycosylation	O
,	O
a	O
deglycosylated	O
form	O
of	O
FVIII	S-Protein
was	O
generated	O
by	O
enzymatic	O
cleavage	O
of	O
carbohydrate	O
chains	O
.	O

The	O
biochemical	O
properties	O
of	O
fully	O
glycosylated	O
and	O
completely	O
deglycosylated	O
forms	O
of	O
rFVIII	S-Protein
(	O
degly	O
rFVIII	S-Protein
)	O
were	O
compared	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
size	O
exclusion	O
chromatography	O
,	O
and	O
clotting	O
activity	O
studies	O
.	O

The	O
biological	O
activity	O
of	O
degly	O
FVIII	S-Protein
decreased	O
in	O
comparison	O
to	O
the	O
fully	O
glycosylated	O
protein	O
.	O

The	O
ability	O
of	O
degly	O
rFVIII	S-Protein
to	O
interact	O
with	O
phosphatidylserine	O
containing	O
membranes	O
was	O
partly	O
impaired	O
.	O

Data	O
suggested	O
that	O
glycosylation	O
significantly	O
influences	O
the	O
stability	O
and	O
the	O
biologically	O
relevant	O
macromolecular	O
interactions	O
of	O
FVIII	S-Protein
.	O

The	O
effect	O
of	O
glycosylation	O
on	O
immunogenicity	O
was	O
investigated	O
in	O
a	O
murine	O
model	O
of	O
hemophilia	O
A	O
.	O

Studies	O
showed	O
that	O
deletion	O
of	O
glycosylation	O
did	O
not	O
increase	O
immunogenicity	O
.	O

NBR1	S-Protein
and	O
p62	S-Protein
as	O
cargo	O
receptors	O
for	O
selective	O
autophagy	O
of	O
ubiquitinated	O
targets	O
.	O

Autophagy	O
is	O
an	O
evolutionary	O
conserved	O
cell	O
survival	O
process	O
for	O
degradation	O
of	O
long	O
-	O
lived	O
proteins	O
,	O
damaged	O
organelles	O
and	O
protein	O
aggregates	O
.	O

The	O
mammalian	O
proteins	O
p62	S-Protein
and	O
NBR1	S-Protein
are	O
selectively	O
degraded	O
by	O
autophagy	O
and	O
can	O
act	O
as	O
cargo	O
receptors	O
or	O
adaptors	O
for	O
the	O
autophagic	O
degradation	O
of	O
ubiquitinated	O
substrates	O
.	O

Despite	O
differing	O
in	O
size	O
and	O
primary	O
sequence	O
,	O
both	O
proteins	O
share	O
a	O
similar	O
domain	O
architecture	O
containing	O
an	O
N	O
-	O
terminal	O
PB1	O
domain	O
,	O
a	O
LIR	O
motif	O
interacting	O
with	O
ATG8	O
family	O
proteins	O
,	O
and	O
a	O
C	O
-	O
terminal	O
UBA	O
domain	O
interacting	O
with	O
ubiquitin	S-Protein
.	O

The	O
LIR	O
motif	O
is	O
essential	O
for	O
their	O
autophagic	O
degradation	O
,	O
indicating	O
that	O
ATG8	O
family	O
proteins	O
are	O
responsible	O
for	O
the	O
docking	O
of	O
p62	S-Protein
and	O
NBR1	S-Protein
to	O
nucleating	O
autophagosomes	O
.	O

p62	S-Protein
and	O
NBR1	S-Protein
co	O
-	O
operate	O
in	O
the	O
sequestration	O
of	O
misfolded	O
and	O
ubiquitinated	O
proteins	O
in	O
p62	S-Protein
bodies	O
and	O
are	O
both	O
required	O
for	O
their	O
degradation	O
by	O
autophagy	O
.	O

Here	O
we	O
discuss	O
the	O
role	O
of	O
p62	S-Protein
and	O
NBR1	S-Protein
in	O
degradation	O
of	O
ubiquitinated	O
cargoes	O
and	O
the	O
putative	O
role	O
of	O
LIR	O
as	O
a	O
general	O
motif	O
for	O
docking	O
of	O
proteins	O
to	O
ATG8	O
family	O
proteins	O
.	O

Lung	O
cancer	O
-	O
associated	O
JmjC	O
domain	O
protein	O
mdig	S-Protein
suppresses	O
formation	O
of	O
tri	O
-	O
methyl	O
lysine	O
9	O
of	O
histone	B-Protein
H3	E-Protein
.	O

Lung	O
cancer	O
is	O
the	O
most	O
common	O
cancer	O
worldwide	O
,	O
accounting	O
for	O
1	O
.	O
3	O
million	O
cancer	O
deaths	O
annually	O
.	O

Despite	O
extensive	O
studies	O
over	O
the	O
past	O
decade	O
,	O
the	O
detailed	O
mechanism	O
about	O
the	O
initiation	O
and	O
development	O
of	O
the	O
lung	O
cancer	O
is	O
still	O
elusive	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
showed	O
that	O
overexpression	O
of	O
mdig	S-Protein
is	O
a	O
common	O
feature	O
of	O
the	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Gene	O
silencing	O
or	O
overexpression	O
of	O
mdig	S-Protein
revealed	O
that	O
mdig	S-Protein
is	O
involved	O
in	O
demethylation	O
of	O
tri	O
-	O
methyl	O
lysine	O
9	O
on	O
histone	B-Protein
H3	E-Protein
,	O
leading	O
to	O
an	O
increase	O
in	O
ribosomal	O
RNA	O
expression	O
.	O

The	O
transcriptional	O
regulation	O
of	O
ribosomal	O
RNA	O
gene	O
by	O
mdig	S-Protein
is	O
achieved	O
through	O
abrogating	O
tri	O
-	O
methyl	O
lysine	O
9	O
on	O
histone	B-Protein
H3	E-Protein
and	O
enhancing	O
RNA	O
polymerase	O
I	O
occupancy	O
in	O
the	O
promoter	O
region	O
of	O
the	O
ribosomal	O
RNA	O
gene	O
as	O
demonstrated	O
by	O
chromatin	O
immunoprecipitation	O
.	O

The	O
pronounced	O
expression	O
of	O
mdig	S-Protein
in	O
lung	O
cancer	O
tissues	O
but	O
not	O
normal	O
lung	O
tissues	O
,	O
thus	O
,	O
suggests	O
that	O
mdig	S-Protein
possesses	O
oncogenic	O
property	O
through	O
antagonizing	O
tri	O
-	O
methyl	O
lysine	O
9	O
on	O
histone	B-Protein
H3	E-Protein
and	O
promoting	O
ribosomal	O
RNA	O
synthesis	O
.	O

Nicotinamide	O
reduces	O
dopamine	O
in	O
postnatal	O
hypothalamus	O
and	O
causes	O
dopamine	O
-	O
deficient	O
phenotype	O
.	O

Dopamine	O
is	O
an	O
important	O
neurotransmitter	O
in	O
the	O
human	O
central	O
nervous	O
system	O
and	O
also	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
postnatal	O
brains	O
.	O

We	O
previously	O
reported	O
that	O
nicotinamide	O
,	O
a	O
SIRT1	S-Protein
inhibitor	O
,	O
regulates	O
tyrosine	B-Protein
hydroxylase	E-Protein
(	O
TH	S-Protein
)	O
expression	O
in	O
vitro	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
nicotinamide	O
-	O
mediated	O
TH	S-Protein
regulation	O
in	O
vivo	O
,	O
nicotinamide	O
was	O
chronically	O
injected	O
into	O
neonatal	O
mice	O
.	O

Interestingly	O
,	O
nicotinamide	O
-	O
treated	O
mice	O
were	O
smaller	O
in	O
size	O
,	O
and	O
their	O
locomotor	O
activity	O
was	O
reduced	O
.	O

L	O
-	O
DOPA	O
treatment	O
caused	O
hypersensitive	O
locomotor	O
activity	O
that	O
indicates	O
a	O
dopamine	O
-	O
depleted	O
state	O
.	O

These	O
changes	O
seemed	O
to	O
be	O
associated	O
with	O
dopamine	O
metabolism	O
in	O
hypothalamus	O
,	O
since	O
dopamine	O
in	O
hypothalamus	O
was	O
reduced	O
but	O
not	O
in	O
striatum	O
.	O

The	O
present	O
study	O
suggests	O
that	O
the	O
regulation	O
of	O
dopamine	O
metabolism	O
during	O
the	O
postnatal	O
development	O
is	O
important	O
and	O
the	O
underlying	O
molecular	O
mechanisms	O
may	O
be	O
associated	O
with	O
SIRT1	S-Protein
signaling	O
.	O

Differential	O
methylation	O
pattern	O
of	O
ID4	S-Protein
,	O
SFRP1	S-Protein
,	O
and	O
SHP1	S-Protein
between	O
acute	O
myeloid	O
leukemia	O
and	O
chronic	O
myeloid	O
leukemia	O
.	O

To	O
gain	O
insight	O
into	O
the	O
differential	O
mechanism	O
of	O
gene	O
promoter	O
hypermethylation	O
in	O
acute	O
and	O
chronic	O
leukemia	O
,	O
we	O
identified	O
the	O
methylation	O
status	O
on	O
one	O
part	O
of	O
5	O
'	O
CpG	O
rich	O
region	O
of	O
8	O
genes	O
,	O
DAB2IP	S-Protein
,	O
DLC	B-Protein
-	I-Protein
1	E-Protein
,	O
H	B-Protein
-	I-Protein
cadherin	E-Protein
,	O
ID4	S-Protein
,	O
Integrin	B-Protein
alpha4	E-Protein
,	O
RUNX3	S-Protein
,	O
SFRP1	S-Protein
,	O
and	O
SHP1	S-Protein
in	O
bone	O
marrows	O
from	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
and	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
patients	O
.	O

Also	O
,	O
we	O
compared	O
the	O
methylation	O
status	O
of	O
genes	O
in	O
AML	O
and	O
CML	O
using	O
methylation	O
-	O
specific	O
PCR	O
(	O
MSP	O
)	O
.	O

The	O
frequencies	O
of	O
DNA	O
methylation	O
of	O
ID4	S-Protein
,	O
SFRP1	S-Protein
,	O
and	O
SHP1	S-Protein
were	O
higher	O
in	O
AML	O
patients	O
compared	O
to	O
those	O
in	O
CML	O
patients	O
.	O

In	O
contrast	O
,	O
no	O
statistical	O
difference	O
between	O
AML	O
and	O
CML	O
was	O
detected	O
for	O
other	O
genes	O
such	O
as	O
DLC	B-Protein
-	I-Protein
1	E-Protein
,	O
DAB2IP	S-Protein
,	O
H	B-Protein
-	I-Protein
cadherin	E-Protein
,	O
Integrin	B-Protein
alpha4	E-Protein
,	O
and	O
RUNX3	S-Protein
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
these	O
methylation	O
-	O
controlled	O
genes	O
may	O
have	O
different	O
roles	O
in	O
AML	O
and	O
CML	O
,	O
and	O
thus	O
,	O
may	O
act	O
as	O
a	O
biological	O
marker	O
of	O
AML	O
.	O

Proteasome	O
inhibition	O
modulates	O
kinase	O
activation	O
in	O
neural	O
cells	O
:	O
relevance	O
to	O
ubiquitination	O
,	O
ribosomes	O
,	O
and	O
survival	O
.	O

In	O
this	O
study	O
we	O
examined	O
whether	O
established	O
signal	O
transduction	O
cascades	O
,	O
p44	S-Protein
/	O
42	S-Protein
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
ERK1	S-Protein
/	O
2	S-Protein
)	O
and	O
Jun	O
N	O
-	O
terminal	O
kinases	O
(	O
JNK	O
)	O
pathways	O
,	O
are	O
altered	O
in	O
N2a	O
neural	O
cells	O
in	O
response	O
to	O
proteasome	O
inhibition	O
.	O

Additionally	O
,	O
we	O
sought	O
to	O
elucidate	O
the	O
relative	O
contribution	O
of	O
these	O
signal	O
transduction	O
pathways	O
to	O
the	O
multiple	O
downstream	O
effects	O
of	O
proteasome	O
inhibition	O
.	O

Our	O
data	O
indicate	O
that	O
ERK1	S-Protein
/	O
2	S-Protein
and	O
JNK	O
are	O
activated	O
in	O
response	O
to	O
proteasome	O
inhibition	O
.	O

Washout	O
of	O
proteasome	O
inhibitor	O
(	O
MG132	O
)	O
results	O
in	O
an	O
enhancement	O
of	O
ERK1	S-Protein
/	O
2	S-Protein
activation	O
and	O
amelioration	O
of	O
JNK	O
activation	O
.	O

Treatment	O
with	O
an	O
established	O
MAPK	O
inhibitor	O
resulted	O
in	O
an	O
increase	O
in	O
proteasome	O
inhibitor	O
toxicity	O
,	O
and	O
incubation	O
with	O
JNK	O
inhibitor	O
was	O
observed	O
to	O
attenuate	O
proteasome	O
inhibitor	O
toxicity	O
significantly	O
.	O

Subsequent	O
studies	O
demonstrated	O
that	O
inhibition	O
of	O
ERK1	S-Protein
/	O
2	S-Protein
and	O
JNK	O
activity	O
does	O
not	O
alter	O
the	O
gross	O
increase	O
in	O
ubiquitinated	O
protein	O
following	O
proteasome	O
inhibitor	O
administration	O
.	O

Similarly	O
,	O
ERK1	S-Protein
/	O
2	S-Protein
and	O
JNK	O
activity	O
do	O
not	O
appear	O
to	O
play	O
a	O
role	O
in	O
the	O
disruption	O
of	O
polysomes	O
following	O
proteasome	O
inhibitor	O
administration	O
in	O
neural	O
cells	O
.	O

Together	O
these	O
data	O
indicate	O
that	O
ERK1	S-Protein
/	O
2	S-Protein
and	O
JNK	O
activation	O
may	O
play	O
differential	O
roles	O
in	O
modulating	O
neurochemical	O
disturbances	O
and	O
neurotoxicity	O
induced	O
by	O
proteasome	O
inhibition	O
.	O

Epigenetic	O
regulation	O
of	O
the	O
alternatively	O
activated	O
macrophage	O
phenotype	O
.	O

Alternatively	O
activated	O
(	O
M2	O
)	O
macrophages	O
play	O
critical	O
roles	O
in	O
diverse	O
chronic	O
diseases	O
,	O
including	O
parasite	O
infections	O
,	O
cancer	O
,	O
and	O
allergic	O
responses	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
acquisition	O
and	O
maintenance	O
of	O
their	O
phenotype	O
.	O

We	O
report	O
that	O
M2	O
-	O
macrophage	O
marker	O
genes	O
are	O
epigenetically	O
regulated	O
by	O
reciprocal	O
changes	O
in	O
histone	B-Protein
H3	E-Protein
lysine	O
-	O
4	O
(	O
H3K4	S-Protein
)	O
and	O
histone	B-Protein
H3	E-Protein
lysine	O
-	O
27	O
(	O
H3K27	S-Protein
)	O
methylation	O
;	O
and	O
the	O
latter	O
methylation	O
marks	O
are	O
removed	O
by	O
the	O
H3K27	O
demethylase	O
Jumonji	B-Protein
domain	I-Protein
containing	I-Protein
3	E-Protein
(	O
Jmjd3	S-Protein
)	O
.	O

We	O
found	O
that	O
continuous	O
interleukin	B-Protein
-	I-Protein
4	E-Protein
(	O
IL	B-Protein
-	I-Protein
4	E-Protein
)	O
treatment	O
leads	O
to	O
decreased	O
H3K27	S-Protein
methylation	O
,	O
at	O
the	O
promoter	O
of	O
M2	O
marker	O
genes	O
,	O
and	O
a	O
concomitant	O
increase	O
in	O
Jmjd3	S-Protein
expression	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
IL	B-Protein
-	I-Protein
4	E-Protein
-	O
dependent	O
Jmjd3	S-Protein
expression	O
is	O
mediated	O
by	O
STAT6	S-Protein
,	O
a	O
major	O
transcription	O
factor	O
of	O
IL	B-Protein
-	I-Protein
4	E-Protein
-	O
mediated	O
signaling	O
.	O

After	O
IL	B-Protein
-	I-Protein
4	E-Protein
stimulation	O
,	O
activated	O
STAT6	S-Protein
is	O
increased	O
and	O
binds	O
to	O
consensus	O
sites	O
at	O
the	O
Jmjd3	S-Protein
promoter	O
.	O

Increased	O
Jmjd3	S-Protein
contributes	O
to	O
the	O
decrease	O
of	O
H3K27	S-Protein
dimethylation	O
and	O
trimethylation	O
(	O
H3K27me2	O
/	O
3	O
)	O
marks	O
as	O
well	O
as	O
the	O
transcriptional	O
activation	O
of	O
specific	O
M2	O
marker	O
genes	O
.	O

The	O
decrease	O
in	O
H3K27me2	O
/	O
3	O
and	O
increase	O
in	O
Jmjd3	S-Protein
recruitment	O
were	O
confirmed	O
by	O
in	O
vivo	O
studies	O
using	O
a	O
Schistosoma	O
mansoni	O
egg	O
-	O
challenged	O
mouse	O
model	O
,	O
a	O
well	O
-	O
studied	O
system	O
known	O
to	O
support	O
an	O
M2	O
phenotype	O
.	O

Collectively	O
,	O
these	O
data	O
indicate	O
that	O
chromatin	O
remodeling	O
is	O
mechanistically	O
important	O
in	O
the	O
acquisition	O
of	O
the	O
M2	O
-	O
macrophage	O
phenotype	O
.	O

The	O
F	O
-	O
box	O
protein	O
FBXO45	S-Protein
promotes	O
the	O
proteasome	O
-	O
dependent	O
degradation	O
of	O
p73	S-Protein
.	O

The	O
transcription	O
factor	O
p73	S-Protein
,	O
a	O
member	O
of	O
the	O
p53	S-Protein
family	O
,	O
mediates	O
cell	O
-	O
cycle	O
arrest	O
and	O
apoptosis	O
in	O
response	O
to	O
DNA	O
damage	O
-	O
induced	O
cellular	O
stress	O
,	O
acting	O
thus	O
as	O
a	O
proapoptotic	O
gene	O
.	O

Similar	O
to	O
p53	S-Protein
,	O
p73	S-Protein
activity	O
is	O
regulated	O
by	O
post	O
-	O
translational	O
modification	O
,	O
including	O
phosphorylation	O
,	O
acetylation	O
and	O
ubiquitylation	O
.	O

In	O
C	O
.	O
elegans	O
,	O
the	O
F	O
-	O
box	O
protein	O
FSN	B-Protein
-	I-Protein
1	E-Protein
controls	O
germline	O
apoptosis	O
by	O
regulating	O
CEP	B-Protein
-	I-Protein
1	E-Protein
,	O
the	O
single	O
ancestral	O
p53	S-Protein
family	O
member	O
.	O

Here	O
we	O
report	O
that	O
FBXO45	S-Protein
,	O
the	O
human	O
ortholog	O
of	O
FSN	B-Protein
-	I-Protein
1	E-Protein
,	O
binds	O
specifically	O
to	O
p73	S-Protein
triggering	O
its	O
proteasome	O
-	O
dependent	O
degradation	O
.	O

Importantly	O
,	O
SCF	O
(	O
FBXO45	S-Protein
)	O
ubiquitylates	O
p73	S-Protein
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Moreover	O
,	O
siRNA	O
-	O
mediated	O
depletion	O
of	O
FBXO45	S-Protein
stabilizes	O
p73	S-Protein
and	O
concomitantly	O
induces	O
cell	O
death	O
in	O
a	O
p53	S-Protein
-	O
independent	O
manner	O
.	O

All	O
together	O
,	O
these	O
results	O
show	O
that	O
the	O
orphan	O
F	O
-	O
box	O
protein	O
FBXO45	S-Protein
regulates	O
the	O
stability	O
of	O
p73	S-Protein
,	O
highlighting	O
a	O
conserved	O
pathway	O
evolved	O
from	O
nematode	O
to	O
human	O
by	O
which	O
the	O
p53	S-Protein
members	O
are	O
regulated	O
by	O
an	O
SCF	O
-	O
dependent	O
mechanism	O
.	O

Structural	O
basis	O
for	O
binding	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
to	O
the	O
oxygen	O
-	O
sensing	O
prolyl	O
hydroxylases	O
.	O

The	O
oxygen	O
-	O
dependent	O
hydroxylation	O
of	O
proline	O
residues	O
in	O
the	O
alpha	O
subunit	O
of	O
hypoxia	O
-	O
inducible	O
transcription	O
factor	O
(	O
HIFalpha	O
)	O
is	O
central	O
to	O
the	O
hypoxic	O
response	O
in	O
animals	O
.	O

Prolyl	O
hydroxylation	O
of	O
HIFalpha	O
increases	O
its	O
binding	O
to	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	E-Protein
protein	O
(	O
pVHL	S-Protein
)	O
,	O
so	O
signaling	O
for	O
degradation	O
via	O
the	O
ubiquitin	S-Protein
-	O
proteasome	O
system	O
.	O

The	O
HIF	O
prolyl	O
hydroxylases	O
(	O
PHDs	O
,	O
prolyl	O
hydroxylase	O
domain	O
enzymes	O
)	O
are	O
related	O
to	O
the	O
collagen	O
prolyl	O
hydroxylases	O
,	O
but	O
form	O
unusually	O
stable	O
complexes	O
with	O
their	O
Fe	O
(	O
II	O
)	O
cofactor	O
and	O
2	O
-	O
oxoglutarate	O
cosubstrate	O
.	O

We	O
report	O
crystal	O
structures	O
of	O
the	O
catalytic	O
domain	O
of	O
PHD2	S-Protein
,	O
the	O
most	O
important	O
of	O
the	O
human	O
PHDs	O
,	O
in	O
complex	O
with	O
the	O
C	O
-	O
terminal	O
oxygen	O
-	O
dependent	O
degradation	O
domain	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

Together	O
with	O
biochemical	O
analyses	O
,	O
the	O
results	O
reveal	O
that	O
PHD	O
catalysis	O
involves	O
a	O
mobile	O
region	O
that	O
isolates	O
the	O
hydroxylation	O
site	O
and	O
stabilizes	O
the	O
PHD2	S-Protein
.	O
Fe	O
(	O
II	O
)	O
.	O
2OG	O
complex	O
.	O

The	O
results	O
will	O
be	O
of	O
use	O
in	O
the	O
design	O
of	O
PHD	O
inhibitors	O
aimed	O
at	O
treating	O
anemia	O
and	O
ischemic	O
disease	O
.	O

Proteasomal	O
inhibition	O
alters	O
the	O
trafficking	O
of	O
the	O
neurotrophin	O
receptor	O
TrkA	S-Protein
.	O

Neurotrophin	O
receptors	O
of	O
the	O
Trk	O
family	O
promote	O
neuronal	O
survival	O
.	O

The	O
signal	O
transduction	O
of	O
Trk	O
receptors	O
is	O
regulated	O
by	O
endosomal	O
trafficking	O
.	O

Monoubiquitination	O
of	O
receptor	O
tyrosine	O
kinases	O
is	O
an	O
established	O
signal	O
for	O
sorting	O
of	O
internalized	O
receptors	O
to	O
late	O
endosomes	O
.	O

The	O
NGF	O
receptor	O
TrkA	S-Protein
is	O
sorted	O
to	O
late	O
endosomes	O
and	O
undergoes	O
ubiquitination	O
,	O
indicating	O
a	O
so	O
far	O
undefined	O
regulatory	O
role	O
of	O
proteasomal	O
activity	O
in	O
the	O
trafficking	O
of	O
TrkA	S-Protein
.	O

Surprisingly	O
,	O
we	O
found	O
that	O
proteasomal	O
inhibition	O
alters	O
the	O
trafficking	O
of	O
TrkA	S-Protein
from	O
the	O
late	O
endosomal	O
sorting	O
pathway	O
to	O
the	O
recycling	O
pathway	O
.	O

Many	O
neurodegenerative	O
diseases	O
are	O
associated	O
with	O
impaired	O
proteasomal	O
activity	O
.	O

Thus	O
,	O
our	O
study	O
suggests	O
that	O
missorting	O
of	O
neurotrophic	O
receptors	O
might	O
contribute	O
to	O
neuronal	O
death	O
in	O
those	O
neurodegenerative	O
diseases	O
that	O
are	O
known	O
to	O
be	O
associated	O
with	O
impaired	O
proteasomal	O
function	O
.	O

Purification	O
and	O
characterization	O
of	O
a	O
transgenic	O
corn	O
grain	O
-	O
derived	O
recombinant	O
collagen	B-Protein
type	I-Protein
I	I-Protein
alpha	I-Protein
1	E-Protein
.	O

Corn	O
offers	O
advantages	O
as	O
a	O
transgenic	O
host	O
for	O
producing	O
recombinant	O
proteins	O
required	O
at	O
large	O
volumes	O
(	O
1	O
,	O
000	O
'	O
s	O
of	O
tons	O
per	O
year	O
)	O
and	O
low	O
cost	O
(	O
less	O
than	O
US	O
$	O
50	O
/	O
kg	O
)	O
by	O
generating	O
them	O
as	O
co	O
-	O
products	O
of	O
biorefining	O
.	O

We	O
describe	O
the	O
purification	O
and	O
characterization	O
of	O
a	O
corn	O
grain	O
-	O
derived	O
mammalian	O
structural	O
protein	O
having	O
such	O
market	O
characteristics	O
:	O
a	O
full	O
length	O
recombinant	O
collagen	B-Protein
type	I-Protein
I	I-Protein
alpha	I-Protein
1	E-Protein
(	O
rCI	B-Protein
alpha	I-Protein
1	E-Protein
)	O
chain	O
.	O

Material	O
properties	O
of	O
interest	O
are	O
gelation	O
behavior	O
,	O
which	O
would	O
depend	O
on	O
as	O
yet	O
unverified	O
ability	O
of	O
corn	O
to	O
carry	O
out	O
post	O
-	O
translational	O
prolyl	O
hydroxylation	O
and	O
formation	O
of	O
triple	O
helical	O
conformation	O
.	O

The	O
starting	O
material	O
was	O
grain	O
where	O
the	O
expression	O
of	O
rCI	B-Protein
alpha	I-Protein
1	E-Protein
had	O
been	O
directed	O
by	O
an	O
embryo	O
-	O
specific	O
promoter	O
.	O

Purification	O
consisted	O
of	O
extraction	O
at	O
low	O
pH	O
followed	O
by	O
membrane	O
and	O
chromatographic	O
steps	O
to	O
isolate	O
rCI	B-Protein
alpha	I-Protein
1	E-Protein
for	O
characterization	O
.	O

The	O
amino	O
acid	O
composition	O
and	O
immunoreactivity	O
of	O
CI	B-Protein
alpha	I-Protein
1	E-Protein
was	O
similar	O
to	O
that	O
of	O
an	O
analogous	O
native	O
human	O
CI	B-Protein
alpha	I-Protein
1	E-Protein
and	O
to	O
rCI	B-Protein
alpha	I-Protein
1	E-Protein
produced	O
by	O
the	O
yeast	O
Pichia	O
pastoris	O
.	O

Tandem	O
mass	O
spectrometry	O
confirmed	O
the	O
primary	O
sequence	O
of	O
the	O
corn	O
-	O
derived	O
rCI	B-Protein
alpha	I-Protein
1	E-Protein
with	O
46	O
%	O
coverage	O
.	O

Fragments	O
of	O
the	O
rCI	B-Protein
alpha	I-Protein
1	E-Protein
chains	O
were	O
also	O
observed	O
,	O
possibly	O
caused	O
by	O
endogenous	O
plant	O
proteases	O
.	O

The	O
corn	O
-	O
derived	O
rCI	B-Protein
alpha	I-Protein
1	E-Protein
had	O
a	O
low	O
level	O
of	O
prolyl	O
hydroxylation	O
(	O
approximately	O
1	O
%	O
versus	O
11	O
%	O
)	O
relative	O
to	O
animal	O
-	O
derived	O
CI	B-Protein
alpha	I-Protein
1	E-Protein
and	O
folded	O
into	O
its	O
characteristic	O
triple	O
-	O
helical	O
structure	O
as	O
indicated	O
by	O
its	O
resistance	O
to	O
pepsin	O
digestion	O
below	O
its	O
melting	O
temperature	O
of	O
26	O
(	O
o	O
)	O
C	O
.	O

The	O
29	O
amino	O
acid	O
foldon	O
fused	O
to	O
the	O
C	O
-	O
terminus	O
to	O
initiate	O
triple	O
helix	O
formation	O
was	O
not	O
cleaved	O
from	O
the	O
rCI	B-Protein
alpha	I-Protein
1	E-Protein
chains	O
,	O
but	O
could	O
be	O
removed	O
by	O
pepsin	O
treatment	O
.	O

Glycosylation	O
of	O
proteinase	B-Protein
3	E-Protein
(	O
PR3	S-Protein
)	O
is	O
not	O
required	O
for	O
its	O
reactivity	O
with	O
antineutrophil	O
cytoplasmic	O
antibodies	O
(	O
ANCA	O
)	O
in	O
Wegener	O
'	O
s	O
granulomatosis	O
.	O

OBJECTIVE	O
:	O
The	O
glycosylation	O
status	O
of	O
autoantigens	O
appears	O
to	O
be	O
crucial	O
for	O
the	O
pathogenesis	O
of	O
some	O
autoimmune	O
diseases	O
,	O
since	O
carbohydrates	O
play	O
a	O
crucial	O
role	O
in	O
the	O
distinction	O
of	O
self	O
from	O
non	O
-	O
self	O
.	O

Proteinase	B-Protein
3	E-Protein
(	O
PR3	S-Protein
)	O
,	O
the	O
main	O
target	O
antigen	O
for	O
anti	O
-	O
neutrophil	O
cytoplasmic	O
antibodies	O
(	O
ANCA	O
)	O
in	O
patients	O
with	O
Wegener	O
'	O
s	O
granulomatosis	O
(	O
WG	O
)	O
,	O
contains	O
two	O
Asn	O
-	O
linked	O
glycosylation	O
sites	O
.	O

The	O
present	O
study	O
explores	O
the	O
influence	O
of	O
the	O
glycosylation	O
status	O
of	O
PR3	S-Protein
on	O
the	O
PR3	S-Protein
recognition	O
by	O
ANCA	O
in	O
a	O
well	O
characterized	O
population	O
of	O
patients	O
with	O
WG	O
.	O

METHODS	O
:	O
Forty	O
-	O
four	O
patients	O
with	O
WG	O
(	O
459	O
serum	O
samples	O
)	O
who	O
participated	O
in	O
a	O
multicenter	O
randomized	O
trial	O
,	O
were	O
tested	O
by	O
capture	O
ELISA	O
for	O
ANCA	O
against	O
PR3	S-Protein
and	O
deglycosylated	O
recombinant	O
variants	O
of	O
PR3	S-Protein
.	O

RESULTS	O
:	O
The	O
patients	O
were	O
followed	O
for	O
a	O
median	O
of	O
27	O
months	O
,	O
and	O
the	O
median	O
number	O
of	O
serum	O
samples	O
per	O
patient	O
was	O
10	O
.	O

At	O
baseline	O
,	O
the	O
correlation	O
between	O
the	O
levels	O
of	O
ANCA	O
against	O
PR3	S-Protein
and	O
against	O
all	O
the	O
deglycosylated	O
recombinant	O
variants	O
of	O
PR3	S-Protein
were	O
greater	O
than	O
0	O
.	O
94	O
(	O
?	O
<	O
0	O
.	O
001	O
for	O
all	O
the	O
comparisons	O
)	O
.	O

Longitudinal	O
analyses	O
comparing	O
the	O
levels	O
of	O
ANCA	O
against	O
PR3	S-Protein
versus	O
all	O
the	O
deglycosylated	O
recombinant	O
variants	O
of	O
PR3	S-Protein
,	O
using	O
linear	O
mixed	O
models	O
,	O
showed	O
no	O
significant	O
statistical	O
differences	O
(	O
rho	O
>	O
or	O
=	O
0	O
.	O
90	O
in	O
all	O
cases	O
)	O
.	O

CONCLUSION	O
:	O
The	O
glycosylation	O
status	O
of	O
PR3	S-Protein
has	O
no	O
impact	O
on	O
its	O
recognition	O
by	O
ANCA	O
in	O
WG	O
.	O

The	O
E3	O
ubiquitin	S-Protein
ligase	O
TEB4	S-Protein
mediates	O
degradation	O
of	O
type	B-Protein
2	I-Protein
iodothyronine	I-Protein
deiodinase	E-Protein
.	O

The	O
endoplasmic	O
reticulum	O
resident	O
thyroid	O
hormone	O
-	O
activating	O
type	B-Protein
2	I-Protein
deiodinase	E-Protein
(	O
D2	S-Protein
)	O
is	O
inactivated	O
by	O
ubiquitination	O
via	O
the	O
hedgehog	O
-	O
inducible	O
WSB	B-Protein
-	I-Protein
1	E-Protein
.	O

Ubiquitinated	O
D2	S-Protein
can	O
then	O
be	O
subsequently	O
taken	O
up	O
by	O
the	O
proteasomal	O
system	O
or	O
be	O
reactivated	O
by	O
USP	B-Protein
-	I-Protein
33	E-Protein
/	O
20	S-Protein
-	O
mediated	O
deubiquitination	O
.	O

Given	O
that	O
heterologously	O
expressed	O
D2	S-Protein
accumulates	O
in	O
Saccharomyces	O
cerevisiae	O
lacking	O
the	O
E3	O
ligase	O
Doa10	S-Protein
,	O
we	O
tested	O
whether	O
the	O
human	O
Doa10	S-Protein
ortholog	O
,	O
TEB4	S-Protein
,	O
plays	O
a	O
role	O
in	O
D2	S-Protein
ubiquitination	O
and	O
degradation	O
.	O

In	O
a	O
setting	O
of	O
transient	O
coexpression	O
in	O
HEK	O
-	O
293	O
cells	O
,	O
TEB4	S-Protein
and	O
D2	S-Protein
could	O
be	O
coimmunoprecipitated	O
,	O
and	O
additional	O
TEB4	S-Protein
expression	O
decreased	O
D2	S-Protein
activity	O
by	O
approximately	O
50	O
%	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

A	O
highly	O
efficient	O
TEB4	S-Protein
knockdown	O
(	O
>	O
90	O
%	O
reduction	O
in	O
mRNA	O
and	O
protein	O
levels	O
)	O
decreased	O
D2	S-Protein
ubiquitination	O
and	O
increased	O
D2	S-Protein
activity	O
and	O
protein	O
levels	O
by	O
about	O
fourfold	O
.	O

The	O
other	O
activating	O
deiodinase	O
,	O
D1	S-Protein
,	O
or	O
a	O
truncated	O
D2	S-Protein
molecule	O
(	O
Delta18	B-Protein
-	I-Protein
D2	E-Protein
)	O
that	O
lacks	O
a	O
critical	O
instability	O
domain	O
was	O
not	O
affected	O
by	O
TEB4	S-Protein
knockdown	O
.	O

Furthermore	O
,	O
TEB4	S-Protein
knockdown	O
prolonged	O
D2	S-Protein
activity	O
half	O
-	O
life	O
at	O
least	O
fourfold	O
,	O
even	O
under	O
conditions	O
known	O
to	O
promote	O
D2	S-Protein
ubiquitination	O
.	O

Neither	O
exposure	O
to	O
1	O
microM	O
of	O
the	O
proteasomal	O
inhibitor	O
MG132	O
for	O
24	O
h	O
nor	O
RNA	O
interference	O
WSB	B-Protein
-	I-Protein
1	E-Protein
knockdown	O
resulted	O
in	O
additive	O
effects	O
on	O
D2	O
expression	O
when	O
combined	O
with	O
TEB4	S-Protein
knockdown	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
MSTO	O
-	O
211	O
cells	O
,	O
which	O
endogenously	O
express	O
D2	S-Protein
,	O
after	O
TEB4	S-Protein
knockdown	O
using	O
a	O
lentivirus	O
-	O
based	O
transduction	O
strategy	O
.	O

While	O
TEB4	S-Protein
expression	O
predominates	O
in	O
the	O
hematopoietic	O
lineage	O
,	O
both	O
WSB	B-Protein
-	I-Protein
1	E-Protein
and	O
TEB4	S-Protein
are	O
coexpressed	O
with	O
D2	S-Protein
in	O
a	O
number	O
of	O
tissues	O
and	O
cell	O
types	O
,	O
except	O
the	O
thyroid	O
and	O
brown	O
adipose	O
tissue	O
,	O
where	O
TEB4	S-Protein
expression	O
is	O
minimal	O
.	O

We	O
conclude	O
that	O
TEB4	S-Protein
interacts	O
with	O
and	O
mediates	O
loss	O
of	O
D2	S-Protein
activity	O
,	O
indicating	O
that	O
D2	S-Protein
ubiquitination	O
and	O
degradation	O
can	O
be	O
tissue	O
specific	O
,	O
depending	O
on	O
WSB	B-Protein
-	I-Protein
1	E-Protein
and	O
TEB4	S-Protein
expression	O
levels	O
.	O

The	O
19S	O
proteasome	O
positively	O
regulates	O
histone	S-Protein
methylation	O
at	O
cytokine	O
inducible	O
genes	O
.	O

Studies	O
indicate	O
that	O
the	O
19S	O
proteasome	O
functions	O
in	O
the	O
epigenetic	O
regulation	O
of	O
transcription	O
.	O

We	O
have	O
shown	O
that	O
as	O
in	O
yeast	O
,	O
components	O
of	O
the	O
19S	O
proteasome	O
are	O
crucial	O
for	O
regulating	O
inducible	O
histone	S-Protein
acetylation	O
events	O
in	O
mammalian	O
cells	O
.	O

The	O
19S	O
ATPase	O
Sug1	S-Protein
binds	O
to	O
histone	S-Protein
acetyltransferases	O
and	O
to	O
acetylated	O
histone	B-Protein
H3	E-Protein
and	O
,	O
in	O
the	O
absence	O
of	O
Sug1	S-Protein
,	O
histone	B-Protein
H3	E-Protein
acetylation	O
is	O
dramatically	O
decreased	O
at	O
mammalian	O
promoters	O
.	O

Research	O
in	O
yeast	O
further	O
indicates	O
that	O
the	O
ortholog	O
of	O
Sug1	S-Protein
,	O
Rpt6	S-Protein
,	O
is	O
a	O
link	O
between	O
ubiquitination	O
of	O
histone	B-Protein
H2B	E-Protein
and	O
H3	S-Protein
lysine	O
4	O
trimethylation	O
(	O
H3K4me3	S-Protein
)	O
.	O

To	O
characterize	O
the	O
role	O
that	O
the	O
19S	O
proteasome	O
plays	O
in	O
regulating	O
additional	O
activating	O
modifications	O
,	O
we	O
examined	O
the	O
methylation	O
and	O
ubiquitination	O
status	O
of	O
histones	S-Protein
at	O
inducible	O
mammalian	O
genes	O
.	O

We	O
find	O
that	O
Sug1	S-Protein
is	O
crucial	O
for	O
regulating	O
histone	B-Protein
H3K4me3	E-Protein
and	O
H3R17me2	S-Protein
at	O
the	O
cytokine	O
inducible	O
MHC	O
-	O
II	O
and	O
CIITA	S-Protein
promoters	O
.	O

In	O
the	O
absence	O
of	O
Sug1	S-Protein
,	O
histone	B-Protein
H3K4me3	E-Protein
and	O
H3R17me2	S-Protein
are	O
dramatically	O
decreased	O
,	O
but	O
the	O
loss	O
of	O
Sug1	S-Protein
has	O
no	O
significant	O
effect	O
on	O
H3K36me3	S-Protein
or	O
H2BK120ub	S-Protein
.	O

Our	O
observation	O
that	O
a	O
subunit	O
of	O
hCompass	O
interacts	O
with	O
additional	O
activating	O
histone	S-Protein
modifying	O
enzymes	O
,	O
but	O
fails	O
to	O
bind	O
the	O
CIITA	S-Protein
promoter	O
in	O
the	O
absence	O
of	O
Sug1	S-Protein
,	O
strongly	O
implicates	O
Sug1	S-Protein
in	O
recruiting	O
enzyme	O
complexes	O
responsible	O
for	O
initiating	O
mammalian	O
transcription	O
.	O

Enhancement	O
of	O
L	O
-	O
tryptophan	O
5	O
-	O
hydroxylation	O
activity	O
by	O
structure	O
-	O
based	O
modification	O
of	O
L	B-Protein
-	I-Protein
phenylalanine	I-Protein
4	I-Protein
-	I-Protein
hydroxylase	E-Protein
from	O
Chromobacterium	O
violaceum	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
enhance	O
l	O
-	O
tryptophan	O
hydroxylation	O
activity	O
of	O
l	B-Protein
-	I-Protein
phenylalanine	I-Protein
4	I-Protein
-	I-Protein
hydroxylase	E-Protein
.	O

It	O
had	O
been	O
known	O
that	O
l	B-Protein
-	I-Protein
phenylalanine	I-Protein
4	I-Protein
-	I-Protein
hydroxylase	E-Protein
from	O
Chromobacterium	O
violaceum	O
could	O
convert	O
l	O
-	O
tryptophan	O
to	O
5	O
-	O
hydroxy	O
-	O
l	O
-	O
tryptophan	O
and	O
l	O
-	O
phenylalanine	O
to	O
l	O
-	O
tyrosine	O
;	O
however	O
,	O
the	O
activity	O
for	O
l	O
-	O
tryptophan	O
was	O
extremely	O
low	O
compared	O
to	O
l	O
-	O
phenylalanine	O
activity	O
levels	O
.	O

We	O
used	O
the	O
information	O
on	O
the	O
crystal	O
structures	O
of	O
aromatic	O
amino	O
acid	O
hydroxylases	O
to	O
generate	O
C	O
.	O
violaceuml	O
-	O
phenylalanine	B-Protein
4	I-Protein
-	I-Protein
hydroxylase	E-Protein
with	O
high	O
l	O
-	O
tryptophan	O
hydroxylating	O
activity	O
.	O

In	O
silico	O
structural	O
modeling	O
analysis	O
suggested	O
that	O
hydrophobic	O
and	O
/	O
or	O
stacking	O
interactions	O
with	O
the	O
substrate	O
and	O
cofactor	O
at	O
L101	O
and	O
W180	O
in	O
C	O
.	O
violaceuml	O
-	O
phenylalanine	B-Protein
4	I-Protein
-	I-Protein
hydroxylase	E-Protein
would	O
increase	O
hydroxylation	O
activity	O
.	O

Based	O
on	O
this	O
hypothesis	O
,	O
we	O
introduced	O
a	O
saturation	O
mutagenesis	O
towards	O
these	O
sites	O
followed	O
by	O
the	O
evaluation	O
of	O
5	O
-	O
hydroxy	O
-	O
l	O
-	O
tryptophan	O
productivity	O
using	O
a	O
modified	O
Gibbs	O
assay	O
.	O

Three	O
and	O
nine	O
positive	O
mutants	O
were	O
obtained	O
from	O
the	O
L101	O
and	O
W180	O
mutant	O
libraries	O
,	O
respectively	O
.	O

Among	O
the	O
mutants	O
,	O
L101Y	O
and	O
W180F	O
showed	O
the	O
highest	O
l	O
-	O
tryptophan	O
hydroxylation	O
activity	O
at	O
the	O
respective	O
residues	O
.	O

Steady	O
-	O
state	O
kinetic	O
analysis	O
revealed	O
that	O
k	O
(	O
cat	O
)	O
values	O
for	O
l	O
-	O
tryptophan	O
hydroxylation	O
were	O
increased	O
from	O
0	O
.	O
40	O
(	O
wild	O
-	O
type	O
)	O
to	O
1	O
.	O
02	O
(	O
L101Y	O
)	O
and	O
0	O
.	O
51	O
s	O
(	O
-	O
1	O
)	O
(	O
W180F	O
)	O
.	O

In	O
addition	O
,	O
the	O
double	O
mutant	O
(	O
L101Y	O
-	O
W180F	O
)	O
displayed	O
higher	O
l	O
-	O
tryptophan	O
hydroxylation	O
activity	O
than	O
the	O
wild	O
-	O
type	O
and	O
the	O
W180F	O
and	O
L101Y	O
mutants	O
.	O

The	O
k	O
(	O
cat	O
)	O
value	O
of	O
L101Y	O
-	O
W180F	O
increased	O
to	O
2	O
.	O
08	O
s	O
(	O
-	O
1	O
)	O
,	O
showing	O
a	O
5	O
.	O
2	O
-	O
fold	O
increase	O
compared	O
to	O
wild	O
-	O
type	O
enzyme	O
levels	O
.	O

Histone	B-Protein
H2BK123	E-Protein
monoubiquitination	O
is	O
the	O
critical	O
determinant	O
for	O
H3K4	S-Protein
and	O
H3K79	S-Protein
trimethylation	O
by	O
COMPASS	O
and	O
Dot1	S-Protein
.	O

Histone	B-Protein
H2B	E-Protein
monoubiquitination	O
by	O
Rad6	S-Protein
/	O
Bre1	S-Protein
is	O
required	O
for	O
the	O
trimethylation	O
of	O
both	O
histone	O
H3K4	S-Protein
and	O
H3K79	S-Protein
by	O
COMPASS	O
and	O
Dot1	S-Protein
methyltransferases	O
,	O
respectively	O
.	O

The	O
dependency	O
of	O
methylation	O
at	O
H3K4	S-Protein
and	O
H3K79	S-Protein
on	O
the	O
monoubiquitination	O
of	O
H2BK123	S-Protein
was	O
recently	O
challenged	O
,	O
and	O
extragenic	O
mutations	O
in	O
the	O
strain	O
background	O
used	O
for	O
previous	O
studies	O
or	O
epitope	O
-	O
tagged	O
proteins	O
were	O
suggested	O
to	O
be	O
the	O
sources	O
of	O
this	O
discrepancy	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
H3K4	S-Protein
and	O
H3K79	S-Protein
methylation	O
is	O
solely	O
dependent	O
on	O
H2B	S-Protein
monoubiquitination	O
regardless	O
of	O
any	O
additional	O
alteration	O
to	O
the	O
H2B	S-Protein
sequence	O
or	O
genome	O
.	O

Furthermore	O
,	O
we	O
report	O
that	O
Y131	O
,	O
one	O
of	O
the	O
yeast	O
histone	B-Protein
H2A	E-Protein
/	O
H2B	S-Protein
shuffle	O
strains	O
widely	O
used	O
for	O
the	O
last	O
decade	O
in	O
the	O
field	O
of	O
chromatin	O
and	O
transcription	O
biology	O
,	O
carries	O
a	O
wild	O
-	O
type	O
copy	O
of	O
each	O
of	O
the	O
HTA2	S-Protein
and	O
HTB2	S-Protein
genes	O
under	O
the	O
GAL1	S-Protein
/	O
10	S-Protein
promoter	O
on	O
chromosome	O
II	O
.	O

Therefore	O
,	O
we	O
generated	O
the	O
entire	O
histone	B-Protein
H2A	E-Protein
and	O
H2B	S-Protein
alanine	O
-	O
scanning	O
mutant	O
strains	O
in	O
another	O
background	O
,	O
which	O
does	O
not	O
express	O
wild	O
-	O
type	O
histones	S-Protein
.	O

SKP2	S-Protein
and	O
CKS1	S-Protein
promote	O
degradation	O
of	O
cell	O
cycle	O
regulators	O
and	O
are	O
associated	O
with	O
hepatocellular	O
carcinoma	O
prognosis	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
The	O
cell	O
cycle	O
regulators	O
P21	S-Protein
(	O
WAF1	S-Protein
)	O
,	O
P27	S-Protein
(	O
KIP1	S-Protein
)	O
,	O
P57	S-Protein
(	O
KIP2	S-Protein
)	O
,	O
P130	S-Protein
,	O
RASSF1A	S-Protein
,	O
and	O
FOXO1	S-Protein
are	O
down	O
-	O
regulated	O
during	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
pathogenesis	O
.	O

We	O
investigated	O
the	O
role	O
of	O
the	O
ubiquitin	S-Protein
ligase	O
subunits	O
CKS1	S-Protein
and	O
SKP2	S-Protein
,	O
which	O
regulate	O
proteasome	O
degradation	O
of	O
cell	O
cycle	O
regulators	O
,	O
in	O
HCC	O
progression	O
.	O

METHODS	O
:	O
Human	O
HCC	O
tissues	O
from	O
patients	O
with	O
better	O
(	O
HCCB	O
,	O
>	O
3	O
years	O
survival	O
)	O
and	O
poorer	O
prognosis	O
(	O
HCCP	O
,	O
<	O
3	O
years	O
survival	O
)	O
and	O
HCC	O
cell	O
lines	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
The	O
promoters	O
of	O
P21	S-Protein
(	O
WAF1	S-Protein
)	O
,	O
P27	S-Protein
(	O
KIP1	S-Protein
)	O
,	O
and	O
P57	S-Protein
(	O
KIP2	S-Protein
)	O
were	O
more	O
frequently	O
hypermethylated	O
in	O
HCCP	O
than	O
HCCB	O
.	O

Messenger	O
RNA	O
levels	O
of	O
these	O
genes	O
were	O
up	O
-	O
regulated	O
in	O
samples	O
in	O
which	O
these	O
genes	O
were	O
not	O
methylated	O
;	O
protein	O
levels	O
increased	O
only	O
in	O
HCCB	O
because	O
of	O
CKS1	S-Protein
-	O
and	O
SKP2	S-Protein
-	O
dependent	O
ubiquitination	O
of	O
these	O
proteins	O
in	O
HCCP	O
.	O

The	O
level	O
of	O
SKP2	S-Protein
expression	O
correlated	O
with	O
rate	O
of	O
HCC	O
cell	O
proliferation	O
and	O
level	O
of	O
microvascularization	O
of	O
samples	O
and	O
was	O
inversely	O
correlated	O
with	O
apoptosis	O
and	O
survival	O
.	O

In	O
HCCB	O
,	O
SKP2	S-Protein
activity	O
was	O
balanced	O
by	O
degradation	O
by	O
the	O
ubiquitin	S-Protein
ligase	O
anaphase	O
-	O
promoting	O
complex	O
/	O
cyclosome	O
(	O
APC	O
/	O
C	O
)	O
-	O
CDH1	S-Protein
and	O
up	O
-	O
regulation	O
of	O
SKP2	S-Protein
suppressor	O
histidine	B-Protein
triad	I-Protein
nucleotide	I-Protein
binding	I-Protein
protein	I-Protein
1	E-Protein
(	O
HINT1	S-Protein
)	O
.	O

In	O
HCCP	O
,	O
however	O
,	O
SKP2	S-Protein
was	O
not	O
degraded	O
because	O
of	O
down	O
-	O
regulation	O
of	O
the	O
phosphatase	O
CDC14B	S-Protein
,	O
CDK2	S-Protein
-	O
dependent	O
serine	O
phosphorylation	O
(	O
which	O
inhibits	O
interaction	O
between	O
CDH1	S-Protein
and	O
SKP2	S-Protein
)	O
,	O
and	O
HINT1	S-Protein
inactivation	O
.	O

In	O
HCC	O
cells	O
,	O
small	O
interfering	O
RNA	O
knockdown	O
of	O
SKP2	S-Protein
reduced	O
proliferation	O
and	O
ubiquitination	O
of	O
the	O
cell	O
cycle	O
regulators	O
,	O
whereas	O
SKP2	S-Protein
increased	O
proliferation	O
and	O
reduced	O
expression	O
of	O
cell	O
cycle	O
regulators	O
.	O

CONCLUSIONS	O
:	O
Ubiquitination	O
and	O
proteasome	O
degradation	O
of	O
P21WAF1	S-Protein
,	O
P27KIP1	S-Protein
,	O
P57KIP2	S-Protein
,	O
P130	S-Protein
,	O
RASSF1A	S-Protein
,	O
and	O
FOXO1	S-Protein
and	O
mechanisms	O
that	O
prevent	O
degradation	O
of	O
SKP2	S-Protein
by	O
APC	O
/	O
C	O
-	O
CDH1	S-Protein
contribute	O
to	O
HCC	O
progression	O
.	O

CKS1	S-Protein
-	O
SKP2	S-Protein
ligase	O
might	O
be	O
developed	O
as	O
a	O
therapeutic	O
target	O
or	O
diagnostic	O
marker	O
.	O

PTPIP51	S-Protein
mRNA	O
and	O
protein	O
expression	O
in	O
tissue	O
microarrays	O
and	O
promoter	O
methylation	O
of	O
benign	O
prostate	O
hyperplasia	O
and	O
prostate	O
carcinoma	O
.	O

BACKGROUND	O
:	O
Protein	B-Protein
tyrosine	I-Protein
phosphatase	I-Protein
interacting	I-Protein
protein	I-Protein
51	E-Protein
(	O
PTPIP51	S-Protein
)	O
shows	O
a	O
tissue	O
-	O
specific	O
expression	O
pattern	O
and	O
is	O
associated	O
with	O
cellular	O
differentiation	O
and	O
apoptosis	O
in	O
several	O
mammalian	O
tissues	O
.	O

Overexpression	O
of	O
the	O
full	O
-	O
length	O
protein	O
enhances	O
apoptosis	O
.	O

It	O
is	O
also	O
expressed	O
in	O
various	O
carcinomas	O
.	O

In	O
this	O
study	O
the	O
expression	O
of	O
PTPIP51	S-Protein
and	O
its	O
in	O
vitro	O
interaction	O
partners	O
was	O
investigated	O
in	O
human	O
benign	O
prostate	O
hyperplasia	O
(	O
BPH	O
)	O
and	O
in	O
prostate	O
carcinoma	O
(	O
PCa	O
)	O
.	O

METHODS	O
:	O
Tissue	O
microarrays	O
of	O
human	O
BPH	O
and	O
PCa	O
were	O
analyzed	O
by	O
immunohistochemistry	O
.	O

For	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
cryo	O
samples	O
of	O
BPH	O
and	O
PCa	O
were	O
used	O
.	O

Bisulfite	O
DNA	O
treatment	O
,	O
followed	O
by	O
sequencing	O
of	O
PCR	O
products	O
was	O
performed	O
in	O
order	O
to	O
analyze	O
CpGs	O
methylation	O
within	O
the	O
promoter	O
region	O
of	O
the	O
PTPIP51	S-Protein
gene	O
.	O

RESULTS	O
:	O
PTPIP51	S-Protein
mRNA	O
and	O
protein	O
expression	O
was	O
detected	O
in	O
prostatic	O
epithelia	O
of	O
BPH	O
and	O
in	O
tumor	O
cells	O
of	O
PCa	O
,	O
respectively	O
,	O
and	O
within	O
smooth	O
muscle	O
cells	O
of	O
the	O
stromal	O
compartment	O
.	O

A	O
stronger	O
expression	O
was	O
present	O
in	O
nerve	O
fibers	O
,	O
particularly	O
in	O
PCa	O
,	O
in	O
immune	O
cells	O
and	O
in	O
smooth	O
muscle	O
and	O
endothelial	O
cells	O
of	O
vessels	O
of	O
BPH	O
and	O
PCa	O
.	O

On	O
mRNA	O
levels	O
,	O
a	O
slightly	O
elevated	O
expression	O
of	O
PTPIP51	S-Protein
was	O
observed	O
in	O
the	O
PCa	O
group	O
as	O
tested	O
by	O
real	O
-	O
time	O
quantitative	O
PCR	O
analyses	O
.	O

Methylation	O
experiments	O
revealed	O
that	O
at	O
least	O
70	O
%	O
of	O
methylated	O
CpGs	O
in	O
the	O
CpG	O
island	O
of	O
the	O
PTPIP51	S-Protein
gene	O
promoter	O
region	O
were	O
identified	O
in	O
BPH	O
samples	O
.	O

In	O
contrast	O
,	O
a	O
loss	O
of	O
methylation	O
has	O
been	O
found	O
in	O
the	O
PCa	O
group	O
.	O

CONCLUSION	O
:	O
The	O
promoter	O
methylation	O
status	O
of	O
PTPIP51	S-Protein
seems	O
to	O
influence	O
the	O
expression	O
of	O
PTPIP51	S-Protein
,	O
which	O
was	O
seen	O
as	O
elevated	O
in	O
the	O
PCa	O
.	O

Deubiquitinase	O
activities	O
required	O
for	O
hepatocyte	B-Protein
growth	I-Protein
factor	E-Protein
-	O
induced	O
scattering	O
of	O
epithelial	O
cells	O
.	O

The	O
scattering	O
response	O
of	O
epithelial	O
cells	O
to	O
activation	O
of	O
the	O
Met	S-Protein
receptor	O
tyrosine	O
kinase	O
represents	O
one	O
facet	O
of	O
an	O
"	O
invasive	O
growth	O
"	O
program	O
.	O

It	O
is	O
a	O
complex	O
event	O
that	O
incorporates	O
loss	O
of	O
cell	O
-	O
cell	O
adhesion	O
,	O
morphological	O
changes	O
,	O
and	O
cell	O
motility	O
.	O

Ubiquitination	O
is	O
a	O
reversible	O
posttranslational	O
modification	O
that	O
may	O
target	O
proteins	O
for	O
degradation	O
or	O
coordinate	O
signal	O
transduction	O
pathways	O
.	O

There	O
are	O
approximately	O
79	O
active	O
deubiquitinating	O
enzymes	O
(	O
DUBs	O
)	O
predicted	O
in	O
the	O
human	O
genome	O
.	O

Here	O
,	O
via	O
a	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
library	O
approach	O
,	O
we	O
have	O
identified	O
12	O
DUBs	O
that	O
are	O
necessary	O
for	O
aspects	O
of	O
the	O
hepatocyte	B-Protein
growth	I-Protein
factor	E-Protein
(	O
HGF	S-Protein
)	O
-	O
dependent	O
scattering	O
response	O
of	O
A549	O
cells	O
.	O

Different	O
phenotypes	O
are	O
evident	O
that	O
range	O
from	O
full	O
loss	O
of	O
scattering	O
,	O
similar	O
to	O
receptor	O
knockdown	O
(	O
e	O
.	O
g	O
.	O
,	O
USP30	S-Protein
,	O
USP33	S-Protein
,	O
USP47	S-Protein
)	O
,	O
to	O
loss	O
of	O
cell	O
-	O
cell	O
contacts	O
even	O
in	O
the	O
absence	O
of	O
HGF	S-Protein
but	O
defective	O
motility	O
(	O
e	O
.	O
g	O
.	O
,	O
USP3	S-Protein
,	O
ATXN3L	S-Protein
)	O
.	O

The	O
knockdowns	O
do	O
not	O
incur	O
defective	O
receptor	O
,	O
phosphatidylinositol	O
3	O
-	O
kinase	O
,	O
or	O
MAP	O
kinase	O
activation	O
.	O

Our	O
data	O
suggest	O
widespread	O
involvement	O
of	O
the	O
ubiquitin	S-Protein
system	O
at	O
multiple	O
stages	O
of	O
the	O
Met	S-Protein
activation	O
response	O
,	O
implying	O
significant	O
crosstalk	O
with	O
phosphorylation	O
-	O
based	O
transduction	O
pathways	O
.	O

Development	O
of	O
small	O
-	O
molecule	O
inhibitors	O
of	O
particular	O
DUBs	O
may	O
offer	O
a	O
therapeutic	O
approach	O
to	O
contain	O
metastasis	O
.	O

A	O
luminal	O
flavoprotein	O
in	O
endoplasmic	O
reticulum	O
-	O
associated	O
degradation	O
.	O

The	O
quality	O
control	O
system	O
of	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
discriminates	O
between	O
native	O
and	O
nonnative	O
proteins	O
.	O

The	O
latter	O
are	O
degraded	O
by	O
the	O
ER	O
-	O
associated	O
degradation	O
(	O
ERAD	O
)	O
pathway	O
.	O

Whereas	O
many	O
cytosolic	O
and	O
membrane	O
components	O
of	O
this	O
system	O
are	O
known	O
,	O
only	O
few	O
luminal	O
players	O
have	O
been	O
identified	O
.	O

In	O
this	O
study	O
,	O
we	O
characterize	O
ERFAD	S-Protein
(	O
ER	B-Protein
flavoprotein	I-Protein
associated	I-Protein
with	I-Protein
degradation	E-Protein
)	O
,	O
an	O
ER	O
luminal	O
flavoprotein	O
that	O
functions	O
in	O
ERAD	O
.	O

Upon	O
knockdown	O
of	O
ERFAD	S-Protein
,	O
the	O
degradation	O
of	O
the	O
ERAD	O
model	O
substrate	O
ribophorin	O
332	O
is	O
delayed	O
,	O
and	O
the	O
overall	O
level	O
of	O
polyubiquitinated	O
cellular	O
proteins	O
is	O
decreased	O
.	O

We	O
also	O
identify	O
the	O
ERAD	O
components	O
SEL1L	S-Protein
,	O
OS	B-Protein
-	I-Protein
9	E-Protein
and	O
ERdj5	S-Protein
,	O
a	O
known	O
reductase	O
of	O
ERAD	O
substrates	O
,	O
as	O
interaction	O
partners	O
of	O
ERFAD	S-Protein
.	O

Our	O
data	O
show	O
that	O
ERFAD	S-Protein
facilitates	O
the	O
dislocation	O
of	O
certain	O
ERAD	O
substrates	O
to	O
the	O
cytosol	O
,	O
and	O
we	O
discuss	O
the	O
findings	O
in	O
relation	O
to	O
a	O
potential	O
redox	O
function	O
of	O
the	O
protein	O
.	O

Human	O
deoxyhypusine	B-Protein
hydroxylase	E-Protein
,	O
an	O
enzyme	O
involved	O
in	O
regulating	O
cell	O
growth	O
,	O
activates	O
O2	O
with	O
a	O
nonheme	O
diiron	O
center	O
.	O

Deoxyhypusine	B-Protein
hydroxylase	E-Protein
is	O
the	O
key	O
enzyme	O
in	O
the	O
biosynthesis	O
of	O
hypusine	O
containing	O
eukaryotic	O
translation	O
initiation	O
factor	O
5A	O
(	O
eIF5A	O
)	O
,	O
which	O
plays	O
an	O
essential	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
.	O

Recombinant	O
human	O
deoxyhypusine	B-Protein
hydroxylase	E-Protein
(	O
hDOHH	S-Protein
)	O
has	O
been	O
reported	O
to	O
have	O
oxygen	O
-	O
and	O
iron	O
-	O
dependent	O
activity	O
,	O
an	O
estimated	O
iron	O
/	O
holoprotein	O
stoichiometry	O
of	O
2	O
,	O
and	O
a	O
visible	O
band	O
at	O
630	O
nm	O
responsible	O
for	O
the	O
blue	O
color	O
of	O
the	O
as	O
-	O
isolated	O
protein	O
.	O

EPR	O
,	O
Mossbauer	O
,	O
and	O
XAS	O
spectroscopic	O
results	O
presented	O
herein	O
provide	O
direct	O
spectroscopic	O
evidence	O
that	O
hDOHH	S-Protein
has	O
an	O
antiferromagnetically	O
coupled	O
diiron	O
center	O
with	O
histidines	O
and	O
carboxylates	O
as	O
likely	O
ligands	O
,	O
as	O
suggested	O
by	O
mutagenesis	O
experiments	O
.	O

Resonance	O
Raman	O
experiments	O
show	O
that	O
its	O
blue	O
chromophore	O
arises	O
from	O
a	O
(	O
mu	O
-	O
1	O
,	O
2	O
-	O
peroxo	O
)	O
diiron	O
(	O
III	O
)	O
center	O
that	O
forms	O
in	O
the	O
reaction	O
of	O
the	O
reduced	O
enzyme	O
with	O
O2	O
,	O
so	O
the	O
peroxo	O
form	O
of	O
hDOHH	S-Protein
is	O
unusually	O
stable	O
.	O

Nevertheless	O
we	O
demonstrate	O
that	O
it	O
can	O
carry	O
out	O
the	O
hydroxylation	O
of	O
the	O
deoxyhypusine	O
residue	O
present	O
in	O
the	O
elF5A	O
substrate	O
.	O

Despite	O
a	O
lack	O
of	O
sequence	O
similarity	O
,	O
hDOHH	S-Protein
has	O
a	O
nonheme	O
diiron	O
active	O
site	O
that	O
resembles	O
both	O
in	O
structure	O
and	O
function	O
those	O
found	O
in	O
methane	O
and	O
toluene	O
monooxygenases	O
,	O
bacterial	O
and	O
mammalian	O
ribonucleotide	O
reductases	O
,	O
and	O
stearoyl	O
acyl	O
carrier	O
protein	O
Delta9	B-Protein
-	I-Protein
desaturase	E-Protein
from	O
plants	O
,	O
suggesting	O
that	O
the	O
oxygen	O
-	O
activating	O
diiron	O
motif	O
is	O
a	O
solution	O
arrived	O
at	O
by	O
convergent	O
evolution	O
.	O

Notably	O
,	O
hDOHH	S-Protein
is	O
the	O
only	O
example	O
thus	O
far	O
of	O
a	O
human	O
hydroxylase	O
with	O
such	O
a	O
diiron	O
active	O
site	O
.	O

Peli1	S-Protein
facilitates	O
TRIF	S-Protein
-	O
dependent	O
Toll	O
-	O
like	O
receptor	O
signaling	O
and	O
proinflammatory	O
cytokine	O
production	O
.	O

Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
are	O
pivotal	O
in	O
innate	O
immunity	O
and	O
inflammation	O
.	O

Here	O
we	O
show	O
that	O
genetic	O
deficiency	O
in	O
Peli1	S-Protein
,	O
an	O
E3	O
ubiquitin	S-Protein
ligase	O
,	O
attenuated	O
the	O
induction	O
of	O
proinflammatory	O
cytokines	O
by	O
ligands	O
of	O
TLR3	S-Protein
and	O
TLR4	S-Protein
and	O
rendered	O
mice	O
resistant	O
to	O
septic	O
shock	O
.	O

Peli1	S-Protein
was	O
required	O
for	O
TLR3	S-Protein
-	O
induced	O
activation	O
of	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
and	O
its	O
'	O
downstream	O
'	O
target	O
,	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
but	O
was	O
dispensable	O
for	O
IKK	O
-	O
NF	O
-	O
kappaB	O
activation	O
induced	O
by	O
several	O
other	O
TLRs	O
and	O
the	O
interleukin	O
1	O
(	O
IL	O
-	O
1	O
)	O
receptor	O
.	O

Notably	O
,	O
Peli1	S-Protein
bound	O
to	O
and	O
ubiquitinated	O
RIP1	S-Protein
,	O
a	O
signaling	O
molecule	O
that	O
mediates	O
IKK	O
activation	O
induced	O
by	O
the	O
TLR3	S-Protein
and	O
TLR4	S-Protein
adaptor	O
TRIF	S-Protein
.	O

Our	O
findings	O
suggest	O
that	O
Peli1	S-Protein
is	O
a	O
ubiquitin	S-Protein
ligase	O
needed	O
for	O
the	O
transmission	O
of	O
TRIF	S-Protein
-	O
dependent	O
TLR	O
signals	O
.	O

Tankyrase	O
inhibition	O
stabilizes	O
axin	S-Protein
and	O
antagonizes	O
Wnt	O
signalling	O
.	O

The	O
stability	O
of	O
the	O
Wnt	O
pathway	O
transcription	O
factor	O
beta	B-Protein
-	I-Protein
catenin	E-Protein
is	O
tightly	O
regulated	O
by	O
the	O
multi	O
-	O
subunit	O
destruction	O
complex	O
.	O

Deregulated	O
Wnt	O
pathway	O
activity	O
has	O
been	O
implicated	O
in	O
many	O
cancers	O
,	O
making	O
this	O
pathway	O
an	O
attractive	O
target	O
for	O
anticancer	O
therapies	O
.	O

However	O
,	O
the	O
development	O
of	O
targeted	O
Wnt	O
pathway	O
inhibitors	O
has	O
been	O
hampered	O
by	O
the	O
limited	O
number	O
of	O
pathway	O
components	O
that	O
are	O
amenable	O
to	O
small	O
molecule	O
inhibition	O
.	O

Here	O
,	O
we	O
used	O
a	O
chemical	O
genetic	O
screen	O
to	O
identify	O
a	O
small	O
molecule	O
,	O
XAV939	O
,	O
which	O
selectively	O
inhibits	O
beta	B-Protein
-	I-Protein
catenin	E-Protein
-	O
mediated	O
transcription	O
.	O

XAV939	O
stimulates	O
beta	B-Protein
-	I-Protein
catenin	E-Protein
degradation	O
by	O
stabilizing	O
axin	S-Protein
,	O
the	O
concentration	O
-	O
limiting	O
component	O
of	O
the	O
destruction	O
complex	O
.	O

Using	O
a	O
quantitative	O
chemical	O
proteomic	O
approach	O
,	O
we	O
discovered	O
that	O
XAV939	O
stabilizes	O
axin	O
by	O
inhibiting	O
the	O
poly	O
-	O
ADP	O
-	O
ribosylating	O
enzymes	O
tankyrase	B-Protein
1	E-Protein
and	O
tankyrase	B-Protein
2	E-Protein
.	O

Both	O
tankyrase	O
isoforms	O
interact	O
with	O
a	O
highly	O
conserved	O
domain	O
of	O
axin	S-Protein
and	O
stimulate	O
its	O
degradation	O
through	O
the	O
ubiquitin	S-Protein
-	O
proteasome	O
pathway	O
.	O

Thus	O
,	O
our	O
study	O
provides	O
new	O
mechanistic	O
insights	O
into	O
the	O
regulation	O
of	O
axin	S-Protein
protein	O
homeostasis	O
and	O
presents	O
new	O
avenues	O
for	O
targeted	O
Wnt	O
pathway	O
therapies	O
.	O

Differential	O
expression	O
of	O
glucocorticoid	B-Protein
receptor	E-Protein
transcripts	O
in	O
major	O
depressive	O
disorder	O
is	O
not	O
epigenetically	O
programmed	O
.	O

Hyperactivity	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
is	O
one	O
of	O
the	O
most	O
consistent	O
findings	O
in	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

Impaired	O
HPA	O
feedback	O
may	O
be	O
due	O
to	O
the	O
lower	O
glucocorticoid	B-Protein
receptor	E-Protein
(	O
GR	S-Protein
)	O
or	O
mineralocorticoid	B-Protein
receptor	E-Protein
(	O
MR	S-Protein
)	O
levels	O
in	O
the	O
forebrain	O
.	O

GR	S-Protein
levels	O
are	O
transcriptionally	O
controlled	O
by	O
multiple	O
untranslated	O
alternative	O
first	O
exons	O
,	O
each	O
with	O
its	O
own	O
promoter	O
providing	O
a	O
mechanism	O
for	O
tissue	O
-	O
specific	O
fine	O
-	O
tuning	O
of	O
GR	S-Protein
levels	O
.	O

Recently	O
epigenetic	O
methylation	O
of	O
these	O
GR	S-Protein
promoters	O
was	O
shown	O
to	O
modulate	O
hippocampal	O
GR	S-Protein
levels	O
.	O

Here	O
we	O
investigate	O
in	O
post	O
-	O
mortem	O
brain	O
tissues	O
whether	O
in	O
MDD	O
HPA	O
axis	O
hyperactivity	O
may	O
be	O
due	O
to	O
epigenetic	O
modulation	O
of	O
GR	S-Protein
transcript	O
variants	O
.	O

Levels	O
of	O
GRalpha	S-Protein
,	O
GRbeta	S-Protein
and	O
GR	B-Protein
-	I-Protein
P	E-Protein
transcripts	O
were	O
homogeneous	O
throughout	O
the	O
limbic	O
system	O
,	O
with	O
GRalpha	S-Protein
being	O
the	O
most	O
abundant	O
(	O
83	O
%	O
)	O
,	O
followed	O
by	O
GR	B-Protein
-	I-Protein
P	E-Protein
(	O
5	O
-	O
6	O
%	O
)	O
while	O
GRbeta	S-Protein
was	O
barely	O
detectable	O
(	O
0	O
.	O
02	O
%	O
)	O
.	O

Among	O
the	O
alternative	O
first	O
exons	O
,	O
1B	O
and	O
1C	O
were	O
the	O
most	O
active	O
,	O
while	O
1E	O
and	O
1J	O
showed	O
the	O
lowest	O
expression	O
and	O
transcript	O
1F	O
expressed	O
intermediate	O
levels	O
of	O
about	O
1	O
%	O
.	O

In	O
MDD	O
,	O
total	O
GR	S-Protein
levels	O
were	O
unaltered	O
,	O
although	O
GRalpha	S-Protein
was	O
decreased	O
in	O
the	O
amygdala	O
and	O
cingulate	O
gyrus	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
;	O
transcripts	O
containing	O
exons	O
1B	O
,	O
1C	O
and	O
1F	O
were	O
lower	O
,	O
and	O
1D	O
and1J	O
were	O
increased	O
in	O
some	O
regions	O
.	O

NGFI	B-Protein
-	I-Protein
A	E-Protein
,	O
a	O
transcription	O
factor	O
of	O
exon	O
1F	O
was	O
down	O
-	O
regulated	O
in	O
the	O
hippocampus	O
of	O
MDD	O
patients	O
;	O
concomitantly	O
exon	O
1F	O
expression	O
was	O
reduced	O
.	O

Bisulphite	O
sequencing	O
of	O
the	O
alternative	O
promoters	O
showed	O
low	O
methylation	O
levels	O
in	O
both	O
MDD	O
and	O
control	O
brains	O
.	O

Promoter	O
1F	O
was	O
uniformly	O
unmethylated	O
,	O
suggesting	O
that	O
reduced	O
1F	O
transcript	O
levels	O
are	O
not	O
linked	O
to	O
promoter	O
methylation	O
but	O
to	O
the	O
observed	O
dearth	O
of	O
NGFI	B-Protein
-	I-Protein
A	E-Protein
.	O

Previous	O
studies	O
showed	O
high	O
methylation	O
levels	O
in	O
the	O
1F	O
promoter	O
,	O
associated	O
with	O
childhood	O
abuse	O
.	O

Provided	O
our	O
donors	O
were	O
not	O
abused	O
,	O
our	O
results	O
suggest	O
that	O
the	O
pathomechanism	O
of	O
MDD	O
is	O
similar	O
but	O
nevertheless	O
distinct	O
from	O
that	O
of	O
abuse	O
victims	O
,	O
explaining	O
the	O
clinical	O
similarity	O
of	O
both	O
conditions	O
and	O
that	O
susceptibility	O
to	O
depression	O
may	O
be	O
either	O
predisposed	O
by	O
early	O
trauma	O
or	O
developed	O
independent	O
of	O
such	O
a	O
condition	O
.	O

However	O
,	O
this	O
should	O
be	O
further	O
confirmed	O
in	O
dedicated	O
studies	O
in	O
larger	O
cohorts	O
.	O

The	O
role	O
of	O
asparagine	O
-	O
linked	O
glycosylation	O
site	O
on	O
the	O
catalytic	O
domain	O
of	O
matriptase	S-Protein
in	O
its	O
zymogen	O
activation	O
.	O

Matriptase	S-Protein
is	O
a	O
type	O
II	O
transmembrane	O
serine	O
protease	O
containing	O
one	O
potential	O
site	O
for	O
asparagine	O
-	O
linked	O
glycosylation	O
(	O
N	O
-	O
glycosylation	O
)	O
on	O
the	O
catalytic	O
domain	O
(	O
Asn772	O
)	O
.	O

It	O
has	O
been	O
found	O
that	O
the	O
activation	O
of	O
matriptase	S-Protein
zymogen	O
occurs	O
via	O
a	O
mechanism	O
requiring	O
its	O
own	O
activity	O
and	O
that	O
the	O
N	O
-	O
glycosylation	O
site	O
is	O
critical	O
for	O
the	O
activation	O
.	O

The	O
present	O
study	O
aimed	O
to	O
determine	O
the	O
underlying	O
reasons	O
for	O
the	O
site	O
requirement	O
using	O
Madin	O
-	O
Darby	O
canine	O
kidney	O
cells	O
stably	O
expressing	O
recombinant	O
variants	O
of	O
rat	O
matriptase	S-Protein
.	O

A	O
full	O
-	O
length	O
variant	O
with	O
glutamine	O
substitution	O
at	O
Asn772	O
appeared	O
to	O
be	O
unable	O
to	O
undergo	O
activation	O
because	O
of	O
its	O
catalytic	O
incompetence	O
(	O
i	O
.	O
e	O
.	O
,	O
decreased	O
availability	O
of	O
the	O
soluble	O
catalytic	O
domain	O
and	O
/	O
or	O
of	O
the	O
correctly	O
folded	O
domain	O
)	O
.	O

This	O
was	O
evidenced	O
by	O
the	O
observations	O
that	O
(	O
i	O
)	O
a	O
recombinant	O
catalytic	O
domain	O
of	O
matriptase	S-Protein
with	O
glutamine	O
substitution	O
at	O
the	O
site	O
corresponding	O
to	O
matriptase	S-Protein
Asn772	O
[	O
N772Q	O
-	O
CD	O
-	O
Myc	O
(	O
His	O
)	O
(	O
6	O
)	O
]	O
was	O
not	O
detected	O
in	O
the	O
medium	O
conditioned	O
by	O
transfected	O
cells	O
but	O
was	O
on	O
the	O
cell	O
surface	O
and	O
(	O
ii	O
)	O
purified	O
N772Q	O
-	O
CD	O
-	O
Myc	O
(	O
His	O
)	O
(	O
6	O
)	O
exhibited	O
markedly	O
reduced	O
activity	O
toward	O
a	O
peptide	O
substrate	O
.	O

It	O
is	O
concluded	O
that	O
N	O
-	O
glycosylation	O
site	O
at	O
Asn772	O
of	O
matriptase	S-Protein
is	O
required	O
for	O
the	O
zymogen	O
activation	O
because	O
it	O
plays	O
an	O
important	O
role	O
in	O
rendering	O
this	O
protease	O
catalytically	O
competent	O
in	O
the	O
cellular	O
environment	O
.	O

Occurrence	O
of	O
sulfate	O
in	O
an	O
asparagine	O
-	O
linked	O
complex	O
oligosaccharide	O
of	O
chicken	O
adipose	O
lipoprotein	B-Protein
lipase	E-Protein
.	O

After	O
adipocytes	O
were	O
labeled	O
with	O
Na2	O
[	O
35SO4	O
]	O
,	O
immunoadsorbed	O
with	O
immobilized	O
antilipoprotein	O
lipase	O
,	O
and	O
subjected	O
to	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
fluorography	O
,	O
a	O
labeled	O
band	O
was	O
identified	O
at	O
59	O
,	O
700	O
daltons	O
,	O
the	O
molecular	O
mass	O
of	O
chicken	O
lipoprotein	B-Protein
lipase	E-Protein
(	O
LPL	S-Protein
)	O
.	O

Excess	O
unlabeled	O
LPL	S-Protein
prevented	O
the	O
immunoadsorption	O
of	O
this	O
labeled	O
species	O
,	O
hence	O
the	O
labeled	O
species	O
was	O
determined	O
to	O
be	O
LPL	S-Protein
.	O

Digestion	O
of	O
LPL	S-Protein
with	O
endo	B-Protein
-	I-Protein
beta	I-Protein
-	I-Protein
N	I-Protein
-	I-Protein
acetylglucosaminidase	I-Protein
H	E-Protein
(	O
Endo	B-Protein
H	E-Protein
)	O
caused	O
a	O
shift	O
in	O
mobility	O
of	O
LPL	S-Protein
in	O
SDS	O
-	O
PAGE	O
with	O
no	O
loss	O
of	O
radioactivity	O
,	O
whereas	O
digestion	O
with	O
glycopeptidase	O
F	O
resulted	O
in	O
removal	O
of	O
99	O
%	O
of	O
the	O
radioactivity	O
.	O

Adipocytes	O
cultured	O
with	O
Trans35S	O
-	O
label	O
and	O
tunicamycin	O
produced	O
an	O
LPL	S-Protein
species	O
of	O
52	O
,	O
000	O
daltons	O
,	O
but	O
tunicamycin	O
abolished	O
the	O
incorporation	O
of	O
35SO4	O
into	O
LPL	S-Protein
.	O

This	O
established	O
that	O
35SO4	O
was	O
incorporated	O
into	O
an	O
N	O
-	O
linked	O
oligosaccharide	O
of	O
LPL	S-Protein
.	O

Endo	O
H	O
digestion	O
of	O
pulse	O
-	O
chase	O
labeled	O
LPL	S-Protein
revealed	O
the	O
presence	O
of	O
two	O
complex	O
and	O
one	O
high	O
mannose	O
-	O
type	O
N	O
-	O
linked	O
oligosaccharides	O
.	O

A	O
single	O
35SO4	O
-	O
labeled	O
tryptic	O
peptide	O
was	O
isolated	O
by	O
reverse	O
phase	O
chromatography	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
the	O
peptide	O
established	O
that	O
the	O
35SO4	O
oligosaccharide	O
is	O
conjugated	O
at	O
Asn	O
-	O
45	O
.	O

Behavior	O
of	O
the	O
35SO4	O
-	O
labeled	O
oligosaccharide	O
on	O
concanavalin	O
A	O
-	O
agarose	O
,	O
sequential	O
exoglycosidase	O
digestion	O
,	O
and	O
chemical	O
analysis	O
of	O
the	O
35SO4	O
oligosaccharide	O
confirms	O
that	O
this	O
moiety	O
is	O
of	O
the	O
complex	O
type	O
.	O

Sequential	O
exoglycosidase	O
digestion	O
,	O
thin	O
layer	O
chromatography	O
of	O
the	O
released	O
monosaccharides	O
,	O
and	O
the	O
use	O
of	O
glycosylation	O
inhibitors	O
established	O
that	O
the	O
sulfated	O
sugar	O
is	O
a	O
core	O
N	O
-	O
acetylglucosamine	O
(	O
GlcNAc	O
)	O
.	O

The	O
data	O
show	O
that	O
chicken	O
LPL	S-Protein
contains	O
two	O
complex	O
and	O
one	O
high	O
mannose	O
N	O
-	O
linked	O
oligosaccharides	O
and	O
that	O
35SO4	O
is	O
incorporated	O
into	O
LPL	S-Protein
on	O
a	O
GlcNAc	O
residue	O
of	O
a	O
complex	O
oligosaccharide	O
located	O
at	O
Asn	O
-	O
45	O
.	O

Effect	O
of	O
hydroxyl	O
substitution	O
of	O
flavone	O
on	O
angiogenesis	O
and	O
free	O
radical	O
scavenging	O
activities	O
:	O
a	O
structure	O
-	O
activity	O
relationship	O
studies	O
using	O
computational	O
tools	O
.	O

Angiogenesis	O
is	O
a	O
key	O
process	O
needed	O
for	O
the	O
growth	O
and	O
survival	O
of	O
solid	O
tumors	O
.	O

Anti	O
-	O
angiogenesis	O
may	O
arrest	O
the	O
tumor	O
growth	O
and	O
keep	O
check	O
on	O
cancer	O
metastasis	O
.	O

Developing	O
antiangiogenic	O
agents	O
have	O
remained	O
a	O
significant	O
hope	O
in	O
the	O
mainstream	O
of	O
anticancer	O
research	O
.	O

The	O
free	O
radical	O
implications	O
in	O
the	O
initiation	O
of	O
cancers	O
are	O
well	O
established	O
.	O

In	O
the	O
present	O
studies	O
,	O
simple	O
flavone	O
and	O
flavones	O
with	O
hydroxyl	O
substitution	O
in	O
'	O
A	O
'	O
and	O
'	O
C	O
'	O
ring	O
at	O
3	O
,	O
5	O
,	O
6	O
,	O
and	O
7	O
were	O
studied	O
for	O
antiangiogenic	O
activities	O
using	O
chorioallantoic	O
membrane	O
(	O
CAM	O
)	O
model	O
and	O
kinetics	O
of	O
DPPH	O
(	O
2	O
,	O
2	O
-	O
diphenyl	O
-	O
1	O
-	O
picryl	O
hydrazine	O
)	O
and	O
superoxide	O
anion	O
radical	O
(	O
SOR	O
)	O
scavenging	O
activities	O
.	O

The	O
docking	O
of	O
selected	O
flavones	O
with	O
specific	O
angiogenic	O
targets	O
such	O
as	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	S-Protein
)	O
,	O
hypoxia	O
inducible	O
factor	O
(	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
)	O
and	O
vascular	B-Protein
endothelial	I-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
-	I-Protein
2	E-Protein
(	O
VEGFR2	S-Protein
)	O
from	O
human	O
origin	O
was	O
carried	O
out	O
to	O
focus	O
the	O
possible	O
underlying	O
mechanism	O
of	O
anti	O
-	O
angiogenesis	O
.	O

The	O
result	O
of	O
the	O
present	O
studies	O
shows	O
that	O
the	O
3	O
-	O
hydroxy	O
substitution	O
of	O
the	O
flavone	O
was	O
found	O
to	O
be	O
the	O
most	O
promising	O
lead	O
for	O
antiangiogenic	O
activity	O
in	O
CAM	O
model	O
.	O

The	O
same	O
was	O
true	O
for	O
DPPH	O
reduction	O
with	O
greater	O
velocity	O
as	O
compared	O
to	O
other	O
hydroxyl	O
substitutions	O
.	O

However	O
the	O
7	O
-	O
and	O
6	O
-	O
hydroxy	O
substitution	O
were	O
observed	O
to	O
be	O
more	O
favourable	O
for	O
SOR	O
scavenging	O
activities	O
as	O
compared	O
to	O
other	O
hydroxyl	O
substitutions	O
.	O

The	O
docking	O
experiments	O
shows	O
that	O
the	O
VEGFR2	S-Protein
seems	O
to	O
be	O
a	O
structurally	O
compatible	O
target	O
for	O
tight	O
binding	O
of	O
the	O
flavones	O
especially	O
with	O
3	O
-	O
hydroxy	O
substitution	O
(	O
-	O
9	O
.	O
78	O
kcal	O
/	O
mole	O
)	O
as	O
compared	O
to	O
VEGF	S-Protein
(	O
-	O
8	O
.	O
47	O
kcal	O
/	O
mole	O
)	O
and	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
(	O
-	O
8	O
.	O
99	O
kcal	O
/	O
mole	O
)	O
.	O

The	O
quantum	O
chemical	O
descriptors	O
of	O
the	O
test	O
flavones	O
related	O
to	O
free	O
radical	O
scavenging	O
and	O
other	O
biological	O
activities	O
were	O
calculated	O
using	O
computational	O
tools	O
.	O

The	O
data	O
is	O
discussed	O
in	O
the	O
light	O
of	O
structure	O
-	O
activity	O
relationship	O
.	O

Discrete	O
domains	O
of	O
MARCH1	S-Protein
mediate	O
its	O
localization	O
,	O
functional	O
interactions	O
,	O
and	O
posttranscriptional	O
control	O
of	O
expression	O
.	O

Within	O
APCs	O
,	O
ubiquitination	O
regulates	O
the	O
trafficking	O
of	O
immune	O
modulators	O
such	O
as	O
MHC	O
class	O
II	O
and	O
CD86	S-Protein
(	O
B7	B-Protein
.	I-Protein
2	E-Protein
)	O
molecules	O
.	O

MARCH1	S-Protein
(	O
membrane	O
-	O
associated	O
RING	O
-	O
CH	O
)	O
,	O
a	O
newly	O
identified	O
ubiquitin	S-Protein
E3	O
ligase	O
expressed	O
in	O
APCs	O
,	O
ubiquitinates	O
MHC	O
class	O
II	O
,	O
thereby	O
reducing	O
its	O
surface	O
expression	O
.	O

Following	O
LPS	O
-	O
induced	O
maturation	O
of	O
dendritic	O
cells	O
,	O
MARCH1	S-Protein
mRNA	O
is	O
down	O
-	O
regulated	O
and	O
MHC	O
class	O
II	O
is	O
redistributed	O
to	O
the	O
cell	O
surface	O
from	O
endosomal	O
compartments	O
.	O

Here	O
,	O
we	O
show	O
that	O
MARCH1	S-Protein
expression	O
is	O
also	O
regulated	O
at	O
the	O
posttranscriptional	O
level	O
.	O

In	O
primary	O
dendritic	O
cell	O
and	O
APC	O
cell	O
lines	O
of	O
murine	O
origin	O
,	O
MARCH1	S-Protein
had	O
a	O
half	O
-	O
life	O
of	O
<	O
30	O
min	O
.	O

MARCH1	S-Protein
degradation	O
appears	O
to	O
occur	O
partly	O
in	O
lysosomes	O
,	O
since	O
inhibiting	O
lysosomal	O
activity	O
stabilized	O
MARCH1	S-Protein
.	O

Similar	O
stabilization	O
was	O
observed	O
when	O
MARCH1	S-Protein
-	O
expressing	O
cells	O
were	O
treated	O
with	O
cysteine	O
protease	O
inhibitors	O
.	O

Mutational	O
analyses	O
of	O
MARCH1	S-Protein
defined	O
discrete	O
domains	O
required	O
for	O
destabilization	O
,	O
proper	O
localization	O
,	O
and	O
functional	O
interaction	O
with	O
substrates	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
MARCH1	S-Protein
expression	O
is	O
regulated	O
at	O
a	O
posttranscriptional	O
level	O
by	O
trafficking	O
within	O
the	O
endolysosomal	O
pathway	O
where	O
MARCH1	S-Protein
is	O
proteolyzed	O
.	O

The	O
short	O
half	O
-	O
life	O
of	O
MARCH1	S-Protein
permits	O
very	O
rapid	O
changes	O
in	O
the	O
levels	O
of	O
the	O
protein	O
in	O
response	O
to	O
changes	O
in	O
the	O
mRNA	O
,	O
resulting	O
in	O
efficient	O
induction	O
of	O
Ag	O
presentation	O
once	O
APCs	O
receive	O
maturational	O
signals	O
.	O

Ubiquitination	O
and	O
degradation	O
of	O
the	O
thrombopoietin	O
receptor	O
c	B-Protein
-	I-Protein
Mpl	E-Protein
.	O

Regulation	O
of	O
growth	O
factor	O
and	O
cytokine	O
signaling	O
is	O
essential	O
for	O
maintaining	O
physiologic	O
numbers	O
of	O
circulating	O
hematopoietic	O
cells	O
.	O

Thrombopoietin	S-Protein
(	O
Tpo	S-Protein
)	O
,	O
acting	O
through	O
its	O
receptor	O
c	B-Protein
-	I-Protein
Mpl	E-Protein
,	O
is	O
required	O
for	O
hematopoietic	O
stem	O
cell	O
maintenance	O
and	O
megakaryopoiesis	O
.	O

Therefore	O
,	O
the	O
negative	O
regulation	O
of	O
Tpo	S-Protein
signaling	O
is	O
critical	O
in	O
many	O
aspects	O
of	O
hematopoiesis	O
.	O

In	O
this	O
study	O
,	O
we	O
determine	O
the	O
mechanisms	O
of	O
c	B-Protein
-	I-Protein
Mpl	E-Protein
degradation	O
in	O
the	O
negative	O
regulation	O
of	O
Tpo	S-Protein
signaling	O
.	O

We	O
found	O
that	O
,	O
after	O
Tpo	S-Protein
stimulation	O
,	O
c	B-Protein
-	I-Protein
Mpl	E-Protein
is	O
degraded	O
by	O
both	O
the	O
lysosomal	O
and	O
proteasomal	O
pathways	O
and	O
c	B-Protein
-	I-Protein
Mpl	E-Protein
is	O
rapidly	O
ubiquitinated	O
.	O

Using	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
were	O
able	O
to	O
determine	O
that	O
c	B-Protein
-	I-Protein
Mpl	E-Protein
is	O
ubiquitinated	O
on	O
both	O
of	O
its	O
intracellular	O
lysine	O
(	O
K	O
)	O
residues	O
(	O
K	O
(	O
553	O
)	O
and	O
K	O
(	O
573	O
)	O
)	O
.	O

By	O
mutating	O
these	O
residues	O
to	O
arginine	O
,	O
ubiquitination	O
and	O
degradation	O
were	O
significantly	O
reduced	O
and	O
caused	O
hyperproliferation	O
in	O
cell	O
lines	O
expressing	O
these	O
mutated	O
receptors	O
.	O

Using	O
short	O
interfering	O
RNA	O
and	O
dominant	O
negative	O
overexpression	O
,	O
we	O
also	O
found	O
that	O
c	B-Protein
-	I-Protein
Cbl	E-Protein
,	O
which	O
is	O
activated	O
by	O
Tpo	S-Protein
,	O
acts	O
as	O
an	O
E3	O
ubiquitin	S-Protein
ligase	O
in	O
the	O
ubiquitination	O
of	O
c	B-Protein
-	I-Protein
Mpl	E-Protein
.	O

Our	O
findings	O
identify	O
a	O
previously	O
unknown	O
negative	O
regulatory	O
pathway	O
for	O
Tpo	S-Protein
signaling	O
that	O
may	O
significantly	O
impact	O
our	O
understanding	O
of	O
the	O
mechanisms	O
affecting	O
the	O
growth	O
and	O
differentiation	O
of	O
hematopoietic	O
stem	O
cells	O
and	O
megakaryocytes	O
.	O

Jmjd1a	S-Protein
demethylase	O
-	O
regulated	O
histone	S-Protein
modification	O
is	O
essential	O
for	O
cAMP	B-Protein
-	I-Protein
response	I-Protein
element	I-Protein
modulator	E-Protein
-	O
regulated	O
gene	O
expression	O
and	O
spermatogenesis	O
.	O

Spermatogenesis	O
,	O
a	O
fundamental	O
process	O
in	O
the	O
male	O
reproductive	O
system	O
,	O
requires	O
a	O
series	O
of	O
tightly	O
controlled	O
epigenetic	O
and	O
genetic	O
events	O
in	O
germ	O
cells	O
ranging	O
from	O
spermatogonia	O
to	O
spermatozoa	O
.	O

Jmjd1a	S-Protein
is	O
a	O
key	O
epigenetic	O
regulator	O
expressed	O
in	O
the	O
testis	O
.	O

It	O
specifically	O
demethylates	O
mono	O
-	O
and	O
di	O
-	O
methylated	O
histone	B-Protein
H3	E-Protein
lysine	O
9	O
(	O
H3K9me1	S-Protein
and	O
H3K9me2	S-Protein
)	O
but	O
not	O
tri	O
-	O
methylated	O
H3K9	S-Protein
(	O
H3K9me3	S-Protein
)	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
a	O
Jmjd1a	S-Protein
antibody	O
for	O
immunohistochemistry	O
and	O
found	O
Jmjd1a	S-Protein
was	O
specifically	O
produced	O
in	O
pachytene	O
and	O
secondary	O
spermatocytes	O
.	O

Disruption	O
of	O
the	O
Jmjd1a	S-Protein
gene	O
in	O
mice	O
significantly	O
increased	O
H3K9me1	S-Protein
and	O
H3K9me2	S-Protein
levels	O
in	O
pachytene	O
spermatocytes	O
and	O
early	O
elongating	O
spermatids	O
without	O
affecting	O
H3K9me3	S-Protein
levels	O
.	O

Concurrently	O
,	O
the	O
levels	O
of	O
histone	S-Protein
acetylation	O
were	O
decreased	O
in	O
Jmjd1a	S-Protein
knock	O
-	O
out	O
germ	O
cells	O
.	O

This	O
suggests	O
Jmjd1a	S-Protein
promotes	O
transcriptional	O
activation	O
by	O
lowering	O
histone	S-Protein
methylation	O
and	O
increasing	O
histone	S-Protein
acetylation	O
.	O

Interestingly	O
,	O
the	O
altered	O
histone	S-Protein
modifications	O
in	O
Jmjd1a	S-Protein
-	O
deficient	O
germ	O
cells	O
caused	O
diminished	O
cAMP	B-Protein
-	I-Protein
response	I-Protein
element	I-Protein
modulator	E-Protein
(	O
Crem	S-Protein
)	O
recruitment	O
to	O
chromatin	O
and	O
decreased	O
expression	O
of	O
the	O
Crem	S-Protein
coactivator	O
Act	S-Protein
and	O
their	O
target	O
genes	O
Tnp1	S-Protein
(	O
transition	B-Protein
protein	I-Protein
1	E-Protein
)	O
,	O
Tnp2	S-Protein
,	O
Prm1	S-Protein
(	O
protamine	B-Protein
1	E-Protein
)	O
,	O
and	O
Prm2	S-Protein
,	O
all	O
of	O
which	O
are	O
essential	O
for	O
chromatin	O
condensation	O
in	O
spermatids	O
.	O

In	O
agreement	O
with	O
these	O
findings	O
,	O
Jmjd1a	S-Protein
deficiency	O
caused	O
extensive	O
germ	O
cell	O
apoptosis	O
and	O
blocked	O
spermatid	O
elongation	O
,	O
resulting	O
in	O
severe	O
oligozoospermia	O
,	O
small	O
testes	O
,	O
and	O
infertility	O
in	O
male	O
mice	O
.	O

These	O
results	O
indicate	O
that	O
the	O
Jmjd1a	S-Protein
-	O
controlled	O
epigenetic	O
histone	S-Protein
modifications	O
are	O
crucial	O
for	O
Crem	S-Protein
-	O
regulated	O
gene	O
expression	O
and	O
spermatogenesis	O
.	O

Suppression	O
of	O
cancer	O
cell	O
growth	O
by	O
promoting	O
cyclin	B-Protein
D1	E-Protein
degradation	O
.	O

The	O
cyclin	B-Protein
D1	E-Protein
proto	O
-	O
oncoprotein	O
is	O
a	O
crucial	O
regulator	O
in	O
cell	O
-	O
cycle	O
progression	O
,	O
and	O
aberrant	O
overexpression	O
of	O
cyclin	B-Protein
D1	E-Protein
is	O
linked	O
to	O
tumorigenesis	O
of	O
many	O
different	O
cancer	O
types	O
.	O

By	O
screening	O
ubiquitinated	O
cyclin	B-Protein
D1	E-Protein
as	O
a	O
substrate	O
with	O
a	O
deubiquitinase	O
library	O
,	O
we	O
have	O
identified	O
USP2	S-Protein
as	O
a	O
specific	O
deubiquitinase	O
for	O
cyclin	B-Protein
D1	E-Protein
.	O

USP2	S-Protein
directly	O
interacts	O
with	O
cyclin	B-Protein
D1	E-Protein
and	O
promotes	O
its	O
stabilization	O
by	O
antagonizing	O
ubiquitin	S-Protein
-	O
dependent	O
degradation	O
.	O

Conversely	O
,	O
USP2	S-Protein
knockdown	O
destabilizes	O
cyclin	B-Protein
D1	E-Protein
and	O
induces	O
growth	O
arrest	O
in	O
the	O
human	O
cancer	O
lines	O
where	O
cell	O
growth	O
is	O
dependent	O
on	O
cyclin	B-Protein
D1	E-Protein
expression	O
.	O

Of	O
note	O
,	O
cyclin	B-Protein
D1	E-Protein
is	O
not	O
universally	O
required	O
for	O
cell	O
-	O
cycle	O
progression	O
.	O

Inactivation	O
of	O
USP2	S-Protein
has	O
either	O
very	O
mild	O
effects	O
on	O
cell	O
growth	O
in	O
normal	O
human	O
fibroblasts	O
or	O
no	O
effect	O
in	O
the	O
cancer	O
cells	O
that	O
do	O
not	O
express	O
cyclin	B-Protein
D1	E-Protein
.	O

These	O
findings	O
suggest	O
that	O
targeting	O
USP2	S-Protein
is	O
an	O
effective	O
approach	O
to	O
induce	O
growth	O
suppression	O
in	O
the	O
cancer	O
cells	O
addicted	O
to	O
cyclin	B-Protein
D1	E-Protein
expression	O
.	O

Production	O
and	O
N	O
-	O
glycosylation	O
of	O
recombinant	O
human	O
cell	O
adhesion	O
molecule	O
L1	S-Protein
from	O
insect	O
cells	O
using	O
the	O
stable	O
expression	O
system	O
.	O

Effect	O
of	O
dimethyl	O
sulfoxide	O
.	O

L1	S-Protein
is	O
a	O
cell	O
adhesion	O
molecule	O
that	O
is	O
heavily	O
glycosylated	O
and	O
is	O
essential	O
for	O
normal	O
development	O
of	O
the	O
central	O
nervous	O
system	O
.	O

In	O
this	O
work	O
,	O
we	O
compare	O
the	O
N	O
-	O
glycosylation	O
of	O
the	O
L1	S-Protein
mutant	O
that	O
consists	O
of	O
immunoglobulin	O
domains	O
5	O
and	O
6	O
(	O
L1	S-Protein
/	O
Ig5	O
-	O
6	O
)	O
,	O
expressed	O
in	O
insect	O
Spodoptera	O
frugiperda	O
Sf9	O
and	O
Trichoplusia	O
ni	O
Tn	O
cells	O
,	O
using	O
the	O
stable	O
expression	O
system	O
.	O

L1	S-Protein
/	O
Ig5	O
-	O
6	O
levels	O
of	O
30	O
and	O
8mgl	O
(	O
-	O
1	O
)	O
were	O
obtained	O
from	O
the	O
two	O
cell	O
lines	O
,	O
respectively	O
.	O

The	O
N	O
-	O
glycans	O
were	O
characterized	O
by	O
high	O
-	O
performance	O
anion	O
-	O
exchange	O
-	O
chromatography	O
with	O
pulsed	O
-	O
amperometric	O
-	O
detection	O
and	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
.	O

The	O
N	O
-	O
glycans	O
from	O
Sf9	O
cells	O
were	O
more	O
homogeneous	O
and	O
consisted	O
predominantly	O
of	O
the	O
paucimannose	O
-	O
type	O
structure	O
Manalpha6	O
(	O
Manalpha3	O
)	O
Manbeta4GlcNAcbeta4	O
(	O
Fucalpha6	O
)	O
GlcNAc	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
N	O
-	O
glycans	O
from	O
Tn	O
cells	O
were	O
more	O
heterogeneous	O
and	O
consisted	O
of	O
paucimannose	O
-	O
type	O
structures	O
with	O
or	O
without	O
terminal	O
N	O
-	O
acetylglucosamine	O
.	O

Allergenic	O
proximal	O
alpha3	O
-	O
linked	O
fucose	O
was	O
only	O
found	O
in	O
Tn	O
cells	O
.	O

Dimethyl	O
sulfoxide	O
at	O
1	O
.	O
5	O
%	O
concentration	O
has	O
been	O
found	O
to	O
increase	O
the	O
levels	O
of	O
L1	S-Protein
/	O
Ig5	O
-	O
6	O
and	O
the	O
L1	S-Protein
ectodomain	O
in	O
the	O
Sf9	O
and	O
Tn	O
cells	O
,	O
without	O
affecting	O
cell	O
viability	O
nor	O
protein	O
integrity	O
.	O

Furthermore	O
,	O
the	O
N	O
-	O
glycan	O
composition	O
of	O
L1	S-Protein
/	O
Ig5	O
-	O
6	O
was	O
not	O
affected	O
by	O
dimethyl	O
sulfoxide	O
,	O
with	O
only	O
a	O
slight	O
increase	O
in	O
the	O
percentage	O
of	O
the	O
minor	O
high	O
-	O
mannose	O
-	O
type	O
structures	O
.	O

TdT	B-Protein
interacting	I-Protein
factor	I-Protein
1	E-Protein
enhances	O
TdT	S-Protein
ubiquitylation	O
through	O
recruitment	O
of	O
BPOZ	B-Protein
-	I-Protein
2	E-Protein
into	O
nucleus	O
from	O
cytoplasm	O
.	O

We	O
isolated	O
human	O
cDNA	O
clone	O
encoding	O
Bood	B-Protein
POZ	I-Protein
containing	I-Protein
gene	I-Protein
type	I-Protein
2	E-Protein
(	O
BPOZ	B-Protein
-	I-Protein
2	E-Protein
)	O
as	O
a	O
gene	O
with	O
a	O
product	O
that	O
binds	O
to	O
TdT	B-Protein
interacting	I-Protein
factor	I-Protein
1	E-Protein
(	O
TdIF1	S-Protein
)	O
using	O
a	O
yeast	O
two	O
-	O
hybrid	O
system	O
.	O

BPOZ	B-Protein
-	I-Protein
2	E-Protein
is	O
an	O
adaptor	O
for	O
E3	O
ligase	O
CUL3	S-Protein
and	O
participates	O
in	O
developmental	O
processes	O
.	O

The	O
binding	O
between	O
BPOZ	B-Protein
-	I-Protein
2	E-Protein
and	O
TdIF1	S-Protein
was	O
confirmed	O
by	O
GST	O
pull	O
-	O
down	O
and	O
immunoprecipitation	O
assays	O
using	O
specific	O
antibodies	O
against	O
BPOZ	B-Protein
-	I-Protein
2	E-Protein
and	O
TdIF1	S-Protein
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Although	O
when	O
BPOZ	B-Protein
-	I-Protein
2	E-Protein
solely	O
was	O
expressed	O
in	O
COS7	O
cells	O
,	O
BPOZ	B-Protein
-	I-Protein
2	E-Protein
was	O
observed	O
mainly	O
within	O
the	O
cytoplasm	O
,	O
co	O
-	O
transfection	O
of	O
pEGFP	O
-	O
BPOZ	O
-	O
2	O
and	O
pDsRed	O
-	O
TdIF1	O
into	O
COS7	O
cells	O
resulted	O
in	O
co	O
-	O
localization	O
of	O
EGFP	S-Protein
-	O
BPOZ	B-Protein
-	I-Protein
2	E-Protein
and	O
DsRed	S-Protein
-	O
TdIF1	S-Protein
within	O
the	O
nucleus	O
.	O

TdIF1	S-Protein
may	O
recruit	O
BPOZ	B-Protein
-	I-Protein
2	E-Protein
into	O
the	O
nucleus	O
from	O
the	O
cytoplasm	O
by	O
directly	O
binding	O
to	O
BPOZ	B-Protein
-	I-Protein
2	E-Protein
.	O

BPOZ	B-Protein
-	I-Protein
2	E-Protein
enhanced	O
TdT	S-Protein
ubiquitylation	O
when	O
TdIF1	S-Protein
was	O
expressed	O
together	O
with	O
BPOZ	B-Protein
-	I-Protein
2	E-Protein
in	O
293T	O
cells	O
,	O
strongly	O
suggesting	O
that	O
the	O
recruitment	O
of	O
BPOZ	B-Protein
-	I-Protein
2	E-Protein
into	O
the	O
nucleus	O
from	O
the	O
cytoplasm	O
is	O
significant	O
for	O
the	O
TdT	S-Protein
ubiquitylation	O
within	O
the	O
nucleus	O
.	O

Hydroxylation	O
of	O
4	O
-	O
methylphenylalanine	O
by	O
rat	O
liver	O
phenylalanine	B-Protein
hydroxylase	E-Protein
.	O

Rat	O
liver	O
phenylalanine	B-Protein
hydroxylase	E-Protein
that	O
has	O
been	O
activated	O
with	O
lysolecithin	O
catalyzes	O
the	O
hydroxylation	O
of	O
4	O
-	O
methylphenylalanine	O
in	O
the	O
presence	O
of	O
a	O
pterin	O
cofactor	O
.	O

Two	O
products	O
,	O
4	O
-	O
hydroxymethylphenylalanine	O
and	O
3	O
-	O
methyltyrosine	O
,	O
can	O
be	O
detected	O
.	O

The	O
total	O
amount	O
of	O
amino	O
acids	O
hydroxylated	O
is	O
equal	O
to	O
the	O
amount	O
of	O
tetrahydropterin	O
oxidized	O
.	O

Isotopic	O
labeling	O
studies	O
with	O
18O2	O
and	O
H2	O
(	O
18	O
)	O
O	O
show	O
that	O
the	O
hydroxyl	O
groups	O
of	O
both	O
products	O
are	O
derived	O
from	O
molecular	O
oxygen	O
and	O
not	O
from	O
water	O
.	O

Results	O
obtained	O
with	O
2H	O
-	O
labeled	O
substrates	O
support	O
the	O
conclusion	O
that	O
these	O
products	O
are	O
formed	O
via	O
different	O
mechanistic	O
pathways	O
.	O

Our	O
previous	O
investigations	O
on	O
substrate	O
analogs	O
,	O
as	O
well	O
as	O
the	O
present	O
results	O
,	O
indicate	O
that	O
a	O
highly	O
reactive	O
oxygen	O
-	O
containing	O
intermediate	O
,	O
such	O
as	O
an	O
enzyme	O
-	O
bound	O
iron	O
-	O
oxo	O
compound	O
,	O
must	O
be	O
the	O
hydroxylating	O
species	O
.	O

Our	O
present	O
results	O
could	O
stimulate	O
further	O
discussion	O
of	O
the	O
possibility	O
that	O
the	O
reaction	O
mechanism	O
for	O
the	O
"	O
NIH	O
-	O
shift	O
"	O
of	O
the	O
methyl	O
group	O
may	O
not	O
involve	O
the	O
spontaneous	O
opening	O
of	O
an	O
epoxide	O
intermediate	O
.	O

The	O
Neurospora	O
peptide	O
:	O
N	O
-	O
glycanase	O
ortholog	O
PNG1	S-Protein
is	O
essential	O
for	O
cell	O
polarity	O
despite	O
its	O
lack	O
of	O
enzymatic	O
activity	O
.	O

Secretory	O
proteins	O
are	O
subjected	O
to	O
a	O
stringent	O
endoplasmic	O
reticulum	O
-	O
based	O
quality	O
control	O
system	O
that	O
distinguishes	O
aberrant	O
from	O
correctly	O
folded	O
proteins	O
.	O

The	O
cytoplasmic	O
peptide	O
:	O
N	O
-	O
glycanase	O
cleaves	O
oligosaccharides	O
from	O
misfolded	O
glycoproteins	O
and	O
prepares	O
them	O
for	O
degradation	O
by	O
the	O
26	O
S	O
proteasome	O
.	O

In	O
contrast	O
to	O
abundant	O
in	O
vitro	O
data	O
on	O
its	O
enzymatic	O
function	O
,	O
the	O
in	O
vivo	O
relevance	O
of	O
peptide	O
:	O
N	O
-	O
glycanase	O
activity	O
remains	O
unclear	O
.	O

Here	O
we	O
show	O
that	O
the	O
PNG1	S-Protein
ortholog	O
from	O
the	O
filamentous	O
ascomycete	O
Neurospora	O
crassa	O
is	O
an	O
essential	O
protein	O
,	O
and	O
its	O
deletion	O
results	O
in	O
strong	O
polarity	O
defects	O
.	O

PNG1	S-Protein
and	O
its	O
predicted	O
binding	O
partner	O
RAD23	S-Protein
have	O
distinct	O
functions	O
in	O
N	O
.	O
crassa	O
and	O
are	O
involved	O
in	O
cell	O
wall	O
integrity	O
and	O
DNA	O
repair	O
,	O
respectively	O
.	O

Moreover	O
,	O
wild	O
type	O
PNG1	S-Protein
has	O
substitutions	O
in	O
essential	O
catalytic	O
amino	O
acids	O
,	O
and	O
its	O
deglycosylation	O
activity	O
is	O
lost	O
.	O

These	O
substitutions	O
are	O
conserved	O
in	O
many	O
PNG1	S-Protein
orthologs	O
of	O
the	O
fungal	O
kingdom	O
,	O
implying	O
a	O
so	O
far	O
unrecognized	O
enzyme	O
-	O
independent	O
function	O
of	O
PNG1	S-Protein
that	O
may	O
only	O
become	O
apparent	O
in	O
highly	O
polar	O
cells	O
such	O
as	O
fungal	O
hyphae	O
.	O

Recruitment	O
of	O
the	O
ESCRT	O
machinery	O
to	O
a	O
putative	O
seven	O
-	O
transmembrane	O
-	O
domain	O
receptor	O
is	O
mediated	O
by	O
an	O
arrestin	O
-	O
related	O
protein	O
.	O

Mammalian	O
arrestins	O
have	O
a	O
major	O
role	O
in	O
the	O
intracellular	O
trafficking	O
of	O
seven	O
-	O
transmembrane	O
(	O
7TM	O
)	O
receptors	O
.	O

The	O
fungal	O
ambient	O
pH	O
signaling	O
pathway	O
involves	O
an	O
arrestin	O
-	O
related	O
protein	O
,	O
PalF	S-Protein
/	O
Rim8	S-Protein
,	O
and	O
the	O
ESCRT	O
(	O
endosomal	O
sorting	O
complex	O
required	O
for	O
transport	O
)	O
machinery	O
.	O

We	O
found	O
that	O
in	O
Saccharomyces	O
cerevisiae	O
,	O
Rim8	S-Protein
binds	O
to	O
both	O
the	O
putative	O
7TM	O
pH	O
sensor	O
Rim21	S-Protein
and	O
the	O
ESCRT	O
-	O
I	O
subunit	O
Vps23	S-Protein
.	O

We	O
show	O
that	O
an	O
SXP	O
motif	O
in	O
Rim8	S-Protein
mediates	O
binding	O
to	O
the	O
Vps23	S-Protein
ubiquitin	S-Protein
E2	O
variant	O
(	O
UEV	O
)	O
domain	O
and	O
that	O
a	O
monoubiquitinated	O
residue	O
near	O
the	O
SXP	O
motif	O
contributes	O
to	O
this	O
interaction	O
.	O

We	O
present	O
evidence	O
that	O
Rim8	S-Protein
ubiquitination	O
is	O
dependent	O
on	O
the	O
Rsp5	S-Protein
E3	O
ubiquitin	S-Protein
ligase	O
and	O
triggered	O
upon	O
binding	O
of	O
Vps23	S-Protein
UEV	O
to	O
both	O
the	O
SXP	O
motif	O
and	O
ubiquitin	S-Protein
,	O
thus	O
suggesting	O
a	O
two	O
-	O
step	O
binding	O
mechanism	O
.	O

We	O
further	O
show	O
that	O
Rim8	S-Protein
coimmunoprecipitates	O
with	O
ESCRT	O
-	O
I	O
subunits	O
Vps23	S-Protein
and	O
Vps28	S-Protein
,	O
supporting	O
the	O
idea	O
that	O
binding	O
of	O
Rim8	S-Protein
to	O
Vps23	S-Protein
mediates	O
the	O
association	O
of	O
Rim8	S-Protein
with	O
the	O
ESCRT	O
-	O
I	O
complex	O
.	O

Fluorescence	O
microscopic	O
analyses	O
indicate	O
that	O
overexpressed	O
Rim8	S-Protein
and	O
Vps23	S-Protein
colocalize	O
at	O
cortical	O
punctate	O
structures	O
,	O
providing	O
additional	O
evidence	O
of	O
the	O
interaction	O
between	O
these	O
two	O
proteins	O
.	O

Strikingly	O
,	O
our	O
findings	O
indicate	O
that	O
evolutionary	O
conserved	O
mechanisms	O
control	O
the	O
recruitment	O
of	O
the	O
ESCRT	O
machinery	O
to	O
Pal	O
/	O
Rim	O
proteins	O
in	O
fungi	O
and	O
retroviral	O
Gag	O
proteins	O
in	O
animal	O
cells	O
.	O

HPV	O
status	O
-	O
independent	O
association	O
of	O
alcohol	O
and	O
tobacco	O
exposure	O
or	O
prior	O
radiation	O
therapy	O
with	O
promoter	O
methylation	O
of	O
FUSSEL18	S-Protein
,	O
EBF3	S-Protein
,	O
IRX1	S-Protein
,	O
and	O
SEPT9	S-Protein
,	O
but	O
not	O
SLC5A8	S-Protein
,	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
.	O

Head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
(	O
HNSCC	O
)	O
is	O
an	O
aggressive	O
malignancy	O
with	O
more	O
than	O
half	O
a	O
million	O
people	O
being	O
diagnosed	O
with	O
the	O
disease	O
annually	O
.	O

Within	O
the	O
last	O
2	O
decades	O
,	O
the	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
has	O
been	O
found	O
to	O
be	O
associated	O
with	O
this	O
malignancy	O
.	O

More	O
recently	O
,	O
HPV	O
-	O
infected	O
HNSCC	O
has	O
been	O
found	O
to	O
exhibit	O
higher	O
levels	O
of	O
global	O
DNA	O
methylation	O
.	O

In	O
a	O
recent	O
study	O
,	O
we	O
identified	O
five	O
tumor	O
suppressive	O
genes	O
(	O
IRX1	S-Protein
,	O
EBF3	S-Protein
,	O
SLC5A8	S-Protein
,	O
SEPT9	S-Protein
,	O
and	O
FUSSEL18	S-Protein
)	O
as	O
frequently	O
methylated	O
in	O
HNSCC	O
biopsies	O
using	O
a	O
global	O
methylation	O
analysis	O
via	O
restriction	O
landmark	O
genomic	O
scanning	O
.	O

In	O
this	O
study	O
,	O
we	O
verify	O
these	O
genes	O
as	O
valid	O
methylation	O
markers	O
in	O
two	O
separate	O
sets	O
of	O
HNSCC	O
specimens	O
.	O

By	O
using	O
the	O
available	O
clinical	O
information	O
linked	O
to	O
the	O
patient	O
specimens	O
,	O
we	O
found	O
a	O
strong	O
association	O
between	O
promoter	O
methylation	O
of	O
FUSSEL18	S-Protein
,	O
IRX1	S-Protein
,	O
and	O
EBF3	S-Protein
and	O
prior	O
radiation	O
therapy	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
irrespective	O
of	O
HPV	O
status	O
.	O

Also	O
,	O
promoter	O
methylation	O
of	O
FUSSEL18	S-Protein
and	O
SEPTIN9	S-Protein
was	O
found	O
to	O
correlate	O
significantly	O
with	O
exposure	O
to	O
alcohol	O
and	O
tobacco	O
(	O
P	O
=	O
0	O
.	O
021	O
)	O
.	O

Importantly	O
,	O
in	O
this	O
study	O
,	O
we	O
preliminarily	O
show	O
a	O
trend	O
between	O
HPV16	O
positivity	O
and	O
specific	O
target	O
gene	O
hypermethylation	O
of	O
IRX1	S-Protein
,	O
EBF3	S-Protein
,	O
SLC5A8	S-Protein
,	O
and	O
SEPT9	S-Protein
.	O

If	O
replicated	O
in	O
a	O
larger	O
study	O
,	O
the	O
HPV	O
status	O
may	O
be	O
a	O
patient	O
selection	O
biomarker	O
when	O
determining	O
the	O
most	O
efficacious	O
treatment	O
modality	O
for	O
these	O
different	O
subsets	O
of	O
patients	O
(	O
e	O
.	O
g	O
.	O
,	O
inclusion	O
or	O
exclusion	O
of	O
epigenetic	O
therapies	O
)	O
.	O

Equally	O
notable	O
and	O
independent	O
of	O
HPV	O
status	O
,	O
hypermethylation	O
of	O
the	O
promoters	O
of	O
a	O
subset	O
of	O
these	O
genes	O
in	O
recurrences	O
especially	O
in	O
the	O
setting	O
of	O
prior	O
radiation	O
or	O
in	O
the	O
setting	O
of	O
alcohol	O
and	O
tobacco	O
use	O
might	O
help	O
guide	O
adjunctive	O
inclusion	O
or	O
exclusion	O
or	O
epigenetic	O
therapy	O
.	O

Posttranslational	O
modifications	O
of	O
rat	O
proenkephalin	S-Protein
overexpressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

Rat	O
proenkephalin	S-Protein
was	O
overexpressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
using	O
the	O
dihydrofolate	B-Protein
reductase	E-Protein
-	O
coupled	O
genetic	O
amplification	O
method	O
.	O

About	O
2	O
mg	O
purified	O
protein	O
could	O
be	O
obtained	O
from	O
250	O
ml	O
conditioned	O
medium	O
;	O
multiple	O
successive	O
harvests	O
could	O
be	O
obtained	O
from	O
the	O
same	O
roller	O
bottle	O
.	O

Degradation	O
of	O
proenkephalin	S-Protein
released	O
into	O
the	O
conditioned	O
medium	O
was	O
reduced	O
significantly	O
in	O
the	O
presence	O
of	O
2	O
%	O
fetal	O
bovine	O
serum	O
.	O

Forty	O
-	O
eight	O
percent	O
of	O
recombinant	O
proenkephalin	S-Protein
was	O
glycosylated	O
;	O
glycosylation	O
could	O
be	O
entirely	O
prevented	O
by	O
the	O
addition	O
of	O
tunicamycin	O
.	O

Two	O
-	O
dimensional	O
isoelectric	O
focusing	O
experiments	O
showed	O
that	O
recombinant	O
proenkephalin	S-Protein
exhibited	O
considerable	O
charge	O
heterogeneity	O
,	O
with	O
two	O
major	O
unglycosylated	O
isoelectric	O
forms	O
and	O
six	O
or	O
seven	O
glycosylated	O
isoelectric	O
forms	O
.	O

The	O
estimated	O
isoelectric	O
points	O
of	O
the	O
major	O
unglycosylated	O
proenkephalins	S-Protein
were	O
6	O
.	O
0	O
and	O
6	O
.	O
1	O
,	O
while	O
glycosylated	O
proenkephalins	S-Protein
ranged	O
in	O
pI	O
from	O
5	O
.	O
7	O
-	O
6	O
.	O
1	O
.	O

Some	O
of	O
this	O
isoelectric	O
heterogeneity	O
is	O
due	O
to	O
phosphorylation	O
;	O
[	O
32P	O
]	O
orthophosphate	O
was	O
readily	O
incorporated	O
into	O
serine	O
residues	O
within	O
newly	O
synthesized	O
proenkephalin	S-Protein
.	O

Mechanisms	O
of	O
c	B-Protein
-	I-Protein
myc	E-Protein
degradation	O
by	O
nickel	O
compounds	O
and	O
hypoxia	O
.	O

Nickel	O
(	O
Ni	O
)	O
compounds	O
have	O
been	O
found	O
to	O
cause	O
cancer	O
in	O
humans	O
and	O
animal	O
models	O
and	O
to	O
transform	O
cells	O
in	O
culture	O
.	O

At	O
least	O
part	O
of	O
this	O
effect	O
is	O
mediated	O
by	O
stabilization	O
of	O
hypoxia	O
inducible	O
factor	O
(	O
HIF1a	S-Protein
)	O
and	O
activating	O
its	O
downstream	O
signaling	O
.	O

Recent	O
studies	O
reported	O
that	O
hypoxia	O
signaling	O
might	O
either	O
antagonize	O
or	O
enhance	O
c	B-Protein
-	I-Protein
myc	E-Protein
activity	O
depending	O
on	O
cell	O
context	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
nickel	O
on	O
c	B-Protein
-	I-Protein
myc	E-Protein
levels	O
,	O
and	O
demonstrated	O
that	O
nickel	O
,	O
hypoxia	O
,	O
and	O
other	O
hypoxia	O
mimetics	O
degraded	O
c	B-Protein
-	I-Protein
myc	E-Protein
protein	O
in	O
a	O
number	O
of	O
cancer	O
cells	O
(	O
A549	O
,	O
MCF	O
-	O
7	O
,	O
MDA	O
-	O
453	O
,	O
and	O
BT	O
-	O
474	O
)	O
.	O

The	O
degradation	O
of	O
the	O
c	B-Protein
-	I-Protein
Myc	E-Protein
protein	O
was	O
mediated	O
by	O
the	O
26S	O
proteosome	O
.	O

Interestingly	O
,	O
knockdown	O
of	O
both	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
and	O
HIF	B-Protein
-	I-Protein
2alpha	E-Protein
attenuated	O
c	B-Protein
-	I-Protein
Myc	E-Protein
degradation	O
induced	O
by	O
Nickel	O
and	O
hypoxia	O
,	O
suggesting	O
the	O
functional	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
and	O
HIF	B-Protein
-	I-Protein
2alpha	E-Protein
was	O
required	O
for	O
c	B-Protein
-	I-Protein
myc	E-Protein
degradation	O
.	O

Further	O
studies	O
revealed	O
two	O
potential	O
pathways	O
mediated	O
nickel	O
and	O
hypoxia	O
induced	O
c	B-Protein
-	I-Protein
myc	E-Protein
degradation	O
.	O

Phosphorylation	O
of	O
c	B-Protein
-	I-Protein
myc	E-Protein
at	O
T58	O
was	O
significantly	O
increased	O
in	O
cells	O
exposed	O
to	O
nickel	O
or	O
hypoxia	O
,	O
leading	O
to	O
increased	O
ubiquitination	O
through	O
Fbw7	S-Protein
ubiquitin	O
ligase	O
.	O

In	O
addition	O
,	O
nickel	O
and	O
hypoxia	O
exposure	O
decreased	O
USP28	S-Protein
,	O
a	O
c	B-Protein
-	I-Protein
myc	E-Protein
de	O
-	O
ubiquitinating	O
enzyme	O
,	O
contributing	O
to	O
a	O
higher	O
steady	O
state	O
level	O
of	O
c	B-Protein
-	I-Protein
myc	E-Protein
ubiquitination	O
and	O
promoting	O
c	B-Protein
-	I-Protein
myc	E-Protein
degradation	O
.	O

Furthermore	O
,	O
the	O
reduction	O
of	O
USP28	S-Protein
protein	O
by	O
hypoxia	O
signaling	O
is	O
due	O
to	O
both	O
protein	O
degradation	O
and	O
transcriptional	O
repression	O
.	O

Nickel	O
and	O
hypoxia	O
exposure	O
significantly	O
increased	O
the	O
levels	O
of	O
dimethylated	O
H3	S-Protein
lysine	O
9	O
at	O
the	O
USP28	S-Protein
promoter	O
and	O
repressed	O
its	O
expression	O
.	O

Our	O
study	O
demonstrated	O
that	O
Nickel	O
and	O
hypoxia	O
exposure	O
increased	O
c	B-Protein
-	I-Protein
myc	E-Protein
T58	O
phosphorylation	O
and	O
decreased	O
USP28	S-Protein
protein	O
levels	O
in	O
cancer	O
cells	O
,	O
which	O
both	O
lead	O
to	O
enhanced	O
c	B-Protein
-	I-Protein
myc	E-Protein
ubiquitination	O
and	O
proteasomal	O
degradation	O
.	O

Fgfr3	S-Protein
is	O
a	O
transcriptional	O
target	O
of	O
Ap2delta	S-Protein
and	O
Ash2l	S-Protein
-	O
containing	O
histone	S-Protein
methyltransferase	O
complexes	O
.	O

Polycomb	O
(	O
PcG	O
)	O
and	O
trithorax	O
(	O
trxG	O
)	O
proteins	O
play	O
important	O
roles	O
in	O
establishing	O
lineage	O
-	O
specific	O
genetic	O
programs	O
through	O
induction	O
of	O
chromatin	O
modifications	O
that	O
lead	O
to	O
gene	O
silencing	O
or	O
activation	O
.	O

Previously	O
,	O
we	O
described	O
an	O
association	O
between	O
the	O
MLL	S-Protein
/	O
SET1	S-Protein
complexes	O
and	O
a	O
highly	O
restricted	O
,	O
gene	O
-	O
specific	O
DNA	O
-	O
binding	O
protein	O
Ap2delta	S-Protein
that	O
is	O
required	O
for	O
recruitment	O
of	O
the	O
MLL	S-Protein
/	O
SET1	S-Protein
complex	O
to	O
target	O
Hoxc8	S-Protein
specifically	O
.	O

Here	O
,	O
we	O
reduced	O
levels	O
of	O
Ap2delta	S-Protein
and	O
Ash2l	S-Protein
in	O
the	O
neuroblastoma	O
cell	O
line	O
,	O
Neuro2A	O
,	O
and	O
analyzed	O
their	O
gene	O
expression	O
profiles	O
using	O
whole	O
-	O
genome	O
mouse	O
cDNA	O
microarrays	O
.	O

This	O
analysis	O
yielded	O
42	O
genes	O
that	O
are	O
potentially	O
co	O
-	O
regulated	O
by	O
Ap2delta	S-Protein
and	O
Ash2l	S-Protein
,	O
and	O
we	O
have	O
identified	O
evolutionarily	O
conserved	O
Ap2	O
-	O
binding	O
sites	O
in	O
20	O
of	O
them	O
.	O

To	O
determine	O
whether	O
some	O
of	O
these	O
were	O
direct	O
targets	O
of	O
the	O
Ap2delta	S-Protein
-	O
Ash2l	S-Protein
complex	O
,	O
we	O
analyzed	O
several	O
promoters	O
for	O
the	O
presence	O
of	O
Ap2delta	S-Protein
and	O
Ash2l	S-Protein
by	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
.	O

Among	O
the	O
targets	O
we	O
screened	O
,	O
we	O
identified	O
Fgfr3	S-Protein
as	O
a	O
direct	O
transcriptional	O
target	O
of	O
the	O
Ap2delta	S-Protein
-	O
Ash2l	S-Protein
complex	O
.	O

Additionally	O
,	O
we	O
found	O
that	O
Ap2delta	S-Protein
is	O
necessary	O
for	O
the	O
recruitment	O
of	O
Ash2l	S-Protein
-	O
containing	O
complexes	O
to	O
this	O
promoter	O
and	O
that	O
this	O
recruitment	O
leads	O
to	O
trimethylation	O
of	O
lysine	O
4	O
of	O
histone	B-Protein
H3	E-Protein
(	O
H3K4me3	S-Protein
)	O
.	O

Thus	O
,	O
we	O
have	O
identified	O
several	O
candidate	O
targets	O
of	O
complexes	O
containing	O
Ap2delta	S-Protein
and	O
Ash2l	S-Protein
that	O
can	O
be	O
used	O
to	O
further	O
elucidate	O
their	O
roles	O
during	O
development	O
and	O
showed	O
that	O
Fgfr3	S-Protein
is	O
a	O
novel	O
direct	O
target	O
of	O
these	O
complexes	O
.	O

Investigating	O
the	O
dependence	O
of	O
the	O
hypoxia	O
-	O
inducible	O
factor	O
hydroxylases	O
(	O
factor	B-Protein
inhibiting	I-Protein
HIF	E-Protein
and	O
prolyl	B-Protein
hydroxylase	I-Protein
domain	I-Protein
2	E-Protein
)	O
on	O
ascorbate	O
and	O
other	O
reducing	O
agents	O
.	O

The	O
HIF	O
(	O
hypoxia	O
-	O
inducible	O
factor	O
)	O
hydroxylases	O
[	O
PHDs	O
or	O
EGLNs	O
(	O
prolyl	O
hydroxylases	O
)	O
,	O
which	O
in	O
humans	O
are	O
PHD	B-Protein
isoforms	I-Protein
1	E-Protein
-	O
3	S-Protein
,	O
and	O
FIH	S-Protein
(	O
factor	B-Protein
inhibiting	I-Protein
HIF	E-Protein
)	O
]	O
regulate	O
HIF	O
levels	O
and	O
activity	O
.	O

These	O
enzymes	O
are	O
Fe	O
(	O
II	O
)	O
/	O
2	O
-	O
oxoglutarate	O
-	O
dependent	O
oxygenases	O
,	O
many	O
of	O
which	O
are	O
stimulated	O
by	O
ascorbate	O
.	O

We	O
have	O
investigated	O
the	O
ascorbate	O
dependence	O
of	O
PHD2	S-Protein
-	O
catalysed	O
hydroxylation	O
of	O
two	O
prolyl	O
hydroxylation	O
sites	O
in	O
human	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
,	O
and	O
of	O
FIH	S-Protein
-	O
catalysed	O
hydroxylation	O
of	O
asparaginyl	O
hydroxylation	O
sites	O
in	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
and	O
in	O
a	O
consensus	O
ankyrin	O
repeat	O
domain	O
peptide	O
.	O

The	O
initial	O
rate	O
and	O
extent	O
of	O
hydroxylation	O
was	O
increased	O
in	O
the	O
presence	O
of	O
ascorbate	O
for	O
each	O
of	O
these	O
reactions	O
.	O

When	O
ascorbate	O
was	O
replaced	O
with	O
structural	O
analogues	O
,	O
the	O
results	O
revealed	O
that	O
the	O
ascorbate	O
side	O
chain	O
was	O
not	O
important	O
in	O
its	O
contribution	O
to	O
HIF	O
hydroxylase	O
catalysis	O
,	O
whereas	O
modifications	O
to	O
the	O
ene	O
-	O
diol	O
portion	O
of	O
the	O
molecule	O
negated	O
the	O
ability	O
to	O
promote	O
hydroxylation	O
.	O

We	O
investigated	O
whether	O
alternative	O
reducing	O
agents	O
(	O
glutathione	O
and	O
dithiothreitol	O
)	O
could	O
be	O
used	O
to	O
promote	O
HIF	O
hydroxylase	O
activity	O
,	O
and	O
found	O
partial	O
stimulation	O
of	O
hydroxylation	O
in	O
an	O
apparently	O
enzyme	O
-	O
and	O
substrate	O
-	O
specific	O
manner	O
.	O

The	O
results	O
raise	O
the	O
possibility	O
of	O
developing	O
reducing	O
agents	O
targeted	O
to	O
specific	O
HIF	O
hydroxylase	O
-	O
catalysed	O
reactions	O
.	O

A	O
model	O
of	O
partnership	O
co	O
-	O
opted	O
by	O
the	O
homeodomain	O
protein	O
TGIF	S-Protein
and	O
the	O
Itch	S-Protein
/	O
AIP4	S-Protein
ubiquitin	S-Protein
ligase	O
for	O
effective	O
execution	O
of	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
cytotoxicity	O
.	O

The	O
homeodomain	O
protein	O
TGIF	S-Protein
functions	O
as	O
a	O
negative	O
regulator	O
of	O
multiple	O
classes	O
of	O
transcription	O
factors	O
.	O

Here	O
we	O
report	O
on	O
the	O
characterization	O
of	O
TGIF	S-Protein
as	O
an	O
essential	O
component	O
of	O
the	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	E-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
)	O
cytotoxic	O
program	O
.	O

This	O
proapoptotic	O
role	O
of	O
TGIF	S-Protein
does	O
not	O
appear	O
to	O
rely	O
on	O
transcriptional	O
modulation	O
but	O
instead	O
is	O
executed	O
in	O
conjunction	O
with	O
Itch	S-Protein
/	O
AIP4	S-Protein
,	O
an	O
E3	O
ubiquitin	S-Protein
ligase	O
operating	O
in	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
-	O
induced	O
apoptosis	O
through	O
its	O
ability	O
to	O
target	O
the	O
caspase	O
antagonist	O
cFlip	S-Protein
(	O
L	O
)	O
for	O
degradation	O
.	O

Notably	O
,	O
we	O
found	O
that	O
activation	O
of	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
signaling	O
induced	O
the	O
association	O
of	O
TGIF	S-Protein
with	O
Itch	S-Protein
/	O
AIP4	S-Protein
,	O
resulting	O
in	O
increased	O
accessibility	O
of	O
cFlip	S-Protein
(	O
L	O
)	O
for	O
association	O
and	O
ubiquitination	O
by	O
Itch	S-Protein
/	O
AIP4	S-Protein
.	O

Moreover	O
,	O
we	O
show	O
that	O
Itch	S-Protein
/	O
AIP4	S-Protein
can	O
also	O
stabilize	O
the	O
TGIF	S-Protein
protein	O
in	O
response	O
to	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
by	O
triggering	O
its	O
monoubiquitination	O
at	O
lysine	O
259	O
,	O
thereby	O
revealing	O
the	O
existence	O
of	O
a	O
functional	O
network	O
that	O
can	O
evolve	O
into	O
a	O
positive	O
feedback	O
loop	O
for	O
ensuring	O
effective	O
execution	O
of	O
the	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
apoptotic	O
signaling	O
.	O

The	O
TRC8	S-Protein
ubiquitin	S-Protein
ligase	O
is	O
sterol	O
regulated	O
and	O
interacts	O
with	O
lipid	O
and	O
protein	O
biosynthetic	O
pathways	O
.	O

TRC8	S-Protein
/	O
RNF139	S-Protein
encodes	O
an	O
endoplasmic	O
reticulum	O
-	O
resident	O
E3	O
ubiquitin	S-Protein
ligase	O
that	O
inhibits	O
growth	O
in	O
a	O
RING	O
-	O
and	O
ubiquitylation	O
-	O
dependent	O
manner	O
.	O

TRC8	S-Protein
also	O
contains	O
a	O
predicted	O
sterol	O
-	O
sensing	O
domain	O
.	O

Here	O
,	O
we	O
report	O
that	O
TRC8	S-Protein
protein	O
levels	O
are	O
sterol	O
responsive	O
and	O
that	O
it	O
binds	O
and	O
stimulates	O
ubiquitylation	O
of	O
the	O
endoplasmic	O
reticulum	O
anchor	O
protein	O
INSIG	O
.	O

Induction	O
of	O
TRC8	S-Protein
destabilized	O
the	O
precursor	O
forms	O
of	O
the	O
transcription	O
factors	O
SREBP	B-Protein
-	I-Protein
1	E-Protein
and	O
SREBP	B-Protein
-	I-Protein
2	E-Protein
.	O

Loss	O
of	O
SREBP	O
precursors	O
was	O
proteasome	O
dependent	O
,	O
required	O
a	O
functional	O
RING	O
domain	O
,	O
occurred	O
without	O
generating	O
processed	O
nuclear	O
forms	O
,	O
and	O
suppressed	O
SREBP	O
target	O
genes	O
.	O

TRC8	S-Protein
knockdown	O
had	O
opposite	O
effects	O
in	O
sterol	O
-	O
deprived	O
cells	O
.	O

In	O
Drosophila	O
,	O
growth	O
inhibition	O
by	O
DTrc8	S-Protein
was	O
genetically	O
suppressed	O
by	O
loss	O
of	O
specific	O
Mprlp	O
,	O
Padlp	O
N	O
-	O
terminal	O
domain	O
-	O
containing	O
proteins	O
found	O
in	O
the	O
COP9	O
signalosome	O
and	O
eIF3	O
.	O

DTrc8	S-Protein
genetically	O
and	O
physically	O
interacted	O
with	O
two	O
eIF3	O
subunits	O
:	O
eIF3f	S-Protein
and	O
eIF3h	S-Protein
.	O

Coimmunoprecipitation	O
experiments	O
confirmed	O
these	O
interactions	O
in	O
mammalian	O
cells	O
,	O
and	O
TRC8	S-Protein
overexpression	O
suppressed	O
polysome	O
profiles	O
.	O

Moreover	O
,	O
high	O
-	O
molecular	O
weight	O
ubiquitylated	O
proteins	O
were	O
observed	O
in	O
eIF3	O
immunoprecipitations	O
from	O
TRC8	S-Protein
-	O
overexpressing	O
cells	O
.	O

Thus	O
,	O
TRC8	S-Protein
function	O
may	O
provide	O
a	O
regulatory	O
link	O
between	O
the	O
lipid	O
and	O
protein	O
biosynthetic	O
pathways	O
.	O

Processing	O
of	O
CD109	S-Protein
by	O
furin	S-Protein
and	O
its	O
role	O
in	O
the	O
regulation	O
of	O
TGF	B-Protein
-	I-Protein
beta	E-Protein
signaling	O
.	O

CD109	S-Protein
is	O
a	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
-	O
anchored	O
glycoprotein	O
,	O
whose	O
expression	O
is	O
upregulated	O
in	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
lung	O
,	O
esophagus	O
,	O
uterus	O
and	O
oral	O
cavity	O
.	O

CD109	S-Protein
negatively	O
regulates	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta	O
signaling	O
in	O
keratinocytes	O
by	O
directly	O
modulating	O
receptor	O
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
further	O
characterized	O
CD109	S-Protein
regulation	O
of	O
TGF	O
-	O
beta	O
signaling	O
and	O
cell	O
proliferation	O
.	O

We	O
found	O
that	O
CD109	S-Protein
is	O
produced	O
as	O
a	O
205	O
kDa	O
glycoprotein	O
,	O
which	O
is	O
then	O
processed	O
in	O
the	O
Golgi	O
apparatus	O
into	O
180	O
kDa	O
and	O
25	O
kDa	O
proteins	O
by	O
furin	S-Protein
(	O
furinase	S-Protein
)	O
.	O

180	O
kDa	O
CD109	S-Protein
associated	O
with	O
GPI	O
-	O
anchored	O
25	O
kDa	O
CD109	S-Protein
on	O
the	O
cell	O
surface	O
and	O
was	O
also	O
secreted	O
into	O
the	O
culture	O
medium	O
.	O

To	O
investigate	O
whether	O
furinase	S-Protein
cleavage	O
of	O
CD109	S-Protein
is	O
necessary	O
for	O
its	O
biological	O
activity	O
,	O
we	O
mutated	O
arginine	O
1273	O
in	O
the	O
CD109	S-Protein
furinase	S-Protein
cleavage	O
motif	O
(	O
amino	O
acid	O
1270	O
-	O
RRRR	O
-	O
1273	O
)	O
to	O
serine	O
(	O
R1273S	O
)	O
.	O

Interestingly	O
,	O
CD109	S-Protein
R1273S	O
neither	O
significantly	O
impaired	O
TGF	O
-	O
beta	O
signaling	O
nor	O
affected	O
TGF	O
-	O
beta	O
-	O
mediated	O
suppression	O
of	O
cell	O
growth	O
,	O
although	O
it	O
was	O
expressed	O
on	O
the	O
cell	O
surface	O
as	O
a	O
205	O
kDa	O
protein	O
.	O

Consistent	O
with	O
this	O
finding	O
,	O
the	O
180	O
kDa	O
and	O
25	O
kDa	O
CD109	S-Protein
complex	O
,	O
but	O
not	O
CD109	S-Protein
R1273S	O
,	O
associated	O
with	O
the	O
type	B-Protein
I	I-Protein
TGF	I-Protein
-	I-Protein
beta	I-Protein
receptor	E-Protein
.	O

These	O
findings	O
indicate	O
that	O
processing	O
of	O
CD109	S-Protein
into	O
180	O
kDa	O
and	O
25	O
kDa	O
proteins	O
by	O
furin	S-Protein
,	O
followed	O
by	O
complex	O
formation	O
with	O
the	O
type	B-Protein
I	I-Protein
TGF	I-Protein
-	I-Protein
beta	I-Protein
receptor	E-Protein
is	O
required	O
for	O
the	O
regulation	O
of	O
TGF	O
-	O
beta	O
signaling	O
in	O
cancer	O
cells	O
and	O
keratinocytes	O
.	O

Histone	B-Protein
H3	E-Protein
Thr	O
45	O
phosphorylation	O
is	O
a	O
replication	O
-	O
associated	O
post	O
-	O
translational	O
modification	O
in	O
S	O
.	O
cerevisiae	O
.	O

Post	O
-	O
translational	O
histone	S-Protein
modifications	O
are	O
crucial	O
for	O
the	O
regulation	O
of	O
numerous	O
DNA	O
-	O
templated	O
processes	O
,	O
and	O
are	O
thought	O
to	O
mediate	O
both	O
alteration	O
of	O
chromatin	O
dynamics	O
and	O
recruitment	O
of	O
effector	O
proteins	O
to	O
specific	O
regions	O
of	O
the	O
genome	O
.	O

In	O
particular	O
,	O
histone	S-Protein
Ser	O
/	O
Thr	O
phosphorylation	O
regulates	O
multiple	O
nuclear	O
functions	O
in	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
including	O
transcription	O
,	O
DNA	O
damage	O
repair	O
,	O
mitosis	O
,	O
apoptosis	O
and	O
sporulation	O
.	O

Although	O
modifications	O
to	O
chromatin	O
during	O
replication	O
remain	O
poorly	O
understood	O
,	O
a	O
number	O
of	O
recent	O
studies	O
have	O
described	O
acetylation	O
of	O
the	O
histone	B-Protein
H3	E-Protein
N	O
-	O
terminal	O
alpha	O
-	O
helix	O
(	O
alphaN	O
helix	O
)	O
at	O
Lys	O
56	O
as	O
a	O
modification	O
that	O
is	O
important	O
for	O
maintenance	O
of	O
genomic	O
integrity	O
during	O
DNA	O
replication	O
and	O
repair	O
.	O

Here	O
,	O
we	O
report	O
phosphorylation	O
of	O
H3	S-Protein
Thr	O
45	O
(	O
H3	S-Protein
-	O
T45	O
)	O
,	O
a	O
histone	S-Protein
modification	O
also	O
located	O
within	O
the	O
H3	S-Protein
alphaN	O
helix	O
in	O
S	O
.	O
cerevisiae	O
.	O

Thr	O
45	O
phosphorylation	O
peaks	O
during	O
DNA	O
replication	O
,	O
and	O
is	O
mediated	O
by	O
the	O
S	O
phase	O
kinase	O
Cdc7	S-Protein
-	O
Dbf4	S-Protein
as	O
part	O
of	O
a	O
multiprotein	O
complex	O
identified	O
in	O
this	O
study	O
.	O

Furthermore	O
,	O
loss	O
of	O
phosphorylated	O
H3	S-Protein
-	O
T45	O
causes	O
phenotypes	O
consistent	O
with	O
replicative	O
defects	O
,	O
and	O
prolonged	O
replication	O
stress	O
results	O
in	O
H3	S-Protein
-	O
T45	O
phosphorylation	O
accumulation	O
over	O
time	O
.	O

Notably	O
,	O
the	O
phenotypes	O
described	O
here	O
are	O
independent	O
of	O
Lys	O
56	O
acetylation	O
status	O
,	O
and	O
combinatorial	O
mutations	O
to	O
both	O
Thr	O
45	O
and	O
Lys	O
56	O
of	O
H3	S-Protein
cause	O
synthetic	O
growth	O
defects	O
.	O

Together	O
,	O
these	O
data	O
identify	O
and	O
characterize	O
H3	S-Protein
-	O
T45	O
phosphorylation	O
as	O
a	O
replication	O
-	O
associated	O
histone	O
modification	O
in	O
budding	O
yeast	O
.	O

Daxx	S-Protein
is	O
reciprocally	O
regulated	O
by	O
Mdm2	S-Protein
and	O
Hausp	S-Protein
.	O

Daxx	S-Protein
is	O
a	O
multifunctional	O
protein	O
,	O
regulating	O
a	O
wide	O
range	O
of	O
important	O
functions	O
including	O
apoptosis	O
and	O
transcription	O
.	O

However	O
,	O
the	O
way	O
Daxx	S-Protein
is	O
regulated	O
is	O
poorly	O
understood	O
.	O

In	O
our	O
previous	O
studies	O
,	O
we	O
have	O
found	O
that	O
Daxx	S-Protein
forms	O
a	O
complex	O
with	O
the	O
E3	O
ubiquitin	S-Protein
ligase	O
Mdm2	S-Protein
and	O
the	O
de	O
-	O
ubiquitinase	O
Hausp	S-Protein
.	O

In	O
the	O
present	O
work	O
,	O
we	O
show	O
that	O
Daxx	S-Protein
is	O
ubiquitinated	O
by	O
Mdm2	S-Protein
in	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
systems	O
and	O
Mdm2	S-Protein
reduces	O
Daxx	S-Protein
expression	O
upon	O
over	O
-	O
expression	O
.	O

We	O
further	O
demonstrate	O
that	O
Hausp	S-Protein
critically	O
controls	O
the	O
cellular	O
level	O
of	O
Daxx	S-Protein
most	O
likely	O
by	O
inducing	O
Daxx	S-Protein
de	O
-	O
ubiquitination	O
.	O

These	O
results	O
reveal	O
Mdm2	S-Protein
and	O
Hausp	S-Protein
as	O
important	O
regulators	O
for	O
Daxx	S-Protein
functions	O
by	O
controlling	O
Daxx	S-Protein
ubiquitination	O
and	O
stability	O
.	O

Proteasome	O
nuclear	O
activity	O
affects	O
chromosome	O
stability	O
by	O
controlling	O
the	O
turnover	O
of	O
Mms22	S-Protein
,	O
a	O
protein	O
important	O
for	O
DNA	O
repair	O
.	O

To	O
expand	O
the	O
known	O
spectrum	O
of	O
genes	O
that	O
maintain	O
genome	O
stability	O
,	O
we	O
screened	O
a	O
recently	O
released	O
collection	O
of	O
temperature	O
sensitive	O
(	O
Ts	O
)	O
yeast	O
mutants	O
for	O
a	O
chromosome	O
instability	O
(	O
CIN	O
)	O
phenotype	O
.	O

Proteasome	O
subunit	O
genes	O
represented	O
a	O
major	O
functional	O
group	O
,	O
and	O
subsequent	O
analysis	O
demonstrated	O
an	O
evolutionarily	O
conserved	O
role	O
in	O
CIN	O
.	O

Analysis	O
of	O
individual	O
proteasome	O
core	O
and	O
lid	O
subunit	O
mutations	O
showed	O
that	O
the	O
CIN	O
phenotype	O
at	O
semi	O
-	O
permissive	O
temperature	O
is	O
associated	O
with	O
failure	O
of	O
subunit	O
localization	O
to	O
the	O
nucleus	O
.	O

The	O
resultant	O
proteasome	O
dysfunction	O
affects	O
chromosome	O
stability	O
by	O
impairing	O
the	O
kinetics	O
of	O
double	O
strand	O
break	O
(	O
DSB	O
)	O
repair	O
.	O

We	O
show	O
that	O
the	O
DNA	O
repair	O
protein	O
Mms22	S-Protein
is	O
required	O
for	O
DSB	O
repair	O
,	O
and	O
recruited	O
to	O
chromatin	O
in	O
a	O
ubiquitin	S-Protein
-	O
dependent	O
manner	O
as	O
a	O
result	O
of	O
DNA	O
damage	O
.	O

Moreover	O
,	O
subsequent	O
proteasome	O
-	O
mediated	O
degradation	O
of	O
Mms22	S-Protein
is	O
necessary	O
and	O
sufficient	O
for	O
cell	O
cycle	O
progression	O
through	O
the	O
G	O
(	O
2	O
)	O
/	O
M	O
arrest	O
induced	O
by	O
DNA	O
damage	O
.	O

Our	O
results	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
a	O
double	O
strand	O
break	O
repair	O
protein	O
is	O
a	O
proteasome	O
target	O
,	O
and	O
thus	O
link	O
nuclear	O
proteasomal	O
activity	O
and	O
DSB	O
repair	O
.	O

Ubiquitination	O
of	O
PTEN	S-Protein
(	O
phosphatase	B-Protein
and	I-Protein
tensin	I-Protein
homolog	E-Protein
)	O
inhibits	O
phosphatase	O
activity	O
and	O
is	O
enhanced	O
by	O
membrane	O
targeting	O
and	O
hyperosmotic	O
stress	O
.	O

The	O
PTEN	S-Protein
(	O
phosphatase	B-Protein
and	I-Protein
tensin	I-Protein
homolog	E-Protein
)	O
tumor	O
suppressor	O
is	O
a	O
phosphatase	O
that	O
inhibits	O
phosphoinositide	O
3	O
-	O
kinase	O
-	O
dependent	O
signaling	O
by	O
metabolizing	O
the	O
phosphoinositide	O
lipid	O
phosphatidylinositol	O
3	O
,	O
4	O
,	O
5	O
-	O
trisphosphate	O
(	O
PtdInsP	O
(	O
3	O
)	O
)	O
at	O
the	O
plasma	O
membrane	O
.	O

PTEN	S-Protein
can	O
be	O
mono	O
-	O
or	O
polyubiquitinated	O
,	O
and	O
this	O
appears	O
to	O
control	O
its	O
nuclear	O
localization	O
and	O
stability	O
,	O
respectively	O
.	O

Although	O
PTEN	S-Protein
phosphorylation	O
at	O
a	O
cluster	O
of	O
C	O
-	O
terminal	O
serine	O
and	O
threonine	O
residues	O
has	O
been	O
shown	O
to	O
stabilize	O
the	O
protein	O
and	O
inhibit	O
polyubiquitination	O
and	O
plasma	O
membrane	O
localization	O
,	O
details	O
of	O
the	O
regulation	O
of	O
ubiquitination	O
are	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
plasma	O
membrane	O
targeting	O
of	O
PTEN	S-Protein
greatly	O
enhances	O
PTEN	S-Protein
ubiquitination	O
and	O
that	O
phosphorylation	O
of	O
PTEN	S-Protein
in	O
vitro	O
does	O
not	O
affect	O
subsequent	O
ubiquitination	O
.	O

These	O
data	O
suggest	O
that	O
C	O
-	O
terminal	O
phosphorylation	O
indirectly	O
regulates	O
ubiquitination	O
by	O
controlling	O
membrane	O
localization	O
.	O

We	O
also	O
show	O
that	O
either	O
mono	O
-	O
or	O
polyubiquitination	O
in	O
vitro	O
greatly	O
reduces	O
PTEN	S-Protein
phosphatase	O
activity	O
.	O

Finally	O
,	O
we	O
show	O
that	O
hyperosmotic	O
stress	O
increases	O
both	O
PTEN	S-Protein
ubiquitination	O
and	O
cellular	O
PtdInsP	O
(	O
3	O
)	O
levels	O
well	O
before	O
a	O
reduction	O
in	O
PTEN	S-Protein
protein	O
levels	O
is	O
observed	O
.	O

Both	O
PTEN	S-Protein
ubiquitination	O
and	O
elevated	O
PtdInsP	O
(	O
3	O
)	O
levels	O
were	O
reduced	O
within	O
10	O
min	O
after	O
removal	O
of	O
the	O
hyperosmotic	O
stress	O
.	O

Our	O
data	O
indicate	O
that	O
ubiquitination	O
may	O
represent	O
a	O
regulated	O
mechanism	O
of	O
direct	O
reversible	O
control	O
over	O
the	O
PTEN	S-Protein
enzyme	O
.	O

N	O
-	O
glycan	O
-	O
dependent	O
quality	O
control	O
of	O
the	O
Na	B-Protein
,	I-Protein
K	I-Protein
-	I-Protein
ATPase	I-Protein
beta	I-Protein
(	I-Protein
2	I-Protein
)	I-Protein
subunit	E-Protein
.	O

Bulky	O
hydrophilic	O
N	O
-	O
glycans	O
stabilize	O
the	O
proper	O
tertiary	O
structure	O
of	O
glycoproteins	O
.	O

In	O
addition	O
,	O
N	O
-	O
glycans	O
comprise	O
the	O
binding	O
sites	O
for	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
-	O
resident	O
lectins	O
that	O
assist	O
correct	O
folding	O
of	O
newly	O
synthesized	O
glycoproteins	O
.	O

To	O
reveal	O
the	O
role	O
of	O
N	O
-	O
glycans	O
in	O
maturation	O
of	O
the	O
Na	B-Protein
,	I-Protein
K	I-Protein
-	I-Protein
ATPase	I-Protein
beta	I-Protein
(	I-Protein
2	I-Protein
)	I-Protein
subunit	E-Protein
in	O
the	O
ER	O
,	O
the	O
effects	O
of	O
preventing	O
or	O
modifying	O
the	O
beta	O
(	O
2	O
)	O
subunit	O
N	O
-	O
glycosylation	O
on	O
trafficking	O
of	O
the	O
subunit	O
and	O
its	O
binding	O
to	O
the	O
ER	O
lectin	O
chaperone	O
,	O
calnexin	S-Protein
,	O
were	O
studied	O
in	O
MDCK	O
cells	O
.	O

Preventing	O
N	O
-	O
glycosylation	O
abolishes	O
binding	O
of	O
the	O
beta	O
(	O
2	O
)	O
subunit	O
to	O
calnexin	S-Protein
and	O
results	O
in	O
the	O
ER	O
retention	O
of	O
the	O
subunit	O
.	O

Furthermore	O
,	O
the	O
fully	O
N	O
-	O
glycosylated	O
beta	O
(	O
2	O
)	O
subunit	O
is	O
retained	O
in	O
the	O
ER	O
when	O
glycan	O
-	O
calnexin	S-Protein
interactions	O
are	O
prevented	O
by	O
castanospermine	O
,	O
showing	O
that	O
N	O
-	O
glycan	O
-	O
mediated	O
calnexin	S-Protein
binding	O
is	O
required	O
for	O
correct	O
subunit	O
folding	O
.	O

Calnexin	S-Protein
binding	O
persists	O
for	O
several	O
hours	O
after	O
translation	O
is	O
stopped	O
with	O
cycloheximide	O
,	O
suggesting	O
that	O
the	O
beta	O
(	O
2	O
)	O
subunit	O
undergoes	O
repeated	O
post	O
-	O
translational	O
calnexin	S-Protein
-	O
assisted	O
folding	O
attempts	O
.	O

Homology	O
modeling	O
of	O
the	O
beta	O
(	O
2	O
)	O
subunit	O
using	O
the	O
crystal	O
structure	O
of	O
the	O
alpha	B-Protein
(	I-Protein
1	I-Protein
)	E-Protein
-	O
beta	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
Na	I-Protein
,	I-Protein
K	I-Protein
-	I-Protein
ATPase	E-Protein
shows	O
the	O
presence	O
of	O
a	O
relatively	O
hydrophobic	O
amino	O
acid	O
cluster	O
proximal	O
to	O
N	O
-	O
glycosylation	O
sites	O
2	O
and	O
7	O
.	O

Combined	O
,	O
but	O
not	O
separate	O
,	O
removal	O
of	O
sites	O
2	O
and	O
7	O
dramatically	O
impairs	O
calnexin	S-Protein
binding	O
and	O
prevents	O
the	O
export	O
of	O
the	O
beta	O
(	O
2	O
)	O
subunit	O
from	O
the	O
ER	O
.	O

Similarly	O
,	O
hydrophilic	O
substitution	O
of	O
two	O
hydrophobic	O
amino	O
acids	O
in	O
this	O
cluster	O
disrupts	O
both	O
beta	O
(	O
2	O
)	O
-	O
calnexin	S-Protein
binding	O
and	O
trafficking	O
of	O
the	O
subunit	O
to	O
the	O
Golgi	O
.	O

Therefore	O
,	O
the	O
hydrophobic	O
residues	O
in	O
the	O
proximity	O
of	O
N	O
-	O
glycans	O
2	O
and	O
7	O
are	O
required	O
for	O
post	O
-	O
translational	O
calnexin	S-Protein
binding	O
to	O
these	O
N	O
-	O
glycans	O
in	O
incompletely	O
folded	O
conformers	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
necessary	O
for	O
maturation	O
of	O
the	O
Na	B-Protein
,	I-Protein
K	I-Protein
-	I-Protein
ATPase	I-Protein
beta	I-Protein
(	I-Protein
2	I-Protein
)	I-Protein
subunit	E-Protein
.	O

The	O
Cellular	O
lysine	O
methyltransferase	O
Set7	B-Protein
/	I-Protein
9	E-Protein
-	O
KMT7	S-Protein
binds	O
HIV	O
-	O
1	O
TAR	S-Protein
RNA	O
,	O
monomethylates	O
the	O
viral	O
transactivator	O
Tat	S-Protein
,	O
and	O
enhances	O
HIV	O
transcription	O
.	O

The	O
Tat	S-Protein
protein	O
of	O
HIV	O
-	O
1	O
plays	O
an	O
essential	O
role	O
in	O
HIV	O
gene	O
expression	O
by	O
promoting	O
efficient	O
elongation	O
of	O
viral	O
transcripts	O
.	O

Posttranslational	O
modifications	O
of	O
Tat	S-Protein
fine	O
-	O
tune	O
interactions	O
of	O
Tat	S-Protein
with	O
cellular	O
cofactors	O
and	O
TAR	S-Protein
RNA	O
,	O
a	O
stem	O
-	O
loop	O
structure	O
at	O
the	O
5	O
'	O
ends	O
of	O
viral	O
transcripts	O
.	O

Here	O
,	O
we	O
identify	O
the	O
lysine	O
methyltransferase	O
Set7	B-Protein
/	I-Protein
9	E-Protein
(	O
KMT7	S-Protein
)	O
as	O
a	O
coactivator	O
of	O
HIV	O
transcription	O
.	O

Set7	B-Protein
/	I-Protein
9	E-Protein
-	O
KMT7	S-Protein
associates	O
with	O
the	O
HIV	O
promoter	O
in	O
vivo	O
and	O
monomethylates	O
lysine	O
51	O
,	O
a	O
highly	O
conserved	O
residue	O
located	O
in	O
the	O
RNA	O
-	O
binding	O
domain	O
of	O
Tat	S-Protein
.	O

Knockdown	O
of	O
Set7	B-Protein
/	I-Protein
9	E-Protein
-	O
KMT7	S-Protein
suppresses	O
Tat	S-Protein
transactivation	O
of	O
the	O
HIV	O
promoter	O
,	O
but	O
does	O
not	O
affect	O
the	O
transcriptional	O
activity	O
of	O
methylation	O
-	O
deficient	O
Tat	S-Protein
(	O
K51A	O
)	O
.	O

Set7	B-Protein
/	I-Protein
9	E-Protein
-	O
KMT7	S-Protein
binds	O
TAR	S-Protein
RNA	O
by	O
itself	O
and	O
in	O
complex	O
with	O
Tat	S-Protein
and	O
the	O
positive	O
transcription	O
elongation	O
factor	O
P	O
-	O
TEFb	O
.	O

Our	O
findings	O
uncover	O
a	O
positive	O
role	O
for	O
Set7	B-Protein
/	I-Protein
9	E-Protein
-	O
KMT7	S-Protein
and	O
Tat	S-Protein
methylation	O
during	O
early	O
steps	O
of	O
the	O
Tat	S-Protein
transactivation	O
cycle	O
.	O

N4BP1	S-Protein
is	O
a	O
newly	O
identified	O
nucleolar	O
protein	O
that	O
undergoes	O
SUMO	O
-	O
regulated	O
polyubiquitylation	O
and	O
proteasomal	O
turnover	O
at	O
promyelocytic	O
leukemia	O
nuclear	O
bodies	O
.	O

A	O
number	O
of	O
proteins	O
can	O
be	O
conjugated	O
with	O
both	O
ubiquitin	S-Protein
and	O
the	O
small	O
ubiquitin	S-Protein
-	O
related	O
modifier	O
(	O
SUMO	O
)	O
,	O
with	O
crosstalk	O
between	O
these	O
two	O
post	O
-	O
translational	O
modifications	O
serving	O
to	O
regulate	O
protein	O
function	O
and	O
stability	O
.	O

We	O
previously	O
identified	O
N4BP1	S-Protein
as	O
a	O
substrate	O
for	O
monoubiquitylation	O
by	O
the	O
E3	O
ubiquitin	S-Protein
ligase	O
Nedd4	S-Protein
.	O

Here	O
,	O
we	O
describe	O
Nedd4	S-Protein
-	O
mediated	O
polyubiquitylation	O
and	O
proteasomal	O
degradation	O
of	O
N4BP1	S-Protein
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
N4BP1	S-Protein
can	O
be	O
conjugated	O
with	O
SUMO1	S-Protein
and	O
that	O
this	O
abrogates	O
N4BP1	S-Protein
ubiquitylation	O
.	O

Consistent	O
with	O
this	O
,	O
endogenous	O
N4BP1	S-Protein
is	O
stabilized	O
in	O
primary	O
embryonic	O
fibroblasts	O
from	O
mutants	O
of	O
the	O
desumoylating	O
enzyme	O
SENP1	S-Protein
,	O
which	O
show	O
increased	O
steady	O
-	O
state	O
sumoylation	O
levels	O
.	O

We	O
have	O
localized	O
endogenous	O
N4BP1	S-Protein
predominantly	O
to	O
the	O
nucleolus	O
in	O
primary	O
cells	O
.	O

However	O
,	O
a	O
small	O
fraction	O
is	O
found	O
at	O
promyelocytic	O
leukemia	O
(	O
PML	O
)	O
nuclear	O
bodies	O
(	O
NBs	O
)	O
.	O

In	O
cells	O
deficient	O
for	O
SENP1	S-Protein
or	O
in	O
wild	O
-	O
type	O
cells	O
treated	O
with	O
the	O
proteasome	O
inhibitor	O
MG132	O
,	O
there	O
is	O
considerable	O
accumulation	O
of	O
N4BP1	S-Protein
at	O
PML	O
NBs	O
.	O

These	O
findings	O
suggest	O
a	O
dynamic	O
interaction	O
between	O
subnuclear	O
compartments	O
,	O
and	O
a	O
role	O
for	O
post	O
-	O
translational	O
modification	O
by	O
ubiquitin	S-Protein
and	O
SUMO	O
in	O
the	O
regulation	O
of	O
nucleolar	O
protein	O
turnover	O
.	O

Long	O
intronic	O
GAA	O
repeats	O
causing	O
Friedreich	O
ataxia	O
impede	O
transcription	O
elongation	O
.	O

Friedreich	O
ataxia	O
is	O
a	O
degenerative	O
disease	O
caused	O
by	O
deficiency	O
of	O
the	O
protein	O
frataxin	S-Protein
(	O
FXN	S-Protein
)	O
.	O

An	O
intronic	O
expansion	O
of	O
GAA	O
triplets	O
in	O
the	O
FXN	S-Protein
-	O
encoding	O
gene	O
,	O
FXN	S-Protein
,	O
causes	O
gene	O
silencing	O
and	O
thus	O
reduced	O
FXN	S-Protein
protein	O
levels	O
.	O

Although	O
it	O
is	O
widely	O
assumed	O
that	O
GAA	O
repeats	O
block	O
transcription	O
via	O
the	O
assembly	O
of	O
an	O
inaccessible	O
chromatin	O
structure	O
marked	O
by	O
methylated	O
H3K9	S-Protein
,	O
direct	O
proof	O
for	O
this	O
is	O
lacking	O
.	O

In	O
this	O
study	O
,	O
we	O
analysed	O
different	O
histone	S-Protein
modification	O
patterns	O
along	O
the	O
human	O
FXN	S-Protein
gene	O
in	O
FRDA	O
patient	O
-	O
derived	O
lymphoblastoid	O
cell	O
lines	O
.	O

We	O
show	O
that	O
FXN	S-Protein
mRNA	O
synthesis	O
,	O
but	O
not	O
turnover	O
rates	O
are	O
affected	O
by	O
an	O
expanded	O
GAA	O
repeat	O
tract	O
.	O

Importantly	O
,	O
rather	O
than	O
preventing	O
transcription	O
initiation	O
,	O
long	O
GAA	O
repeat	O
tracts	O
affect	O
transcription	O
at	O
the	O
elongation	O
step	O
and	O
this	O
can	O
occur	O
independently	O
of	O
H3K9	S-Protein
methylation	O
.	O

Our	O
data	O
demonstrate	O
that	O
finding	O
novel	O
strategies	O
to	O
overcome	O
the	O
transcription	O
elongation	O
problem	O
may	O
develop	O
into	O
promising	O
new	O
treatments	O
for	O
FRDA	O
.	O

Targeting	O
Toll	O
-	O
like	O
receptors	O
:	O
emerging	O
therapeutics	O
?	O

There	O
is	O
a	O
growing	O
interest	O
in	O
the	O
targeting	O
of	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
cancer	O
,	O
rheumatoid	O
arthritis	O
,	O
inflammatory	O
bowel	O
disease	O
and	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
.	O

Several	O
new	O
compounds	O
are	O
now	O
undergoing	O
preclinical	O
and	O
clinical	O
evaluation	O
,	O
with	O
a	O
particular	O
focus	O
on	O
TLR7	S-Protein
and	O
TLR9	S-Protein
activators	O
as	O
adjuvants	O
in	O
infection	O
and	O
cancer	O
,	O
and	O
inhibitors	O
of	O
TLR2	S-Protein
,	O
TLR4	S-Protein
,	O
TLR7	S-Protein
and	O
TLR9	S-Protein
for	O
the	O
treatment	O
of	O
sepsis	O
and	O
inflammatory	O
diseases	O
.	O

Here	O
,	O
we	O
focus	O
on	O
TLRs	O
that	O
hold	O
the	O
most	O
promise	O
for	O
drug	O
discovery	O
research	O
,	O
highlighting	O
agents	O
that	O
are	O
in	O
the	O
discovery	O
phase	O
and	O
in	O
clinical	O
trials	O
,	O
and	O
on	O
the	O
emerging	O
new	O
aspects	O
of	O
TLR	O
-	O
mediated	O
signalling	O
-	O
such	O
as	O
control	O
by	O
ubiquitination	O
and	O
regulation	O
by	O
microRNAs	O
-	O
that	O
might	O
offer	O
further	O
possibilities	O
of	O
therapeutic	O
manipulation	O
.	O

Structural	O
insights	O
into	O
the	O
assembly	O
and	O
function	O
of	O
the	O
SAGA	O
deubiquitinating	O
module	O
.	O

SAGA	O
is	O
a	O
transcriptional	O
coactivator	O
complex	O
that	O
is	O
conserved	O
across	O
eukaryotes	O
and	O
performs	O
multiple	O
functions	O
during	O
transcriptional	O
activation	O
and	O
elongation	O
.	O

One	O
role	O
is	O
deubiquitination	O
of	O
histone	B-Protein
H2B	E-Protein
,	O
and	O
this	O
activity	O
resides	O
in	O
a	O
distinct	O
subcomplex	O
called	O
the	O
deubiquitinating	O
module	O
(	O
DUBm	O
)	O
,	O
which	O
contains	O
the	O
ubiquitin	O
-	O
specific	O
protease	O
Ubp8	S-Protein
,	O
bound	O
to	O
Sgf11	S-Protein
,	O
Sus1	S-Protein
,	O
and	O
Sgf73	S-Protein
.	O

The	O
deubiquitinating	O
activity	O
depends	O
on	O
the	O
presence	O
of	O
all	O
four	O
DUBm	O
proteins	O
.	O

We	O
report	O
here	O
the	O
1	O
.	O
90	O
angstrom	O
resolution	O
crystal	O
structure	O
of	O
the	O
DUBm	O
bound	O
to	O
ubiquitin	S-Protein
aldehyde	O
,	O
as	O
well	O
as	O
the	O
2	O
.	O
45	O
angstrom	O
resolution	O
structure	O
of	O
the	O
uncomplexed	O
DUBm	O
.	O

The	O
structure	O
reveals	O
an	O
arrangement	O
of	O
protein	O
domains	O
that	O
gives	O
rise	O
to	O
a	O
highly	O
interconnected	O
complex	O
,	O
which	O
is	O
stabilized	O
by	O
eight	O
structural	O
zinc	O
atoms	O
that	O
are	O
critical	O
for	O
enzymatic	O
activity	O
.	O

The	O
structure	O
suggests	O
a	O
model	O
for	O
how	O
interactions	O
with	O
the	O
other	O
DUBm	O
proteins	O
activate	O
Ubp8	S-Protein
and	O
allows	O
us	O
to	O
speculate	O
about	O
how	O
the	O
DUBm	O
binds	O
to	O
monoubiquitinated	O
histone	B-Protein
H2B	E-Protein
in	O
nucleosomes	O
.	O

The	O
envelope	S-Protein
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
interacts	O
with	O
the	O
non	B-Protein
-	I-Protein
structural	I-Protein
protein	I-Protein
3	E-Protein
and	O
is	O
ubiquitinated	O
.	O

To	O
analyze	O
the	O
proteins	O
interacting	O
with	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
envelope	S-Protein
(	O
E	S-Protein
)	O
protein	O
,	O
a	O
SARS	O
-	O
CoV	O
was	O
engineered	O
including	O
two	O
tags	O
associated	O
to	O
the	O
E	S-Protein
protein	O
.	O

Using	O
this	O
virus	O
,	O
complexes	O
of	O
SARS	O
-	O
CoV	O
E	S-Protein
and	O
other	O
proteins	O
were	O
purified	O
using	O
a	O
tandem	O
affinity	O
purification	O
system	O
.	O

Several	O
viral	O
and	O
cell	O
proteins	O
including	O
spike	O
,	O
membrane	O
,	O
non	B-Protein
-	I-Protein
structural	I-Protein
protein	I-Protein
3	E-Protein
(	O
nsp3	S-Protein
)	O
,	O
dynein	O
heavy	O
chain	O
,	O
fatty	B-Protein
acid	I-Protein
synthase	E-Protein
and	O
transmembrane	B-Protein
protein	I-Protein
43	E-Protein
bound	O
E	S-Protein
protein	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
focused	O
on	O
the	O
binding	O
of	O
E	S-Protein
protein	O
to	O
nsp3	S-Protein
in	O
infected	O
cells	O
and	O
cell	O
-	O
free	O
systems	O
.	O

This	O
interaction	O
was	O
mediated	O
by	O
the	O
N	O
-	O
terminal	O
acidic	O
domain	O
of	O
nsp3	S-Protein
.	O

Moreover	O
,	O
nsp3	S-Protein
and	O
E	S-Protein
protein	O
colocalized	O
during	O
the	O
infection	O
.	O

It	O
was	O
shown	O
that	O
E	S-Protein
protein	O
was	O
ubiquitinated	O
in	O
vitro	O
and	O
in	O
cell	O
culture	O
,	O
suggesting	O
that	O
the	O
interaction	O
between	O
nsp3	S-Protein
and	O
E	S-Protein
protein	O
may	O
play	O
a	O
role	O
in	O
the	O
E	S-Protein
protein	O
ubiquitination	O
status	O
and	O
therefore	O
on	O
its	O
turnover	O
.	O

Caveolin	B-Protein
-	I-Protein
1	E-Protein
mediates	O
endotoxin	O
inhibition	O
of	O
endothelin	B-Protein
-	I-Protein
1	E-Protein
-	O
induced	O
endothelial	B-Protein
nitric	I-Protein
oxide	I-Protein
synthase	E-Protein
activity	O
in	O
liver	O
sinusoidal	O
endothelial	O
cells	O
.	O

Endothelin	B-Protein
-	I-Protein
1	E-Protein
(	O
ET	B-Protein
-	I-Protein
1	E-Protein
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
regulation	O
of	O
endothelial	B-Protein
nitric	I-Protein
oxide	I-Protein
synthase	E-Protein
(	O
eNOS	S-Protein
)	O
activation	O
in	O
liver	O
sinusoidal	O
endothelial	O
cells	O
(	O
LSECs	O
)	O
.	O

In	O
the	O
presence	O
of	O
endotoxin	O
,	O
an	O
increase	O
in	O
caveolin	B-Protein
-	I-Protein
1	E-Protein
(	O
Cav	B-Protein
-	I-Protein
1	E-Protein
)	O
expression	O
impairs	O
ET	B-Protein
-	I-Protein
1	E-Protein
/	O
eNOS	S-Protein
signaling	O
;	O
however	O
,	O
the	O
molecular	O
mechanism	O
is	O
unknown	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
Cav	B-Protein
-	I-Protein
1	E-Protein
in	O
the	O
regulation	O
of	O
LPS	O
suppression	O
of	O
ET	B-Protein
-	I-Protein
1	E-Protein
-	O
mediated	O
eNOS	S-Protein
activation	O
in	O
LSECs	O
by	O
examining	O
the	O
effect	O
of	O
caveolae	O
disruption	O
using	O
methyl	O
-	O
beta	O
-	O
cyclodextrin	O
(	O
CD	O
)	O
and	O
filipin	O
.	O

Treatment	O
with	O
5	O
mM	O
CD	O
for	O
30	O
min	O
increased	O
eNOS	S-Protein
activity	O
(	O
+	O
255	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

A	O
dose	O
(	O
0	O
.	O
25	O
microg	O
/	O
ml	O
)	O
of	O
filipin	O
for	O
30	O
min	O
produced	O
a	O
similar	O
effect	O
(	O
+	O
111	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CD	O
induced	O
the	O
perinuclear	O
localization	O
of	O
Cav	B-Protein
-	I-Protein
1	E-Protein
and	O
eNOS	S-Protein
and	O
stimulated	O
NO	O
production	O
in	O
the	O
same	O
region	O
.	O

Readdition	O
of	O
0	O
.	O
5	O
mM	O
cholesterol	O
to	O
saturate	O
CD	O
reversed	O
these	O
effects	O
.	O

Both	O
the	O
combined	O
treatment	O
with	O
CD	O
and	O
ET	B-Protein
-	I-Protein
1	E-Protein
(	O
CD	O
+	O
ET	B-Protein
-	I-Protein
1	E-Protein
)	O
and	O
with	O
filipin	O
and	O
ET	B-Protein
-	I-Protein
1	E-Protein
stimulated	O
eNOS	S-Protein
activity	O
;	O
however	O
,	O
pretreatment	O
with	O
endotoxin	O
(	O
LPS	O
)	O
abrogated	O
these	O
effects	O
.	O

Following	O
LPS	O
pretreatment	O
,	O
CD	O
+	O
ET	B-Protein
-	I-Protein
1	E-Protein
failed	O
to	O
stimulate	O
eNOS	S-Protein
activity	O
(	O
+	O
51	O
%	O
,	O
P	O
>	O
0	O
.	O
05	O
)	O
,	O
which	O
contributed	O
to	O
the	O
reduced	O
levels	O
of	O
eNOS	S-Protein
-	O
Ser1177	O
phosphorylation	O
and	O
eNOS	S-Protein
-	O
Thr495	O
dephosphorylation	O
,	O
the	O
LPS	O
/	O
CD	O
-	O
induced	O
overexpression	O
and	O
translocation	O
of	O
Cav	B-Protein
-	I-Protein
1	E-Protein
in	O
the	O
perinuclear	O
region	O
,	O
and	O
the	O
increased	O
perinuclear	O
colocalization	O
of	O
eNOS	S-Protein
with	O
Cav	B-Protein
-	I-Protein
1	E-Protein
.	O

These	O
results	O
supported	O
the	O
hypothesis	O
that	O
Cav	B-Protein
-	I-Protein
1	E-Protein
mediates	O
the	O
action	O
of	O
endotoxin	O
in	O
suppressing	O
ET	B-Protein
-	I-Protein
1	E-Protein
-	O
mediated	O
eNOS	S-Protein
activation	O
and	O
demonstrated	O
that	O
the	O
manipulation	O
of	O
caveolae	O
produces	O
significant	O
effects	O
on	O
ET	B-Protein
-	I-Protein
1	E-Protein
-	O
mediated	O
eNOS	S-Protein
activity	O
in	O
LSECs	O
.	O

Doxorubicin	O
attached	O
to	O
HPMA	O
copolymer	O
via	O
amide	O
bond	O
modifies	O
the	O
glycosylation	O
pattern	O
of	O
EL4	O
cells	O
.	O

To	O
avoid	O
the	O
side	O
effects	O
of	O
the	O
anti	O
-	O
cancer	O
drug	O
doxorubicin	O
(	O
Dox	O
)	O
,	O
we	O
conjugated	O
this	O
drug	O
to	O
a	O
N	O
-	O
(	O
2	O
-	O
hydroxypropyl	O
)	O
methacrylamide	O
(	O
HPMA	O
)	O
copolymer	O
backbone	O
.	O

Dox	O
was	O
conjugated	O
via	O
an	O
amide	O
bond	O
(	O
Dox	O
-	O
HPMA	O
(	O
AM	O
)	O
,	O
PK1	O
)	O
or	O
a	O
hydrazone	O
pH	O
-	O
sensitive	O
bond	O
(	O
Dox	O
-	O
HPMA	O
(	O
HYD	O
)	O
)	O
.	O

In	O
contrast	O
to	O
Dox	O
and	O
Dox	O
-	O
HPMA	O
(	O
HYD	O
)	O
,	O
Dox	O
-	O
HPMA	O
(	O
AM	O
)	O
accumulates	O
within	O
the	O
cell	O
'	O
s	O
intracellular	O
membranes	O
,	O
including	O
those	O
of	O
the	O
Golgi	O
complex	O
and	O
endoplasmic	O
reticulum	O
,	O
both	O
involved	O
in	O
protein	O
glycosylation	O
.	O

Flow	O
cytometry	O
was	O
used	O
to	O
determine	O
lectin	O
binding	O
and	O
cell	O
death	O
,	O
immunoblot	O
to	O
characterize	O
the	O
presence	O
of	O
CD7	S-Protein
,	O
CD43	S-Protein
,	O
CD44	S-Protein
,	O
and	O
CD45	S-Protein
,	O
and	O
high	O
-	O
performance	O
anion	O
exchange	O
chromatography	O
with	O
pulsed	O
amperometric	O
detector	O
analysis	O
for	O
characterization	O
of	O
plasma	O
membrane	O
saccharide	O
composition	O
.	O

Incubation	O
of	O
EL4	O
cells	O
with	O
Dox	O
-	O
HPMA	O
(	O
AM	O
)	O
conjugate	O
,	O
in	O
contrast	O
to	O
Dox	O
or	O
Dox	O
-	O
HPMA	O
(	O
HYD	O
)	O
,	O
increased	O
the	O
amounts	O
of	O
membrane	O
surface	O
-	O
associated	O
glycoproteins	O
,	O
as	O
well	O
as	O
saccharide	O
moieties	O
recognized	O
by	O
peanut	O
agglutinin	S-Protein
,	O
Erythrina	O
cristagalli	O
,	O
or	O
galectin	B-Protein
-	I-Protein
1	E-Protein
lectins	O
.	O

Only	O
Dox	O
-	O
HPMA	O
(	O
AM	O
)	O
increased	O
expression	O
of	O
the	O
highly	O
glycosylated	O
membrane	O
glycoprotein	O
CD43	S-Protein
,	O
while	O
expression	O
of	O
others	O
(	O
CD7	S-Protein
,	O
CD44	S-Protein
,	O
and	O
CD45	S-Protein
)	O
was	O
unaffected	O
.	O

The	O
binding	O
sites	O
for	O
galectin	B-Protein
-	I-Protein
1	E-Protein
are	O
present	O
on	O
CD43	S-Protein
molecule	O
.	O

Furthermore	O
,	O
we	O
present	O
that	O
EL4	O
treated	O
with	O
Dox	O
-	O
HPMA	O
(	O
AM	O
)	O
possesses	O
increased	O
sensitivity	O
to	O
galectin	B-Protein
-	I-Protein
1	E-Protein
-	O
induced	O
apoptosis	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
Dox	O
-	O
HPMA	O
(	O
AM	O
)	O
treatment	O
changes	O
glycosylation	O
of	O
the	O
EL4	O
T	O
cell	O
lymphoma	O
surface	O
and	O
sensitizes	O
the	O
cells	O
to	O
galectin	B-Protein
-	I-Protein
1	E-Protein
-	O
induced	O
apoptosis	O
.	O

Conserved	O
role	O
of	O
SIRT1	S-Protein
orthologs	O
in	O
fasting	O
-	O
dependent	O
inhibition	O
of	O
the	O
lipid	O
/	O
cholesterol	O
regulator	O
SREBP	O
.	O

The	O
sterol	O
regulatory	O
element	O
-	O
binding	O
protein	O
(	O
SREBP	O
)	O
transcription	O
factor	O
family	O
is	O
a	O
critical	O
regulator	O
of	O
lipid	O
and	O
sterol	O
homeostasis	O
in	O
eukaryotes	O
.	O

In	O
mammals	O
,	O
SREBPs	O
are	O
highly	O
active	O
in	O
the	O
fed	O
state	O
to	O
promote	O
the	O
expression	O
of	O
lipogenic	O
and	O
cholesterogenic	O
genes	O
and	O
facilitate	O
fat	O
storage	O
.	O

During	O
fasting	O
,	O
SREBP	O
-	O
dependent	O
lipid	O
/	O
cholesterol	O
synthesis	O
is	O
rapidly	O
diminished	O
in	O
the	O
mouse	O
liver	O
;	O
however	O
,	O
the	O
mechanism	O
has	O
remained	O
incompletely	O
understood	O
.	O

Moreover	O
,	O
the	O
evolutionary	O
conservation	O
of	O
fasting	O
regulation	O
of	O
SREBP	O
-	O
dependent	O
programs	O
of	O
gene	O
expression	O
and	O
control	O
of	O
lipid	O
homeostasis	O
has	O
been	O
unclear	O
.	O

We	O
demonstrate	O
here	O
a	O
conserved	O
role	O
for	O
orthologs	O
of	O
the	O
NAD	O
(	O
+	O
)	O
-	O
dependent	O
deacetylase	O
SIRT1	S-Protein
in	O
metazoans	O
in	O
down	O
-	O
regulation	O
of	O
SREBP	O
orthologs	O
during	O
fasting	O
,	O
resulting	O
in	O
inhibition	O
of	O
lipid	O
synthesis	O
and	O
fat	O
storage	O
.	O

Our	O
data	O
reveal	O
that	O
SIRT1	S-Protein
can	O
directly	O
deacetylate	O
SREBP	O
,	O
and	O
modulation	O
of	O
SIRT1	S-Protein
activity	O
results	O
in	O
changes	O
in	O
SREBP	O
ubiquitination	O
,	O
protein	O
stability	O
,	O
and	O
target	O
gene	O
expression	O
.	O

In	O
addition	O
,	O
chemical	O
activators	O
of	O
SIRT1	S-Protein
inhibit	O
SREBP	O
target	O
gene	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
correlating	O
with	O
decreased	O
hepatic	O
lipid	O
and	O
cholesterol	O
levels	O
and	O
attenuated	O
liver	O
steatosis	O
in	O
diet	O
-	O
induced	O
and	O
genetically	O
obese	O
mice	O
.	O

We	O
conclude	O
that	O
SIRT1	S-Protein
orthologs	O
play	O
a	O
critical	O
role	O
in	O
controlling	O
SREBP	O
-	O
dependent	O
gene	O
regulation	O
governing	O
lipid	O
/	O
cholesterol	O
homeostasis	O
in	O
metazoans	O
in	O
response	O
to	O
fasting	O
cues	O
.	O

These	O
findings	O
may	O
have	O
important	O
biomedical	O
implications	O
for	O
the	O
treatment	O
of	O
metabolic	O
disorders	O
associated	O
with	O
aberrant	O
lipid	O
/	O
cholesterol	O
homeostasis	O
,	O
including	O
metabolic	O
syndrome	O
and	O
atherosclerosis	O
.	O

Characterization	O
and	O
developmental	O
expression	O
of	O
the	O
chicken	O
B	O
-	O
G	O
heterodimer	O
.	O

Monoclonal	O
antibody	O
R7	O
-	O
3	O
recognized	O
an	O
erythroid	O
specific	O
cell	O
surface	O
molecule	O
with	O
a	O
m	O
.	O
w	O
.	O
of	O
approximately	O
98	O
kilodaltons	O
(	O
Kd	O
)	O
under	O
nonreducing	O
conditions	O
and	O
molecules	O
of	O
40	O
and	O
44	O
Kd	O
under	O
reducing	O
conditions	O
on	O
both	O
embryonic	O
-	O
and	O
adult	O
-	O
derived	O
peripheral	O
RBC	O
.	O

Immunochemical	O
characterization	O
,	O
including	O
limited	O
peptide	O
map	O
analyses	O
of	O
these	O
molecules	O
,	O
provided	O
evidence	O
that	O
mAb	O
R7	O
-	O
3	O
was	O
recognizing	O
the	O
MHC	O
coded	O
B	O
-	O
G	O
heterodimer	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
monoclonal	O
antibody	O
that	O
recognizes	O
the	O
B	O
-	O
G	O
heterodimer	O
.	O

Affinity	O
binding	O
studies	O
suggested	O
that	O
mAb	O
R7	O
-	O
3	O
preferentially	O
recognized	O
the	O
44	O
Kd	O
molecule	O
.	O

Immune	O
depletion	O
analyses	O
demonstrated	O
the	O
presence	O
of	O
a	O
single	O
population	O
of	O
B	O
-	O
G	O
heterodimers	O
.	O

Endoglycosidase	B-Protein
-	I-Protein
F	E-Protein
and	O
neuraminidase	O
digestions	O
suggested	O
that	O
the	O
44	O
and	O
40	O
Kd	O
molecules	O
contained	O
very	O
little	O
,	O
if	O
any	O
,	O
carbohydrate	O
.	O

B	O
-	O
G	O
heterodimer	O
expression	O
was	O
examined	O
on	O
primitive	O
and	O
definitive	O
RBC	O
during	O
embryonic	O
development	O
.	O

B	O
-	O
G	O
heterodimer	O
expression	O
was	O
not	O
detected	O
on	O
RBC	O
of	O
other	O
avians	O
.	O

Selective	O
carboxyl	O
methylation	O
of	O
structurally	O
altered	O
calmodulins	S-Protein
in	O
Xenopus	O
oocytes	O
.	O

The	O
eucaryotic	O
protein	O
carboxyl	O
methyltransferase	O
specifically	O
modifies	O
atypical	O
D	O
-	O
aspartyl	O
and	O
L	O
-	O
isoaspartyl	O
residues	O
which	O
are	O
generated	O
spontaneously	O
as	O
proteins	O
age	O
.	O

The	O
selectivity	O
of	O
the	O
enzyme	O
for	O
altered	O
proteins	O
in	O
intact	O
cells	O
was	O
explored	O
by	O
co	O
-	O
injecting	O
Xenopus	O
laevis	O
oocytes	O
with	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
[	O
methyl	O
-	O
3H	O
]	O
methionine	O
and	O
structurally	O
altered	O
calmodulins	O
generated	O
during	O
a	O
14	O
-	O
day	O
preincubation	O
in	O
vitro	O
.	O

Control	O
experiments	O
indicated	O
that	O
the	O
oocyte	O
protein	O
carboxyl	O
methyltransferase	O
was	O
not	O
saturated	O
with	O
endogenous	O
substrates	O
,	O
since	O
protein	O
carboxyl	O
methylation	O
rates	O
could	O
be	O
stimulated	O
up	O
to	O
8	O
-	O
fold	O
by	O
increasing	O
concentrations	O
of	O
injected	O
calmodulin	S-Protein
.	O

The	O
oocyte	O
protein	O
carboxyl	O
methyltransferase	O
showed	O
strong	O
selectivities	O
for	O
bovine	O
brain	O
and	O
bacterially	O
synthesized	O
calmodulins	S-Protein
which	O
had	O
been	O
preincubated	O
in	O
the	O
presence	O
of	O
1	O
mM	O
EDTA	O
relative	O
to	O
calmodulins	O
which	O
had	O
been	O
preincubated	O
with	O
1	O
mM	O
CaCl2	O
.	O

Radioactive	O
methyl	O
groups	O
were	O
incorporated	O
into	O
base	O
-	O
stable	O
linkages	O
with	O
recombinant	O
calmodulin	S-Protein
as	O
well	O
as	O
into	O
carboxyl	O
methyl	O
esters	O
following	O
its	O
microinjection	O
into	O
oocytes	O
.	O

This	O
base	O
-	O
stable	O
radioactivity	O
most	O
likely	O
represents	O
the	O
trimethylation	O
of	O
lysine	O
115	O
,	O
a	O
highly	O
conserved	O
post	O
-	O
translational	O
modification	O
which	O
is	O
present	O
in	O
bovine	O
and	O
Xenopus	O
but	O
not	O
in	O
bacterially	O
synthesized	O
calmodulin	S-Protein
.	O

Endogenous	O
oocyte	O
calmodulin	S-Protein
incorporates	O
radioactivity	O
into	O
both	O
carboxyl	O
methyl	O
esters	O
and	O
into	O
base	O
-	O
stable	O
linkages	O
following	O
microinjection	O
of	O
oocytes	O
with	O
S	O
-	O
adenosyl	O
-	O
[	O
methyl	O
-	O
3H	O
]	O
methionine	O
alone	O
.	O

The	O
rate	O
of	O
oocyte	O
calmodulin	S-Protein
carboxyl	O
methylation	O
in	O
injected	O
oocytes	O
is	O
calculated	O
to	O
be	O
similar	O
to	O
that	O
of	O
lysine	O
115	O
trimethylation	O
,	O
suggesting	O
that	O
the	O
rate	O
of	O
calmodulin	S-Protein
carboxyl	O
methylation	O
is	O
similar	O
to	O
that	O
of	O
calmodulin	S-Protein
synthesis	O
.	O

At	O
steady	O
state	O
,	O
oocyte	O
calmodulin	S-Protein
contains	O
approximately	O
0	O
.	O
0002	O
esters	O
/	O
mol	O
of	O
protein	O
,	O
which	O
turn	O
over	O
rapidly	O
.	O

The	O
results	O
suggest	O
the	O
quantitative	O
significance	O
of	O
carboxyl	O
methylation	O
in	O
the	O
metabolism	O
of	O
oocyte	O
calmodulin	S-Protein
.	O

[	O
Hyp3	O
]	O
-	O
bradykinin	S-Protein
and	O
[	O
Hyp3	O
]	O
-	O
Lys	O
-	O
bradykinin	S-Protein
interact	O
with	O
B2	B-Protein
-	I-Protein
bradykinin	I-Protein
receptors	E-Protein
and	O
stimulate	O
inositol	O
phosphate	O
production	O
in	O
cultured	O
human	O
fibroblasts	O
.	O

The	O
recently	O
isolated	O
,	O
naturally	O
occurring	O
peptide	O
hormones	O
[	O
Hyp3	O
]	O
-	O
bradykinin	S-Protein
and	O
[	O
Hyp3	O
]	O
-	O
Lys	O
-	O
bradykinin	S-Protein
were	O
investigated	O
for	O
their	O
agonist	O
activity	O
on	O
solubilized	O
binding	O
sites	O
from	O
human	O
fibroblasts	O
.	O

Both	O
ligands	O
competed	O
with	O
[	O
3H	O
]	O
bradykinin	S-Protein
binding	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
with	O
potencies	O
similar	O
to	O
bradykinin	S-Protein
(	O
BK	S-Protein
)	O
and	O
Lys	O
-	O
BK	S-Protein
.	O

Biological	O
activity	O
was	O
assessed	O
by	O
determination	O
of	O
inositol	O
phosphate	O
accumulation	O
and	O
cyclic	O
3	O
'	O
,	O
5	O
'	O
-	O
adenosine	O
monophosphate	O
synthesis	O
in	O
intact	O
cultured	O
cells	O
.	O

Stimulation	O
by	O
the	O
hydroxylated	O
peptides	O
resulted	O
in	O
a	O
pronounced	O
accumulation	O
of	O
both	O
parameters	O
with	O
similar	O
effectiveness	O
as	O
BK	S-Protein
and	O
Lys	O
-	O
BK	S-Protein
.	O

These	O
results	O
indicate	O
that	O
[	O
Hyp3	O
]	O
-	O
BK	S-Protein
and	O
[	O
Hyp3	O
]	O
-	O
Lys	O
-	O
BK	S-Protein
are	O
agonists	O
at	O
the	O
bradykinin	S-Protein
receptor	O
system	O
with	O
properties	O
comparable	O
to	O
their	O
non	O
-	O
hydroxylated	O
analogues	O
.	O

This	O
suggests	O
that	O
hydroxylation	O
of	O
kinins	S-Protein
does	O
not	O
alter	O
receptor	O
interaction	O
or	O
signal	O
transduction	O
in	O
cultured	O
human	O
fibroblasts	O
.	O

Modulation	O
of	O
lysosomal	O
-	O
associated	O
membrane	O
glycoproteins	O
during	O
retinoic	O
acid	O
-	O
induced	O
embryonal	O
carcinoma	O
cell	O
differentiation	O
.	O

Differentiation	O
of	O
the	O
murine	O
embryonal	O
carcinoma	O
(	O
EC	O
)	O
cell	O
lines	O
F	O
-	O
9	O
and	O
PC	O
-	O
13	O
,	O
induced	O
by	O
beta	O
-	O
all	O
transretinoic	O
acid	O
(	O
RA	O
)	O
resulted	O
in	O
an	O
increased	O
level	O
of	O
two	O
lysosomal	O
-	O
associated	O
membrane	O
glycoproteins	O
(	O
LAMP	B-Protein
-	I-Protein
1	E-Protein
and	O
LAMP	B-Protein
-	I-Protein
2	E-Protein
)	O
.	O

After	O
differentiation	O
,	O
the	O
levels	O
of	O
both	O
LAMPs	O
in	O
the	O
EC	O
cells	O
were	O
comparable	O
to	O
those	O
found	O
in	O
visceral	O
and	O
parietal	O
endoderm	O
cell	O
lines	O
(	O
PSA	O
-	O
5E	O
and	O
PYS	O
-	O
2	O
,	O
respectively	O
)	O
.	O

RA	O
treatment	O
of	O
the	O
EC	O
cells	O
also	O
resulted	O
in	O
an	O
increase	O
in	O
the	O
apparent	O
Mr	O
of	O
both	O
LAMPs	O
apparently	O
due	O
to	O
increased	O
glycosylation	O
because	O
the	O
deglycosylated	O
LAMP	B-Protein
-	I-Protein
1	E-Protein
from	O
undifferentiated	O
and	O
from	O
differentiated	O
cells	O
had	O
a	O
similar	O
electrophoretic	O
migration	O
.	O

Indeed	O
,	O
the	O
binding	O
of	O
125I	O
-	O
labeled	O
L	B-Protein
-	I-Protein
phytohemagglutinin	E-Protein
(	O
L	B-Protein
-	I-Protein
PHA	E-Protein
)	O
to	O
glycoproteins	O
with	O
Mr	O
or	O
90	O
,	O
000	O
-	O
130	O
,	O
000	O
increased	O
after	O
differentiation	O
and	O
about	O
24	O
times	O
more	O
125I	O
-	O
labeled	O
L	B-Protein
-	I-Protein
PHA	E-Protein
bound	O
to	O
LAMP	B-Protein
-	I-Protein
1	E-Protein
isolated	O
by	O
immunoprecipitation	O
from	O
extracts	O
of	O
RA	O
-	O
treated	O
F	O
-	O
9	O
cells	O
than	O
to	O
LAMP	B-Protein
-	I-Protein
1	E-Protein
from	O
undifferentiated	O
cells	O
.	O

The	O
increased	O
level	O
of	O
the	O
LAMPs	O
was	O
detected	O
in	O
F	O
-	O
9	O
cells	O
treated	O
with	O
greater	O
than	O
10	O
(	O
-	O
7	O
)	O
M	O
RA	O
and	O
required	O
greater	O
than	O
48	O
h	O
of	O
treatment	O
as	O
did	O
the	O
increased	O
expression	O
of	O
the	O
B1	O
chain	O
of	O
laminin	O
,	O
an	O
established	O
marker	O
for	O
differentiation	O
in	O
this	O
system	O
.	O

LAMP	B-Protein
-	I-Protein
1	E-Protein
-	O
and	O
L	B-Protein
-	I-Protein
PHA	E-Protein
-	O
reactive	O
glycoproteins	O
were	O
localized	O
by	O
fluorescence	O
techniques	O
to	O
intracellular	O
vesicles	O
,	O
presumably	O
lysosomes	O
,	O
and	O
to	O
the	O
cell	O
surface	O
and	O
both	O
increased	O
after	O
RA	O
treatment	O
.	O

LAMP	B-Protein
-	I-Protein
2	E-Protein
was	O
barely	O
detectable	O
intracellularly	O
in	O
undifferentiated	O
cells	O
but	O
could	O
be	O
detected	O
clearly	O
after	O
differentiation	O
.	O

In	O
contrast	O
,	O
no	O
LAMP	B-Protein
-	I-Protein
2	E-Protein
could	O
be	O
detected	O
on	O
the	O
cell	O
surface	O
either	O
before	O
or	O
after	O
differentiation	O
of	O
F	O
-	O
9	O
cells	O
.	O

The	O
increased	O
level	O
and	O
glycosylation	O
of	O
both	O
LAMP	B-Protein
-	I-Protein
1	E-Protein
and	O
LAMP	B-Protein
-	I-Protein
2	E-Protein
was	O
observed	O
also	O
in	O
cells	O
treated	O
with	O
a	O
synthetic	O
chalcone	O
carboxylic	O
acid	O
analog	O
of	O
RA	O
and	O
by	O
combination	O
of	O
either	O
retinoid	O
with	O
dibutyryl	O
cyclic	O
AMP	O
.	O

These	O
results	O
demonstrate	O
that	O
differentiation	O
of	O
EC	O
cells	O
is	O
accompanied	O
by	O
changes	O
in	O
the	O
synthesis	O
and	O
glycosylation	O
of	O
LAMP	O
glycoproteins	O
and	O
that	O
these	O
changes	O
are	O
specific	O
for	O
the	O
cell	O
type	O
that	O
results	O
after	O
differentiation	O
.	O

Cleavage	O
of	O
a	O
hydrophilic	O
C	O
-	O
terminal	O
domain	O
increases	O
growth	O
-	O
inhibitory	O
activity	O
of	O
oncostatin	B-Protein
M	E-Protein
.	O

Oncostatin	B-Protein
M	E-Protein
is	O
a	O
polypeptide	O
cytokine	O
,	O
produced	O
by	O
normal	O
and	O
malignant	O
hematopoietic	O
cells	O
,	O
that	O
has	O
several	O
in	O
vitro	O
activities	O
,	O
including	O
the	O
ability	O
to	O
inhibit	O
growth	O
of	O
cultured	O
carcinoma	O
cells	O
.	O

Here	O
we	O
present	O
a	O
structural	O
and	O
functional	O
comparison	O
of	O
two	O
oncostatin	B-Protein
M	E-Protein
-	O
related	O
proteins	O
(	O
Mr	O
36	O
,	O
000	O
and	O
32	O
,	O
000	O
)	O
secreted	O
by	O
COS	O
cells	O
transfected	O
with	O
oncostatin	B-Protein
M	E-Protein
cDNA	O
.	O

The	O
smaller	O
of	O
these	O
forms	O
lacked	O
a	O
hydrophilic	O
C	O
-	O
terminal	O
domain	O
comprising	O
predominantly	O
basic	O
amino	O
acids	O
.	O

This	O
domain	O
was	O
also	O
absent	O
from	O
native	O
oncostatin	B-Protein
M	E-Protein
produced	O
by	O
U937	O
cells	O
.	O

The	O
32	O
,	O
000	O
-	O
Mr	O
form	O
of	O
oncostatin	B-Protein
M	E-Protein
was	O
not	O
produced	O
by	O
cells	O
transfected	O
with	O
plasmids	O
(	O
G195	O
and	O
G196	O
)	O
in	O
which	O
a	O
potential	O
trypsinlike	O
cleavage	O
site	O
within	O
the	O
hydrophilic	O
C	O
-	O
terminal	O
domain	O
was	O
altered	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

A	O
32	O
,	O
000	O
-	O
Mr	O
fragment	O
was	O
produced	O
by	O
trypsin	O
treatment	O
of	O
the	O
36	O
,	O
000	O
-	O
Mr	O
form	O
of	O
oncostatin	B-Protein
M	E-Protein
.	O

These	O
observations	O
suggest	O
that	O
the	O
32	O
,	O
000	O
-	O
Mr	O
form	O
of	O
oncostatin	B-Protein
M	E-Protein
was	O
derived	O
from	O
the	O
227	O
-	O
amino	O
-	O
acid	O
propeptide	O
by	O
proteolytic	O
cleavage	O
at	O
or	O
near	O
the	O
paired	O
basic	O
residues	O
at	O
positions	O
195	O
and	O
196	O
.	O

Pro	O
-	O
oncostatin	B-Protein
M	E-Protein
was	O
equally	O
active	O
in	O
radioreceptor	O
assays	O
as	O
the	O
processed	O
form	O
but	O
was	O
5	O
-	O
to	O
60	O
-	O
fold	O
less	O
active	O
in	O
growth	O
inhibition	O
assays	O
.	O

Likewise	O
,	O
nonprocessed	O
mutant	O
protein	O
encoded	O
by	O
plasmid	O
G196	O
was	O
equally	O
active	O
in	O
the	O
radioreceptor	O
assays	O
as	O
the	O
processed	O
form	O
but	O
was	O
five	O
-	O
to	O
ninefold	O
less	O
active	O
in	O
growth	O
inhibition	O
assays	O
.	O

Thus	O
,	O
the	O
highly	O
charged	O
C	O
-	O
terminal	O
domain	O
of	O
pro	O
-	O
oncostatin	B-Protein
M	E-Protein
is	O
not	O
required	O
for	O
receptor	O
binding	O
or	O
growth	O
-	O
inhibitory	O
activity	O
but	O
may	O
alter	O
the	O
functional	O
properties	O
of	O
the	O
molecule	O
.	O

Propeptide	O
processing	O
of	O
oncostatin	B-Protein
M	E-Protein
may	O
be	O
important	O
for	O
regulating	O
in	O
vivo	O
activities	O
of	O
this	O
cytokine	O
.	O

Synthesis	O
and	O
charge	O
-	O
transfer	O
properties	O
of	O
two	O
acth	S-Protein
analogues	O
containing	O
pentamethylphenylalanine	O
in	O
position	O
9	O
.	O

In	O
order	O
to	O
investigate	O
the	O
possible	O
role	O
of	O
the	O
Trp	O
residue	O
in	O
ACTH	S-Protein
as	O
a	O
change	O
-	O
transfer	O
donor	O
in	O
the	O
activation	O
of	O
ACTH	S-Protein
receptors	O
,	O
two	O
ACTH	S-Protein
analogues	O
(	O
beta	O
-	O
corticotrophins	O
(	O
I	O
-	O
24	O
)	O
with	O
L	O
-	O
Ser1	O
and	O
D	O
-	O
Ser1	O
,	O
respectively	O
)	O
containing	O
pentamethylphenylalanine	O
instead	O
of	O
Trp	O
have	O
been	O
synthesized	O
.	O

In	O
these	O
syntheses	O
a	O
new	O
,	O
alkaline	O
-	O
labile	O
,	O
amino	O
-	O
protecting	O
group	O
,	O
the	O
methylsulphonylethyloxycarbonyl	O
group	O
,	O
was	O
employed	O
.	O

The	O
association	O
constants	O
of	O
ACTH	S-Protein
(	O
I	O
-	O
24	O
)	O
and	O
(	O
Pmp9	O
)	O
-	O
ACTH	S-Protein
(	O
I	O
-	O
24	O
)	O
with	O
the	O
water	O
-	O
soluble	O
acceptor	O
paraquat	O
,	O
were	O
nearly	O
equal	O
.	O

A	O
core	O
protein	O
epitope	O
of	O
the	O
polymorphic	B-Protein
epithelial	I-Protein
mucin	E-Protein
detected	O
by	O
the	O
monoclonal	O
antibody	O
SM	O
-	O
3	O
is	O
selectively	O
exposed	O
in	O
a	O
range	O
of	O
primary	O
carcinomas	O
.	O

The	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
SM	O
-	O
3	O
,	O
which	O
was	O
raised	O
to	O
chemically	O
deglycosylated	O
milk	O
mucin	O
,	O
reacts	O
with	O
an	O
epitope	O
present	O
on	O
the	O
core	O
protein	O
of	O
this	O
mucin	O
which	O
we	O
have	O
referred	O
to	O
as	O
PEM	S-Protein
(	O
polymorphic	B-Protein
epithelial	I-Protein
mucin	E-Protein
)	O
.	O

Although	O
this	O
mucin	O
is	O
abundantly	O
expressed	O
by	O
both	O
the	O
lactating	O
breast	O
and	O
breast	O
carcinomas	O
,	O
the	O
antibody	O
SM	O
-	O
3	O
shows	O
very	O
little	O
or	O
no	O
reactivity	O
on	O
the	O
former	O
but	O
does	O
react	O
with	O
92	O
%	O
of	O
breast	O
carcinomas	O
.	O

Furthermore	O
,	O
SM	O
-	O
3	O
stains	O
primary	O
carcinomas	O
of	O
the	O
lung	O
,	O
colon	O
and	O
ovary	O
,	O
but	O
on	O
the	O
corresponding	O
normal	O
tissue	O
the	O
epitope	O
is	O
expressed	O
at	O
a	O
much	O
reduced	O
level	O
or	O
not	O
at	O
all	O
.	O

These	O
results	O
indicate	O
that	O
an	O
epitope	O
masked	O
in	O
the	O
normal	O
mucin	O
is	O
exposed	O
in	O
the	O
mucin	O
produced	O
by	O
tumour	O
cells	O
,	O
perhaps	O
due	O
to	O
aberrant	O
glycosylation	O
.	O

An	O
extensive	O
immunohistochemical	O
study	O
of	O
other	O
normal	O
tissues	O
reveals	O
that	O
the	O
majority	O
show	O
only	O
weak	O
focal	O
staining	O
with	O
SM	O
-	O
3	O
or	O
none	O
at	O
all	O
,	O
the	O
distal	O
tubules	O
and	O
collecting	O
ducts	O
of	O
the	O
kidney	O
,	O
and	O
sebaceous	O
glands	O
being	O
the	O
only	O
normal	O
tissues	O
studied	O
to	O
show	O
homogeneously	O
positive	O
staining	O
.	O

Demethylation	O
of	O
the	O
gene	O
expressing	O
a	O
yolk	O
protein	O
precursor	O
in	O
quail	O
.	O

Japanese	O
quail	O
produce	O
more	O
egg	O
-	O
yolk	O
protein	O
per	O
gram	O
of	O
body	O
weight	O
than	O
chickens	O
do	O
.	O

Because	O
cytosine	O
phosphoguanine	O
(	O
CpG	O
)	O
methylation	O
has	O
been	O
reported	O
to	O
correlate	O
inversely	O
with	O
gene	O
activity	O
,	O
the	O
demethylation	O
of	O
cytosine	O
residues	O
in	O
the	O
quail	O
vitellogenin	B-Protein
2	E-Protein
(	O
Vg2	S-Protein
)	O
gene	O
was	O
assessed	O
as	O
a	O
possible	O
contributing	O
factor	O
.	O

Vitellogenin	O
genes	O
are	O
normally	O
transcribed	O
in	O
the	O
liver	O
of	O
female	O
Japanese	O
quail	O
that	O
are	O
sexually	O
mature	O
.	O

Changes	O
in	O
the	O
methylation	O
pattern	O
of	O
CCGG	O
sites	O
of	O
the	O
quail	O
Vg2	S-Protein
gene	O
were	O
studied	O
using	O
the	O
methyl	O
-	O
sensitive	O
restriction	O
endonucleases	O
Msp	B-Protein
I	E-Protein
and	O
Hpa	B-Protein
II	E-Protein
.	O

At	O
least	O
five	O
CCGG	O
sites	O
were	O
detected	O
within	O
the	O
transcribed	O
region	O
of	O
the	O
Vg2	S-Protein
gene	O
;	O
one	O
or	O
two	O
of	O
these	O
sites	O
were	O
hypomethylated	O
in	O
all	O
tissues	O
examined	O
in	O
male	O
and	O
female	O
quail	O
,	O
two	O
sites	O
underwent	O
transcription	O
-	O
dependent	O
demethylation	O
in	O
the	O
liver	O
of	O
laying	O
females	O
and	O
also	O
in	O
the	O
liver	O
of	O
males	O
following	O
estradiol	O
injection	O
(	O
64	O
mumol	O
estradiol	O
/	O
mL	O
of	O
absolute	O
ethanol	O
at	O
.	O
25	O
mL	O
/	O
100	O
g	O
of	O
BW	O
)	O
,	O
and	O
another	O
site	O
was	O
demethylated	O
in	O
the	O
liver	O
of	O
estradiol	O
-	O
injected	O
males	O
but	O
not	O
in	O
laying	O
females	O
.	O

Two	O
further	O
sites	O
present	O
within	O
the	O
5	O
'	O
flanking	O
sequences	O
or	O
5	O
'	O
structural	O
region	O
underwent	O
transcription	O
-	O
dependent	O
demethylation	O
in	O
the	O
liver	O
of	O
laying	O
females	O
and	O
of	O
estradiol	O
-	O
treated	O
males	O
;	O
one	O
or	O
both	O
of	O
these	O
sites	O
appears	O
to	O
be	O
demethylated	O
in	O
the	O
oviduct	O
.	O

Another	O
site	O
,	O
within	O
the	O
3	O
'	O
flanking	O
sequences	O
or	O
the	O
3	O
'	O
structural	O
gene	O
region	O
,	O
underwent	O
estradiol	O
-	O
dependent	O
demethylation	O
in	O
the	O
liver	O
and	O
the	O
oviduct	O
.	O

The	O
expression	O
-	O
linked	O
demethylation	O
of	O
the	O
CCGG	O
sites	O
in	O
the	O
Vg2	S-Protein
gene	O
of	O
quail	O
appears	O
to	O
be	O
similar	O
to	O
that	O
reported	O
for	O
the	O
chicken	O
VTGII	S-Protein
gene	O
.	O

The	O
results	O
of	O
this	O
study	O
did	O
not	O
explain	O
the	O
enhanced	O
production	O
of	O
yolk	O
protein	O
in	O
Japanese	O
quail	O
,	O
but	O
did	O
suggest	O
the	O
presence	O
of	O
a	O
fundamental	O
,	O
conserved	O
mechanism	O
that	O
must	O
play	O
an	O
important	O
role	O
in	O
the	O
expression	O
of	O
the	O
avian	O
Vg	O
gene	O
.	O

Immunological	O
studies	O
of	O
the	O
glycoprotein	O
allergen	O
Ag	B-Protein
-	I-Protein
54	E-Protein
(	O
Cla	B-Protein
h	I-Protein
II	E-Protein
)	O
in	O
Cladosporium	O
herbarum	O
with	O
special	O
attention	O
to	O
the	O
carbohydrate	O
and	O
protein	O
moieties	O
.	O

The	O
glycoprotein	O
allergen	O
Ag	B-Protein
-	I-Protein
54	E-Protein
(	O
Cla	B-Protein
h	I-Protein
II	E-Protein
)	O
isolated	O
from	O
Cladosporium	O
herbarum	O
was	O
split	O
into	O
its	O
carbohydrate	O
and	O
protein	O
moieties	O
by	O
using	O
alkaline	O
-	O
borohydride	O
treatment	O
and	O
deglycosylation	O
,	O
respectively	O
.	O

The	O
native	O
Ag	B-Protein
-	I-Protein
54	E-Protein
,	O
the	O
deglycosylated	O
protein	O
and	O
the	O
protein	O
-	O
free	O
carbohydrate	O
moieties	O
were	O
tested	O
for	O
IgE	O
-	O
binding	O
activity	O
by	O
radioallergosorbent	O
test	O
inhibition	O
using	O
selected	O
sera	O
from	O
individuals	O
with	O
C	O
.	O
herbarum	O
allergy	O
.	O

The	O
deglycosylated	O
material	O
had	O
a	O
stronger	O
allergenic	O
activity	O
than	O
the	O
native	O
Ag	B-Protein
-	I-Protein
54	E-Protein
with	O
all	O
the	O
sera	O
tested	O
.	O

The	O
Ag	B-Protein
-	I-Protein
54	E-Protein
carbohydrate	O
moieties	O
were	O
not	O
found	O
to	O
possess	O
any	O
IgE	O
-	O
binding	O
activity	O
.	O

The	O
galactoglucomannan	O
part	O
of	O
the	O
carbohydrate	O
moiety	O
was	O
isolated	O
and	O
it	O
was	O
demonstrated	O
to	O
precipitate	O
IgG	O
rabbit	O
antibody	O
.	O

Removal	O
of	O
the	O
galactofuranose	O
units	O
by	O
mild	O
acid	O
hydrolysis	O
did	O
not	O
alter	O
the	O
IgG	O
-	O
binding	O
capacity	O
of	O
the	O
polysaccharide	O
,	O
indicating	O
that	O
galactofuranose	O
was	O
not	O
immunodominant	O
.	O

Inhibitors	O
of	O
2	O
-	O
ketoglutarate	O
-	O
dependent	O
dioxygenases	O
block	O
aspartyl	O
beta	O
-	O
hydroxylation	O
of	O
recombinant	O
human	O
factor	B-Protein
IX	E-Protein
in	O
several	O
mammalian	O
expression	O
systems	O
.	O

While	O
a	O
role	O
has	O
been	O
ascribed	O
to	O
the	O
gamma	O
-	O
carboxyglutamate	O
(	O
Gla	O
)	O
residues	O
in	O
vitamin	O
K	O
-	O
dependent	O
coagulation	O
proteins	O
and	O
the	O
enzyme	O
catalyzing	O
this	O
posttranslational	O
modification	O
has	O
been	O
identified	O
and	O
partially	O
characterized	O
,	O
both	O
the	O
functional	O
significance	O
of	O
a	O
second	O
posttranslationally	O
synthesized	O
amino	O
acid	O
found	O
in	O
these	O
proteins	O
,	O
beta	O
-	O
hydroxyaspartate	O
(	O
Hya	O
)	O
,	O
and	O
the	O
aspartyl	O
beta	O
-	O
hydroxylating	O
enzyme	O
remain	O
to	O
be	O
determined	O
.	O

We	O
now	O
report	O
that	O
inhibitors	O
of	O
2	O
-	O
ketoglutarate	O
-	O
dependent	O
dioxygenases	O
,	O
such	O
as	O
dipyridyl	O
,	O
o	O
-	O
phenanthroline	O
,	O
and	O
pyridine	O
2	O
,	O
4	O
-	O
dicarboxylate	O
,	O
block	O
hydroxylation	O
of	O
Asp64	O
in	O
recombinant	O
factor	B-Protein
IX	E-Protein
molecules	O
produced	O
in	O
three	O
different	O
mammalian	O
expression	O
systems	O
.	O

This	O
hydroxylation	O
was	O
not	O
inhibited	O
by	O
the	O
specific	O
copper	O
chelators	O
2	O
,	O
9	O
-	O
dimethylphenanthroline	O
or	O
D	O
-	O
penicillamine	O
.	O

The	O
Gla	O
levels	O
in	O
these	O
proteins	O
were	O
unaffected	O
by	O
these	O
compounds	O
and	O
demonstrate	O
that	O
carboxylation	O
proceeds	O
independently	O
of	O
hydroxylation	O
.	O

Using	O
these	O
Hya	O
-	O
deficient	O
recombinant	O
factor	B-Protein
IX	E-Protein
molecules	O
we	O
demonstrate	O
that	O
this	O
residue	O
does	O
not	O
play	O
a	O
significant	O
role	O
in	O
factor	B-Protein
IX	E-Protein
binding	O
to	O
endothelial	O
cells	O
under	O
equilibrium	O
conditions	O
.	O

From	O
additional	O
binding	O
studies	O
we	O
have	O
concluded	O
that	O
the	O
Gla	O
domain	O
of	O
factor	B-Protein
IX	E-Protein
is	O
a	O
major	O
cell	O
binding	O
domain	O
of	O
factor	B-Protein
IX	E-Protein
.	O

Furthermore	O
,	O
in	O
contrast	O
to	O
studies	O
demonstrating	O
a	O
marked	O
loss	O
of	O
one	O
-	O
stage	O
clotting	O
activity	O
in	O
recombinant	O
factors	B-Protein
IX	E-Protein
following	O
site	O
-	O
directed	O
mutations	O
of	O
Asp64	O
to	O
neutral	O
or	O
basic	O
residues	O
(	O
Rees	O
,	O
D	O
.	O
J	O
.	O
G	O
.	O
,	O
Jones	O
,	O
I	O
.	O
M	O
.	O
,	O
Handford	O
,	O
P	O
.	O
A	O
.	O
,	O
Walter	O
,	O
S	O
.	O
J	O
.	O
,	O
Esnouf	O
,	O
M	O
.	O
P	O
.	O
,	O
Smith	O
,	O
K	O
.	O
J	O
.	O
,	O
and	O
Brownlee	O
,	O
G	O
.	O
J	O
.	O
(	O
1988	O
)	O
EMBO	O
J	O
.	O
7	O
,	O
2053	O
-	O
2061	O
)	O
,	O
we	O
have	O
not	O
found	O
a	O
decrease	O
of	O
one	O
-	O
stage	O
clotting	O
activity	O
with	O
Hya	O
-	O
deficient	O
factor	B-Protein
IX	E-Protein
.	O

Hya	O
-	O
deficient	O
proteins	O
produced	O
in	O
this	O
manner	O
may	O
prove	O
to	O
be	O
more	O
appropriate	O
to	O
elucidate	O
the	O
function	O
of	O
Hya	O
than	O
those	O
produced	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Aspartyl	B-Protein
beta	I-Protein
-	I-Protein
hydroxylase	E-Protein
:	O
in	O
vitro	O
hydroxylation	O
of	O
a	O
synthetic	O
peptide	O
based	O
on	O
the	O
structure	O
of	O
the	O
first	O
growth	O
factor	O
-	O
like	O
domain	O
of	O
human	O
factor	B-Protein
IX	E-Protein
.	O

beta	O
-	O
Hydroxylation	O
of	O
aspartic	O
acid	O
is	O
a	O
post	O
-	O
translational	O
modification	O
that	O
occurs	O
in	O
several	O
vitamin	O
K	O
-	O
dependent	O
coagulation	O
proteins	O
.	O

By	O
use	O
of	O
a	O
synthetic	O
substrate	O
comprised	O
of	O
the	O
first	O
epidermal	O
growth	O
factor	O
-	O
like	O
domain	O
in	O
human	O
factor	B-Protein
IX	E-Protein
and	O
either	O
mouse	O
L	O
-	O
cell	O
extracts	O
or	O
rat	O
liver	O
microsomes	O
as	O
the	O
source	O
of	O
enzyme	O
,	O
in	O
vitro	O
aspartyl	O
beta	O
-	O
hydroxylation	O
was	O
accomplished	O
.	O

Aspartyl	B-Protein
beta	I-Protein
-	I-Protein
hydroxylase	E-Protein
appears	O
to	O
require	O
the	O
same	O
cofactors	O
as	O
known	O
alpha	O
-	O
ketoglutarate	O
-	O
dependent	O
dioxygenases	O
.	O

The	O
hydroxylation	O
reaction	O
proceeds	O
with	O
the	O
same	O
stereospecificity	O
and	O
occurs	O
only	O
at	O
the	O
aspartate	O
corresponding	O
to	O
the	O
position	O
seen	O
in	O
vivo	O
.	O

Further	O
purification	O
and	O
characterization	O
of	O
this	O
enzymatic	O
activity	O
should	O
now	O
be	O
possible	O
.	O

Role	O
of	O
glycosylation	O
for	O
beta	B-Protein
2	I-Protein
-	I-Protein
adrenoceptor	E-Protein
function	O
in	O
A431	O
cells	O
.	O

A431	O
cells	O
incubated	O
with	O
tunicamycin	O
(	O
0	O
.	O
15	O
micrograms	O
/	O
ml	O
)	O
for	O
40	O
h	O
under	O
conditions	O
where	O
incorporation	O
of	O
[	O
3H	O
]	O
leucine	O
into	O
protein	O
was	O
inhibited	O
less	O
than	O
10	O
%	O
expressed	O
mainly	O
a	O
beta	O
-	O
receptor	O
species	O
of	O
about	O
Mr	O
40	O
,	O
000	O
which	O
was	O
ascribed	O
to	O
the	O
nonglycosylated	O
form	O
of	O
the	O
beta	O
-	O
receptor	O
of	O
about	O
Mr	O
75	O
,	O
000	O
found	O
in	O
normal	O
A431	O
cells	O
by	O
photoaffinity	O
labeling	O
.	O

However	O
,	O
the	O
tunicamycin	O
-	O
treated	O
cells	O
expressed	O
the	O
same	O
number	O
of	O
specific	O
beta	O
2	O
-	O
receptor	O
-	O
binding	O
sites	O
as	O
untreated	O
cells	O
.	O

Moreover	O
,	O
the	O
aglycoreceptors	O
had	O
the	O
same	O
ligand	O
binding	O
properties	O
as	O
beta	O
-	O
adrenoceptors	O
from	O
control	O
cells	O
;	O
but	O
,	O
functional	O
tests	O
of	O
the	O
receptor	O
from	O
tunicamycin	O
-	O
treated	O
cells	O
in	O
reconstituted	O
lipid	O
vesicles	O
showed	O
that	O
receptors	O
from	O
tunicamycin	O
-	O
treated	O
cells	O
had	O
lost	O
coupling	O
efficiency	O
.	O

The	O
coupling	O
defect	O
was	O
at	O
the	O
receptor	O
level	O
since	O
control	O
experiments	O
indicated	O
that	O
the	O
other	O
components	O
of	O
the	O
signal	O
transmission	O
chain	O
from	O
beta	O
-	O
adrenoceptor	O
to	O
adenylate	O
cyclase	O
,	O
the	O
stimulatory	O
regulatory	O
GTP	O
-	O
binding	O
protein	O
of	O
adenylate	O
cyclase	O
and	O
adenylate	O
cyclase	O
,	O
were	O
fully	O
functional	O
.	O

Homologous	O
desensitization	O
in	O
tunicamycin	O
-	O
treated	O
cells	O
was	O
characterized	O
by	O
export	O
from	O
the	O
cell	O
surface	O
and	O
sequestration	O
of	O
about	O
the	O
same	O
number	O
of	O
beta	O
-	O
adrenoceptors	O
as	O
in	O
normal	O
desensitized	O
cells	O
but	O
without	O
further	O
reduction	O
of	O
hormonally	O
stimulated	O
adenylate	O
cyclase	O
below	O
the	O
low	O
level	O
already	O
attained	O
in	O
nondesensitized	O
tunicamycin	O
-	O
treated	O
cells	O
.	O

This	O
was	O
explained	O
by	O
assuming	O
that	O
the	O
receptors	O
removed	O
in	O
the	O
course	O
of	O
homologous	O
desensitization	O
from	O
the	O
surface	O
of	O
tunicamycin	O
-	O
treated	O
cells	O
were	O
already	O
nonfunctional	O
.	O

Thus	O
,	O
beta	O
-	O
adrenergic	O
desensitization	O
in	O
tunicamycin	O
-	O
treated	O
cells	O
is	O
characterized	O
by	O
the	O
functional	O
disengagement	O
of	O
receptor	O
removal	O
and	O
loss	O
of	O
adenylate	O
cyclase	O
activity	O
.	O

IgE	O
receptor	O
on	O
human	O
lymphocytes	O
.	O

IV	O
.	O

Further	O
analysis	O
of	O
its	O
structure	O
and	O
of	O
the	O
role	O
of	O
N	O
-	O
linked	O
carbohydrates	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
the	O
low	O
affinity	O
receptor	O
for	O
IgE	O
(	O
Fc	B-Protein
epsilon	I-Protein
R	I-Protein
II	E-Protein
)	O
on	O
human	O
B	O
lymphocytes	O
was	O
comprised	O
of	O
three	O
components	O
with	O
apparent	O
Mr	O
of	O
45	O
,	O
65	O
to	O
95	O
,	O
and	O
37	O
kDa	O
.	O

The	O
present	O
results	O
indicate	O
that	O
the	O
37	O
-	O
kDa	O
component	O
is	O
a	O
soluble	O
degradation	O
fragment	O
of	O
the	O
45	O
-	O
kDa	O
component	O
and	O
they	O
also	O
suggest	O
that	O
the	O
65	O
-	O
to	O
95	O
-	O
kDa	O
component	O
is	O
probably	O
made	O
of	O
aggregates	O
of	O
the	O
above	O
components	O
that	O
are	O
formed	O
after	O
solubilization	O
of	O
the	O
cells	O
.	O

The	O
45	O
-	O
kDa	O
component	O
appears	O
to	O
be	O
a	O
glycoprotein	O
containing	O
several	O
sialic	O
acid	O
residues	O
,	O
O	O
-	O
linked	O
carbohydrates	O
and	O
one	O
N	O
-	O
linked	O
carbohydrate	O
chain	O
that	O
is	O
of	O
the	O
complex	O
type	O
.	O

Partial	O
digestion	O
of	O
the	O
purified	O
65	O
-	O
to	O
95	O
-	O
,	O
45	O
-	O
,	O
and	O
37	O
-	O
kDa	O
molecules	O
with	O
alpha	B-Protein
-	I-Protein
chymotrypsin	E-Protein
or	O
protease	B-Protein
V8	E-Protein
generates	O
several	O
fragments	O
with	O
identical	O
mobility	O
on	O
SDS	O
-	O
PAGE	O
.	O

The	O
37	O
kDa	O
is	O
not	O
N	O
-	O
glycosylated	O
but	O
like	O
the	O
IgE	B-Protein
-	I-Protein
binding	I-Protein
factors	E-Protein
present	O
in	O
the	O
culture	O
supernatant	O
of	O
Fc	O
epsilon	O
R	O
-	O
bearing	O
cells	O
,	O
it	O
contains	O
sialic	O
acid	O
and	O
O	O
-	O
linked	O
carbohydrates	O
.	O

On	O
incubation	O
with	O
protease	O
inhibitors	O
,	O
the	O
Mr	O
of	O
IgE	B-Protein
-	I-Protein
binding	I-Protein
factors	E-Protein
(	O
BF	O
)	O
is	O
shifted	O
from	O
25	O
-	O
27	O
to	O
37	O
kDa	O
,	O
indicating	O
that	O
IgE	B-Protein
-	I-Protein
BF	E-Protein
are	O
derived	O
from	O
the	O
proteolytic	O
cleavage	O
of	O
the	O
37	O
-	O
kDa	O
molecule	O
,	O
previously	O
identified	O
as	O
a	O
membrane	O
component	O
of	O
Fc	O
epsilon	O
R	O
.	O

On	O
incubation	O
with	O
N	O
-	O
glycosylation	O
inhibitors	O
,	O
the	O
production	O
of	O
IgE	B-Protein
-	I-Protein
BF	E-Protein
is	O
significantly	O
increased	O
indicating	O
that	O
N	O
-	O
glycosylation	O
inhibits	O
the	O
degradation	O
of	O
Fc	O
epsilon	O
R	O
into	O
IgE	B-Protein
-	I-Protein
BF	E-Protein
.	O

Inasmuch	O
as	O
the	O
effect	O
of	O
glycosylation	O
inhibitors	O
is	O
not	O
prevented	O
by	O
monensin	O
,	O
it	O
is	O
concluded	O
that	O
all	O
the	O
IgE	B-Protein
-	I-Protein
BF	E-Protein
are	O
derived	O
from	O
surface	O
Fc	O
epsilon	O
R	O
and	O
not	O
from	O
their	O
intracellular	O
precursors	O
.	O

Reduced	O
S	O
-	O
adenosylmethionine	O
:	O
protein	O
-	O
lysine	O
N	O
-	O
methyltransferase	O
activity	O
(	O
protein	O
methylase	O
III	O
)	O
in	O
shiverer	O
mutant	O
mouse	O
brain	O
.	O

Mice	O
with	O
the	O
dysmyelinating	O
mutation	O
shiverer	O
were	O
studied	O
by	O
measuring	O
the	O
activity	O
of	O
two	O
protein	O
methylases	O
and	O
myelin	O
marker	O
enzymes	O
in	O
the	O
brain	O
.	O

It	O
was	O
observed	O
that	O
S	O
-	O
adenosylmethionine	O
:	O
protein	O
-	O
lysine	O
N	O
-	O
methyltransferase	O
(	O
protein	O
methylase	O
III	O
,	O
EC	O
.	O
2	O
.	O
1	O
.	O
1	O
.	O
43	O
)	O
activity	O
is	O
significantly	O
reduced	O
in	O
phenotypically	O
affected	O
homozygous	O
shiverer	O
(	O
shi	O
/	O
shi	O
)	O
mutant	O
mouse	O
brain	O
compared	O
to	O
the	O
unaffected	O
heterozygous	O
littermate	O
brain	O
.	O

This	O
reduction	O
in	O
enzyme	O
activity	O
is	O
manifested	O
mainly	O
by	O
reduced	O
formation	O
of	O
trimethyllysine	O
during	O
the	O
in	O
vitro	O
methylation	O
of	O
histone	S-Protein
.	O

In	O
contrast	O
,	O
myelin	O
marker	O
enzymes	O
such	O
as	O
2	B-Protein
'	I-Protein
,	I-Protein
3	I-Protein
'	I-Protein
-	I-Protein
cyclic	I-Protein
nucleotide	I-Protein
3	I-Protein
'	I-Protein
-	I-Protein
phosphohydrolase	E-Protein
and	O
5	B-Protein
'	I-Protein
-	I-Protein
nucleotidase	E-Protein
as	O
well	O
as	O
S	O
-	O
adenosyl	O
-	O
methionine	O
:	O
protein	O
-	O
carboxyl	O
O	O
-	O
methyltransferase	O
(	O
protein	O
methylase	O
II	O
,	O
EC	O
.	O
2	O
.	O
1	O
.	O
1	O
.	O
24	O
)	O
activities	O
were	O
not	O
significantly	O
affected	O
in	O
these	O
strains	O
of	O
mice	O
.	O

Insulin	S-Protein
resistance	O
in	O
denervated	O
skeletal	O
muscle	O
.	O

Inability	O
of	O
insulin	S-Protein
to	O
stimulate	O
dephosphorylation	O
of	O
glycogen	B-Protein
synthase	E-Protein
in	O
denervated	O
rat	O
epitrochlearis	O
muscles	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
insulin	S-Protein
and	O
motor	O
denervation	O
on	O
the	O
phosphorylation	O
of	O
glycogen	B-Protein
synthase	E-Protein
in	O
skeletal	O
muscle	O
.	O

Rat	O
epitrochlearis	O
muscles	O
were	O
denervated	O
in	O
vivo	O
3	O
days	O
before	O
the	O
contralateral	O
and	O
denervated	O
muscles	O
were	O
incubated	O
in	O
vitro	O
with	O
32Pi	O
to	O
label	O
sites	O
in	O
glycogen	B-Protein
synthase	E-Protein
.	O

The	O
32P	O
-	O
labeled	O
synthase	O
was	O
rapidly	O
immunoprecipitated	O
from	O
extracts	O
under	O
conditions	O
which	O
prevented	O
changes	O
in	O
the	O
phosphorylation	O
state	O
of	O
the	O
enzyme	O
.	O

When	O
32P	O
-	O
labeled	O
synthase	O
from	O
contralateral	O
muscles	O
was	O
cleaved	O
with	O
CNBr	O
,	O
essentially	O
all	O
of	O
the	O
32P	O
was	O
recovered	O
in	O
two	O
fragments	O
,	O
denoted	O
CB	O
-	O
1	O
and	O
CB	O
-	O
2	O
.	O

Incubating	O
these	O
muscles	O
with	O
insulin	S-Protein
decreased	O
the	O
32P	O
content	O
of	O
each	O
fragment	O
by	O
approximately	O
25	O
%	O
,	O
indicating	O
that	O
the	O
hormone	O
stimulated	O
dephosphorylation	O
of	O
at	O
least	O
two	O
sites	O
.	O

Peptide	O
mapping	O
by	O
reverse	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
was	O
performed	O
to	O
resolve	O
phosphorylation	O
sites	O
more	O
completely	O
.	O

The	O
results	O
suggest	O
that	O
the	O
enzyme	O
was	O
phosphorylated	O
in	O
sites	O
1a	O
,	O
1b	O
,	O
2	O
,	O
3	O
(	O
a	O
+	O
b	O
+	O
c	O
)	O
,	O
and	O
5	O
.	O

Insulin	S-Protein
stimulated	O
dephosphorylation	O
of	O
sites	O
in	O
peptides	O
presumed	O
to	O
contain	O
sites	O
1b	O
,	O
2	O
,	O
and	O
3	O
(	O
a	O
+	O
b	O
+	O
c	O
)	O
.	O

Synthase	O
from	O
denervated	O
muscles	O
appeared	O
to	O
contain	O
the	O
same	O
amount	O
of	O
phosphate	O
as	O
enzyme	O
from	O
contralateral	O
muscles	O
,	O
and	O
denervation	O
did	O
not	O
detectably	O
affect	O
the	O
distribution	O
of	O
32P	O
within	O
the	O
subunit	O
.	O

However	O
,	O
denervation	O
abolished	O
the	O
effect	O
of	O
insulin	S-Protein
on	O
decreasing	O
the	O
32P	O
content	O
of	O
synthase	O
.	O

The	O
results	O
indicate	O
that	O
the	O
insulin	S-Protein
resistance	O
induced	O
by	O
denervation	O
involves	O
a	O
loss	O
in	O
the	O
ability	O
of	O
insulin	S-Protein
to	O
stimulate	O
dephosphorylation	O
of	O
glycogen	B-Protein
synthase	E-Protein
.	O

Rabbit	O
secretory	O
components	O
of	O
different	O
allotypes	O
vary	O
in	O
their	O
carbohydrate	O
content	O
and	O
their	O
sites	O
of	O
N	O
-	O
linked	O
glycosylation	O
.	O

The	O
asparagine	O
-	O
linked	O
glycosylation	O
sites	O
in	O
rabbit	O
high	O
and	O
low	O
Mr	O
secretory	B-Protein
components	E-Protein
(	O
SC	S-Protein
)	O
have	O
been	O
determined	O
for	O
the	O
three	O
known	O
allotypes	O
,	O
t61	O
,	O
t62	O
,	O
and	O
t63	O
.	O

Purified	O
SC	O
polypeptides	O
were	O
subjected	O
to	O
mild	O
periodate	O
oxidation	O
of	O
terminal	O
nonreducing	O
sugars	O
followed	O
by	O
selective	O
reduction	O
with	O
[	O
3H	O
]	O
sodium	O
borohydride	O
,	O
SC	S-Protein
polypeptides	O
were	O
further	O
proteolytically	O
cleaved	O
,	O
and	O
the	O
3H	O
-	O
labeled	O
peptides	O
were	O
isolated	O
and	O
characterized	O
.	O

Both	O
high	O
and	O
low	O
Mr	O
SCs	S-Protein
of	O
the	O
three	O
allotypes	O
possess	O
a	O
common	O
glycosylation	O
site	O
at	O
the	O
asparagine	O
residue	O
position	O
400	O
,	O
whereas	O
the	O
second	O
site	O
,	O
in	O
the	O
amino	O
-	O
terminal	O
domain	O
of	O
SC	S-Protein
,	O
was	O
found	O
to	O
be	O
variable	O
:	O
the	O
t61	O
and	O
t63	O
allotypes	O
contained	O
a	O
glycosylation	O
site	O
at	O
positions	O
70	O
and	O
90	O
,	O
respectively	O
.	O

Moreover	O
,	O
although	O
the	O
t62	O
allotype	O
was	O
found	O
to	O
contain	O
a	O
triplet	O
acceptor	O
site	O
(	O
N	O
-	O
X	O
-	O
S	O
)	O
at	O
positions	O
90	O
-	O
92	O
,	O
analyses	O
showed	O
that	O
less	O
than	O
30	O
%	O
of	O
the	O
t62	O
allotype	O
peptides	O
encompassing	O
this	O
region	O
were	O
glycosylated	O
at	O
residue	O
90	O
.	O

Furthermore	O
,	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
t61	O
SC	S-Protein
in	O
the	O
region	O
of	O
residues	O
69	O
-	O
90	O
varies	O
by	O
8	O
and	O
10	O
amino	O
acid	O
substitutions	O
when	O
compared	O
with	O
the	O
t62	O
and	O
t63	O
allotype	O
sequences	O
,	O
respectively	O
.	O

However	O
,	O
neither	O
the	O
variation	O
in	O
amino	O
acid	O
sequence	O
nor	O
the	O
variation	O
in	O
degree	O
or	O
site	O
of	O
glycosylation	O
measurably	O
affected	O
the	O
non	O
-	O
covalent	O
binding	O
of	O
domain	O
1	O
to	O
dimeric	O
IgA	O
.	O

Pharmacogenetics	O
of	O
N	O
-	O
methylation	O
:	O
heritability	O
of	O
human	O
erythrocyte	O
histamine	B-Protein
N	I-Protein
-	I-Protein
methyltransferase	E-Protein
activity	O
.	O

Histamine	B-Protein
N	I-Protein
-	I-Protein
methyltransferase	E-Protein
(	O
HNMT	S-Protein
)	O
catalyzes	O
the	O
N	O
tau	O
-	O
methylation	O
of	O
histamine	O
.	O

HNMT	S-Protein
is	O
present	O
in	O
many	O
human	O
tissues	O
,	O
including	O
the	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
.	O

Our	O
study	O
evaluated	O
the	O
possible	O
role	O
of	O
inheritance	O
in	O
the	O
regulation	O
of	O
individual	O
variations	O
in	O
human	O
RBC	O
HNMT	S-Protein
activity	O
.	O

HNMT	S-Protein
activity	O
was	O
measured	O
in	O
RBC	O
lysates	O
from	O
241	O
members	O
of	O
51	O
nuclear	O
families	O
.	O

After	O
correction	O
for	O
the	O
gender	O
-	O
specific	O
effects	O
of	O
age	O
,	O
the	O
frequency	O
distribution	O
of	O
RBC	O
HNMT	S-Protein
activities	O
was	O
unimodal	O
,	O
and	O
activities	O
varied	O
threefold	O
within	O
2	O
SDs	O
of	O
the	O
mean	O
.	O

The	O
correlation	O
of	O
HNMT	S-Protein
activities	O
in	O
RBCs	O
from	O
45	O
pairs	O
of	O
spouses	O
was	O
only	O
0	O
.	O
070	O
,	O
indicating	O
that	O
shared	O
environment	O
did	O
not	O
result	O
in	O
similar	O
activities	O
among	O
genetically	O
unrelated	O
individuals	O
.	O

Correlation	O
coefficients	O
were	O
also	O
calculated	O
for	O
pairs	O
of	O
genetically	O
related	O
individuals	O
.	O

All	O
of	O
these	O
correlations	O
were	O
significant	O
except	O
the	O
mother	O
-	O
oldest	O
son	O
correlation	O
.	O

The	O
majority	O
of	O
the	O
correlations	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
predicted	O
for	O
a	O
trait	O
with	O
a	O
heritability	O
of	O
1	O
.	O
0	O
(	O
100	O
%	O
)	O
.	O

Our	O
results	O
demonstrate	O
a	O
significant	O
familial	O
aggregation	O
of	O
human	O
RBC	O
HNMT	S-Protein
activity	O
and	O
suggest	O
that	O
inheritance	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
variation	O
in	O
the	O
activity	O
of	O
this	O
N	O
-	O
methyltransferase	O
enzyme	O
in	O
the	O
human	O
RBC	O
.	O

Underhydroxylated	O
minor	O
cartilage	O
collagen	O
precursors	O
cannot	O
form	O
stable	O
triple	O
helices	O
.	O

Matrix	O
-	O
free	O
cells	O
from	O
chick	O
-	O
embryo	O
sterna	O
were	O
incubated	O
with	O
various	O
concentrations	O
of	O
2	O
,	O
2	O
'	O
-	O
bipyridyl	O
,	O
an	O
iron	O
chelator	O
that	O
inhibits	O
prolyl	O
hydroxylase	O
and	O
lysyl	O
hydroxylase	O
.	O

At	O
concentrations	O
in	O
the	O
region	O
of	O
0	O
.	O
1	O
mM	O
,	O
significant	O
effects	O
on	O
cartilage	O
collagen	O
hydroxylation	O
and	O
secretion	O
were	O
observed	O
.	O

When	O
the	O
underhydroxylated	O
collagens	O
were	O
subsequently	O
digested	O
with	O
chymotrypsin	O
or	O
chymotrypsin	O
plus	O
trypsin	O
at	O
4	O
degrees	O
C	O
for	O
15	O
min	O
,	O
the	O
minor	O
cartilage	O
collagen	O
precursors	O
(	O
namely	O
types	O
IX	O
and	O
XI	O
)	O
were	O
extensively	O
degraded	O
;	O
type	B-Protein
II	I-Protein
procollagen	E-Protein
was	O
only	O
partially	O
susceptible	O
and	O
was	O
converted	O
into	O
underhydroxylated	O
collagen	O
.	O

The	O
results	O
demonstrate	O
that	O
there	O
were	O
significant	O
differences	O
in	O
triple	O
-	O
helix	O
stability	O
among	O
cartilage	O
collagens	O
such	O
that	O
the	O
underhydroxylated	O
minor	O
collagen	O
precursors	O
were	O
unable	O
to	O
attain	O
a	O
native	O
structure	O
under	O
conditions	O
where	O
type	B-Protein
II	I-Protein
procollagen	E-Protein
was	O
successful	O
.	O

N	O
-	O
acetylated	O
endorphins	O
in	O
ovine	O
anterior	O
pituitary	O
and	O
neuro	O
-	O
intermediate	O
lobe	O
.	O

We	O
have	O
used	O
an	O
antiserum	O
for	O
immunohistochemistry	O
and	O
RIA	O
/	O
RP	O
-	O
HPLC	O
which	O
recognizes	O
all	O
fragments	O
of	O
N	O
-	O
acetylated	O
endorphin	O
(	O
NacEP	O
)	O
.	O

In	O
the	O
rat	O
neuro	O
-	O
intermediate	O
lobe	O
(	O
N	O
-	O
IL	O
)	O
,	O
in	O
addition	O
to	O
the	O
N	O
-	O
acetylated	O
forms	O
of	O
immunoreactive	O
-	O
beta	B-Protein
-	I-Protein
endorphin	E-Protein
(	O
ir	O
-	O
beta	B-Protein
EP	E-Protein
)	O
already	O
reported	O
,	O
we	O
have	O
demonstrated	O
Nac	O
beta	B-Protein
EP	E-Protein
as	O
a	O
minor	O
component	O
.	O

In	O
the	O
sheep	O
pituitary	O
processing	O
of	O
beta	B-Protein
EP	E-Protein
is	O
markedly	O
different	O
.	O

In	O
the	O
anterior	O
pituitary	O
(	O
AP	O
)	O
,	O
staining	O
was	O
indistinguishable	O
with	O
beta	B-Protein
EP	E-Protein
and	O
NacEP	O
antisera	O
,	O
in	O
contrast	O
with	O
the	O
rat	O
where	O
many	O
fewer	O
AP	O
cells	O
stained	O
with	O
the	O
NacEP	O
antiserum	O
.	O

Secondly	O
,	O
as	O
in	O
the	O
rat	O
,	O
all	O
N	O
-	O
IL	O
cells	O
stained	O
with	O
both	O
antisera	O
;	O
on	O
RP	O
-	O
HPLC	O
,	O
however	O
,	O
the	O
major	O
forms	O
of	O
NacEP	O
in	O
the	O
sheep	O
N	O
-	O
IL	O
were	O
Nac	O
beta	B-Protein
EP	E-Protein
(	O
approximately	O
40	O
%	O
)	O
,	O
Nac	O
beta	B-Protein
EP	E-Protein
(	O
approximately	O
25	O
%	O
)	O
and	O
Nac	O
beta	B-Protein
EP	E-Protein
(	O
approximately	O
20	O
%	O
)	O
,	O
with	O
Nac	O
beta	B-Protein
EP	E-Protein
(	O
approximately	O
2	O
%	O
)	O
as	O
a	O
minor	O
component	O
.	O

A	O
similar	O
profile	O
was	O
seen	O
on	O
RP	O
-	O
HPLC	O
of	O
sheep	O
AP	O
.	O

These	O
data	O
suggest	O
that	O
(	O
1	O
)	O
patterns	O
of	O
processing	O
in	O
sheep	O
AP	O
are	O
similar	O
to	O
those	O
in	O
N	O
-	O
IL	O
,	O
though	O
the	O
extent	O
of	O
acetylation	O
is	O
less	O
and	O
(	O
2	O
)	O
in	O
the	O
sheep	O
pituitary	O
low	O
molecular	O
weight	O
acetylated	O
fragments	O
predominate	O
,	O
in	O
contrast	O
with	O
the	O
rat	O
.	O

Catalytic	O
properties	O
of	O
NADPH	B-Protein
-	I-Protein
specific	I-Protein
dihydropteridine	I-Protein
reductase	E-Protein
from	O
bovine	O
liver	O
.	O

The	O
catalytic	O
properties	O
of	O
a	O
new	O
type	O
of	O
dihydropteridine	O
reductase	O
,	O
NADPH	B-Protein
-	I-Protein
specific	I-Protein
dihydropteridine	I-Protein
reductase	E-Protein
[	O
EC	O
1	O
.	O
6	O
.	O
99	O
.	O
10	O
]	O
,	O
from	O
bovine	O
liver	O
,	O
were	O
studied	O
and	O
compared	O
with	O
those	O
of	O
the	O
previously	O
characterized	O
enzyme	O
,	O
NADH	B-Protein
-	I-Protein
specific	I-Protein
dihydropteridine	I-Protein
reductase	E-Protein
[	O
EC	O
1	O
.	O
6	O
.	O
99	O
.	O
7	O
]	O
.	O

With	O
quinonoid	O
-	O
dihydro	O
-	O
6	O
-	O
methylpterin	O
,	O
approximate	O
Km	O
values	O
of	O
NADPH	B-Protein
-	I-Protein
specific	I-Protein
dihydropteridine	I-Protein
reductase	E-Protein
for	O
NADPH	O
and	O
NADH	O
were	O
estimated	O
to	O
be	O
1	O
.	O
4	O
micron	O
and	O
2	O
,	O
900	O
microns	O
,	O
respectively	O
.	O

The	O
Vmax	O
values	O
were	O
1	O
.	O
34	O
mumol	O
/	O
min	O
/	O
mg	O
with	O
NADPH	O
and	O
1	O
.	O
02	O
mumol	O
/	O
min	O
/	O
mg	O
with	O
NADPH	O
.	O

With	O
NADPH	O
,	O
the	O
Km	O
values	O
of	O
the	O
enzyme	O
for	O
the	O
quinonoid	O
-	O
dihydro	O
forms	O
of	O
6	O
-	O
methylpterin	O
and	O
biopterin	O
were	O
1	O
.	O
4	O
micron	O
and	O
6	O
.	O
8	O
microns	O
,	O
respectively	O
.	O

The	O
enzyme	O
was	O
inhibited	O
by	O
its	O
reaction	O
product	O
,	O
NADP	O
+	O
,	O
in	O
a	O
competitive	O
manner	O
,	O
and	O
the	O
inhibition	O
constant	O
was	O
determined	O
to	O
be	O
3	O
.	O
2	O
microns	O
.	O

The	O
enzyme	O
was	O
severely	O
inhibited	O
by	O
L	O
-	O
thyroxine	O
and	O
by	O
2	O
,	O
6	O
-	O
dichlorophenolindophenol	O
.	O

Genomic	O
hypomethylation	O
and	O
far	O
-	O
5	O
'	O
sequence	O
alterations	O
are	O
associated	O
with	O
carcinogen	O
-	O
induced	O
activation	O
of	O
the	O
hamster	O
thymidine	B-Protein
kinase	E-Protein
gene	O
.	O

We	O
have	O
investigated	O
the	O
mechanism	O
of	O
activation	O
of	O
an	O
inactive	O
but	O
functionally	O
intact	O
hamster	O
thymidine	B-Protein
kinase	E-Protein
(	O
TK	S-Protein
)	O
gene	O
by	O
the	O
chemical	O
carcinogen	O
N	O
-	O
methyl	O
-	O
N	O
'	O
-	O
nitro	O
-	O
N	O
-	O
nitrosoguanidine	O
.	O

Following	O
carcinogen	O
treatment	O
of	O
TK	O
-	O
RJK92	O
Chinese	O
hamster	O
cells	O
,	O
aminopterin	O
-	O
resistant	O
(	O
HATr	O
)	O
colonies	O
appeared	O
at	O
a	O
frequency	O
50	O
-	O
fold	O
higher	O
than	O
in	O
untreated	O
controls	O
.	O

More	O
than	O
80	O
%	O
of	O
these	O
HATr	O
variants	O
expressed	O
TK	S-Protein
enzymatic	O
activity	O
and	O
were	O
divided	O
into	O
high	O
-	O
and	O
low	O
-	O
activity	O
classes	O
.	O

In	O
all	O
TK	S-Protein
+	O
variants	O
,	O
TK	S-Protein
expression	O
was	O
correlated	O
with	O
demethylation	O
in	O
the	O
5	O
'	O
region	O
of	O
the	O
TK	S-Protein
gene	O
and	O
the	O
appearance	O
a	O
1	O
,	O
400	O
-	O
nucleotide	O
TK	S-Protein
mRNA	O
.	O

Using	O
high	O
-	O
performance	O
liquid	O
chromatography	O
to	O
measure	O
the	O
level	O
of	O
genomic	O
methylation	O
,	O
we	O
found	O
that	O
four	O
of	O
five	O
high	O
-	O
activity	O
lines	O
demonstrated	O
extensive	O
genomic	O
hypomethylation	O
(	O
approximately	O
25	O
%	O
of	O
normal	O
level	O
)	O
that	O
was	O
associated	O
with	O
demethylation	O
of	O
all	O
TK	S-Protein
gene	O
copies	O
.	O

Restriction	O
endonuclease	O
analysis	O
of	O
15	O
low	O
-	O
activity	O
lines	O
revealed	O
four	O
instances	O
of	O
sequence	O
alterations	O
in	O
the	O
far	O
-	O
5	O
'	O
region	O
of	O
the	O
TK	S-Protein
gene	O
and	O
one	O
instance	O
of	O
a	O
tandem	O
low	O
-	O
copy	O
amplification	O
.	O

In	O
these	O
lines	O
,	O
the	O
structurally	O
altered	O
gene	O
copy	O
was	O
demethylated	O
.	O

Thus	O
,	O
we	O
propose	O
that	O
a	O
chemical	O
carcinogen	O
can	O
activate	O
TK	S-Protein
expression	O
by	O
several	O
different	O
mechanisms	O
.	O

Focal	O
demethylation	O
with	O
or	O
without	O
gene	O
rearrangement	O
was	O
associated	O
with	O
low	O
TK	S-Protein
activity	O
,	O
whereas	O
demethylation	O
throughout	O
the	O
genome	O
was	O
associated	O
with	O
high	O
TK	S-Protein
activity	O
.	O

The	O
effect	O
of	O
oxygen	O
partial	O
pressure	O
on	O
protein	O
synthesis	O
and	O
collagen	O
hydroxylation	O
by	O
mature	O
periodontal	O
tissues	O
maintained	O
in	O
organ	O
cultures	O
.	O

Mature	O
periodontal	O
tissues	O
from	O
adult	O
-	O
mouse	O
first	O
mandibular	O
molars	O
were	O
cultured	O
in	O
a	O
continuous	O
-	O
flow	O
organ	O
-	O
culture	O
system	O
which	O
allowed	O
the	O
regulation	O
of	O
both	O
ascorbic	O
acid	O
concentration	O
and	O
pO	O
(	O
2	O
)	O
(	O
oxygen	O
partial	O
pressure	O
)	O
.	O

Protein	O
synthesis	O
was	O
measured	O
by	O
analysing	O
the	O
incorporation	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
proline	O
into	O
collagenous	O
and	O
non	O
-	O
collagenous	O
proteins	O
during	O
the	O
last	O
24h	O
of	O
a	O
2	O
-	O
day	O
culture	O
.	O

At	O
low	O
pO	O
(	O
2	O
)	O
[	O
16	O
.	O
0kPa	O
(	O
approx	O
.	O
120mmHg	O
)	O
]	O
approx	O
.	O
60	O
%	O
of	O
protein	O
-	O
incorporated	O
[	O
(	O
3	O
)	O
H	O
]	O
proline	O
was	O
found	O
in	O
collagenous	O
proteins	O
.	O

However	O
,	O
it	O
was	O
evident	O
that	O
this	O
collagen	O
was	O
considerably	O
underhydroxylated	O
.	O

At	O
high	O
pO	O
(	O
2	O
)	O
[	O
56	O
.	O
0kPa	O
(	O
approx	O
.	O
420mmHg	O
)	O
]	O
,	O
both	O
the	O
amount	O
of	O
collagen	O
deposited	O
in	O
the	O
tissues	O
and	O
the	O
degree	O
of	O
hydroxylation	O
were	O
increased	O
considerably	O
.	O

In	O
contrast	O
,	O
no	O
significant	O
effect	O
on	O
non	O
-	O
collagenous	O
protein	O
was	O
observed	O
.	O

Tissues	O
cultured	O
at	O
low	O
pO	O
(	O
2	O
)	O
for	O
the	O
first	O
48h	O
were	O
unable	O
to	O
respond	O
to	O
a	O
subsequent	O
increase	O
in	O
pO	O
(	O
2	O
)	O
during	O
the	O
last	O
24h	O
.	O

Analysis	O
of	O
pepsin	O
-	O
solubilized	O
collagen	O
alpha	O
-	O
chains	O
labelled	O
with	O
[	O
(	O
14	O
)	O
C	O
]	O
glycine	O
demonstrated	O
the	O
synthesis	O
of	O
both	O
type	O
-	O
I	O
and	O
type	B-Protein
-	I-Protein
III	I-Protein
collagens	E-Protein
by	O
explants	O
cultured	O
for	O
48h	O
at	O
high	O
pO	O
(	O
2	O
)	O
.	O

Type	B-Protein
-	I-Protein
III	I-Protein
collagen	E-Protein
comprised	O
20	O
-	O
30	O
%	O
of	O
the	O
radioactivity	O
in	O
alpha	O
-	O
chains	O
in	O
both	O
the	O
periodontal	O
ligament	O
and	O
the	O
tissues	O
of	O
the	O
alveolar	O
process	O
.	O

The	O
pattern	O
of	O
protein	O
synthesis	O
in	O
the	O
alveolar	O
tissues	O
at	O
high	O
pO	O
(	O
2	O
)	O
was	O
similar	O
to	O
that	O
observed	O
in	O
these	O
tissues	O
in	O
vivo	O
.	O

However	O
,	O
in	O
the	O
cultured	O
periodontal	O
ligament	O
the	O
proportions	O
of	O
non	O
-	O
collagenous	O
proteins	O
and	O
type	B-Protein
-	I-Protein
III	I-Protein
collagens	E-Protein
were	O
increased	O
in	O
comparison	O
with	O
the	O
tissue	O
in	O
vivo	O
.	O

Collagen	O
synthesis	O
by	O
cultured	O
skin	O
fibroblasts	O
from	O
siblings	O
with	O
hydroxylysine	O
-	O
deficient	O
collagen	O
.	O

It	O
has	O
been	O
previously	O
shown	O
that	O
dermis	O
from	O
subjects	O
with	O
hydroxylysine	O
-	O
deficient	O
collagen	O
contains	O
approximately	O
5	O
%	O
of	O
normal	O
levels	O
of	O
hydroxylysine	O
and	O
sonicates	O
of	O
skin	O
fibroblasts	O
contain	O
less	O
than	O
15	O
%	O
of	O
normal	O
levels	O
of	O
collagen	O
lysyl	O
hydroxylase	O
activity	O
.	O

However	O
,	O
cultures	O
of	O
dermal	O
fibroblasts	O
from	O
two	O
siblings	O
with	O
hydroxylysine	O
-	O
deficient	O
collagen	O
(	O
Ehlers	O
-	O
Danlos	O
Syndrome	O
Type	O
VI	O
)	O
compared	O
to	O
fibroblasts	O
from	O
normal	O
subjects	O
synthesize	O
collagen	O
containing	O
approximately	O
50	O
%	O
of	O
normal	O
amounts	O
of	O
hydroxylysine	O
.	O

The	O
lysyl	O
hydroxylase	O
deficient	O
cultures	O
synthesize	O
both	O
Type	O
I	O
and	O
Type	B-Protein
III	I-Protein
collagen	E-Protein
in	O
the	O
same	O
proportion	O
as	O
control	O
cultures	O
.	O

Both	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	E-Protein
and	O
alpha	B-Protein
2	E-Protein
chains	O
are	O
similarly	O
reduced	O
in	O
hydroxylysine	O
content	O
.	O

Collagen	O
prolyl	O
hydroxylation	O
by	O
normal	O
collagen	O
lysyl	O
hydroxylation	O
is	O
the	O
same	O
with	O
or	O
without	O
ascorbate	O
supplementation	O
.	O

In	O
mutant	O
cells	O
the	O
rate	O
of	O
prolyl	O
hydroxylation	O
measured	O
after	O
release	O
of	O
inhibition	O
by	O
alpha	O
,	O
alpha	O
'	O
-	O
dipyridyl	O
is	O
the	O
same	O
as	O
in	O
control	O
cells	O
.	O

The	O
rate	O
of	O
lysyl	O
hydroxylation	O
is	O
reduced	O
in	O
mutant	O
cells	O
but	O
only	O
to	O
approximately	O
50	O
%	O
of	O
normal	O
.	O

Concomitant	O
hydroxylation	O
of	O
proline	O
and	O
lysine	O
residues	O
in	O
collagen	S-Protein
using	O
purified	O
enzymes	O
in	O
vitro	O
.	O

Concomitant	O
hydroxylation	O
of	O
proline	O
and	O
lysine	O
residues	O
in	O
protocollagen	S-Protein
was	O
studied	O
using	O
purified	O
enzymes	O
.	O

The	O
data	O
suggest	O
that	O
prolyl	O
4	O
-	O
hydroxylase	O
(	O
prolyl	O
-	O
glycyl	O
-	O
peptide	O
,	O
2	O
-	O
oxoglutarate	O
:	O
oxygen	O
oxidoreductase	O
(	O
4	O
-	O
hydroxylating	O
)	O
,	O
EC	O
1	O
.	O
14	O
.	O
11	O
.	O
2	O
)	O
and	O
lysyl	O
hydroxylase	O
(	O
peptidyllysine	O
,	O
2	O
-	O
oxoglutarate	O
;	O
oxygen	O
5	O
-	O
oxidoreductase	O
,	O
EC	O
1	O
.	O
14	O
.	O
11	O
.	O
4	O
)	O
are	O
competing	O
for	O
the	O
protocollagen	S-Protein
substrate	O
,	O
this	O
competition	O
resulting	O
in	O
an	O
inhibition	O
of	O
the	O
lysyl	O
hydroxylase	O
but	O
not	O
of	O
the	O
prolyl	O
4	O
-	O
hydroxylase	O
reaction	O
.	O

When	O
the	O
same	O
protocollagen	S-Protein
was	O
used	O
for	O
these	O
hydroxylases	O
,	O
the	O
affinity	O
of	O
prolyl	O
4	O
-	O
hydroxylase	O
to	O
the	O
protocollagen	S-Protein
substrate	O
was	O
about	O
2	O
-	O
fold	O
higher	O
than	O
that	O
of	O
lysyl	O
hydroxylase	O
.	O

Hydroxylation	O
of	O
lysine	O
residues	O
in	O
protocollagen	S-Protein
had	O
no	O
effect	O
on	O
the	O
affinity	O
of	O
prolyl	O
4	O
-	O
hydroxylase	O
,	O
whereas	O
hydroxylation	O
of	O
proline	O
residues	O
decreased	O
the	O
affinity	O
of	O
lysyl	O
hydroxylase	O
to	O
one	O
-	O
half	O
of	O
the	O
value	O
determined	O
before	O
the	O
hydroxylation	O
.	O

When	O
enzyme	O
preparations	O
containing	O
different	O
ratios	O
of	O
lysyl	O
hydroxylase	O
activity	O
to	O
prolyl	O
4	O
-	O
hydroxylase	O
activity	O
were	O
used	O
to	O
hydroxylase	O
protocollagen	S-Protein
substrate	O
,	O
it	O
was	O
found	O
that	O
in	O
the	O
case	O
of	O
a	O
low	O
ratio	O
the	O
hydroxylation	O
of	O
lysine	O
residues	O
seemed	O
to	O
proceed	O
only	O
after	O
a	O
short	O
lag	O
period	O
.	O

Accordingly	O
,	O
it	O
seems	O
probable	O
that	O
most	O
proline	O
residues	O
are	O
hydroxylated	O
to	O
4	O
-	O
hydroxyproline	O
residues	O
before	O
hydroxylation	O
of	O
lysine	O
residues	O
if	O
the	O
prolyl	O
4	O
-	O
hydroxylase	O
and	O
lysyl	O
hydroxylase	O
are	O
present	O
as	O
free	O
enzymes	O
competing	O
for	O
the	O
same	O
protocollagen	S-Protein
substrate	O
.	O

Reductive	O
activation	O
of	O
methanol	O
:	O
5	O
-	O
hydroxybenzimidazolylcobamide	O
methyltransferase	O
of	O
Methanosarcina	O
barkeri	O
.	O

Methanol	O
:	O
5	O
-	O
hydroxybenzimidazolylcobamide	O
methyltransferase	O
(	O
MT1	O
)	O
from	O
Methanosarcina	O
barkeri	O
,	O
which	O
is	O
one	O
of	O
the	O
enzymes	O
responsible	O
for	O
the	O
transmethylation	O
from	O
methanol	O
to	O
coenzyme	O
M	O
,	O
was	O
found	O
to	O
be	O
activated	O
in	O
the	O
presence	O
of	O
hydrogenase	O
and	O
ferredoxin	S-Protein
.	O

This	O
activation	O
was	O
shown	O
to	O
involve	O
a	O
reduction	O
of	O
the	O
bound	O
corrinoid	O
to	O
the	O
Co	O
(	O
I	O
)	O
level	O
,	O
and	O
was	O
demonstrated	O
by	O
spectrophotometry	O
and	O
chemical	O
conversion	O
of	O
reduced	O
MT1	O
to	O
its	O
methylated	O
form	O
.	O

The	O
reducing	O
system	O
of	O
hydrogenase	O
and	O
ferredoxin	S-Protein
was	O
able	O
to	O
reduce	O
dithiols	O
,	O
like	O
dithiodiethanesulfonate	O
and	O
cystine	O
to	O
their	O
monomers	O
,	O
in	O
the	O
presence	O
of	O
a	O
corrinoid	O
,	O
which	O
acts	O
as	O
an	O
electron	O
carrier	O
.	O

The	O
ferredoxin	S-Protein
was	O
purified	O
133	O
-	O
fold	O
and	O
was	O
tentatively	O
identified	O
on	O
the	O
basis	O
of	O
spectral	O
properties	O
and	O
iron	O
content	O
of	O
3	O
.	O
8	O
-	O
4	O
.	O
0	O
atoms	O
iron	O
per	O
molecule	O
ferredoxin	O
(	O
12	O
,	O
000	O
daltons	O
)	O
.	O

Structural	O
aspects	O
of	O
hydroxyproline	O
-	O
containing	O
proteins	O
.	O

The	O
occurrence	O
of	O
hydroxyproline	O
(	O
Hyp	O
)	O
in	O
collagen	O
,	O
C1q	O
and	O
acetylcholineesterase	S-Protein
(	O
AChE	S-Protein
)	O
raises	O
important	O
questions	O
concerning	O
the	O
role	O
of	O
this	O
unusual	O
imino	O
acid	O
in	O
the	O
structure	O
and	O
function	O
of	O
these	O
proteins	O
.	O

Available	O
data	O
on	O
collagen	O
indicate	O
that	O
Hyp	O
is	O
necessary	O
for	O
the	O
normal	O
secretion	O
of	O
the	O
protein	O
after	O
its	O
synthesis	O
and	O
for	O
the	O
integrity	O
of	O
the	O
triple	O
-	O
helical	O
conformation	O
.	O

Studies	O
from	O
our	O
laboratory	O
have	O
dealt	O
with	O
the	O
structural	O
aspects	O
of	O
the	O
posttranslational	O
conversion	O
of	O
proline	O
to	O
hydroxyproline	O
in	O
collagen	O
mediated	O
by	O
prolyl	O
hydroxylase	O
.	O

We	O
proposed	O
that	O
the	O
beta	O
-	O
turn	O
conformation	O
at	O
the	O
Pro	O
-	O
Gly	O
segments	O
in	O
the	O
nascent	O
procollagen	O
molecule	O
are	O
the	O
sites	O
of	O
the	O
enzymatic	O
hydroxylation	O
and	O
that	O
this	O
conformation	O
changes	O
over	O
to	O
the	O
collagen	O
-	O
like	O
helix	O
as	O
a	O
result	O
of	O
the	O
hydroxylation	O
process	O
.	O

Recently	O
,	O
we	O
have	O
provided	O
additional	O
experimental	O
support	O
to	O
our	O
proposal	O
by	O
a	O
)	O
synthesizing	O
specific	O
beta	O
-	O
turn	O
oligopeptides	O
containing	O
the	O
Pro	O
-	O
Gly	O
as	O
well	O
as	O
Pro	O
-	O
Ala	O
and	O
Pro	O
-	O
DAla	O
sequences	O
and	O
showing	O
that	O
these	O
act	O
as	O
inhibitors	O
of	O
the	O
enzymatic	O
hydroxylation	O
of	O
a	O
synthetic	O
substrate	O
and	O
b	O
)	O
demonstrating	O
,	O
by	O
circular	O
dichroism	O
spectroscopy	O
,	O
the	O
occurrence	O
of	O
a	O
conformational	O
change	O
leading	O
to	O
the	O
triple	O
-	O
helix	O
as	O
a	O
direct	O
consequence	O
of	O
proline	O
hydroxylation	O
in	O
a	O
non	O
-	O
helical	O
polypeptide	O
substrate	O
.	O

We	O
have	O
also	O
observed	O
that	O
the	O
acquisition	O
of	O
hydroxylation	O
results	O
in	O
a	O
significant	O
enhancement	O
of	O
the	O
rate	O
of	O
folding	O
of	O
the	O
polypeptide	O
chain	O
from	O
the	O
unfolded	O
to	O
the	O
triple	O
-	O
helical	O
conformation	O
.	O

We	O
believe	O
that	O
our	O
observations	O
on	O
proline	O
hydroxylation	O
in	O
collagen	O
should	O
also	O
be	O
applicable	O
to	O
C1q	O
and	O
acetylcholineesterase	O
both	O
of	O
which	O
share	O
the	O
general	O
structural	O
and	O
functional	O
properties	O
of	O
collagen	O
in	O
their	O
"	O
tail	O
"	O
regions	O
.	O

Using	O
the	O
techniques	O
employed	O
in	O
collagen	O
studies	O
,	O
one	O
should	O
be	O
able	O
to	O
assess	O
the	O
role	O
of	O
hydroxyproline	O
in	O
the	O
folding	O
,	O
structural	O
stabilities	O
and	O
functions	O
of	O
C1q	O
and	O
AChE	S-Protein
.	O

This	O
would	O
also	O
involve	O
the	O
study	O
of	O
the	O
unhydroxylated	O
and	O
hydroxylated	O
precursors	O
of	O
these	O
proteins	O
which	O
may	O
share	O
common	O
structural	O
features	O
with	O
their	O
collagen	O
counterparts	O
.	O

Finally	O
,	O
a	O
systematic	O
study	O
of	O
hydroxyproline	O
-	O
containing	O
peptides	O
and	O
polypeptides	O
has	O
been	O
initiated	O
by	O
us	O
so	O
as	O
to	O
understand	O
the	O
exact	O
manner	O
in	O
which	O
Hyp	S-Protein
participates	O
in	O
the	O
formation	O
and	O
stability	O
of	O
the	O
triple	O
-	O
helical	O
conformation	O
in	O
the	O
proteins	O
in	O
which	O
it	O
occurs	O
.	O

Ehlers	O
-	O
Danlos	O
syndrome	O
type	O
VI	O
:	O
collagen	O
type	O
specificity	O
of	O
defective	O
lysyl	O
hydroxylation	O
in	O
various	O
tissues	O
.	O

The	O
Ehlers	O
-	O
Danlos	O
syndrome	O
type	O
VI	O
is	O
an	O
inherited	O
disorder	O
of	O
collagen	O
metabolism	O
characterized	O
by	O
a	O
defective	O
lysyl	O
hydroxylase	O
.	O

The	O
resulting	O
lack	O
of	O
hydroxylysine	O
has	O
been	O
found	O
in	O
several	O
connective	O
tissues	O
,	O
all	O
of	O
which	O
show	O
varying	O
degrees	O
of	O
clinical	O
symptoms	O
.	O

In	O
the	O
present	O
study	O
,	O
collagen	O
was	O
isolated	O
from	O
different	O
connective	O
tissues	O
and	O
the	O
degree	O
of	O
hydroxylation	O
of	O
lysyl	O
residues	O
was	O
determined	O
.	O

Subsequently	O
,	O
collagen	O
types	O
I	O
,	O
II	S-Protein
,	O
III	S-Protein
,	O
IV	O
,	O
and	O
V	O
have	O
been	O
prepared	O
from	O
a	O
number	O
of	O
tissues	O
.	O

Insufficient	O
hydroxylation	O
of	O
lysyl	O
residues	O
was	O
found	O
in	O
type	O
I	O
and	O
type	B-Protein
III	I-Protein
collagen	E-Protein
,	O
whereas	O
types	B-Protein
II	E-Protein
,	O
IV	O
,	O
and	O
V	O
showed	O
normal	O
amounts	O
of	O
hydroxylysine	O
.	O

The	O
expression	O
of	O
the	O
defect	O
,	O
even	O
for	O
type	O
I	O
and	O
type	B-Protein
III	I-Protein
collagen	E-Protein
,	O
varied	O
widely	O
from	O
one	O
tissue	O
to	O
another	O
.	O

A	O
complete	O
lack	O
of	O
hydroxylysine	O
was	O
observed	O
in	O
skin	O
,	O
while	O
it	O
was	O
less	O
pronounced	O
in	O
tissues	O
such	O
as	O
bone	O
,	O
tendon	O
,	O
lung	O
,	O
or	O
kidney	O
.	O

The	O
data	O
suggest	O
the	O
presence	O
of	O
several	O
isoenzymes	O
having	O
varying	O
affinities	O
to	O
the	O
different	O
collagen	O
types	O
.	O

Studies	O
of	O
acetylation	O
and	O
deacetylation	O
in	O
high	O
mobility	O
group	O
proteins	O
.	O

Identification	O
of	O
the	O
sites	O
of	O
acetylation	O
in	O
high	B-Protein
mobility	I-Protein
group	I-Protein
proteins	I-Protein
14	E-Protein
and	O
17	S-Protein
.	O

Duck	O
erythrocytes	O
were	O
incubated	O
with	O
[	O
3H	O
]	O
acetate	O
both	O
in	O
the	O
presence	O
and	O
absence	O
of	O
sodium	O
butyrate	O
.	O

Subsequent	O
perchloric	O
acid	O
extraction	O
of	O
the	O
nuclei	O
,	O
followed	O
by	O
selective	O
acetone	O
precipitation	O
,	O
CM	O
-	O
Sephadex	O
ion	O
exchange	O
chromatography	O
,	O
and	O
gel	O
filtration	O
yielded	O
radioactively	O
labeled	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
proteins	O
HMG	B-Protein
-	I-Protein
14	E-Protein
and	O
HMG	B-Protein
-	I-Protein
17	E-Protein
in	O
pure	O
form	O
.	O

Extensive	O
enzymatic	O
degradation	O
of	O
the	O
proteins	O
followed	O
by	O
amino	O
acid	O
analysis	O
of	O
the	O
digests	O
yielded	O
a	O
significant	O
amount	O
of	O
material	O
eluting	O
in	O
the	O
position	O
of	O
epsilon	O
-	O
N	O
-	O
acetyllysine	O
.	O

Furthermore	O
,	O
automated	O
Edman	O
degradation	O
of	O
intact	O
3H	O
-	O
labeled	O
HMG	B-Protein
-	I-Protein
14	E-Protein
and	O
HMG	B-Protein
-	I-Protein
17	E-Protein
identified	O
the	O
specific	O
sites	O
of	O
acetylation	O
of	O
these	O
proteins	O
.	O

In	O
both	O
erythrocyte	O
HMGs	O
isolated	O
from	O
cells	O
not	O
exposed	O
to	O
butyrate	O
,	O
the	O
lysine	O
residue	O
at	O
position	O
2	O
was	O
the	O
only	O
one	O
found	O
to	O
be	O
labeled	O
.	O

However	O
,	O
one	O
additional	O
site	O
in	O
HMG	B-Protein
-	I-Protein
14	E-Protein
and	O
two	O
additional	O
sites	O
in	O
HMG	B-Protein
-	I-Protein
17	E-Protein
were	O
found	O
in	O
the	O
proteins	O
from	O
cells	O
incubated	O
in	O
butyrate	O
.	O

Finally	O
,	O
studies	O
of	O
the	O
enzymatic	O
deacetylation	O
of	O
HMG	B-Protein
-	I-Protein
14	E-Protein
and	O
HMG	B-Protein
-	I-Protein
17	E-Protein
confirmed	O
that	O
both	O
nuclear	O
proteins	O
serve	O
as	O
deacetylase	O
substrates	O
and	O
that	O
butyrate	O
inhibits	O
their	O
deacetylation	O
,	O
just	O
as	O
in	O
the	O
case	O
of	O
other	O
HMG	O
proteins	O
and	O
nucleosomal	O
core	O
histones	S-Protein
.	O

Guide	O
-	O
lines	O
in	O
the	O
design	O
of	O
new	O
antiestrogens	O
and	O
cytotoxic	O
-	O
linked	O
estrogens	O
for	O
the	O
treatment	O
of	O
breast	O
cancer	O
.	O

Antiestrogens	O
(	O
Tamoxifen	O
)	O
are	O
used	O
for	O
the	O
treatment	O
of	O
breast	O
cancer	O
.	O

However	O
these	O
compounds	O
are	O
also	O
weak	O
estrogens	O
that	O
may	O
stimulate	O
tumor	O
growth	O
.	O

Cytotoxic	O
-	O
linked	O
estrogens	O
(	O
Estradiol	O
Mustard	O
,	O
Estracyt	O
)	O
are	O
devoid	O
of	O
major	O
therapeutic	O
activity	O
.	O

This	O
led	O
to	O
search	O
for	O
new	O
antiestrogens	O
devoid	O
of	O
estrogenicity	O
and	O
for	O
active	O
cytotoxic	O
-	O
estrogens	O
.	O

Hydroxylation	O
of	O
C	O
-	O
4	O
of	O
triphenylethylene	O
antiestrogens	O
(	O
tamoxifen	O
,	O
CI	O
628	O
and	O
U	O
23	O
,	O
469	O
)	O
largely	O
increases	O
their	O
binding	O
affinity	O
for	O
the	O
estrogen	B-Protein
receptor	E-Protein
(	O
ER	S-Protein
)	O
.	O

Hydroxylation	O
also	O
increases	O
the	O
in	O
vitro	O
antitumor	O
activity	O
of	O
the	O
drugs	O
as	O
shown	O
by	O
their	O
higher	O
ability	O
to	O
inhibit	O
the	O
growth	O
of	O
the	O
ER	S-Protein
-	O
positive	O
cell	O
line	O
MCF	O
-	O
7	O
.	O

Triphenylethylene	O
antiestrogens	O
contain	O
an	O
aminoethoxy	O
side	O
chain	O
which	O
appears	O
essential	O
for	O
their	O
physiological	O
activity	O
.	O

Removal	O
of	O
the	O
chain	O
of	O
tamoxifen	O
suppresses	O
its	O
antiestrogenicity	O
and	O
antitumor	O
activity	O
.	O

The	O
grafting	O
of	O
side	O
chains	O
on	O
a	O
weak	O
estrogen	O
of	O
the	O
gem	O
-	O
diphenylethylene	O
category	O
produces	O
"	O
symmetrical	O
"	O
antiestrogens	O
devoid	O
of	O
estrogenic	O
activity	O
.	O

This	O
observation	O
raises	O
the	O
question	O
of	O
the	O
role	O
played	O
by	O
the	O
third	O
phenyl	O
ring	O
of	O
the	O
triphenylethylenes	O
since	O
the	O
trans	O
-	O
isomers	O
of	O
the	O
latter	O
display	O
antiestrogenicity	O
and	O
the	O
cis	O
-	O
isomers	O
estrogenicity	O
.	O

Comparison	O
of	O
the	O
binding	O
affinity	O
for	O
ER	S-Protein
and	O
antitumor	O
activity	O
of	O
di	O
-	O
and	O
triphenylethylene	O
antiestrogens	O
suggests	O
that	O
this	O
third	O
phenyl	O
ring	O
increases	O
the	O
interaction	O
with	O
ER	S-Protein
of	O
the	O
4	O
-	O
phenolic	O
group	O
of	O
the	O
drugs	O
and	O
/	O
or	O
their	O
aminoethoxy	O
side	O
chain	O
.	O

An	O
analogue	O
of	O
this	O
chain	O
is	O
without	O
any	O
biological	O
activity	O
suggesting	O
that	O
the	O
di	O
-	O
(	O
tri	O
)	O
pheny	O
-	O
lalkene	O
structure	O
is	O
required	O
for	O
promoting	O
the	O
interaction	O
of	O
the	O
chain	O
with	O
ER	S-Protein
.	O

New	O
chemical	O
structures	O
yielding	O
antiestrogens	O
with	O
antitumor	O
activity	O
are	O
also	O
reviewed	O
.	O

New	O
cytotoxic	O
estrogens	O
designed	O
for	O
producing	O
lethal	O
damage	O
of	O
DNA	O
show	O
a	O
low	O
binding	O
affinity	O
for	O
ER	S-Protein
.	O

Moreover	O
,	O
there	O
is	O
no	O
evidence	O
suggesting	O
specific	O
antitumor	O
activity	O
.	O

Such	O
activity	O
may	O
be	O
more	O
easily	O
obtained	O
with	O
estrogens	O
bearing	O
reagents	O
for	O
proteins	O
rather	O
than	O
DNA	O
.	O

The	O
biological	O
properties	O
of	O
a	O
2	O
-	O
mesylate	O
derivative	O
of	O
estrone	O
irreversibly	O
interacting	O
with	O
ER	S-Protein
supports	O
the	O
concept	O
.	O

On	O
MCF	O
-	O
7	O
cells	O
,	O
the	O
drug	O
displays	O
a	O
strong	O
antitumor	O
activity	O
which	O
can	O
only	O
be	O
suppressed	O
by	O
high	O
,	O
equimolar	O
,	O
concentrations	O
of	O
estradiol	O
.	O

It	O
is	O
devoid	O
of	O
cytotoxic	O
activity	O
on	O
the	O
ER	O
-	O
negative	O
cell	O
line	O
Evsa	O
-	O
T	O
suggesting	O
that	O
ER	S-Protein
is	O
involved	O
in	O
its	O
action	O
.	O

A	O
single	O
2	O
'	O
-	O
hydroxyl	O
group	O
converts	O
B	O
-	O
DNA	O
to	O
A	O
-	O
DNA	O
.	O

Crystal	O
structure	O
of	O
the	O
DNA	O
-	O
RNA	O
chimeric	O
decamer	O
duplex	O
d	O
(	O
CCGGC	O
)	O
r	O
(	O
G	O
)	O
d	O
(	O
CCGG	O
)	O
with	O
a	O
novel	O
intermolecular	O
G	O
-	O
C	O
base	O
-	O
paired	O
quadruplet	O
.	O

We	O
have	O
found	O
that	O
the	O
introduction	O
of	O
a	O
single	O
2	O
'	O
-	O
hydroxyl	O
group	O
on	O
the	O
sugar	O
-	O
phosphate	O
backbone	O
of	O
the	O
B	O
-	O
DNA	O
decamer	O
d	O
(	O
CCGGCGCCGG	O
)	O
transforms	O
it	O
to	O
A	O
-	O
DNA	O
.	O

Thus	O
,	O
for	O
the	O
first	O
time	O
the	O
X	O
-	O
ray	O
structures	O
of	O
the	O
same	O
sequence	O
have	O
been	O
observed	O
in	O
both	O
the	O
A	O
and	O
B	O
-	O
DNA	O
conformations	O
,	O
permitting	O
a	O
comparison	O
.	O

Crystals	O
of	O
the	O
DNA	O
-	O
RNA	O
chimeric	O
decamer	O
d	O
(	O
CCGGC	O
)	O
r	O
(	O
G	O
)	O
d	O
(	O
CCGG	O
)	O
belong	O
to	O
the	O
orthorhombic	O
space	O
group	O
P2	O
(	O
1	O
)	O
2	O
(	O
1	O
)	O
2	O
(	O
1	O
)	O
with	O
unit	O
cell	O
dimensions	O
a	O
=	O
25	O
.	O
63	O
A	O
,	O
b	O
=	O
45	O
.	O
24	O
A	O
and	O
c	O
=	O
47	O
.	O
99	O
A	O
,	O
and	O
one	O
decamer	O
duplex	O
in	O
the	O
asymmetric	O
unit	O
.	O

The	O
structure	O
was	O
solved	O
by	O
a	O
rigid	O
body	O
search	O
using	O
the	O
coordinates	O
of	O
the	O
isomorphous	O
structure	O
d	O
(	O
CCCGGCCGGG	O
)	O
and	O
refined	O
to	O
an	O
R	O
value	O
of	O
0	O
.	O
136	O
using	O
2753	O
unique	O
reflections	O
at	O
1	O
.	O
9	O
A	O
resolution	O
.	O

The	O
final	O
model	O
contains	O
406	O
nucleotide	O
atoms	O
and	O
61	O
water	O
molecules	O
.	O

The	O
chimeric	O
duplex	O
exhibits	O
typical	O
A	O
-	O
DNA	O
geometry	O
,	O
with	O
all	O
the	O
sugars	O
in	O
the	O
C	O
(	O
3	O
'	O
)	O
-	O
endo	O
puckering	O
and	O
the	O
base	O
-	O
pairs	O
inclined	O
and	O
displaced	O
from	O
the	O
helix	O
axis	O
.	O

The	O
2	O
'	O
-	O
hydroxyl	O
groups	O
on	O
rG6	O
and	O
rG16	O
protrude	O
into	O
the	O
minor	O
groove	O
surface	O
and	O
form	O
different	O
types	O
of	O
hydrogen	O
bonds	O
;	O
that	O
on	O
strand	O
1	O
forms	O
an	O
intermolecular	O
hydrogen	O
bond	O
with	O
the	O
furanose	O
ring	O
O	O
(	O
4	O
'	O
)	O
of	O
a	O
symmetry	O
-	O
related	O
C1	O
residue	O
,	O
while	O
that	O
on	O
strand	O
2	O
is	O
involved	O
in	O
two	O
water	O
bridges	O
.	O

Crystal	O
packing	O
forces	O
the	O
G4	O
-	O
G17	O
base	O
-	O
pair	O
in	O
the	O
top	O
half	O
of	O
the	O
duplex	O
to	O
slide	O
significantly	O
into	O
the	O
minor	O
groove	O
compared	O
to	O
the	O
corresponding	O
G7	O
-	O
G14	O
base	O
-	O
pair	O
in	O
the	O
bottom	O
half	O
,	O
resulting	O
in	O
these	O
base	O
-	O
pairs	O
exhibiting	O
different	O
base	O
stacking	O
and	O
intermolecular	O
interactions	O
.	O

The	O
base	O
G4	O
of	O
the	O
G4	O
-	O
G17	O
base	O
-	O
pair	O
forms	O
an	O
unorthodox	O
base	O
"	O
triple	O
"	O
,	O
G4	O
*	O
(	O
G10	O
-	O
C11	O
)	O
,	O
hydrogen	O
-	O
bonding	O
through	O
its	O
minor	O
groove	O
sites	O
N	O
(	O
2	O
)	O
and	O
N	O
(	O
3	O
)	O
to	O
the	O
minor	O
groove	O
atoms	O
N	O
(	O
2	O
)	O
and	O
O	O
(	O
2	O
)	O
of	O
both	O
bases	O
of	O
the	O
G10	O
-	O
C11	O
base	O
-	O
pair	O
of	O
a	O
symmetry	O
-	O
related	O
molecule	O
.	O

The	O
base	O
G10	O
of	O
this	O
triple	O
in	O
turn	O
forms	O
a	O
second	O
similar	O
unorthodox	O
base	O
triple	O
,	O
G10	O
*	O
(	O
G3	O
*	O
C18	O
)	O
,	O
with	O
the	O
adjacent	O
base	O
-	O
pair	O
G3	O
-	O
C18	O
of	O
the	O
duplex	O
,	O
thus	O
G10	O
is	O
involved	O
in	O
a	O
double	O
triple	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
the	O
bottom	O
half	O
of	O
the	O
duplex	O
,	O
the	O
C7	S-Protein
-	O
G14	S-Protein
base	O
-	O
pair	O
is	O
involved	O
only	O
in	O
a	O
single	O
similar	O
unorthodox	O
base	O
triple	O
with	O
G20	O
,	O
(	O
C7	O
-	O
G14	O
)	O
*	O
G20	O
,	O
while	O
the	O
adjacent	O
base	O
-	O
pair	O
rG6	S-Protein
-	O
C15	S-Protein
is	O
involved	O
in	O
a	O
novel	O
quadruple	O
with	O
C1	S-Protein
-	O
G20	S-Protein
,	O
(	O
rG6	O
-	O
C15	O
)	O
*	O
(	O
C1	O
-	O
G20	O
)	O
,	O
where	O
the	O
latter	O
base	O
-	O
pairs	O
are	O
hydrogen	O
-	O
bonded	O
to	O
each	O
other	O
via	O
the	O
minor	O
groove	O
sites	O
G	O
(	O
N	O
(	O
2	O
)	O
)	O
.	O
.	O
.	O
C	O
(	O
O	O
(	O
2	O
)	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

In	O
vivo	O
activity	O
of	O
tyrosine	B-Protein
hydroxylase	E-Protein
in	O
rat	O
adrenal	O
glands	O
following	O
administration	O
of	O
quinpirole	O
and	O
dopamine	O
.	O

Using	O
adrenal	O
dopamine	O
as	O
indicator	O
we	O
have	O
previously	O
obtained	O
evidence	O
that	O
quinpirole	O
and	O
several	O
other	O
agonists	O
on	O
dopamine	O
D2	O
-	O
like	O
receptors	O
acutely	O
stimulate	O
the	O
synthesis	O
of	O
adrenal	O
catecholamines	O
.	O

In	O
the	O
present	O
study	O
we	O
measured	O
the	O
effect	O
of	O
quinpirole	O
and	O
dopamine	O
on	O
the	O
hydroxylation	O
of	O
tyrosine	O
in	O
the	O
adrenals	O
,	O
using	O
the	O
method	O
of	O
DOPA	O
(	O
3	O
,	O
4	O
-	O
dihydroxyphenylalanine	O
)	O
accumulation	O
following	O
the	O
administration	O
of	O
the	O
inhibitor	O
of	O
aromatic	B-Protein
L	I-Protein
-	I-Protein
amino	I-Protein
acid	I-Protein
decarboxylase	E-Protein
NSD	O
1015	O
(	O
3	O
-	O
hydroxybenzylhydrazyne	O
)	O
.	O

In	O
view	O
of	O
the	O
large	O
amounts	O
of	O
catecholamines	O
in	O
the	O
adrenal	O
tissue	O
samples	O
,	O
this	O
necessitated	O
a	O
modification	O
of	O
the	O
method	O
for	O
analysing	O
DOPA	O
.	O

Both	O
quinpirole	O
and	O
dopamine	O
significantly	O
enhanced	O
the	O
rate	O
of	O
DOPA	O
accumulation	O
in	O
the	O
adrenals	O
,	O
indicating	O
stimulation	O
of	O
adrenal	O
tyrosine	B-Protein
hydroxylase	E-Protein
.	O

The	O
effect	O
of	O
dopamine	O
was	O
blocked	O
by	O
domperidone	O
,	O
a	O
dopamine	B-Protein
D2	I-Protein
receptor	E-Protein
antagonist	O
that	O
penetrates	O
poorly	O
into	O
the	O
central	O
nervous	O
system	O
.	O

Thus	O
the	O
effect	O
of	O
dopamine	O
,	O
which	O
itself	O
penetrates	O
poorly	O
into	O
the	O
central	O
nervous	O
system	O
,	O
was	O
presumably	O
mediated	O
peripherally	O
.	O

Similarly	O
epinine	O
,	O
i	O
.	O
e	O
.	O
the	O
N	O
-	O
methyl	O
derivative	O
of	O
dopamine	O
,	O
appeared	O
to	O
enhance	O
adrenal	O
catecholamine	O
synthesis	O
,	O
as	O
indicated	O
by	O
an	O
elevated	O
adrenal	O
dopamine	O
level	O
.	O

The	O
data	O
support	O
the	O
view	O
that	O
stimulation	O
of	O
peripherally	O
located	O
dopamine	O
D2	O
-	O
like	O
receptors	O
can	O
enhance	O
the	O
rate	O
of	O
adrenal	O
catecholamine	O
synthesis	O
by	O
stimulating	O
the	O
activity	O
of	O
tyrosine	B-Protein
hydroxylase	E-Protein
.	O

Purification	O
and	O
characterization	O
of	O
human	O
recombinant	O
IgE	O
-	O
Fc	O
fragments	O
that	O
bind	O
to	O
the	O
human	O
high	O
affinity	O
IgE	O
receptor	O
.	O

The	O
Fc	O
-	O
region	O
of	O
immunoglobulin	O
E	O
(	O
IgE	O
)	O
comprising	O
C	O
epsilon	O
2	O
,	O
C	O
epsilon	O
3	O
,	O
and	O
C	O
epsilon	O
4	O
domains	O
is	O
sufficient	O
for	O
binding	O
to	O
the	O
alpha	O
chain	O
of	O
the	O
high	O
affinity	O
IgE	O
-	O
Fc	O
receptor	O
(	O
Fc	B-Protein
epsilon	I-Protein
RI	I-Protein
alpha	E-Protein
)	O
.	O

In	O
order	O
to	O
identify	O
the	O
smallest	O
Fc	O
fragment	O
capable	O
of	O
binding	O
to	O
the	O
Fc	B-Protein
epsilon	I-Protein
RI	I-Protein
alpha	E-Protein
with	O
high	O
affinity	O
,	O
various	O
regions	O
of	O
the	O
IgE	O
-	O
Fc	O
molecule	O
were	O
expressed	O
in	O
COS	O
cells	O
and	O
investigated	O
for	O
their	O
ability	O
to	O
bind	O
Fc	B-Protein
epsilon	I-Protein
RI	I-Protein
alpha	E-Protein
.	O

The	O
smallest	O
fragment	O
that	O
showed	O
Fc	B-Protein
epsilon	I-Protein
RI	I-Protein
alpha	E-Protein
binding	O
activity	O
spans	O
amino	O
acids	O
329	O
-	O
547	O
and	O
lacks	O
the	O
entire	O
C	O
epsilon	O
2	O
domain	O
.	O

Two	O
active	O
fragments	O
,	O
viz	O
.	O

Fc	O
epsilon	O
(	O
315	O
-	O
547	O
)	O
(	O
containing	O
Cys328	O
which	O
is	O
responsible	O
for	O
interchain	O
S	O
-	O
S	O
bonding	O
)	O
and	O
Fc	O
epsilon	O
(	O
329	O
-	O
547	O
)	O
,	O
have	O
been	O
overexpressed	O
in	O
CHO	O
cells	O
and	O
purified	O
to	O
homogeneity	O
.	O

The	O
purified	O
proteins	O
bind	O
to	O
the	O
Fc	B-Protein
epsilon	I-Protein
RI	I-Protein
alpha	E-Protein
with	O
high	O
affinity	O
,	O
similar	O
to	O
native	O
IgE	O
.	O

SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
analyses	O
indicate	O
that	O
Fc	O
epsilon	O
(	O
315	O
-	O
547	O
)	O
is	O
an	O
S	O
-	O
S	O
-	O
linked	O
dimer	O
of	O
apparent	O
molecular	O
mass	O
of	O
68	O
kDa	O
.	O

Fc	O
epsilon	O
(	O
329	O
-	O
547	O
)	O
appears	O
on	O
SDS	O
-	O
gel	O
as	O
three	O
distinct	O
bands	O
at	O
approximately	O
32	O
kDa	O
,	O
both	O
under	O
reducing	O
and	O
nonreducing	O
conditions	O
.	O

However	O
,	O
size	O
exclusion	O
chromatography	O
and	O
analytical	O
ultracentrifugation	O
studies	O
suggest	O
that	O
Fc	O
epsilon	O
(	O
329	O
-	O
547	O
)	O
also	O
remains	O
associated	O
as	O
a	O
dimer	O
.	O

The	O
presence	O
of	O
N	O
-	O
linked	O
glycosylation	O
was	O
detected	O
in	O
both	O
proteins	O
.	O

The	O
deglycosylated	O
form	O
of	O
Fc	O
epsilon	O
(	O
315	O
-	O
547	O
)	O
was	O
isolated	O
after	O
Endo	O
F	O
/	O
N	O
-	O
glycosidase	O
F	O
digestion	O
and	O
demonstrated	O
to	O
have	O
binding	O
activity	O
comparable	O
to	O
that	O
of	O
the	O
mock	O
-	O
digested	O
protein	O
.	O

These	O
results	O
suggest	O
that	O
the	O
presence	O
of	O
N	O
-	O
linked	O
sugars	O
is	O
not	O
necessary	O
for	O
Fc	B-Protein
epsilon	I-Protein
RI	I-Protein
alpha	E-Protein
binding	O
.	O

Both	O
proteins	O
blocked	O
the	O
release	O
of	O
histamine	O
from	O
RBL	O
cells	O
expressing	O
human	O
Fc	B-Protein
epsilon	I-Protein
RI	I-Protein
alpha	E-Protein
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
availability	O
of	O
these	O
recombinant	O
IgE	O
-	O
Fc	O
proteins	O
will	O
be	O
helpful	O
in	O
elucidating	O
the	O
key	O
epitopes	O
essential	O
for	O
the	O
binding	O
of	O
IgE	O
to	O
its	O
high	O
affinity	O
receptor	O
.	O

Pathways	O
of	O
processing	O
of	O
the	O
gastrin	S-Protein
precursor	O
in	O
rat	O
antral	O
mucosa	O
.	O

The	O
precursor	O
of	O
the	O
acid	O
-	O
stimulating	O
hormone	O
gastrin	S-Protein
gives	O
rise	O
to	O
multiple	O
peptides	O
differing	O
markedly	O
in	O
biological	O
activity	O
,	O
but	O
the	O
relevant	O
biosynthetic	O
pathways	O
are	O
poorly	O
understood	O
.	O

We	O
have	O
used	O
antibodies	O
to	O
amidated	O
gastrins	O
,	O
gastrins	S-Protein
with	O
COOH	O
-	O
terminal	O
glycine	O
(	O
Gly	O
)	O
gastrins	S-Protein
with	O
COOH	O
-	O
terminal	O
hydroxyglycine	O
(	O
GlyOH	O
)	O
and	O
to	O
the	O
COOH	O
terminus	O
of	O
progastrin	S-Protein
,	O
to	O
immunoprecipitate	O
peptides	O
labeled	O
with	O
[	O
35S	O
]	O
sulfate	O
or	O
[	O
3H	O
]	O
tyrosine	O
during	O
incubation	O
of	O
rat	O
antral	O
mucosa	O
in	O
vitro	O
.	O

Labeled	O
progastrin	S-Protein
was	O
detectable	O
after	O
30	O
min	O
of	O
continuous	O
incubation	O
with	O
isotopic	O
precursors	O
,	O
G34	S-Protein
and	O
G34	S-Protein
-	O
Gly	O
after	O
60	O
min	O
,	O
and	O
G17	S-Protein
and	O
G17	S-Protein
-	O
Gly	O
after	O
120	O
min	O
.	O

Pulse	O
chase	O
experiments	O
indicated	O
that	O
progastrin	S-Protein
is	O
converted	O
to	O
G34	S-Protein
-	O
Gly	O
which	O
then	O
follows	O
one	O
of	O
two	O
pathways	O
:	O
(	O
a	O
)	O
hydroxylation	O
of	O
COOH	O
-	O
terminal	O
Gly	O
and	O
conversion	O
to	O
G34	S-Protein
followed	O
by	O
cleavage	O
yielding	O
G17	S-Protein
,	O
or	O
(	O
b	O
)	O
cleavage	O
to	O
G17	S-Protein
-	O
Gly	O
.	O

The	O
kinetics	O
of	O
G17	S-Protein
-	O
Gly	O
and	O
G17	S-Protein
labeling	O
were	O
similar	O
,	O
suggesting	O
that	O
G17	S-Protein
-	O
Gly	O
is	O
a	O
product	O
in	O
its	O
own	O
right	O
,	O
and	O
not	O
simply	O
an	O
intermediate	O
in	O
G17	S-Protein
synthesis	O
.	O

Since	O
the	O
two	O
peptides	O
are	O
reported	O
to	O
have	O
distinct	O
biological	O
activities	O
,	O
they	O
appear	O
to	O
be	O
alternative	O
mature	O
products	O
of	O
progastrin	S-Protein
processing	O
.	O

The	O
role	O
of	O
N	O
-	O
glycosylation	O
in	O
the	O
targeting	O
and	O
activity	O
of	O
the	O
GLYT1	S-Protein
glycine	O
transporter	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
N	O
-	O
glycosylation	O
in	O
the	O
function	O
of	O
the	O
high	O
affinity	O
glycine	O
transporter	O
GLYT1	S-Protein
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
the	O
glycosylation	O
inhibitor	O
tunicamycin	O
as	O
well	O
as	O
the	O
effect	O
of	O
the	O
disruption	O
of	O
the	O
putative	O
glycosylation	O
sites	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
of	O
proteins	O
from	O
GLYT1	S-Protein
-	O
transfected	O
COS	O
cells	O
reveals	O
a	O
major	O
band	O
of	O
80	O
-	O
100	O
kDa	O
and	O
a	O
minor	O
one	O
of	O
57	O
kDa	O
.	O

Treatment	O
with	O
tunicamycin	O
produces	O
a	O
40	O
%	O
inhibition	O
in	O
transport	O
activity	O
and	O
a	O
decrease	O
in	O
the	O
intensity	O
of	O
the	O
80	O
-	O
100	O
-	O
kDa	O
band	O
,	O
whereas	O
the	O
57	O
-	O
kDa	O
band	O
decreases	O
in	O
size	O
to	O
yield	O
a	O
47	O
-	O
kDa	O
protein	O
corresponding	O
to	O
the	O
unglycosylated	O
form	O
of	O
the	O
transporter	O
.	O

Simultaneous	O
mutation	O
of	O
Asn	O
-	O
169	O
,	O
Asn	O
-	O
172	O
,	O
Asn	O
-	O
182	O
,	O
and	O
Asn	O
-	O
188	O
to	O
Gln	O
also	O
produces	O
the	O
47	O
-	O
kDa	O
form	O
of	O
the	O
protein	O
,	O
indicating	O
that	O
there	O
are	O
no	O
additional	O
sites	O
for	O
N	O
-	O
glycosylation	O
.	O

Progressive	O
mutation	O
of	O
the	O
potential	O
glycosylation	O
sites	O
produces	O
a	O
progressive	O
decrease	O
in	O
transport	O
activity	O
and	O
in	O
size	O
of	O
the	O
protein	O
,	O
indicating	O
that	O
the	O
four	O
putative	O
glycosylation	O
sites	O
are	O
actually	O
glycosylated	O
.	O

N	O
-	O
Glycosylation	O
of	O
the	O
GLYT1	S-Protein
is	O
not	O
indispensable	O
for	O
the	O
transport	O
activity	O
itself	O
,	O
as	O
demonstrated	O
by	O
enzymatic	O
deglycosylation	O
of	O
the	O
transporter	O
.	O

Analysis	O
of	O
surface	O
proteins	O
by	O
biotinylation	O
and	O
by	O
immunofluorescence	O
demonstrates	O
that	O
a	O
significant	O
portion	O
of	O
the	O
unglycosylated	O
GLYT1	S-Protein
mutant	O
remains	O
in	O
the	O
intracellular	O
compartment	O
.	O

This	O
suggests	O
that	O
the	O
carbohydrate	O
moiety	O
of	O
glycine	O
transporter	O
GLYT1	S-Protein
is	O
necessary	O
for	O
the	O
proper	O
trafficking	O
of	O
the	O
protein	O
to	O
the	O
plasma	O
membrane	O
.	O

Enhanced	O
tropoelastin	S-Protein
-	O
degrading	O
activity	O
during	O
cell	O
passages	O
in	O
cultured	O
smooth	O
muscle	O
cells	O
.	O

Tropoelastin	S-Protein
expression	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
during	O
serial	O
cell	O
passages	O
from	O
the	O
primary	O
to	O
the	O
tertiary	O
culture	O
was	O
studied	O
.	O

The	O
level	O
of	O
tropoelastin	S-Protein
was	O
found	O
to	O
be	O
greatly	O
reduced	O
as	O
the	O
number	O
of	O
cell	O
passages	O
increased	O
.	O

The	O
translational	O
activity	O
and	O
level	O
of	O
elastin	S-Protein
mRNA	O
were	O
essentially	O
unchanged	O
throughout	O
the	O
cell	O
passages	O
.	O

The	O
reduction	O
in	O
tropoelastin	S-Protein
expression	O
was	O
not	O
due	O
to	O
the	O
repetitive	O
trypsin	O
treatment	O
nor	O
to	O
the	O
prolyl	O
hydroxylation	O
level	O
of	O
the	O
newly	O
-	O
synthesized	O
elastin	S-Protein
.	O

A	O
comparable	O
decline	O
in	O
tropoelastin	S-Protein
expression	O
was	O
also	O
found	O
with	O
increasing	O
cell	O
division	O
in	O
the	O
primary	O
cultures	O
plated	O
at	O
different	O
cell	O
densities	O
.	O

A	O
pulse	O
-	O
chase	O
experiment	O
revealed	O
that	O
the	O
newly	O
-	O
synthesized	O
elastin	S-Protein
in	O
the	O
tertiary	O
culture	O
degraded	O
more	O
rapidly	O
than	O
that	O
in	O
the	O
primary	O
culture	O
.	O

The	O
culture	O
medium	O
harvested	O
from	O
the	O
tertiary	O
culture	O
exhibited	O
a	O
higher	O
tropoelastin	S-Protein
-	O
degrading	O
activity	O
than	O
that	O
from	O
the	O
primary	O
culture	O
in	O
the	O
test	O
-	O
tube	O
.	O

The	O
degrading	O
activity	O
of	O
the	O
tertiary	O
culture	O
was	O
inhibited	O
by	O
the	O
addition	O
of	O
1	O
mM	O
ethylenediaminetetraacetic	O
acid	O
or	O
1	O
mM	O
phenylmethylsulfonyl	O
fluoride	O
,	O
but	O
not	O
by	O
1	O
mM	O
N	O
-	O
ethylmaleimide	O
.	O

These	O
results	O
suggest	O
that	O
the	O
reduction	O
in	O
tropoelastin	S-Protein
expression	O
during	O
the	O
cell	O
passages	O
from	O
the	O
primary	O
to	O
the	O
tertiary	O
culture	O
is	O
due	O
to	O
the	O
enhanced	O
tropoelastin	S-Protein
-	O
degrading	O
activity	O
of	O
the	O
tertiary	O
culture	O
.	O

The	O
transition	O
to	O
tropoelastin	S-Protein
-	O
degrading	O
phenotype	O
during	O
cell	O
passages	O
may	O
explain	O
the	O
biological	O
mechanisms	O
of	O
smooth	O
muscle	O
cell	O
migration	O
from	O
the	O
media	O
to	O
the	O
intima	O
observed	O
in	O
the	O
pathological	O
conditions	O
.	O

Osteogenic	B-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
(	O
OP	B-Protein
-	I-Protein
1	E-Protein
)	O
expression	O
and	O
processing	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
:	O
isolation	O
of	O
a	O
soluble	O
complex	O
containing	O
the	O
mature	O
and	O
pro	O
-	O
domains	O
of	O
OP	B-Protein
-	I-Protein
1	E-Protein
.	O

We	O
have	O
characterized	O
the	O
expression	O
and	O
processing	O
of	O
Osteogenic	B-Protein
Protein	I-Protein
-	I-Protein
1	E-Protein
(	O
hOP	B-Protein
-	I-Protein
1	E-Protein
)	O
,	O
a	O
bone	O
morphogenic	O
protein	O
of	O
the	O
TGF	O
-	O
beta	O
family	O
,	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

The	O
hOP	B-Protein
-	I-Protein
1	E-Protein
is	O
initially	O
synthesized	O
as	O
a	O
monomeric	O
50	O
kDa	O
pro	O
-	O
protein	O
that	O
is	O
dimerized	O
,	O
glycosylated	O
,	O
and	O
then	O
proteolytically	O
cleaved	O
at	O
the	O
Arg	O
-	O
Xaa	O
-	O
Xaa	O
-	O
Arg	O
maturation	O
site	O
in	O
an	O
acidic	O
cellular	O
compartment	O
before	O
secretion	O
into	O
the	O
medium	O
.	O

Of	O
the	O
four	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
two	O
are	O
used	O
,	O
one	O
in	O
the	O
mature	O
domain	O
and	O
one	O
in	O
the	O
pro	O
-	O
domain	O
.	O

Gel	O
permeation	O
chromatography	O
of	O
secreted	O
hOP	B-Protein
-	I-Protein
1	E-Protein
in	O
physiological	O
buffers	O
yields	O
an	O
apparent	O
molecular	O
weight	O
of	O
110	O
-	O
120	O
k	O
,	O
indicating	O
that	O
after	O
proteolytic	O
processing	O
the	O
two	O
pro	O
-	O
domains	O
remain	O
non	O
-	O
covalently	O
associated	O
with	O
the	O
disulfide	O
linked	O
mature	O
dimer	O
in	O
a	O
complex	O
termed	O
soluble	O
hOP	B-Protein
-	I-Protein
1	E-Protein
.	O

Purified	O
soluble	O
hOP	B-Protein
-	I-Protein
1	E-Protein
is	O
significantly	O
more	O
soluble	O
in	O
physiological	O
buffers	O
than	O
the	O
purified	O
mature	O
OP	B-Protein
-	I-Protein
1	E-Protein
.	O

Boar	O
spermadhesin	O
PSP	B-Protein
-	I-Protein
II	E-Protein
:	O
location	O
of	O
posttranslational	O
modifications	O
,	O
heterodimer	O
formation	O
with	O
PSP	B-Protein
-	I-Protein
I	E-Protein
glycoforms	O
and	O
effect	O
of	O
dimerization	O
on	O
the	O
ligand	O
-	O
binding	O
capabilities	O
of	O
the	O
subunits	O
.	O

Spermadhesin	O
PSP	B-Protein
-	I-Protein
II	E-Protein
was	O
isolated	O
from	O
the	O
non	O
-	O
heparin	O
-	O
binding	O
fraction	O
of	O
boar	O
seminal	O
plasma	O
;	O
its	O
disulphide	O
bridge	O
pattern	O
,	O
and	O
the	O
location	O
of	O
a	O
single	O
N	O
-	O
glycosylation	O
site	O
were	O
established	O
.	O

PSP	B-Protein
-	I-Protein
II	E-Protein
forms	O
a	O
heterodimer	O
with	O
specific	O
N	O
-	O
glycoforms	O
of	O
PSP	B-Protein
-	I-Protein
I	E-Protein
.	O

Although	O
both	O
subunits	O
possess	O
heparin	O
-	O
binding	O
capability	O
,	O
the	O
PSP	B-Protein
-	I-Protein
I	E-Protein
/	O
PSP	B-Protein
-	I-Protein
II	E-Protein
complex	O
does	O
not	O
.	O

The	O
heterodimer	O
contains	O
binding	O
sites	O
for	O
zona	O
pellucida	O
glycoproteins	O
and	O
soybean	O
trypsin	O
inhibitor	O
located	O
in	O
the	O
PSP	B-Protein
-	I-Protein
II	E-Protein
subunit	O
.	O

However	O
,	O
the	O
PSP	B-Protein
-	I-Protein
I	E-Protein
/	O
PSP	B-Protein
-	I-Protein
II	E-Protein
heterodimer	O
binds	O
only	O
loosely	O
to	O
the	O
sperm	O
surface	O
and	O
is	O
easily	O
removed	O
during	O
in	O
vitro	O
capacitation	O
,	O
suggesting	O
that	O
the	O
zona	O
pellucida	O
binding	O
activity	O
may	O
not	O
be	O
relevant	O
for	O
gamete	O
interaction	O
.	O

Our	O
results	O
show	O
that	O
dimerization	O
of	O
spermadhesins	O
PSP	B-Protein
-	I-Protein
I	E-Protein
and	O
PSP	B-Protein
-	I-Protein
II	E-Protein
markedly	O
affects	O
their	O
binding	O
capabilities	O
.	O

The	O
alpha	O
subunit	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
oligosaccharyltransferase	O
complex	O
is	O
essential	O
for	O
vegetative	O
growth	O
of	O
yeast	O
and	O
is	O
homologous	O
to	O
mammalian	O
ribophorin	B-Protein
I	E-Protein
.	O

Oligosaccharyltransferase	O
mediates	O
the	O
transfer	O
of	O
a	O
preassembled	O
high	O
mannose	O
oligosaccharide	O
from	O
a	O
lipid	O
-	O
linked	O
oligosaccharide	O
donor	O
to	O
consensus	O
glycosylation	O
acceptor	O
sites	O
in	O
newly	O
synthesized	O
proteins	O
in	O
the	O
lumen	O
of	O
the	O
rough	O
endoplasmic	O
reticulum	O
.	O

The	O
Saccharomyces	O
cerevisiae	O
oligosaccharyltransferase	O
is	O
an	O
oligomeric	O
complex	O
composed	O
of	O
six	O
nonidentical	O
subunits	O
(	O
alpha	O
-	O
zeta	O
)	O
,	O
two	O
of	O
which	O
are	O
glycoproteins	O
(	O
alpha	O
and	O
beta	O
)	O
.	O

The	O
beta	O
and	O
delta	O
subunits	O
of	O
the	O
oligosaccharyltransferase	O
are	O
encoded	O
by	O
the	O
WBP1	S-Protein
and	O
SWP1	S-Protein
genes	O
.	O

Here	O
we	O
describe	O
the	O
functional	O
characterization	O
of	O
the	O
OST1	S-Protein
gene	O
that	O
encodes	O
the	O
alpha	O
subunit	O
of	O
the	O
oligosaccharyltransferase	O
.	O

Protein	O
sequence	O
analysis	O
revealed	O
a	O
significant	O
sequence	O
identity	O
between	O
the	O
Saccharomyces	O
cerevisiae	O
Ost1	S-Protein
protein	O
and	O
ribophorin	B-Protein
I	E-Protein
,	O
a	O
previously	O
identified	O
subunit	O
of	O
the	O
mammalian	O
oligosaccharyltransferase	O
.	O

A	O
disruption	O
of	O
the	O
OST1	S-Protein
locus	O
was	O
not	O
tolerated	O
in	O
haploid	O
yeast	O
showing	O
that	O
expression	O
of	O
the	O
Ost1	S-Protein
protein	O
is	O
essential	O
for	O
vegetative	O
growth	O
of	O
yeast	O
.	O

An	O
analysis	O
of	O
a	O
series	O
of	O
conditional	O
ost1	S-Protein
mutants	O
demonstrated	O
that	O
defects	O
in	O
the	O
Ost1	S-Protein
protein	O
cause	O
pleiotropic	O
underglycosylation	O
of	O
soluble	O
and	O
membrane	O
-	O
bound	O
glycoproteins	O
at	O
both	O
the	O
permissive	O
and	O
restrictive	O
growth	O
temperatures	O
.	O

Microsomal	O
membranes	O
isolated	O
from	O
ost1	S-Protein
mutant	O
yeast	O
showed	O
marked	O
reductions	O
in	O
the	O
in	O
vitro	O
transfer	O
of	O
high	O
mannose	O
oligosaccharide	O
from	O
exogenous	O
lipid	O
-	O
linked	O
oligosaccharide	O
to	O
a	O
glycosylation	O
site	O
acceptor	O
tripeptide	O
.	O

Microsomal	O
membranes	O
isolated	O
from	O
the	O
ost1	S-Protein
mutants	O
contained	O
elevated	O
amounts	O
of	O
the	O
Kar2	S-Protein
stress	O
-	O
response	O
protein	O
.	O

Bovine	O
retinal	B-Protein
rod	I-Protein
guanyl	I-Protein
cyclase	E-Protein
represents	O
a	O
new	O
N	O
-	O
glycosylated	O
subtype	O
of	O
membrane	O
-	O
bound	O
guanyl	O
cyclases	O
.	O

The	O
molecular	O
properties	O
of	O
retinal	B-Protein
rod	I-Protein
guanyl	I-Protein
cyclase	E-Protein
were	O
investigated	O
.	O

Peptides	O
were	O
derived	O
from	O
a	O
112	O
-	O
kDa	O
protein	O
previously	O
identified	O
as	O
the	O
particulate	O
bovine	O
retinal	B-Protein
rod	I-Protein
guanyl	I-Protein
cyclase	E-Protein
.	O

The	O
peptides	O
showed	O
100	O
%	O
identity	O
to	O
the	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
cloned	O
human	O
retina	B-Protein
-	I-Protein
specific	I-Protein
membrane	I-Protein
guanyl	I-Protein
cyclase	E-Protein
,	O
whereas	O
identity	O
to	O
the	O
members	O
of	O
the	O
natriuretic	O
peptide	O
receptor	O
guanyl	O
cyclases	O
was	O
14	O
-	O
59	O
%	O
.	O

The	O
112	O
-	O
kDa	O
protein	O
was	O
further	O
purified	O
by	O
a	O
new	O
approach	O
using	O
wheat	O
-	O
germ	O
agglutinin	S-Protein
chromatography	O
.	O

This	O
indicated	O
N	O
-	O
linked	O
glycosylation	O
in	O
retinal	B-Protein
rod	I-Protein
guanyl	I-Protein
cyclase	E-Protein
.	O

N	O
-	O
glycosylation	O
was	O
unexpected	O
from	O
the	O
sequence	O
of	O
the	O
human	O
retina	B-Protein
-	I-Protein
specific	I-Protein
membrane	I-Protein
guanyl	I-Protein
cyclase	E-Protein
,	O
although	O
it	O
is	O
a	O
common	O
property	O
of	O
natriuretic	O
peptide	O
receptors	O
.	O

Therefore	O
,	O
we	O
further	O
analyzed	O
the	O
carbohydrate	O
composition	O
of	O
bovine	O
retinal	B-Protein
rod	I-Protein
guanyl	I-Protein
cyclase	E-Protein
by	O
lectin	O
binding	O
using	O
the	O
lectins	O
Galanthus	O
nivalis	O
agglutinin	S-Protein
,	O
Sambucus	O
nigra	O
agglutinin	S-Protein
,	O
Maackia	O
amurensis	O
agglutinin	S-Protein
,	O
Ricinus	O
communis	O
agglutinin	S-Protein
,	O
Datura	O
stramonium	O
agglutinin	S-Protein
,	O
peanut	O
agglutinin	S-Protein
and	O
by	O
chromatography	O
of	O
the	O
purified	O
enzyme	O
using	O
concanavalin	O
-	O
A	O
-	O
Sepharose	O
.	O

The	O
oligosaccharide	O
side	O
chains	O
were	O
of	O
the	O
high	O
-	O
mannose	O
type	O
or	O
hybrid	O
type	O
,	O
probably	O
with	O
mannose	O
,	O
N	O
-	O
acetylglucosamine	O
and	O
sialic	O
acid	O
as	O
terminal	O
sugars	O
.	O

Enzymic	O
deglycosylation	O
by	O
N	B-Protein
-	I-Protein
glycosidase	I-Protein
F	E-Protein
was	O
achieved	O
after	O
proteolytic	O
digestion	O
with	O
endoproteinase	O
Glu	B-Protein
-	I-Protein
C	E-Protein
.	O

Lectins	O
neither	O
influenced	O
the	O
basal	O
nor	O
the	O
stimulated	O
guanyl	O
-	O
cyclase	O
activity	O
at	O
low	O
calcium	O
concentrations	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
particulate	B-Protein
rod	I-Protein
guanyl	I-Protein
cyclase	E-Protein
represents	O
an	O
unusual	O
new	O
subtype	O
of	O
membrane	O
-	O
bound	O
guanyl	O
cyclases	O
.	O

[	O
Recent	O
progress	O
in	O
TSH	B-Protein
receptor	E-Protein
research	O
-	O
-	O
relationship	O
of	O
its	O
structural	O
characteristics	O
to	O
ligand	O
binding	O
,	O
glycosylation	O
and	O
signal	O
transduction	O
]	O

Extensive	O
mutagenesis	O
studies	O
of	O
the	O
long	O
extracellular	O
domain	O
of	O
the	O
TSH	B-Protein
receptor	E-Protein
(	O
TSHR	S-Protein
)	O
revealed	O
important	O
residues	O
(	O
Cys	O
-	O
301	O
,	O
Tyr	O
-	O
385	O
and	O
Cys	O
-	O
390	O
)	O
for	O
binding	O
of	O
TSH	O
in	O
its	O
C	O
-	O
terminal	O
region	O
.	O

These	O
two	O
cysteines	O
were	O
postulated	O
to	O
form	O
a	O
disulfide	O
bond	O
catalyzed	O
by	O
TSH	O
.	O

On	O
the	O
other	O
hand	O
,	O
binding	O
sites	O
of	O
a	O
thyroid	O
stimulating	O
antibody	O
were	O
located	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
extracellular	O
domain	O
.	O

The	O
long	O
extracellular	O
domain	O
of	O
the	O
TSHR	S-Protein
has	O
5	O
or	O
6	O
possible	O
asparagine	O
-	O
linked	O
glycosylation	O
sites	O
.	O

However	O
,	O
only	O
two	O
sites	O
are	O
essential	O
for	O
the	O
expression	O
of	O
a	O
functional	O
receptor	O
among	O
them	O
.	O

Although	O
point	O
mutation	O
at	O
residue	O
113	O
of	O
the	O
human	O
TSHR	S-Protein
lost	O
TSH	O
binding	O
,	O
the	O
equivalent	O
mutation	O
of	O
the	O
rat	O
TSHR	S-Protein
did	O
not	O
,	O
implying	O
a	O
difference	O
in	O
the	O
significance	O
of	O
sugar	O
chains	O
among	O
species	O
.	O

G	O
protein	O
interaction	O
sites	O
have	O
recently	O
been	O
defined	O
by	O
mutagenesis	O
studies	O
.	O

However	O
,	O
the	O
details	O
of	O
how	O
TSH	O
binding	O
to	O
the	O
long	O
extracellular	O
domain	O
causes	O
conformational	O
change	O
in	O
the	O
transmembrane	O
domain	O
remains	O
to	O
be	O
elucidated	O
.	O

The	O
general	O
secretory	O
pathway	O
of	O
Klebsiella	O
oxytoca	O
:	O
no	O
evidence	O
for	O
relocalization	O
or	O
assembly	O
of	O
pilin	O
-	O
like	O
PulG	S-Protein
protein	O
into	O
a	O
multiprotein	O
complex	O
.	O

It	O
has	O
been	O
proposed	O
that	O
the	O
four	O
type	O
IV	O
pilin	O
-	O
like	O
proteins	O
that	O
are	O
required	O
for	O
extracellular	O
protein	O
secretion	O
by	O
the	O
general	O
secretory	O
pathway	O
(	O
GSP	O
)	O
might	O
assemble	O
into	O
a	O
trans	O
-	O
periplasm	O
complex	O
resembling	O
a	O
type	O
IV	O
pilus	O
.	O

To	O
test	O
this	O
idea	O
,	O
we	O
examined	O
the	O
subcellular	O
distribution	O
and	O
oligomeric	O
state	O
of	O
PulG	S-Protein
,	O
one	O
of	O
the	O
type	O
IV	O
pilin	O
-	O
like	O
proteins	O
required	O
for	O
pullulanase	S-Protein
secretion	O
in	O
Klebsiella	O
oxytoca	O
.	O

Fractionation	O
of	O
Escherichia	O
coli	O
cells	O
carrying	O
a	O
single	O
copy	O
of	O
each	O
pul	O
gene	O
showed	O
that	O
PulG	S-Protein
protein	O
was	O
located	O
in	O
two	O
distinct	O
envelope	O
fractions	O
corresponding	O
to	O
the	O
outer	O
and	O
cytoplasmic	O
membranes	O
.	O

The	O
protein	O
was	O
partially	O
released	O
by	O
treating	O
the	O
membranes	O
with	O
Triton	O
X	O
-	O
100	O
+	O
EDTA	O
or	O
at	O
high	O
pH	O
,	O
but	O
not	O
by	O
Triton	O
X	O
-	O
100	O
alone	O
or	O
by	O
8	O
M	O
urea	O
,	O
6	O
M	O
guanidine	O
hydrochloride	O
or	O
1	O
M	O
NaCl	O
.	O

Like	O
type	O
IV	O
pilins	O
,	O
non	O
-	O
sedimentable	O
PulG	S-Protein
that	O
had	O
been	O
released	O
from	O
the	O
membranes	O
at	O
high	O
pH	O
could	O
be	O
sedimented	O
by	O
centrifugation	O
when	O
the	O
pH	O
was	O
lowered	O
.	O

Treatment	O
of	O
whole	O
cells	O
,	O
sphaeroplasts	O
or	O
isolated	O
membranes	O
with	O
a	O
cleavable	O
cross	O
-	O
linking	O
agent	O
produced	O
mainly	O
PulG	S-Protein
homodimers	O
.	O

Previous	O
studies	O
showed	O
that	O
both	O
PulO	S-Protein
,	O
which	O
cleaves	O
and	O
N	O
-	O
methylates	O
the	O
PulG	S-Protein
precursor	O
,	O
and	O
PulE	S-Protein
,	O
a	O
putative	O
ATP	O
-	O
binding	O
protein	O
,	O
share	O
extensive	O
sequence	O
identity	O
with	O
proteins	O
known	O
to	O
be	O
required	O
for	O
type	O
IV	O
pilus	O
processing	O
and	O
assembly	O
.	O

However	O
,	O
mutations	O
which	O
disrupted	O
either	O
pulE	S-Protein
or	O
pulO	S-Protein
,	O
or	O
indeed	O
the	O
complete	O
absence	O
of	O
all	O
other	O
components	O
of	O
the	O
pullulanase	S-Protein
secretion	O
apparatus	O
,	O
had	O
little	O
or	O
no	O
effect	O
on	O
any	O
of	O
the	O
properties	O
of	O
PulG	S-Protein
protein	O
described	O
above	O
.	O

We	O
conclude	O
that	O
there	O
is	O
no	O
evidence	O
that	O
PulG	S-Protein
protein	O
assembles	O
into	O
a	O
stable	O
multiprotein	O
complex	O
or	O
that	O
processing	O
of	O
the	O
PulG	S-Protein
precursor	O
causes	O
a	O
detectable	O
change	O
in	O
its	O
subcellular	O
distribution	O
.	O

Stimulatory	O
effects	O
of	O
lung	O
cytochrome	B-Protein
b5	E-Protein
on	O
benzphetamine	O
N	O
-	O
demethylation	O
in	O
a	O
reconstituted	O
system	O
containing	O
lung	O
cytochrome	O
P450LgM2	O
.	O

Cytochrome	B-Protein
b5	E-Protein
was	O
partially	O
purified	O
from	O
sheep	O
lung	O
microsomes	O
in	O
the	O
presence	O
of	O
detergents	O
Emulgen	O
913	O
and	O
cholate	O
by	O
three	O
consecutive	O
DEAE	O
-	O
cellulose	O
and	O
Sephadex	O
G	O
-	O
100	O
gel	O
filtration	O
chromatographies	O
.	O

The	O
specific	O
content	O
of	O
cytochrome	B-Protein
b5	E-Protein
was	O
16	O
.	O
5	O
nmol	O
/	O
mg	O
protein	O
and	O
purified	O
cytochrome	B-Protein
b5	E-Protein
fractions	O
were	O
free	O
of	O
cytochrome	O
P450	O
,	O
NADPH	B-Protein
-	I-Protein
cytochrome	I-Protein
P450	I-Protein
reductase	E-Protein
and	O
NADH	O
-	O
cytochrome	O
b5	O
reductase	O
activities	O
.	O

The	O
influences	O
of	O
increasing	O
concentrations	O
of	O
lung	O
cytochrome	B-Protein
b5	E-Protein
on	O
benzphetamine	O
N	O
-	O
demethylation	O
reactions	O
were	O
examined	O
in	O
four	O
different	O
reconstitution	O
systems	O
containing	O
lung	O
cytochrome	O
P450LgM2	O
,	O
lung	O
cytochrome	B-Protein
P450	I-Protein
reductase	E-Protein
and	O
lipid	O
.	O

In	O
each	O
system	O
concentration	O
of	O
reductase	O
was	O
doubled	O
with	O
respect	O
to	O
former	O
system	O
.	O

In	O
all	O
systems	O
cytochrome	B-Protein
b5	E-Protein
stimulated	O
benzphetamine	O
N	O
-	O
demethylase	O
activity	O
especially	O
when	O
cytochrome	B-Protein
b5	E-Protein
was	O
present	O
at	O
0	O
.	O
5	O
:	O
1	O
molar	O
ratio	O
with	O
respect	O
to	O
cytochrome	O
P450LgM2	O
.	O

Besides	O
,	O
the	O
greatest	O
fold	O
of	O
increase	O
in	O
benzphetamine	O
N	O
-	O
demethylation	O
activity	O
due	O
to	O
addition	O
of	O
cytochrome	B-Protein
b5	E-Protein
was	O
observed	O
in	O
System	O
1	O
with	O
the	O
lowest	O
concentration	O
of	O
reductase	O
.	O

Extracellular	O
and	O
cytoplasmic	O
CuZn	O
superoxide	O
dismutases	O
from	O
Brugia	O
lymphatic	O
filarial	O
nematode	O
parasites	O
.	O

We	O
have	O
isolated	O
full	O
-	O
length	O
cDNAs	O
encoding	O
two	O
distinct	O
types	O
of	O
CuZn	O
superoxide	O
dismutases	O
(	O
SODs	O
)	O
from	O
the	O
filarial	O
nematode	O
parasite	O
Brugia	O
pahangi	O
.	O

The	O
derived	O
amino	O
acid	O
sequences	O
suggested	O
that	O
one	O
class	O
of	O
cDNAs	O
represented	O
a	O
cytoplasmic	O
form	O
of	O
SOD	O
and	O
the	O
second	O
class	O
represented	O
an	O
extracellular	O
(	O
EC	O
)	O
variant	O
.	O

The	O
predicted	O
proteins	O
were	O
highly	O
homologous	O
to	O
each	O
other	O
,	O
but	O
the	O
sequence	O
of	O
the	O
latter	O
contained	O
an	O
additional	O
43	O
residues	O
at	O
the	O
N	O
terminus	O
,	O
the	O
first	O
16	O
of	O
which	O
were	O
markedly	O
hydrophobic	O
,	O
and	O
four	O
potential	O
sites	O
for	O
N	O
-	O
linked	O
glycosylation	O
.	O

Western	O
blotting	O
(	O
immunoblotting	O
)	O
with	O
an	O
antiserum	O
to	O
a	O
partial	O
SOD	O
expressed	O
in	O
Escherichia	O
coli	O
revealed	O
two	O
proteins	O
with	O
estimated	O
molecular	O
masses	O
of	O
19	O
and	O
29	O
kDa	O
.	O

Digestion	O
with	O
N	B-Protein
-	I-Protein
glycanase	E-Protein
indicated	O
that	O
the	O
latter	O
protein	O
corresponded	O
to	O
the	O
EC	O
form	O
,	O
as	O
it	O
possessed	O
N	O
-	O
linked	O
oligosaccharide	O
chains	O
at	O
three	O
sites	O
,	O
leaving	O
a	O
peptide	O
backbone	O
with	O
an	O
estimated	O
molecular	O
mass	O
of	O
22	O
kDa	O
,	O
which	O
was	O
consistent	O
with	O
the	O
additional	O
27	O
amino	O
acids	O
predicted	O
from	O
the	O
cDNA	O
sequence	O
.	O

Gel	O
filtration	O
indicated	O
that	O
both	O
enzymes	O
were	O
dimeric	O
in	O
their	O
native	O
forms	O
,	O
in	O
contrast	O
to	O
the	O
human	O
EC	B-Protein
-	I-Protein
SOD	E-Protein
,	O
which	O
is	O
tetrameric	O
.	O

Comparison	O
of	O
the	O
primary	O
structure	O
of	O
the	O
parasite	O
EC	B-Protein
-	I-Protein
SOD	E-Protein
with	O
that	O
of	O
the	O
human	O
EC	O
enzyme	O
revealed	O
two	O
major	O
differences	O
:	O
the	O
N	O
-	O
terminal	O
extension	O
of	O
the	O
parasite	O
enzyme	O
was	O
shorter	O
by	O
25	O
residues	O
,	O
and	O
it	O
also	O
lacked	O
the	O
C	O
-	O
terminal	O
charged	O
extension	O
which	O
mediates	O
binding	O
to	O
cell	O
surface	O
sulfated	O
proteoglycans	O
.	O

Lavage	O
of	O
Mongolian	O
jirds	O
infected	O
intraperitoneally	O
with	O
Brugia	O
malayi	O
resulted	O
in	O
the	O
recovery	O
of	O
filarial	O
CuZn	O
SODs	O
,	O
principally	O
the	O
EC	O
form	O
,	O
indicating	O
that	O
this	O
form	O
of	O
SOD	O
is	O
secreted	O
in	O
vivo	O
.	O

This	O
EC	O
enzyme	O
may	O
contribute	O
to	O
parasite	O
persistence	O
by	O
neutralizing	O
superoxide	O
generated	O
by	O
activated	O
leukocytes	O
,	O
thus	O
acting	O
as	O
both	O
an	O
antioxidant	O
and	O
an	O
anti	O
-	O
inflammatory	O
factor	O
.	O

B	O
cell	O
-	O
specific	O
demethylation	O
:	O
a	O
novel	O
role	O
for	O
the	O
intronic	O
kappa	B-Protein
chain	E-Protein
enhancer	O
sequence	O
.	O

We	O
studied	O
the	O
molecular	O
mechanism	O
of	O
demethylation	O
and	O
its	O
role	O
in	O
kappa	B-Protein
chain	E-Protein
gene	O
regulation	O
.	O

Following	O
transfection	O
into	O
B	O
cell	O
cultures	O
,	O
this	O
gene	O
undergoes	O
regional	O
demethylation	O
in	O
a	O
process	O
that	O
is	O
developmentally	O
regulated	O
in	O
a	O
lineage	O
-	O
and	O
stage	O
-	O
specific	O
manner	O
.	O

Although	O
a	O
germline	O
V	O
kappa	S-Protein
promoter	O
is	O
not	O
required	O
for	O
the	O
demodification	O
activity	O
,	O
a	O
fragment	O
containing	O
the	O
intronic	O
kappa	B-Protein
chain	E-Protein
transcriptional	O
enhancer	O
and	O
the	O
nearby	O
matrix	O
attachment	O
region	O
is	O
essential	O
.	O

In	O
its	O
natural	O
location	O
downstream	O
to	O
the	O
J	O
kappa	S-Protein
5	O
sequence	O
,	O
this	O
element	O
induces	O
bidirectional	O
demodification	O
of	O
plasmid	O
constructs	O
in	O
a	O
distance	O
-	O
and	O
orientation	O
-	O
independent	O
manner	O
.	O

When	O
this	O
enhancer	O
is	O
placed	O
in	O
an	O
upstream	O
position	O
,	O
however	O
,	O
the	O
kappa	S-Protein
gene	O
remains	O
modified	O
and	O
transcriptionally	O
inactive	O
,	O
demonstrating	O
that	O
demethylation	O
is	O
required	O
for	O
kappa	B-Protein
chain	E-Protein
activation	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
kappa	S-Protein
enhancer	O
plays	O
a	O
dual	O
role	O
in	O
regulating	O
B	O
cell	O
differentiation	O
by	O
inducing	O
demethylation	O
and	O
by	O
promoting	O
tissue	O
-	O
specific	O
transcription	O
.	O

Erythropoietin	S-Protein
structure	O
-	O
function	O
relationships	O
.	O

Mutant	O
proteins	O
that	O
test	O
a	O
model	O
of	O
tertiary	O
structure	O
.	O

On	O
the	O
basis	O
of	O
its	O
primary	O
sequence	O
and	O
the	O
location	O
of	O
its	O
disulfide	O
bonds	O
,	O
we	O
propose	O
a	O
structural	O
model	O
of	O
the	O
erythropoietic	O
hormone	O
erythropoietin	S-Protein
(	O
Epo	S-Protein
)	O
which	O
predicts	O
a	O
four	O
alpha	O
-	O
helical	O
bundle	O
motif	O
,	O
in	O
common	O
with	O
other	O
cytokines	O
.	O

In	O
order	O
to	O
test	O
this	O
model	O
,	O
site	O
-	O
directed	O
mutants	O
were	O
prepared	O
by	O
high	O
level	O
transient	O
expression	O
in	O
Cos7	O
cells	O
and	O
analyzed	O
by	O
a	O
radioimmuno	O
assay	O
and	O
by	O
bioassays	O
utilizing	O
mouse	O
and	O
human	O
Epo	S-Protein
-	O
dependent	O
cell	O
lines	O
.	O

Deletions	O
of	O
5	O
to	O
8	O
residues	O
within	O
predicted	O
alpha	O
-	O
helices	O
resulted	O
in	O
the	O
failure	O
of	O
export	O
of	O
the	O
mutant	O
protein	O
from	O
the	O
cell	O
.	O

In	O
contrast	O
,	O
deletions	O
at	O
the	O
NH2	O
terminus	O
(	O
delta	O
2	O
-	O
5	O
)	O
,	O
the	O
COOH	O
terminus	O
(	O
delta	O
163	O
-	O
166	O
)	O
,	O
or	O
in	O
predicted	O
interhelical	O
loops	O
(	O
AB	O
:	O
delta	O
32	O
-	O
36	O
,	O
delta	O
53	O
-	O
57	O
;	O
BC	O
:	O
delta	O
78	O
-	O
82	O
;	O
CD	O
:	O
delta	O
111	O
-	O
119	O
)	O
resulted	O
in	O
the	O
export	O
of	O
immunologically	O
detectable	O
Epo	S-Protein
muteins	O
that	O
were	O
biologically	O
active	O
.	O

The	O
mutein	O
delta	O
48	O
-	O
52	O
could	O
be	O
readily	O
detected	O
by	O
radioimmunoassay	O
but	O
had	O
markedly	O
decreased	O
biological	O
activity	O
.	O

However	O
,	O
replacement	O
of	O
each	O
of	O
these	O
deleted	O
residues	O
by	O
serine	O
resulted	O
in	O
Epo	S-Protein
muteins	O
with	O
full	O
biological	O
activity	O
.	O

Replacement	O
of	O
Cys29	O
and	O
Cys33	O
by	O
tyrosine	O
residues	O
also	O
resulted	O
in	O
the	O
export	O
of	O
fully	O
active	O
Epo	S-Protein
.	O

Therefore	O
,	O
this	O
small	O
disulfide	O
loop	O
is	O
not	O
critical	O
to	O
Epo	S-Protein
'	O
s	O
stability	O
or	O
function	O
.	O

The	O
properties	O
of	O
the	O
muteins	O
that	O
we	O
tested	O
are	O
consistent	O
with	O
our	O
proposed	O
model	O
of	O
tertiary	O
structure	O
.	O

Methylation	O
status	O
of	O
immunoglobulin	B-Protein
kappa	E-Protein
gene	O
segments	O
correlates	O
with	O
their	O
recombination	O
potential	O
.	O

We	O
have	O
previously	O
shown	O
that	O
unlike	O
endogenous	O
chi	S-Protein
genes	O
,	O
unrearranged	O
chi	S-Protein
transgenes	O
undergo	O
V	O
chi	O
-	O
J	O
chi	O
recombination	O
in	O
Tas	O
well	O
as	O
B	O
cells	O
of	O
transgenic	O
mice	O
.	O

To	O
determine	O
whether	O
the	O
difference	O
in	O
recombination	O
specificity	O
of	O
the	O
transgenic	O
and	O
endogenous	O
chi	S-Protein
genes	O
is	O
associated	O
with	O
differences	O
in	O
DNA	O
structure	O
,	O
the	O
methylation	O
status	O
of	O
the	O
endogenous	O
genes	O
and	O
three	O
unrearranged	O
chi	S-Protein
transgenes	O
was	O
compared	O
.	O

The	O
J	O
chi	O
-	O
C	O
chi	O
locus	O
of	O
the	O
transgenes	O
was	O
found	O
to	O
be	O
hypomethylated	O
in	O
all	O
tissues	O
of	O
the	O
transgenic	O
mice	O
.	O

In	O
contrast	O
,	O
methylation	O
of	O
the	O
endogenous	O
chi	S-Protein
genes	O
was	O
tissue	O
and	O
developmentally	O
regulated	O
.	O

Hypomethylation	O
of	O
the	O
endogenous	O
J	O
chi	O
-	O
C	O
chi	O
region	O
occurs	O
only	O
in	O
cells	O
of	O
the	O
B	O
lineage	O
undergoing	O
,	O
or	O
having	O
completed	O
chi	O
gene	O
recombination	O
.	O

Transfection	O
of	O
fibroblasts	O
from	O
transgenic	O
and	O
control	O
mice	O
with	O
the	O
recombination	O
activating	O
genes	O
,	O
Rag1	S-Protein
and	O
Rag2	S-Protein
,	O
led	O
to	O
a	O
high	O
level	O
of	O
rearrangement	O
of	O
the	O
hypomethylated	O
transgenic	O
,	O
but	O
not	O
the	O
endogenous	O
chi	O
genes	O
.	O

These	O
results	O
suggest	O
that	O
hypomethylation	O
defines	O
an	O
accessible	O
state	O
of	O
the	O
chi	S-Protein
locus	O
and	O
that	O
methylation	O
/	O
demethylation	O
could	O
be	O
involved	O
in	O
the	O
control	O
of	O
chi	O
gene	O
rearrangement	O
during	O
lymphocyte	O
differentiation	O
.	O

Selective	O
use	O
of	O
H4	S-Protein
acetylation	O
sites	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
acetylation	O
of	O
specific	O
lysine	O
residues	O
in	O
the	O
histone	B-Protein
H4	E-Protein
may	O
play	O
a	O
role	O
in	O
regulating	O
various	O
genes	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
[	O
Grunstein	O
(	O
1990	O
)	O
Annu	O
.	O
Rev	O
.	O
Cell	O
Biol	O
.	O
6	O
,	O
643	O
-	O
678	O
]	O
.	O

The	O
detailed	O
consideration	O
of	O
this	O
possibility	O
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
information	O
on	O
the	O
frequency	O
with	O
which	O
different	O
H4	S-Protein
lysine	O
residues	O
are	O
acetylated	O
in	O
yeast	O
.	O

In	O
this	O
paper	O
,	O
we	O
use	O
Western	O
blotting	O
from	O
acid	O
/	O
urea	O
/	O
Triton	O
gels	O
and	O
immunostaining	O
with	O
antisera	O
specific	O
for	O
H4	S-Protein
molecules	O
acetylated	O
at	O
particular	O
lysine	O
residues	O
to	O
show	O
that	O
70	O
-	O
80	O
%	O
of	O
H4	S-Protein
molecules	O
in	O
S	O
.	O
cerevisiae	O
contain	O
one	O
or	O
more	O
acetylated	O
lysines	O
,	O
and	O
that	O
lysines	O
-	O
5	O
,	O
-	O
8	O
,	O
-	O
12	O
and	O
-	O
16	O
are	O
acetylated	O
in	O
an	O
ordered	O
,	O
non	O
-	O
random	O
fashion	O
.	O

The	O
monoacetylated	O
isoform	O
(	O
H4Ac1	S-Protein
)	O
is	O
acetylated	O
predominantly	O
at	O
lysine	O
-	O
16	O
(	O
rarely	O
at	O
lysine	O
-	O
12	O
)	O
,	O
H4Ac2	S-Protein
is	O
acetylated	O
at	O
lysine	O
-	O
16	O
and	O
at	O
either	O
lysine	O
-	O
12	O
or	O
at	O
-	O
8	O
,	O
while	O
lysine	O
-	O
5	O
is	O
acetylated	O
frequently	O
only	O
in	O
H4Ac3	S-Protein
and	O
in	O
H4Ac4	S-Protein
.	O

Partial	O
characterization	O
of	O
the	O
rH1	S-Protein
sodium	O
channel	O
protein	O
from	O
rat	O
heart	O
using	O
subtype	O
-	O
specific	O
antibodies	O
.	O

Three	O
subtype	O
-	O
specific	O
antisera	O
were	O
generated	O
against	O
peptides	O
corresponding	O
to	O
portions	O
of	O
the	O
amino	O
terminus	O
,	O
interdomain	O
1	O
-	O
2	O
,	O
and	O
carboxy	O
terminus	O
of	O
the	O
rH1	S-Protein
sodium	O
channel	O
primary	O
sequence	O
to	O
confirm	O
the	O
expression	O
of	O
this	O
protein	O
in	O
the	O
adult	O
rat	O
heart	O
and	O
to	O
determine	O
selected	O
biochemical	O
properties	O
of	O
this	O
protein	O
that	O
might	O
contribute	O
to	O
its	O
subtype	O
-	O
specific	O
characteristics	O
.	O

All	O
three	O
antisera	O
identify	O
a	O
240	O
-	O
kD	O
band	O
on	O
Western	O
blots	O
of	O
partially	O
purified	O
cardiac	O
membrane	O
proteins	O
and	O
by	O
immunoprecipitation	O
of	O
iodinated	O
partially	O
purified	O
membrane	O
proteins	O
.	O

Unlike	O
other	O
characterized	O
mammalian	O
sodium	O
channels	O
,	O
no	O
beta	O
subunit	O
is	O
detected	O
in	O
association	O
with	O
the	O
rH1	B-Protein
alpha	I-Protein
subunit	E-Protein
.	O

The	O
rH1	B-Protein
alpha	I-Protein
subunit	E-Protein
is	O
a	O
complex	O
sialoglycoprotein	O
as	O
evidenced	O
by	O
its	O
interaction	O
with	O
wheat	O
germ	O
agglutinin	O
-	O
Sepharose	O
and	O
by	O
reduction	O
in	O
its	O
apparent	O
molecular	O
weight	O
after	O
treatment	O
with	O
neuraminidase	O
;	O
deglycosylation	O
with	O
N	O
-	O
glycanase	O
confirms	O
that	O
the	O
rH1	S-Protein
protein	O
contains	O
significantly	O
less	O
carbohydrate	O
than	O
other	O
sodium	O
channel	O
proteins	O
characterized	O
to	O
date	O
(	O
5	O
%	O
versus	O
25	O
%	O
to	O
30	O
%	O
)	O
.	O

Consistent	O
with	O
electrophysiological	O
studies	O
indicating	O
a	O
role	O
of	O
phosphorylation	O
in	O
channel	O
regulation	O
,	O
the	O
rH1	B-Protein
alpha	I-Protein
subunit	E-Protein
can	O
be	O
phosphorylated	O
by	O
the	O
catalytic	O
subunit	O
of	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
A	O
.	O

The	O
possible	O
functional	O
significance	O
of	O
these	O
findings	O
is	O
discussed	O
.	O

Frog	O
prodermorphin	S-Protein
expressed	O
in	O
mammalian	O
cells	O
is	O
partly	O
converted	O
to	O
the	O
hydroxyproline	O
containing	O
precursor	O
.	O

Using	O
recombinant	O
vaccinia	O
virus	O
,	O
we	O
have	O
expressed	O
in	O
mammalian	O
cells	O
the	O
cDNA	O
coding	O
for	O
the	O
precursor	O
of	O
dermorphin	S-Protein
,	O
a	O
D	O
-	O
alanine	O
containing	O
opioid	O
peptide	O
from	O
the	O
skin	O
of	O
the	O
South	O
American	O
frog	O
Phyllomedusa	O
sauvagei	O
.	O

HeLa	O
cells	O
and	O
AtT	O
-	O
20	O
cells	O
produced	O
prodermorphin	S-Protein
where	O
proline	O
-	O
6	O
of	O
dermorphin	S-Protein
was	O
partly	O
hydroxylated	O
.	O

This	O
was	O
demonstrated	O
by	O
digesting	O
the	O
partially	O
purified	O
precursors	O
with	O
trypsin	O
and	O
carboxypeptidase	O
B	O
.	O

After	O
immunoprecipitation	O
and	O
separation	O
by	O
HPLC	O
,	O
two	O
decapeptides	O
were	O
detected	O
which	O
differed	O
by	O
the	O
presence	O
of	O
proline	O
or	O
hydroxy	O
-	O
proline	O
at	O
position	O
6	O
.	O

This	O
demonstrates	O
that	O
HeLa	O
cells	O
as	O
well	O
as	O
AtT	O
-	O
20	O
cells	O
can	O
perform	O
the	O
post	O
-	O
translational	O
conversion	O
of	O
certain	O
proline	O
residues	O
to	O
hydroxyproline	O
in	O
a	O
foreign	O
hormone	O
precursor	O
expressed	O
in	O
these	O
cells	O
.	O

Expression	O
of	O
biologically	O
active	O
human	O
factor	B-Protein
VIII	E-Protein
using	O
a	O
baculovirus	O
vector	O
.	O

Factor	B-Protein
VIII	E-Protein
is	O
a	O
complex	O
,	O
plasma	O
glycoprotein	O
involved	O
in	O
the	O
process	O
of	O
blood	O
coagulation	O
.	O

Production	O
of	O
the	O
recombinant	O
molecule	O
has	O
largely	O
been	O
confined	O
to	O
mammalian	O
cell	O
systems	O
which	O
have	O
,	O
in	O
general	O
,	O
proven	O
to	O
be	O
inefficient	O
producers	O
of	O
factor	B-Protein
VIII	E-Protein
.	O

The	O
use	O
of	O
a	O
baculovirus	O
expression	O
system	O
may	O
provide	O
increased	O
levels	O
of	O
this	O
glycoprotein	O
,	O
although	O
it	O
is	O
not	O
certain	O
that	O
insect	O
cell	O
-	O
derived	O
factor	B-Protein
VIII	E-Protein
will	O
be	O
biologically	O
active	O
.	O

The	O
N	O
-	O
linked	O
glycosylation	O
patterns	O
in	O
insect	O
cells	O
,	O
until	O
recently	O
thought	O
to	O
be	O
less	O
complex	O
than	O
in	O
mammalian	O
cells	O
,	O
may	O
influence	O
activity	O
and	O
/	O
or	O
secretory	O
ability	O
.	O

To	O
this	O
end	O
we	O
engineered	O
a	O
B	O
domain	O
-	O
deleted	O
factor	B-Protein
VIII	E-Protein
cDNA	O
sequence	O
for	O
expression	O
in	O
Spodoptera	O
frugiperda	O
cells	O
.	O

The	O
construct	O
retained	O
the	O
native	O
signal	O
sequence	O
to	O
allow	O
secretion	O
of	O
recombinant	O
protein	O
into	O
the	O
culture	O
medium	O
.	O

Initial	O
studies	O
revealed	O
the	O
production	O
of	O
secreted	O
factor	B-Protein
VIII	E-Protein
,	O
and	O
this	O
protein	O
was	O
shown	O
to	O
possess	O
coagulation	O
activity	O
.	O

The	O
presence	O
of	O
N	O
-	O
linked	O
oligosaccharide	O
residues	O
was	O
demonstrated	O
,	O
the	O
glycosylated	O
molecule	O
being	O
of	O
a	O
similar	O
size	O
to	O
that	O
expressed	O
in	O
mammalian	O
cells	O
.	O

Entry	O
of	O
polyunsaturated	O
fatty	O
acids	O
into	O
the	O
brain	O
:	O
evidence	O
that	O
high	O
-	O
density	O
lipoprotein	O
-	O
induced	O
methylation	O
of	O
phosphatidylethanolamine	O
and	O
phospholipase	O
A2	O
are	O
involved	O
.	O

The	O
conversion	O
of	O
phosphatidylethanolamine	O
(	O
PE	O
)	O
into	O
phosphatidylcholine	O
(	O
PC	O
)	O
by	O
a	O
sequence	O
of	O
three	O
transmethylation	O
reactions	O
is	O
shown	O
to	O
be	O
stimulated	O
by	O
the	O
apolipoprotein	O
E	O
-	O
free	O
subclass	O
of	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL3	O
)	O
in	O
isolated	O
bovine	O
brain	O
capillary	O
(	O
BBC	O
)	O
membranes	O
,	O
HDL3	O
-	O
induced	O
stimulation	O
of	O
BBC	O
membranes	O
pulsed	O
with	O
[	O
methyl	O
-	O
14C	O
]	O
methionine	O
causes	O
a	O
transient	O
increase	O
in	O
each	O
methylated	O
phospholipid	O
,	O
i	O
.	O
e	O
.	O
phosphatidyl	O
-	O
N	O
-	O
monomethylethanolamine	O
(	O
PMME	O
)	O
,	O
phosphatidyl	O
-	O
NN	O
-	O
dimethylethanolamine	O
(	O
PDME	O
)	O
and	O
PC	O
.	O

PC	O
substrate	O
arising	O
from	O
the	O
activation	O
of	O
PE	B-Protein
N	I-Protein
-	I-Protein
methyltransferase	E-Protein
(	O
PEMT	S-Protein
)	O
is	O
hydrolysed	O
by	O
a	O
phospholipase	O
A2	O
(	O
PLA2	O
)	O
,	O
as	O
demonstrated	O
by	O
the	O
accumulation	O
of	O
lysophosphatidylcholine	O
(	O
lyso	O
-	O
PC	O
)	O
.	O

When	O
PE	O
containing	O
[	O
14C	O
]	O
arachidonic	O
acid	O
in	O
the	O
sn	O
-	O
2	O
position	O
(	O
[	O
14C	O
]	O
PAPE	O
)	O
is	O
incorporated	O
into	O
BBC	O
membranes	O
,	O
HDL3	O
stimulation	O
induces	O
the	O
formation	O
of	O
PMME	O
,	O
PDME	O
,	O
PC	O
and	O
lyso	O
-	O
PC	O
and	O
the	O
release	O
of	O
[	O
14C	O
]	O
arachidonic	O
acid	O
,	O
which	O
correlates	O
with	O
the	O
previous	O
production	O
of	O
lyso	O
-	O
PC	O
,	O
suggesting	O
that	O
HDL3	O
stimulates	O
a	O
PLA2	O
that	O
can	O
release	O
polyunsaturated	O
fatty	O
acids	O
(	O
PUFA	O
)	O
.	O

Both	O
PEMT	S-Protein
and	O
PLA2	O
activities	O
depend	O
on	O
a	O
HDL3	O
concentration	O
in	O
the	O
range	O
0	O
-	O
50	O
micrograms	O
/	O
ml	O
and	O
are	O
strictly	O
dependent	O
on	O
HDL3	O
binding	O
,	O
because	O
HDL3	O
modified	O
by	O
tetranitromethane	O
is	O
no	O
longer	O
able	O
to	O
bind	O
to	O
specific	O
receptors	O
and	O
to	O
trigger	O
PEMT	O
and	O
PLA2	O
activation	O
.	O

Moreover	O
,	O
HDL3	O
prelabelled	O
with	O
[	O
14C	O
]	O
PAPE	O
can	O
stimulate	O
PDME	O
and	O
lyso	O
-	O
PC	O
synthesis	O
in	O
BBC	O
membranes	O
in	O
the	O
presence	O
of	O
S	O
-	O
adenosylmethionine	O
,	O
suggesting	O
that	O
HDL3	O
can	O
supply	O
BBC	O
membranes	O
in	O
polyunsaturated	O
PE	O
and	O
can	O
activate	O
enzymes	O
involved	O
in	O
PE	O
N	O
-	O
methylation	O
and	O
PUFA	O
release	O
.	O

The	O
results	O
support	O
the	O
hypothesis	O
of	O
a	O
close	O
relationship	O
between	O
HDL3	O
binding	O
,	O
PE	O
methylation	O
and	O
PUFA	O
release	O
,	O
and	O
suggest	O
that	O
the	O
PC	O
pool	O
arising	O
from	O
PE	O
could	O
be	O
used	O
as	O
a	O
pathway	O
for	O
the	O
supply	O
of	O
PUFA	O
to	O
the	O
brain	O
.	O

Structural	O
characterization	O
of	O
variant	O
forms	O
of	O
arylsulfatase	B-Protein
A	E-Protein
that	O
associate	O
with	O
alcoholism	O
.	O

Several	O
electrophoretic	O
forms	O
of	O
human	O
platelet	O
arylsulfatase	B-Protein
A	E-Protein
(	O
ASA	S-Protein
)	O
,	O
including	O
variant	O
type	O
IIIa	O
and	O
normal	O
type	O
IV	O
(	O
a	O
)	O
,	O
have	O
been	O
identified	O
by	O
nondenaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

An	O
alcoholic	O
population	O
that	O
we	O
have	O
analyzed	O
is	O
enriched	O
in	O
variant	O
type	O
IIIa	O
compared	O
with	O
nonalcoholic	O
psychiatric	O
and	O
normal	O
controls	O
.	O

Individuals	O
with	O
the	O
IIIa	O
enzyme	O
possess	O
greatly	O
reduced	O
levels	O
of	O
ASA	S-Protein
activity	O
.	O

To	O
understand	O
further	O
the	O
structural	O
basis	O
for	O
the	O
differences	O
and	O
their	O
potential	O
biological	O
consequences	O
,	O
the	O
nature	O
of	O
the	O
ASA	S-Protein
variant	O
expressed	O
by	O
fibroblasts	O
from	O
different	O
individuals	O
was	O
explored	O
.	O

The	O
electrophoretic	O
patterns	O
of	O
fibroblast	O
ASA	S-Protein
from	O
the	O
IIIa	O
and	O
IV	O
(	O
a	O
)	O
individuals	O
differ	O
in	O
degree	O
of	O
phosphorylation	O
.	O

Furthermore	O
,	O
fibroblast	O
ASA	S-Protein
from	O
IIIa	O
individuals	O
lacks	O
an	O
N	O
-	O
linked	O
glycan	O
found	O
in	O
ASA	S-Protein
from	O
IV	O
(	O
a	O
)	O
individuals	O
.	O

In	O
addition	O
,	O
differences	O
in	O
peptide	O
and	O
/	O
or	O
posttranslational	O
modification	O
unrelated	O
to	O
the	O
N	O
-	O
linked	O
carbohydrate	O
or	O
phosphorylation	O
exist	O
between	O
the	O
fibroblast	O
ASA	S-Protein
from	O
IIIa	O
and	O
IV	O
(	O
a	O
)	O
individuals	O
.	O

The	O
finding	O
that	O
both	O
fibroblasts	O
and	O
platelets	O
exhibit	O
related	O
electrophoretic	O
isoform	O
patterns	O
characteristic	O
of	O
the	O
donor	O
'	O
s	O
ASA	S-Protein
type	O
allows	O
for	O
the	O
use	O
of	O
fibroblasts	O
to	O
study	O
the	O
impact	O
of	O
ethanol	O
on	O
the	O
metabolism	O
of	O
cells	O
possessing	O
different	O
ASA	S-Protein
types	O
.	O

Purification	O
and	O
characterization	O
of	O
Kurloff	O
cell	O
sialoglycoproteins	O
with	O
acid	O
phosphatase	O
activity	O
.	O

The	O
major	O
alpha	O
2	O
-	O
6	O
sialoglycoproteins	O
in	O
detergent	O
-	O
extracts	O
of	O
Kurloff	O
cells	O
were	O
purified	O
by	O
anion	O
-	O
exchange	O
and	O
Sambucus	O
nigra	O
agglutinin	O
-	O
affinity	O
chromatographies	O
.	O

The	O
similar	O
ultrastructural	O
localisations	O
of	O
(	O
1	O
)	O
S	O
.	O
nigra	O
agglutinin	O
-	O
gold	O
conjugates	O
and	O
(	O
2	O
)	O
acid	O
phosphatase	O
activities	O
on	O
the	O
Kurloff	O
body	O
and	O
particularly	O
on	O
its	O
myelin	O
figures	O
indicated	O
that	O
the	O
major	O
alpha	O
2	O
-	O
6	O
sialoglycoproteins	O
of	O
the	O
Kurloff	O
cell	O
had	O
acid	O
phosphatase	O
activity	O
.	O

Two	O
-	O
dimensional	O
electrophoresis	O
showed	O
that	O
these	O
tartrate	O
-	O
sensitive	O
phosphatases	O
corresponded	O
to	O
2	O
acidic	O
(	O
pI	O
3	O
.	O
4	O
-	O
3	O
.	O
7	O
)	O
polypeptides	O
of	O
36	O
and	O
34	O
kDa	O
.	O

Hydrolysis	O
with	O
peptide	B-Protein
-	I-Protein
N	I-Protein
-	I-Protein
glycosidases	I-Protein
F	E-Protein
gave	O
a	O
33	O
kDa	O
apoprotein	O
rich	O
in	O
alanine	O
,	O
glutamic	O
acid	O
,	O
tyrosine	O
and	O
lysin	O
.	O

A	O
lectin	O
-	O
affinity	O
study	O
demonstrated	O
that	O
they	O
contained	O
hybrid	O
type	O
bisected	O
and	O
fucosylated	O
N	O
-	O
linked	O
oligosaccharides	O
.	O

Cytotoxic	O
properties	O
were	O
previously	O
attributed	O
to	O
Kurloff	O
cells	O
and	O
other	O
studies	O
suggested	O
that	O
not	O
only	O
acid	O
phosphatases	O
but	O
also	O
alpha	O
2	O
-	O
6	O
-	O
linked	O
sialic	O
acid	O
residues	O
themselves	O
may	O
participate	O
in	O
natural	O
killer	O
activity	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
sixth	O
structural	O
protein	O
of	O
Lelystad	O
virus	O
:	O
the	O
glycoprotein	O
GP2	S-Protein
encoded	O
by	O
ORF2	S-Protein
is	O
incorporated	O
in	O
virus	O
particles	O
.	O

Previously	O
we	O
have	O
shown	O
that	O
Lelystad	O
virus	O
(	O
LV	O
)	O
contains	O
five	O
structural	O
proteins	O
,	O
a	O
nucleocapsid	O
protein	O
N	S-Protein
,	O
an	O
integral	O
membrane	O
protein	O
M	S-Protein
,	O
and	O
three	O
glycoproteins	O
GP3	S-Protein
,	O
GP4	S-Protein
,	O
and	O
GP5	S-Protein
.	O

In	O
this	O
study	O
we	O
identified	O
a	O
sixth	O
structural	O
protein	O
of	O
Lelystad	O
virus	O
.	O

The	O
protein	O
has	O
an	O
apparent	O
molecular	O
weight	O
of	O
29	O
to	O
30	O
kDa	O
,	O
was	O
recognized	O
by	O
an	O
ORF2	S-Protein
-	O
specific	O
antipeptide	O
serum	O
in	O
Western	O
immunoblotting	O
using	O
sucrose	O
gradient	O
purified	O
LV	O
virions	O
,	O
and	O
was	O
shown	O
to	O
be	O
N	O
-	O
glycosylated	O
.	O

It	O
was	O
therefore	O
designated	O
GP2	S-Protein
.	O

The	O
GP2	S-Protein
protein	O
was	O
also	O
immunoprecipitated	O
by	O
ORF2	S-Protein
-	O
specific	O
antipeptide	O
serum	O
from	O
lysates	O
and	O
extracellular	O
virus	O
of	O
CL2621	O
cells	O
infected	O
with	O
LV	O
.	O

A	O
fraction	O
of	O
the	O
GP2	S-Protein
protein	O
present	O
in	O
these	O
lysates	O
contained	O
an	O
intrachain	O
disulfide	O
bond	O
.	O

Endoglycosidase	B-Protein
H	E-Protein
treatment	O
of	O
immunoprecipitates	O
indicated	O
that	O
the	O
endoglycosidase	B-Protein
H	E-Protein
-	O
sensitive	O
N	O
-	O
glycans	O
of	O
the	O
GP2	S-Protein
protein	O
become	O
endoglycosidase	B-Protein
H	E-Protein
-	O
resistant	O
during	O
passage	O
through	O
the	O
Golgi	O
compartment	O
in	O
cells	O
infected	O
with	O
LV	O
.	O

In	O
contrast	O
,	O
the	O
N	O
-	O
glycans	O
of	O
the	O
GP2	S-Protein
protein	O
expressed	O
individually	O
in	O
a	O
recombinant	O
Semliki	O
Forest	O
virus	O
remained	O
endoglycosidase	B-Protein
H	E-Protein
-	O
sensitive	O
,	O
indicating	O
that	O
the	O
GP2	S-Protein
protein	O
was	O
retained	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O

LV	O
is	O
the	O
first	O
arterivirus	O
which	O
has	O
been	O
demonstrated	O
to	O
contain	O
six	O
virion	O
-	O
associated	O
proteins	O
,	O
one	O
nucleocapsid	B-Protein
protein	E-Protein
,	O
one	O
integral	O
membrane	B-Protein
protein	E-Protein
,	O
and	O
four	O
glycoproteins	O
.	O

Comparison	O
of	O
O	O
-	O
linked	O
carbohydrate	O
chains	O
in	O
MUC	B-Protein
-	I-Protein
1	E-Protein
mucin	O
from	O
normal	O
breast	O
epithelial	O
cell	O
lines	O
and	O
breast	O
carcinoma	O
cell	O
lines	O
.	O

Demonstration	O
of	O
simpler	O
and	O
fewer	O
glycan	O
chains	O
in	O
tumor	O
cells	O
.	O

MUC	B-Protein
-	I-Protein
1	E-Protein
mucin	O
is	O
considered	O
to	O
be	O
aberrantly	O
glycosylated	O
in	O
breast	O
,	O
ovary	O
,	O
and	O
other	O
carcinomas	O
in	O
comparison	O
with	O
mucin	O
from	O
corresponding	O
normal	O
tissues	O
.	O

In	O
order	O
to	O
clarify	O
these	O
differences	O
in	O
glycosylation	O
,	O
we	O
have	O
compared	O
the	O
O	O
-	O
linked	O
carbohydrate	O
chains	O
from	O
MUC	B-Protein
-	I-Protein
1	E-Protein
immunoprecipitated	O
from	O
[	O
3H	O
]	O
GlcN	O
-	O
labeled	O
breast	O
epithelial	O
cell	O
lines	O
(	O
MMSV1	O
-	O
1	O
,	O
MTSV1	O
-	O
7	O
,	O
and	O
HB	O
-	O
2	O
)	O
derived	O
from	O
cells	O
cultured	O
from	O
human	O
milk	O
,	O
with	O
three	O
breast	O
cancer	O
cell	O
lines	O
(	O
MCF	O
-	O
7	O
,	O
BT	O
-	O
20	O
,	O
and	O
T47D	O
)	O
.	O

Analysis	O
by	O
high	O
pH	O
anion	O
chromatography	O
showed	O
that	O
the	O
normal	O
cell	O
lines	O
had	O
a	O
higher	O
ratio	O
of	O
GlcN	O
/	O
GalN	O
and	O
more	O
complex	O
oligosaccharide	O
profiles	O
than	O
the	O
cancer	O
cell	O
lines	O
.	O

Structural	O
analyses	O
were	O
carried	O
out	O
on	O
the	O
oligosaccharides	O
from	O
MTSV1	O
-	O
7	O
and	O
T47D	O
MUC	B-Protein
-	I-Protein
1	E-Protein
,	O
and	O
the	O
following	O
structures	O
were	O
proposed	O
.	O

MUC	B-Protein
-	I-Protein
1	E-Protein
from	O
T47D	O
had	O
rather	O
a	O
simple	O
glycosylation	O
pattern	O
,	O
with	O
NeuAcalpha2	O
-	O
3Galbeta1	O
-	O
3GalNAc	O
-	O
ol	O
,	O
Galbeta1	O
-	O
3GalNAc	O
-	O
ol	O
,	O
and	O
GalNAc	O
-	O
ol	O
predominating	O
;	O
in	O
contrast	O
,	O
MUC	B-Protein
-	I-Protein
1	E-Protein
from	O
MTSV1	O
-	O
7	O
had	O
more	O
complex	O
structures	O
,	O
including	O
a	O
number	O
of	O
disialo	O
,	O
core	O
2	O
species	O
,	O
i	O
.	O
e	O
.	O
NeuAcalpha2	O
-	O
3Galbeta1	O
-	O
4GlcNAcbeta1	O
-	O
6	O
[	O
NeuAcalpha2	O
-	O
3Galbeta1	O
-	O
3	O
]	O
GalNAc	O
-	O
ol	O
and	O
NeuAcalpha2	O
-	O
3Galbeta1	O
-	O
4GlcNAcbeta1	O
-	O
6	O
[	O
NeuAcalpha2	O
-	O
3Galbeta1	O
-	O
4GlcNAcbet	O
a1	O
-	O
3Galbeta1	O
-	O
3	O
]	O
GalNAc	O
-	O
ol	O
.	O

Double	O
-	O
labeling	O
experiments	O
with	O
[	O
3H	O
]	O
GlcN	O
and	O
14C	O
-	O
aminoacids	O
and	O
analysis	O
of	O
GalNAc	O
or	O
GalNAc	O
-	O
ol	O
:	O
protein	O
ratios	O
in	O
MUC	B-Protein
-	I-Protein
1	E-Protein
showed	O
that	O
there	O
was	O
also	O
a	O
significant	O
difference	O
in	O
the	O
degree	O
of	O
glycosylation	O
of	O
the	O
mucin	O
between	O
the	O
two	O
cell	O
types	O
.	O

We	O
conclude	O
that	O
MUC	B-Protein
-	I-Protein
1	E-Protein
from	O
breast	O
cancer	O
cell	O
lines	O
has	O
simpler	O
,	O
and	O
fewer	O
,	O
carbohydrate	O
chains	O
than	O
MUC	B-Protein
-	I-Protein
1	E-Protein
from	O
normal	O
breast	O
epithelial	O
cells	O
,	O
and	O
that	O
these	O
differences	O
,	O
combined	O
or	O
separately	O
,	O
explain	O
the	O
differential	O
tumor	O
specificity	O
of	O
some	O
MUC	B-Protein
-	I-Protein
1	E-Protein
antibodies	O
and	O
T	O
cells	O
.	O

5	O
-	O
Formyltetrahydrofolate	O
regulates	O
homocysteine	O
remethylation	O
in	O
human	O
neuroblastoma	O
.	O

The	O
metabolic	O
role	O
of	O
5	O
-	O
formyltetrahydrofolate	O
is	O
not	O
known	O
;	O
however	O
,	O
it	O
is	O
an	O
inhibitor	O
of	O
several	O
folate	O
-	O
dependent	O
enzymes	O
including	O
serine	O
hydroxymethyltransferase	O
.	O

Methenyltetrahydrofolate	B-Protein
synthetase	E-Protein
(	O
MTHFS	S-Protein
)	O
is	O
the	O
only	O
enzyme	O
known	O
to	O
metabolize	O
5	O
-	O
formyltetrahydrofolate	O
and	O
catalyzes	O
the	O
conversion	O
of	O
5	O
-	O
formyltetrahydrofolate	O
to	O
5	O
,	O
10	O
-	O
methenyltetrahydrofolate	O
.	O

In	O
order	O
to	O
address	O
the	O
function	O
of	O
5	O
-	O
formyltetrahydrofolate	O
in	O
mammalian	O
cells	O
,	O
intracellular	O
5	O
-	O
formyltetrahydrofolate	O
levels	O
were	O
depleted	O
in	O
human	O
5Y	O
neuroblastoma	O
by	O
overexpressing	O
the	O
human	O
cDNA	O
encoding	O
MTHFS	S-Protein
(	O
5YMTHFS	O
cells	O
)	O
.	O

When	O
cultured	O
with	O
2	O
mM	O
exogenous	O
glycine	O
,	O
the	O
intracellular	O
serine	O
and	O
glycine	O
concentrations	O
in	O
5YMTHFS	O
cells	O
are	O
elevated	O
approximately	O
3	O
-	O
fold	O
relative	O
to	O
5Y	O
cells	O
;	O
5YMTHFS	O
cells	O
do	O
not	O
contain	O
measurable	O
levels	O
of	O
free	O
methionine	O
and	O
display	O
a	O
30	O
-	O
40	O
%	O
decrease	O
in	O
cell	O
proliferation	O
rates	O
compared	O
with	O
5Y	O
cells	O
.	O

Medium	O
supplemented	O
with	O
pharmacological	O
levels	O
of	O
exogenous	O
folinate	O
or	O
methionine	O
ameliorated	O
the	O
glycine	O
induced	O
growth	O
inhibition	O
.	O

Analysis	O
of	O
the	O
folate	O
derivatives	O
demonstrated	O
that	O
5	O
-	O
methyltetrahydrofolate	O
accounts	O
for	O
30	O
%	O
of	O
total	O
cellular	O
folate	O
in	O
5Y	O
cells	O
when	O
cultured	O
with	O
5	O
mM	O
exogenous	O
glycine	O
.	O

5YMTHFS	O
cells	O
do	O
not	O
contain	O
detectable	O
levels	O
of	O
5	O
-	O
methyltetrahydrofolate	O
under	O
the	O
same	O
culture	O
conditions	O
.	O

These	O
results	O
suggest	O
that	O
5	O
-	O
formyltetrahydrofolate	O
inhibits	O
serine	O
hydroxymethyltransferase	O
activity	O
in	O
vivo	O
and	O
that	O
serine	O
synthesis	O
and	O
homocysteine	O
remethylation	O
compete	O
for	O
one	O
-	O
carbon	O
units	O
in	O
the	O
cytoplasm	O
.	O

Biochemical	O
analysis	O
of	O
a	O
bladder	O
-	O
cancer	O
-	O
associated	O
mucin	O
:	O
structural	O
features	O
and	O
epitope	O
characterization	O
.	O

Three	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
,	O
M344	O
,	O
M300	O
and	O
M75	O
,	O
were	O
shown	O
to	O
define	O
a	O
unique	O
tumour	O
-	O
associated	O
antigen	O
(	O
TAA	O
)	O
of	O
superficial	O
bladder	O
tumours	O
.	O

The	O
antigenic	O
determinants	O
are	O
expressed	O
on	O
a	O
very	O
-	O
high	O
-	O
molecular	O
-	O
mass	O
component	O
and	O
,	O
in	O
about	O
50	O
%	O
of	O
the	O
positive	O
samples	O
,	O
one	O
determinant	O
is	O
also	O
detected	O
on	O
a	O
62	O
kDa	O
molecular	O
species	O
,	O
observed	O
only	O
under	O
reducing	O
conditions	O
.	O

The	O
objectives	O
of	O
the	O
present	O
study	O
were	O
to	O
characterize	O
further	O
this	O
TAA	O
by	O
analysing	O
(	O
1	O
)	O
the	O
biochemical	O
nature	O
of	O
the	O
epitopes	O
recognized	O
by	O
the	O
three	O
mAbs	O
,	O
and	O
(	O
2	O
)	O
the	O
biochemical	O
and	O
structural	O
features	O
of	O
the	O
molecule	O
bearing	O
them	O
.	O

The	O
antigenicity	O
was	O
resistant	O
to	O
heat	O
denaturation	O
,	O
trypsin	S-Protein
and	O
alpha	B-Protein
-	I-Protein
chymotrypsin	E-Protein
treatments	O
but	O
highly	O
sensitive	O
to	O
papain	S-Protein
and	O
Pronase	O
digestion	O
.	O

NaIO4	O
oxidation	O
decreased	O
reactivity	O
to	O
mAbs	O
M344	O
and	O
M300	O
but	O
enhanced	O
reactivity	O
to	O
mAb	O
M75	O
.	O

The	O
three	O
determinants	O
were	O
insensitive	O
to	O
beta	B-Protein
-	I-Protein
galactosidase	E-Protein
and	O
alpha	O
-	O
L	O
-	O
fucosidase	O
but	O
were	O
sensitive	O
to	O
Vibrio	O
cholerae	O
neuraminidase	S-Protein
.	O

None	O
of	O
the	O
three	O
mAbs	O
reacted	O
with	O
ovine	O
,	O
bovine	O
or	O
porcine	O
submaxillary	O
mucins	O
.	O

Deglycosylation	O
with	O
O	O
-	O
glycosidase	O
or	O
trifluoromethanesulphonic	O
acid	O
completely	O
abolished	O
the	O
reactivity	O
of	O
the	O
mAbs	O
whereas	O
N	B-Protein
-	I-Protein
glycosidase	I-Protein
F	E-Protein
deglycosylation	O
had	O
no	O
appreciable	O
effect	O
.	O

The	O
presence	O
on	O
the	O
molecule	O
of	O
cryptic	O
Gal	O
(	O
beta	O
(	O
1	O
-	O
3	O
)	O
)	O
GalNAc	O
as	O
a	O
major	O
core	O
disaccharide	O
was	O
demonstrated	O
by	O
a	O
heterologous	O
sandwich	O
assay	O
using	O
mAb	O
M75	O
and	O
peanut	O
agglutinin	S-Protein
.	O

Thiol	O
reduction	O
using	O
beta	O
-	O
mercaptoethanol	O
increased	O
mobility	O
of	O
the	O
high	O
-	O
molecular	O
-	O
mass	O
component	O
in	O
polyacrylamide	O
gels	O
.	O

We	O
thus	O
conclude	O
that	O
mAbs	O
M344	O
and	O
M300	O
react	O
with	O
sialylated	O
carbohydrate	O
epitopes	O
,	O
and	O
mAb	O
M75	O
reacts	O
with	O
a	O
partially	O
cryptic	O
and	O
periodate	O
-	O
resistant	O
sialylated	O
epitope	O
expressed	O
on	O
a	O
typical	O
secreted	O
high	O
-	O
molecular	O
-	O
mass	O
oligomeric	O
mucin	O
which	O
we	O
named	O
MAUB	S-Protein
for	O
mucin	O
antigen	O
of	O
the	O
urinary	O
bladder	O
.	O

Cloning	O
and	O
characterization	O
of	O
a	O
calcium	O
-	O
sensing	O
receptor	O
from	O
the	O
hypercalcemic	O
New	O
Zealand	O
white	O
rabbit	O
reveals	O
unaltered	O
responsiveness	O
to	O
extracellular	O
calcium	O
.	O

The	O
extracellular	B-Protein
Ca2	I-Protein
+	I-Protein
(	I-Protein
Ca	I-Protein
(	I-Protein
0	I-Protein
)	I-Protein
2	I-Protein
+	I-Protein
)	I-Protein
-	I-Protein
sensing	I-Protein
receptor	E-Protein
(	O
CaR	S-Protein
)	O
recently	O
cloned	O
from	O
mammalian	O
parathyroid	O
,	O
kidney	O
,	O
brain	O
,	O
and	O
thyroid	O
plays	O
a	O
central	O
role	O
in	O
maintaining	O
near	O
constancy	O
of	O
Ca	O
(	O
0	O
)	O
2	O
+	O
.	O

We	O
previously	O
showed	O
that	O
the	O
hypercalcemia	O
normally	O
present	O
in	O
New	O
Zealand	O
white	O
rabbits	O
is	O
associated	O
with	O
an	O
elevated	O
set	O
point	O
for	O
Ca	O
(	O
02	O
+	O
)	O
-	O
regulated	O
PTH	S-Protein
release	O
(	O
the	O
level	O
of	O
Ca	O
(	O
0	O
)	O
2	O
+	O
half	O
-	O
maximally	O
inhibiting	O
hormonal	O
secretion	O
)	O
.	O

This	O
observation	O
suggested	O
an	O
alteration	O
in	O
the	O
Ca	O
(	O
02	O
+	O
)	O
-	O
sensing	O
mechanism	O
in	O
the	O
rabbit	O
parathyroid	O
,	O
a	O
possibility	O
we	O
have	O
now	O
pursued	O
by	O
isolating	O
and	O
characterizing	O
the	O
rabbit	O
homolog	O
of	O
the	O
CaR	S-Protein
.	O

The	O
cloned	O
rabbit	O
kidney	O
CaR	S-Protein
(	O
RabCaR	S-Protein
)	O
shares	O
a	O
high	O
degree	O
of	O
overall	O
homology	O
(	O
>	O
90	O
%	O
amino	O
acid	O
identity	O
)	O
with	O
the	O
bovine	O
,	O
human	O
,	O
and	O
rat	O
CaRs	S-Protein
,	O
although	O
it	O
differs	O
slightly	O
in	O
several	O
regions	O
of	O
the	O
extracellular	O
domain	O
potentially	O
involved	O
in	O
binding	O
ligands	O
.	O

By	O
Northern	O
analysis	O
and	O
/	O
or	O
immunohistochemistry	O
,	O
a	O
similar	O
or	O
identical	O
receptor	O
is	O
also	O
expressed	O
in	O
parathyroid	O
,	O
thyroid	O
C	O
cells	O
,	O
small	O
and	O
large	O
intestine	O
,	O
and	O
in	O
the	O
thick	O
ascending	O
limb	O
and	O
collecting	O
ducts	O
of	O
the	O
kidney	O
.	O

When	O
expressed	O
transiently	O
in	O
HEK293	O
cells	O
and	O
assayed	O
functionally	O
through	O
CaR	S-Protein
agonist	O
-	O
evoked	O
increases	O
in	O
Ca	O
(	O
i	O
)	O
2	O
+	O
,	O
the	O
rabbit	O
CaR	S-Protein
shows	O
apparent	O
affinities	O
for	O
Ca	O
(	O
0	O
)	O
2	O
+	O
,	O
Mg	O
(	O
0	O
)	O
2	O
+	O
,	O
and	O
Gd	O
(	O
0	O
)	O
3	O
+	O
that	O
are	O
indistinguishable	O
from	O
those	O
observed	O
in	O
studies	O
carried	O
out	O
concomitantly	O
using	O
the	O
human	O
CaR	S-Protein
.	O

Therefore	O
,	O
at	O
least	O
as	O
assessed	O
by	O
its	O
ability	O
to	O
increase	O
Ca	O
(	O
i	O
)	O
2	O
+	O
when	O
expressed	O
in	O
HEK293	O
cells	O
,	O
the	O
intrinsic	O
functional	O
properties	O
of	O
the	O
rabbit	O
CaR	S-Protein
cannot	O
explain	O
the	O
hypercalcemia	O
observed	O
in	O
vivo	O
in	O
the	O
New	O
Zealand	O
white	O
rabbit	O
.	O

Identification	O
of	O
N	O
(	O
G	O
)	O
-	O
methylarginine	O
residues	O
in	O
human	O
heterogeneous	O
RNP	O
protein	O
A1	S-Protein
:	O
Phe	O
/	O
Gly	O
-	O
Gly	O
-	O
Gly	O
-	O
Arg	O
-	O
Gly	O
-	O
Gly	O
-	O
Gly	O
/	O
Phe	O
is	O
a	O
preferred	O
recognition	O
motif	O
.	O

Three	O
sites	O
of	O
N	O
(	O
G	O
)	O
,	O
N	O
(	O
G	O
)	O
-	O
arginine	O
methylation	O
have	O
been	O
located	O
at	O
residues	O
205	O
,	O
217	O
,	O
and	O
224	O
in	O
the	O
glycine	O
-	O
rich	O
,	O
COOH	O
-	O
terminal	O
one	O
-	O
third	O
of	O
the	O
HeLa	O
A1	S-Protein
heterogeneous	O
ribonucleoprotein	O
.	O

Together	O
with	O
the	O
previously	O
determined	O
dimethylated	O
arginine	O
at	O
position	O
193	O
[	O
Williams	O
et	O
al	O
.	O
,	O
(	O
1985	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
U	O
.	O
S	O
.	O
A	O
.	O
82	O
,	O
5666	O
-	O
5670	O
]	O
,	O
it	O
is	O
evident	O
that	O
all	O
four	O
sites	O
fall	O
within	O
a	O
span	O
of	O
sequence	O
between	O
residues	O
190	O
and	O
233	O
that	O
contains	O
multiple	O
Arg	O
-	O
Gly	O
-	O
(	O
Gly	O
)	O
sequences	O
interspersed	O
with	O
phenylalanine	O
residues	O
.	O

These	O
RGG	O
boxes	O
have	O
been	O
postulated	O
to	O
represent	O
an	O
RNA	O
binding	O
motif	O
[	O
Kiledjian	O
and	O
Dreyfuss	O
(	O
1992	O
)	O
EMBO	O
J	O
.	O
11	O
,	O
2655	O
-	O
2664	O
]	O
.	O

Dimethylation	O
of	O
HeLa	O
A1	S-Protein
appears	O
to	O
be	O
quantitative	O
at	O
each	O
of	O
the	O
four	O
positions	O
.	O

Arginines	O
205	O
and	O
224	O
have	O
been	O
methylated	O
in	O
vitro	O
by	O
a	O
nuclear	B-Protein
protein	I-Protein
arginine	I-Protein
methyltransferase	E-Protein
using	O
recombinant	O
(	O
unmethylated	O
)	O
A1	S-Protein
as	O
substrate	O
.	O

This	O
suggests	O
A1	S-Protein
may	O
be	O
an	O
in	O
vivo	O
substrate	O
for	O
this	O
enzyme	O
.	O

Examination	O
of	O
sequences	O
surrounding	O
the	O
sites	O
of	O
methylation	O
in	O
A1	S-Protein
along	O
with	O
a	O
compilation	O
from	O
the	O
literature	O
of	O
sites	O
that	O
have	O
been	O
identified	O
in	O
other	O
nuclear	O
RNA	O
binding	O
proteins	O
suggests	O
a	O
methylase	O
-	O
preferred	O
recognition	O
sequence	O
of	O
Phe	O
/	O
Gly	O
-	O
Gly	O
-	O
Gly	O
-	O
Arg	O
-	O
Gly	O
-	O
Gly	O
-	O
Gly	O
/	O
Phe	O
,	O
with	O
the	O
COOH	O
-	O
terminal	O
flanking	O
glycine	O
being	O
obligatory	O
.	O

Taken	O
together	O
with	O
data	O
in	O
the	O
literature	O
,	O
identification	O
of	O
the	O
sites	O
of	O
A1	S-Protein
arginine	O
methylation	O
strongly	O
suggests	O
a	O
role	O
for	O
this	O
modification	O
in	O
modulating	O
the	O
interaction	O
of	O
A1	S-Protein
with	O
nucleic	O
acids	O
.	O

Plasma	O
sialyltransferase	O
levels	O
in	O
psychiatric	O
disorders	O
as	O
a	O
possible	O
indicator	O
of	O
HPA	O
axis	O
function	O
.	O

A	O
dysfunction	O
in	O
the	O
regulation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
,	O
possibly	O
attributed	O
to	O
a	O
change	O
in	O
glucocorticoid	B-Protein
receptor	E-Protein
(	O
GR	S-Protein
)	O
functionality	O
,	O
has	O
been	O
implicated	O
in	O
depression	O
.	O

We	O
have	O
measured	O
both	O
lymphocyte	O
GR	S-Protein
receptor	O
binding	O
parameters	O
and	O
plasma	O
sialyltransferase	O
activity	O
,	O
as	O
a	O
biochemical	O
marker	O
of	O
GR	S-Protein
function	O
,	O
in	O
two	O
groups	O
of	O
patients	O
suffering	O
from	O
depression	O
or	O
schizophrenia	O
and	O
in	O
a	O
group	O
of	O
age	O
-	O
and	O
sex	O
-	O
matched	O
controls	O
.	O

While	O
there	O
was	O
a	O
significant	O
increase	O
in	O
plasma	O
cortisol	O
levels	O
in	O
the	O
depressed	O
group	O
,	O
there	O
were	O
no	O
changes	O
in	O
the	O
lymphocyte	O
GR	S-Protein
binding	O
parameters	O
(	O
K	O
(	O
m	O
)	O
and	O
Bmax	O
)	O
.	O

There	O
was	O
,	O
however	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	O
sialyltransferase	O
:	O
cortisol	O
ratio	O
in	O
the	O
depressed	O
group	O
suggesting	O
an	O
inability	O
of	O
the	O
raised	O
cortisol	O
levels	O
to	O
induce	O
enzyme	O
expression	O
and	O
this	O
ratio	O
may	O
provide	O
a	O
useful	O
biochemical	O
marker	O
of	O
cortisol	O
receptor	O
function	O
.	O

Although	O
there	O
was	O
an	O
increase	O
in	O
the	O
plasma	O
activity	O
of	O
the	O
alpha	O
2	O
,	O
6	O
sialyltransferase	O
isozyme	O
in	O
the	O
schizophrenic	O
group	O
,	O
no	O
other	O
changes	O
were	O
determined	O
.	O

Therefore	O
,	O
while	O
the	O
total	O
plasma	O
sialyltransferase	O
:	O
cortisol	O
ratio	O
reflects	O
HPA	O
axis	O
function	O
,	O
alterations	O
in	O
specific	O
isozyme	O
activity	O
may	O
also	O
be	O
associated	O
with	O
other	O
CNS	O
disease	O
states	O
.	O

Expression	O
and	O
characterization	O
of	O
the	O
human	O
erythrocyte	O
anion	O
exchanger	O
in	O
a	O
baculovirus	O
/	O
Sf	O
-	O
9	O
cell	O
system	O
.	O

The	O
human	O
erythrocyte	B-Protein
anion	I-Protein
-	I-Protein
exchange	I-Protein
protein	E-Protein
(	O
HAE1	S-Protein
)	O
has	O
been	O
expressed	O
in	O
insect	O
Sf	O
-	O
9	O
cells	O
using	O
a	O
recombinant	O
baculovirus	O
.	O

We	O
subcloned	O
the	O
full	O
-	O
length	O
cDNA	O
encoding	O
HAE1	S-Protein
into	O
the	O
baculovirus	O
expression	O
vector	O
pVL1392	O
and	O
cotransfected	O
Sf	O
-	O
9	O
cells	O
with	O
the	O
recombinant	O
vector	O
and	O
wild	O
-	O
type	O
AcMNPV	O
DNA	O
to	O
obtain	O
recombinant	O
baculovirus	O
.	O

The	O
expressed	O
protein	O
was	O
targeted	O
to	O
the	O
Sf	O
-	O
9	O
plasma	O
membrane	O
at	O
an	O
apparent	O
density	O
of	O
approximately	O
0	O
.	O
5	O
x	O
10	O
(	O
6	O
)	O
copies	O
/	O
cell	O
as	O
determined	O
by	O
quantitative	O
autoradiography	O
using	O
an	O
HAE1	S-Protein
-	O
specific	O
monoclonal	O
antibody	O
.	O

Unlike	O
native	O
HAE1	S-Protein
,	O
the	O
expressed	O
protein	O
was	O
not	O
glycosylated	O
.	O

Transport	O
studies	O
with	O
HAE1	S-Protein
-	O
recombinant	O
-	O
infected	O
Sf	O
-	O
9	O
cells	O
showed	O
saturable	O
[	O
Km	O
(	O
Cl	O
-	O
)	O
=	O
44	O
mM	O
;	O
Vmax	O
(	O
Cl	O
-	O
)	O
=	O
48	O
mEq	O
/	O
liter	O
of	O
cell	O
waters	O
min	O
]	O
and	O
H2DIDS	O
-	O
inhibitable	O
(	O
K	O
(	O
O	O
.	O
5	O
)	O
=	O
34	O
microM	O
)	O
36Cl	O
-	O
uptake	O
that	O
was	O
not	O
present	O
in	O
uninfected	O
cells	O
.	O

We	O
also	O
found	O
that	O
extracellular	O
SO4	O
(	O
2	O
-	O
)	O
reduced	O
36Cl	O
-	O
influx	O
[	O
K	O
(	O
0	O
.	O
5	O
)	O
(	O
(	O
SO4	O
)	O
2	O
-	O
)	O
=	O
26	O
mM	O
]	O
,	O
presumably	O
through	O
substrate	O
competition	O
as	O
in	O
erythrocytes	O
.	O

Finally	O
,	O
we	O
observed	O
that	O
H2DIDS	O
-	O
inhibitable	O
36Cl	O
-	O
efflux	O
was	O
reduced	O
by	O
77	O
%	O
in	O
the	O
nominal	O
absence	O
of	O
a	O
suitable	O
counter	O
-	O
anion	O
in	O
the	O
external	O
solution	O
(	O
HCO3	O
(	O
-	O
)	O
-	O
free	O
,	O
all	O
-	O
glucuronate	O
medium	O
)	O
,	O
thereby	O
providing	O
strong	O
evidence	O
for	O
an	O
obligatory	O
exchange	O
mechanism	O
.	O

We	O
conclude	O
that	O
there	O
is	O
high	O
-	O
level	O
expression	O
of	O
+	O
+	O
+	O
HAE1	S-Protein
functional	O
activity	O
in	O
recombinant	O
baculovirus	O
-	O
infected	O
Sf	O
-	O
9	O
cells	O
and	O
that	O
this	O
system	O
will	O
prove	O
useful	O
for	O
kinetic	O
and	O
structural	O
analyses	O
of	O
the	O
HAE1	S-Protein
protein	O
.	O

Site	O
-	O
specific	O
de	O
-	O
N	O
-	O
glycosylation	O
of	O
diglycosylated	O
ovalbumin	S-Protein
in	O
hen	O
oviduct	O
by	O
endogenous	O
peptide	B-Protein
:	I-Protein
N	I-Protein
-	I-Protein
glycanase	E-Protein
as	O
a	O
quality	O
control	O
system	O
for	O
newly	O
synthesized	O
proteins	O
.	O

Hen	O
ovalbumin	S-Protein
(	O
OVA	S-Protein
)	O
is	O
known	O
to	O
exist	O
as	O
a	O
singly	O
N	O
-	O
glycosylated	O
form	O
with	O
a	O
glycan	O
chain	O
on	O
Asn	O
-	O
292	O
in	O
egg	O
white	O
.	O

Previous	O
studies	O
showed	O
that	O
di	O
-	O
N	O
-	O
glycosylated	O
form	O
of	O
OVA	S-Protein
[	O
Di	O
-	O
OVA	S-Protein
;	O
CHO	O
-	O
Asn	O
-	O
292	O
/	O
CHO	O
-	O
Asn	O
-	O
311	O
(	O
CHO	O
,	O
N	O
-	O
glycan	O
chain	O
)	O
]	O
,	O
which	O
has	O
two	O
N	O
-	O
glycan	O
chains	O
on	O
Asn	O
-	O
292	O
and	O
Asn	O
-	O
311	O
,	O
was	O
expressed	O
only	O
transiently	O
in	O
hen	O
oviduct	O
.	O

Di	O
-	O
OVA	S-Protein
was	O
not	O
found	O
in	O
egg	O
white	O
,	O
suggesting	O
that	O
this	O
form	O
cannot	O
be	O
secreted	O
normally	O
and	O
may	O
possibly	O
be	O
converted	O
to	O
mono	O
-	O
N	O
-	O
glycosylated	O
OVA	S-Protein
(	O
CHO	O
-	O
Asn	O
-	O
292	O
/	O
Asp	O
-	O
311	O
)	O
by	O
the	O
action	O
of	O
peptide	B-Protein
:	I-Protein
N	I-Protein
-	I-Protein
glycanase	E-Protein
(	O
PNGase	S-Protein
)	O
during	O
synthesis	O
and	O
secretion	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
the	O
putative	O
PNGase	S-Protein
activity	O
in	O
the	O
homogenate	O
of	O
hen	O
oviduct	O
,	O
purified	O
1	O
,	O
000	O
-	O
fold	O
,	O
and	O
designated	O
as	O
PNGase	B-Protein
HO	E-Protein
.	O

We	O
examined	O
the	O
reactivity	O
of	O
Di	O
-	O
OVA	S-Protein
to	O
PNGase	B-Protein
HO	E-Protein
and	O
found	O
that	O
this	O
enzyme	O
site	O
-	O
specifically	O
cleaved	O
off	O
the	O
glycan	O
chain	O
at	O
Asn	O
-	O
311	O
to	O
convert	O
Di	O
-	O
OVA	S-Protein
into	O
the	O
mono	O
-	O
N	O
-	O
glycosylated	O
form	O
(	O
CHO	O
-	O
Asn	O
-	O
292	O
/	O
Asp	O
-	O
311	O
)	O
.	O

In	O
contrast	O
,	O
this	O
enzyme	O
was	O
found	O
not	O
to	O
act	O
on	O
the	O
mono	O
-	O
N	O
-	O
glycosylated	O
OVA	S-Protein
(	O
CHO	O
-	O
Asn	O
-	O
292	O
/	O
Asn	O
-	O
311	O
)	O
found	O
in	O
egg	O
white	O
when	O
it	O
was	O
tested	O
as	O
a	O
substrate	O
.	O

The	O
present	O
findings	O
support	O
our	O
view	O
that	O
de	O
-	O
N	O
-	O
glycosylation	O
catalyzed	O
by	O
PNGase	S-Protein
may	O
be	O
involved	O
in	O
quality	O
control	O
of	O
newly	O
synthesized	O
proteins	O
by	O
converting	O
its	O
diglycosylated	O
form	O
into	O
the	O
mono	O
-	O
N	O
-	O
glycosylated	O
form	O
that	O
can	O
be	O
secreted	O
.	O

However	O
,	O
the	O
alternative	O
possibility	O
that	O
de	O
-	O
N	O
-	O
glycosylation	O
may	O
trigger	O
cytosolic	O
degradation	O
of	O
the	O
aberrantly	O
glycosylated	O
glycoprotein	O
cannot	O
be	O
ruled	O
out	O
.	O

Alteration	O
of	O
the	O
kinetics	O
of	O
type	O
I	O
procollagen	O
synthesis	O
in	O
human	O
osteosarcoma	O
cells	O
by	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
.	O

The	O
kinetics	O
of	O
type	O
I	O
procollagen	O
synthesis	O
in	O
a	O
human	O
osteosarcoma	O
cell	O
line	O
,	O
MG	O
63	O
,	O
were	O
investigated	O
after	O
treatment	O
with	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2	O
D3	O
)	O
,	O
a	O
hormonal	O
inducer	O
of	O
phenotypic	O
differentiation	O
.	O

Pulse	O
label	O
and	O
chase	O
experiments	O
demonstrated	O
greatly	O
enhanced	O
production	O
and	O
more	O
rapid	O
reduction	O
of	O
intracellular	O
procollagen	O
molecules	O
in	O
the	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2	O
D3	O
-	O
treated	O
cells	O
as	O
compared	O
to	O
the	O
nontreated	O
case	O
.	O

After	O
a	O
chase	O
for	O
1	O
h	O
,	O
labeled	O
procollagen	O
was	O
reduced	O
by	O
nine	O
-	O
tenths	O
in	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2	O
D3	O
-	O
treated	O
cells	O
,	O
while	O
half	O
of	O
the	O
radioactivity	O
still	O
remained	O
in	O
nontreated	O
cells	O
.	O

The	O
expression	O
rate	O
of	O
type	O
I	O
collagen	O
,	O
which	O
was	O
examined	O
by	O
pulse	O
label	O
experiment	O
,	O
was	O
elevated	O
in	O
association	O
with	O
an	O
increase	O
in	O
the	O
mRNA	O
coding	O
for	O
the	O
type	B-Protein
I	I-Protein
collagen	I-Protein
alpha	I-Protein
1	E-Protein
chain	O
by	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2	O
D3	O
treatment	O
.	O

However	O
,	O
the	O
amount	O
of	O
intracellular	O
procollagen	O
present	O
after	O
4	O
h	O
continuous	O
labeling	O
was	O
almost	O
the	O
same	O
,	O
independent	O
of	O
the	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2	O
D3	O
treatment	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
strage	O
of	O
the	O
molecule	O
was	O
not	O
affected	O
.	O

The	O
results	O
therefore	O
suggest	O
an	O
increase	O
in	O
both	O
the	O
synthesis	O
and	O
secretion	O
of	O
type	O
I	O
collagen	O
.	O

The	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2	O
D3	O
treatment	O
was	O
also	O
found	O
to	O
induce	O
the	O
alpha	O
subunit	O
of	O
prolyl	O
4	O
-	O
hydroxylase	O
and	O
to	O
be	O
associated	O
with	O
an	O
elevated	O
level	O
of	O
hydroxyproline	O
in	O
the	O
procollagen	O
.	O

Moreover	O
,	O
gelatinase	B-Protein
B	E-Protein
-	O
resistant	O
procollagen	O
molecules	O
,	O
indicative	O
of	O
intracellular	O
procollagen	O
molecules	O
in	O
the	O
stable	O
triple	O
helical	O
form	O
,	O
were	O
detected	O
only	O
in	O
the	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2	O
D3	O
-	O
treated	O
cells	O
.	O

These	O
data	O
suggest	O
more	O
efficient	O
proline	O
hydroxylation	O
is	O
involved	O
in	O
rapid	O
secretion	O
of	O
procollagen	O
after	O
hormone	O
administration	O
.	O

The	O
present	O
evidence	O
points	O
to	O
posttranslational	O
control	O
of	O
procollagen	O
synthesis	O
.	O

Hereditary	O
hyperferritinemia	O
-	O
cataract	O
syndrome	O
:	O
relationship	O
between	O
phenotypes	O
and	O
specific	O
mutations	O
in	O
the	O
iron	O
-	O
responsive	O
element	O
of	O
ferritin	B-Protein
light	I-Protein
-	I-Protein
chain	E-Protein
mRNA	O
.	O

Recent	O
reports	O
have	O
described	O
families	O
in	O
whom	O
a	O
combination	O
of	O
elevated	O
serum	O
ferritin	O
not	O
related	O
to	O
iron	O
overload	O
and	O
congenital	O
nuclear	O
cataract	O
is	O
transmitted	O
as	O
an	O
autosomal	O
dominant	O
trait	O
.	O

We	O
have	O
studied	O
the	O
molecular	O
pathogenesis	O
of	O
hyperferritinemia	O
in	O
two	O
families	O
showing	O
different	O
phenotypic	O
expression	O
of	O
this	O
new	O
genetic	O
disorder	O
.	O

Serum	O
ferritin	O
levels	O
ranged	O
from	O
950	O
to	O
1	O
,	O
890	O
microg	O
/	O
L	O
in	O
affected	O
individuals	O
from	O
family	O
1	O
,	O
and	O
from	O
366	O
to	O
635	O
microg	O
/	O
L	O
in	O
those	O
from	O
family	O
2	O
.	O

Cataract	O
was	O
clinically	O
manifested	O
in	O
family	O
1	O
and	O
asymptomatic	O
in	O
family	O
2	O
.	O

By	O
using	O
monoclonal	O
antibodies	O
specific	O
for	O
the	O
H	S-Protein
and	O
L	B-Protein
ferritin	E-Protein
subunits	O
,	O
serum	O
ferritin	O
was	O
found	O
to	O
be	O
essentially	O
L	O
type	O
in	O
both	O
normal	O
and	O
affected	O
individuals	O
.	O

The	O
latter	O
also	O
showed	O
normal	O
amounts	O
of	O
H	B-Protein
-	I-Protein
type	I-Protein
ferritin	E-Protein
in	O
circulating	O
mononuclear	O
cells	O
;	O
on	O
the	O
contrary	O
,	O
L	B-Protein
-	I-Protein
type	I-Protein
ferritin	E-Protein
contents	O
were	O
13	O
times	O
normal	O
in	O
family	O
1	O
and	O
five	O
times	O
normal	O
in	O
family	O
2	O
on	O
average	O
.	O

Serum	O
ferritin	O
was	O
glycosylated	O
in	O
both	O
normal	O
and	O
affected	O
individuals	O
.	O

There	O
was	O
a	O
close	O
relationship	O
between	O
mononuclear	O
cell	O
L	B-Protein
-	I-Protein
type	I-Protein
ferritin	E-Protein
content	O
and	O
serum	O
ferritin	O
concentration	O
(	O
r	O
=	O
0	O
.	O
95	O
,	O
P	O
<	O
.	O
00001	O
)	O
,	O
suggesting	O
that	O
the	O
excess	O
production	O
of	O
ferritin	O
in	O
cells	O
was	O
directly	O
responsible	O
for	O
the	O
hyperferritinemia	O
.	O

The	O
dysregulated	O
L	O
-	O
subunit	O
synthesis	O
was	O
found	O
to	O
result	O
from	O
different	O
point	O
mutations	O
in	O
a	O
noncoding	O
sequence	O
of	O
genomic	O
L	O
-	O
subunit	O
DNA	O
,	O
which	O
behaves	O
as	O
an	O
mRNA	O
cis	O
-	O
acting	O
element	O
known	O
as	O
iron	O
regulatory	O
element	O
(	O
IRE	O
)	O
.	O

Affected	O
individuals	O
from	O
family	O
1	O
were	O
heterozygous	O
for	O
a	O
point	O
mutation	O
(	O
a	O
single	O
G	O
to	O
A	O
change	O
)	O
in	O
the	O
highly	O
conserved	O
,	O
three	O
-	O
nucleotide	O
motif	O
forming	O
the	O
IRE	O
bulge	O
.	O

Affected	O
members	O
from	O
family	O
2	O
were	O
heterozygous	O
for	O
a	O
double	O
point	O
mutation	O
in	O
the	O
IRE	O
lower	O
stem	O
.	O

Using	O
a	O
gel	O
retardation	O
assay	O
,	O
the	O
observed	O
molecular	O
lesions	O
were	O
shown	O
to	O
variably	O
reduce	O
the	O
IRE	O
affinity	O
for	O
an	O
iron	O
regulatory	O
protein	O
(	O
IRP	O
)	O
,	O
which	O
inhibits	O
ferritin	O
mRNA	O
translation	O
.	O

The	O
direct	O
relationship	O
between	O
the	O
degree	O
of	O
hyperferritinemia	O
and	O
severity	O
of	O
cataract	O
suggests	O
that	O
this	O
latter	O
is	O
the	O
consequence	O
of	O
excessive	O
ferritin	O
production	O
within	O
the	O
lens	O
fibers	O
.	O

These	O
findings	O
provide	O
strong	O
evidence	O
that	O
serum	O
ferritin	O
is	O
a	O
byproduct	O
of	O
intracellular	O
ferritin	O
synthesis	O
and	O
that	O
the	O
L	O
-	O
subunit	O
gene	O
on	O
chromosome	O
19	O
is	O
the	O
source	O
of	O
glycosylated	O
serum	O
ferritin	O
.	O

From	O
a	O
practical	O
standpoint	O
,	O
this	O
new	O
genetic	O
disorder	O
should	O
be	O
taken	O
into	O
account	O
by	O
clinicians	O
when	O
facing	O
a	O
high	O
serum	O
ferritin	O
in	O
an	O
apparently	O
healthy	O
person	O
.	O

Changes	O
in	O
the	O
secretion	O
and	O
glycosylation	O
of	O
fibronectin	S-Protein
by	O
human	O
skin	O
fibroblasts	O
associated	O
with	O
tuberous	O
sclerosis	O
.	O

Fibroblasts	O
from	O
skin	O
and	O
skin	O
lesions	O
of	O
patients	O
with	O
tuberous	O
sclerosis	O
(	O
TS	O
)	O
and	O
from	O
skin	O
of	O
normal	O
individuals	O
were	O
grown	O
in	O
culture	O
.	O

ELISA	O
showed	O
that	O
the	O
spent	O
medium	O
of	O
those	O
derived	O
from	O
TS	O
skin	O
lesions	O
contained	O
significantly	O
more	O
fibronectin	S-Protein
(	O
FN	S-Protein
)	O
than	O
spent	O
medium	O
from	O
the	O
other	O
cells	O
.	O

Amino	O
acid	O
compositional	O
analysis	O
of	O
the	O
FN	S-Protein
from	O
TS	O
and	O
normal	O
sources	O
revealed	O
no	O
substantial	O
differences	O
.	O

However	O
the	O
FN	S-Protein
of	O
fibroblasts	O
from	O
TS	O
-	O
skin	O
lesions	O
was	O
shown	O
by	O
HPAEC	O
to	O
contain	O
a	O
two	O
-	O
to	O
three	O
-	O
fold	O
increased	O
content	O
of	O
carbohydrate	O
.	O

The	O
changed	O
monosaccharide	O
composition	O
was	O
consistent	O
with	O
an	O
increased	O
content	O
of	O
N	O
-	O
and	O
O	O
-	O
linked	O
glycans	O
and	O
with	O
the	O
former	O
containing	O
polylactosamine	O
chains	O
.	O

Fibroblasts	O
from	O
a	O
normal	O
individual	O
were	O
shown	O
to	O
proliferate	O
more	O
slowly	O
and	O
to	O
produce	O
larger	O
cells	O
when	O
grown	O
on	O
FN	S-Protein
from	O
a	O
TS	O
skin	O
lesion	O
compared	O
to	O
growth	O
on	O
FN	S-Protein
from	O
normal	O
skin	O
.	O

Biological	O
methylation	O
of	O
myelin	B-Protein
basic	I-Protein
protein	E-Protein
:	O
enzymology	O
and	O
biological	O
significance	O
.	O

Myelin	O
is	O
a	O
membrane	O
characteristic	O
of	O
the	O
nervous	O
tissue	O
and	O
functions	O
as	O
an	O
insulator	O
to	O
increase	O
the	O
velocity	O
of	O
the	O
stimuli	O
being	O
transmitted	O
between	O
a	O
nerve	O
cell	O
body	O
and	O
its	O
target	O
.	O

Myelin	O
isolated	O
from	O
human	O
and	O
bovine	O
nervous	O
tissue	O
is	O
composed	O
of	O
approximately	O
80	O
%	O
lipid	O
and	O
20	O
%	O
protein	O
,	O
and	O
30	O
%	O
of	O
the	O
protein	O
fraction	O
constitutes	O
myelin	B-Protein
basic	I-Protein
protein	E-Protein
(	O
MBP	S-Protein
)	O
.	O

MBP	S-Protein
has	O
an	O
unusual	O
amino	O
acid	O
at	O
Res	O
-	O
107	O
as	O
a	O
mixture	O
of	O
NG	O
-	O
monomethylarginine	O
and	O
NG	O
,	O
N	O
'	O
G	O
-	O
dimethylarginine	O
.	O

The	O
formation	O
of	O
these	O
methylarginine	O
derivatives	O
is	O
catalysed	O
by	O
one	O
of	O
the	O
subtypes	O
of	O
protein	O
methylase	O
I	O
,	O
which	O
specifically	O
methylates	O
Res	O
-	O
107	O
of	O
this	O
protein	O
.	O

Evidence	O
is	O
presented	O
to	O
demonstrate	O
an	O
involvement	O
of	O
this	O
biological	O
methylation	O
in	O
the	O
integrity	O
and	O
maintenance	O
of	O
myelin	O
.	O

Mevalonate	O
-	O
regulated	O
mechanisms	O
in	O
cell	O
growth	O
control	O
:	O
role	O
of	O
dolichyl	O
phosphate	O
in	O
expression	O
of	O
the	O
insulin	B-Protein
-	I-Protein
like	I-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
1	I-Protein
receptor	E-Protein
(	O
IGF	B-Protein
-	I-Protein
1R	E-Protein
)	O
in	O
comparison	O
to	O
Ras	O
prenylation	O
and	O
expression	O
of	O
c	B-Protein
-	I-Protein
myc	E-Protein
.	O

One	O
or	O
more	O
mevalonate	O
derivatives	O
of	O
non	O
-	O
sterol	O
type	O
have	O
been	O
proposed	O
to	O
be	O
of	O
indispensable	O
importance	O
for	O
cell	O
growth	O
.	O

Conceivable	O
mevalonate	O
-	O
dependent	O
mechanisms	O
involved	O
in	O
growth	O
control	O
are	O
farnesylation	O
of	O
Ras	O
proteins	O
,	O
regulation	O
of	O
c	B-Protein
-	I-Protein
myc	E-Protein
expression	O
,	O
and	O
N	O
-	O
linked	O
glycosylation	O
of	O
the	O
IGF	B-Protein
-	I-Protein
1	I-Protein
receptor	E-Protein
.	O

The	O
latter	O
mechanism	O
might	O
be	O
rate	O
-	O
limited	O
by	O
dolichyl	O
phosphate	O
,	O
which	O
acts	O
as	O
a	O
donor	O
of	O
oligosaccharides	O
in	O
glycoprotein	O
synthesis	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O

In	O
order	O
to	O
study	O
the	O
significance	O
for	O
cell	O
proliferation	O
of	O
the	O
three	O
aforementioned	O
mevalonate	O
-	O
dependent	O
processings	O
,	O
their	O
inhibitory	O
response	O
due	O
to	O
mevalonate	O
deprivation	O
was	O
explored	O
and	O
compared	O
with	O
the	O
effect	O
on	O
DNA	O
synthesis	O
in	O
the	O
malignant	O
melanoma	O
cell	O
line	O
SK	O
-	O
MEL	O
-	O
2	O
.	O

We	O
found	O
that	O
mevalonate	O
depletion	O
due	O
to	O
treatment	O
with	O
3	O
microM	O
lovastatin	O
for	O
24	O
h	O
,	O
which	O
efficiently	O
growth	O
-	O
arrested	O
the	O
cells	O
,	O
hardly	O
at	O
all	O
affected	O
the	O
expression	O
of	O
c	B-Protein
-	I-Protein
myc	E-Protein
,	O
and	O
although	O
Ras	O
prenylation	O
was	O
inhibited	O
by	O
50	O
%	O
,	O
the	O
most	O
pronounced	O
effect	O
of	O
lovastatin	O
was	O
seen	O
on	O
N	O
-	O
linked	O
glycosylation	O
of	O
IGF	B-Protein
-	I-Protein
1	I-Protein
receptors	E-Protein
,	O
which	O
was	O
inhibited	O
by	O
more	O
than	O
95	O
%	O
.	O

The	O
order	O
and	O
magnitude	O
of	O
the	O
decreased	O
IGF	B-Protein
-	I-Protein
1	I-Protein
receptor	E-Protein
glycosylation	O
,	O
which	O
was	O
followed	O
by	O
a	O
decreased	O
expression	O
of	O
IGF	B-Protein
-	I-Protein
1	I-Protein
receptors	E-Protein
at	O
the	O
cell	O
membrane	O
,	O
correlated	O
well	O
with	O
the	O
inhibition	O
of	O
DNA	O
synthesis	O
.	O

We	O
investigated	O
whether	O
dolichol	O
,	O
and	O
in	O
particular	O
dolichyl	O
phosphate	O
,	O
through	O
its	O
participation	O
in	O
N	O
-	O
linked	O
glycosylation	O
,	O
act	O
as	O
regulators	O
of	O
IGF	B-Protein
-	I-Protein
1	I-Protein
receptor	E-Protein
expression	O
.	O

First	O
,	O
we	O
could	O
confirm	O
that	O
exogenous	O
dolichol	O
became	O
phosphorylated	O
and	O
in	O
this	O
form	O
took	O
part	O
in	O
the	O
glycosylation	O
processing	O
.	O

Secondly	O
,	O
we	O
showed	O
that	O
dolichyl	O
phosphate	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
could	O
increase	O
the	O
number	O
of	O
IGF	B-Protein
-	I-Protein
1	I-Protein
receptors	E-Protein
at	O
the	O
cell	O
membrane	O
,	O
simultaneously	O
as	O
DNA	O
synthesis	O
was	O
stimulated	O
.	O

Taken	O
together	O
,	O
our	O
results	O
provide	O
direct	O
evidence	O
for	O
an	O
important	O
role	O
of	O
dolichyl	O
phosphate	O
as	O
a	O
regulator	O
of	O
cell	O
growth	O
through	O
limiting	O
N	O
-	O
linked	O
glycosylation	O
of	O
the	O
IGF	B-Protein
-	I-Protein
1	I-Protein
receptor	E-Protein
.	O

Ascorbate	O
induction	O
of	O
collagen	S-Protein
synthesis	O
as	O
a	O
means	O
for	O
elucidating	O
a	O
mechanism	O
of	O
quantitative	O
control	O
of	O
tissue	O
-	O
specific	O
function	O
.	O

Ascorbic	O
acid	O
displays	O
the	O
characteristics	O
of	O
an	O
ideal	O
inducer	O
of	O
tissue	O
-	O
specific	O
function	O
in	O
primary	O
avian	O
tendon	O
cells	O
in	O
culture	O
.	O

It	O
is	O
a	O
highly	O
specific	O
,	O
potent	O
stimulator	O
of	O
collagen	S-Protein
synthesis	O
,	O
it	O
demonstrates	O
slow	O
reversible	O
kinetics	O
,	O
and	O
it	O
has	O
no	O
effect	O
on	O
growth	O
rate	O
of	O
the	O
cultured	O
cells	O
.	O

Kinetic	O
analysis	O
of	O
ascorbate	O
induction	O
of	O
collagen	S-Protein
synthesis	O
was	O
used	O
to	O
determine	O
the	O
critical	O
steps	O
in	O
this	O
complex	O
biosynthetic	O
pathway	O
.	O

Full	O
hydroxylation	O
of	O
the	O
proline	O
residues	O
in	O
collagen	S-Protein
,	O
although	O
probably	O
a	O
necessary	O
step	O
for	O
collagen	S-Protein
induction	O
,	O
was	O
in	O
itself	O
not	O
sufficient	O
for	O
achieving	O
either	O
increased	O
secretion	O
or	O
increased	O
synthesis	O
.	O

On	O
the	O
other	O
hand	O
,	O
an	O
increase	O
in	O
secretion	O
rate	O
,	O
which	O
required	O
both	O
the	O
presence	O
of	O
ascorbate	O
and	O
a	O
high	O
cell	O
density	O
,	O
did	O
correlate	O
with	O
the	O
later	O
stimulation	O
in	O
procollagen	S-Protein
production	O
.	O

The	O
process	O
of	O
procollagen	S-Protein
secretion	O
,	O
therefore	O
,	O
meets	O
the	O
minimal	O
requirements	O
for	O
the	O
rate	O
-	O
limiting	O
step	O
.	O

The	O
fact	O
that	O
the	O
cells	O
maintained	O
a	O
large	O
pool	O
of	O
intracellular	O
procollagen	S-Protein
despite	O
changes	O
in	O
the	O
rates	O
of	O
translation	O
or	O
secretion	O
led	O
us	O
to	O
postulate	O
a	O
possible	O
feedback	O
between	O
the	O
level	O
of	O
the	O
internal	O
procollagen	S-Protein
pool	O
and	O
the	O
rate	O
of	O
procollagen	S-Protein
synthesis	O
.	O

Fucosylation	O
of	O
disaccharide	O
precursors	O
of	O
sialyl	O
LewisX	O
inhibit	O
selectin	O
-	O
mediated	O
cell	O
adhesion	O
.	O

We	O
showed	O
previously	O
that	O
HL	O
-	O
60	O
and	O
F9	O
mouse	O
embryonal	O
carcinoma	O
cells	O
will	O
take	O
up	O
and	O
deblock	O
peracetylated	O
Galbeta1	O
-	O
4GlcNAcbeta	O
-	O
O	O
-	O
naphthalenemethanol	O
(	O
Galbeta1	O
-	O
4GlcNAc	O
-	O
NM	O
)	O
and	O
use	O
the	O
disaccharide	O
as	O
a	O
primer	O
of	O
oligosaccharide	O
chains	O
(	O
Sarkar	O
,	O
A	O
.	O
K	O
.	O
,	O
Fritz	O
,	O
T	O
.	O
A	O
.	O
,	O
Taylor	O
,	O
W	O
.	O
H	O
.	O
,	O
and	O
Esko	O
,	O
J	O
.	O
D	O
.	O
(	O
1995	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
U	O
.	O
S	O
.	O
A	O
.	O
92	O
,	O
3323	O
-	O
3327	O
)	O
.	O

We	O
now	O
report	O
that	O
another	O
disaccharide	O
,	O
acetylated	O
GlcNAcbeta1	O
-	O
3Gal	O
-	O
naphthalenemethanol	O
(	O
GlcNAcbeta1	O
-	O
3Gal	O
-	O
NM	O
)	O
,	O
has	O
even	O
greater	O
potency	O
and	O
that	O
both	O
compounds	O
will	O
inhibit	O
sialyl	O
LewisX	O
(	O
sLex	O
)	O
-	O
dependent	O
cell	O
adhesion	O
.	O

When	O
fed	O
to	O
U937	O
cells	O
,	O
acetylated	O
forms	O
of	O
Galbeta1	O
-	O
4GlcNAc	O
-	O
NM	O
and	O
GlcNAcbeta1	O
-	O
3Gal	O
-	O
NM	O
primed	O
oligosaccharides	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Analysis	O
of	O
compounds	O
assembled	O
on	O
Galbeta1	O
-	O
4GlcNAc	O
-	O
NM	O
showed	O
only	O
one	O
product	O
,	O
namely	O
Galbeta1	O
-	O
4	O
(	O
Fucalpha1	O
-	O
3	O
)	O
GlcNAc	O
-	O
NM	O
.	O

In	O
contrast	O
,	O
GlcNAcbeta1	O
-	O
3Gal	O
-	O
NM	O
generated	O
Galbeta1	O
-	O
4GlcNAcbeta1	O
-	O
3Gal	O
-	O
NM	O
,	O
Galbeta1	O
-	O
4	O
(	O
Fucalpha1	O
-	O
3	O
)	O
GlcNAcbeta1	O
-	O
3Gal	O
-	O
NM	O
,	O
NeuAcalpha2	O
-	O
3Galbeta1	O
-	O
4GlcNAcbeta1	O
-	O
3Gal	O
-	O
NM	O
,	O
and	O
NeuAcalpha2	O
-	O
3Galbeta1	O
-	O
4	O
(	O
Fucalpha1	O
-	O
3	O
)	O
GlcNAcbeta1	O
-	O
3Gal	O
-	O
NM	O
.	O

Both	O
compounds	O
decreased	O
the	O
incorporation	O
of	O
[	O
3H	O
]	O
fucose	O
into	O
cellular	O
glycoconjugates	O
,	O
without	O
affecting	O
the	O
incorporation	O
of	O
[	O
3H	O
]	O
mannosamine	O
,	O
a	O
precursor	O
of	O
sialic	O
acid	O
residues	O
.	O

Moreover	O
,	O
the	O
overall	O
extent	O
of	O
sialylation	O
was	O
not	O
affected	O
based	O
on	O
the	O
reactivity	O
of	O
cells	O
to	O
fluorescein	O
isothiocyanate	O
-	O
conjugated	O
Maackia	O
amurensis	O
lectin	O
.	O

Priming	O
inhibited	O
expression	O
of	O
sLex	O
on	O
cell	O
surface	O
glycoconjugates	O
,	O
which	O
reduced	O
E	B-Protein
-	I-Protein
selectin	E-Protein
-	O
dependent	O
cell	O
adhesion	O
to	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
-	O
activated	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

GlcNAcbeta1	O
-	O
3Gal	O
-	O
NM	O
and	O
Galbeta1	O
-	O
4GlcNAc	O
-	O
NM	O
represent	O
starting	O
points	O
for	O
making	O
enzyme	O
-	O
specific	O
,	O
site	O
-	O
directed	O
inhibitors	O
of	O
glycosyltransferases	O
that	O
could	O
act	O
in	O
living	O
cells	O
.	O

Mapping	O
peptide	O
-	O
binding	O
domains	O
of	O
the	O
human	O
V1a	B-Protein
vasopressin	I-Protein
receptor	E-Protein
with	O
a	O
photoactivatable	O
linear	O
peptide	O
antagonist	O
.	O

The	O
study	O
of	O
antagonist	O
-	O
binding	O
domains	O
of	O
the	O
human	O
V1a	B-Protein
vasopressin	I-Protein
receptor	E-Protein
was	O
performed	O
using	O
a	O
radioiodinated	O
photoreactive	O
peptide	O
antagonist	O
.	O

This	O
ligand	O
displayed	O
a	O
high	O
affinity	O
for	O
the	O
receptor	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cell	O
membranes	O
,	O
and	O
specifically	O
labeled	O
two	O
protein	O
bands	O
with	O
apparent	O
molecular	O
mass	O
at	O
85	O
-	O
90	O
and	O
46	O
kDa	O
.	O

Our	O
results	O
clearly	O
show	O
that	O
the	O
V1a	B-Protein
receptor	E-Protein
is	O
degraded	O
during	O
incubation	O
with	O
the	O
ligand	O
and	O
that	O
the	O
46	O
-	O
kDa	O
species	O
is	O
probably	O
the	O
result	O
of	O
the	O
85	O
-	O
90	O
-	O
kDa	O
species	O
proteolytic	O
cleavage	O
.	O

Truncation	O
of	O
the	O
receptor	O
was	O
then	O
confirmed	O
by	O
deglycosylation	O
with	O
N	B-Protein
-	I-Protein
glycosidase	I-Protein
F	E-Protein
.	O

A	O
monoclonal	O
antibody	O
directed	O
against	O
a	O
c	B-Protein
-	I-Protein
Myc	E-Protein
epitope	O
added	O
at	O
the	O
receptor	O
NH2	O
terminus	O
allowed	O
immunoprecipitation	O
of	O
the	O
85	O
-	O
90	O
-	O
kDa	O
photolabeled	O
species	O
.	O

The	O
46	O
-	O
kDa	O
photolabeled	O
protein	O
never	O
immunoprecipitated	O
,	O
indicating	O
that	O
the	O
truncated	O
form	O
of	O
the	O
receptor	O
lacks	O
the	O
NH2	O
terminus	O
region	O
.	O

To	O
localize	O
photolabeled	O
domains	O
of	O
the	O
receptor	O
,	O
the	O
46	O
-	O
kDa	O
protein	O
was	O
cleaved	O
with	O
V8	S-Protein
and	O
/	O
or	O
Lys	B-Protein
-	I-Protein
C	I-Protein
endoproteinases	E-Protein
.	O

The	O
identity	O
of	O
the	O
smallest	O
photolabeled	O
fragment	O
,	O
observed	O
at	O
approximately	O
6	O
kDa	O
,	O
was	O
then	O
confirmed	O
by	O
mutation	O
of	O
the	O
potential	O
V8	O
cleavage	O
sites	O
.	O

Our	O
results	O
indicate	O
that	O
covalent	O
labeling	O
of	O
the	O
vasopressin	B-Protein
V1a	I-Protein
receptor	E-Protein
with	O
the	O
photoreactive	O
antagonist	O
occurs	O
in	O
a	O
region	O
including	O
transmembrane	O
domain	O
VII	O
(	O
residues	O
Asn327	O
-	O
Lys370	O
)	O
.	O

Absence	O
of	O
methylation	O
of	O
CpG	O
dinucleotides	O
within	O
the	O
promoter	O
of	O
the	O
breast	O
cancer	O
susceptibility	O
gene	O
BRCA2	S-Protein
in	O
normal	O
tissues	O
and	O
in	O
breast	O
and	O
ovarian	O
cancers	O
.	O

Germline	O
mutations	O
of	O
the	O
BRCA2	S-Protein
gene	O
on	O
chromosome	O
13q12	O
-	O
q13	O
predispose	O
to	O
the	O
development	O
of	O
early	O
-	O
onset	O
breast	O
cancer	O
and	O
ovarian	O
cancer	O
.	O

Loss	O
of	O
heterozygosity	O
detected	O
using	O
chromosome	O
13q	O
markers	O
in	O
the	O
vicinity	O
of	O
BRCA2	S-Protein
is	O
observed	O
in	O
most	O
cancers	O
arising	O
in	O
carriers	O
of	O
germline	O
BRCA2	S-Protein
mutations	O
and	O
also	O
in	O
30	O
-	O
50	O
%	O
of	O
sporadic	O
breast	O
and	O
ovarian	O
cancers	O
.	O

However	O
,	O
somatic	O
mutations	O
of	O
BRCA2	S-Protein
are	O
extremely	O
rare	O
in	O
sporadic	O
cancers	O
.	O

We	O
have	O
examined	O
the	O
hypothesis	O
that	O
expression	O
of	O
the	O
BRCA2	S-Protein
gene	O
may	O
be	O
suppressed	O
in	O
sporadic	O
breast	O
cancers	O
by	O
a	O
mechanism	O
that	O
is	O
associated	O
with	O
increased	O
methylation	O
of	O
cytosine	O
residues	O
in	O
the	O
promoter	O
region	O
.	O

Using	O
a	O
HpaII	S-Protein
/	O
MspI	S-Protein
digestion	O
-	O
polymerase	O
chain	O
reaction	O
based	O
assay	O
,	O
the	O
presence	O
of	O
5	O
-	O
methylcytosine	O
in	O
three	O
CpG	O
dinucleotides	O
within	O
the	O
BRCA2	S-Protein
promoter	O
was	O
assessed	O
in	O
18	O
breast	O
or	O
ovarian	O
cancer	O
cell	O
lines	O
,	O
in	O
an	O
SV40	O
large	B-Protein
T	I-Protein
antigen	E-Protein
immortalized	O
cell	O
line	O
derived	O
from	O
normal	O
breast	O
epithelial	O
cells	O
,	O
in	O
64	O
primary	O
sporadic	O
breast	O
cancers	O
and	O
peripheral	O
blood	O
leucocytes	O
from	O
these	O
cases	O
and	O
in	O
a	O
number	O
of	O
other	O
normal	O
human	O
tissues	O
.	O

Methylation	O
was	O
not	O
detected	O
in	O
any	O
of	O
the	O
tissues	O
examined	O
,	O
suggesting	O
that	O
this	O
mechanism	O
of	O
transcriptional	O
repression	O
is	O
unlikely	O
to	O
explain	O
the	O
absence	O
of	O
somatic	O
mutations	O
in	O
sporadic	O
cancers	O
.	O

Expression	O
and	O
hemocyte	O
-	O
targeting	O
of	O
a	O
Campoletis	O
sonorensis	O
polydnavirus	O
cysteine	O
-	O
rich	O
gene	O
in	O
Heliothis	O
virescens	O
larvae	O
.	O

The	O
polydnavirus	O
associated	O
with	O
the	O
parasitic	O
wasp	O
Campoletis	O
sonorensis	O
is	O
injected	O
into	O
the	O
lepidopteran	O
insect	O
,	O
Heliothis	O
virescens	O
,	O
during	O
parasitization	O
,	O
after	O
which	O
viral	O
gene	O
products	O
suppress	O
the	O
cellular	O
immune	O
system	O
of	O
the	O
hosts	O
.	O

Four	O
related	O
cysteine	O
-	O
rich	O
polydnavirus	O
gene	O
have	O
been	O
identified	O
in	O
parasitized	O
H	O
.	O
virescens	O
larvae	O
and	O
grouped	O
into	O
a	O
family	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
expression	O
and	O
hemocyte	O
targeting	O
of	O
the	O
cysteine	O
-	O
rich	O
VHv1	B-Protein
.	I-Protein
4	E-Protein
protein	O
.	O

Full	O
-	O
length	O
and	O
truncated	O
VHv1	B-Protein
.	I-Protein
4	E-Protein
proteins	O
were	O
produced	O
in	O
a	O
bacterial	O
expression	O
system	O
,	O
and	O
the	O
purified	O
proteins	O
were	O
used	O
to	O
raise	O
polyclonal	O
antisera	O
.	O

In	O
immunoblots	O
the	O
VHv1	B-Protein
.	I-Protein
4	E-Protein
protein	O
was	O
detected	O
in	O
parasitized	O
insects	O
as	O
early	O
as	O
6	O
h	O
and	O
throughout	O
the	O
entire	O
course	O
of	O
parasitism	O
.	O

The	O
VHv1	B-Protein
.	I-Protein
4	E-Protein
protein	O
appeared	O
predominantly	O
in	O
the	O
plasma	O
fraction	O
of	O
hemolymph	O
from	O
parasitized	O
larvae	O
,	O
suggesting	O
that	O
this	O
protein	O
is	O
secreted	O
.	O

The	O
VHv1	B-Protein
.	I-Protein
4	E-Protein
protein	O
expressed	O
from	O
a	O
recombinant	O
baculovirus	O
was	O
secreted	O
in	O
two	O
lepidopteran	O
cell	O
lines	O
and	O
in	O
larvae	O
injected	O
with	O
the	O
recombinant	O
virus	O
.	O

Digestion	O
with	O
endoglycosidases	O
suggests	O
that	O
the	O
VHv1	B-Protein
.	I-Protein
4	E-Protein
protein	O
is	O
glycosylated	O
at	O
multiple	O
N	O
-	O
glycosylation	O
sites	O
.	O

Immunofluorescence	O
assays	O
showed	O
that	O
the	O
VHv1	B-Protein
.	I-Protein
4	E-Protein
protein	O
binds	O
to	O
the	O
hemocytes	O
,	O
most	O
notably	O
the	O
granulocytes	O
,	O
in	O
H	O
.	O
virescens	O
larvae	O
.	O

After	O
binding	O
,	O
the	O
VHv1	B-Protein
.	I-Protein
4	E-Protein
protein	O
was	O
internalized	O
,	O
probably	O
by	O
endocytosis	O
.	O

Specific	O
binding	O
of	O
the	O
VHv1	B-Protein
.	I-Protein
4	E-Protein
to	O
granulocytes	O
implies	O
an	O
important	O
function	O
in	O
the	O
suppression	O
of	O
host	O
cellular	O
encapsulation	O
response	O
.	O

N	O
-	O
glycosylation	O
is	O
requisite	O
for	O
the	O
enzyme	O
activity	O
and	O
Golgi	O
retention	O
of	O
N	B-Protein
-	I-Protein
acetylglucosaminyltransferase	I-Protein
III	E-Protein
.	O

UDP	B-Protein
-	I-Protein
N	I-Protein
-	I-Protein
acetylglucosamine	I-Protein
:	I-Protein
beta	I-Protein
-	I-Protein
D	I-Protein
-	I-Protein
mannoside	I-Protein
beta	I-Protein
-	I-Protein
1	I-Protein
,	I-Protein
4N	I-Protein
-	I-Protein
acetylglucosaminyltransferase	I-Protein
III	E-Protein
(	O
GnT	B-Protein
-	I-Protein
III	E-Protein
,	O
EC	O
2	O
.	O
4	O
.	O
1	O
.	O
144	O
)	O
is	O
a	O
glycoprotein	O
involved	O
in	O
the	O
biosynthesis	O
of	O
N	O
-	O
linked	O
oligosaccharides	O
.	O

Rat	O
GnT	B-Protein
-	I-Protein
III	E-Protein
contains	O
three	O
potential	O
N	O
-	O
glycosylation	O
sites	O
,	O
which	O
have	O
been	O
predicted	O
to	O
be	O
Asn243	O
,	O
Asn261	O
,	O
and	O
Asn399	O
.	O

To	O
study	O
the	O
roles	O
of	O
N	O
-	O
glycosylation	O
in	O
the	O
GnT	B-Protein
-	I-Protein
III	E-Protein
function	O
,	O
rat	O
GnT	B-Protein
-	I-Protein
III	E-Protein
was	O
expressed	O
in	O
COS	O
-	O
1	O
cells	O
under	O
tunicamycin	O
or	O
castanospermine	O
treatment	O
.	O

The	O
tunicamycin	O
-	O
treated	O
GnT	B-Protein
-	I-Protein
III	E-Protein
,	O
which	O
was	O
not	O
N	O
-	O
glycosylated	O
,	O
had	O
almost	O
no	O
activity	O
.	O

The	O
castanospermine	O
-	O
treated	O
GnT	B-Protein
-	I-Protein
III	E-Protein
was	O
not	O
localized	O
in	O
the	O
Golgi	O
,	O
but	O
glucosylation	O
did	O
not	O
affect	O
its	O
activity	O
.	O

To	O
clarify	O
the	O
role	O
of	O
individual	O
N	O
-	O
glycosylations	O
,	O
we	O
obtained	O
a	O
series	O
of	O
mutant	O
cDNAs	O
in	O
which	O
some	O
or	O
all	O
of	O
the	O
potential	O
glycosylation	O
sites	O
were	O
eliminated	O
by	O
site	O
-	O
directed	O
mutagenesis	O
,	O
and	O
expressed	O
them	O
in	O
COS	O
-	O
1	O
cells	O
.	O

All	O
the	O
mutants	O
exhibited	O
lower	O
enzyme	O
activity	O
than	O
the	O
wild	O
-	O
type	O
,	O
but	O
deglycosylation	O
at	O
individual	O
sites	O
had	O
different	O
effects	O
on	O
the	O
enzyme	O
activity	O
.	O

The	O
deglycosylation	O
at	O
Asn243	O
or	O
Asn261	O
was	O
more	O
effective	O
on	O
the	O
activity	O
than	O
that	O
at	O
Asn399	O
.	O

The	O
enzyme	O
activity	O
decreased	O
as	O
the	O
number	O
of	O
glycosylation	O
sites	O
decreased	O
.	O

The	O
null	O
glycosylation	O
mutant	O
had	O
no	O
activity	O
,	O
corresponding	O
to	O
the	O
case	O
of	O
tunicamycin	O
-	O
treated	O
wild	O
-	O
type	O
GnT	B-Protein
-	I-Protein
III	E-Protein
.	O

Kinetic	O
analysis	O
revealed	O
that	O
the	O
deglycosylation	O
at	O
Asn243	O
or	O
Asn261	O
resulted	O
in	O
slightly	O
lower	O
affinity	O
for	O
the	O
donor	O
substrate	O
,	O
but	O
the	O
other	O
mutation	O
did	O
not	O
significantly	O
change	O
the	O
K	O
(	O
m	O
)	O
value	O
for	O
either	O
the	O
donor	O
or	O
acceptor	O
.	O

None	O
of	O
the	O
mutant	O
GnT	B-Protein
-	I-Protein
IIIs	E-Protein
showed	O
perinuclear	O
localization	O
or	O
Golgi	O
retention	O
,	O
that	O
was	O
observed	O
for	O
the	O
wild	O
-	O
type	O
protein	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
that	O
the	O
glycosyltransferase	O
localized	O
in	O
the	O
Golgi	O
apparatus	O
requires	O
N	O
-	O
glycosylation	O
for	O
its	O
activity	O
and	O
retention	O
.	O

Functional	O
expression	O
of	O
human	O
mannan	B-Protein
-	I-Protein
binding	I-Protein
proteins	E-Protein
(	O
MBPs	S-Protein
)	O
in	O
human	O
hepatoma	O
cell	O
lines	O
infected	O
by	O
recombinant	O
vaccinia	O
virus	O
:	O
post	O
-	O
translational	O
modification	O
,	O
molecular	O
assembly	O
,	O
and	O
differentiation	O
of	O
serum	O
and	O
liver	O
MBP	S-Protein
.	O

Human	O
mannan	B-Protein
-	I-Protein
binding	I-Protein
proteins	E-Protein
(	O
MBPs	S-Protein
)	O
occur	O
in	O
two	O
forms	O
,	O
serum	O
MBP	S-Protein
(	O
S	O
-	O
MBP	S-Protein
)	O
and	O
liver	O
MBP	S-Protein
(	O
L	O
-	O
MBP	S-Protein
)	O
,	O
both	O
of	O
which	O
are	O
synthesized	O
in	O
the	O
liver	O
from	O
a	O
single	O
form	O
of	O
human	O
MBP	S-Protein
mRNA	O
.	O

To	O
investigate	O
further	O
the	O
mechanisms	O
of	O
post	O
-	O
translational	O
modification	O
,	O
molecular	O
assembly	O
and	O
differentiation	O
of	O
S	O
-	O
MBP	S-Protein
and	O
L	O
-	O
MBP	S-Protein
in	O
vitro	O
,	O
we	O
expressed	O
a	O
full	O
-	O
length	O
human	O
MBP	S-Protein
cDNA	O
in	O
three	O
human	O
hepatoma	O
cell	O
lines	O
,	O
using	O
the	O
vaccinia	O
virus	O
expression	O
system	O
.	O

The	O
expression	O
of	O
human	O
MBP	S-Protein
cDNA	O
reproduced	O
the	O
native	O
MBP	S-Protein
differentiation	O
of	O
S	O
-	O
MBP	S-Protein
and	O
L	O
-	O
MBP	S-Protein
in	O
human	O
hepatoma	O
cells	O
.	O

The	O
recombinant	O
S	O
-	O
MBP	S-Protein
was	O
secreted	O
into	O
the	O
medium	O
,	O
and	O
the	O
recombinant	O
L	O
-	O
MBP	S-Protein
retained	O
in	O
the	O
cells	O
.	O

The	O
former	O
had	O
the	O
ability	O
to	O
activate	O
the	O
complement	O
through	O
the	O
classical	O
or	O
lectin	O
pathway	O
but	O
the	O
latter	O
did	O
not	O
.	O

Furthermore	O
,	O
one	O
notable	O
difference	O
between	O
the	O
two	O
MBPs	S-Protein
was	O
the	O
degree	O
of	O
oligomerization	O
through	O
interchain	O
disulfide	O
bonds	O
between	O
subunits	O
.	O

In	O
addition	O
,	O
we	O
showed	O
that	O
both	O
S	O
-	O
MBP	S-Protein
and	O
L	O
-	O
MBP	S-Protein
undergo	O
hydroxylation	O
of	O
lysine	O
and	O
proline	O
residues	O
in	O
collagen	O
-	O
like	O
sequences	O
,	O
and	O
that	O
the	O
hydroxylysine	O
is	O
glycosylated	O
to	O
form	O
glucosylgalactosylhydroxylysine	O
(	O
GluGalHyl	O
)	O
and	O
galactosylhydroxylysine	O
(	O
GalHyl	O
)	O
.	O

Hydroxylation	O
was	O
required	O
for	O
S	O
-	O
MBP	S-Protein
to	O
be	O
assembled	O
into	O
large	O
complexes	O
,	O
the	O
apparent	O
molecular	O
sizes	O
of	O
which	O
were	O
estimated	O
to	O
be	O
200	O
-	O
1	O
,	O
300	O
kDa	O
by	O
SDS	O
-	O
PAGE	O
under	O
non	O
-	O
reducing	O
conditions	O
and	O
gel	O
filtration	O
under	O
non	O
-	O
denaturing	O
conditions	O
.	O

The	O
hydroxylation	O
and	O
subsequent	O
glycosylation	O
and	O
oligomerization	O
were	O
inhibited	O
by	O
alpha	O
,	O
alpha	O
'	O
-	O
dipyridyl	O
,	O
an	O
inhibitor	O
of	O
collagen	O
lysyl	O
and	O
prolyl	O
hydroxylases	O
.	O

These	O
results	O
suggested	O
that	O
newly	O
synthesized	O
lectins	O
undergo	O
post	O
-	O
translational	O
modifications	O
unique	O
to	O
the	O
two	O
forms	O
of	O
MBP	S-Protein
,	O
S	O
-	O
MBP	S-Protein
,	O
and	O
L	O
-	O
MBP	S-Protein
,	O
in	O
human	O
hepatocytes	O
and	O
hepatoma	O
cells	O
,	O
and	O
that	O
the	O
collagen	O
-	O
like	O
domains	O
of	O
the	O
MBPs	S-Protein
play	O
an	O
important	O
role	O
in	O
promoting	O
molecular	O
assembly	O
.	O

Fibrinogen	O
Kaiserslautern	O
(	O
gamma	O
380	O
Lys	O
to	O
Asn	O
)	O
:	O
a	O
new	O
glycosylated	O
fibrinogen	O
variant	O
with	O
delayed	O
polymerization	O
.	O

An	O
adult	O
woman	O
diagnosed	O
with	O
cerebral	O
thrombosis	O
following	O
a	O
caesarean	O
section	O
was	O
found	O
to	O
have	O
severely	O
prolonged	O
thrombin	S-Protein
and	O
reptilase	S-Protein
times	O
.	O

Five	O
other	O
family	O
members	O
also	O
had	O
prolonged	O
,	O
but	O
variable	O
,	O
thrombin	S-Protein
and	O
reptilase	S-Protein
times	O
.	O

Analysis	O
of	O
purified	O
fibrinogen	O
on	O
reducing	O
SDS	O
-	O
PAGE	O
revealed	O
an	O
additional	O
band	O
,	O
in	O
all	O
family	O
members	O
,	O
which	O
migrated	O
immediately	O
below	O
the	O
normal	O
B	O
beta	O
band	O
.	O

Western	O
blotting	O
indicated	O
that	O
this	O
band	O
was	O
a	O
gamma	O
chain	O
and	O
endoglycosidase	O
-	O
F	O
digestion	O
established	O
that	O
it	O
contained	O
an	O
additional	O
oligosaccharide	O
side	O
chain	O
.	O

Partial	O
acid	O
hydrolysis	O
localized	O
the	O
new	O
oligosaccharide	O
to	O
the	O
C	O
-	O
terminus	O
of	O
the	O
gamma	O
chain	O
.	O

Amplification	O
of	O
this	O
region	O
by	O
PCR	O
and	O
subsequent	O
DNA	O
sequencing	O
demonstrated	O
a	O
single	O
base	O
substitution	O
altering	O
the	O
normal	O
380	O
Lys	O
(	O
AAG	O
)	O
codon	O
to	O
Asn	O
(	O
AAT	O
)	O
,	O
producing	O
a	O
new	O
Asn	O
-	O
Lys	O
-	O
Thr	O
glycosylation	O
site	O
.	O

The	O
propositus	O
and	O
one	O
other	O
family	O
member	O
were	O
homozygous	O
for	O
this	O
mutation	O
but	O
the	O
remaining	O
four	O
family	O
members	O
were	O
heterozygous	O
.	O

The	O
polymerization	O
of	O
purified	O
fibrin	O
monomers	O
from	O
the	O
propositus	O
was	O
grossly	O
abnormal	O
;	O
however	O
,	O
the	O
polymerization	O
curve	O
was	O
almost	O
normalized	O
by	O
the	O
removal	O
of	O
terminal	O
sialic	O
acid	O
residues	O
.	O

This	O
suggests	O
that	O
the	O
polymerization	O
defect	O
was	O
primarily	O
caused	O
by	O
additional	O
negatively	O
charged	O
sialic	O
acid	O
residues	O
present	O
on	O
the	O
new	O
oligosaccharide	O
.	O

Further	O
analysis	O
of	O
the	O
D	O
domain	O
of	O
purified	O
fibrinogen	O
established	O
that	O
calcium	O
binding	O
to	O
the	O
high	O
affinity	O
site	O
remained	O
unaffected	O
by	O
the	O
bulky	O
carbohydrate	O
side	O
chain	O
or	O
negatively	O
charged	O
sialic	O
acid	O
residues	O
.	O

Chimeric	O
chemoreceptors	O
in	O
Escherichia	O
coli	O
:	O
signaling	O
properties	O
of	O
Tar	S-Protein
-	O
Tap	S-Protein
and	O
Tap	S-Protein
-	O
Tar	S-Protein
hybrids	O
.	O

The	O
Tap	S-Protein
(	O
taxis	O
toward	O
peptides	O
)	O
receptor	O
and	O
the	O
periplasmic	O
dipeptide	O
-	O
binding	O
protein	O
(	O
DBP	O
)	O
of	O
Escherichia	O
coli	O
together	O
mediate	O
chemotactic	O
responses	O
to	O
dipeptides	O
.	O

Tap	S-Protein
is	O
a	O
low	O
-	O
abundance	O
receptor	O
.	O

It	O
is	O
present	O
in	O
5	O
-	O
to	O
10	O
-	O
fold	O
-	O
fewer	O
copies	O
than	O
high	O
-	O
abundance	O
receptors	O
like	O
Tar	S-Protein
and	O
Tsr	S-Protein
.	O

Cells	O
expressing	O
Tap	S-Protein
as	O
the	O
sole	O
receptor	O
,	O
even	O
from	O
a	O
multicopy	O
plasmid	O
at	O
5	O
-	O
to	O
10	O
-	O
fold	O
-	O
overexpressed	O
levels	O
,	O
do	O
not	O
generate	O
sufficient	O
clockwise	O
(	O
CW	O
)	O
signal	O
to	O
tumble	O
and	O
thus	O
swim	O
exclusively	O
smoothly	O
(	O
run	O
)	O
.	O

To	O
study	O
the	O
signaling	O
properties	O
of	O
Tap	S-Protein
in	O
detail	O
,	O
we	O
constructed	O
reciprocal	O
hybrids	O
between	O
Tap	S-Protein
and	O
Tar	S-Protein
fused	O
in	O
the	O
linker	O
region	O
between	O
the	O
periplasmic	O
and	O
cytoplasmic	O
domains	O
.	O

The	O
Tapr	O
hybrid	O
senses	O
dipeptides	O
and	O
is	O
a	O
good	O
CW	O
-	O
signal	O
generator	O
,	O
whereas	O
the	O
Tarp	O
hybrid	O
senses	O
aspartate	O
but	O
is	O
a	O
poor	O
CW	O
-	O
signal	O
generator	O
.	O

Thus	O
,	O
the	O
poor	O
CW	O
signaling	O
of	O
Tap	S-Protein
is	O
a	O
property	O
of	O
its	O
cytoplasmic	O
domain	O
.	O

Eighteen	O
residues	O
at	O
the	O
carboxyl	O
terminus	O
of	O
high	O
-	O
abundance	O
receptors	O
,	O
including	O
the	O
NWETF	O
sequence	O
that	O
binds	O
the	O
CheR	S-Protein
methylesterase	O
,	O
are	O
missing	O
in	O
Tap	S-Protein
.	O

The	O
Tart	O
protein	O
,	O
created	O
by	O
removing	O
these	O
18	O
residues	O
from	O
Tar	S-Protein
,	O
has	O
diminished	O
CW	O
-	O
signaling	O
ability	O
.	O

The	O
Tapl	O
protein	O
,	O
made	O
by	O
adding	O
the	O
last	O
18	O
residues	O
of	O
Tar	S-Protein
to	O
the	O
carboxyl	O
terminus	O
of	O
Tap	S-Protein
,	O
also	O
does	O
not	O
support	O
CW	O
flagellar	O
rotation	O
.	O

However	O
,	O
Tart	O
and	O
Tapl	O
cross	O
-	O
react	O
well	O
with	O
antibody	O
directed	O
against	O
the	O
conserved	O
cytoplasmic	O
region	O
of	O
Tsr	S-Protein
,	O
whereas	O
Tap	S-Protein
does	O
not	O
cross	O
-	O
react	O
with	O
this	O
antibody	O
.	O

Tap	S-Protein
does	O
cross	O
-	O
react	O
,	O
however	O
,	O
with	O
antibody	O
directed	O
against	O
the	O
low	O
-	O
abundance	O
chemoreceptor	O
Trg	S-Protein
.	O

The	O
hybrid	O
,	O
truncated	O
,	O
and	O
extended	O
receptors	O
exhibit	O
various	O
levels	O
of	O
methylation	O
.	O

However	O
,	O
Tar	S-Protein
and	O
Tapl	O
,	O
which	O
contain	O
a	O
consensus	O
CheR	S-Protein
-	O
binding	O
motif	O
(	O
NWETF	O
)	O
at	O
their	O
carboxyl	O
termini	O
,	O
exhibit	O
the	O
highest	O
basal	O
levels	O
of	O
methylation	O
,	O
as	O
expected	O
.	O

We	O
conclude	O
that	O
no	O
simple	O
correlation	O
exists	O
between	O
the	O
abundance	O
of	O
a	O
receptor	O
,	O
its	O
methylation	O
level	O
,	O
and	O
its	O
CW	O
-	O
signaling	O
ability	O
.	O

The	O
rat	O
norepinephrine	B-Protein
transporter	E-Protein
:	O
molecular	O
cloning	O
from	O
PC12	O
cells	O
and	O
functional	O
expression	O
.	O

The	O
rat	O
norepinephrine	B-Protein
transporter	E-Protein
(	O
rNET	S-Protein
)	O
cDNA	O
from	O
the	O
PC12	O
pheochromocytoma	O
cell	O
line	O
has	O
been	O
cloned	O
by	O
RT	O
-	O
PCR	O
and	O
characterized	O
.	O

The	O
cDNA	O
encodes	O
an	O
integral	O
membrane	O
protein	O
consisting	O
of	O
617	O
amino	O
acids	O
which	O
contains	O
twelve	O
putative	O
transmembrane	O
domains	O
,	O
two	O
potential	O
N	O
-	O
glycosylation	O
sites	O
,	O
two	O
potential	O
phosphorylation	O
sites	O
for	O
protein	O
kinase	O
C	O
and	O
one	O
phosphorylation	O
site	O
for	O
casein	O
kinase	O
II	O
.	O

The	O
nucleotide	O
and	O
deduced	O
amino	O
acid	O
sequence	O
shows	O
a	O
high	O
level	O
of	O
homology	O
to	O
the	O
human	O
and	O
the	O
bovine	O
norepinephrine	B-Protein
transporter	E-Protein
and	O
less	O
homology	O
to	O
the	O
rat	O
dopamine	B-Protein
transporter	E-Protein
(	O
rDAT	S-Protein
)	O
.	O

Heterologous	O
expression	O
of	O
rNET	S-Protein
in	O
HEK293	O
cells	O
revealed	O
that	O
uptake	O
of	O
[	O
3H	O
]	O
norepinephrine	O
is	O
sodium	O
-	O
and	O
chloride	O
-	O
dependent	O
and	O
highly	O
sensitive	O
to	O
the	O
selective	O
norepinephrine	B-Protein
transporter	E-Protein
inhibitors	O
desipramine	O
and	O
nisoxetine	O
.	O

The	O
cloned	O
rNET	S-Protein
cDNA	O
provides	O
the	O
opportunity	O
to	O
investigate	O
this	O
transporter	O
in	O
heterologous	O
expression	O
systems	O
and	O
adds	O
a	O
new	O
member	O
to	O
the	O
family	O
of	O
sodium	O
-	O
and	O
chloride	O
-	O
dependent	O
neurotransmitter	O
transporters	O
.	O

Collagen	S-Protein
cross	O
-	O
links	O
in	O
mineralizing	O
tissues	O
:	O
a	O
review	O
of	O
their	O
chemistry	O
,	O
function	O
,	O
and	O
clinical	O
relevance	O
.	O

Bone	O
collagen	S-Protein
cross	O
-	O
links	O
are	O
now	O
widely	O
used	O
to	O
assess	O
bone	O
resorption	O
levels	O
in	O
many	O
metabolic	O
bone	O
diseases	O
.	O

The	O
post	O
-	O
translational	O
modifications	O
of	O
bone	O
and	O
other	O
mineralizing	O
collagens	S-Protein
are	O
significantly	O
different	O
from	O
those	O
of	O
other	O
type	B-Protein
I	I-Protein
collagen	E-Protein
matrices	O
,	O
a	O
fact	O
that	O
has	O
been	O
exploited	O
during	O
recent	O
advances	O
in	O
the	O
development	O
of	O
biochemical	O
markers	O
of	O
bone	O
resorption	O
.	O

The	O
enzymatic	O
collagen	S-Protein
cross	O
-	O
linking	O
mechanism	O
is	O
based	O
upon	O
aldehyde	O
formation	O
from	O
specific	O
telopeptide	O
lysine	O
or	O
hydroxylysine	O
residues	O
.	O

The	O
immature	O
ketoimine	O
cross	O
-	O
links	O
in	O
bone	O
form	O
via	O
the	O
condensation	O
of	O
a	O
telopeptide	O
aldehyde	O
with	O
a	O
helical	O
lysine	O
or	O
hydroxylysine	O
.	O

Subsequent	O
maturation	O
to	O
the	O
pyridinoline	O
and	O
pyrrole	O
cross	O
-	O
links	O
occur	O
by	O
further	O
reaction	O
of	O
the	O
ketoimines	O
with	O
telopeptide	O
aldehydes	O
.	O

In	O
mineralizing	O
tissues	O
,	O
a	O
relatively	O
low	O
level	O
of	O
lysyl	O
hydroxylation	O
results	O
in	O
low	O
levels	O
of	O
hydroxylysyl	O
pyridinoline	O
,	O
and	O
the	O
occurrence	O
of	O
the	O
largely	O
bone	O
specific	O
lysyl	O
pyridinoline	O
and	O
pyrrolic	O
cross	O
-	O
links	O
.	O

The	O
collagen	S-Protein
post	O
-	O
translational	O
modifications	O
appear	O
to	O
play	O
an	O
integral	O
role	O
in	O
matrix	O
mineralization	O
.	O

The	O
matrix	O
of	O
the	O
turkey	O
tendon	O
only	O
mineralizes	O
after	O
a	O
remodeling	O
of	O
the	O
collagen	S-Protein
and	O
the	O
subsequent	O
formation	O
of	O
a	O
modified	O
matrix	O
more	O
typical	O
of	O
bone	O
than	O
tendon	O
.	O

Further	O
,	O
disturbances	O
in	O
the	O
post	O
-	O
translational	O
modification	O
of	O
collagen	S-Protein
can	O
also	O
affect	O
the	O
mineralization	O
density	O
and	O
crystal	O
structure	O
of	O
the	O
tissue	O
.	O

In	O
addition	O
to	O
their	O
use	O
as	O
a	O
convenient	O
measure	O
of	O
matrix	O
degradation	O
,	O
collagen	S-Protein
cross	O
-	O
links	O
are	O
of	O
significant	O
importance	O
for	O
the	O
biomechanical	O
integrity	O
of	O
bone	O
.	O

Recent	O
studies	O
of	O
osteoporotic	O
bone	O
,	O
for	O
example	O
,	O
have	O
demonstrated	O
that	O
subtle	O
perturbations	O
in	O
the	O
pattern	O
of	O
lysine	O
hydroxylation	O
result	O
in	O
changes	O
in	O
the	O
cross	O
-	O
link	O
profile	O
.	O

These	O
alterations	O
,	O
specifically	O
changes	O
in	O
the	O
level	O
of	O
the	O
pyrrolic	O
cross	O
-	O
link	O
,	O
also	O
correlate	O
with	O
the	O
strength	O
of	O
the	O
bone	O
.	O

Further	O
research	O
into	O
the	O
biochemistry	O
of	O
bone	O
collagen	S-Protein
cross	O
-	O
links	O
may	O
expand	O
current	O
understanding	O
and	O
their	O
clinical	O
application	O
in	O
metabolic	O
bone	O
disease	O
.	O

This	O
review	O
also	O
demonstrates	O
the	O
potential	O
for	O
further	O
study	O
into	O
this	O
area	O
to	O
provide	O
more	O
subtle	O
information	O
into	O
the	O
mechanisms	O
and	O
etiology	O
of	O
disease	O
and	O
aging	O
of	O
mineralizing	O
tissues	O
.	O

BMP1	S-Protein
-	O
related	O
metalloproteinases	O
promote	O
the	O
development	O
of	O
ventral	O
mesoderm	O
in	O
early	O
Xenopus	O
embryos	O
.	O

Bone	B-Protein
morphogenetic	I-Protein
protein	I-Protein
1	E-Protein
(	O
BMP1	S-Protein
)	O
is	O
a	O
metalloproteinase	O
closely	O
related	O
to	O
Drosophila	O
Tolloid	S-Protein
(	O
Tld	S-Protein
)	O
.	O

Tld	S-Protein
regulates	O
dorsoventral	O
patterning	O
in	O
early	O
Drosophila	O
embryos	O
by	O
enhancing	O
the	O
activity	O
of	O
Dpp	S-Protein
,	O
a	O
member	O
of	O
the	O
TGF	O
-	O
beta	O
family	O
most	O
closely	O
related	O
to	O
BMP2	S-Protein
and	O
BMP4	S-Protein
.	O

In	O
Xenopus	O
BMP4	S-Protein
appears	O
to	O
play	O
an	O
essential	O
role	O
in	O
dorsoventral	O
patterning	O
,	O
promoting	O
the	O
development	O
of	O
ventral	O
fates	O
during	O
gastrula	O
stages	O
.	O

To	O
determine	O
if	O
BMP1	S-Protein
has	O
a	O
role	O
in	O
regulating	O
the	O
activity	O
of	O
BMP4	S-Protein
,	O
we	O
have	O
isolated	O
cDNAs	O
for	O
Xenopus	O
BMP1	S-Protein
and	O
a	O
novel	O
closely	O
related	O
gene	O
that	O
we	O
have	O
called	O
xolloid	S-Protein
(	O
xld	S-Protein
)	O
.	O

Whereas	O
xbmp1	S-Protein
is	O
uniformly	O
expressed	O
at	O
all	O
stages	O
tested	O
,	O
the	O
initial	O
uniform	O
expression	O
of	O
xld	S-Protein
becomes	O
localized	O
to	O
two	O
posterior	O
ectodermal	O
patches	O
flanking	O
the	O
neural	O
plate	O
and	O
later	O
to	O
the	O
inner	O
ectoderm	O
of	O
the	O
developing	O
tailbud	O
.	O
xld	S-Protein
is	O
also	O
expressed	O
in	O
dorsal	O
regions	O
of	O
the	O
brain	O
during	O
tailbud	O
stages	O
and	O
is	O
especially	O
abundant	O
in	O
the	O
ventricular	O
layer	O
of	O
the	O
dorsal	O
hindbrain	O
caudal	O
to	O
the	O
otic	O
vesicle	O
.	O

Overexpression	O
of	O
either	O
gene	O
inhibits	O
the	O
development	O
of	O
dorsoanterior	O
structures	O
in	O
whole	O
embryos	O
and	O
ventralizes	O
activin	O
-	O
induced	O
dorsal	O
mesoderm	O
in	O
animal	O
caps	O
.	O

Since	O
ventralization	O
of	O
activin	O
-	O
induced	O
animal	O
caps	O
can	O
be	O
blocked	O
by	O
coinjecting	O
a	O
dominant	O
-	O
inhibitory	O
receptor	O
for	O
BMP2	S-Protein
and	O
BMP4	S-Protein
,	O
we	O
suggest	O
a	O
role	O
for	O
BMP1	S-Protein
and	O
Xld	S-Protein
in	O
regulating	O
the	O
ventralizing	O
activity	O
of	O
these	O
molecules	O
.	O

Deleterious	O
actions	O
of	O
chronic	O
ethanol	O
treatment	O
on	O
the	O
glycosylation	O
of	O
rat	O
brain	O
clusterin	S-Protein
.	O

Clusterin	S-Protein
is	O
a	O
N	O
-	O
glycosylated	O
sialoglycoprotein	O
present	O
in	O
rat	O
brain	O
cells	O
.	O

Clusterin	S-Protein
,	O
which	O
elicits	O
aggregation	O
in	O
a	O
wide	O
variety	O
of	O
cells	O
,	O
has	O
been	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
synaptic	O
remodeling	O
through	O
its	O
cell	O
adhesion	O
property	O
or	O
lipid	O
transport	O
capacity	O
in	O
the	O
brain	O
.	O

Sialic	O
acid	O
residues	O
in	O
clusterin	S-Protein
may	O
be	O
responsible	O
for	O
its	O
structural	O
conformation	O
,	O
stability	O
and	O
functional	O
ability	O
.	O

Maturation	O
of	O
clusterin	S-Protein
is	O
governed	O
by	O
the	O
relative	O
actions	O
of	O
sialyltransferases	O
and	O
sialidases	O
that	O
are	O
present	O
in	O
brain	O
microsomes	O
,	O
golgi	O
bodies	O
,	O
cytosol	O
and	O
plasma	O
membranes	O
.	O

We	O
have	O
earlier	O
reported	O
that	O
chronic	O
ethanol	O
treatment	O
in	O
rats	O
has	O
a	O
damaging	O
effect	O
on	O
the	O
hepatic	O
glycosylation	O
machinery	O
.	O

Others	O
have	O
reported	O
increased	O
hydrolysis	O
of	O
brain	O
sialoconjugates	O
in	O
rats	O
following	O
chronic	O
ethanol	O
administration	O
.	O

Specificity	O
of	O
the	O
effects	O
of	O
chronic	O
ethanol	O
treatment	O
in	O
the	O
brain	O
in	O
relation	O
to	O
the	O
glycosylation	O
process	O
,	O
is	O
still	O
obscure	O
.	O

Therefore	O
,	O
in	O
this	O
investigation	O
,	O
we	O
have	O
studied	O
the	O
specific	O
effects	O
of	O
chronic	O
ethanol	O
treatment	O
on	O
the	O
glycosylation	O
of	O
rat	O
brain	O
clusterin	S-Protein
and	O
the	O
causes	O
that	O
may	O
lead	O
to	O
any	O
possible	O
defects	O
in	O
the	O
glycosylation	O
process	O
.	O

We	O
have	O
determined	O
the	O
effects	O
of	O
chronic	O
ethanol	O
treatment	O
on	O
(	O
i	O
)	O
the	O
incorporation	O
of	O
labeled	O
leucine	O
and	O
N	O
-	O
acetylmannosamine	O
into	O
immunoprecipitable	O
clusterin	S-Protein
in	O
whole	O
brain	O
homogenate	O
,	O
microsomes	O
,	O
golgi	O
,	O
cytosol	O
,	O
plasma	O
membrane	O
and	O
synaptosomes	O
,	O
(	O
ii	O
)	O
enzymatic	O
activities	O
of	O
sialyltransferases	O
in	O
golgi	O
and	O
synaptosomes	O
,	O
and	O
sialidase	O
in	O
brain	O
cytosol	O
and	O
plasma	O
membranes	O
,	O
and	O
(	O
iii	O
)	O
de	O
novo	O
synthetic	O
rate	O
of	O
rat	O
brain	O
cytosolic	B-Protein
sialidase	E-Protein
.	O

Our	O
results	O
showed	O
that	O
chronic	O
ethanol	O
treatment	O
in	O
rats	O
resulted	O
in	O
(	O
1	O
)	O
a	O
decreased	O
sialation	O
index	O
of	O
brain	O
clusterin	S-Protein
by	O
47	O
.	O
2	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
56	O
.	O
7	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
51	O
.	O
7	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
64	O
.	O
8	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
54	O
.	O
5	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
respectively	O
,	O
in	O
whole	O
brain	O
homogenate	O
,	O
golgi	O
,	O
cytosol	O
,	O
plasma	O
membranes	O
,	O
and	O
synaptosomes	O
;	O
(	O
2	O
)	O
a	O
46	O
.	O
1	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
12	O
.	O
5	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
decreased	O
activities	O
of	O
brain	O
sialyltransferases	O
,	O
respectively	O
,	O
in	O
the	O
golgi	O
and	O
the	O
synaptosomal	O
fractions	O
;	O
(	O
3	O
)	O
a	O
70	O
.	O
1	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
42	O
.	O
6	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
increased	O
activities	O
of	O
sialidases	O
,	O
respectively	O
,	O
in	O
the	O
cytosol	O
and	O
plasma	O
membrane	O
fractions	O
;	O
and	O
(	O
4	O
)	O
a	O
22	O
.	O
2	O
%	O
-	O
64	O
.	O
3	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
increased	O
incorporation	O
of	O
labeled	O
leucine	O
into	O
brain	O
cytosolic	B-Protein
sialidase	E-Protein
.	O

Our	O
findings	O
have	O
clearly	O
established	O
that	O
long	O
-	O
term	O
ethanol	O
treatment	O
in	O
rats	O
leads	O
to	O
a	O
marked	O
impairment	O
in	O
the	O
glycosylation	O
of	O
rat	O
brain	O
clusterin	S-Protein
as	O
a	O
result	O
of	O
altered	O
activities	O
of	O
brain	O
sialation	O
and	O
desialation	O
enzymes	O
.	O

In	O
particular	O
,	O
the	O
specific	O
increase	O
noted	O
in	O
brain	O
sialidase	O
activity	O
was	O
due	O
to	O
concomitant	O
increases	O
in	O
its	O
synthetic	O
rate	O
.	O

These	O
defects	O
in	O
the	O
glycosylation	O
of	O
brain	O
clusterin	S-Protein
may	O
lead	O
to	O
changes	O
in	O
the	O
molecular	O
conformation	O
of	O
clusterin	S-Protein
,	O
and	O
thus	O
,	O
may	O
result	O
in	O
its	O
structural	O
instability	O
and	O
/	O
or	O
functional	O
impairment	O
.	O

RAMPs	O
regulate	O
the	O
transport	O
and	O
ligand	O
specificity	O
of	O
the	O
calcitonin	B-Protein
-	I-Protein
receptor	I-Protein
-	I-Protein
like	I-Protein
receptor	E-Protein
.	O

Calcitonin	O
-	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
and	O
adrenomedullin	S-Protein
are	O
related	O
peptides	O
with	O
distinct	O
pharmacological	O
profiles	O
.	O

Here	O
we	O
show	O
that	O
a	O
receptor	O
with	O
seven	O
transmembrane	O
domains	O
,	O
the	O
calcitonin	B-Protein
-	I-Protein
receptor	I-Protein
-	I-Protein
like	I-Protein
receptor	E-Protein
(	O
CRLR	S-Protein
)	O
,	O
can	O
function	O
as	O
either	O
a	O
CGRP	O
receptor	O
or	O
an	O
adrenomedullin	S-Protein
receptor	O
,	O
depending	O
on	O
which	O
members	O
of	O
a	O
new	O
family	O
of	O
single	O
-	O
transmembrane	O
-	O
domain	O
proteins	O
,	O
which	O
we	O
have	O
called	O
receptor	O
-	O
activity	O
-	O
modifying	O
proteins	O
or	O
RAMPs	O
,	O
are	O
expressed	O
.	O

RAMPs	O
are	O
required	O
to	O
transport	O
CRLR	S-Protein
to	O
the	O
plasma	O
membrane	O
.	O

RAMP1	S-Protein
presents	O
the	O
receptor	O
at	O
the	O
cell	O
surface	O
as	O
a	O
mature	O
glycoprotein	O
and	O
a	O
CGRP	O
receptor	O
.	O

RAMP2	S-Protein
-	O
transported	O
receptors	O
are	O
core	O
-	O
glycosylated	O
and	O
are	O
adrenomedullin	S-Protein
receptors	O
.	O

Secondary	O
structure	O
of	O
P	O
-	O
glycoprotein	O
investigated	O
by	O
circular	O
dichroism	O
and	O
amino	O
acid	O
sequence	O
analysis	O
.	O

P	O
-	O
glycoprotein	O
(	O
Pgp	S-Protein
)	O
is	O
a	O
plasma	O
membrane	O
protein	O
known	O
as	O
an	O
ATP	O
-	O
dependent	O
drug	O
-	O
efflux	O
pump	O
that	O
confers	O
multidrug	O
resistance	O
to	O
tumor	O
cells	O
.	O

Structural	O
analysis	O
of	O
Pgp	S-Protein
was	O
investigated	O
by	O
circular	O
dichroism	O
(	O
CD	O
)	O
for	O
the	O
first	O
time	O
and	O
in	O
combination	O
with	O
amino	O
acid	O
sequence	O
analysis	O
.	O

CD	O
of	O
highly	O
purified	O
Pgp	S-Protein
from	O
human	O
,	O
rat	O
and	O
murine	O
Pgp	S-Protein
-	O
overexpressing	O
drug	O
resistant	O
cells	O
revealed	O
slight	O
variations	O
in	O
the	O
spectral	O
shape	O
when	O
recorded	O
in	O
the	O
presence	O
of	O
dodecyl	O
maltoside	O
(	O
DM	O
)	O
.	O

These	O
species	O
-	O
dependent	O
variations	O
in	O
CD	O
shapes	O
resulted	O
from	O
the	O
interaction	O
of	O
the	O
oligosaccharidic	O
part	O
with	O
the	O
protein	O
core	O
since	O
they	O
were	O
abolished	O
either	O
in	O
the	O
presence	O
of	O
sodium	O
dodecyl	O
sulfate	O
(	O
SDS	O
)	O
or	O
after	O
deglycosylation	O
,	O
the	O
latter	O
not	O
altering	O
the	O
Pgp	S-Protein
ATP	O
-	O
dependent	O
drug	O
transport	O
activity	O
.	O

Whatever	O
the	O
level	O
of	O
Pgp	S-Protein
glycosylation	O
and	O
the	O
detergent	O
used	O
(	O
SDS	O
or	O
DM	O
)	O
,	O
the	O
content	O
in	O
secondary	O
structure	O
deduced	O
from	O
deconvolution	O
of	O
CD	O
spectra	O
is	O
almost	O
the	O
same	O
for	O
the	O
three	O
sources	O
of	O
Pgp	S-Protein
and	O
estimated	O
to	O
43	O
%	O
alpha	O
-	O
helix	O
,	O
16	O
%	O
beta	O
-	O
sheet	O
,	O
15	O
%	O
beta	O
-	O
turn	O
and	O
26	O
%	O
of	O
other	O
structures	O
.	O

These	O
data	O
,	O
which	O
constitute	O
the	O
first	O
report	O
of	O
Pgp	S-Protein
structure	O
analysis	O
by	O
circular	O
dichroism	O
,	O
are	O
consistent	O
with	O
the	O
48	O
%	O
alpha	O
-	O
helix	O
and	O
16	O
%	O
beta	O
-	O
sheets	O
global	O
contents	O
predicted	O
by	O
using	O
recently	O
reported	O
efficient	O
secondary	O
structure	O
prediction	O
methods	O
.	O

This	O
consistency	O
reinforces	O
the	O
reliability	O
of	O
the	O
probable	O
nature	O
and	O
localization	O
of	O
predicted	O
Pgp	S-Protein
secondary	O
structure	O
elements	O
.	O

This	O
provides	O
a	O
good	O
framework	O
for	O
precise	O
3D	O
structure	O
modeling	O
of	O
Pgp	S-Protein
by	O
homology	O
with	O
proteins	O
of	O
known	O
3D	O
structure	O
,	O
as	O
it	O
is	O
illustrated	O
here	O
for	O
the	O
A	O
motifs	O
of	O
the	O
ATP	O
-	O
binding	O
domains	O
of	O
Pgp	S-Protein
.	O

Methylation	O
of	O
the	O
p16INK4A	S-Protein
gene	O
in	O
multiple	O
myeloma	O
.	O

The	O
p16INK4A	S-Protein
(	O
p16	S-Protein
)	O
binds	O
to	O
both	O
cyclin	O
D	O
-	O
CDK4	S-Protein
and	O
cyclin	O
D	O
-	O
CDK6	S-Protein
and	O
inhibits	O
the	O
progression	O
of	O
the	O
cell	O
cycle	O
from	O
G1	O
to	O
S	O
phase	O
.	O

Loss	O
of	O
expression	O
of	O
this	O
protein	O
can	O
occur	O
by	O
several	O
mechanisms	O
including	O
structural	O
alterations	O
.	O

Recent	O
studies	O
have	O
suggested	O
that	O
the	O
loss	O
of	O
expression	O
of	O
p16	S-Protein
can	O
occur	O
by	O
hypermethylation	O
of	O
the	O
gene	O
.	O

The	O
methylation	O
status	O
of	O
the	O
p16	S-Protein
gene	O
in	O
multiple	O
myeloma	O
was	O
examined	O
in	O
three	O
myeloma	O
cell	O
lines	O
(	O
U266	O
,	O
RPMI8226	O
and	O
IM9	O
)	O
and	O
16	O
primary	O
myeloma	O
samples	O
using	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
MSP	O
)	O
.	O

The	O
U266	O
and	O
RPMI8226	O
cell	O
lines	O
contained	O
a	O
completely	O
methylated	O
p16	S-Protein
gene	O
and	O
the	O
IM9	O
line	O
had	O
a	O
partially	O
methylated	O
p16	S-Protein
gene	O
.	O

Identical	O
results	O
were	O
obtained	O
by	O
another	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
based	O
methylation	O
assay	O
system	O
as	O
well	O
as	O
Southern	O
blotting	O
after	O
using	O
a	O
methylation	O
-	O
sensitive	O
restriction	O
enzyme	O
.	O

The	O
U266	O
cell	O
line	O
expressed	O
no	O
p16	S-Protein
,	O
and	O
the	O
IM9	O
had	O
weak	O
expression	O
as	O
determined	O
by	O
reverse	O
transcript	O
(	O
RT	O
-	O
)	O
PCR	O
.	O

The	O
U266	O
cells	O
began	O
to	O
express	O
,	O
and	O
IM9	O
increased	O
the	O
accumulation	O
of	O
,	O
the	O
p16	S-Protein
RNA	O
after	O
treatment	O
with	O
the	O
demethylating	O
agent	O
5	O
'	O
-	O
aza	O
-	O
2	O
-	O
deoxycytidine	O
(	O
10	O
(	O
-	O
6	O
)	O
-	O
10	O
(	O
-	O
5	O
)	O
M	O
)	O
.	O

This	O
suggested	O
that	O
the	O
levels	O
of	O
methylation	O
of	O
the	O
p16	S-Protein
gene	O
detected	O
by	O
the	O
MSP	O
technique	O
correlated	O
with	O
the	O
regulation	O
of	O
transcription	O
of	O
this	O
gene	O
.	O

Examination	O
of	O
the	O
primary	O
myeloma	O
samples	O
showed	O
that	O
eight	O
of	O
16	O
(	O
50	O
%	O
)	O
contained	O
a	O
methylated	O
p16	S-Protein
gene	O
.	O

We	O
have	O
previously	O
found	O
that	O
alterations	O
of	O
the	O
p16	S-Protein
gene	O
,	O
such	O
as	O
deletions	O
and	O
point	O
mutations	O
,	O
are	O
rare	O
in	O
primary	O
multiple	O
myeloma	O
;	O
none	O
of	O
the	O
16	O
samples	O
included	O
in	O
this	O
study	O
had	O
p16	S-Protein
gene	O
alterations	O
.	O

Our	O
results	O
suggest	O
that	O
methylation	O
of	O
the	O
p16	S-Protein
gene	O
may	O
contribute	O
to	O
the	O
development	O
and	O
/	O
or	O
progression	O
of	O
multiple	O
myeloma	O
.	O

Fine	O
structural	O
and	O
functional	O
consequences	O
of	O
deglycosylation	O
of	O
the	O
platelet	O
adhesion	O
receptor	O
GPIb	O
-	O
IX	O
(	O
CD	O
42b	O
)	O
.	O

To	O
investigate	O
the	O
role	O
of	O
the	O
glycosylation	O
of	O
the	O
platelet	O
receptor	O
glycoprotein	O
Ib	O
(	O
GPIb	O
,	O
CD	O
42b	O
)	O
,	O
platelets	O
and	O
purified	O
GPIb	O
were	O
deglycosylated	O
by	O
neuraminidase	O
,	O
O	O
-	O
and	O
N	O
-	O
glycosidases	O
.	O

N	O
-	O
deglycosylation	O
and	O
neuraminic	O
-	O
acid	O
cleavage	O
had	O
little	O
effect	O
on	O
ristocetin	O
and	O
botrocetin	O
-	O
induced	O
platelet	O
agglutination	O
.	O

However	O
,	O
O	O
-	O
deglycosylation	O
reduced	O
the	O
response	O
by	O
approximately	O
50	O
%	O
,	O
and	O
total	O
deglycosylation	O
(	O
the	O
combination	O
of	O
all	O
three	O
glycosidases	O
)	O
fully	O
abolished	O
the	O
response	O
to	O
ristocetin	O
.	O

Interestingly	O
,	O
binding	O
of	O
von	B-Protein
Willebrand	I-Protein
Factor	E-Protein
(	O
vWF	S-Protein
)	O
to	O
purified	O
GPIb	O
in	O
the	O
presence	O
of	O
ristocetin	O
and	O
botrocetin	O
in	O
a	O
standardized	O
microtiter	O
plate	O
assay	O
was	O
not	O
altered	O
by	O
partial	O
or	O
even	O
by	O
total	O
deglycosylation	O
.	O

Electron	O
microscopy	O
indicated	O
that	O
the	O
normally	O
stretched	O
approximately	O
50	O
nm	O
long	O
molecule	O
was	O
approximately	O
32	O
nm	O
after	O
N	O
-	O
deglycosylation	O
,	O
approximately	O
20	O
nm	O
after	O
O	O
-	O
deglycosylation	O
,	O
and	O
reduced	O
in	O
a	O
approximately	O
15	O
nm	O
long	O
collapse	O
by	O
total	O
deglycosylation	O
.	O

These	O
results	O
suggest	O
that	O
deglycosylation	O
has	O
major	O
structural	O
impacts	O
on	O
GPIb	O
,	O
strongly	O
impairing	O
platelet	O
-	O
vWF	S-Protein
interactions	O
;	O
however	O
,	O
vWF	S-Protein
binding	O
to	O
isolated	O
GPIb	O
remains	O
unaffected	O
.	O

Identification	O
of	O
a	O
374	O
amino	O
acid	O
protein	O
encoded	O
by	O
RNA	O
segment	O
6	O
of	O
influenza	O
C	O
virus	O
.	O

Unspliced	O
mRNA	O
from	O
RNA	O
segment	O
6	O
of	O
influenza	O
C	O
virus	O
contains	O
a	O
single	O
open	O
reading	O
frame	O
that	O
potentially	O
encodes	O
a	O
polypeptide	O
of	O
374	O
amino	O
acids	O
.	O

This	O
polypeptide	O
,	O
which	O
has	O
not	O
been	O
identified	O
as	O
yet	O
,	O
is	O
predicted	O
to	O
contain	O
the	O
complete	O
amino	O
acid	O
sequence	O
of	O
the	O
matrix	O
protein	O
,	O
M1	S-Protein
,	O
as	O
well	O
as	O
that	O
of	O
a	O
small	O
integral	O
membrane	O
protein	O
,	O
CM2	S-Protein
.	O

Here	O
,	O
we	O
found	O
that	O
small	O
amounts	O
of	O
two	O
previously	O
unrecognized	O
proteins	O
with	O
apparent	O
molecular	O
masses	O
of	O
42	O
(	O
P42	S-Protein
)	O
and	O
44	O
kDa	O
(	O
P44	S-Protein
)	O
were	O
immunoprecipitated	O
with	O
immune	O
serum	O
against	O
CM2	S-Protein
.	O

The	O
electrophoretic	O
mobilities	O
of	O
P42	S-Protein
and	O
P44	S-Protein
varied	O
depending	O
on	O
virus	O
strain	O
,	O
indicating	O
that	O
they	O
are	O
virus	O
-	O
coded	O
.	O

Treatment	O
of	O
infected	O
cells	O
with	O
tunicamycin	O
and	O
digestion	O
of	O
immunoprecipitated	O
proteins	O
with	O
various	O
endoglycosidases	O
revealed	O
that	O
P42	S-Protein
is	O
modified	O
by	O
the	O
addition	O
of	O
a	O
high	O
-	O
mannose	O
oligosaccharide	O
chain	O
to	O
generate	O
P44	S-Protein
.	O

A	O
monoclonal	O
antibody	O
against	O
M1	S-Protein
,	O
like	O
anti	O
-	O
CM2	S-Protein
serum	O
,	O
was	O
able	O
to	O
immunoprecipitate	O
both	O
the	O
P42	S-Protein
and	O
P44	S-Protein
proteins	O
.	O

Furthermore	O
,	O
the	O
tryptic	O
peptide	O
map	O
of	O
either	O
P42	S-Protein
or	O
P44	S-Protein
was	O
indistinguishable	O
from	O
the	O
map	O
of	O
the	O
mixture	O
of	O
M1	S-Protein
and	O
CM2	S-Protein
.	O

These	O
results	O
,	O
taken	O
together	O
,	O
suggest	O
strongly	O
that	O
P42	S-Protein
and	O
P44	S-Protein
correspond	O
to	O
the	O
374	O
amino	O
acid	O
protein	O
encoded	O
by	O
unspliced	O
RNA	O
segment	O
6	O
mRNA	O
and	O
its	O
N	O
-	O
glycosylated	O
form	O
,	O
respectively	O
.	O

The	O
amino	O
acid	O
sequences	O
of	O
carboxypeptidases	B-Protein
I	E-Protein
and	O
II	S-Protein
from	O
Aspergillus	O
niger	O
and	O
their	O
stability	O
in	O
the	O
presence	O
of	O
divalent	O
cations	O
.	O

The	O
amino	O
acid	O
sequences	O
of	O
serine	O
carboxypeptidase	B-Protein
I	E-Protein
(	O
CPD	B-Protein
-	I-Protein
I	E-Protein
)	O
and	O
II	S-Protein
(	O
CPD	B-Protein
-	I-Protein
II	E-Protein
)	O
,	O
respectively	O
,	O
from	O
Aspergillus	O
niger	O
have	O
been	O
determined	O
by	O
conventional	O
Edman	O
degradation	O
of	O
the	O
reduced	O
and	O
vinylpyridinated	O
enzymes	O
and	O
peptides	O
hereof	O
generated	O
by	O
cleavage	O
with	O
cyanogen	O
bromide	O
,	O
iodobenzoic	O
acid	O
,	O
glutamic	O
acid	O
cleaving	O
enzyme	O
,	O
AspN	O
-	O
endoproteinase	O
and	O
EndoLysC	O
proteinase	O
.	O

CPD	B-Protein
-	I-Protein
I	E-Protein
consists	O
of	O
a	O
single	O
peptide	O
chain	O
of	O
471	O
amino	O
acid	O
residues	O
,	O
three	O
disulfide	O
bridges	O
and	O
nine	O
N	O
-	O
glycosylated	O
asparaginyl	O
residues	O
,	O
while	O
CPD	B-Protein
-	I-Protein
II	E-Protein
consists	O
of	O
a	O
single	O
peptide	O
chain	O
of	O
481	O
amino	O
acid	O
residues	O
,	O
has	O
three	O
disulfide	O
bridges	O
,	O
one	O
free	O
cysteinyl	O
residue	O
and	O
nine	O
glycosylated	O
asparaginyl	O
residues	O
.	O

The	O
enzymes	O
are	O
closely	O
related	O
to	O
carboxypeptidase	O
S3	O
from	O
Penicillium	O
janthinellum	O
.	O

Both	O
Ca2	O
+	O
and	O
Mg2	O
+	O
stabilize	O
CPD	B-Protein
-	I-Protein
I	E-Protein
as	O
well	O
as	O
CPD	B-Protein
-	I-Protein
II	E-Protein
,	O
at	O
basic	O
pH	O
values	O
,	O
Ca2	O
+	O
being	O
most	O
effective	O
,	O
while	O
the	O
divalent	O
ions	O
have	O
no	O
effect	O
on	O
the	O
activity	O
of	O
the	O
two	O
enzymes	O
.	O

N	O
-	O
Hydroxy	O
-	O
amide	O
analogues	O
of	O
MHC	O
-	O
class	O
I	O
peptide	O
ligands	O
with	O
nanomolar	O
binding	O
affinities	O
.	O

A	O
novel	O
class	O
of	O
major	O
histocompatibility	O
complex	O
class	O
I	O
(	O
MHC	O
-	O
I	O
)	O
ligands	O
containing	O
an	O
N	O
-	O
hydroxyamide	O
bond	O
was	O
designed	O
on	O
the	O
basis	O
of	O
the	O
natural	O
epitope	O
SIINFEKL	O
,	O
and	O
synthesized	O
on	O
solid	O
phase	O
.	O

The	O
capacity	O
of	O
these	O
compounds	O
to	O
bind	O
to	O
the	O
MHC	O
-	O
I	O
molecule	O
H	B-Protein
-	I-Protein
2Kb	E-Protein
and	O
to	O
induce	O
T	O
cell	O
responses	O
was	O
analysed	O
in	O
comparison	O
with	O
the	O
corresponding	O
glycine	O
containing	O
variant	O
of	O
SIINFEKL	O
.	O

Binding	O
to	O
the	O
MHC	O
molecule	O
was	O
diminished	O
by	O
the	O
N	O
-	O
hydroxy	O
group	O
at	O
positions	O
2	O
and	O
3	O
of	O
the	O
oligomer	O
and	O
improved	O
in	O
the	O
case	O
of	O
positions	O
4	O
,	O
5	O
,	O
6	O
and	O
7	O
.	O

No	O
change	O
was	O
seen	O
for	O
position	O
1	O
.	O

The	O
efficacy	O
of	O
T	O
cell	O
stimulation	O
was	O
strongly	O
reduced	O
by	O
the	O
modification	O
of	O
all	O
positions	O
except	O
for	O
position	O
1	O
.	O

A	O
complete	O
loss	O
of	O
activity	O
was	O
found	O
for	O
the	O
N	O
-	O
hydroxy	O
variant	O
in	O
positions	O
4	O
and	O
6	O
.	O

N	O
-	O
Hydroxy	O
amide	O
-	O
containing	O
peptides	O
displayed	O
an	O
enhanced	O
stability	O
to	O
enzymatic	O
degradation	O
.	O

This	O
new	O
class	O
of	O
MHC	O
ligand	O
can	O
become	O
instrumental	O
as	O
immunomodulatory	O
reagent	O
in	O
various	O
disease	O
situations	O
.	O
